PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HORSBURGH, CR				HORSBURGH, CR			HEALING BY DESIGN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							WINDOW; VIEW				HORSBURGH, CR (corresponding author), EMORY UNIV,SCH MED,ATLANTA,GA 30303, USA.			Horsburgh, C./0000-0001-6838-7895				Bosker G, 1987, Architecture, V76, P35; Broadbent D. E., 1971, DECISION STRESS; Carpman, 1993, DESIGN CARES PLANNIN; Cousins N., 1979, ANATOMY ILLNESS; Cunningham Jr R. M., 1948, MOD HOSP, V71, P51; EVANS GW, 1980, PSYCHOL BULL, V88, P259, DOI 10.1037/0033-2909.88.2.259; EVANS GW, 1980, J APPL PSYCHOL, V65, P474, DOI 10.1037/0021-9010.65.4.474; GASKIE MF, 1990, ARCHIT REC, V178, P87; GASKIE MF, 1986, ARCHIT REC, V176, P115; GREER NR, 1986, ARCHITECTURE-AIA J, V75, P68; HAMLIN TF, 1940, PENCIL POINTS, V21, P711; Kaplan R, 1989, EXPERIENCE NATURE PS; Kaplan S., 1982, COGNITION ENV FUNCTI; KNIGHT C, 1987, ARCHITECTURE-AIA J, V76, P48; Kubler-Ross E., 1969, DEATH DYING; MALKIN J, 1992, HOSPITAL INTERIOR AR; MARBERRY SO, 1994, ARCHIT REC, V182, P98; MARTIN DP, 1990, HOSP HEALTH SERV ADM, V35, P591; MOORE EO, 1981, J ENVIRON SYST, V11, P17, DOI 10.2190/KM50-WH2K-K2D1-DM69; Moyers B., 1993, HEALING MIND; Saegert S., 1976, ENV PSYCHOL PEOPLE T, P218; Shumaker S. A., 1982, ENV STRESS, P179; SLOANE DC, 1994, J ARCHIT EDUC, V48, P82, DOI 10.2307/1425315; SOBEL DS, 1994, PARTNERS HLTH EMPOWE; STOLLER JK, 1988, ARCHITECTURE-AIA J, V77, P121; Strain JJ, 1975, PSYCHOL CARE MED ILL, P23; THOMPSON JD, 1975, HOSPITAL SOCIAL ARCH; Trites D K, 1969, Mod Hosp, V112, P94; Ulrich R. S., 1979, Landscape Research, V4, P17, DOI 10.1080/01426397908705892; ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402; VERDERBER S, 1986, ENVIRON BEHAV, V18, P450, DOI 10.1177/0013916586184002; VERDERBER S, 1987, J ARCHIT PLAN RES, V4, P120; 1994, HOSPITAL STATISTICS	33	49	49	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					735	740		10.1056/NEJM199509143331117	http://dx.doi.org/10.1056/NEJM199509143331117			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV227	7637767				2022-12-28	WOS:A1995RV22700031
J	NANDA, R; AMINI, J				NANDA, R; AMINI, J			DIVERTICULITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											NANDA, R (corresponding author), DWIGHT D EISENHOWER MED CTR,LEAVENWORTH,KS 66048, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					498	498		10.1056/NEJM199508243330806	http://dx.doi.org/10.1056/NEJM199508243330806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623882				2022-12-28	WOS:A1995RP75900006
J	VESA, J; HELLSTEN, E; VERKRUYSE, LA; CAMP, LA; RAPOLA, J; SANTAVUORI, P; HOFMANN, SL; PELTONEN, L				VESA, J; HELLSTEN, E; VERKRUYSE, LA; CAMP, LA; RAPOLA, J; SANTAVUORI, P; HOFMANN, SL; PELTONEN, L			MUTATIONS IN THE PALMITOYL PROTEIN THIOESTERASE GENE CAUSING INFANTILE NEURONAL CEROID-LIPOFUSCINOSIS	NATURE			English	Article							L-MYC; CHROMOSOME-1; POLYMORPHISM; ASSIGNMENT; JUVENILE; DISEASE; CLONING; MAPS; FORM; 1P32	NEURONAL ceroid lipofuscinoses (NCL) represent a group of common progressive encephalopathies of children which have a global incidence of 1 in 12,500 (ref. 1). These severe brain diseases are divided into three autosomal recessive subtypes, assigned to different chromosomal loci(2-4). The infantile subtype of NCL (INCL), linked to chromosome 1p32, is characterized by early visual loss and rapidly progressing mental deterioration, resulting in a pat electroencephalogram by 3 years of age; death occurs at 8 to 11 years(5), and characteristic storage bodies are found in brain and other tissues at autopsy(6). The molecular pathogenesis underlying the selective loss of neurons of neocortical origin has remained unknown. Here we report the identification, by positional candidate methods, of defects in the palmitoyl-protein thioesterase gene in all 42 Finnish INCL patients and several non-Finnish patients. The most common mutation results in intracellular accumulation of the polypeptide and undetectable enzyme activity in the brain of patients.	NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,SF-00300 HELSINKI,FINLAND; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV HELSINKI,CHILDRENS HOSP,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT CHILD NEUROL,SF-00290 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Helsinki; University of Helsinki								CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; ERLANSON CH, 1970, SCAND J GASTROENTERO, V5, P333; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8; HEISKANEN M, 1994, BIOTECHNIQUES, V17, P928; HELLSTEN E, 1993, GENOMICS, V16, P720, DOI 10.1006/geno.1993.1253; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JARVELA I, 1991, GENOMICS, V9, P170, DOI 10.1016/0888-7543(91)90235-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PROLA RL, 1984, J BIOL CHEM, V259, P3350; RAPOLA J, 1973, BRAIN, V96, P833, DOI 10.1093/brain/96.4.833; Rider J A, 1988, Am J Med Genet Suppl, V5, P21; RILKONEN A, 1994, DNA CELL BIOL, V13, P257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTAVUORI P, 1974, DEV MED CHILD NEUROL, V16, P644; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; SYVANEN AC, 1989, FEBS LETT, V258, P71, DOI 10.1016/0014-5793(89)81618-7; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WILLIAMS R, 1993, AM J HUM GENET, V53, P931; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379	30	587	592	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					584	587		10.1038/376584a0	http://dx.doi.org/10.1038/376584a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637805				2022-12-28	WOS:A1995RP75600048
J	DRESCHER, U; KREMOSER, C; HANDWERKER, C; LOSCHINGER, J; NODA, M; BONHOEFFER, F				DRESCHER, U; KREMOSER, C; HANDWERKER, C; LOSCHINGER, J; NODA, M; BONHOEFFER, F			IN-VITRO GUIDANCE OF RETINAL GANGLION-CELL AXONS BY RAGS, A 25 KDA TECTAL PROTEIN RELATED TO LIGANDS FOR EPH RECEPTOR TYROSINE KINASES	CELL			English	Article							GROWTH CONES; ANCHORED PROTEINS; NEURONS INVITRO; COLLAPSE; POSITION; FAMILY; BRAIN; GENE; IDENTIFICATION; RECOGNITION	The results of previous in vitro experiments indicate that a glycosylphosphatidylinositol (GPl)-anchored protein may play an important role in the guidance of temporal retinal axons during the formation of the topographically ordered retinotectal projection. We have purified and cloned a GPl-anchored, 25 kDa glycoprotein that is a good candidate for a molecule involved in this process. During the time of innervation by retinal ganglion cells, this protein is gradedly expressed in the posterior part of the developing tectum, In two different in vitro assay systems, the recombinant protein induces growth cone collapse and repulsion of retinal ganglion cell axons. These phenomena are observed for axons of temporal as well as nasal origin, indicating that an additional activity may be necessary to confer the nasotemporal specificity observed in previous assays, We named the protein RAGS (for repulsive axon guidance signal), The sequence of RAGS shows significant homology to recently identified ligands for receptor tyrosine kinases of the Eph subfamily.			DRESCHER, U (corresponding author), MAX PLANCK INST DEV BIOL, DEPT PHYS BIOL, D-72076 TUBINGEN, GERMANY.		Noda, Masaharu/D-7146-2016; Drescher, Uwe/C-5438-2009	Noda, Masaharu/0000-0002-3796-524X; 				BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; CROWE J, 1992, QUIAEXPRESS INSTRUCT; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; FAWCETT JW, 1989, J CELL SCI, V92, P93; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FLETCHER FA, 1994, ONCOGENE, V9, P3241; FLETCHER FA, 1994, GENOMICS, V24, P127, DOI 10.1006/geno.1994.1589; GILLARDIHEBENST.P, 1992, ONCOGENE, V7, P2499; GLERER A, 1987, DEVELOPMENT, V101, P479; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JOHNSTON AR, 1991, DEVELOPMENT, V113, P409; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MOORMAN SJ, 1990, J NEUROSCI, V10, P3158; MULLER B, 1992, THESIS U TUBINGEN TU; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAQUALE EB, 1994, DEV BIOL, V163, P491; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RAPER JA, 1990, EXP NEUROBIOL, V109, P71; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; SIMON DK, 1992, NEURON, V9, P977, DOI 10.1016/0896-6273(92)90249-D; STAHL B, 1990, NEURON, V5, P733; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VONBOXBERG Y, 1993, NEURON, V10, P345; VONBOXBERG Y, 1988, ANAL BIOCHEM, V169, P372; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; 1992, SEQUENCE ANAL SOFTWA	72	742	759	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					359	370		10.1016/0092-8674(95)90425-5	http://dx.doi.org/10.1016/0092-8674(95)90425-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634326	Bronze			2022-12-28	WOS:A1995RP24200006
J	GODOWSKI, PJ; MARK, MR; CHEN, JA; SADICK, MD; RAAB, H; HAMMOND, RG				GODOWSKI, PJ; MARK, MR; CHEN, JA; SADICK, MD; RAAB, H; HAMMOND, RG			REEVALUATION OF THE ROLES OF PROTEIN-S AND GAS6 AS LIGANDS FOR THE RECEPTOR TYROSINE KINASE RSE/TYRO-3	CELL			English	Article							GROWTH		GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	GODOWSKI, PJ (corresponding author), GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080, USA.			Hammonds, Glenn/0000-0003-0727-121X				MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARK MR, 1994, J BIOL CHEM, V269, P10720; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	6	189	201	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					355	358		10.1016/0092-8674(95)90424-7	http://dx.doi.org/10.1016/0092-8674(95)90424-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634325	Bronze			2022-12-28	WOS:A1995RP24200005
J	HASHIMOTO, K; HIRAI, M; KUROSAWA, Y				HASHIMOTO, K; HIRAI, M; KUROSAWA, Y			A GENE OUTSIDE THE HUMAN MHC RELATED TO CLASSICAL HLA CLASS-I GENES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGENS; SEQUENCE; ASSIGNMENT; CDNA; ZN-ALPHA-2-GLYCOPROTEIN; EXPRESSION; XENOPUS; CLONING; FAMILY	By presenting antigenic peptides to T lymphocytes, major histocompatibility complex (MHC) class I molecules play important roles in the human immune system. Knowledge is limited on the evolutionary history of human MHC class I-related molecules. An expressed class I gene, MRI, has now been identified on human chromosome 1q25, outside the MHC. In contrast to other known human divergent class I genes, MR1 encodes peptide-binding domains similar to those encoded by human leukocyte antigen (HLA) class I genes on chromosome 6 and by nonmammalian classical MHC class I genes. This gene may thus contribute to understanding the evolution of the MHC.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	HASHIMOTO, K (corresponding author), FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN.							ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ARAKI T, 1988, P NATL ACAD SCI USA, V85, P679, DOI 10.1073/pnas.85.3.679; ARUFFO A, 1989, J IMMUNOL, V143, P1723; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; BRILES WE, 1993, IMMUNOGENETICS, V37, P408, DOI 10.1007/BF00222464; BRUNS GA, 1991, CYTOGENET CELL GENET, V58, P103, DOI 10.1159/000133161; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; ELLIS SA, 1990, J IMMUNOL, V144, P731; FLAJNIK MF, 1993, EMBO J, V12, P4385, DOI 10.1002/j.1460-2075.1993.tb06123.x; GRIMHOLT U, 1993, IMMUNOGENETICS, V37, P469, DOI 10.1007/BF00222473; GROSSBERGER D, 1992, IMMUNOGENETICS, V36, P166, DOI 10.1007/BF00661093; GUILD BC, 1983, P NATL ACAD SCI-BIOL, V80, P2894, DOI 10.1073/pnas.80.10.2894; GUILLEMOT F, 1988, EMBO J, V7, P2775, DOI 10.1002/j.1460-2075.1988.tb03132.x; HASHIMOTO K, 1992, P NATL ACAD SCI USA, V89, P2209, DOI 10.1073/pnas.89.6.2209; HASHIMOTO K, 1990, P NATL ACAD SCI USA, V87, P6863, DOI 10.1073/pnas.87.17.6863; HASHIMOTO K, 1991, MOL EVOLUTION MAJOR, P103; ICHIHARA Y, 1992, IMMUNOL LETT, V33, P277, DOI 10.1016/0165-2478(92)90073-W; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MILLER MM, 1994, P NATL ACAD SCI USA, V91, P4397, DOI 10.1073/pnas.91.10.4397; OKAMURA K, 1993, J IMMUNOL, V151, P188; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SHUM BP, 1993, J IMMUNOL, V151, P5376; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UEYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P696, DOI 10.1016/0006-291X(91)91844-3; WATKINS DI, 1990, NATURE, V346, P60, DOI 10.1038/346060a0; WATTS S, 1989, IMMUNOGENETICS, V30, P390, DOI 10.1007/BF02425281; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2; ZEMMOUR J, 1991, IMMUNOGENETICS, V33, P310, DOI 10.1007/BF00216690	32	147	148	2	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					693	695		10.1126/science.7624800	http://dx.doi.org/10.1126/science.7624800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624800				2022-12-28	WOS:A1995RM70200035
J	MATSUMOTO, Y; KIM, K				MATSUMOTO, Y; KIM, K			EXCISION OF DEOXYRIBOSE PHOSPHATE RESIDUES BY DNA-POLYMERASE-BETA DURING DNA-REPAIR	SCIENCE			English	Article							SULFATE-POLYACRYLAMIDE GELS; SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; HUMAN-CELLS; NOVIKOFF HEPATOMA; MESSENGER-RNA; DAMAGED DNA; IDENTIFICATION; ACID; DOMAIN	Eukaryotic DNA polymerase beta (pol beta) can catalyze DNA synthesis during base excision DNA repair. It is shown here that pol beta also catalyzes release of 5'-terminal deoxyribose phosphate (dRP) residues from incised apurinic-apyrimidinic sites, which are common intermediate products in base excision repair. The catalytic domain for this activity resides within an amino-terminal 8-kilodalton fragment of pol beta, which comprises a distinct structural domain of the enzyme. Magnesium is required for the release of dRP from double-stranded DNA but not from a single-stranded oligonucleotide. Analysis of the released products indicates that the excision reaction occurs by beta-elimination rather than hydrolysis.			MATSUMOTO, Y (corresponding author), FOX CHASE CANC CTR,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19111, USA.			Matsumoto, Yoshihiro/0000-0001-6580-7188	NCI NIH HHS [CA06927, CA63154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063154, P30CA006927, R01CA063154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BAILLY V, 1988, BIOCHEM J, V253, P553, DOI 10.1042/bj2530553; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HADI SM, 1971, BIOCHEMISTRY-US, V10, P4986, DOI 10.1021/bi00802a024; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Matsumoto Y., UNPUB; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; PRASAD R, 1994, J BIOL CHEM, V269, P18096; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; THOMAS DC, 1982, BIOCHEMISTRY-US, V21, P5060, DOI 10.1021/bi00263a033; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587	34	616	629	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					699	702		10.1126/science.7624801	http://dx.doi.org/10.1126/science.7624801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624801				2022-12-28	WOS:A1995RM70200037
J	FRANK, J; ZHU, J; PENCZEK, P; LI, YH; SRIVASTAVA, S; VERSCHOOR, A; RADERMACHER, M; GRASSUCCI, R; LATA, RK; AGRAWAL, RK				FRANK, J; ZHU, J; PENCZEK, P; LI, YH; SRIVASTAVA, S; VERSCHOOR, A; RADERMACHER, M; GRASSUCCI, R; LATA, RK; AGRAWAL, RK			A MODEL OF PROTEIN-SYNTHESIS BASED ON CRYOELECTRON MICROSCOPY OF THE E-COLI RIBOSOME	NATURE			English	Article							3-DIMENSIONAL RECONSTRUCTION; IMAGE-RECONSTRUCTION; ESCHERICHIA-COLI; SINGLE PARTICLES; RNA; SUBUNIT; TUNNEL; ICE	THE ribosome is formed by assembly of proteins and nucleic acids, and synthesizes proteins according to genetic instructions in all organisms. Many of the biochemical steps of this fundamental process are known, but a detailed understanding requires a well-defined structural model of the ribosome. Electron microscopy combined with image reconstruction of two-dimensional crystals or single ribosomes(4) has been the most promising technique, but the resolution of the resulting models has been insufficient. Here we report a 25-Angstrom reconstruction of the ribosome from Escherichia coli, obtained by combining 4,300 projections of ice-embedded single particles. Our new reconstruction reveals a channel in the small ribosomal subunit and a bifurcating tunnel in the large subunit which may constitute pathways for the incoming message and the nascent polypeptide chain, respectively. Based on these new findings, a three-dimensional model of the basic framework of protein synthesis is presented.	SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12222; SUNY ALBANY,DEPT COMP SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	FRANK, J (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,BOX 509,ALBANY,NY 12201, USA.							AVILASAKAR AJ, 1994, J MOL BIOL, V239, P689, DOI 10.1006/jmbi.1994.1406; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; EASTERWOOD TR, 1994, NUCLEIC ACIDS RES, V22, P3779, DOI 10.1093/nar/22.18.3779; EISENSTEIN M, 1991, BIOCHIMIE, V73, P879, DOI 10.1016/0300-9084(91)90129-O; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1990, RIBOSOME, P107; GILBERT P, 1972, J THEOR BIOL, V36, P105, DOI 10.1016/0022-5193(72)90180-4; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MONTESANORODITIS L, 1994, J BIOL CHEM, V269, P6458; OAKES MI, 1990, J MOL BIOL, V211, P897, DOI 10.1016/0022-2836(90)90082-W; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; SCHRODER RR, 1990, J STRUCT BIOL, V105, P28, DOI 10.1016/1047-8477(90)90095-T; SHATSKY IN, 1991, BIOCHIMIE, V73, P937, DOI 10.1016/0300-9084(91)90135-N; SUNDARALINGAM M, 1975, P101; YONATH A, 1989, TRENDS BIOCHEM SCI, V14, P329, DOI 10.1016/0968-0004(89)90166-7; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	24	353	363	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					441	444		10.1038/376441a0	http://dx.doi.org/10.1038/376441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630422				2022-12-28	WOS:A1995RM63900057
J	KOLLEF, MH				KOLLEF, MH			ADULT-RESPIRATORY-DISTRESS-SYNDROME AFTER SMOKE-INHALATION FROM BURNING POISON-IVY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							LUNG				KOLLEF, MH (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							ALLEN JN, 1989, NEW ENGL J MED, V321, P569, DOI 10.1056/NEJM198908313210903; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; FORRESTER JM, 1990, AM REV RESPIR DIS, V142, P462, DOI 10.1164/ajrccm/142.2.462; HOLT PG, 1993, EUR RESPIR J, V6, P120; KALISH RS, 1994, J CLIN INVEST, V93, P2039, DOI 10.1172/JCI117198; KALISH RS, 1991, ARCH DERMATOL, V127, P1558, DOI 10.1001/archderm.127.10.1558; KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106; SCHUSTER DP, 1994, AM J RESP CRIT CARE, V149, P245, DOI 10.1164/ajrccm.149.1.8111590; WEISS SM, 1964, CLIN CHEST MED, V15, P103	9	1	1	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					358	359						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609271				2022-12-28	WOS:A1995RJ89800043
J	DAVIDSON, PT				DAVIDSON, PT			MANAGING TUBERCULOSIS DURING PREGNANCY	LANCET			English	Editorial Material									UNIV SO CALIF,SCH MED,LOS ANGELES,CA	University of Southern California	DAVIDSON, PT (corresponding author), TB CONTROL PROGRAM LOS ANGELES CTY,LOS ANGELES,CA, USA.		Addis, Antonio/K-1865-2019	Addis, Antonio/0000-0003-0962-9959				CARTER EJ, 1994, CHEST, V106, P1466, DOI 10.1378/chest.106.5.1466; DAUTZENBERG B, 1988, REV MAL RESPIR, V5, P279; DEMARCH P, 1974, CHEST, V68, P800; FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151; GOOD JT, 1981, AM J OBSTET GYNECOL, V140, P492, DOI 10.1016/0002-9378(81)90222-2; HAMADEH MA, 1992, CHEST, V101, P1114, DOI 10.1378/chest.101.4.1114; JANA N, 1994, INT J GYNECOL OBSTET, V44, P119, DOI 10.1016/0020-7292(94)90064-7; MARGONO F, 1994, OBSTET GYNECOL, V83, P911, DOI 10.1097/00006250-199406000-00001; SCHAEFER G, 1975, OBSTET GYNECOL, V46, P706; SNIDER DE, 1980, AM REV RESPIR DIS, V122, P65; 1994, AM J RESP CRIT CARE, V149, P1359; 1994, REPORTED TUBERCULOSI, P1	12	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					199	200		10.1016/S0140-6736(95)91263-0	http://dx.doi.org/10.1016/S0140-6736(95)91263-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616796				2022-12-28	WOS:A1995RK41900005
J	HALL, ZW				HALL, ZW			LAMININ BETA-2 (S-LAMININ) - A NEW PLAYER AT THE SYNAPSE	SCIENCE			English	Editorial Material							FIBER BASAL LAMINA; ACETYLCHOLINE-RECEPTORS; NEUROMUSCULAR-JUNCTION; AGRIN; PROTEIN; SITES; COMPONENTS		NIMH,CELL BIOL LAB,SYNAPT MECHANISMS SECT,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	HALL, ZW (corresponding author), NINCDS,BETHESDA,MD 20814, USA.							ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; DANIELS MP, 1990, J CELL SCI, V97, P615; HALL ZW, 1993, NEURON S, V10, P99; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LIETH E, 1992, DEV BIOL, V149, P41, DOI 10.1016/0012-1606(92)90262-F; MARTIN PT, 1995, SCIENCE, V269, P413, DOI 10.1126/science.7618109; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; SANES JR, 1979, J CELL BIOL, V83, P357, DOI 10.1083/jcb.83.2.357; SANES JR, 1983, COLD SPRING HARB SYM, V48, P667, DOI 10.1101/SQB.1983.048.01.070; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SILBERSTEIN L, 1982, NATURE, V295, P143, DOI 10.1038/295143a0; WALLACE BG, 1989, J NEUROSCI, V9, P1294	20	10	11	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					362	363		10.1126/science.7618101	http://dx.doi.org/10.1126/science.7618101			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618101				2022-12-28	WOS:A1995RK42700037
J	ZHOU, JS; NOCEK, JM; DEVAN, ML; HOFFMAN, BM				ZHOU, JS; NOCEK, JM; DEVAN, ML; HOFFMAN, BM			INHIBITOR-ENHANCED ELECTRON-TRANSFER - COPPER CYTOCHROME-C AS A REDOX-INERT PROBE OF TERNARY COMPLEXES	SCIENCE			English	Article							CRYSTAL-STRUCTURE; EMISSION-SPECTRA; PEROXIDASE; BINDING; PROTEINS; PLASTOCYANIN; ABSORPTION	Copper-substituted cytochrome c (CuCc) has been used as a structurally faithful, redox-inert inhibitor to probe the mechanism of electron transfer (ET) between Cc molecules and cytochrome c peroxidase (CcP). This inhibitor enhances photoinduced ET quenching of the triplet excited state of a zinc-substituted protein (ZnCcP or ZnCc) by its iron(lll) partner (Fe(3+)Cc or Fe(3+)CcP). These results show that CcP and Cc form a ternary complex in which one Cc molecule binds tightly at a surface domain of CcP having low ET reactivity, whereas the second Cc molecule binds weakly to the 1:1 complex at a second domain I with markedly greater (similar to 10(3)) reactivity. These results also rule out the possibility that Cc bound at the second domain cooperatively enhances ET to Cc at the first domain. The multiphasic kinetics observed for the photoproduced ET intermediate do not reflect electron self-exchange between two Cc molecules within the ternary complex.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University			Nocek, Judith/D-1254-2010		NHLBI NIH HHS [HL13531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013531, R37HL013531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNI H, 1995, BIOCHEMISTRY-US, V34, P5744, DOI 10.1021/bi00017a006; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; CHANG IJ, 1991, J AM CHEM SOC, V113, P7056, DOI 10.1021/ja00018a064; CHURCH WB, 1986, J BIOL CHEM, V261, P234; CLARKE MJ, 1991, STRUCT BONDING BERLI, V75; DIXON DW, 1989, BIOPHYS J, V56, P339, DOI 10.1016/S0006-3495(89)82680-3; ENGESETH HR, 1984, J BIOL CHEM, V259, P4822; FINDLAY MC, 1977, J AM CHEM SOC, V99, P5168, DOI 10.1021/ja00457a043; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; KANG CH, 1977, J BIOL CHEM, V252, P919; LIU RQ, 1995, BIOCHEMISTRY-US, V34, P973, DOI 10.1021/bi00003a032; MAUK MR, 1994, BIOCHEMISTRY-US, V33, P12609, DOI 10.1021/bi00208a011; MCLENDON G, 1993, J AM CHEM SOC, V115, P3665, DOI 10.1021/ja00062a035; MOORE GR, 1980, J INORG BIOCHEM, V12, P1, DOI 10.1016/S0162-0134(00)80039-2; MOSER CC, 1988, BIOCHEMISTRY-US, V27, P2450, DOI 10.1021/bi00407a031; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; Sigel H., 1991, METAL IONS BIOL SYST, V27; SILVERMAN RB, 1988, MECHANISM BASED ENZY; STEMP EDA, 1993, BIOCHEMISTRY-US, V32, P10848, DOI 10.1021/bi00091a041; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; VANDERKOOI JM, 1975, EUR J BIOCHEM, V60, P199, DOI 10.1111/j.1432-1033.1975.tb20992.x; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; WALLIN SA, 1991, J AM CHEM SOC, V113, P1842, DOI 10.1021/ja00005a065; ZHANG QP, 1991, MOL CRYST LIQ CRYST, V194, P343, DOI 10.1080/00268949108041186; Zhou J.-S., UNPUB; ZHOU JS, 1993, J AM CHEM SOC, V115, P10796, DOI 10.1021/ja00076a042; ZHOU JS, 1993, J AM CHEM SOC, V115, P11008, DOI 10.1021/ja00076a076; ZHOU JS, 1994, SCIENCE, V265, P1693, DOI 10.1126/science.8085152	33	56	57	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 14	1995	269	5221					204	207		10.1126/science.7618081	http://dx.doi.org/10.1126/science.7618081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618081				2022-12-28	WOS:A1995RJ02900033
J	TARPY, SP; CELLI, BR				TARPY, SP; CELLI, BR			LONG-TERM OXYGEN-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; VENTILATORY MUSCLE RECRUITMENT; CHEST WALL MECHANICS; AIR-FLOW OBSTRUCTION; CHRONIC LUNG-DISEASE; HYPOXEMIC PATIENTS; EXERCISE CAPACITY; MEDICAL PROGRESS; MILD HYPOXEMIA; SLEEP		ST ELIZABETH HOSP, DEPT PULM & CRIT CARE, BOSTON, MA 02135 USA; BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Boston University; Tufts University								ADAMO J P, 1990, Respiratory Care, V35, P153; [Anonymous], 1980, Ann Intern Med, V93, P391; ASTIN TW, 1967, AM REV RESPIR DIS, V95, P567; Barach AL, 1922, J AMER MED ASSOC, V79, P693, DOI 10.1001/jama.1922.02640090001001; BARKER AF, 1994, CHEST, V105, P248, DOI 10.1378/chest.105.1.248; BENDITT J, 1993, AM REV RESPIR DIS, V147, P1207, DOI 10.1164/ajrccm/147.5.1207; BLOCK AJ, 1974, CHEST, V65, P279, DOI 10.1378/chest.65.3.279; BRADLEY BL, 1978, AM REV RESPIR DIS, V118, P239; BYE PTP, 1985, AM REV RESPIR DIS, V132, P236; CALVERLEY PMA, 1982, AM REV RESPIR DIS, V126, P206; CHRISTOPHER KL, 1987, ANN INTERN MED, V107, P802, DOI 10.7326/0003-4819-107-6-802; COUSER JI, 1989, AM REV RESPIR DIS, V139, P627, DOI 10.1164/ajrccm/139.3.627; CRINER GJ, 1987, J APPL PHYSIOL, V63, P195, DOI 10.1152/jappl.1987.63.1.195; DEAN NC, 1992, AM REV RESPIR DIS, V146, P941, DOI 10.1164/ajrccm/146.4.941; DODD DS, 1984, AM REV RESPIR DIS, V129, P33; DONAHOE M, 1989, AM REV RESPIR DIS, V140, P385, DOI 10.1164/ajrccm/140.2.385; DOUGLAS NJ, 1990, AM REV RESPIR DIS, V141, P1055, DOI 10.1164/ajrccm/141.4_Pt_1.1055; FERGUSON GT, 1993, NEW ENGL J MED, V328, P1017; FLEETHAM J, 1982, AM REV RESPIR DIS, V126, P429; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1989, CHEST, V95, P757, DOI 10.1378/chest.95.4.757; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; GRANT I, 1982, ARCH INTERN MED, V142, P1470, DOI 10.1001/archinte.142.8.1470; GRANT I, 1987, ARCH GEN PSYCHIAT, V44, P999; HEATON RK, 1983, ARCH INTERN MED, V143, P1941, DOI 10.1001/archinte.143.10.1941; HEIMLICH HJ, 1989, CHEST, V95, P1008, DOI 10.1378/chest.95.5.1008; JOHNSON JT, 1991, ANN OTO RHINOL LARYN, V100, P108, DOI 10.1177/000348949110000205; KOO KW, 1975, AM J MED, V58, P663, DOI 10.1016/0002-9343(75)90502-1; KROP HD, 1973, CHEST, V64, P317, DOI 10.1378/chest.64.3.317; Levi-Valensi P, 1983, MED THORACA S4, V5, P502; LEVIVALENSI P, 1992, EUR RESPIR J, V5, P645; LEVIVALENSI P, 1992, EUR RESPIR J, V5, P301; LOCK SH, 1992, THORAX, V47, P98, DOI 10.1136/thx.47.2.98; Luft U., 1965, HDB PHYSL, P1099; MACNEE W, 1988, AM REV RESPIR DIS, V137, P1289, DOI 10.1164/ajrccm/137.6.1289; MARTINEZ FJ, 1990, AM REV RESPIR DIS, V142, P276, DOI 10.1164/ajrccm/142.2.276; MORRISON DA, 1992, CHEST, V102, P542, DOI 10.1378/chest.102.2.542; ODONOHUE WJ, 1995, CHEST, V107, P301, DOI 10.1378/chest.107.2.301; ODONOHUE WJ, 1990, AM REV RESPIR DIS, V142, P721; PRIGATANO GP, 1983, J CONSULT CLIN PSYCH, V51, P108, DOI 10.1037/0022-006X.51.1.108; ROBIN ED, 1958, J CLIN INVEST, V37, P981, DOI 10.1172/JCI103694; SLIWINSKI P, 1992, AM REV RESPIR DIS, V146, P665; STANEK KA, 1979, J APPL PHYSIOL, V46, P1115, DOI 10.1152/jappl.1979.46.6.1115; TABACHNIK E, 1981, J APPL PHYSIOL, V51, P557, DOI 10.1152/jappl.1981.51.3.557; TARPY S, 1992, AM REV RESPIR DIS, V146, pA646; TIEP BL, 1990, CLIN CHEST MED, V11, P505; TIEP BL, 1987, CHEST, V92, P263, DOI 10.1378/chest.92.2.263; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29; WEINBERGER SE, 1993, NEW ENGL J MED, V328, P1389, DOI 10.1056/NEJM199305133281906; WEINBERGER SE, 1993, NEW ENGL J MED, V328, P1462, DOI 10.1056/NEJM199305203282007; WEITZENBLUM E, 1985, AM REV RESPIR DIS, V131, P493, DOI 10.1164/arrd.1985.131.4.493; WRIGHT JL, 1992, LUNG, V170, P109	52	130	131	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					710	714		10.1056/NEJM199509143331107	http://dx.doi.org/10.1056/NEJM199509143331107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637750				2022-12-28	WOS:A1995RV22700007
J	KOBASHIGAWA, JA; KATZNELSON, S; LAKS, H; JOHNSON, JA; YEATMAN, L; WANG, XM; CHIA, D; TERASAKI, PI; SABAD, A; COGERT, GA; TROSIAN, K; HAMILTON, MA; MORIGUCHI, JD; KAWATA, N; HAGE, A; DRINKWATER, DC; STEVENSON, LW				KOBASHIGAWA, JA; KATZNELSON, S; LAKS, H; JOHNSON, JA; YEATMAN, L; WANG, XM; CHIA, D; TERASAKI, PI; SABAD, A; COGERT, GA; TROSIAN, K; HAMILTON, MA; MORIGUCHI, JD; KAWATA, N; HAGE, A; DRINKWATER, DC; STEVENSON, LW			EFFECT OF PRAVASTATIN ON OUTCOMES AFTER CARDIAC TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; HEART-TRANSPLANTATION; VASCULAR REJECTION; LOVASTATIN; CYTOTOXICITY; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; REGRESSION; RECIPIENTS; REVERSAL	Background. Hypercholesterolemia is common after cardiac transplantation and may contribute to the development of coronary vasculopathy. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to be effective and safe in lowering cholesterol levels after cardiac transplantation. Cell-culture studies using inhibitors of HMG-CoA reductase have suggested an immunosuppressive effect. Methods. Early after transplantation, we randomly assigned consecutive patients to receive either pravastatin (47 patients) or no HMG-CoA reductase inhibitor (50 patients). Results. Twelve months after transplantation, the pravastatin group had lower mean (+/-SD) cholesterol levels than the control group (193+/-36 vs. 248+/-49 mg per deciliter, P<0.001), less frequent cardiac rejection accompanied by hemodynamic compromise (3 vs. 14 patients, P=0.005), better survival (94 percent vs. 78 percent, P=0.025), and a lower incidence of coronaryvasculopathy in the transplant as determined by angiography and at autopsy (3 vs. 10 patients, P=0.049). There was no difference between the two groups in the incidence of mild or moderate episodes of cardiac rejection. In a subgroup of study patients, intracoronary ultrasound measurements at base line and one year after transplantation showed less progression in the pravastatin group in maximal intimal thickness (0.11+/-0.09 mm, vs. 0.23+/-0.16 mm in the control group; P=0.002) and in the intimal index (0.05+/-0.03 vs. 0.10+/-0.10 P=0.031). In a subgroup of patients, the cytotoxicity of natural killer cells was lower in the pravastatin group than in the control group (9.8 percent vs. 22.2 percent specific lysis, P=0.014). Conclusions. After cardiac transplantation, pravastatin had beneficial effects on cholesterol levels, the incidence of rejection causing hemodynamic compromise, one-year survival, and the incidence of coronary vasculopathy.	UNIV CALIF LOS ANGELES, SCH MED, DIV CARDIOTHORAC SURG, LOS ANGELES, CA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital	KOBASHIGAWA, JA (corresponding author), UNIV CALIF LOS ANGELES, MED CTR, SCH MED, DIV CARDIOL, CHS 47-123, LOS ANGELES, CA 90024 USA.			Kobashigawa, Jon/0000-0001-9308-3172				[Anonymous], 1993, Am J Cardiol, V72, P1031; BLANKENHORN DH, 1993, WESTERN J MED, V159, P172; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CORPIER CL, 1988, JAMA-J AM MED ASSOC, V260, P239, DOI 10.1001/jama.260.2.239; CUTTS JL, 1989, J CELL PHYSIOL, V139, P550, DOI 10.1002/jcp.1041390314; CUTTS JL, 1990, J CELL PHYSIOL, V145, P244, DOI 10.1002/jcp.1041450208; DOYLE JW, 1988, J CELL PHYSIOL, V137, P133, DOI 10.1002/jcp.1041370116; EICH D, 1991, J HEART LUNG TRANSPL, V10, P45; ENSLEY RD, 1991, TRANSPLANT P, V23, P1130; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAMMOND EH, 1992, J HEART LUNG TRANSPL, V11, pS111; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KIRBY JA, 1990, TRANSPLANTATION, V50, P225, DOI 10.1097/00007890-199008000-00010; KOBASHIGAWA JA, 1990, CIRCULATION, V82, P281; KREUZER J, 1991, ATHEROSCLEROSIS, V90, P203, DOI 10.1016/0021-9150(91)90116-K; LIN H, 1994, J HEART LUNG TRANSPL, V13, P824; LINN AJ, 1991, ADV EXPT MED BIOL, V288, P269; MCPHERSON R, 1993, J CLIN IMMUNOL, V13, P439, DOI 10.1007/BF00920019; MEISER BM, 1993, TRANSPLANT P, V25, P2077; MILLER LW, 1993, J AM COLL CARDIOL, V22, P41, DOI 10.1016/0735-1097(93)90814-H; SHAO ZG, 1988, AM J CARDIOL, V62, P876, DOI 10.1016/0002-9149(88)90885-5; SHARPLES LD, 1991, TRANSPLANTATION, V52, P244, DOI 10.1097/00007890-199108000-00012; TOTTERMAN TH, 1989, TRANSPLANTATION, V47, P817, DOI 10.1097/00007890-198905000-00014; WANG XM, 1993, HUM IMMUNOL, V37, P264; YOSHIMURA N, 1992, TRANSPLANTATION, V53, P94, DOI 10.1097/00007890-199201000-00018	25	1036	1069	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					621	627		10.1056/NEJM199509073331003	http://dx.doi.org/10.1056/NEJM199509073331003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637722				2022-12-28	WOS:A1995RR84000003
J	IMRIE, KR; KOVACS, MJ; SELBY, D; LIPTON, J; PATTERSON, BJ; PANTALONY, D; POLDRE, P; NGAN, BY; KEATING, A				IMRIE, KR; KOVACS, MJ; SELBY, D; LIPTON, J; PATTERSON, BJ; PANTALONY, D; POLDRE, P; NGAN, BY; KEATING, A			ISOLATED CHLOROMA - THE EFFECT OF EARLY ANTILEUKEMIC THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							GRANULOCYTIC SARCOMA; LEUKEMIA; TRANSLOCATION	Objective: To evaluate the effect of antileukemic chemotherapy administered at diagnosis on the survival of patients with isolated chloroma. Design: Retrospective review of locally identified patients and analysis of cases from the medical literature. Patients: The records of all patients with isolated chloroma identified at three teaching hospitals in Toronto between 1980 and 1994 were reviewed. A MEDLINE search was done to identify all cases of isolated chloroma reported in the English-language medical literature. Patients with a previous known hematologic disorder were excluded. Measurements: The effect of therapy on 1) the interval between diagnosis of chloroma and diagnosis of acute myeloid leukemia and 2) survival was determined. Results: 7 local patients and 83 published cases were identified, for a total of 90 evaluable patients. For the entire group, the median time to the diagnosis of acute myeloid leukemia was 9 months, and median survival was 22 months. Chemotherapy was administered to 49 patients (54%) at diagnosis of chloroma. Significantly fewer patients treated with chemotherapy subsequently developed acute myeloid leukemia (41% compared with 71%; P = 0.001). Survival was longer in patients treated with chemotherapy (>50% alive with a median follow-up of 25 months compared with a median survival of 13 months for those initially untreated; P = 0.001). Multivariate analysis showed that neither local radiotherapy nor surgery had an effect on survival. Conclusions: Administration of antileukemic chemotherapy at diagnosis of chloroma is associated with a significantly lower probability of developing acute myeloid leukemia and with longer survival.	TORONTO GEN HOSP, TORONTO, ON M5G 2C4, CANADA; PRINCESS MARGARET HOSP, TORONTO, ON, CANADA; VICTORIA HOSP, LONDON, ON, CANADA; SUNNYBROOK HLTH SCI CTR, N YORK, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Victoria; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center			Kovacs, Michael/G-3315-2011					ABE R, 1986, CANCER, V58, P1260, DOI 10.1002/1097-0142(19860915)58:6<1260::AID-CNCR2820580614>3.0.CO;2-O; Dock G., 1893, AM J MED SCI, V106, P152, DOI DOI 10.1097/00000441-189308000-00003; ESHGHABADI M, 1986, J CLIN ONCOL, V4, P912, DOI 10.1200/JCO.1986.4.6.912; HESTON JF, 1986, 45 YEARS CANCER INCI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAUSE JR, 1979, CANCER-AM CANCER SOC, V44, P1017, DOI 10.1002/1097-0142(197909)44:3<1017::AID-CNCR2820440333>3.0.CO;2-I; MEIS JM, 1986, CANCER-AM CANCER SOC, V58, P2697, DOI 10.1002/1097-0142(19861215)58:12<2697::AID-CNCR2820581225>3.0.CO;2-R; NEIMAN RS, 1981, CANCER-AM CANCER SOC, V48, P1426, DOI 10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G; SWIRSKY DM, 1984, BRIT J HAEMATOL, V56, P199, DOI 10.1111/j.1365-2141.1984.tb03948.x; WIERNIK PH, 1970, BLOOD-J HEMATOL, V35, P361, DOI 10.1182/blood.V35.3.361.361; YATES J, 1982, BLOOD, V60, P454	11	167	172	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					351	353		10.7326/0003-4819-123-5-199509010-00005	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625623				2022-12-28	WOS:A1995RQ98800005
J	BENN, CS; WHITTLE, H; AABY, P; BALE, C; MICHAELSEN, KF; OLSEN, J				BENN, CS; WHITTLE, H; AABY, P; BALE, C; MICHAELSEN, KF; OLSEN, J			VITAMIN-A AND MEASLES VACCINATION	LANCET			English	Letter									RES DEPT HUMAN NUTR,COPENHAGEN,DENMARK; AARHUS UNIV,INST EPIDEMIOL & SOCIAL MED,AARHUS,DENMARK; MRC LABS,FAJARA,GAMBIA; PROJECTO SAUDE BANDIM,BISSAU,GUINEA BISSAU	Aarhus University; MRC Laboratory Molecular Biology	BENN, CS (corresponding author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN S,DENMARK.							JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9; WHITTLE HC, 1988, LANCET, V1, P963; 1988, VITAMIN A SUPPLEMENT	3	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					503	504						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637497				2022-12-28	WOS:A1995RP85700042
J	FALK, RH				FALK, RH			THE THUMB SIGN IN MARFANS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											FALK, RH (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.								0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					430	430		10.1056/NEJM199508173330706	http://dx.doi.org/10.1056/NEJM199508173330706			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616992				2022-12-28	WOS:A1995RP24300006
J	GRUBB, NR; ELTON, RA; FOX, KAA				GRUBB, NR; ELTON, RA; FOX, KAA			IN-HOSPITAL MORTALITY AFTER OUT-OF-HOSPITAL CARDIAC-ARREST	LANCET			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY RESUSCITATION; HEALTH-PROFESSIONALS; UTSTEIN STYLE; SURVIVAL; DEFIBRILLATION; EMERGENCY; EXPERIENCE; STATEMENT; SCOTLAND	In-hospital management of out-of-hospital cardiac arrest is complicated by uncertainty about prognosis and the need to identify markers of adverse outcome in individuals surviving initial resuscitation. We sought to identify factors that predict in-hospital death among patients who initially survive out-of-hospital cardiac arrest. We investigated 346 consecutive cases of out-of-hospital cardiac arrest received by a single centre in Edinburgh, UK (270 cases examined retrospectively, 76 prospectively). Of the retrospective cohort, 246 cases were thought to be of cardiac origin. There were associations between in-hospital mortality and pre-arrest variables, resuscitation variables, and factors measured during admission. Crew-witnessed arrests were associated with low mortality; arrest rhythm (p<0.001), resuscitation by a health professional (p<0.05), conscious level on admission (p<0.001), and requirement for ventilaton (p<0.05) independently predicted in-hospital mortality. A weighted prognostic scoring system based on three of these variables accurately predicted the likelihood of in-hospital death in the prospective test group. Further assessment of conscious level during admission with the Glasgow coma score predicted mortality rates in the study population, but coma did not predict a hopeless prognosis in individual cases unless it persisted for 72 h or more. Accurate prognostic assessment of out-of-hospital cardiac arrest survivors can be made from information available on admission. Of factors that independently predicted outcome, the skill of the resuscitator is most readily modified. This suggests that public training in resuscitation may reduce mortality rates.	UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,MED STAT UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	GRUBB, NR (corresponding author), UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Fox, keith A A/I-3742-2013	Fox, Keith/0000-0002-0140-2752				AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; BOSSAERT L, 1989, RESUSCITATION, V17, pS57; COBB LA, 1982, ANN NY ACAD SCI, V382, P330, DOI 10.1111/j.1749-6632.1982.tb55228.x; COBB LA, 1992, CIRCULATION, V85, P98; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUSACK S, 1992, ARCH EMERG MED, V9, P203; DICKEY W, 1992, BRIT HEART J, V67, P334; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; JENNETT B, 1975, LANCET, V1, P480; JUCHEMS R, 1993, RESUSCITATION, V26, P23, DOI 10.1016/0300-9572(93)90159-N; ROWLEY JM, 1990, BRIT HEART J, V64, P309; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; TORPPEDERSEN C, 1991, RESUSCITATION, V21, P283, DOI 10.1016/0300-9572(91)90053-2; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7; ZIPES DP, 1992, CIRCULATION, V85, P160	22	94	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					417	421		10.1016/S0140-6736(95)92784-0	http://dx.doi.org/10.1016/S0140-6736(95)92784-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623574				2022-12-28	WOS:A1995RN65600013
J	SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM				SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM			RISKS OF OROFACIAL CLEFTS IN CHILDREN BORN TO WOMEN USING MULTIVITAMINS CONTAINING FOLIC-ACID PERICONCEPTIONALLY	LANCET			English	Article							NEURAL-TUBE DEFECTS; VITAMIN SUPPLEMENTATION; PREVENT RECURRENCE; WESTERN-AUSTRALIA; DIETARY-FOLATE; ORAL CLEFTS; PREGNANCY; LIP; SMOKING; PALATE	Women are advised to take folic acid before they conceive as a precaution against neural-tube defects. However, the use of folic acid in preventing orofacial clefts is unknown. We investigated whether a woman's periconceptional use of multivitamins containing folic acid was associated with a reduced risk of orofacial clefts. We derived data from a population-based case-control study of fetuses and liveborn infants with orofacial anomalies among a 1987-89 cohort of births in California. We interviewed 731 (84.7%) of eligible mothers with orofacial cleft case infants and 734 (78.2%) mothers with non-malformed control infants. We found a reduced risk of orofacial clefts if the mother had used multivitamins containing folic acid during the period from one month before through two months after conception. The odds ratios ranged from 0.50-0.73 depending on cleft phenotype. Controlling for the potential influence of other variables did not substantially alter the results. Maternal daily consumption of cereal containing folic acid was also associated with a reduced risk of orofacial clefts. Women who used multivitamins containing folic acid periconceptionally had a 25-50% reduction in risk for offspring with orofacial clefts compared to women who did not use such vitamins. However, this association may not be attributable to folic acid specifically, but may be a consequence of other multivitamin supplement components, or behaviours, that are highly correlated with the use of multivitamins containing folic acid.	CHILDRENS HOSP,DEPT MED GENET,OAKLAND,CA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	SHAW, GM (corresponding author), MARCH DIMES BIRTH DEFECTS FDN,CALIF BIRTH DEFECTS MONITORING PROGRAM,EMERYVILLE,CA, USA.			Shaw, Gary/0000-0001-7438-4914				BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; BOWER C, 1992, AM J MED GENET, V44, P647, DOI 10.1002/ajmg.1320440524; Briggs R M, 1976, Clin Plast Surg, V3, P647; CONWAY H, 1958, Plast Reconstr Surg Transplant Bull, V22, P450, DOI 10.1097/00006534-195811000-00003; Croen L A, 1991, Paediatr Perinat Epidemiol, V5, P423, DOI 10.1111/j.1365-3016.1991.tb00728.x; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DANSKY LV, 1987, ANN NEUROL, V21, P176, DOI 10.1002/ana.410210210; DOUGLAS B, 1958, Plast Reconstr Surg Transplant Bull, V22, P94, DOI 10.1097/00006534-195808000-00002; HILL L, 1988, J EPIDEMIOL COMMUN H, V42, P1, DOI 10.1136/jech.42.1.1; JORDAN RL, 1977, TERATOLOGY, V15, P73, DOI 10.1002/tera.1420150110; KHOURY MJ, 1989, AM J DIS CHILD, V143, P333, DOI 10.1001/archpedi.1989.02150150091023; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; NELSON MM, 1960, CIBA F S CONGENITAL, P134; PEER LA, 1964, PLAST RECONSTR SURG, V34, P358; PEER LA, 1958, PLAST RECONSTR SURG, V22, P422; SAXEN I, 1975, INT J EPIDEMIOL, V4, P37, DOI 10.1093/ije/4.1.37; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1983, LANCET, V1, P1027; TOLAROVA M, 1982, LANCET, V2, P217; TOLAROVA M, 1987, SCAND J PLAST RECONS, V21, P19, DOI 10.3109/02844318709083574; WAITZMAN NJ, 1994, INQUIRY-J HEALTH CAR, V31, P188; WEGNER C, 1992, NEUROLOGY, V42, P17; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WITTER FR, 1982, AM J OBSTET GYNECOL, V144, P857, DOI 10.1016/0002-9378(82)90369-6; 1991, STATISTICS EPIIDEMIO; 1991, LANCET, V338, P131; 1989, HLTH HABITS HIST QUE	30	373	387	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					393	396		10.1016/S0140-6736(95)92778-6	http://dx.doi.org/10.1016/S0140-6736(95)92778-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623568				2022-12-28	WOS:A1995RN65600007
J	MARTIN, SJ; GREEN, DR				MARTIN, SJ; GREEN, DR			PROTEASE ACTIVATION DURING APOPTOSIS - DEATH BY 1000 CUTS	CELL			English	Review							CELL-DEATH; GENE CED-3; ENZYME				MARTIN, SJ (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,11149 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Martin, Seamus/0000-0002-8539-3143				CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; COTTER TG, 1992, CANCER RES, V52, P997; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1995, IN PRESS CANCER RES; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; KAMENS J, 1995, IN PRESS J BIOL CHEM; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAYALAR C, 1995, IN PRESS P NATL ACAD; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LAZEBNIK YA, 1995, IN PRESS P NATL ACAD; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V275, P81; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NEAMATI N, 1995, J IMMUNOL, V154, P3788; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WRIGHT SC, 1994, J EXP MED, V180, P2113, DOI 10.1084/jem.180.6.2113; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	1251	1285	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					349	352		10.1016/0092-8674(95)90422-0	http://dx.doi.org/10.1016/0092-8674(95)90422-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634323	Bronze			2022-12-28	WOS:A1995RP24200003
J	LONGO, DR; BROWNSON, RC; KRUSE, RL				LONGO, DR; BROWNSON, RC; KRUSE, RL			SMOKING BANS IN US HOSPITALS - RESULTS OF A NATIONAL SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							WORKSITE; TOBACCO	Objective.-To examine compliance and characteristics of hospitals with tobacco control standards enacted by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Design and Setting.-On-site national survey of hospitals as part of routine JCAHO accreditation visits. Participants.-A total of 3327 US hospitals received site visits in 1992 and 1993 and were matched with American Hospital Association Annual Survey of Hospitals data. Main Outcome Measures.-Compliance or noncompliance with tobacco control standards; location in a tobacco-producing state, and organizational characteristics, including provision of psychiatric/alcohol-chemical dependency services. Results.-Two years after implementation, 95.6% of hospitals met the new JCAHO smoking ban standard; 90.9% of hospitals were in compliance with a second smoking standard requiring development and use of medical criteria for physician-ordered exceptions to the ban. Hospitals in tobacco-producing states had higher-than-average rates of compliance when compared with hospitals in other states. Hospitals providing psychiatric and/or substance abuse services had lower-than-average rates of compliance. Conclusion.-This first industry-wide smoking ban has been successful. However, hospitals should consider evaluating the use of medical exceptions to this policy.	ST LOUIS UNIV,SCH PUBL HLTH,DEPT COMMUNITY HLTH,ST LOUIS,MO 63103	Saint Louis University	LONGO, DR (corresponding author), UNIV MISSOURI,SCH MED,DEPT FAMILY & COMMUNITY MED,MA306 MED SCI BLDG,COLUMBIA,MO 65212, USA.			Kruse, Robin/0000-0001-9759-7218				Beemer B R, 1993, J Psychosoc Nurs Ment Health Serv, V31, P12; BERMAN EJ, 1985, JAMA-J AM MED ASSOC, V254, P3420, DOI 10.1001/jama.1985.03360240032007; BORLAND R, 1991, AUST J PUBLIC HEALTH, V15, P130; BRIGHAM J, 1994, AM J PUBLIC HEALTH, V84, P773, DOI 10.2105/AJPH.84.5.773; BROWNSON RC, IN PRESS TOBACCO CON; Budney A J, 1993, J Subst Abuse, V5, P117, DOI 10.1016/0899-3289(93)90056-H; Burtaine J, 1988, N J Med, V85, P143; Christenson G M, 1988, AAOHN J, V36, P262; DAWLEY HH, 1983, INT J ADDICT, V18, P1033, DOI 10.3109/10826088309033070; GLASGOW RE, 1984, J CONSULT CLIN PSYCH, V52, P137, DOI 10.1037/0022-006X.52.1.137; GOLDSMITH JR, 1993, J SUBST ABUSE TREAT, V10, P107; HO AMH, 1985, JAMA-J AM MED ASSOC, V253, P2999, DOI 10.1001/jama.253.20.2999; KOTTKE TE, 1989, NEW YORK STATE J MED, V89, P38; MEADE TW, 1977, BRIT J PREV SOC MED, V31, P25; NOVOTNY T, 1995, 5TH ANN PREV CTR C A; Stark M J, 1993, J Subst Abuse, V5, P175, DOI 10.1016/0899-3289(93)90060-O; TYE JB, 1989, HOSP HEALTH SERV ADM, V34, P445; 1993, 1992 ANN SURVEY HOSP; 1991, SURVEY TOBACCO USE 1; 1988, HLTH CONSEQUENCES SM; 1986, MMWR-MORBID MORTAL W, V35, P745	21	38	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					488	491		10.1001/jama.274.6.488	http://dx.doi.org/10.1001/jama.274.6.488			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629959				2022-12-28	WOS:A1995RM69900030
J	ARRANZ, M; COLLIER, D; SODHI, M; BALL, D; ROBERTS, G; PRICE, J; SHAM, P; KERWIN, R				ARRANZ, M; COLLIER, D; SODHI, M; BALL, D; ROBERTS, G; PRICE, J; SHAM, P; KERWIN, R			ASSOCIATION BETWEEN CLOZAPINE RESPONSE AND ALLELIC VARIATION IN 5HT(2A) RECEPTOR GENE	LANCET			English	Note								We report allelic association between a polymorphism (T102C) within the coding region of the 5-HT2A gene (HTR2A, 13q14-21) and response to clozapine in schizophrenic patients. Homozygosity for the C102 allele was more frequent (30/57, 53%) among patients who did not respond to clozapine than in those who responded (23/92, 25%). This finding is evidence that allelic variation of genes which encode neurotransmitter receptors can influence clinical response to antipsychotic drugs.	INST PSYCHIAT,NEUROPSYCHOPHARMACOL SECT,LONDON SE5 8AF,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC NEUROPATHOL,HARLOW CM19 5AD,ESSEX,ENGLAND	University of London; King's College London; GlaxoSmithKline	ARRANZ, M (corresponding author), INST PSYCHIAT,MOLEC GENET SECT,LONDON SE5 8AF,ENGLAND.		Price, Jack/G-9510-2011	Sodhi, Monsheel/0000-0002-8261-3040				ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; LEYSEN JE, 1994, J CLIN PSYCHIAT, V55, P5; PILOWSKY LS, 1992, LANCET, V340, P199, DOI 10.1016/0140-6736(92)90467-H; SHAIKH S, 1993, LANCET, V341, P116, DOI 10.1016/0140-6736(93)92594-J; VANTOL HHM, 1992, NATURE, V358, P149; WARREN JT, 1993, HUM MOL GENET, V2, P338, DOI 10.1093/hmg/2.3.338	6	289	302	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					281	282		10.1016/S0140-6736(95)92168-0	http://dx.doi.org/10.1016/S0140-6736(95)92168-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630250				2022-12-28	WOS:A1995RL75700013
J	BAKOULA, CG; KAFRITSA, YJ; KAVADIAS, GD; LAZOPOULOU, DD; THEODORIDOU, MC; MARAVELIAS, KP; MATSANIOTIS, NS				BAKOULA, CG; KAFRITSA, YJ; KAVADIAS, GD; LAZOPOULOU, DD; THEODORIDOU, MC; MARAVELIAS, KP; MATSANIOTIS, NS			OBJECTIVE PASSIVE-SMOKING INDICATORS AND RESPIRATORY MORBIDITY IN YOUNG-CHILDREN	LANCET			English	Note							ENVIRONMENTAL TOBACCO-SMOKE; URINARY COTININE; EXPOSURE	Exposure to environmental tobacco smoke is associated with increased respiratory morbidity in young children, but few studies have assessed such exposure objectively by urinary cotinine measurements. 501 children aged 1-5 years, a random 5% sample of children attending an outpatient clinic, were classified as exposed or nonexposed to environmental tobacco smoke with a cut-off of 10 ng cotinine per mg creatinine in urine. Exposed children were 3.5 times (95% Cl 1.56-7.90, p<0.0024) more likely to have increased respiratory morbidity (three or more episodes during the previous 12 months) than non-exposed children after adjustment for potential confounding factors.	UNIV ATHENS,DEPT PAEDIAT 1,ATHENS,GREECE; UNIV ATHENS,DEPT FORENS MED & TOXICOL,ATHENS,GREECE	National & Kapodistrian University of Athens; National & Kapodistrian University of Athens								CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; DALLAVORGIA P, 1990, SCAND J SOC MED, V18, P81, DOI 10.1177/140349489001800201; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V788, P696; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; MARBURY MC, 1993, AM J EPIDEMIOL, V137, P1089, DOI 10.1093/oxfordjournals.aje.a116612; REESE AC, 1992, AM REV RESPIR DIS, V146, P66, DOI 10.1164/ajrccm/146.1.66; RICHARDSON MA, 1988, J ALLERGY CLIN IMMUN, V81, P1032, DOI 10.1016/0091-6749(88)90175-3; RUBIN DH, 1988, YALE J BIOL MED, V61, P401; STRACHAN DP, 1990, AM REV RESPIR DIS, V142, P147, DOI 10.1164/ajrccm/142.1.147; WALD NJ, 1984, LANCET, V1, P230	10	46	50	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					280	281		10.1016/S0140-6736(95)92167-2	http://dx.doi.org/10.1016/S0140-6736(95)92167-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL757	7630249				2022-12-28	WOS:A1995RL75700012
J	LIFSON, AR				LIFSON, AR			PREVENTING AIDS - HAVE WE LOST OUR WAY	LANCET			English	Editorial Material							PROPHYLAXIS				LIFSON, AR (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455, USA.							[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P655; FIELDS BN, 1994, NATURE, V369, P95, DOI 10.1038/369095a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; LIFSON AR, 1995, ANN INTERN MED, V122, P262, DOI 10.7326/0003-4819-122-4-199502150-00004; LIFSON AR, 1994, LANCET, V343, P1306, DOI 10.1016/S0140-6736(94)92462-7; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; QUAGLIARELLO VJ, 1995, LANCET, V345, P548, DOI 10.1016/S0140-6736(95)90465-4; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; 1995, WKLY EPIDEMIOL REC, V70, P5; 1993, MMWR-MORBID MORTAL W, V42, P1; 1992, MMWR-MORBID MORTAL W, V41, P1	15	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					262	263		10.1016/S0140-6736(95)92160-5	http://dx.doi.org/10.1016/S0140-6736(95)92160-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630242				2022-12-28	WOS:A1995RL75700005
J	HELD, W; ROLAND, J; RAULET, DH				HELD, W; ROLAND, J; RAULET, DH			ALLELIC EXCLUSION OF LY49-FAMILY GENES ENCODING CLASS-I MHC-SPECIFIC RECEPTORS ON NK CELLS	NATURE			English	Article							NATURAL-KILLER-CELLS; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEINS; MULTIGENE FAMILY; ANTIGEN; LY-49; IDENTIFICATION; COMPLEX; CLONING; NKR-P1	AN important feature of natural killer (NK) cell activity is the lysis of cells that have extinguished expression of some or all class I major histocompatibility (MHC) molecules(1-7). Accordingly, the Ly49A NK-cell antigen receptor has been shown to deliver an inhibitory signal to NK cells on encounter with D-d or D-k class I MHC on target cells(4). Ly49A belongs to a family of eight or more highly related, tightly linked genes(2,8-10). Expression of Ly49A and Ly49C, another member of the Ly49 family with distinct MHC specificity, define subpopulations of NK cells that are only partly overlapping(10-12). The mechanisms regulating the expression of Ly49 family members are unknown. We show here that the Ly49A and Ly49C NK-cell receptors are each subject to allelic exclusion. Because Ly49 genes are not thought to undergo DNA rearrangement(13,14), allelic exclusion of Ly49 genes could involve a mechanism distinct from that used by B and T lymphocytes(15,16) and is likely to play an important role in the genesis of a putative NK-cell repertoire specific for class I molecules.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; INST PASTEUR,DEPT IMMUNOL,F-75724 PARIS,FRANCE	University of California System; University of California Berkeley; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HELD, W (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Raulet, David/0000-0002-1257-8649				BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; Casanova J L, 1993, Methods Mol Biol, V23, P191; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAN PY, 1989, J IMMUNOL, V142, P1727; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CORREA I, 1994, EUR J IMMUNOL, V24, P1323, DOI 10.1002/eji.1830240613; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; KARLHOFER FM, 1994, J IMMUNOL, V153, P2407; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; NAGASAWA R, 1987, J IMMUNOL, V138, P815; RAULET D, IN PRESS SEMIN IMMUN, V7; RAULET DH, 1980, J IMMUNOL, V125, P1136; ROLAND J, 1992, INT IMMUNOL, V4, P699, DOI 10.1093/intimm/4.6.699; SENTMAN CL, 1989, J EXP MED, V170, P191, DOI 10.1084/jem.170.1.191; SMITH HRC, 1994, J IMMUNOL, V153, P1068; STONEMAN E, 1993, J IMMUNOL, V150, pA1465; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TAKEI F, 1983, J IMMUNOL, V130, P2794; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; WONG S, 1991, J IMMUNOL, V147, P1417; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	30	175	176	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					355	358		10.1038/376355a0	http://dx.doi.org/10.1038/376355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630404				2022-12-28	WOS:A1995RL44300051
J	GUO, WW; MASON, JS; STONE, CG; MORGAN, SA; MADU, SI; BALDINI, A; LINDSAY, EA; BIESECKER, LG; COPELAND, KC; HORLICK, MNB; PETTIGREW, AL; ZANARIA, E; MCCABE, ERB				GUO, WW; MASON, JS; STONE, CG; MORGAN, SA; MADU, SI; BALDINI, A; LINDSAY, EA; BIESECKER, LG; COPELAND, KC; HORLICK, MNB; PETTIGREW, AL; ZANARIA, E; MCCABE, ERB			DIAGNOSIS OF X-LINKED ADRENAL HYPOPLASIA CONGENITA BY MUTATION ANALYSIS OF THE DAX1 GENE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLYCEROL KINASE-DEFICIENCY; HYPOGONADOTROPIC HYPOGONADISM; XP21; SEQUENCES; DELETION; DISTAL; REGION; LOCI	Objective.-To develop a rapid diagnostic approach to individuals with the X-linked cytomegalic form of adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism (HH) due to mutations in DAX1, a new member of the nuclear hormone receptor gene superfamily. Design.-Molecular genetic diagnostic investigations of individuals with AHC and their relatives included polymerase chain reaction amplification of DAX1 for identification of intragenic mutations and fluorescence in situ hybridization with a cosmid containing the DAX1 gene for evaluation of larger deletions. Participants.-Families that had males affected with AHC were evaluated for mutations involving the DAX1 gene. Results.-DAX1 mutations were identified in four families that had males affected with AHC. Two apparently independent pedigrees had an identical frameshift mutation due to a single base pair deletion, and a third had a larger deletion involving the entire DAX1 locus, The fourth family was evaluated by fluorescence in situ hybridization for prenatal diagnosis, and both the DAX1 locus and the contiguous glycerol kinase region were deleted. Conclusions.-Molecular genetic and molecular cytogenetic techniques represent rapid and complementary approaches to the diagnosis of mutations in the DAX1 gene responsible for AHC and the associated HH. Specific diagnosis of the cause of adrenal insufficiency in these boys permits anticipatory management of the HH and prenatal counseling for parents of the affected child and other members of their families.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; NIH,CTR HUMAN GENOME RES,BETHESDA,MD 20892; ST LUKES ROOSEVELT HOSP,DEPT PEDIAT,NEW YORK,NY; UNIV KENTUCKY,SCH MED,DEPT PATHOL,LEXINGTON,KY 40536; UNIV PAVIA,DEPT HUMAN PATHOL,I-27100 PAVIA,ITALY	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; Mount Sinai St. Luke's; Mount Sinai West; University of Kentucky; University of Pavia			genes, anthony/F-2541-2012; Biesecker, Leslie/AAG-2526-2021; Baldini, Antonio/M-2355-2015	Baldini, Antonio/0000-0002-5330-0256	NICHD NIH HHS [P30 HD27823, P30 HD24064, R01 HD22563] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022563, P30HD027823] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BATCH JA, 1991, J PAEDIATR CHILD H, V27, P108, DOI 10.1111/j.1440-1754.1991.tb00363.x; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; ELLISON KA, 1993, AM J MED GENET, V47, P1124, DOI 10.1002/ajmg.1320470736; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOLDEN MP, 1977, AM J DIS CHILD, V131, P1117, DOI 10.1001/archpedi.1977.02120230063010; GOONEWARDENA P, 1989, CLIN GENET, V35, P5; GUO WW, 1993, NAT GENET, V4, P367, DOI 10.1038/ng0893-367; HAY ID, 1981, ARCH DIS CHILD, V56, P715, DOI 10.1136/adc.56.9.715; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAVERTY CRA, 1973, OBSTET GYNECOL, V41, P655; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Martin M.M., 1985, INT J ADOLESC MED HL, V1, P119; MATSUMOTO T, 1988, AM J MED GENET, V31, P603, DOI 10.1002/ajmg.1320310315; McCabe ER, 1995, METABOLIC BASIS INHE, P1631; McKusick V.A., 1992, MENDELIAN INHERITANC; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; PARTSCH CJ, 1989, HORM METAB RES, V21, P623, DOI 10.1055/s-2007-1009303; RICHARDS B, 1991, NUCLEIC ACIDS RES, V19, P1944, DOI 10.1093/nar/19.8.1944; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WORLEY KC, 1992, GENOMICS, V13, P957, DOI 10.1016/0888-7543(92)90007-F; WORLEY KC, 1995, AM J MED GENET, V57, P615, DOI 10.1002/ajmg.1320570420; WORLEY KC, 1993, GENOMICS, V16, P407, DOI 10.1006/geno.1993.1204; YATES JRW, 1987, CYTOGENET CELL GENET, V46, P723; ZACHMANN M, 1980, J PEDIATR-US, V97, P255, DOI 10.1016/S0022-3476(80)80486-0; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	26	85	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					324	330		10.1001/jama.274.4.324	http://dx.doi.org/10.1001/jama.274.4.324			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609262				2022-12-28	WOS:A1995RJ89800035
J	BURTSCHER, M; LIKAR, R; NACHBAUER, W; SCHAFFERT, W; PHILADELPHY, M				BURTSCHER, M; LIKAR, R; NACHBAUER, W; SCHAFFERT, W; PHILADELPHY, M			IBUPROFEN VERSUS SUMATRIPTAN FOR HIGH-ALTITUDE HEADACHE	LANCET			English	Letter											BURTSCHER, M (corresponding author), UNIV INNSBRUCK, DEPT SPORT SCI, A-6020 INNSBRUCK, AUSTRIA.		Burtscher, Martin/M-7015-2019	Burtscher, Martin/0000-0002-5232-3632				BARTSCH P, 1994, LANCET, V344, P1445, DOI 10.1016/S0140-6736(94)90617-3; BROOME JR, 1994, AVIAT SPACE ENVIR MD, V65, P19; KAUBE H, 1993, BRIT J PHARMACOL, V109, P788, DOI 10.1111/j.1476-5381.1993.tb13643.x; OLESEN J, 1994, NEW ENGL J MED, V331, P1713, DOI 10.1056/NEJM199412223312510; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272	5	30	30	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 22	1995	346	8969					254	255		10.1016/S0140-6736(95)91303-3	http://dx.doi.org/10.1016/S0140-6736(95)91303-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616830				2022-12-28	WOS:A1995RK41900057
J	NICHOLSON, KEA; ROGERS, JEG				NICHOLSON, KEA; ROGERS, JEG			LESSON OF THE WEEK - COCAINE AND ADRENALINE PASTE - A FATAL COMBINATION	BRITISH MEDICAL JOURNAL			English	Article							ABSORPTION		NORFOLK & NORWICH HOSP,DEPT ANAESTHESIA,NORWICH NR1 3SR,NORFOLK,ENGLAND; ADDENBROOKES HOSP,DEPT ANAESTHESIA,CAMBRIDGE CB2 2QQ,ENGLAND	Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Addenbrooke's Hospital; University of Cambridge								ADRIANI J, 1964, JAMA-J AM MED ASSOC, V188, P711; BROMLEY L, 1988, ANAESTHESIA, V43, P356, DOI 10.1111/j.1365-2044.1988.tb09011.x; FEEHAN HF, 1976, PLAST RECONSTR SURG, V57, P62, DOI 10.1097/00006534-197601000-00012; FLEMING JA, 1990, ANESTHESIOLOGY, V73, P518; JOHNS ME, 1977, T AM ACAD OPHTHALMOL, V84, P969; LIPS FJ, 1987, ANAESTH INTENS CARE, V15, P141, DOI 10.1177/0310057X8701500204; PFLEIDERER AG, 1988, CLIN OTOLARYNGOL, V13, P421, DOI 10.1111/j.1365-2273.1988.tb00315.x; Reynolds J.E.F., 1993, MARTINDALE THE EXTRA; 1994, BMA RPS27 BRIT MED A, P485	9	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					250	251		10.1136/bmj.311.6999.250	http://dx.doi.org/10.1136/bmj.311.6999.250			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627047	Green Published			2022-12-28	WOS:A1995RL44100031
J	ROWLAND, D				ROWLAND, D			MEDICAID AT 30 - NEW CHALLENGES FOR THE NATIONS HEALTH-SAFETY NET	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ROWLAND, D (corresponding author), HENRY J KAISER FAMILY FDN,1450 G ST NW,SUITE 250,WASHINGTON,DC 20005, USA.							HOLAHAN J, 1995, CHANGING COMPOSITION; HOLAHAN J, 1995, IMPACT SENATE HOUSE; KU L, 1994, MEDICAID DISPROPORTI; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; ROGERS DE, 1982, NEW ENGL J MED, V307, P13, DOI 10.1056/NEJM198207013070103; ROWLAND D, 1992, MEDICAID CROSSROADS; ROWLAND D, 1995, MEDICAID MANAGED CAR; ROWLAND D, 1995, COMMUNICATION   0315; 1994, 1993 STATE EXPENDITU; 1995, MEDICAID FEDERAL STA; 1995, BUDGET RESOLUTIONS; 1995, HLTH NEEDS MEDICAID; 1995, SOURCES HLTH INSURAN; 1994, MEDICAID MANAGED CAR; 1995, KAISER COMMISSION UP; 1995, PRIMER FEDERAL BUDGE; 1995, MEDICAID SPENDING PR	17	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					271	273		10.1001/jama.274.3.271	http://dx.doi.org/10.1001/jama.274.3.271			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609240				2022-12-28	WOS:A1995RH93700037
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - CHOOSING AND INSTALLING SOFTWARE	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,LONDON,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND	Brunel University; Imperial College London; Gloucestershire Royal Hospital	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					179	182		10.1136/bmj.311.6998.179	http://dx.doi.org/10.1136/bmj.311.6998.179			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613434	Green Published			2022-12-28	WOS:A1995RK15900028
J	BAI, YW; SOSNICK, TR; MAYNE, L; ENGLANDER, SW				BAI, YW; SOSNICK, TR; MAYNE, L; ENGLANDER, SW			PROTEIN-FOLDING INTERMEDIATES - NATIVE-STATE HYDROGEN-EXCHANGE	SCIENCE			English	Article							CYTOCHROME-C; GUANIDINIUM CHLORIDE; FERROCYTOCHROME-C; FREE-ENERGY; HEMOGLOBIN; RESOLUTION; FRAGMENT; COMPLEX; MODEL; CORE	The hydrogen exchange behavior of native cytochrome c in low concentrations of denaturant reveals a sequence of metastable, partially unfolded forms that occupy free energy levels reaching up to the fully unfolded state. The step from one form to another is accomplished by the unfolding of one or more cooperative units of structure. The cooperative units are entire omega loops or mutually stabilizing pairs of whole helices and loops. The partially unfolded forms detected by hydrogen exchange appear to represent the major intermediates in the reversible, dynamic unfolding reactions that occur even at native conditions and thus may define the major pathway for cytochrome c folding.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104	University of Pennsylvania			Freed, Karl F/J-7764-2018	Freed, Karl F/0000-0001-6240-2599	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31847, R01 GM031847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI Y, 1994, THESIS U PENNSYLVANI; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAI YW, 1994, PROTEINS, V20, P4, DOI 10.1002/prot.340200103; BREMS DN, 1983, J BIOL CHEM, V258, P3655; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P10271; ENGLANDER SW, 1992, SCIENCE, V256, P1684, DOI 10.1126/science.256.5064.1684; ENGLANDER SW, 1975, ANN NY ACAD SCI, V244, P10, DOI 10.1111/j.1749-6632.1975.tb41518.x; ENGLANDER SW, 1984, Q REV BIOPHYS, V15, P521; FERSHT AR, 1994, CURR OPIN STRUC BIOL, V4, P67, DOI 10.1016/S0959-440X(94)90061-2; FISHER A, 1992, ARCH BIOCHEM BIOPHYS, V296, P1, DOI 10.1016/0003-9861(92)90538-8; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; JENG MF, 1992, J MOL BIOL, V221, P1045; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9609, DOI 10.1021/bi00088a013; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA Y, 1993, BIOCHEMISTRY-US, V32, P1219, DOI 10.1021/bi00056a004; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LINDERSTROMLANG KU, 1955, CHEM SOC SPEC PUBL, V2, P1; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MAYO SL, 1993, SCIENCE, V262, P873, DOI 10.1126/science.8235609; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; NALL BT, 1986, BIOCHEMISTRY-US, V25, P2974, DOI 10.1021/bi00358a036; Pace C N, 1986, Methods Enzymol, V131, P266; PTITSYN OB, 1975, BIOPHYS CHEM, V3, P1, DOI 10.1016/0301-4622(75)80033-0; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; QIAN H, 1994, BIOCHEMISTRY-US, V33, P8167, DOI 10.1021/bi00193a001; RIDGE JA, 1981, BIOCHEMISTRY-US, V20, P1662; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROSENBERG A, 1968, J BIOL CHEM, V243, P5193; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; Schechter E, 1967, BIOPOLYMERS, V5, P788; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WAND AJ, 1989, BIOCHEMISTRY-US, V28, P186, DOI 10.1021/bi00427a026; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; WOODWARD C, 1993, TRENDS BIOCHEM SCI, V18, P359, DOI 10.1016/0968-0004(93)90086-3; WU LC, 1993, BIOCHEMISTRY-US, V32, P10271, DOI 10.1021/bi00089a050	43	1000	1009	4	85	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					192	197		10.1126/science.7618079	http://dx.doi.org/10.1126/science.7618079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618079	Green Accepted			2022-12-28	WOS:A1995RJ02900030
J	BENNICKE, K; CONRAD, C; SABROE, S; SORENSEN, HT				BENNICKE, K; CONRAD, C; SABROE, S; SORENSEN, HT			CIGARETTE-SMOKING AND BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate cigarette smoking in relation to the risk of breast cancer. Design-interviews with women referred for mammography. Setting-Hjorring District Hospital, a public, population based hospital in Denmark. Subjects-3240 women aged 15-99 years referred for mammography during 1 June 1989 to 1 November 1991. Main outcome measures-Smoking, parity, age, reason for referral, breast cancer. Results-In a multiple logistic regression analysis adjusted for six variables a pronounced increased risk of breast cancer was found in women who had smoked for over 20 years, and this was significant in women who had smoked for over 30 years (odds ratio 1.6, 95% confidence interval 1.1 to 2.3). The median age of women with breast cancer was 59 (range 31-81) years for smokers and 67 (38-92) years for nonsmokers. The difference of eight years between the median ages was significant (P<0.01). Conclusion-Smoking may increase the risk of breast cancer after 30 years of smoking.	HJORRING DIST HOSP,DEPT RADIOL,DK-9800 HJORRING,DENMARK; AARHUS UNIV,DEPT EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,STENO INST PUBL HLTH,DANISH EPIDEMIOL SCI CTR,AARHUS,DENMARK	Aarhus University; Aarhus University			Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040				BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; HIATT RA, 1986, JNCI-J NATL CANCER I, V76, P833; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KRALL EA, 1989, AM J PUBLIC HEALTH, V79, P200, DOI 10.2105/AJPH.79.2.200; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; Osler M, 1992, DANSKERNES RYGEVANER; PALMER JR, 1993, EPIDEMIOL REV, V5, P145; PETRAKIS NL, 1980, CANCER RES, V40, P188; ROTH HD, 1994, J CLIN EPIDEMIOL, V47, P207, DOI 10.1016/0895-4356(94)90026-4; VOGT TM, 1977, AM J PUBLIC HEALTH, V67, P545, DOI 10.2105/AJPH.67.6.545	12	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1431	1433		10.1136/bmj.310.6992.1431	http://dx.doi.org/10.1136/bmj.310.6992.1431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613275	Green Published			2022-12-28	WOS:A1995RC10500015
J	WILLIAMS, C				WILLIAMS, C			HEALTHY EATING - CLARIFYING ADVICE ABOUT FRUIT AND VEGETABLES	BRITISH MEDICAL JOURNAL			English	Article								Consumers need health information which is clear and unambiguous. Advice to ''eat more fruit and vegetables'' gives consumers no guidance on the quantities involved. Popular advice is to eat ''five portions a day.'' This paper provides a rationale for determining which foods are included within this advice-for example, processed foods such as baked beans are but potatoes and nuts should not be. It also describes how much of the most commonly consumed fruit and vegetables constitutes a ''portion.'' A bowlful of salad, for example, is needed to make up a portion but an apple or banana on its own will count.			WILLIAMS, C (corresponding author), LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HUMAN NUTR UNIT,LONDON WC1H 0BT,ENGLAND.							ANDERSON A, 1993, WORKING PAPER SERIES, V931; DOMEL SB, 1993, J NUTR EDUC, V25, P352; Gregory F., 1990, DIETARY NUTR SURVEY; MARSHALL J, 1992, EAT LIFE DIET; SAINSBURY J, 1994, TAKE 5 HLTH EATING F; 1993, FOOD PORTION SIZES; 1991, WHICH WAY HLTH   APR, P48; 1994, KEY HLTH EAT 5 FRUIT; 1994, 46 DEP HLTH REP HLTH; 1990, WHO TECHNICAL REPORT, V797; 1994, DIETARY NUTRITIONAL; 1994, HLTH NATION; 1991, EAT WELL LIVE WELL; 1992, FOOD GUIDE PYRAMID B; 1993, SCOTTISH DIET SCOTLA; 1994, BALANCE GOOD HLTH IN; 1994, 5 DAY BETTER HLTH; 1991, WHICH, V1, P224; 1994, HOUSEHOLD FOOD CONSU; 1994, FRESH IS BEAUTIFUL; 1992, MCCANCE WIDDOWSONS C	21	104	105	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1453	1455		10.1136/bmj.310.6992.1453	http://dx.doi.org/10.1136/bmj.310.6992.1453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613282	Green Published			2022-12-28	WOS:A1995RC10500028
J	LACHS, MS; PILLEMER, K				LACHS, MS; PILLEMER, K			CURRENT CONCEPTS - ABUSE AND NEGLECT OF ELDERLY PERSONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VIOLENCE; PREVALENCE; EMERGENCY; HOME		CORNELL UNIV, DEPT HUMAN DEV & FAMILY STUDIES, ITHACA, NY 14853 USA	Cornell University	LACHS, MS (corresponding author), CORNELL UNIV, MED CTR,NEW YORK HOSP,DEPT MED, DIV GEN INTERNAL MED,GERIATR UNIT, 515 E 71ST ST, NEW YORK, NY 10021 USA.			Pillemer, Karl/0000-0002-7700-3563	NIMH NIH HHS [1 R01 MH2613] Funding Source: Medline; PHS HHS [1 K0800580] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMMERMAN RT, 1990, TREATMENT FAMILY VIO; BLAKELY BE, 1991, J GERONTOL SOC WORK, V17, P183, DOI 10.1300/J083v17n01_14; Block M., 1979, BATTERED ELDER SYNDR; BRISTOWE E, 1989, J ELDER ABUSE NEGL, V1, P45; BURSTON GR, 1975, BRIT MED J, V3, P592, DOI 10.1136/bmj.3.5983.592-a; CLARKDANIELS CL, 1990, ANN EMERG MED, V19, P970, DOI 10.1016/S0196-0644(05)82556-9; COYNE AC, 1993, AM J PSYCHIAT, V150, P643; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fulmer Terry T., 1987, INADEQUATE CARE ELDE; GIOGLIO GR, 1983, ELDER ABUSE NEW JERS; Heisler C. J., 1991, J ELDER ABUSE NEGL, V3, P23; HOMER AC, 1990, BRIT MED J, V301, P1359, DOI 10.1136/bmj.301.6765.1359; JOHNSON TF, 1991, ELDER MISTREATMENT D; JONES J, 1988, ANN EMERG MED, V17, P1006, DOI 10.1016/S0196-0644(88)80436-0; JONES JS, 1990, GERIATRIC EMERGENCY, P533; KANE RS, 1991, AM J MED, V90, P263; LACHS MS, 1994, J AM GERIATR SOC, V42, P169, DOI 10.1111/j.1532-5415.1994.tb04947.x; LAU EE, 1979, AGING, V299, P10; MOON A, 1993, GERONTOLOGIST, V33, P386, DOI 10.1093/geront/33.3.386; OGG J, 1992, BRIT MED J, V305, P998, DOI 10.1136/bmj.305.6860.998; OMalley H., 1981, ELDER ABUSE MASSACHU; OMALLEY TA, 1984, J AM GERIATR SOC, V32, P362, DOI 10.1111/j.1532-5415.1984.tb02041.x; OMALLEY TA, 1983, ANN INTERN MED, V98, P998, DOI 10.7326/0003-4819-98-6-998; PAVEZA GJ, 1992, GERONTOLOGIST, V32, P493, DOI 10.1093/geront/32.4.493; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PHILLIPS LR, 1983, J ADV NURS, V8, P379, DOI 10.1111/j.1365-2648.1983.tb00461.x; PILLEMER K, 1992, J GERONTOL, V47, pS165, DOI 10.1093/geronj/47.4.S165; PILLEMER K, 1989, GERONTOLOGIST, V29, P314, DOI 10.1093/geront/29.3.314; PILLEMER K, 1988, GERONTOLOGIST, V28, P51, DOI 10.1093/geront/28.1.51; PILLEMER K, 1985, SOC PROBL, V33, P148; PILLEMER K, 1989, AM J ORTHOPSYCHIAT, V59, P179, DOI 10.1111/j.1939-0025.1989.tb01649.x; PILLEMER K, 1986, ELDER ABUSE CONFLICT, P236; Podnieks E., 1992, J ELDER ABUSE NEGL, V4, P5, DOI [DOI 10.1300/J084V04N01_02, 10.1300/j084v04n01_02]; Quinn M. J., 1986, ELDER ABUSE NEGLECT; Rathbone-McCuan E., 1992, SELF NEGLECTING ELDE; SALEND E, 1984, GERONTOLOGIST, V24, P61, DOI 10.1093/geront/24.1.61; Stark E., 1988, HDB FAMILY VIOLENCE, P293; STEINMETZ SK, 1987, HDB MARRIAGE FAMILY, P725; STEUER J, 1980, J AM GERIATR SOC, V28, P372, DOI 10.1111/j.1532-5415.1980.tb01101.x; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; TATARA T, 1993, J ELDER ABUSE NEGL, V5, P35, DOI DOI 10.1300/J084V05N04_04; WATSON MM, 1993, J ELDER ABUSE NEGL, V5, P95; Wolf R. S., 1990, TREATMENT FAMILY VIO, P310; WOLF RS, 1988, J AM GERIATR SOC, V36, P758, DOI 10.1111/j.1532-5415.1988.tb07187.x; WOLF RS, 1989, HELPING ELDERLY VICT; 1991, HRD9174 GEN ACC OFF; 1988, ELDER MISTREATMENT G; 1991, ELDER ABUSE WHAT CAN; 1992, AM MED ASS DIAGNOSTI	50	225	233	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					437	443		10.1056/NEJM199502163320706	http://dx.doi.org/10.1056/NEJM199502163320706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF770	7632211				2022-12-28	WOS:A1995QF77000006
J	BELLET, PS; KALINYAK, KA; SHUKLA, R; GELFAND, MJ; RUCKNAGEL, DL				BELLET, PS; KALINYAK, KA; SHUKLA, R; GELFAND, MJ; RUCKNAGEL, DL			INCENTIVE SPIROMETRY TO PREVENT ACUTE PULMONARY COMPLICATIONS IN SICKLE-CELL DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CHEST SYNDROME; LUNG-DISEASE; ANEMIA; INFARCTION; CHILDREN; ADULTS	Background. This study was designed to determine the incidence of thoracic bone infarction in patients with sickle cell diseases who were hospitalized with acute chest or back pain above the diaphragm and to test the hypothesis that incentive spirometry can decrease the incidence of atelectasis and pulmonary infiltrates. Methods. We conducted a prospective, randomized trial in 29 patients between 8 and 21 years of age with sickle cell diseases who had 38 episodes of acute chest or back pain above the diaphragm and were hospitalized. Each episode of pain was considered to be an independent event. At each hospitalization, patients with normal or unchanged chest radiographs on admission were randomly assigned to treatment with spirometry or to a control nonspirometry group. Each patient in the spirometry group took 10 maximal inspirations using an incentive spirometer every two hours between 8 a.m. and 10 p.m. and while awake during the night until the chest pain subsided. A second radiograph was obtained three or more days after admission, or sooner if clinically necessary, to determine the incidence of pulmonary complications. Bone scanning was performed no sooner than two days after hospital admission to determine the incidence of thoracic bone infarction. Results. The incidence of thoracic bone infarction was 39.5 percent (15 of 38 hospitalizations). Pulmonary complications (atelectasis or infiltrates) developed during only 1 of 19 hospitalizations of patients assigned to the spirometry group, as compared with 8 of 19 hospitalizations of patients in the nonspirometry group (P = 0.019). Among patients with thoracic bone infarction, no pulmonary complications developed in those assigned to the spirometry group during a total of seven hospitalizations, whereas they developed during five of eight hospitalizations in the nonspirometry group (P = 0.025). Conclusions. Thoracic bone infarction is common in patients with sickle cell diseases who are hospitalized with acute chest pain, Incentive spirometry can prevent the pulmonary complications (atelectasis and infiltrates) associated with the acute chest syndrome in patients with sickle cell diseases who are hospitalized with chest or back pain above the diaphragm.	CHILDRENS HOSP,MED CTR,DIV GEN PEDIAT,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,DIV HEMATOL ONCOL,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,CINCINNATI COMPREHENS SICKLE CELL CTR,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,DEPT RADIOL,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT ENVIRONM HLTH,DIV BIOSTATE & EPIDEMIOL,CINCINNATI,OH 45267	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015996] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 P60 HL 15996] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLAS SK, 1991, J NUCL MED, V32, P1617; BARRETTCONNOR E, 1971, AM REV RESPIR DIS, V104, P159; BENDIXEN HH, 1964, ANESTHESIOLOGY, V25, P297, DOI 10.1097/00000542-196405000-00006; BENDIXEN HH, 1964, J APPL PHYSIOL, V19, P195, DOI 10.1152/jappl.1964.19.2.195; BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495-199039010-00008; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1979, ARCH INTERN MED, V139, P67, DOI 10.1001/archinte.139.1.67; CHARACHE S, 1991, DHHS NIH912117 PUBL, P20; CRAVEN JL, 1974, BRIT J SURG, V61, P793, DOI 10.1002/bjs.1800611012; DAVIES SC, 1984, LANCET, V1, P36; DOHI S, 1978, CHEST, V73, P592, DOI 10.1378/chest.73.5.592; FABRY ME, 1989, P NATL ACAD SCI USA, V86, P3808, DOI 10.1073/pnas.86.10.3808; GELFAND MJ, 1993, J NUCL MED, V34, P614; HARCKE HT, 1981, J NUCL MED, V22, P322; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; KRASTINS IRB, 1982, CRIT CARE MED, V10, P525, DOI 10.1097/00003246-198208000-00009; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MILLER ST, 1991, J PEDIATR-US, V118, P30, DOI 10.1016/S0022-3476(05)81839-6; MORRIS CL, 1993, BLOOD, V81, P3138; Olin BR, 1995, DRUG FACTS COMPARISO, P242; Palmer J, 1983, BLOOD, V62, p59a; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; PLATT OS, 1993, HEMATOLOGY INFANCY C, V1, P732; PONCZ M, 1985, J PEDIATR-US, V107, P861, DOI 10.1016/S0022-3476(85)80176-1; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; RUCKNAGEL DL, 1991, LANCET, V337, P831, DOI 10.1016/0140-6736(91)92525-7; RUPPEL G, 1994, MANUAL PULMONARY FUN; Sain A, 1978, Clin Nucl Med, V3, P85, DOI 10.1097/00003072-197803000-00003; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; VICHINSKY E, 1994, BLOOD, V83, P3107; WEIL JV, 1993, AM REV RESPIR DIS, V148, P249, DOI 10.1164/ajrccm/148.1.249	33	171	173	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					699	703		10.1056/NEJM199509143331104	http://dx.doi.org/10.1056/NEJM199509143331104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637747				2022-12-28	WOS:A1995RV22700004
J	VOLPICELLI, JR				VOLPICELLI, JR			NALTREXONE IN ALCOHOL DEPENDENCE	LANCET			English	Editorial Material							DISULFIRAM; THERAPY		VET ADM MED CTR,PHILADELPHIA,PA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	VOLPICELLI, JR (corresponding author), UNIV PENN,DEPT PSYCHIAT,PHILADELPHIA,PA 19104, USA.							ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X; AZRIN NH, 1982, J BEHAV THER EXP PSY, V13, P105, DOI 10.1016/0005-7916(82)90050-7; DORUS W, 1989, JAMA-J AM MED ASSOC, V232, P1646; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391; NATHAN P E, 1986, Annals of Behavioral Medicine, V8, P40; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; ULM RR, IN PRESS J CLIN PSYC; VOLPICELLI JR, 1986, LIFE SCI, V38, P841, DOI 10.1016/0024-3205(86)90601-6; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, IN PRESS AM J PSYCHI	11	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					456	456		10.1016/S0140-6736(95)91316-5	http://dx.doi.org/10.1016/S0140-6736(95)91316-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637475	hybrid			2022-12-28	WOS:A1995RP85700004
J	KINLOCHDELOES, S; HIRSCHEL, BJ; HOEN, B; COOPER, DA; TINDALL, B; CARR, A; SAURAT, JH; CLUMECK, N; LAZZARIN, A; MATHIESEN, L; RAFFI, F; ANTUNES, F; VONOVERBECK, J; LUTHY, R; GLAUSER, M; HAWKINS, D; BAUMBERGER, C; YERLY, S; PERNEGER, TV; PERRIN, L				KINLOCHDELOES, S; HIRSCHEL, BJ; HOEN, B; COOPER, DA; TINDALL, B; CARR, A; SAURAT, JH; CLUMECK, N; LAZZARIN, A; MATHIESEN, L; RAFFI, F; ANTUNES, F; VONOVERBECK, J; LUTHY, R; GLAUSER, M; HAWKINS, D; BAUMBERGER, C; YERLY, S; PERNEGER, TV; PERRIN, L			A CONTROLLED TRIAL OF ZIDOVUDINE IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY HIV-1 INFECTION; CUBIC MILLIMETER; TYPE-1 INFECTION; DISEASE; AIDS; PROGRESSION; THERAPY; PLASMA; STAGE; AZT	Background. It is possible that antiretroviral treatment given early during primary infection with the human immunodeficiency virus (HIV) may reduce acute symptoms, help preserve immune function, and improve the long-term prognosis. Methods. To assess the effect of early antiviral treatment, we conducted a multicenter, double-blind, placebo-controlled trial in which 77 patients with primary HIV infection were randomly assigned to receive either zidovudine (250 mg twice daily; n = 39) or placebo (n = 38) for six months. Results. The mean time from the onset of symptoms until enrollment in the study was 25.1 days. Among the 43 patients who were still symptomatic at the time of enrollment, there was no appreciable difference in the mean (+/-SE) duration of the retroviral syndrome between the zidovudine group (15.0+/-4.1 days) and the placebo group (15.8+/-3.6 days). During a mean follow-up period of 15 months, minor opportunistic infections developed in eight patients: oral candidiasis in four, herpes tester in two, and oral hairy leukoplakia in two. Disease progression was significantly less frequent in the zidovudine group (one opportunistic infection) than in the placebo group (seven opportunistic infections; P = 0.009 by the log-rank test). After adjustment for the base-line CD4 cell count, the patients treated with zidovudine had an average gain of 8.9 CD4 cells per cubic millimeter per month (95 percent confidence interval, -1.4 to 19.1) during the first six months of the study, whereas those receiving placebo had an average loss of 12.0 CD4 cells per cubic millimeter per month (95 percent confidence interval, 5.2 to 18.7), for a between-group difference of 20.9 CD4 cells per cubic millimeter per month (95 percent confidence interval, 8.5 to 33.2; P = 0.001). Conclusions. Antiretroviral therapy administered during primary HIV infection may improve the subsequent clinical course and increase the CD4 cell count.	UNIV HOSP GENEVA,CENT LAB VIROL,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,CTR AIDS,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,DEPT DERMATOL,DIV INFECT DIS,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,INST SOCIAL & PREVENT MED,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP NANCY,DEPT INFECT DIS,NANCY,FRANCE; ST VINCENTS HOSP,HIV MED UNIT,SYDNEY,NSW,AUSTRALIA; UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW,AUSTRALIA; ST PIERRE HOSP,DEPT INFECT DIS,BRUSSELS,BELGIUM; HOSP SAN RAFFAELE,MILAN,ITALY; HVIDOVRE UNIV HOSP,DEPT INFECT DIS,HVIDOVRE,DENMARK; HOP HOTEL DIEU,DEPT INTERNAL MED,NANTES,FRANCE; HOSP SANTA MARIA,DEPT INFECT DIS,LISBON,PORTUGAL; BERN MED POLIKLIN,BERN,SWITZERLAND; UNIV ZURICH HOSP,DIV INFECT DIS,ZURICH,SWITZERLAND; UNIV LAUSANNE HOSP,DIV INFECT DIS,LAUSANNE,SWITZERLAND; CHELSEA & WESTMINSTER HOSP,DEPT GENITOURINARY & HIV MED,ST STEPHENS CLIN,LONDON,ENGLAND	University of Geneva; University of Geneva; University of Geneva; University of Geneva; CHU de Nancy; Universite de Lorraine; St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Copenhagen; Nantes Universite; CHU de Nantes; Universidade de Lisboa; Hospital Santa Maria; University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Imperial College London			; LAZZARIN, Adriano/K-3607-2018	Antunes, Francisco/0000-0001-7932-1154; LAZZARIN, Adriano/0000-0003-2551-7754	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAGE P, 1987, STATISTICAL METHODS; BAUMBERGER C, 1993, AIDS, V7, pS59, DOI 10.1097/00002030-199311002-00013; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLARK SJ, 1994, J INFECT DIS, V170, P194, DOI 10.1093/infdis/170.1.194; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1995, NATURE, V273, P123; KATLAMA C, 1995, 2ND NAT C HUM RETR R; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KINLOCHDELOES S, 1993, CLIN INFECT DIS, V17, P59; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LINDBACK S, 1994, BRIT MED J, V309, P1535, DOI 10.1136/bmj.309.6968.1535; MAYERS DL, 1994, 34TH INT C ANT AG CH; NIU MT, 1993, AIDS RES HUM RETROV, V9, P913, DOI 10.1089/aid.1993.9.913; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PEDERSEN C, 1989, AIDS, V3, P45, DOI 10.1097/00002030-198911000-00009; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TINDALL B, 1991, AIDS, V5, P477, DOI 10.1097/00002030-199105000-00001; TINDALL B, 1993, AIDS, V7, P127, DOI 10.1097/00002030-199301000-00020; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1994, LANCET, V343, P871; 1987, MMWR-MORBID MORTAL W, V36, P522	34	219	219	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					408	413		10.1056/NEJM199508173330702	http://dx.doi.org/10.1056/NEJM199508173330702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616989	Bronze			2022-12-28	WOS:A1995RP24300002
J	DWYER, JH				DWYER, JH			GENES, BLOOD-PRESSURE, AND AFRICAN HERITAGE	LANCET			English	Editorial Material							URBAN				DWYER, JH (corresponding author), UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033, USA.							COOPER R, 1994, J HYPERTENS, V12, P215; GILES WH, 1994, AM J MED SCI, V308, P271, DOI 10.1097/00000441-199411000-00003; MBUYAMBAKABANGU JR, 1986, AM J EPIDEMIOL, V124, P957, DOI 10.1093/oxfordjournals.aje.a114485; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; SEEDAT YK, 1982, J EPIDEMIOL COMMUN H, V36, P256, DOI 10.1136/jech.36.4.256; ZARATE AO, 1994, INT MORTALITY CHARTB	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					392	392		10.1016/S0140-6736(95)92777-8	http://dx.doi.org/10.1016/S0140-6736(95)92777-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623567				2022-12-28	WOS:A1995RN65600006
J	MACGREGOR, D; BAKER, AM; APPEL, RG; OBER, KP; ZALOGA, GP				MACGREGOR, D; BAKER, AM; APPEL, RG; OBER, KP; ZALOGA, GP			HYPEROSMOLAR COMA DUE TO LITHIUM-INDUCED DIABETES-INSIPIDUS	LANCET			English	Discussion							INDUCED POLYURIA; AMELIORATION; THERAPY		WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, PULM CRIT CARE SECT, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, NEPHROL SECT, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, ENDOCRINOL METAB SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	MACGREGOR, D (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT ANESTHESIA, CRIT CARE SECT, WINSTON SALEM, NC 27157 USA.							ANGER MS, 1990, KIDNEY INT, V37, P1211, DOI 10.1038/ki.1990.104; BATLLE DC, 1985, NEW ENGL J MED, V312, P408, DOI 10.1056/NEJM198502143120705; BOTON R, 1987, AM J KIDNEY DIS, V10, P329, DOI 10.1016/S0272-6386(87)80098-7; COGAN E, 1987, AM J PHYSIOL, V252, pF1080, DOI 10.1152/ajprenal.1987.252.6.F1080; FEIBUSCH J, 1980, ANN INTERN MED, V92, P797, DOI 10.7326/0003-4819-92-6-797; GEHEB MA, 1987, CRIT CARE CLIN, V3, P797; GRINDLINGER GA, 1987, CRIT CARE MED, V15, P538, DOI 10.1097/00003246-198705000-00020; HESTBECH J, 1977, KIDNEY INT, V12, P205, DOI 10.1038/ki.1977.102; MARTIN A, 1993, HOSP COMMUNITY PSYCH, V44, P427; NEITHERCUT WD, 1990, POSTGRAD MED J, V66, P479, DOI 10.1136/pgmj.66.776.479; THOMPSON CJ, 1987, POSTGRAD MED J, V63, P979, DOI 10.1136/pgmj.63.745.979; WALKER RG, 1993, KIDNEY INT, V44, pS93; WILLIAMS RH, 1947, ANN INTERN MED, V27, P84, DOI 10.7326/0003-4819-27-1-84; YAMAKI M, 1991, AM J PHYSIOL, V261, pF505, DOI 10.1152/ajprenal.1991.261.3.F505; ZALOGA GP, 1984, CRIT CARE MED, V12, P188, DOI 10.1097/00003246-198403000-00007	15	18	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					413	417		10.1016/S0140-6736(95)92783-2	http://dx.doi.org/10.1016/S0140-6736(95)92783-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623573	Bronze			2022-12-28	WOS:A1995RN65600012
J	SIMOONS, ML				SIMOONS, ML			ANOTHER CORONARY REPERFUSION REGIMEN	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR; IMMEDIATE ANGIOPLASTY; THROMBOLYTIC THERAPY; TRIAL				SIMOONS, ML (corresponding author), UNIV ROTTERDAM HOSP, THORAXCTR, ROTTERDAM, NETHERLANDS.							[Anonymous], 1990, LANCET, V336, P65; BODE C, 1993, CIRCULATION, V88, P292; BOER MJ, 1994, J AM COLL CARDIOL, V23, P1004; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HUNT D, 1992, LANCET, V339, P753; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VERSTRAETE M, 1985, LANCET, V2, P965	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					324	325		10.1016/S0140-6736(95)92219-9	http://dx.doi.org/10.1016/S0140-6736(95)92219-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623525	Green Submitted			2022-12-28	WOS:A1995RM71300002
J	LOOMIS, WF; STERNBERG, PW				LOOMIS, WF; STERNBERG, PW			GENETIC NETWORKS	SCIENCE			English	Editorial Material									CALTECH,DEPT BIOL,PASADENA,CA 91125	California Institute of Technology	LOOMIS, WF (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.			Sternberg, Paul/0000-0002-7699-0173				MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793	1	33	33	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					649	649		10.1126/science.7624792	http://dx.doi.org/10.1126/science.7624792			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624792				2022-12-28	WOS:A1995RM70200021
J	SHAMOO, Y; FRIEDMAN, AM; PARSONS, MR; KONIGSBERG, WH; STEITZ, TA				SHAMOO, Y; FRIEDMAN, AM; PARSONS, MR; KONIGSBERG, WH; STEITZ, TA			CRYSTAL-STRUCTURE OF A REPLICATION FORK SINGLE-STRANDED-DNA BINDING-PROTEIN (T4 GP32) COMPLEXED TO DNA	NATURE			English	Article							GENE 32 PROTEIN; H-1-NMR 500 MHZ; ESCHERICHIA-COLI; BACTERIOPHAGE-T4; SITE; IDENTIFICATION; MUTAGENESIS; RESIDUES	THE single-stranded DNA (ssDNA) binding protein gp32 from bacteriophage T4 is essential for T4 DNA replication, recombination and repair. In vivo gp32 binds ssDNA as the replication fork advances and stimulates repulsion processivity and accuracy by a factor of several hundred(1). Gp32 binding affects nearly every major aspect of DNA metabolism. Among its important functions are: (1) configuring ssDNA templates for efficient use by the replisome including DNA polymerase; (2) melting out adventitious secondary structures; (3) protecting exposed ssDNA from nucleases; and (4) facilitating homologous recombination by binding ssDNA during strand displacement. We have determined the crystal structure of the gp32 DNA binding domain complexed to ssDNA at 2.2 Angstrom resolution. The ssDNA binding cleft comprises regions from three structural subdomains and includes a positively charged surface that runs parallel to a series of hydrophobic pockets formed bg clusters of aromatic side chains. Although only weak electron density is seen for the ssDNA, it indicates that the phosphate backbone contacts an electropositive cleft of the protein, placing the bases in contact with the hydrophobic pockets. The DNA mobility implied by the weak electron density may reflect the role of gp32 as a sequence-independent ssDNA chaperone allowing the largely unstructured ssDNA to slide freely through the cleft.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	SHAMOO, Y (corresponding author), YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA.		Friedman, Alan M/J-2696-2012; Steitz, Thomas A./C-6559-2009	Shamoo, Yousif/0000-0001-9241-8962				ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, X PLOR VERSION 2 2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; DELIUS H, 1972, J MOL BIOL, V67, P341, DOI 10.1016/0022-2836(72)90454-8; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; GIEDROC DP, 1989, BIOCHEMISTRY-US, V28, P2410, DOI 10.1021/bi00432a011; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KHAMIS MI, 1986, BIOCHEMISTRY-US, V25, P5865, DOI 10.1021/bi00368a005; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P50; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAN T, 1989, BIOCHEMISTRY-US, V28, P8833, DOI 10.1021/bi00448a023; PRIGODICH RV, 1984, BIOCHEMISTRY-US, V23, P522, DOI 10.1021/bi00298a019; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; SHAMOO Y, 1988, PROTEINS, V4, P1, DOI 10.1002/prot.340040103; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; SPICER EK, 1979, J BIOL CHEM, V254, P6433; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VANAMERONGEN H, 1990, BIOCHEMISTRY-US, V29, P5619, DOI 10.1021/bi00475a029; YANG W, 1990, J BIOL CHEM, V265, P13553; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	29	222	231	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 27	1995	376	6538					362	366		10.1038/376362a0	http://dx.doi.org/10.1038/376362a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630406				2022-12-28	WOS:A1995RL44300053
J	PAUL, J; BROWN, NM				PAUL, J; BROWN, NM			TINNITUS AND CIPROFLOXACIN	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									SOUTHMEAD GEN HOSP, DEPT MICROBIOL, BRISTOL BS10 5NB, AVON, ENGLAND	Southmead Hospital	PAUL, J (corresponding author), JOHN RADCLIFFE HOSP, PUBL HLTH LAB, OXFORD OX3 9DU, ENGLAND.							BAGGERSJOBACK D, 1989, SCAND J INFECT DIS, P28; CATCHPOLE C, 1994, J ANTIMICROB CHEMOTH, V33, P103, DOI 10.1093/jac/33.1.103; CLAES J, 1991, ANTIMICROB AGENTS CH, V35, P1014, DOI 10.1128/AAC.35.5.1014; SCHACHT P, 1989, AM J MED, V87, pS98, DOI 10.1016/0002-9343(89)90033-8	4	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 22	1995	311	6999					232	232		10.1136/bmj.311.6999.232b	http://dx.doi.org/10.1136/bmj.311.6999.232b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627041	Green Published			2022-12-28	WOS:A1995RL44100024
J	SILFVAST, T; KINNUNEN, A; VARPULA, T				SILFVAST, T; KINNUNEN, A; VARPULA, T			LARYNGEAL EDEMA AFTER ISOSORBIDE DINITRATE SPRAY AND SUBLINGUAL NIFEDIPINE	BRITISH MEDICAL JOURNAL			English	Letter									JORVI HOSP,SF-02740 ESPOO,FINLAND; HELSINKI AREA EMERGENCY MED AIR SERV,SF-01530 VANTAA,FINLAND		SILFVAST, T (corresponding author), HELSINKI UNIV,CENT HOSP,SF-002900 HELSINKI,FINLAND.							BERTEL O, 1983, BRIT MED J, V286, P19, DOI 10.1136/bmj.286.6358.19; BIJORIA K, 1992, ANAESTHESIA, V47, P523, DOI 10.1111/j.1365-2044.1992.tb02280.x; BUSSMANN WD, 1992, CLIN INVESTIGATOR, V70, P1085; MARMOR A, 1988, AM J CARDIOL, V61, pE4	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					232	232		10.1136/bmj.311.6999.232a	http://dx.doi.org/10.1136/bmj.311.6999.232a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627040	Green Published			2022-12-28	WOS:A1995RL44100023
J	EKLAND, EH; SZOSTAK, JW; BARTEL, DP				EKLAND, EH; SZOSTAK, JW; BARTEL, DP			STRUCTURALLY COMPLEX AND HIGHLY-ACTIVE RNA LIGASES DERIVED FROM RANDOM RNA SEQUENCES	SCIENCE			English	Article							RIBOZYMES; SUBSTRATE	Seven families of RNA ligases, previously isolated from random RNA sequences, fall into three classes on the basis of secondary structure and regiospecificity of ligation. Two of the three classes of ribozymes have been engineered to act as true enzymes, catalyzing the multiple-turnover transformation of substrates into products. The most complex of these ribozymes has a minimal catalytic domain of 93 nucleotides. An optimized version of this ribozyme has a k(cat), exceeding one per second, a value far greater than that of most natural RNA catalysts and approaching that of comparable protein enzymes. The fact that such a large and complex ligase emerged from avery limited sampling of sequence space implies the existence of a large number of distinct RNA structures of equivalent complexity and activity.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	EKLAND, EH (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BARTEL DP, UNPUB; CHAPMAN KB, 1995, CHEM BIOL, V2, P325, DOI 10.1016/1074-5521(95)90051-9; Ekland E. H., UNPUB; EKLAND EH, IN PRESS NUCLEIC ACI; HARADA K, 1993, NUCLEIC ACIDS RES, V21, P2287, DOI 10.1093/nar/21.10.2287; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; LLANGASEKARE M, 1995, SCIENCE, V267, P643; LOHMANN R, 1977, J MOL BIOL, V113, P193; LOHRMANN R, 1978, TETRAHEDRON, V34, P853, DOI 10.1016/0040-4020(78)88129-0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; LUCIA J S JR, 1990, Biochemistry, V29, P8813; MODRICH P, 1973, J BIOL CHEM, V21, P7502; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROHATGI R, UNPUB; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0	23	278	292	1	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					364	370		10.1126/science.7618102	http://dx.doi.org/10.1126/science.7618102			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618102				2022-12-28	WOS:A1995RK42700038
J	HIROSE, K; LOCKHART, A; CROSS, RA; AMOS, LA				HIROSE, K; LOCKHART, A; CROSS, RA; AMOS, LA			NUCLEOTIDE-DEPENDENT ANGULAR CHANGE IN KINESIN MOTOR DOMAIN BOUND TO TUBULIN	NATURE			English	Article							MICROTUBULES; MICROSCOPY; IMAGES	KINESIN is a 'motor' molecule, consisting of two head domains, an alpha-helical coiled coil rod, and a tail part that binds to its cargo(1,2). When expressed in a bacterial system, the head domain is functional(3), and can bind to microtubules with the stoichiometry of one head per tubulin dimer. Kinesin moves along microtubules by means of a cyclic process of nucleotide binding, hydrolysis and product release(4,5). We have used negative-stain electron microscopy and image analysis to study the structures of microtubules and tubulin sheets decorated with the motor domain (bead) of kinesin in three states: in the presence of an unhydrolysable ATP analogue, 5'-adenylylimidodiphosphate (AMP-PNP); without nucleotides; and with adenosine 5'-diphosphate (ADP). A single kinesin head bound to a microtubule has a pear-shaped structure, with the broader end towards the 'plus' end of the microtubule under all conditions; the reverse motor, ncd, is similarly oriented. Three-dimensional maps reveal that kinesin heads have a spike that is assumed to form the attachment to the tail of a complete kinesin molecule. This spike is perpendicular to the microtubule axis in the presence of ADP, but points towards the plus end (similar to 45 degrees) in the presence of AMP-PNP or absence of nucleotides. Our results provide direct evidence for a conformational change of the kinesin motor domain during the ATPase cycle.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; MARIE CURIE INST, OXTED RH8 0TL, SURREY, ENGLAND	MRC Laboratory Molecular Biology			Cross, Robert A/F-1798-2011; Hirose, Keiko/M-5429-2018	Cross, Robert A/0000-0002-0004-7832; Amos, Linda/0000-0001-8305-5346; Hirose, Keiko/0000-0003-4587-8346				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; DALLAI R, 1990, J STRUCT BIOL, V103, P164, DOI 10.1016/1047-8477(90)90020-D; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROSE K, IN PRESS J MOL BIOL; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; KUO SC, 1991, J CELL SCI, P135; LANZAVECCHIA S, 1994, J STRUCT BIOL, V113, P225, DOI 10.1006/jsbi.1994.1057; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MIKKAWA M, 1994, J CELL BIOL, V127, P1965; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WADE RH, 1993, J STRUCT BIOL, V110, P1, DOI 10.1006/jsbi.1993.1001; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	25	110	111	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					277	279		10.1038/376277a0	http://dx.doi.org/10.1038/376277a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617042				2022-12-28	WOS:A1995RK33100053
J	TRIGWELL, P; HATCHER, S; JOHNSON, M; STANLEY, P; HOUSE, A				TRIGWELL, P; HATCHER, S; JOHNSON, M; STANLEY, P; HOUSE, A			ABNORMAL ILLNESS BEHAVIOR IN CHRONIC FATIGUE SYNDROME AND MULTIPLE-SCLEROSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTVIRAL FATIGUE; GUIDELINES; HEALTH	Objective-To investigate the presence of abnormal illness behaviour in patients with a diagnosis of chronic fatigue syndrome. Design-A cross sectional descriptive study using the illness behaviour questionnaire to compare illness behaviour scores and illness behaviour profiles of patients with chronic fatigue syndrome and patients with multiple sclerosis. Setting-A multidisciplinary fatigue clinic and a teaching hospital neurology outpatient clinic. Subjects-98 patients satisfying the Oxford criteria for chronic fatigue syndrome and 78 patients with a diagnosis of multiple sclerosis. Main outcome measure-Responses to the 62 item illness behaviour questionnaire. Results-90 (92%) patients in the chronic fatigue syndrome group and 70 (90%) in the multiple sclerosis group completed the illness behaviour questionnaire. Both groups had significantly high scores on the general hypochondriasis and disease conviction subscales and significantly low scores on the psychological versus somatic concern subscale, as measured in relation to normative data. There were, however, no significant differences in the subscale scores between the two groups and the two groups had identical illness behaviour profiles. Conclusion-Scores on the illness behaviour questionnaire cannot be taken as evidence that chronic fatigue syndrome is a variety of abnormal illness behaviour, because the same profile occurs in multiple sclerosis. Neither can they be taken as evidence that chronic fatigue and multiple sclerosis share an aetiology. More needs to be known about the origins of illness beliefs in chronic fatigue syndrome, especially as they are important in determining outcome.	UNIV LEEDS, LEEDS LS2 9LT, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; SEACROFT HOSP, LEEDS LS14 6UH, W YORKSHIRE, ENGLAND; GEN INFIRM, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND	University of Leeds; Saint James's University Hospital; Leeds General Infirmary	TRIGWELL, P (corresponding author), HIGH ROYDS HOSP, LEEDS LS29 6AQ, W YORKSHIRE, ENGLAND.			House, Allan/0000-0001-8721-8026				CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093/brain/103.2.281; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; FREAL JE, 1984, ARCH PHYS MED REHAB, V65, P135; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; Kleinman Arthur, 1985, CULTURE DEPRESSION S, P429; KRUPP LB, 1988, ARCH NEUROL-CHICAGO, V45, P435, DOI 10.1001/archneur.1988.00520280085020; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; Matthews WB, 1991, MCALPINES MULTIPLE S, P139; MCEVEDY CP, 1970, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.5687.11; MECHANIC D, 1962, J CHRON DIS, V15, P189, DOI 10.1016/0021-9681(62)90068-1; MURRAY M, 1991, CURRENT DEV HLTH PSY, P63; PARSONS T, 1952, SOCIALSYSTEM; PEMBERTON S, IN PRESS BRIT J OCCU; PILOWSKY I, 1969, BRIT J MED PSYCHOL, V42, P347, DOI 10.1111/j.2044-8341.1969.tb02089.x; Pilowsky I., 1983, MANUAL ILLNESS BEHAV; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSER S, 1979, J NEUROL SCI, V40, P159, DOI 10.1016/0022-510X(79)90201-6; SCHWEITZER R, 1994, J PSYCHOSOM RES, V38, P41, DOI 10.1016/0022-3999(94)90007-8; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SMITH GR, 1986, ARCH INTERN MED, V146, P69, DOI 10.1001/archinte.146.1.69; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1990, RECENT ADV NEUROLOGY, V6; WILSON A, 1994, BRIT MED J, V308, P756, DOI 10.1136/bmj.308.6931.756; ZONDERMAN AB, 1985, HEALTH PSYCHOL, V4, P425, DOI 10.1037/0278-6133.4.5.425; 1987, DIAGNOSTIC STATISTIC	25	30	30	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					15	18		10.1136/bmj.311.6996.15	http://dx.doi.org/10.1136/bmj.311.6996.15			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG975	7613314	Green Published			2022-12-28	WOS:A1995RG97500018
J	RIGBY, R				RIGBY, R			OUT OF CONTROL	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1475	1475		10.1136/bmj.310.6992.1475	http://dx.doi.org/10.1136/bmj.310.6992.1475			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613305	Green Published			2022-12-28	WOS:A1995RC10500073
J	FRANKEL, FH				FRANKEL, FH			DISCOVERING NEW MEMORIES IN PSYCHOTHERAPY - CHILDHOOD REVISITED, FANTASY, OR BOTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MULTIPLE PERSONALITY; HYPNOSIS		HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	FRANKEL, FH (corresponding author), BETH ISRAEL HOSP,BOSTON,MA 02215, USA.							BASS E, 1988, COURAGE HEAL; BRAUN BG, 1984, PSYCHIAT ANN, V14, P34, DOI 10.3928/0048-5713-19840101-07; BRIERE J, 1989, THERAPY ADULT MOLEST, P49; BROWN DP, 1986, LONG TERM CASE HYPNO, P286; CECI SJ, 1994, INT J CLIN EXP HYP, V42, P304, DOI 10.1080/00207149408409361; COONS PM, 1994, J NERV MENT DIS, V182, P461, DOI 10.1097/00005053-199408000-00007; Crowder R.G., 1976, PRINCIPLES LEARNING; DYWAN J, 1983, SCIENCE, V222, P184, DOI 10.1126/science.6623071; ERDELYI MH, 1985, PSYCHOANALYSIS FREUD, P218; FELDMANSUMMERS S, 1994, J CONSULT CLIN PSYCH, V62, P636, DOI 10.1037/0022-006X.62.3.636; FRANKEL FH, 1993, AM J PSYCHIAT, V150, P954; FREUD S, 1896, STANDARD EDITION, V3, P191; HERMAN JL, 1987, PSYCHOANAL PSYCHOL, V4, P1, DOI DOI 10.1037/H0079126; Herman Judith, 2001, TRAUMA RECOVERY; JANET P., 1925, PSYCHOL HEALING HIST, VI, P589; KIHLSTROM JF, IN PRESS TRUTH MEMOR; KLUFT RP, 1982, AM J CLIN HYPN, V24, P230; LAURENCE JR, 1983, SCIENCE, V222, P523, DOI 10.1126/science.6623094; LINDSAY DS, 1994, APPL COGNITIVE PSYCH, V8, P281, DOI 10.1002/acp.2350080403; Loftus Elizabeth F, 1996, EYEWITNESS TESTIMONY; Orne M. T., 1988, HYPNOSIS MEMORY, P21; POPE HG, 1995, PSYCHOL MED, V25, P121, DOI 10.1017/S0033291700028142; Putnam F. W., 1989, DIAGNOSIS TREATMENT; Spence DP, 1982, NARRATIVE TRUTH HIST; SPIEGEL D, 1984, PSYCHIAT CLIN N AM, V7, P101; VANDERKOLK BA, 1994, HARVARD REV PSYCHIAT, V1, P253, DOI 10.3109/10673229409017088; WILLIAMS LM, 1994, J CONSULT CLIN PSYCH, V62, P1167, DOI 10.1037//0022-006X.63.3.343; 1985, JAMA-J AM MED ASSOC, V253, P1918; 1994, NOV WORK GROUP INV M; 1994, INT J CLIN EXP HYP, V42, P261; 1994, FREQUENTLY ASKED QUE; 1995, INT J CLIN EXP HYP, V43, P114	32	22	22	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					591	594		10.1056/NEJM199508313330912	http://dx.doi.org/10.1056/NEJM199508313330912			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RQ751	7623912				2022-12-28	WOS:A1995RQ75100012
J	HAUSKNECHT, RU				HAUSKNECHT, RU			METHOTREXATE AND MISOPROSTOL TO TERMINATE EARLY-PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ILLEGAL ABORTION; INJECTION; BRAZIL	Background. Although medical termination of pregnancy is available in Europe and China as an alternative to surgical termination, political and social factors have blocked medical approaches to pregnancy termination in the United States, Methotrexate, which is toxic to trophoblastic tissue, has been used safely to treat unruptured ectopic pregnancies, This report describes the use of a single low dose of methotrexate followed by intravaginal misoprostol for the medical termination of early pregnancy. Methods. Women seeking termination of pregnancy were selected for this study on the basis of their good general health, emotional stability, and a pregnancy of 63 days or less in duration, Each woman received an intramuscular dose of methotrexate (50 mg per square meter of body-surface area). Five to seven days later, 800 mu g of misoprostol was administered intravaginally. If abortion did not occur after seven days, the woman was offered a second dose of misoprostol or vacuum aspiration. Successful abortion was defined as a complete termination of pregnancy within seven days after the first or second administration of misoprostol. Results. A total of 171 of the 178 women enrolled in the study (96 percent) had successful medical abortions. Twenty-five women (14 percent) did not have an abortion after the first dose of misoprostol and received a second dose. Eighteen subsequently had complete abortions, but seven required suction curettage. In all seven women who required suction curettage, there was histologic evidence of disruption in the conceptus, No important side effects or complications were noted. Conclusions. The combination of methotrexate and misoprostol represents a safe and effective alternative to invasive methods for the termination of early pregnancy.	MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY	Icahn School of Medicine at Mount Sinai								BARBOSA RM, 1993, STUD FAMILY PLANN, V24, P236, DOI 10.2307/2939191; BOND GR, 1994, AM J OBSTET GYNECOL, V171, P561, DOI 10.1016/0002-9378(94)90302-6; BUCKSHEE K, 1992, INT J GYNECOL OBSTET, V37, P297, DOI 10.1016/0020-7292(92)90334-F; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COELHO HLL, 1993, LANCET, V341, P1486; COOK RJ, 1992, FAM PLANN PERSPECT, V24, P39, DOI 10.2307/2135726; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; CREININ MD, 1993, CONTRACEPTION, V48, P519, DOI 10.1016/0010-7824(93)90114-M; ELREFAEY H, 1995, NEW ENGL J MED, V332, P983, DOI 10.1056/NEJM199504133321502; FERNANDEZ H, 1993, FERTIL STERIL, V59, P773; FLETCHER HM, 1993, BRIT J OBSTET GYNAEC, V100, P641, DOI 10.1111/j.1471-0528.1993.tb14230.x; GOLDSTEIN SR, 1991, AM J OBSTET GYNECOL, V165, P497, DOI 10.1016/0002-9378(91)90274-U; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; HENSHAW R, 1994, ACTA OBSTET GYN SCAN, V73, P812, DOI 10.3109/00016349409072511; HOLE H, 1975, GEBURTSH FRAUENHEILK, V35, P538; ICHINOE K, 1987, AM J OBSTET GYNECOL, V156, P484, DOI 10.1016/0002-9378(87)90315-2; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; NESKET M, 1976, CANCER S, V37, P1048; ONEILL E, 1976, CANCER, V38, P984, DOI 10.1002/1097-0142(197608)38:2<984::AID-CNCR2820380249>3.0.CO;2-Q; Reich E W, 1978, Birth Defects Orig Artic Ser, V14, P139; ROSENFIELD A, 1992, AM J PUBLIC HEALTH, V82, P1325, DOI 10.2105/AJPH.82.10.1325; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; STOVALL TG, 1993, AM J OBSTET GYNECOL, V168, P1759, DOI 10.1016/0002-9378(93)90687-E; STROHMER H, 1992, HUM REPROD, V7, P1027, DOI 10.1093/oxfordjournals.humrep.a137763; THONG KJ, 1992, CONTRACEPTION, V46, P435, DOI 10.1016/0010-7824(92)90147-L; WILSON J, 1970, ANAT REC, V166, P39	27	120	124	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					537	540		10.1056/NEJM199508313330901	http://dx.doi.org/10.1056/NEJM199508313330901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623901	Bronze			2022-12-28	WOS:A1995RQ75100001
J	BARANGER, AM; PALMER, CR; HAMM, MK; GIEBLER, HA; BRAUWEILER, A; NYBORG, JK; SCHEPARTZ, A				BARANGER, AM; PALMER, CR; HAMM, MK; GIEBLER, HA; BRAUWEILER, A; NYBORG, JK; SCHEPARTZ, A			MECHANISM OF DNA-BINDING ENHANCEMENT BY THE HUMAN T-CELL LEUKEMIA-VIRUS TRANSACTIVATOR TAX	NATURE			English	Article							TRANSCRIPTION FACTOR-II; PROTEIN; LEUKEMIA; DIMERIZATION; FLEXIBILITY; TRANSITION; SEQUENCE; ELEMENTS; REPEATS; HELICES	Tax protein activates transcription of the human T-cell leukaemia virus type I (HTLV-I) genome through three imperfect cyclic AMP-responsive element (CRE) target sites located within the viral promoter(1). Previous work has shown that Tax interacts with the bZIP element of proteins that bind the CRE target site(2-4) to promote peptide dimerization(3,5), suggesting an association between Tax and the bZIP coiled coil. Here we show that the site of interaction with Tax is not the coiled coil, but the basic segment. This interaction increases tbe stability of the GCN4 bZIP dimer by 1.7 kcal mol(-1) and tbe DNA affinity of the dimer by 1.9 kcal mol(-1). The differential effect of Tax on several bZIP-DNA complexes that differ in peptide sequence or DNA conformation suggests a model for Tax action based on stabilization of a distinct DNA-bound protein structure. This model may explain how Tax interacts with transcription factors of considerable sequence diversity to alter patterns of gene expression.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523	Yale University; Yale University; Colorado State University								ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRANKLIN AA, 1995, J BIOMED SCI, V1, P17; GLOVER I, 1983, BIOPOLYMERS, V22, P293, DOI 10.1002/bip.360220138; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; Metallo S J, 1994, Chem Biol, V1, P143, DOI 10.1016/1074-5521(94)90004-3; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; O'NEIL KT, 1990, SCIENCE, V249, P774; PAOLELLA DN, 1994, SCIENCE, V264, P110; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	26	159	161	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					606	608		10.1038/376606a0	http://dx.doi.org/10.1038/376606a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637812				2022-12-28	WOS:A1995RP75600055
J	COHEN, S				COHEN, S			TIME TO RELAX RESEARCH USE OF PATENTS	NATURE			English	Article								The conditions under which research is exempt from European patent law are ambiguous, and current judicial interpretation is too restrictive. A more liberal approach would be a welcome boost to small research-based companies.			COHEN, S (corresponding author), TAYLOR JOYNSON GARRETT,50 VICTORIA EMBANKMENT,LONDON EC4Y 0DX,ENGLAND.							1995, NATURE, V374, P398; 1995, NATURE, V375, P348	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					622	622		10.1038/376622a0	http://dx.doi.org/10.1038/376622a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637816	Bronze			2022-12-28	WOS:A1995RP75600060
J	MACILWAIN, C				MACILWAIN, C			LAST-MINUTE LIFELINE FOR PRINCETON TOKAMAK TESTS	NATURE			English	Editorial Material																		1995, NATURE, V375, P713; 1995, NATURE, V375, P622	2	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					541	541						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637791				2022-12-28	WOS:A1995RP75600005
J	STEINDL, PE; FINN, B; BENDOK, B; ROTHKE, S; ZEE, PC; BLEI, AT				STEINDL, PE; FINN, B; BENDOK, B; ROTHKE, S; ZEE, PC; BLEI, AT			DISRUPTION OF THE DIURNAL RHYTHM OF PLASMA MELATONIN IN CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							CIRCADIAN LOCOMOTOR-ACTIVITY; HEPATIC-ENCEPHALOPATHY; SLEEP; RATS	Objectives: To assess 24-hour plasma melatonin profile as a marker of output rhythm from the circadian clock and to study sleep diaries as reflections of subjective sleep quality in patients with liver cirrhosis. Design: Prospective cohort study. Setting: Clinical research center in a university hospital. Patients: Seven patients with cirrhosis but not alcoholism and seven age-, sex-, and education-matched controls. Measurements: Neuropsychological testing to confirm subclinical hepatic encephalopathy. Plasma melatonin levels measured every 30 minutes for 24 hours by radioimmunoassay. Sleep diaries kept for 1 week before admission. Results: Patients with cirrhosis had markedly elevated melatonin levels during daytime hours; in addition, the time of onset of melatonin increase and the time at which melatonin levels peaked were consistently and significantly delayed in these patients. Sleep diaries indicated more nocturnal awakenings and more frequent daytime naps in patients with cirrhosis. Conclusion: Disruption of the diurnal rhythm of melatonin may reflect alterations of circadian function that could contribute to the disturbances of the sleep-wake cycle frequently seen in patients with cirrhosis.	LAKESIDE VET AFFAIRS MED CTR, DEPT MED 111E, CHICAGO, IL 60611 USA; NW MEM HOSP, CHICAGO, IL USA; REHABIL INST CHICAGO, CHICAGO, IL 60611 USA	Northwestern Memorial Hospital; Shirley Ryan AbilityLab			Zee, Phyllis C/GPF-3704-2022		NCRR NIH HHS [RR 00048] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARENDT J, 1986, BRIT MED J, V292, P1170, DOI 10.1136/bmj.292.6529.1170; ARENDT J, 1988, LANCET, V1, P772; BIRKELAND AJ, 1982, NEUROENDOCRINOLOGY, V34, P126, DOI 10.1159/000123289; CLAUSTRAT B, 1986, J PINEAL RES, V3, P301, DOI 10.1111/j.1600-079X.1986.tb00753.x; COY DL, 1992, GASTROENTEROLOGY, V103, P222, DOI 10.1016/0016-5085(92)91116-L; DAWSON D, 1993, J PINEAL RES, V15, P1, DOI 10.1111/j.1600-079X.1993.tb00503.x; DUCIS I, 1994, J NEUROCHEM, V62, pS37; FINN B, 1993, HEPATO-GASTROENTEROL, V40, P33; FRASER S, 1983, CLIN CHEM, V29, P396; GITLIN N, 1986, J HEPATOL, V3, P75, DOI 10.1016/S0168-8278(86)80149-0; IGUCHI H, 1982, J CLIN ENDOCR METAB, V54, P1025, DOI 10.1210/jcem-54-5-1025; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; MOORE RY, 1983, FED PROC, V42, P2783; Reitan RM., 1979, TRAIL MAKING TEST MA; ROSENTHAL NE, 1991, J CLIN ENDOCR METAB, V73, P225; SACK RL, 1991, J BIOL RHYTHM, V6, P249, DOI 10.1177/074873049100600305; WALDHAUSER F, 1993, INT CONGR SER, V1017, P331; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; YURDAYDIN C, 1990, HEPATOLOGY, V12, P695, DOI 10.1002/hep.1840120413; ZEE PC, 1991, BRAIN RES, V560, P17, DOI 10.1016/0006-8993(91)91209-J	20	114	116	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					274	277		10.7326/0003-4819-123-4-199508150-00005	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611593				2022-12-28	WOS:A1995RN66500005
J	CULLEN, PJ; HSUAN, JJ; TRUONG, O; LETCHER, AJ; JACKSON, TR; DAWSON, AP; IRVINE, RF				CULLEN, PJ; HSUAN, JJ; TRUONG, O; LETCHER, AJ; JACKSON, TR; DAWSON, AP; IRVINE, RF			IDENTIFICATION OF A SPECIFIC INS(1,3,4,5)P-4-BINDING PROTEIN AS A MEMBER OF THE GAP1 FAMILY	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; BUD-SITE-SELECTION; YEAST	INOSITOL 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P-4) is produced rapidly from inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) in stimulated cells(1,2). Despite extensive experimentation, no clearly defined cellular function has yet been described for this inositol phosphate. Binding sites specific for Ins(1,3,4,5)P-4 have been identified in several tissues(3,4), and we have purified one such protein to homogeneity(5). Its high affinity for Ins(1,3,4,5)P-4, and its exquisite specificity for this isomeric configuration(5,6), suggest it may be an Ins(1,3,4,5)P-4 receptor. Here we report the cloning and characterization of this protein as a GTPase-activating protein, specifically a member of the GAP family. In vitro it shows GAP activity against both Rap and Ras, but only the Ras GAP activity is inhibited by phospholipids and is specifically stimulated by Ins(1,3,4,5)P-4.	UNIV E ANGLIA, SCH BIOL SCI, NORWICH NR4 7TJ, NORFOLK, ENGLAND; UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV CAMBRIDGE, BABRAHAM INST, DEPT ZOOL, MOLEC SIGNALLING LAB, CAMBRIDGE CB2 3EJ, ENGLAND	University of East Anglia; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	CULLEN, PJ (corresponding author), BABRAHAM INST, INOSITIDE LAB, BABRAHAM HALL, CAMBRIDGE CB2 4AT, ENGLAND.		Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Cullen, Peter/0000-0002-9070-8349				BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; CORVAZIER E, 1991, BIOCHEM J, V281, P323; CULLEN PJ, 1994, BIOCHEM J, V298, P739, DOI 10.1042/bj2980739; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1992, BIOCHEM J, V288, P149, DOI 10.1042/bj2880149; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HASHII M, 1993, J BIOL CHEM, V268, P19403; IRVINE RF, 1993, CURR BIOL, V3, P540, DOI 10.1016/0960-9822(93)90052-P; IRVINE RF, 1992, INOSITOL PHOSPHATE C, P161; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MANNING DR, 1991, THROMB HAEMOSTASIS, V66, P393; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8846; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914	21	287	289	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					527	530		10.1038/376527a0	http://dx.doi.org/10.1038/376527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637787				2022-12-28	WOS:A1995RN62200049
J	GURDON, JB; MITCHELL, A; MAHONY, D				GURDON, JB; MITCHELL, A; MAHONY, D			DIRECT AND CONTINUOUS ASSESSMENT BY CELLS OF THEIR POSITION IN A MORPHOGEN GRADIENT	NATURE			English	Article							MESODERM INDUCTION; XENOPUS; RESPONSES; ACTIVIN; HOMOLOG	ACCORDING to the morphogen gradient concept(1-5), cells in one part of an embryo secrete diffusible molecules (morphogens) that spread to other nearby cells and activate genes at different threshold concentrations, Strong support for the operation of a morphogen gradient mechanism in vertebrate development has come from the biochemical experiments of Green and Smith(6,7), who induced different kinds of gene expression in amphibian blastula cells exposed to small changes in activin concentration, But the interpretation of these experiments has been complicated by recent reports that cells tested for gene expression 3 hours after exposure to activin fail to show the graded response previously reported at 15 hours(6,7), a result suggesting that cells recognize their position in a gradient by an indirect mechanism, Here we conclude from the in situ analysis of blastula tissue containing activin-loaded beads(11) that cells respond directly to changing morphogen concentrations, in a way that resembles a ratchet-like process.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE,ENGLAND	University of Cambridge	GURDON, JB (corresponding author), CANC RES CAMPAIGN,WELLCOME INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRICKELL PM, 1989, BIOESSAYS, V11, P145, DOI 10.1002/bies.950110508; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1995, BIOESSAYS, V17, P93, DOI 10.1002/bies.950170202; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1994, DEVELOPMENT, V120, P2271; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JONES EA, 1987, DEVELOPMENT, V101, P557; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SYMES K, 1987, DEVELOPMENT, V101, P339; SYMES K, 1994, DEVELOPMENT, V120, P2339; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VIZE PD, 1994, TRENDS GENET, V10, P371, DOI 10.1016/0168-9525(94)90134-1; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1989, DEVELOPMENT, V107, P3	22	133	133	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					520	521		10.1038/376520a0	http://dx.doi.org/10.1038/376520a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637784				2022-12-28	WOS:A1995RN62200046
J	MILLER, JD				MILLER, JD			POTTS PARAPLEGIA TODAY	LANCET			English	Editorial Material							SPINE				MILLER, JD (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1978, J Bone Joint Surg Br, V60-B, P163; COOPER PR, 1993, NEUROSURGERY, V32, P1, DOI 10.1227/00006123-199301000-00001; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003; GROPPER GR, 1982, NEUROSURGERY, V10, P506, DOI 10.1227/00006123-198204000-00017; HODGSON AR, 1960, J BONE JOINT SURG AM, V42, P295, DOI 10.2106/00004623-196042020-00009; REZAI AR, 1995, NEUROSURGERY, V36, P87, DOI 10.1227/00006123-199501000-00011	7	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					264	264						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630244				2022-12-28	WOS:A1995RL75700007
J	HUMPEL, C; LINDQVIST, E; SODERSTROM, S; KYLBERG, A; EBENDAL, T; OLSON, L				HUMPEL, C; LINDQVIST, E; SODERSTROM, S; KYLBERG, A; EBENDAL, T; OLSON, L			MONITORING RELEASE OF NEUROTROPHIC ACTIVITY IN THE BRAINS OF AWAKE RATS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; EXPRESSION; ANTIBODIES	Intracerebral microdialysis of awake rats was used to monitor the possible release of neurotrophic factors from brain cells in response to injury and excitation. Perfusates were tested with ganglia bioassays and enzyme immunoassay. Trophic activity was released after implantation of the microdialysis probe into the hippocampus but not into the striatum, as assessed by increased nerve fiber outgrowth from Remak's ganglion. Kainic acid treatment significantly increased the release of trophic activity from hippocampal sites. These findings suggest that the brain responds to mechanical injury as well as to certain excitatory stimuli by regional extracellular release of neurotrophic activity that is not identical to the actions of known neurotrophic factors.	KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN; UNIV INNSBRUCK, DEPT PSYCHIAT, NEUROCHEM UNIT, A-6020 INNSBRUCK, AUSTRIA; UNIV UPPSALA, CTR BIOMED, DEPT DEV NEUROSCI, S-75123 UPPSALA, SWEDEN	Karolinska Institutet; University of Innsbruck; Uppsala University								AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; EBENDAL T, 1978, ZOON, V6, P235; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EBENDAL T, 1989, NERVE GROWTH FACTORS, P81; EBENDAL T, UNPUB; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Lapchak P A, 1992, Rev Neurosci, V3, P109, DOI [10.1515/REVNEURO.1992.3.1.1, 10.1515/REVNEURO.1992.3.2.109]; Levi-Montalcini R, 1990, PROG NEUROENDOCRINOL, V3, P1; LEVIMONTALCINI R, 1987, BIOSCIENCE REP, V7, P681, DOI 10.1007/BF01116861; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; WETMORE C, 1991, P NATL ACAD SCI USA, V88, P9843, DOI 10.1073/pnas.88.21.9843; WETMORE CJ, 1993, J HISTOCHEM CYTOCHEM, V41, P521, DOI 10.1177/41.4.8450192	15	19	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					552	554		10.1126/science.7624780	http://dx.doi.org/10.1126/science.7624780			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624780				2022-12-28	WOS:A1995RL49500032
J	JEFFREY, PD; RUSO, AA; POLYAK, K; GIBBS, E; HURWITZ, J; MASSAGUE, J; PAVLETICH, NP				JEFFREY, PD; RUSO, AA; POLYAK, K; GIBBS, E; HURWITZ, J; MASSAGUE, J; PAVLETICH, NP			MECHANISM OF CDK ACTIVATION REVEALED BY THE STRUCTURE OF A CYCLINA-CDK2 COMPLEX	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; PHOSPHORYLATION; CYCLINS; BINDING; YEAST; LOCALIZATION; INVITRO; PROGRAM	The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 Angstrom resolution. CyclinA binds to one side of CDK2's catalytic cleft, inducing large conformational changes in its PSTAIRE helix and T-loop. These changes activate the kinase by realigning active site residues and relieving the steric blockade at the entrance of the catalytic cleft.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	JEFFREY, PD (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Massague, Joan/0000-0001-9324-8408; Jeffrey, Philip/0000-0002-4351-5341				BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P273; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STANDART N, 1990, GENE DEV, V4, P1257; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; 1979, SERC4 DAR LAB COLL C	50	1190	1227	2	109	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					313	320		10.1038/376313a0	http://dx.doi.org/10.1038/376313a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630397				2022-12-28	WOS:A1995RL44300040
J	MORI, I; OHSHIMA, Y				MORI, I; OHSHIMA, Y			NEURAL REGULATION OF THERMOTAXIS IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; CHEMOSENSORY NEURONS; CELL LINEAGE; MUTANT; CHEMOTAXIS	THERMAL stimulus is an important environmental factor influencing animal behaviour(1). However, the mechanisms underlying thermosensation and thermal adaptation are poorly understood. The nematode Caenorhabditis elegans can sense a range of environmental temperatures and migrate towards the cultivation temperature on a thermal gradient(2). This modifiable thermotactic response provides an ideal system for studying the cellular and molecular processes involved in thermosensation and thermal information storage. We have identified neurons critical for thermotaxis by killing individual cells in live animals. The results indicate that an amphid sensory neuron, AFD, is a major thermosensory neuron. Some of the genetically defined cryophilic and thermophilic mutant phenotypes were mimicked when amphid interneurons AIY and AIZ, respectively, were killed, indicating that AIY is responsible for thermophilic movement and AIZ for cryophilic movement. We propose a neural model in which regulation of the activities of the two interneurons in opposite directions, depending on the cultivation temperature, is essential for thermotaxis.			MORI, I (corresponding author), KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN.							AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BRENNER S, 1974, GENETICS, V77, P71; Eckert R, 1988, ANIMAL PHYSL; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	14	398	414	1	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					344	348		10.1038/376344a0	http://dx.doi.org/10.1038/376344a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630402				2022-12-28	WOS:A1995RL44300048
J	GIESECKE, J				GIESECKE, J			THE FINE WEB OF SURVEILLANCE	LANCET			English	Editorial Material											GIESECKE, J (corresponding author), SWEDISH INT INFECT DIS CONTROL,DEPT EPIDEMIOL,STOCKHOLM,SWEDEN.								0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					196	196		10.1016/S0140-6736(95)91260-6	http://dx.doi.org/10.1016/S0140-6736(95)91260-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616793				2022-12-28	WOS:A1995RK41900002
J	SLADE, J; BERO, LA; HANAUER, P; BARNES, DE; GLANTZ, SA				SLADE, J; BERO, LA; HANAUER, P; BARNES, DE; GLANTZ, SA			NICOTINE AND ADDICTION - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTES; BLOCKING; VENTS	Objective.-To learn how nicotine has been regarded by a major tobacco company. Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-During a period of 22 years (1962 to 1984), employees of B&W and BAT conducted research and commented on the pharmacology of nicotine. They consistently regarded nicotine as the pharmacological agent that explained tobacco use, In the early part of the period under study, officials of the companies wrote about nicotine addiction explicitly. Inhalation of cigarette smoke by the consumer was recognized throughout the period as necessary for the normal function of a cigarette. The documents contain little indication that research was conducted on either the taste or the flavor of nicotine, The documents reveal an intention on the part of B&W and its corporate parent to affect the function of the body with nicotine.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1962, SMOKING HLTH REPORT; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; Ellis C., 1966, US Patent, Patent No. [3 258 015, 3258015]; Ellis Charles, 1967, US Patent, Patent No. [3 356 094, 3356094]; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; GRUNBERG NE, 1982, ADDICT BEHAV, V7, P317, DOI 10.1016/0306-4603(82)90001-6; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HENNINGFIELD JE, 1992, J CONSULT CLIN PSYCH, V61, P743; JOHNSON R, 1990, Patent No. 4955397; Kessler David A., 1994, TOB CONTROL, V3, P150, DOI DOI 10.1136/TC.3.2.148; KOZLOWSKI LT, 1988, AM J PUBLIC HEALTH, V78, P694, DOI 10.2105/AJPH.78.6.694; KOZLOWSKI LT, 1989, PHARMACOL BIOCHEM BE, V33, P815, DOI 10.1016/0091-3057(89)90476-0; LITZINGER E, 1990, Patent No. 4924886; MARTINI L, 1966, NEUROENDOCRINOLOGY; MEDVEI V, 1992, HIST CLIN ENDOCRINOL; OCKENE J, 1982, PREV MED, V10, P476; PORENSKI H, 1994, Patent No. 5327915; SLADE J, 1993, NICOTINE ADDICTION P, P3; 1988, DHHS CDC888406 US DE; 1989, DHHS CDC898411 US DE; 1964, US DHEW PHS1103 PUBL, V1103; 1980, BRIT MED J, V280, P972	22	85	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					225	233		10.1001/jama.274.3.225	http://dx.doi.org/10.1001/jama.274.3.225			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH937	7609231				2022-12-28	WOS:A1995RH93700028
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - GETTING YOUR COMPUTER UP AND RUNNING	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,UXBRIDGE,MIDDX,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER,ENGLAND	Gloucestershire Royal Hospital									0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					106	109		10.1136/bmj.311.6997.106	http://dx.doi.org/10.1136/bmj.311.6997.106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613362	Green Published			2022-12-28	WOS:A1995RJ03000027
J	GORDON, I				GORDON, I			VESICOURETERAL REFLUX, URINARY-TRACT INFECTION, AND RENAL DAMAGE IN CHILDREN	LANCET			English	Editorial Material							VESICOURETERAL REFLUX; ACID SCINTIGRAPHY; PYELONEPHRITIS		INST CHILD HLTH,LONDON WC1N 3JH,ENGLAND	University of London; University College London	GORDON, I (corresponding author), GREAT ORMOND ST HOSP NHS TRUST,LONDON WC1N 3JH,ENGLAND.							ANDRICH MP, 1992, PEDIATRICS, V90, P436; CHANTLER C, 1980, ARCH DIS CHILD, V55, P435, DOI 10.1136/adc.55.6.435; CRABBE DCG, 1992, J UROLOGY, V148, P1229, DOI 10.1016/S0022-5347(17)36868-4; ELDER JS, 1992, J UROLOGY, V148, P1750, DOI 10.1016/S0022-5347(17)37020-9; GLEESON FV, 1991, ARCH DIS CHILD, V66, P1282, DOI 10.1136/adc.66.11.1282; JAKOBSSON B, 1992, ARCH DIS CHILD, V67, P1338, DOI 10.1136/adc.67.11.1338; ROBERTS JA, 1992, J UROLOGY, V148, P1721, DOI 10.1016/S0022-5347(17)37013-1; ROSENBERG AR, 1992, J UROLOGY, V148, P1746, DOI 10.1016/S0022-5347(17)37019-2; RUSHTON HG, 1992, J UROLOGY, V147, P1327, DOI 10.1016/S0022-5347(17)37555-9; SHERIDAN M, 1991, PEDIATR SURG INT, V6, P214	10	49	54	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					489	490		10.1016/S0140-6736(95)91328-9	http://dx.doi.org/10.1016/S0140-6736(95)91328-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637486				2022-12-28	WOS:A1995RP85700016
J	MACILWAIN, C				MACILWAIN, C			GENE PATENT STUDY DROWNED AS OTA SINKS	NATURE			English	Editorial Material																		1995, NATURE, V375, P711	1	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					541	541						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637791				2022-12-28	WOS:A1995RP75600004
J	WEN, W; MEINKOTH, JL; TSIEN, RY; TAYLOR, SS				WEN, W; MEINKOTH, JL; TSIEN, RY; TAYLOR, SS			IDENTIFICATION OF A SIGNAL FOR RAPID EXPORT OF PROTEINS FROM THE NUCLEUS	CELL			English	Article							SV40 T-ANTIGEN; ESCHERICHIA-COLI; MESSENGER-RNA; PORE COMPLEX; CYCLIC-AMP; 2 STEPS; TRANSPORT; TRANSLOCATION; IMPORT; KINASE	Active nuclear import of protein is controlled by nuclear localization signals (NLSs), but nuclear export is not understood well. Nuclear trafficking of the catalytic (C) subunit of cAMP-dependent protein kinase (cAPK) is critical for regulation of gene expression. The heat-stable inhibitor (PKI) of cAPK contains a nuclear export signal (NES) that triggers rapid, active net extrusion of the C-PKI complex from the nucleus. This NES (residues 35-49), fused or conjugated to heterologous proteins, was sufficient for rapid nuclear export. Hydrophobic residues were critical. The NES is a slightly weaker signal than the SV40 NLS. A sequence containing only residues 37-46, LALKLAGLDI, is also sufficient for nuclear export. This is an example of a protein-based NES having no obvious association with RNA. A similar sequence, LQLPPLERLTL, from Rev, an RNA-binding protein of HIV-1, also is an NES.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of Pennsylvania; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	WEN, W (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.		Meinkoth, Judy L/G-2900-2010		NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BOHNLEIN E, 1991, J VIROL, V65, P7051; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHON MA, 1994, P NATL ACAD SCI USA, V91, P7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; THOMAS J, 1991, J BIOL CHEM, V266, P10906; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1995, J BIOL CHEM, V270, P2041, DOI 10.1074/jbc.270.5.2041; WEN W, 1994, J BIOL CHEM, V269, P32214; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	60	1000	1023	0	44	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					463	473		10.1016/0092-8674(95)90435-2	http://dx.doi.org/10.1016/0092-8674(95)90435-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634336	hybrid			2022-12-28	WOS:A1995RP24200016
J	FRITZ, CC; ZAPP, ML; GREEN, MR				FRITZ, CC; ZAPP, ML; GREEN, MR			A HUMAN NUCLEOPORIN-LIKE PROTEIN THAT SPECIFICALLY INTERACTS WITH HIV REV	NATURE			English	Article							VIRUS TYPE-1 REV; PORE COMPLEX PROTEIN; ACTIVATION DOMAIN; I REX; DEFINITION; MOTIF	THE Rev protein of human immunodeficiency virus type I (HIV-1) facilitates the nuclear export of unspliced and partly spliced viral RNAs. Rev contains an RNA binding domain, required for interaction with HIV-1 RNA, and an effector domain, required for RNA-bound Rev to function. The Rev effector domain is believed to interact with a cellular cofactor required for the Rev response and thus HIV-1 replication(1,2). Here we report the use of a yeast two-hybrid screen to clone human Rev interacting protein (hRIP), which specifically interacts with the Rev effector domain. This hRIP protein has hemology with nucleoporins, a class of proteins that mediate nucleocytoplasmic transport(3,4). These and other properties of hRIP are those expected of a Rev cellular cofactor.			FRITZ, CC (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,SUITE 309,WORCESTER,MA 01605, USA.		Williamson, James R/B-2891-2009	Williamson, James R/0000-0002-8772-468X				CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GORSCH LC, 1995, CELL BIOL, V129, P939; Green MR, 1993, AIDS RES REV, V3, P41; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; ZHANG GH, 1994, NATURE, V372, P809	20	238	243	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					530	533		10.1038/376530a0	http://dx.doi.org/10.1038/376530a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637788				2022-12-28	WOS:A1995RN62200050
J	WIDEN, E; LEHTO, M; KANNINEN, T; WALSTON, J; SHULDINER, AR; GROOP, LC				WIDEN, E; LEHTO, M; KANNINEN, T; WALSTON, J; SHULDINER, AR; GROOP, LC			ASSOCIATION OF A POLYMORPHISM IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE WITH FEATURES OF THE INSULIN-RESISTANCE SYNDROME IN FINNS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-3-ADRENERGIC RECEPTOR; DIABETES-MELLITUS; MUSCLE; OBESITY; GLUCOSE; TISSUE; MEN	Background, Because visceral obesity predicts insulin resistance, we studied whether alterations in the gene encoding for the beta(3)-adrenergic receptor in visceral fat are associated with insulin resistance. Methods. We studied the frequency of a cytosine-to-thymidine mutation that results in the replacement of tryptophan by arginine at position 64 (Trp64Arg) of the beta(3)-adrenergic receptor by restriction-enzyme digestion with BstOl in 335 subjects from western Finland, 207 of whom were nondiabetic and 128 of whom had non-insulin-dependent diabetes mellitus (NIDDM). We also determined the frequency of the mutation in 156 subjects from southern Finland. Sensitivity to insulin was measured by the hyperinsulinemic-euglycemic clamp technique in 66 randomly selected nondiabetic subjects. Results. In the subjects from western Finland, the frequency of the mutated allele was similar in the nondiabetic subjects and the subjects with NIDDM (12 vs, 11 percent), The mean age of the subjects at the onset of diabetes was lower among those with the mutation than those without it (56 vs. 61 years, P = 0,04). Among the nondiabetic subjects, those with the mutation had a higher ratio of waist to hip circumference (P = 0.02), a greater increase in the serum insulin response after the oral administration of glucose (P = 0.05), a higher diastolic blood pressure (82 vs. 78 mm Hg, P = 0.01), and a lower rate of glucose disposal during the clamp study (5.3 vs, 6.5 mg [29 vs. 36 mu mol] per kilogram of body weight per minute; P = 0.04) than the subjects without the mutated allele. In an analysis of sibling pairs, the siblings with the mutation generally had higher waist:hip ratios (P = 0.05) and higher responses of blood glucose and serum insulin after the oral administration of glucose than their siblings without the mutation (P = 0.02 and P = 0.005, respectively). Conclusions. The Trp64Arg allele of the beta(3)-adrenergic receptor is associated with abdominal obesity acid resistance to insulin and may contribute to the early onset of NIDDM.	LUND UNIV,DEPT ENDOCRINOL,LUND,SWEDEN; HELSINKI UNIV HOSP,DEPT MED 4,SF-00170 HELSINKI,FINLAND; JOHNS HOPKINS UNIV,SCH MED,DIV GERIATR MED & GERONTOL,BALTIMORE,MD	Lund University; University of Helsinki; Helsinki University Central Hospital; Johns Hopkins University				Shuldiner, Alan/0000-0001-9921-4305				BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CARO JF, 1991, J CLIN ENDOCR METAB, V73, P691, DOI 10.1210/jcem-73-4-691; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; MARIN P, 1992, METABOLISM, V41, P1242, DOI 10.1016/0026-0495(92)90016-4; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; POULIOT MC, 1992, DIABETES, V41, P826, DOI 10.2337/diabetes.41.7.826; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	17	539	564	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					348	351		10.1056/NEJM199508103330604	http://dx.doi.org/10.1056/NEJM199508103330604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609751				2022-12-28	WOS:A1995RN08200004
J	VLADECK, BC				VLADECK, BC			END-OF-LIFE CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					449	449		10.1001/jama.274.6.449	http://dx.doi.org/10.1001/jama.274.6.449			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629940				2022-12-28	WOS:A1995RM69900006
J	HANKS, M; WURST, W; ANSONCARTWRIGHT, L; AUERBACH, AB; JOYNER, AL				HANKS, M; WURST, W; ANSONCARTWRIGHT, L; AUERBACH, AB; JOYNER, AL			RESCUE OF THE EN-1 MUTANT PHENOTYPE BY REPLACEMENT OF EN-1 WITH EN-2	SCIENCE			English	Article							HOMEO BOX; MOUSE; EXPRESSION; MICE; SEQUENCE; GENES; RECOMBINATION; VERTEBRAE; DELETION; CHICKEN	The related mouse Engrailed genes En-1 and En-2 are expressed from the one- and approximately five-somite stages, respectively, in a similar presumptive mid-hindbrain domain. However, mutations in En-1 and En-2 produce different phenotypes. En-1 mutant mice die at birth with a large mid-hindbrain deletion, whereas En-2 mutants are viable, with cerebellar defects. To determine whether these contrasting phenotypes reflect differences in temporal expression or biochemical activity of the En proteins, En-1 coding sequences were replaced with En-2 sequences by gene targeting. This rescued all En-1 mutant defects, demonstrating that the difference between En-1 and En-2 stems from their divergent expression patterns.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute				Wurst, Wolfgang/0000-0003-4422-7410				CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; HANKS M, UNPUB; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Joyner Alexandra L., 1991, Seminars in Developmental Biology, V2, P435; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; LOGAN C, 1993, DEVELOPMENT, V117, P905; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; WURST W, 1994, DEVELOPMENT, V120, P2065; Wurst W., 1993, Gene targeting: a practical approach., P33; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	24	343	361	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	1995	269	5224					679	682		10.1126/science.7624797	http://dx.doi.org/10.1126/science.7624797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624797				2022-12-28	WOS:A1995RM70200030
J	BLUM, A; WOLINSKY, H				BLUM, A; WOLINSKY, H			AMA REWRITES TOBACCO HISTORY	LANCET			English	Editorial Material									DOCTORS OUGHT CARE,CHICAGO,IL		BLUM, A (corresponding author), DOCTORS OUGHT CARE,HOUSTON,TX, USA.							ROSENBERG J, 1985, CIGARETTE UNDERWORLD, P123; WOLINSKY H, 1995, SERPENT STAFF UNHEAL, P144	2	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					261	261		10.1016/S0140-6736(95)92159-1	http://dx.doi.org/10.1016/S0140-6736(95)92159-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630241				2022-12-28	WOS:A1995RL75700004
J	DOWLING, S; BARRETT, S; WEST, R				DOWLING, S; BARRETT, S; WEST, R			WITH NURSE PRACTITIONERS, WHO NEEDS HOUSE OFFICERS	BRITISH MEDICAL JOURNAL			English	Article								The boundaries between the work of doctors and that of nurses are changing, with nurses taking over important parts of junior hospital doctors' clinical work. In 1993 an exploratory study was carried out to identify the professional, educational, and management issues that such developments raise. Interviews were carried out with a range of stakeholders in three innovatory posts in which nurses were doing much of the clinical work of house officers. A complex picture of perceived benefits and problems for patients, junior doctors, and nurses emerged. These seemed to be associated with (a) the extent to which the contribution of professional nursing was valued in the new role and (b) the amount of clinical discretion which the postholder was allowed, this depending on the type of preparatory education provided and the management of the post. The study points to the need for strategic issues-such as the development of appropriate education and the professional recognition of these new clinical roles-to be addressed at a national and regional level.	UNIV BRISTOL,CTR SOCIAL MANAGEMENT,SCH ADV URBAN STUDIES,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV BRISTOL,FRENCHAY HOSP,DEPT POSTGRAD MED EDUC,BRISTOL BS16 1LE,AVON,ENGLAND	University of Bristol; University of Bristol	DOWLING, S (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.							Cassell C., 2004, ESSENTIAL GUIDE QUAL; Davies C., 1995, GENDER PROFESSIONAL; HAINES A, 1995, BRIT MED J, V310, P815, DOI 10.1136/bmj.310.6983.815; HARRIS A, 1994, J ADV NURS, V20, P874, DOI 10.1046/j.1365-2648.1994.20050874.x; HOLMES S, 1994, BRIT J NURSING, V3, P204; NORMAND CE, 1993, MANAGERIAL ISSUES RE; PEARSON A, 1988, PRIMARY NURSING NURS; POPE C, 1993, BRIT MED J, V306, P315, DOI 10.1136/bmj.306.6873.315; READ S, 1994, REDUCTION JUNIOR DOC; Reason, 1988, HUMAN INQUIRY ACTION; SALVAGE J, 1992, POLICY ISSUES NURSIN; SOWDEN AJ, 1995, BRIT MED J, V310, P142, DOI 10.1136/bmj.310.6973.142; STACEY M, 1992, REGULATING BRIT MED; Walby Sylvia, 1994, MED NURSING PROFESSI; WALMSLEY J, 1993, HLTH WELFARE PRACTIC; WILSONBARNETT J, 1994, INT J NURS STUD, V31, P561, DOI 10.1016/0020-7489(94)90066-3; Yin R.K., 1994, CASE STUDY RES; 1983, HOSPITAL DOCTORS TRA; 1991, JUNIOR DOCTORS NEW D; 1994, EVALUATION NURSE PRA; 1994, INTERFACE JUNIOR DOC; 1992, SCOPE PROFESSIONAL P; 1977, DHSS HC7722 DEP HLTH; 1993, LANCET, V342, P187; 1995, EL9527 NHS MAN EX; 1994, COUNCILS STANDARDS E	26	52	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					309	313		10.1136/bmj.311.7000.309	http://dx.doi.org/10.1136/bmj.311.7000.309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633246	Green Published			2022-12-28	WOS:A1995RM71900034
J	VERKUYL, DAA				VERKUYL, DAA			PRACTICING OBSTETRICS AND GYNECOLOGY IN AREAS WITH A HIGH PREVALENCE OF HIV-INFECTION	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSMISSION; AFRICA											BAYLEY AC, 1990, BRIT J SURG, V77, P863, DOI 10.1002/bjs.1800770806; BORGSTEIN ES, 1994, ARCH DIS CHILD, V71, P165, DOI 10.1136/adc.71.2.165; CARAEL M, 1988, AIDS, V2, P201; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P807, DOI 10.1001/jama.271.11.807; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; GORDON SM, 1994, NEW ENGL J MED, V331, P1469, DOI 10.1056/NEJM199412013312201; HYDE GA, 1994, PEDIATRICS, V94, P940; LULE G, 1994, GENITOURIN MED, V70, P384; MAIMAN M, 1993, CANCER-AM CANCER SOC, V71, P402, DOI 10.1002/1097-0142(19930115)71:2<402::AID-CNCR2820710222>3.0.CO;2-Y; VACCA A, 1994, BRIT J OBSTET GYNAEC, V101, P363, DOI 10.1111/j.1471-0528.1994.tb13640.x; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VERKUYL DAA, 1994, BRIT J OBSTET GYNAEC, V101, P1088, DOI 10.1111/j.1471-0528.1994.tb13590.x; 1994, LANCET, V343, P1464	15	15	15	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					293	296		10.1016/S0140-6736(95)92171-0	http://dx.doi.org/10.1016/S0140-6736(95)92171-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630253				2022-12-28	WOS:A1995RL75700016
J	SCHILLER, PH				SCHILLER, PH			EFFECT OF LESIONS IN VISUAL CORTICAL AREA V4 ON THE RECOGNITION OF TRANSFORMED OBJECTS	NATURE			English	Article							STATE DEPENDENT ACTIVITY; BROAD-BAND CHANNELS; COLOR-OPPONENT; RHESUS-MONKEY; CORTEX; MACAQUE; DISCRIMINATION; PERCEPTION; VISION; DEPTH	THE primate visual system has a remarkable capability for recognizing objects irrespective of the multitude of images they form on the retinal surface by virtue of changes in size, perspective, contrast, colour and partial obstruction by other stimuli in the visual scene. There is increasing evidence that this remarkable capacity is brought about by processes that occur earlier in the visual system than had previously been thought(1-14). Here I show that after ablation of area V4 in the rhesus monkey, major deficits arise in the recognition of objects that have been transformed in size, in the degree of occlusion, and in the amount of contour information provided. The ability to detect these objects when presented individually was unaffected by these lesions.			SCHILLER, PH (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-634,CAMBRIDGE,MA 02139, USA.							DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1992, NATURE, V358, P756, DOI 10.1038/358756a0; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; HEYWOOD CA, 1992, J NEUROSCI, V12, P4056; HEYWOOD CA, 1987, J NEUROSCI, V7, P2601; HUBEL DH, 1970, NATURE, V225, P41, DOI 10.1038/225041a0; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2190; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1991, SCIENCE, V251, P1251, DOI 10.1126/science.2006413; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; SCHILLER PH, IN PRESS BEHAV BRAIN; WALSH V, 1992, BEHAV BRAIN RES, V50, P115, DOI 10.1016/S0166-4328(05)80293-1; WEISKRANTZ L, 1984, BRAIN, V107, P1033, DOI 10.1093/brain/107.4.1033; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0; ZEKI SM, 1973, BRAIN RES, V53, P422, DOI 10.1016/0006-8993(73)90227-8	20	64	64	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					342	344		10.1038/376342a0	http://dx.doi.org/10.1038/376342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630401				2022-12-28	WOS:A1995RL44300047
J	CLEMENTS, GB; GALBRAITH, DN; TAYLOR, KW				CLEMENTS, GB; GALBRAITH, DN; TAYLOR, KW			COXSACKIE-B VIRUS-INFECTION AND ONSET OF CHILDHOOD DIABETES	LANCET			English	Note							MELLITUS	Infection with Coxsackie B viruses has insulin-dependent diabetes mellitus. Nine samples (64%) taken from children at the onset of diabetes were positive for enterovirus RNA by PCR. All of the children were under age six, and five were under age three. By contrast, enterovirus sequences were detected in only two of 45 serum samples from appropriate comparison children (4%). Sequences from six of the positive patients showed strong homology with Coxsachie B3 and B4 viruses, and there were some common patterns among the sequences from infected diabetic children. This is evidence for a role for enteroviruses in childhood diabetes.	ROYAL LONDON HOSP,MED UNIT,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital	CLEMENTS, GB (corresponding author), RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND.							CLEMENTS GB, 1995, J MED VIROL, V45, P156, DOI 10.1002/jmv.1890450208; GALBRAITH DN, IN PRESS J GEN VIROL; HYSTY H, 1995, DIABETES, V44, P652; JONES DB, 1994, DIABETIC MED S2, V11, pS17; KANG Y, 1994, J MED VIROL, V44, P353, DOI 10.1002/jmv.1890440408; SOLIMENA M, 1995, NAT MED, V1, P25, DOI 10.1038/nm0195-25; SZOPA TM, 1993, DIABETOLOGIA, V36, P687, DOI 10.1007/BF00401138; TICHENER PA, 1994, J MED VIROL, V42, P369; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; ZOLL GJ, 1992, J CLIN MICROBIOL, V30, P160, DOI 10.1128/JCM.30.1.160-165.1992	10	206	210	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					221	223		10.1016/S0140-6736(95)91270-3	http://dx.doi.org/10.1016/S0140-6736(95)91270-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616803				2022-12-28	WOS:A1995RK41900012
J	SIGWART, U				SIGWART, U			NONSURGICAL MYOCARDIAL REDUCTION FOR HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY	LANCET			English	Article							MITRAL-VALVE REPLACEMENT; DISOPYRAMIDE; VERAPAMIL; THERAPY	Surgery has been the only therapeutic option in patients with hypertrophic obstructive cardiomyopathy who are resistant to drug treatment and sequential pacemaker therapy. I describe a novel catheter-based technique that may replace surgical myocardial reduction in some patients. The technique aims at selective destruction of the hypertrophied part of the left side of the intraventricular septum. If temporary occlusion of the first major septal artery is shown to reduce the intraventricular pressure gradient significantly, absolute alcohol is injected through the inflated balloon catheter to produce a localised infarct. In the first three patients treated with this method, the size of the septal infarct was sufficient to eliminate any subaortic stenosis immediately. Clinical improvement has been maintained up to 12 months. Non-surgical reduction of the septum in hypertrophic obstructive cardiomyopathy warrants further clinical evaluation.			SIGWART, U (corresponding author), ROYAL BROMPTON HOSP,DEPT INVAS CARDIOL,LONDON SW3 6NP,ENGLAND.							Bonow R O, 1988, Cardiovasc Clin, V19, P221; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BRAUNWALD E, 1989, NEW ENGL J MED, V320, P800, DOI 10.1056/NEJM198903233201209; CHAHINE RA, 1991, J AM COLL CARDIOL, V17, P642; CHATTERJEE K, 1987, AM J CARDIOL, V59, pB146, DOI 10.1016/0002-9149(87)90095-6; COKKINOS DV, 1989, CAN J CARDIOL, V5, P33; DUNCAN WJ, 1991, CAN J CARDIOL, V7, P81; FANANAPAZIR L, 1992, CIRCULATION, V85, P2149, DOI 10.1161/01.CIR.85.6.2149; Gietzen F., 1994, European Heart Journal, V15, P125; GRBIC M, 1982, CIRCULATION, V66, P268; Hassenstein P, 1975, Thoraxchir Vask Chir, V23, P496; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; JULIAN DG, 1989, DISEASES HEART, P933; KAPPENBERGER L, 1995, BRIT HEART J, V73, P107; KRAJCER Z, 1988, CIRCULATION, V78, P135; LEACHMAN RD, 1987, AM J CARDIOL, V60, P1416, DOI 10.1016/0002-9149(87)90637-0; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584; MCINTOSH CL, 1989, ANN THORAC SURG, V47, P236, DOI 10.1016/0003-4975(89)90277-4; MCINTOSH CL, 1988, CIRCULATION, V78, P487, DOI 10.1161/01.CIR.78.3.487; MOHR R, 1989, J THORAC CARDIOV SUR, V97, P666; MORROW AG, 1959, CIRCULATION, V20, P181, DOI 10.1161/01.CIR.20.2.181; POLLICK C, 1988, AM J CARDIOL, V62, P1252, DOI 10.1016/0002-9149(88)90269-X; SEILER C, 1991, J AM COLL CARDIOL, V17, P643; SHERRID M, 1988, AM J CARDIOL, V62, P1085, DOI 10.1016/0002-9149(88)90553-X; Sigwart U, 1983, VENTRICULAR WALL MOT, P206; Sigwart U, 1982, SCHWEIZ MED WOCHENSC, V45, P1631; WALKER WS, 1989, ANN THORAC SURG, V38, P528	29	539	609	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					211	214		10.1016/S0140-6736(95)91267-3	http://dx.doi.org/10.1016/S0140-6736(95)91267-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616800				2022-12-28	WOS:A1995RK41900009
J	THOMSON, R; LAVENDER, M; MADHOK, R				THOMSON, R; LAVENDER, M; MADHOK, R			FORTNIGHTLY REVIEW - HOW TO ENSURE THAT GUIDELINES ARE EFFECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; AUDIT		N TYNE HLTH, NEWCASTLE UPON TYNE, TYNE & WEAR, ENGLAND; S TYNE HLTH COMMISS, S SHIELDS, TYNE & WEAR, ENGLAND		THOMSON, R (corresponding author), UNIV NEWCASTLE, SCH MED, SCH HLTH CARE SCI, DEPT EPIDEMIOL & PUBL HLTH, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND.							[Anonymous], 1993, CHAMBERS DICT; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROWNBRIDGE G, 1986, J ROY COLL GEN PRACT, V36, P198; CHARLTON BG, 1993, LANCET, V342, P99, DOI 10.1016/0140-6736(93)91292-T; CHARLTON JRH, 1983, LANCET, V1, P691; Cluzeau F, 1994, Qual Health Care, V3, P121, DOI 10.1136/qshc.3.3.121; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; DELBECQ AL, 1975, TECHNIQUES PROGRAMME; EDDY DM, 1992, ASSESSING HLTH PRACT; Field MJ., 1992, GUIDELINES CLIN PRAC; Field MJ, 1990, CLIN PRACTICE GUIDEL; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HADORN DC, 1992, JAMA-J AM MED ASSOC, V267, P3311, DOI 10.1001/jama.267.24.3311; HAINES A, 1992, BMJ-BRIT MED J, V305, P785, DOI 10.1136/bmj.305.6857.785; HICKS NR, 1994, BRIT MED J, V309, P730, DOI 10.1136/bmj.309.6956.730; Hurwitz B, 1994, Qual Health Care, V3, P37, DOI 10.1136/qshc.3.1.37; LILFORD RJ, 1992, BMJ-BRIT MED J, V305, P1181, DOI 10.1136/bmj.305.6863.1181; Linstone H.A., 1975, DELPHI METHOD; MACLAREN RE, 1993, ARCH EMERG MED, V10, P138; Madhok R, 1994, Int J Qual Health Care, V6, P73; Madhok R, 1993, Qual Health Care, V2, P27, DOI 10.1136/qshc.2.1.27; MADHOK R, 1993, ORTHOPAEDIC KNOWLEDG, V4, P35; MCKEE M, 1995, BRIT MED J, V310, P101, DOI 10.1136/bmj.310.6972.101; MCKEOWN T, 1979, MED DREAM MIRAGE NEM; McNicol M, 1993, Qual Health Care, V2, P215, DOI 10.1136/qshc.2.4.215; PACKER GJ, 1991, BRIT MED J, V302, P885, DOI 10.1136/bmj.302.6781.885; Russell IT GJ, 1992, HOSP REFERRALS, P179; SHAW CD, 1990, BRIT MED J, V300, P649, DOI 10.1136/bmj.300.6725.649; THOMAS S, 1994, BRIT J GEN PRACT, V44, P242; Thomson R, 1994, Qual Health Care, V3, P65, DOI 10.1136/qshc.3.2.65; THOMSON RG, 1993, AUDIT PURCHASER PROV; 1993, CLIN AUDIR M IMPROVI; 1994, EFFECTIVE HLTH CARE; 1992, LANCET, V339, P1197; 1994, IMPROVING EFFECTIVEN; 1993, IMPROVING CLIN EFFEC; 1993, CLIN GUIDELINES REPO	40	136	138	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 22	1995	311	6999					237	242		10.1136/bmj.311.6999.237	http://dx.doi.org/10.1136/bmj.311.6999.237			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627044	Green Published			2022-12-28	WOS:A1995RL44100027
J	KORN, SJ; IKEDA, SR				KORN, SJ; IKEDA, SR			PERMEATION SELECTIVITY BY COMPETITION IN A DELAYED RECTIFIER POTASSIUM CHANNEL	SCIENCE			English	Article							CALCIUM CHANNELS; ION CONDUCTANCE; K+ CHANNEL; NEURONS; MUSCLE; CELLS	Permeation selectivity was studied in two human potassium channels, Kv2.1 and Kv1.5, expressed in a mouse cell line. With normal concentrations of potassium and sodium, both channels were highly selective for potassium. On removal of potassium, Kv2.1 displayed a large sodium conductance that was inhibited by low concentrations of potassium. The channel showed a competition mechanism of selectivity similar to that of calcium channels. In contrast, Kv1.5 displayed a negligible sodium conductance on removal of potassium. The observation that structurally similar potassium channels show different abilities to conduct sodium provides a basis for understanding the structural determinants of potassium channel selectivity.	MED COLL GEORGIA,DEPT PHARMACOL & TOXICOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University	KORN, SJ (corresponding author), UNIV CONNECTICUT,DEPT PHYSIOL & NEUROBIOL,BOX U-156,STORRS,CT 06269, USA.			Ikeda, Stephen/0000-0002-4088-9508				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BLATZ AL, 1984, J GEN PHYSIOL, V84, P1, DOI 10.1085/jgp.84.1.1; CALLAHAN MJ, 1994, J GEN PHYSIOL, V104, P747, DOI 10.1085/jgp.104.4.747; HAMILL OP, 1981, PFLUGERS ARCH, V381, P85; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1993, BIOPHYS J, V65, P2089, DOI 10.1016/S0006-3495(93)81244-X; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; IKEDA SR, 1992, PFLUG ARCH EUR J PHY, V422, P201, DOI 10.1007/BF00370422; IKEDA SR, 1995, J PHYSIOL-LONDON, V486, P267, DOI 10.1113/jphysiol.1995.sp020809; KORN SJ, UNPUB; LEVITT DG, 1978, BIOPHYS J, V22, P209, DOI 10.1016/S0006-3495(78)85485-X; REUTER H, 1980, J MEMBRANE BIOL, V57, P103, DOI 10.1007/BF01868997; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZHU Y, 1993, J PHYSIOL-LONDON, V468, P441, DOI 10.1113/jphysiol.1993.sp019781	18	83	85	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					410	412		10.1126/science.7618108	http://dx.doi.org/10.1126/science.7618108			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618108				2022-12-28	WOS:A1995RK42700051
J	WEISSKOPF, MG; NICOLL, RA				WEISSKOPF, MG; NICOLL, RA			PRESYNAPTIC CHANGES DURING MOSSY FIBER LTP REVEALED BY NMDA RECEPTOR-MEDIATED SYNAPTIC RESPONSES	NATURE			English	Article							LONG-TERM POTENTIATION; GUINEA-PIG HIPPOCAMPUS; RAT HIPPOCAMPUS; MECHANISMS; PROBABILITY; NEURONS; RELEASE; SLICES; FORMS; BRAIN	ACTIVITY-DEPENDENT changes in synaptic strength are important for learning and memory. Long-term potentiation (LTP) of glutamatergic excitatory synapses following brief repetitive stimulation provides a compelling cellular model for such plasticity(1-4). In the CA1 region of the hippocampus, anatomical studies have revealed large numbers of NMDA (N-methyl-D-aspartate) receptor sites at excitatory synapses(5,6), which express primarily an NMDA receptor-dependent form of LTP(7). In contrast, these studies(5,6) have suggested that messy fibre synapses activate primarily or exclusively alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and, indeed, these synapses express a form of LTP that is entirely independent of NMDA receptors(8,9). Here we present physiological data demonstrating that messy fibres activate a substantial NMDA receptor synaptic component that expresses LTP. The presence of an NMDA receptor response allowed us to use the open-channel NMDA receptor antagonist MK-801 to establish directly that the probability of transmitter release is enhanced during the expression of messy fibre LTP.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; GUSTAFSSON B, 1991, SEMIN NEUROSCI, V2, P321; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; ISAACSON JS, 1990, SOC NEUR ABSTR, V20, P468; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SCHARFMAN HE, 1994, NEUROPHYSIOL, V72, P2167; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; YAMAMOTO C, 1983, EXP BRAIN RES, V51, P128; YAMAMOTO C, 1992, NEUROSCI LETT, V138, P111, DOI 10.1016/0304-3940(92)90484-O; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	27	153	155	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					256	259		10.1038/376256a0	http://dx.doi.org/10.1038/376256a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617037				2022-12-28	WOS:A1995RK33100047
J	BARNES, DE; HANAUER, P; SLADE, J; BERO, LA; GLANTZ, SA				BARNES, DE; HANAUER, P; SLADE, J; BERO, LA; GLANTZ, SA			ENVIRONMENTAL TOBACCO-SMOKE - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PASSIVE SMOKING; LUNG-CANCER; HEART-DISEASE	Objective.-To examine the tobacco industry's public and private responses to rising concern over the health effects of environmental tobacco smoke (ETS). Data Sources.-Documents from Brown and Williamson Tobacco Corporation (B&W), the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-Privately, B&W and BAT began conducting research related to ETS in the mid 1970s. BAT researchers appear to have determined that sidestream smoke produces irritation, that it contains toxic substances including N-nitrosamines, and that it is ''biologically active'' (eg, carcinogenic) in laboratory tests. During the 1980s, the primary purpose of BAT's research related to ETS was to develop a new cigarette that emitted less irritating and less biologically active sidestream smoke. Publicly, the tobacco industry has denied that exposure to ETS has been proven dangerous to health. It has criticized the methodology of published research on ETS, even when some of its own consultants have privately acknowledged that the research was valid, In addition, the industry has funded scientific research with the stated purpose of anticipating and refuting the evidence against ETS. The tobacco industry's strategy regarding passive smoking has been remarkarbly similar to its strategy regarding active smoking. it has privately conducted internal research, at least some of which has supported the conclusion that passive smoking is dangerous to health, while it has publicly denied that the hazards have been proven.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN L, 1977, NY TIMES        0918, P29; [Anonymous], 1986, ENV TOBACCO SMOKE ME; BECKER CG, 1979, AM J PATHOL, V96, P249; BECKER CG, 1977, J EXP MED, V146, P457, DOI 10.1084/jem.146.2.457; BECKER CG, 1976, P NATL ACAD SCI USA, V73, P1712, DOI 10.1073/pnas.73.5.1712; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; Brunnemann K D, 1978, IARC Sci Publ, P343; BRUNNEMANN KD, 1977, CANCER RES, V37, P3218; CUDDEBACK JE, 1976, AM IND HYG ASSOC J, V37, P263, DOI 10.1080/0002889768507453; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FRIEDMAN A, 1993, WALL STREET J   0211, pA1; GARFINKEL L, 1981, JNCI-J NATL CANCER I, V66, P1061, DOI 10.1093/jnci/66.6.1061; GIDDING SS, 1994, CIRCULATION, V90, P2582; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1992, J CLIN EPIDEMIOL, V45, P815, DOI 10.1016/0895-4356(92)90063-S; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; GLANTZ SA, 1983, 12TH P WORLD C TOB H, P287; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; HOFFMANN D, 1994, J TOXICOL ENV HEALTH, V41, P1, DOI 10.1080/15287399409531825; Levin M, 1993, NATION          0809, P168; LEVY D, 1994, USA TODAY       0621, pD1; RUSSELL MAH, 1973, LANCET, V1, P576; Taylor Peter, 1984, SMOKE RING TOBACCO M; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; TURNER S, 1992, ENVIRON INT, V18, P19, DOI 10.1016/0160-4120(92)90207-K; 1992, EPA600690006F; 1993, ANN REV SUMMARY FINA; 1981, BRIT MED J, V283, P914; 1994, ENV TOBACCO SMOKE IN; 1994, OVERSIGHT HEARING TO; 1986, PHS CDC878398 US DEP; 1986, TOBACCO SMOKE NONSMO	34	65	65	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					248	253		10.1001/jama.274.3.248	http://dx.doi.org/10.1001/jama.274.3.248			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609234				2022-12-28	WOS:A1995RH93700031
J	MAYS, N; POPE, C				MAYS, N; POPE, C			RIGOUR AND QUALITATIVE RESEARCH	BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES		UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 6TP,LEICS,ENGLAND	University of Leicester	MAYS, N (corresponding author), KINGS FUND INST,LONDON W2 4HT,ENGLAND.		Cislaghi, Beniamino Ferdinando/A-4811-2009; jittitaworn, wareerat/G-9191-2016					Brannen, 2017, MIXING METHODS QUALI, P3; BRITTEN N, 1993, BRIT J GEN PRACT, V43, P270; Dingwall R, 1992, RES HLTH CARE, P161; Fielding N., 1993, ETHNOGRAPHY RES SOCI; FOWKES FGR, 1991, BRIT MED J, V302, P1136, DOI 10.1136/bmj.302.6785.1136; GARDNER MJ, 1986, BRIT MED J, V292, P810, DOI 10.1136/bmj.292.6523.810; Glaser B.G., 1965, AWARENESS DYING; Krippendorff K., 1980, CONTENT ANAL INTRO I; McKeganey N. P., 1981, INT J SOCIOLOGY SOCI, V1, P58; MECHANIC D, 1989, J HEALTH SOC BEHAV, V30, P147, DOI 10.2307/2137009; Oakley A., 1974, HOUSEWIFE; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; POLLITT C, 1990, J SOC POLICY, V19, P169, DOI 10.1017/S0047279400001987; Seidel J., 1984, QUALITATIVE SOCIOLOG, V7, P110, DOI DOI 10.1007/BF00987111; SILVERMAN D, 1981, SOCIOLOGY HLTH ILLNE, V3, P254, DOI DOI 10.1111/shil.1981.3.issue-3; SILVERMAN D, 1992, RES HLTH CARE DESIGN, P176; SILVERMAN D, 1989, QUAL QUANT, P57; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; Willis, 1992, RES HLTH CARE DESIGN, P189; 1984, CAN MED ASSOC J, V130, P1542	20	1520	1542	1	130	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					109	112		10.1136/bmj.311.6997.109	http://dx.doi.org/10.1136/bmj.311.6997.109			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ030	7613363	Green Published			2022-12-28	WOS:A1995RJ03000028
J	LEAKEY, MG; FEIBEL, CS; MCDOUGALL, I; WALKER, A				LEAKEY, MG; FEIBEL, CS; MCDOUGALL, I; WALKER, A			NEW 4-MILLION-YEAR-OLD HOMINID SPECIES FROM KANAPOI AND ALLIA BAY, KENYA	NATURE			English	Article							HADAR FORMATION; ETHIOPIA; AUSTRALOPITHECUS; MORPHOLOGY; TURKANA	Nine hominid dental, cranial and postcranial specimens from Kanapoi, Henya, and 12 specimens from Allia Bay, Kenya, are described here as a new species of Australopithecus dating from between about 3.9 million and 4.2 million years ago. The mosaic of primitive and derived features shows this species to be a possible ancestor to Australopithecus afarensis and suggests that Ardipithecus ramidus is a sister species to this and all later hominids. A tibia establishes that hominids were bipedal at least half a million years before the previous earliest evidence showed.	RUTGERS STATE UNIV, DEPT ANTHROPOL, NEW BRUNSWICK, NJ 08903 USA; AUSTRALIAN NATL UNIV, RES SCH EARTH SCI, CANBERRA, ACT 0200, AUSTRALIA; PENN STATE UNIV, DEPT ANTHROPOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT BIOL, UNIVERSITY PK, PA 16802 USA	Rutgers State University New Brunswick; Australian National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	LEAKEY, MG (corresponding author), NATL MUSEUMS KENYA, POB 40658, NAIROBI, KENYA.		Klein, Richard G/B-5910-2009					Aiello L, 1990, INTRO HUMAN EVOLUTIO; Brown F. H., 1991, KOOBI FORA RES PROJE, V3, P1; Cebula G.T., 1986, TERRA COGNITA, V6, P139; COFFING K, 1994, AM J PHYS ANTHROPOL, V93, P55, DOI 10.1002/ajpa.1330930104; Day M.H., 1978, EARLY HOMINIDAFRIC, P311; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; Harris J.M., 1987, P524; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; KOHLLARSON L, 1942, SPUREN VORMENSCHEN F; LATIMER B, 1987, AM J PHYS ANTHROPOL, V74, P155, DOI 10.1002/ajpa.1330740204; MCDOUGALL I, 1985, GEOL SOC AM BULL, V96, P159, DOI 10.1130/0016-7606(1985)96<159:KAADOT>2.0.CO;2; MCDOUGALL I, 1988, GEOCHRONOLOGY THERMO; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; NAMWAMBA F, 1983, THESIS U UTAH; PATTERSON B, 1967, SCIENCE, V156, P64, DOI 10.1126/science.156.3771.64; PUECH PF, 1986, J HUM EVOL, V15, P325, DOI 10.1016/S0047-2484(86)80015-X; SENUT B, 1980, COLLEGIUM ANTROPOL, V4, P87; Senut B., 1985, P193; STEVEN TA, 1967, US GEOL SURV PROF D, V575, P47; WARD SC, 1982, AM J PHYS ANTHROPOL, V57, P605, DOI 10.1002/ajpa.1330570407; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	25	343	354	1	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					565	571		10.1038/376565a0	http://dx.doi.org/10.1038/376565a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP756	7637803				2022-12-28	WOS:A1995RP75600043
J	PERINI, G; WAGNER, S; GREEN, MR				PERINI, G; WAGNER, S; GREEN, MR			RECOGNITION OF BZIP PROTEINS BY THE HUMAN T-CELL LEUKEMIA-VIRUS TRANSACTIVATOR TAX	NATURE			English	Article							DNA-BINDING SPECIFICITY; LEUCINE ZIPPER MOTIF; ZTA TRANSACTIVATOR; YEAST GCN4; DOMAIN; DIMERIZATION; ACTIVATOR; FAMILY; CREB; AP-1	HUMAN T-cell leukaemia virus type I(HTLV-I) Tax protein increases the DNA binding of many cellular transcription factors that contain a basic region-leucine zipper (bZIP) DNA-binding domain(1-3). bZIP domains comprise a leucine-rich dimerization motif and a basic region that mediates DNA contact. How Tax recognizes diverse bZIPs is not understood. Here we show that no specific sequence of the leucine zipper is required for a Tax response. In contrast, the basic region is essential for the Tax-mediated DNA-binding increase, which can be eliminated by single substitutions of several conserved amino acids. Surprisingly, Tax alters the relative affinity of a bZIP for different DNA binding sites. Thus, through recognition of the conserved basic region, Tax increases DNA binding and modifies DNA site selection. Tax provides a model for how a single auxiliary factor can regulate multiple sequence-specific DNA-binding proteins.			PERINI, G (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605, USA.							ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEI D, 1994, P NATL ACAD SCI USA, V91, P11318; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	16	136	136	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					602	605		10.1038/376602a0	http://dx.doi.org/10.1038/376602a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637811				2022-12-28	WOS:A1995RP75600054
J	HARRISON, PJ				HARRISON, PJ			S182 - FROM WORM SPERM TO ALZHEIMERS-DISEASE	LANCET			English	Editorial Material							MEMBRANE-PROTEIN; MUTATION; GENE		UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN NEUROL NEUROPATHOL,OXFORD,ENGLAND	Radcliffe Infirmary; University of Oxford	HARRISON, PJ (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD,ENGLAND.			Harrison, Paul/0000-0002-6719-1126				GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; HARRISON P, 1993, BRIT J PSYCHIAT, V163, P2, DOI 10.1192/bjp.163.1.2; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; SCHELLENBERG G, 1991, SCIENCE, V258, P668; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405; 1991, LANCET, V337, P1342	10	1	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					388	388		10.1016/S0140-6736(95)92773-5	http://dx.doi.org/10.1016/S0140-6736(95)92773-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623564				2022-12-28	WOS:A1995RN65600002
J	MADDOX, J				MADDOX, J			DIRECTORY TO THE HUMAN GENOME	NATURE			English	Article																			0	7	7	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					459	460		10.1038/376459a0	http://dx.doi.org/10.1038/376459a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637774				2022-12-28	WOS:A1995RN62200017
J	JACKMAN, RJ; WILBUR, JL; WHITESIDES, GM				JACKMAN, RJ; WILBUR, JL; WHITESIDES, GM			FABRICATION OF SUBMICROMETER FEATURES ON CURVED SUBSTRATES BY MICROCONTACT PRINTING	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; GOLD	Microcontact printing (mu CP) has been used to produce patterned self-assembled monolayers (SAMs) with submicrometer features on curved substrates with radii of curvature as small as 25 micrometers. Wet-chemical etching that uses the patterned SAMs as resists transfers the patterns formed by mu CP into gold. At present, there is no comparable method for microfabrication on curved surfaces.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016511] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-F32 GM16511-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Feely W. E., 1988, 1988 Solid State Sensor and Actuator Workshop. Technical Digest (Cat. No.88TH0215-4), P13, DOI 10.1109/SOLSEN.1988.26421; JACOBSEN SC, 1991, IEEE MICRO ELECTRO MECHANICAL SYSTEMS, P45; JACOBSEN SC, 1989, 1989 IEEE INT C ROBA, V3, P1536; JACOBSEN SC, 1989, FEB P IEEE MICR EL M, P17; KIM E, 1995, J ELECTROCHEM SOC, V142, P628, DOI 10.1149/1.2044112; KUMAR A, 1992, J AM CHEM SOC, V114, P9188, DOI 10.1021/ja00049a061; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; LOPEZ GP, 1993, LANGMUIR, V9, P1513, DOI 10.1021/la00030a015; Puddephatt R.J., 1978, CHEM GOLD; WILBUR JL, 1994, ADV MATER, V6, P600, DOI 10.1002/adma.19940060719; WILBUR JL, IN PRESS ADV MAT; XIA Y, UNPUB; XIA Y, 1994, J AM CHEM SOC, V117, P3274; XIA YN, 1995, ADV MATER, V7, P471, DOI 10.1002/adma.19950070513	15	364	410	3	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					664	666		10.1126/science.7624795	http://dx.doi.org/10.1126/science.7624795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624795				2022-12-28	WOS:A1995RM70200024
J	AVERY, AC; ZHAO, ZS; RODRIGUEZ, A; BIKOFF, EK; SOHEILIAN, M; FOSTER, CS; CANTOR, H				AVERY, AC; ZHAO, ZS; RODRIGUEZ, A; BIKOFF, EK; SOHEILIAN, M; FOSTER, CS; CANTOR, H			RESISTANCE TO HERPES STROMAL KERATITIS CONFERRED BY AN IGG2A-DERIVED PEPTIDE	NATURE			English	Article							T-CELL CLONES; SIMPLEX KERATITIS; ANTIGEN; MICE; MHC; UNRESPONSIVENESS; SUSCEPTIBILITY; DETERMINANTS; LYMPHOCYTES; ALLOTYPE	NOT all peripheral tissue antigens enter the thymus and it is unclear how the immune system remains tolerant to this class of self antigen. As tolerance to self peptides can generate gaps in the T-cell repertoire for cross-reactive foreign antigens(1,2), we investigated whether this mechanism might also diminish autoimmune reactions to similar peptides expressed by peripheral tissues. Herpes stromal keratitis (HSK) is a virally induced autoimmune reaction against corneal tissues mediated by T cells(3-5), and is a leading cause of human blindness(6). Resistance to HSK in mice is associated with allotypic variation in immunoglobulin genes(7,8), possibly because circulating immunoglobin-derived peptides can cross-tolerize T cells specific for corneal tissue autoantigens. Here we show that HSK is mediated by T-cell clones specific for corneal self antigens which also recognize an allotype-bearing peptide derived from IgG2a, and that exposure of HSK-susceptible mice to a soluble form of this peptide confers resistance to HSK. Shared expression of peptide subsequences between sequestered tissue proteins and circulating proteins may be important for maintenance of self-tolerance and prevention of autoimmunity.	HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM,SCH MED, DEPT OPHTHALMOL,HILLES IMMUNOL LAB, BOSTON, MA 02114 USA; HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University	AVERY, AC (corresponding author), HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT PATHOL, IMMUNOPATHOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.		Soheilian, Masoud/AAW-4743-2020; Rodriguez-Garcia, Alejandro/AAI-1045-2019; Avery, Anne/J-8405-2017	Rodriguez-Garcia, Alejandro/0000-0002-1419-2109; Soheilian, Masoud/0000-0001-7508-426X				ABROMSONLEEMAN S, 1995, J IMMUNOL, V154, P388; AKOVA YA, 1993, CURR EYE RES, V12, P1093, DOI 10.3109/02713689309033507; ALEXANDER RJ, 1981, EXP EYE RES, V32, P205, DOI 10.1016/0014-4835(81)90009-9; BARTNES K, 1991, EUR J IMMUNOL, V21, P2365, DOI 10.1002/eji.1830211011; BIKOFF E, 1986, J IMMUNOL, V137, P28; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1411, DOI 10.1002/eji.1830210613; BIKOFF EK, 1989, EUR J IMMUNOL, V19, P1903, DOI 10.1002/eji.1830191022; CALLANAN D, 1988, TRANSPLANTATION, V45, P437, DOI 10.1097/00007890-198802000-00039; CLAVERIE JM, 1988, EUR J IMMUNOL, V18, P1547, DOI 10.1002/eji.1830181012; DAWSON C, 1976, SURV OPHTHALMOL, V21, P11; DEWIT D, 1992, J EXP MED, V175, P9, DOI 10.1084/jem.175.1.9; FELLER DC, 1991, NATURE, V349, P720, DOI 10.1038/349720a0; FOSTER CS, 1986, CLIN IMMUNOL IMMUNOP, V40, P313, DOI 10.1016/0090-1229(86)90036-X; FRIEDMAN S, 1987, IMMUNOGENETICS, V26, P193, DOI 10.1007/BF00346512; GARCHON HJ, 1991, HUM IMMUNOL, V32, P1, DOI 10.1016/0198-8859(91)90113-N; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; MARSHAKROTHSTEIN A, 1980, P NATL ACAD SCI-BIOL, V77, P1120, DOI 10.1073/pnas.77.2.1120; MATZINGER P, 1981, NATURE, V292, P497, DOI 10.1038/292497a0; MERCADAL CM, 1993, J VIROL, V67, P3404, DOI 10.1128/JVI.67.6.3404-3408.1993; METCALF JF, 1979, INFECT IMMUN, V26, P1164, DOI 10.1128/IAI.26.3.1164-1171.1979; MOUDGIL KD, 1993, J EXP MED, V178, P2131, DOI 10.1084/jem.178.6.2131; Niederkorn J Y, 1990, Adv Immunol, V48, P191, DOI 10.1016/S0065-2776(08)60755-5; OPREMCAK EM, 1990, INVEST OPHTH VIS SCI, V31, P305; OPREMCAK EM, 1988, INVEST OPHTH VIS SCI, V29, P749; ROSS J, 1989, Investigative Ophthalmology and Visual Science, V30, P442; RUSSELL RG, 1984, INVEST OPHTH VIS SCI, V25, P938; VIDOVIC D, 1988, NATURE, V336, P222, DOI 10.1038/336222a0	27	99	101	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					431	434		10.1038/376431a0	http://dx.doi.org/10.1038/376431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630419				2022-12-28	WOS:A1995RM63900053
J	BOICE, JD; MANDEL, JS; DOODY, MM				BOICE, JD; MANDEL, JS; DOODY, MM			BREAST-CANCER AMONG RADIOLOGIC TECHNOLOGISTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; RISK; RADIATION; THERAPY; MORTALITY; WORKERS; TUBERCULOSIS; EPIDEMIOLOGY; RADIOTHERAPY; CHILDHOOD	Objective.-To evaluate the risk of breast cancer among women occupationally ex Design.-Case-control study. Participants.-A health survey of 105 385 women radiologic technologists certified by the American Registry of Radiologic Technologists since 1926. Among 79016 respondents, 600 breast cancer cases were identified. Each of 528 eligible subjects with breast cancer was matched to five control subjects based on age, year of certification, and follow-up time. Main Outcome Measures.-Relative risk (RR) estimated as the relative odds ratio for breast cancer over categories of years worked as a radiologic technologist and according to personal and occupational exposure characteristics. Results.-Study subjects had been certified for a mean of 29 years; 63.8% of cases and 62.6% of controls worked as radiologic technologists for 10 years or more. Significant increased risks for breast cancer were associated with early age at menarche (for <11 years of age: RR=1.79; 95% confidence interval [CI], 1.09 to 2.94), nulliparity (RR=1.36; 95% CI, 1.04 to 1.78), first-degree relative with history of breast cancer(RR=2.07; 95% CI, 1.56 to 2.74), prior breast biopsy (RR=1.53; 95% CI, 1.17 to 2.00), alcohol consumption (for >14 alcoholic drinks per week: RR=2.12; 95% CI, 1.06 to 4.27), thyroid cancer (RR=5.36; 95% CI, 1.64 to 17.5), hyperthyroidism (RR=1.66; 95% CI, 1.02 to 2.71), and residence in the northeastern United States (RR=1.66; 95% CI, 1.19 to 2.30). Jobs involving radiotherapy, radioisotopes, or fluoroscopic equipment, however, were not linked to breast cancer risk, nor were personal exposures to fluoroscopy or multifilm procedures. Use of birth control pills, postmenopausal estrogens, or permanent hair dyes also were not risk factors. Based on dosimetry records for 35% of study subjects, cumulative exposures appeared low. Among women who worked more than 20 years, the RR for breast cancer was 1.13 (95% CI, 0.79 to 1.64). Conclusions.-More than 50% of the reported breast cancers could be explained by established risk factors. Employment as a radiologic technologist, however, was not found to increase the risk of breast cancer. The contribution of prolonged exposure to relatively low doses of ionizing radiation to breast cancer risk was too small to be detectable at this time.	UNIV MINNESOTA, SCH PUBL HLTH, DIV ENVIRONM & OCCUPAT HLTH, MINNEAPOLIS, MN USA	University of Minnesota System; University of Minnesota Twin Cities	BOICE, JD (corresponding author), NCI, RADIAT EPIDEMIOL BRANCH, 6130 EXECUT BLVD, EPN ROOM 408, BETHESDA, MD 20892 USA.				DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP005609, N01CP085604, N01CP095614] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP9-5614, N01-CP8-5604, N01-CP0-5609] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, SOURCES EFFECTS IONI; BAVERSTOCK KF, 1989, BIR REPORT, P72; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; BOICE JD, 1992, CANCER, V69, P586, DOI 10.1002/1097-0142(19920115)69:2<586::AID-CNCR2820690251>3.0.CO;2-3; BOICE JD, 1989, INT J CANCER, V44, P7, DOI 10.1002/ijc.2910440103; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; FURST CJ, 1988, JNCI-J NATL CANCER I, V80, P1387, DOI 10.1093/jnci/80.17.1387; GILBERT ES, 1993, RADIAT RES, V136, P408, DOI 10.2307/3578555; GREEN A, 1987, JNCI-J NATL CANCER I, V79, P253; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HIDRETH NG, 1989, NEW ENGL J MED, V321, P1281; HOFFMAN DA, 1989, J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; KENDALL GM, 1992, BRIT MED J, V304, P220, DOI 10.1136/bmj.304.6821.220; KEREIAKES JG, 1980, HDB RAD DOSES NUCLEA; LI FP, 1983, CANCER, V51, P521, DOI 10.1002/1097-0142(19830201)51:3<521::AID-CNCR2820510325>3.0.CO;2-U; LONDON S J, 1989, Journal of the American Medical Association, V262, P2853, DOI 10.1001/jama.262.20.2853; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; LUCAS JN, 1992, INT J RADIAT BIOL, V62, P53, DOI 10.1080/09553009214551821; MACKENZI.I, 1965, BRIT J CANCER, V19, P1, DOI 10.1038/bjc.1965.1; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679; MCLAUGHLIN JR, 1993, INT J EPIDEMIOL, V22, P584, DOI 10.1093/ije/22.4.584; MILLER AB, 1989, NEW ENGL J MED, V321, P1285, DOI 10.1056/NEJM198911093211902; PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; STEBBINGS JH, 1984, AM J IND MED, V5, P435, DOI 10.1002/ajim.4700050604; STRAUME T, 1992, HEALTH PHYS, V62, P122, DOI 10.1097/00004032-199202000-00001; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; WANEBO CK, 1968, NEW ENGL J MED, V279, P667, DOI 10.1056/NEJM196809262791301; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519; WEISS HA, 1994, INT J CANCER, V59, P327, DOI 10.1002/ijc.2910590307; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505	42	52	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					394	401		10.1001/jama.274.5.394	http://dx.doi.org/10.1001/jama.274.5.394			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616635				2022-12-28	WOS:A1995RL41600025
J	NISHIMURA, S				NISHIMURA, S			THE US MEDICAL OCCUPATION OF JAPAN AND HISTORY OF THE JAPANESE-LANGUAGE EDITION OF JAMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV TORONTO,INST HIST & PHILOSOPHY SCI & TECHNOL,TORONTO,ON,CANADA	University of Toronto								HENSHU YT, 1950, JAMA NIHONBAN, V3, P271; HENSHUSHITSU YT, 1949, JAMA NIHONBAN, V1, P69; MIYAZAWA Y, 1980, JAMA NIHONGOBAN, V1, P186; MORTON MC, 1947, CCD SCAP PAPERS; NUGENT DR, 1947, COMMUNICATION   0714; NUGENT DR, 1947, COMMUNICATION   0925; NUGENT DR, 1948, COMMUNICATION   0430; NUGENT DR, 1947, COMMUNICATION   1004; OGATA T, 1948, IGAKU AYUMI     1201, P24; SAMS CF, UNPUB MEDIC; SAMS CF, 1954, COMMUNICATION, P3; SAMS CF, 1948, COMMUNICATION   0304; SEGI M, 1948, NIHON IJI SHINP 0226, P17; TAKEMI T, 1980, JAMA NIHONGOBAN, V1, P132; VEITH I, 1950, CIBA F S, V2, P1214; YAMANOHA T, 1946, NIHON RINSHO KEKKAKU, V6, P111; ZAHN RR, 1947, COMMUNICATION   1103; 1948, RINSHO FUJINKA  1201, P2; 1946, NIHON IJI SHINP 1001, P18	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					436	438						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL416	7616642				2022-12-28	WOS:A1995RL41600033
J	EISENBERG, L				EISENBERG, L			MEDICINE - MOLECULAR, MONETARY, OR MORE THAN BOTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; PROSTATE				EISENBERG, L (corresponding author), HARVARD UNIV,SCH MED,DEPT SOCIAL MED,641 HUNTINGTON AVE,BOSTON,MA 02115, USA.							BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; BLACK WC, 1993, NEW ENGL J MED, V328, P1267; Blaese R M, 1992, Immunodefic Rev, V3, P329; BROOK RH, 1988, LANCET, V1, P750; Cook-Degan R, 1994, GENE WARS SCI POLITI; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; CRAFT N, 1994, BRIT MED J, V309, P1670; Dawson N.A., 1994, PROSTATE CANCER; EISENBERG L, 1980, AM J MED, V69, P277, DOI 10.1016/0002-9343(80)90389-7; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; Fleming C, 1993, JAMA, V269, P2650; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GARNICK MB, 1993, SCI AM MED, V12, P1; GINZBERG E, 1984, NEW ENGL J MED, V310, P1162, DOI 10.1056/NEJM198405033101806; HAMPTON JR, 1975, BRIT MED J, V1, P486; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; Hartley R M, 1987, Am J Med, V82, P513, DOI 10.1016/0002-9343(87)90452-9; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MCKINLAY JB, 1988, INT J HEALTH SERV, V18, P191, DOI 10.2190/YEVW-6C44-YCYE-CGEU; MCKINLAY JB, 1985, INT J HEALTH SERV, V15, P161, DOI 10.2190/JBMN-C0W6-9WFQ-Q5A6; MONTIE JE, 1989, CANCER, V63, P381, DOI 10.1002/1097-0142(19890115)63:2<381::AID-CNCR2820630230>3.0.CO;2-O; MULLEY A, 1994, OUTCOMES CLIN PRACTI, P13; MUMFORD E, 1984, AM J PSYCHIAT, V141, P1145; PEABODY FW, 1927, JAMA-J AM MED ASSOC, V88, P87; PETERSON MC, 1992, WESTERN J MED, V156, P163; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; 1994, AM J PREV MED, V10, P187	34	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					331	334						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609263				2022-12-28	WOS:A1995RJ89800036
J	JAMES, JA; LAING, GJ; LOGAN, S				JAMES, JA; LAING, GJ; LOGAN, S			CHANGING PATTERNS OF IRON-DEFICIENCY ANEMIA IN THE 2ND YEAR OF LIFE	BRITISH MEDICAL JOURNAL			English	Article									ST LEONARDS HOSP,DEPT COMMUNITY CHILD HLTH,LONDON N1 5LZ,ENGLAND; INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1 1EH,ENGLAND	University of London; University College London	JAMES, JA (corresponding author), MONTPELIER HLTH CTR,BATH BLDG,BRISTOL BS6 5PT,AVON,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; HALL DMB, 1991, HLTH ALL CHILDREN PR; IDRADINATA P, 1993, LANCET, V341, P1; JAMES J, 1989, BRIT MED J, V299, P838, DOI 10.1136/bmj.299.6703.838; LOZOFF B, 1994, J PEDIATR-US, V125, P577	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					230	230		10.1136/bmj.311.6999.230	http://dx.doi.org/10.1136/bmj.311.6999.230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627036	Green Published			2022-12-28	WOS:A1995RL44100019
J	DUYAO, MP; AUERBACH, AB; RYAN, A; PERSICHETTI, F; BARNES, GT; MCNEIL, SM; GE, P; VONSATTEL, JP; GUSELLA, JF; JOYNER, AL; MACDONALD, ME				DUYAO, MP; AUERBACH, AB; RYAN, A; PERSICHETTI, F; BARNES, GT; MCNEIL, SM; GE, P; VONSATTEL, JP; GUSELLA, JF; JOYNER, AL; MACDONALD, ME			INACTIVATION OF THE MOUSE HUNTINGTONS-DISEASE GENE HOMOLOG HDH	SCIENCE			English	Article							FRAGILE-X-SYNDROME; EXPRESSION; FMR-1; CELLS; MICE	Huntington's disease (HD) is a dominant neurodegenerative disorder caused by expansion of a CAG repeat in the gene encoding huntingtin, a protein of unknown function. To distinguish between ''loss of function'' and ''gain of function'' models of HD, the murine HD homolog Hdh was inactivated by gene targeting. Mice heterozygous for Hdh inactivation were phenotypically normal, whereas homozygosity resulted in embryonic death. Homozygotes displayed abnormal gastrulation at embryonic day 7.5 and were resorbing by day 8.5. Thus, huntingtin is critical early in embryonic development, before the emergence of the nervous system. That Hdh inactivation does not mimic adult HD neuropathology suggests that the human disease involves a gain of function.	MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129; MT SINAI HOSP,DIV MOLEC & DEV BIOL,TORONTO,ON M5G 1X5,CANADA; MASSACHUSETTS GEN HOSP,MOLEC NEUROPATHOL LAB,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Harvard University; Massachusetts General Hospital				Persichetti, Francesca/0000-0002-9804-644X	NINDS NIH HHS [NS16367, NS32765] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032765, P01NS016367, P50NS016367] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; [Anonymous], 1994, CELL, V78, P23; BARNES GT, 1994, SOMAT CELL MOLEC GEN, V20, P87, DOI 10.1007/BF02290678; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE; GUSELLA JF, 1995, SEMIN CELL BIOL, V6, P21, DOI 10.1016/1043-4682(95)90011-X; GUSELLA JF, 1993, ARCH NEUROL-CHICAGO, V50, P1157, DOI 10.1001/archneur.1993.00540110037003; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Joyner AL, 1993, GENE TARGETING PRACT; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; WURST W, 1993, GENE TARGETING PRACT, P31; 1993, CELL, V72, P971	31	514	531	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					407	410		10.1126/science.7618107	http://dx.doi.org/10.1126/science.7618107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618107				2022-12-28	WOS:A1995RK42700050
J	DULBECCO, R				DULBECCO, R			SALK,JONAS (1914-95) - OBITUARY	NATURE			English	Item About an Individual											DULBECCO, R (corresponding author), SALK INST,POB 85800,SAN DIEGO,CA 92186, USA.								0	2	2	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					216	216		10.1038/376216a0	http://dx.doi.org/10.1038/376216a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617027				2022-12-28	WOS:A1995RK33100028
J	BERO, L; BARNES, DE; HANAUER, P; SLADE, J; GLANTZ, SA				BERO, L; BARNES, DE; HANAUER, P; SLADE, J; GLANTZ, SA			LAWYER CONTROL OF THE TOBACCO INDUSTRYS EXTERNAL RESEARCH-PROGRAM - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the involvement of tobacco industry lawyers in the selection of tobacco industry scientific research projects and to examine how the research was used to influence public policy. Data Sources.-Documents from Brown and Williamson Tobacco Corporation, the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, and received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-The involvement of tobacco industry lawyers in the selection of scientific projects to be funded is in sharp contrast to the industry's public statements about its review process for its external research program. Scientific merit played little role in the selection of external research projects, The results of the projects were used to generate good publicity for the industry, to deflect attention away from tobacco use as a health danger, and to attempt, sometimes surreptitiously, to influence policymakers.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARM,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BECKER CG, 1977, J EXP MED, V146, P457, DOI 10.1084/jem.146.2.457; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; BERO LA, 1993, TOB CONTROL, V2, P103; DURBIN R, 1993, TOB CONTROL, V2, P8; FRIEDMAN GD, 1979, NEW ENGL J MED, V300, P213, DOI 10.1056/NEJM197902013000501; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; 1992, EPA600690006F; 1964, US DHEW PHS PUBLICAT, V1103; 1992, 1992 COUNC TOB RES R	13	76	76	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					241	247		10.1001/jama.274.3.241	http://dx.doi.org/10.1001/jama.274.3.241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609233				2022-12-28	WOS:A1995RH93700030
J	KNAUS, UG; MORRIS, S; DONG, HJ; CHERNOFF, J; BOKOCH, GM				KNAUS, UG; MORRIS, S; DONG, HJ; CHERNOFF, J; BOKOCH, GM			REGULATION OF HUMAN-LEUKOCYTE P21-ACTIVATED KINASES THROUGH G-PROTEIN-COUPLED RECEPTORS	SCIENCE			English	Article							NEUTROPHIL NADPH OXIDASE; ACTIVATION; PHOSPHORYLATION; GTP; TRANSLOCATION; STIMULATION; REQUIREMENT; COMPONENTS	The Rac guanosine 5'-triphosphate (GTP)-binding proteins regulate oxidant production by phagocytic leukocytes. Two Ste20-related p21-activated kinases (PAKs) were identified as targets of Rac in human neutrophils. Activity of the similar to 65- and similar to 68-kilodalton PAKs was rapidly stimulated by chemoattractants acting through pertussis toxin-sensitive heterotrimeric GTP-binding proteins (G proteins). Native and recombinant PAKs phos phorylated the p47(phox) reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase component in a Rac-GTP-dependent manner. The action of PAKs during phagocyte activation by G protein-coupled pathways may contribute to regulation of NADPH oxidase activity.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Scripps Research Institute; Fox Chase Cancer Center	KNAUS, UG (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIAMS NIH HHS [P60 AR40770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOKOCH GM, 1991, CURRENT TOPICS MEMBR, V35, P65; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DING JB, 1993, J BIOL CHEM, V268, P17326; DORSEUIL O, IN PRESS J LEUKOCYTE; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUANG CK, 1988, J BIOL CHEM, V263, P13144; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, UNPUB; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIANG L, 1995, J LEUKOCYTE BIOL, V57, P326, DOI 10.1002/jlb.57.2.326; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NAUSEEF WM, 1990, BLOOD, V76, P2622; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SELLS MA, UNPUB; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; XU XM, 1994, J BIOL CHEM, V269, P23569	31	357	366	1	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					221	223		10.1126/science.7618083	http://dx.doi.org/10.1126/science.7618083			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618083				2022-12-28	WOS:A1995RJ02900039
J	MCNICHOLL, BP; LEE, J				MCNICHOLL, BP; LEE, J			PATIENTS WITH MAJOR TRAUMA WHO DO NOT USE EMERGENCY AMBULANCES	BRITISH MEDICAL JOURNAL			English	Article							FIELD TRIAGE				MCNICHOLL, BP (corresponding author), ROYAL VICTORIA HOSP,DEPT ACCID & EMERGENCY,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND.							KNUDSON P, 1988, J TRAUMA, V28, P602, DOI 10.1097/00005373-198805000-00006; MACKENZIE EJ, 1990, J TRAUMA, V30, P681, DOI 10.1097/00005373-199006000-00005; WEST JG, 1986, J TRAUMA, V26, P655	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1442	1442		10.1136/bmj.310.6992.1442	http://dx.doi.org/10.1136/bmj.310.6992.1442			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613278	Green Published			2022-12-28	WOS:A1995RC10500019
J	HOFMANN, J; CETRON, M; FARLEY, MM; BAUGHMAN, WS; FACKLAM, RR; ELLIOTT, JA; DEAVER, KA; BREIMAN, RF				HOFMANN, J; CETRON, M; FARLEY, MM; BAUGHMAN, WS; FACKLAM, RR; ELLIOTT, JA; DEAVER, KA; BREIMAN, RF			THE PREVALENCE OF DRUG-RESISTANT STREPTOCOCCUS-PNEUMONIAE IN ATLANTA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DAY-CARE-CENTER; UNITED-STATES; ANTIMICROBIAL RESISTANCE; PNEUMOCOCCAL INFECTIONS; PENICILLIN; CHILDREN; DISEASE; VACCINE; MENINGITIS; EFFICACY	Background. Streptococcus pneumoniae is a major cause of illness, and the emergence of drug-resistant strains threatens to complicate the management of pneumococcal infections. We conducted a laboratory-based surveillance for drug-resistant S. pneumoniae among patients with invasive pneumococcal infections in Atlanta. Methods. From January through October 1994, pneumococcal isolates from 431 patients with invasive disease in metropolitan Atlanta were serotyped and tested to determine their susceptibility to various antimicrobial agents. Susceptibility to the antimicrobial agents was defined according to guidelines established by the National Committee for Clinical Laboratory Standards. Results. The annual incidence of invasive pneumococcal infection was 30 cases per 100,000 population, Isolates from 25 percent of the patients were resistant to penicillin (7 percent were highly resistant), and isolates from 26 percent were resistant to trimethoprim-sulfamethoxazole (7 percent highly resistant). Fifteen percent of the isolates were resistant to erythromycin, 9 percent to cefotaxime (4 percent were highly resistant), and 25 percent to multiple drugs. Drug-resistant pneumococci were found in bath children and adults. Children under six years of age were more likely than older children and adults to have isolates resistant to multiple drugs or cefotaxime, Whites were more likely than blacks to have invasive pneumococcal infections caused by drug-resistant organisms. Among white children younger than six years, 41 percent of the S. pneumoniae isolates were resistant to penicillin. Conclusions. Drug-resistant strains of S. pneumoniae are common among both children and adults in Atlanta, Although blacks had a higher incidence of invasive pneumococcal infections than whites, whites were more likely to be infected with a drug-resistant isolate. Control of drug-resistant pneumococci will require more judicious use of antimicrobial agents and wider use of the pneumococcal polysaccharide vaccine.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333; EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA; VET AFFAIRS MED CTR,ATLANTA,GA 30033	Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System								AMITAI Y, 1985, ISRAEL J MED SCI, V21, P340; [Anonymous], 1993, M7A3 NAT COMM CLIN L; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; BUTLER JC, 1995, J INFECT DIS, V171, P885, DOI 10.1093/infdis/171.4.885; CHESNEY PJ, 1992, AM J DIS CHILD, V146, P912, DOI 10.1001/archpedi.1992.02160200034022; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FORD KL, 1991, J PEDIATR-US, V119, P941, DOI 10.1016/S0022-3476(05)83050-1; FRIEDLAND IR, 1993, PEDIATR INFECT DIS J, V12, P196, DOI 10.1097/00006454-199303000-00004; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P337; GABLE CB, 1990, JAMA-J AM MED ASSOC, V264, P2910, DOI 10.1001/jama.264.22.2910; GARCIALEONI ME, 1992, CLIN INFECT DIS, V14, P427, DOI 10.1093/clinids/14.2.427; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAGLUND LA, 1993, J INFECT DIS, V168, P1532, DOI 10.1093/infdis/168.6.1532; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; JACKSON MA, 1984, PEDIATR INFECT DIS J, V3, P129, DOI 10.1097/00006454-198403000-00010; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LEGGIADRO RJ, 1994, PEDIATR INFECT DIS J, V13, P320; LEGGIADRO RJ, 1994, PEDIATRICS, V93, P500; MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; ORANGE M, 1993, PEDIATR INFECT DIS J, V12, P244, DOI 10.1097/00006454-199303000-00015; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; PARIS MM, 1994, ANTIMICROB AGENTS CH, V38, P1320, DOI 10.1128/AAC.38.6.1320; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; RADETSKY MS, 1981, LANCET, V2, P771; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROBINSBROWNE RM, 1984, J HYG-CAMBRIDGE, V93, P9, DOI 10.1017/S0022172400060873; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; SIMBERKOFF MS, 1986, J INFECT DIS, V153, P78, DOI 10.1093/infdis/153.1.78; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; TAN TQ, 1993, PEDIATRICS, V92, P761; TAN TQ, 1992, PEDIATRICS, V90, P928; THOMPSON JW, 1994, PEDIATR INFECT DIS J, V13, P408, DOI 10.1097/00006454-199405000-00013; VILADRICH PF, 1991, ANTIMICROB AGENTS CH, V35, P2467, DOI 10.1128/AAC.35.12.2467; WELBY PL, 1994, PEDIATR INFECT DIS J, V13, P281, DOI 10.1097/00006454-199404000-00007; WENGER JD, 1991, LANCET, V338, P395; 1994, MMWR-MORBID MORTAL W, V43, P31; 1994, MMWR-MORBID MORTAL W, V43, P216; 1992, CP112 BUR CENS DEP C; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, M7A3 NAT COMM CLIN L	48	413	435	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					481	486		10.1056/NEJM199508243330803	http://dx.doi.org/10.1056/NEJM199508243330803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623880				2022-12-28	WOS:A1995RP75900003
J	KIM, Y; EOM, SH; WANG, JM; LEE, DS; SUH, SW; STEITZ, TA				KIM, Y; EOM, SH; WANG, JM; LEE, DS; SUH, SW; STEITZ, TA			CRYSTAL-STRUCTURE OF THERMUS-AQUATICUS DNA-POLYMERASE	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN STRUCTURES; 3'-5' EXONUCLEASE; MECHANISM; FRAGMENT; DOMAIN; SITE	THE DNA polymerase from Thermus aquaticus (Taq polymerase), famous for its use in the polymerase chain reaction, is homologous to Escherichia coli DNA polymerase I (pol I) (ref. 1). Like pol I, Tag polymerase has a domain at its amino terminus (residues 1-290) that has 5' nuclease activity and a domain at its carboxy terminus that catalyses the polymerase reaction. Unlike pol I, the intervening domain in Taq polymerase has lost the editing 3'-5' exonuclease activity. Although the structure of the Klenow fragment of pol I has been known for ten years(2), that of the intact pol I has proved more elusive. The structure of Tag polymerase determined here at 2.4 Angstrom resolution shows that the structures of the polymerase domains of the thermostable enzyme and of the Klenow fragment are nearly identical, whereas the catalytically critical carboxylate residues that bind two metal ions are missing from the remnants of the 3'-5'-exonuclease active site of Taq polymerase. The first view of the 5' nuclease domain, responsible for excising the Okazaki RNA in lagging-strand DNA replication, shows a cluster of conserved divalent metal-ion-binding carboxylates at the bottom of a cleft. The location of this 5'-nuclease active site some 70 Angstrom from the polymerase active site in this crystal form highlights the unanswered question of how this domain works in concert with the polymerase domain to produce a duplex DNA product that contains only a nick.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; SEOUL NATL UNIV,CTR MOLEC CATALYSIS,DEPT CHEM,SEOUL 151742,SOUTH KOREA; KOREAN INST SCI & TECHNOL,KOREA RES INST BIOSCI & BIOTECHNOL,TAEJON 305333,SOUTH KOREA	Yale University; Howard Hughes Medical Institute; Yale University; Seoul National University (SNU); Korea Institute of Science & Technology (KIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB)			Kim, Youngsoo/D-6046-2012; Suh, Won/H-8306-2013; Steitz, Thomas A./C-6559-2009	Suh, Won/0000-0002-1768-4635; 				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1992, E COMMUNICATION; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EOM SH, IN PRESS ACTA CRYS D, V51; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; JONES TA, 1993, E COMMUNICATION; KANKARE J, 1994, PROTEIN ENG, V7, P823, DOI 10.1093/protein/7.7.823; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TEPLYAKOV A, 1994, PROTEIN SCI, V7, P1098; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	29	337	370	2	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					612	616		10.1038/376612a0	http://dx.doi.org/10.1038/376612a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637814				2022-12-28	WOS:A1995RP75600057
J	VOLBERDING, PA; LAGAKOS, SW; GRIMES, JM; STEIN, DS; ROONEY, J; MENG, TC; FISCHL, MA; COLLIER, AC; PHAIR, JP; HIRSCH, MS; HARDY, WD; BALFOUR, HH; REICHMAN, RC				VOLBERDING, PA; LAGAKOS, SW; GRIMES, JM; STEIN, DS; ROONEY, J; MENG, TC; FISCHL, MA; COLLIER, AC; PHAIR, JP; HIRSCH, MS; HARDY, WD; BALFOUR, HH; REICHMAN, RC			A COMPARISON OF IMMEDIATE WITH DEFERRED ZIDOVUDINE THERAPY FOR ASYMPTOMATIC HIV-INFECTED ADULTS WITH CD4 CELL COUNTS OF 500 OR MORE PER CUBIC MILLIMETER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; EFFICACY; AIDS; AZT	Background. The clinical benefits of zidovudine remain unproved in patients with asymptomatic human immunodeficiency virus (HIV) infection when CD4 cell counts exceed 500 per cubic millimeter. We compared zidovudine therapy given immediately with deferred therapy in such subjects. Methods. Beginning in 1987, subjects with asymptomatic HIV infection and 500 or more CD4 cells per cubic millimeter were randomly assigned to receive placebo or zidovudine (either 500 or 1500 mg per day, starting immediately). In 1989, the study was modified so that open-label treatment with 500 mg of zidovudine per day (deferred therapy) was offered when CD4 cell counts fell below 500 per cubic millimeter. The study end points included overall survival, survival free of the acquired immunodeficiency syndrome (AIDS), toxic effects, and changes in CD4 cell counts. Results. There were 1637 subjects who could be evaluated: 547 in the deferred-therapy group, 549 in the group receiving 500 mg of zidovudine immediately, and 541 in the 1500-mg group. The subjects were followed for up to 6.5 years (group medians, 4.8, 4.8, and 4.9, respectively). There was no significant difference in AIDS-free survival in the deferred-therapy group as compared with the low-dose or high-dose groups (81 cases of progression to AIDS or death vs. 81 and 74, respectively; P = 0.95 and P = 0.13) or in overall survival (51 deaths vs. 47 and 46; P = 0.25 and P = 0.16). The decline in CD4 cells was slower in both immediate-therapy groups than in the deferred-therapy group (P<0.001 for both). Adverse effects were uncommon, and before the study modification their incidence was similar among the treatment groups, but severe anemia and granulocytopenia were more frequent in the 1500-mg group than in the deferred-therapy group (P<0.001). Conclusions. In asymptomatic, HIV-infected adults with 500 or more CD4 cells per cubic millimeter, treatment with zidovudine slows the decline in the CD4 cell count but does not significantly prolong either AIDS-free or overall survival. These results do not encourage the routine use of zidovudine monotherapy in this population.	HARVARD UNIV,BOSTON,MA; ALBANY MED COLL,ALBANY,NY; BURROUGHS WELLCOME CO,RALEIGH,NC; UNIV CALIF SAN DIEGO,SAN DIEGO,CA; UNIV MIAMI,MIAMI,FL; UNIV WASHINGTON,SEATTLE,WA; NORTHWESTERN UNIV,CHICAGO,IL; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; UNIV MINNESOTA,MINNEAPOLIS,MN; UNIV ROCHESTER,ROCHESTER,NY	Harvard University; Albany Medical College; Burroughs Wellcome Fund; University of California System; University of California San Diego; University of Miami; University of Washington; University of Washington Seattle; Northwestern University; University of California System; University of California Los Angeles; University of Minnesota System; University of Minnesota Twin Cities; University of Rochester	VOLBERDING, PA (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,995 POTRERO AVE,BLDG 80,WARD 84,SAN FRANCISCO,CA 94110, USA.				NIAID NIH HHS [AI 27663, AI 27763] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027663, P30AI027763] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; Ellenberg S S, 1992, Oncology (Williston Park), V6, P55; ELLENBERG SS, 1991, BMJ-BRIT MED J, V302, P63, DOI 10.1136/bmj.302.6768.63; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; LAGAKOS SW, 1990, STAT MED, V9, P1417, DOI 10.1002/sim.4780091204; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1994, LANCET, V343, P871	15	99	101	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					401	407		10.1056/NEJM199508173330701	http://dx.doi.org/10.1056/NEJM199508173330701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616988				2022-12-28	WOS:A1995RP24300001
J	CLAUSEN, JO; HANSEN, T; BJORBAEK, C; ECHWALD, SM; URHAMMER, SA; RASMUSSEN, S; ANDERSEN, CB; HANSEN, L; ALMIND, K; WINTHER, K; HARALDSDOTTIR, J; BORCHJOHNSEN, K; PEDERSEN, O				CLAUSEN, JO; HANSEN, T; BJORBAEK, C; ECHWALD, SM; URHAMMER, SA; RASMUSSEN, S; ANDERSEN, CB; HANSEN, L; ALMIND, K; WINTHER, K; HARALDSDOTTIR, J; BORCHJOHNSEN, K; PEDERSEN, O			INSULIN-RESISTANCE - INTERACTIONS BETWEEN OBESITY AND A COMMON VARIANT OF INSULIN-RECEPTOR SUBSTRATE-1	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; SENSITIVITY; GLUCOSE; POLYMORPHISMS; PLASMA	We previously discovered two aminoacid polymorphisms in codons 513 and 972 of the protein insulin receptor substrate-1 (IRS-1), which is important in cellular insulin action. We have investigated whether these polymorphisms are associated with changes in insulin sensitivity in a random sample of young healthy adults. Insulin sensitivity and secretion were measured during a combined intravenous glucose and tolbutamide tolerance test in 380 unrelated white subjects aged 18-32. IRS-1 polymorphisms were examined conformation polymorphism and enzyme digestion. No homozygous carrier of the codon-513 variant was identified, but one non-obese man had the codon-972 mutation on both alleles. He had low fasting-serum insulin and C-peptide concentrations and low insulin sensitivity and glucose effectiveness. During a 24 h dexamethasone test, he developed transient diabetes. In their heterozygous forms the codon-513 and codon-972 variants of IRS-1 were found in 3% and 9% of the subjects. Non-obese carriers of either polymorphism had similar insulin sensitivity and pancreatic beta-cell function to non-obese wild-type subjects (no known variants of IRS-1). Analysis of variance showed, however, a significant interaction between obesity (body-mass index greater than or equal to 25 kg/m(2)) and the heterozygous form of the codon-972 variant (p<0.003); obese polymorphism carriers had lower insulin sensitivity than obese non-carriers (mean 6.0 [SD 3.3] vs 12.3 [9.5] x 10(-5) L min(-1) pmol(-1)). The obese carriers of the codon-972 variant were also characterised by a clustering of metabolic cardiovascular risk factors, with raised fasting concentrations of plasma glucose, serum triglyceride, and plasma tissue-plasminogen-activator and its fast-acting inhibitor. With adjustment for known modulators of insulin sensitivity, multivariate analyses showed that the combination of obesity and the codon-972 variant was associated with a 50% reduction in insulin sensitivity (p=0.0008). Our results suggest that the codon-972 IRS-1 gene variant may interact with obesity in the pathogenesis of common insulin-resistant disorders.	STENO DIABET CTR, DK-2820 GENTOFTE, DENMARK; HAGEDORN RES INST, COPENHAGEN, DENMARK; GLOSTRUP POPULAT STUDIES, MED DEPT C, COPENHAGEN, DENMARK; UNIV COPENHAGEN, GLOSTRUP HOSP, DEPT CLIN CHEM, COPENHAGEN, DENMARK; ROYAL VET & AGR UNIV, RES DEPT HUMAN NUTR, COPENHAGEN, DENMARK	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute; University of Copenhagen; University of Copenhagen			Pedersen, Oluf/AAG-8015-2020; Bjorbaek, Christian/S-4727-2019					ALMIND K, 1993, LANCET, V342, P828, DOI 10.1016/0140-6736(93)92694-O; ANDERSEN L, 1993, CLIN CHEM, V39, P578; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ASTRAND PO, 1954, J APPL PHYSIOL, V7, P218, DOI 10.1152/jappl.1954.7.2.218; BEARD JC, 1986, DIABETES, V35, P362, DOI 10.2337/diabetes.35.3.362; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; ECHWALD SM, 1995, DIABETES, V44, P347, DOI 10.2337/diabetes.44.3.347; HAGER J, 1993, LANCET, V342, P1430, DOI 10.1016/0140-6736(93)92793-S; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HITMAN GA, 1995, DIABETOLOGIA, V38, P481, DOI 10.1007/s001250050309; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; IBSEN KK, 1981, ACTA PAEDIATR SCAND, V70, P27, DOI 10.1111/j.1651-2227.1981.tb07168.x; IMAI Y, 1994, J CLIN ENDOCR METAB, V79, P1655, DOI 10.1210/jc.79.6.1655; LAAKSO M, 1994, J CLIN INVEST, V94, P1141, DOI 10.1172/JCI117429; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUNDBAEK K, 1962, BRIT MED J, P1507, DOI 10.1136/bmj.1.5291.1507; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; OKADA T, 1994, J BIOL CHEM, V269, P3568; PACINI G, 1986, COMPUT METH PROG BIO, V23, P113, DOI 10.1016/0169-2607(86)90106-9; RANBY M, 1986, CLIN CHEM, V32, P2160; SHIMOKAWA K, 1994, BIOCHEM BIOPH RES CO, V202, P463, DOI 10.1006/bbrc.1994.1951; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; WHITE MF, 1994, J BIOL CHEM, V269, P1	30	197	206	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					397	402		10.1016/S0140-6736(95)92779-4	http://dx.doi.org/10.1016/S0140-6736(95)92779-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623569				2022-12-28	WOS:A1995RN65600008
J	PRESS, OW; EARY, JF; APPELBAUM, FR; MARTIN, PJ; NELP, WB; GLENN, S; FISHER, DR; PORTER, B; MATTHEWS, DC; GOOLEY, T; BERNSTEIN, ID				PRESS, OW; EARY, JF; APPELBAUM, FR; MARTIN, PJ; NELP, WB; GLENN, S; FISHER, DR; PORTER, B; MATTHEWS, DC; GOOLEY, T; BERNSTEIN, ID			PHASE-II TRIAL OF I-131 B1 (ANTI-CD20) ANTIBODY THERAPY WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR RELAPSED B-CELL LYMPHOMAS	LANCET			English	Article							NON-HODGKINS-LYMPHOMA; BONE-MARROW TRANSPLANTATION; RADIOLABELED MONOCLONAL-ANTIBODIES; MALIGNANT-LYMPHOMA; DISEASE; RADIOIMMUNOTHERAPY; DOSIMETRY; TOXICITY; OKB7	25 patients with relapsed B-cell lymphomas were evaluated with trace-labelled doses (2.5 mg/kg, 185-370 MBq [5-10 mCi]) of I-131-labelled anti-CD20 (B1) antibody in a phase II trial. 22 patients achieved I-131-B1 biodistributions delivering higher doses of radiation to tumour sites than to normal organs and 21 of these were treated with therapeutic infusions of I-131-B1 (12.765-29.045 GBq) followed by autologous haemopoietic stem cell reinfusion. 18 of the 21 treated patients had objective responses, including 16 complete remissions. One patient died of progressive lymphoma and one died of sepsis. Analysis of our phase I and II trials with I-131-labelled B1 reveal a progression-free survival of 62% and an overall survival of 93% with a median follow-up of 2 years. I-131-anti-CD20 (B1) antibody therapy produces complete responses of long duration in most patients with relapsed B-cell lymphomas when given at maximally tolerated doses with autologous stem cell rescue.	UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT RADIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA USA; COULTER CORP, SEATTLE, WA USA; FIRST HILL DIAGNOST IMAGING, SEATTLE, WA USA; PACIFIC NW LAB, RICHLAND, WA 99352 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory	PRESS, OW (corresponding author), UNIV WASHINGTON, CTR CANC, DEPT MED, MAILSTOP RC08, SEATTLE, WA 98195 USA.			Press, Oliver/0000-0002-3147-8037	NCI NIH HHS [P01CA44991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELBAUM FR, 1987, J CLIN ONCOL, V5, P1340, DOI 10.1200/JCO.1987.5.9.1340; ARMITAGE J, 1991, ANN INTERN MED, V114, P1060; ARMITAGE JO, 1993, SEMIN ONCOL, V20, P136; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; BENSINGER W, 1993, BLOOD, V81, P3158; CABANILLAS F, 1994, SEMIN HEMATOL, V31, P30; CRAWFORD SW, 1988, AM REV RESPIR DIS, V137, P682, DOI 10.1164/ajrccm/137.3.682; CZUCZMAN MS, 1993, J CLIN ONCOL, V11, P2021, DOI 10.1200/JCO.1993.11.10.2021; DENARDO GL, 1990, CANCER RES, V50, pS1014; EARY JF, 1990, J NUCL MED, V31, P1257; EARY JF, 1989, MED PHYS, V16, P382, DOI 10.1118/1.596347; FISHER DR, 1991, ANTIBODY IMMUNOCONJ, V4, P655; FISHER RI, 1990, SEMIN ONCOL, V17, P63; FREEDMAN AS, 1993, J CLIN ONCOL, V11, P1841, DOI 10.1200/JCO.1993.11.10.1841; FREEDMAN AS, 1990, J CLIN ONCOL, V8, P784, DOI 10.1200/JCO.1990.8.5.784; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; HORNING SJ, 1987, J CLIN ONCOL, V5, P838, DOI 10.1200/JCO.1987.5.6.838; HORNING SJ, 1994, BLOOD, V83, P881; HORNING SJ, 1994, J CLIN ONCOL, V12, P2552, DOI 10.1200/JCO.1994.12.12.2552; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KNOX SJ, 1994, J IMMUNOTHER, V16, P161; LENHARD RE, 1985, J CLIN ONCOL, V3, P1296, DOI 10.1200/JCO.1985.3.10.1296; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; PETERSEN FB, 1990, J CLIN ONCOL, V8, P638, DOI 10.1200/JCO.1990.8.4.638; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; ROBATINER AZS, 1994, J CLIN ONCOL, V12, P1177; ROSEN ST, 1989, NUCL MED BIOL, V16, P667, DOI 10.1016/0883-2897(89)90093-7; SANDERS JE, 1991, BONE MARROW TRANSPL, V8, P2; SCHEINBERG DA, 1990, J CLIN ONCOL, V8, P792, DOI 10.1200/JCO.1990.8.5.792; VELASQUEZ WS, 1994, J CLIN ONCOL, V12, P1169, DOI 10.1200/JCO.1994.12.6.1169; VRIESENDORP HM, 1991, J CLIN ONCOL, V9, P918, DOI 10.1200/JCO.1991.9.6.918; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; WEAVER CH, 1994, J CLIN ONCOL, V12, P2559, DOI 10.1200/JCO.1994.12.12.2559	35	398	438	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					336	340		10.1016/S0140-6736(95)92225-3	http://dx.doi.org/10.1016/S0140-6736(95)92225-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623531				2022-12-28	WOS:A1995RM71300008
J	NEGISHI, I; MOTOYAMA, N; NAKAYAMA, K; NAKAYAMA, K; SENJU, S; HATAKEYAMA, S; ZHANG, Q; CHAN, AC; LOH, DY				NEGISHI, I; MOTOYAMA, N; NAKAYAMA, K; NAKAYAMA, K; SENJU, S; HATAKEYAMA, S; ZHANG, Q; CHAN, AC; LOH, DY			ESSENTIAL ROLE FOR ZAP-70 IN BOTH POSITIVE AND NEGATIVE SELECTION OF THYMOCYTES	NATURE			English	Article							PROTEIN-TYROSINE KINASE; KILLER-CELLS; T-CELLS; APOPTOSIS; COMPLEX; INVIVO; MICE	DURING thymic development, T cells that can recognize foreign antigen in association with self major histocompatibility complex (MHC) are selected for survival (positive selection) and autoreactive T cells are eliminated (negative selection). Both of these selective events are mediated by interaction between the T-cell receptor (TCR) and the peptid-MHC complex(1) But the signalling pathways that lead to cell survival or to cell death are still unclear. ZAP-70 is a protein tyrosine kinase (PTK) that is associated with the TCR signalling subunits (CD3 and zeta) and is expressed in T cells and natural killer cell(2). It has been shown that ZAP-70 plays a crucial role in T-cell activation(2-5) and development(6-8). Here we show that mice lacking ZAP-70 had neither CD4 nor CD8 single-positive T cells, but human ZAP-70 reconstituted both CD4 and CDS single-positive populations. Moreover, ZAP-70(-/-) thomocytes were not deleted by peptide antigens. Natural killer cell function was intact in the absence of ZAP-70. These data suggest that ZAP-70 is a central signalling molecule during thymic selection for CD4 and CD8 lineage.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV RHEUMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CONE JC, 1993, EUR J IMMUNOL, V23, P2488; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GUNJI Y, 1989, J IMMUNOL, V142, P1748; IWABUCHI K, 1992, P NATL ACAD SCI USA, V89, P9000, DOI 10.1073/pnas.89.19.9000; MADRENAS J, 1994, SCIENCE, V267, P515; MOMBAERTS P, 1994, INT IMMUNOL, V6, P1061, DOI 10.1093/intimm/6.7.1061; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURH CD, 1992, J EXP MED, V176, P611, DOI 10.1084/jem.176.2.611; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VIVLER E, 1993, EUR J IMMUNOL, V23, P1872	25	461	464	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					435	438		10.1038/376435a0	http://dx.doi.org/10.1038/376435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630421				2022-12-28	WOS:A1995RM63900055
J	ROBINSON, LA; STACY, R; SPENCER, JA; BHOPAL, RS				ROBINSON, LA; STACY, R; SPENCER, JA; BHOPAL, RS			HOW TO DO IT - USE FACILITATED CASE DISCUSSIONS FOR SIGNIFICANT EVENT AUDITING	BRITISH MEDICAL JOURNAL			English	Article								An important type of review undertaken routinely in health care teams is analysis of individual cases. This informal process can be turned into a structured and effective form of audit by using an adaptation of the ''critical incident'' technique in facilitated case discussions. Participants are asked to recall personal situations that they feel represent either effective or ineffective practice. From such review of individual cases arise general standards to improve the quality of care. On the basis of a study of audit of deaths in general practice, we describe how to implement such a system, including forming and maintaining the discussion group, methodology, and guidelines for facilitators. Problems that may arise during the case discussions are outlined and their management discussed, including problems within the team and with the process of the discussions.	UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4H,TYNE & WEAR,ENGLAND	Newcastle University - UK	ROBINSON, LA (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4H,TYNE & WEAR,ENGLAND.			Robinson, Louise/0000-0003-0209-2503				BELBIN RM, 1981, MANAGEMENT REALMS WH; Berlin A, 1992, Qual Health Care, V1, P231, DOI 10.1136/qshc.1.4.231; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRAGG JE, 1973, J APPL BEHAV SCI, V9, P727, DOI 10.1177/002188637300900606; Brookfield S., 1986, UNDERSTANDING FACILI; BUCKLEY G, 1990, MED AUDIT GENERAL PR; COLES C, 1990, POSTGRAD MED J S3, V66, P532; Douglas T., 1978, BASIC GROUPWORK; Firth-Cozens J, 1992, Qual Health Care, V1, P252, DOI 10.1136/qshc.1.4.252; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; HARE AP, 1981, AM BEHAV SCI, V24, P695, DOI 10.1177/000276428102400507; HOBBS FDR, 1993, CHANGE TEAMWORK PRIM; McNicol M, 1993, Qual Health Care, V2, P215, DOI 10.1136/qshc.2.4.215; NEWBLE DI, 1976, MED J AUSTRALIA, V2, P180, DOI 10.5694/j.1326-5377.1976.tb134455.x; Newton J, 1992, Qual Health Care, V1, P256, DOI 10.1136/qshc.1.4.256; Plant R., 1987, MANAGING CHANGE MAKI; PRINGLE M, 1994, AUDIT TRENDS, V2, P20; ROBINSON L, 1994, BRIT J GEN PRACT, V44, P461; Rogers EM., 1983, DIFFUSION INNOVATION; WATERSTON T, 1988, MED EDUC, V22, P27, DOI 10.1111/j.1365-2923.1988.tb00405.x; 1983, QUALITY GENERAL PRAC, V2; 1992, BRIT MED J, V304, P1480	22	19	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					315	318		10.1136/bmj.311.7000.315	http://dx.doi.org/10.1136/bmj.311.7000.315			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633248	Green Published			2022-12-28	WOS:A1995RM71900036
J	RUWENDE, C; KHOO, SC; SNOW, AW; YATES, SNR; KWIATKOWSKI, D; GUPTA, S; WARN, P; ALLSOPP, CEM; GILBERT, SC; PESCHU, N; NEWBOLD, CI; GREENWOOD, BM; MARSH, K; HILL, AVS				RUWENDE, C; KHOO, SC; SNOW, AW; YATES, SNR; KWIATKOWSKI, D; GUPTA, S; WARN, P; ALLSOPP, CEM; GILBERT, SC; PESCHU, N; NEWBOLD, CI; GREENWOOD, BM; MARSH, K; HILL, AVS			NATURAL-SELECTION OF HEMIZYGOTES AND HETEROZYGOTES FOR G6PD DEFICIENCY IN AFRICA BY RESISTANCE TO SEVERE MALARIA	NATURE			English	Article							PLASMODIUM-FALCIPARUM; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; VARIANT; DEHYDROGENASE; SEQUENCE; CHILDREN; ENZYME	GLUCOSE-6-PHOSPHATE dehydrogenase (G6PD) deficiency, the most common enzymopathy of humans, affects over 400 million people(1). The geographical correlation of its distribution with the historical endemicity of malaria suggests that this disorder has risen in frequency through natural selection by malaria(2.3). However, attempts to confirm that G6PD deficiency is protective in case-control studies of malaria have yielded conflicting results(4-8). Hence, for this X-linked disorder, it is unclear whether both male hemizygotes and female heterozygotes are protected or, as frequently suggested, only females(1,5-11). Furthermore, how much protection may be afforded is unknown. Here we report that, in two large case-control studies of over 2,000 African children, the common African form of G6PD deficiency (G6PD A-) is associated with a 46-58% reduction in risk of severe malaria for both female heterozygotes and male hemizygotes. A mathematical model incorporating the measured selective advantage against malaria suggests that a counterbalancing selective disadvantage, associated with this enzyme deficiency, has retarded its rise in frequency in malaria-endemic regions. Although G6PD deficiency is now regarded as a generally benign disorder, in earlier environmental conditions it could have been significantly disadvantageous.	UNIV OXFORD, WELLCOME TRUST CTR HUMAN GENET, OXFORD OX3 7BN, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; KEMRI, CLIN RES CTR, KILIFI UNIT, KILIFI, KENYA; MRC LABS, BANJUL, GAMBIA; UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; MRC Laboratory Molecular Biology; University of Oxford			Gilbert, Sarah C./H-2857-2019; HILL, Adrian V>S>/C-1306-2008	Gilbert, Sarah C./0000-0002-6823-9750; Kwiatkowski, Dominic/0000-0002-5023-0176; Snow, Robert/0000-0003-3725-6088	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLISON AC, 1960, NATURE, V186, P531, DOI 10.1038/186531a0; BEUTLER E, 1989, BLOOD, V74, P2550; BEUTLER E, 1990, SEMIN HEMATOL, V27, P137; BIENZLE U, 1972, LANCET, V1, P107; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; GILLES HM, 1967, LANCET, V1, P138; GREENBERG DR, 1993, SOLID STATE ELECTRON, V36, P53, DOI 10.1016/0038-1101(93)90068-2; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; HELLER P, 1979, NEW ENGL J MED, V300, P1001, DOI 10.1056/NEJM197905033001801; HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951; KURDIHAIDAR B, 1990, MOL BIOCHEM PARASIT, V41, P83, DOI 10.1016/0166-6851(90)90099-8; LING IT, 1988, MOL BIOCHEM PARASIT, V31, P47, DOI 10.1016/0166-6851(88)90144-2; Livingstone F. B., 1985, FREQUENCIES HEMOGLOB; Luzzato L, 1989, METABOLIC BASIS INHE, P2237; LUZZATTO L, 1979, LANCET, V1, P1183; LUZZATTO L, 1985, ADV HUM GENET, V14, P217; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARTIN SK, 1979, LANCET, V1, P524; MARTIN SK, 1994, PARASITOL TODAY, V10, P251, DOI 10.1016/0169-4758(94)90133-3; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MILLER LH, 1988, MALARIA PRINCIPLES P, P493; MOTULSKY AG, 1961, LANCET, V1, P1168; MOTULSKY ARNO G., 1960, HUMAN BIOL, V32, P28; ROTH EF, 1983, P NATL ACAD SCI-BIOL, V80, P298, DOI 10.1073/pnas.80.1.298; USANGA EA, 1985, NATURE, V313, P793, DOI 10.1038/313793a0; VULLIAMY TJ, 1991, P NATL ACAD SCI USA, V88, P8568, DOI 10.1073/pnas.88.19.8568	29	409	426	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					246	249		10.1038/376246a0	http://dx.doi.org/10.1038/376246a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617034				2022-12-28	WOS:A1995RK33100044
J	THOMAS, B				THOMAS, B			1965-1995 - MEDICARE AT A CROSSROADS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											THOMAS, B (corresponding author), US HOUSE REPRESENTATIVES,COMM WAYS & MEANS,HLTH SUBCOMM,2208 RAYBURN HOUSE OFF BLDG,WASHINGTON,DC 20515, USA.							THOMAS WM, 1995, ROLL CALL       0619, P1	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					276	278						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609242				2022-12-28	WOS:A1995RH93700039
J	KENDRICK, T; BURNS, T; FREELING, P				KENDRICK, T; BURNS, T; FREELING, P			RANDOMIZED CONTROLLED TRIAL OF TEACHING GENERAL-PRACTITIONERS TO CARRY OUT STRUCTURED ASSESSMENTS OF THEIR LONG-TERM MENTALLY-ILL PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY CARE; SOCIAL DISABLEMENT; FOLLOW-UP; SCHIZOPHRENIA; ILLNESS; CAMBERWELL; DISORDERS; SCHEDULES; BEHAVIOR; PEOPLE	Objective-To assess the impact of teaching general practitioners to carry out structured assessments of their long term mentally ill patients. Design-Randomised controlled trial. Setting-Sixteen group general practices in South Thames (west) region. Subjects-44O adults disabled by long term mental illness. Interventions-Patients were identified by using practice data with help from local psychiatric and social services. In eight practices the practitioners were taught a structured assessment schedule to use with patients every six months for two years. Main outcome measures-Changes in drug treatments, referrals, consultation rates, and recording of preventive health data in the two years after intervention. Results-Follow up data were available on 373 patients (84 . 7%). At least one structured assessment was recorded for 127 patients in the intervention group but only 29 had four assessments recorded. Participating practitioners considered the structured assessment to be time consuming and reported that it did not often lead directly to changes in treatment or referrals. Changes in treatment with neuroleptic drugs and referrals to community psychiatric nurses, however, were significantly more frequent in the intervention group (differences for intervention group minus control group adjusted for activity in two years before intervention were 14 . 3% (95% confidence interval 4 . 3% to 24 . 33%; P < 0 . 01) for neuroleptic drugs and 13 . 3% (2 . 0% to 24 . 6%; P < 0 . 05) for referrals). There were no significant differences in psychiatric admissions, use of the Mental Health Act, drug overdoses, prescriptions, referrals or admissions for physical problems, consultation rates, continuity of care, or recording of preventive data. Conclusions-Teaching general practitioners about the problems of long term mentally ill patients may increase their involvement in patients' psychiatric care. Regular structured assessments do not seem feasible in routine surgery appointments. More training for general practitioners and increased resources such as more nurse time may be necessary if improvements in care of long term mentally ill patients in general practice are to be generalised.			KENDRICK, T (corresponding author), ST GEORGE HOSP,SCH MED,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Kendrick, Tony/H-8558-2014	Kendrick, Tony/0000-0003-1618-9381				ANDERSEN SM, 1990, GEN HOSP PSYCHIAT, V12, P177, DOI 10.1016/0163-8343(90)90077-P; BACHRACH LL, 1988, HOSP COMMUNITY PSYCH, V39, P383; BEBBINGTON P, 1981, PSYCHOL MED, V11, P561, DOI 10.1017/S0033291700052879; BRUGHA TS, 1988, PSYCHOL MED, V18, P443, DOI 10.1017/S0033291700007984; GOLDBERG DP, 1980, LANCET, V2, P521; GROVES T, 1990, BRIT MED J, V300, P923, DOI 10.1136/bmj.300.6729.923; Hassall C, 1977, J R Coll Gen Pract, V27, P605; HIRSCH SR, 1988, PSYCHIATRIC BEDS RES; HOLLOWAY F, 1988, BRIT J PSYCHIAT, V152, P511, DOI 10.1192/bjp.152.4.511; HURRY J, 1987, AUST NZ J PSYCHIAT, V21, P68, DOI 10.3109/00048678709160901; JOHNSTONE EC, 1984, BRIT J PSYCHIAT, V145, P586, DOI 10.1192/bjp.145.6.586; JONES K, 1985, HOSPITAL STUDY LONG; KENDRICK T, 1991, BRIT MED J, V302, P508, DOI 10.1136/bmj.302.6775.508; KENDRICK T, 1994, BRIT J GEN PRACT, V44, P301; MELZER D, 1991, BRIT MED J, V303, P1023, DOI 10.1136/bmj.303.6809.1023; NAZARETH I, 1993, BRIT MED J, V307, P910, DOI 10.1136/bmj.307.6909.910; PARKES C M, 1962, Br Med J, V1, P972; RUTZ W, 1990, ACTA PSYCHIAT SCAND, V82, P399, DOI 10.1111/j.1600-0447.1990.tb03068.x; STURT E, 1987, PSYCHOL MED, V17, P485, DOI 10.1017/S0033291700025046; SYLES WM, 1991, BR J GEN PRACT, V41, P488; WATT DC, 1983, PSYCHOL MED, V13, P663, DOI 10.1017/S0033291700048091; WING J K, 1989, British Journal of Psychiatry, V155, P10; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WING JK, 1990, SOC PSYCH PSYCH EPID, V25, P2; WING JK, 1989, SOC PSYCH PSYCH EPID, V24, P173, DOI 10.1007/BF02351817; WOOFF K, 1988, BRIT J PSYCHIAT, V153, P30, DOI 10.1192/bjp.153.1.30; 1992, STATEMENT FEES ALLOW; 1978, J ROY COLL GEN PRACT, V28, P122; 1987, 1986 DEP HLTH SOC SE	29	69	69	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					93	98		10.1136/bmj.311.6997.93	http://dx.doi.org/10.1136/bmj.311.6997.93			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ030	7613410	Green Published			2022-12-28	WOS:A1995RJ03000023
J	PAPPAS, PG; KAUFFMAN, CA; PERFECT, J; JOHNSON, PC; MCKINSEY, DS; BAMBERGER, DM; HAMILL, R; SHARKEY, PK; CHAPMAN, SW; SOBEL, JD				PAPPAS, PG; KAUFFMAN, CA; PERFECT, J; JOHNSON, PC; MCKINSEY, DS; BAMBERGER, DM; HAMILL, R; SHARKEY, PK; CHAPMAN, SW; SOBEL, JD			ALOPECIA ASSOCIATED WITH FLUCONAZOLE THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							HIGH-DOSE KETOCONAZOLE; FUNGAL-INFECTIONS; PROPHYLAXIS; MENINGITIS; TRIAL	Objective: To describe the association between fluconazole and reversible alopecia. Design: A retrospective survey of 1) patients enrolled in NIAID Mycoses Study Group (MSG) protocols involving the long-term use of fluconazole for treatment of endemic mycoses and 2) patients treated with fluconazole outside of a protocol setting but by the MSG investigators who were MSG members. Setting: 26 MSG sites in the United States. Patients: 33 patients with various deep and superficial mycoses who developed alopecia while receiving fluconazole. Results: 11 of 26 investigators reported a total of 33 patients with substantial alopecia related to fluconazole therapy, Underlying mycoses included blastomycosis, sporotrichosis, histoplasmosis, cryptococcosis, coccidioidomycosis, and mucosal candidiasis. In separate MSG studies, 17 of 136 (12.5%) and 8 of 40 (20%) patients had substantial reversible alopecia associated with fluconazole therapy. Eight patients who were not in the protocol had similar adverse effects. Twenty-nine of 33 patients (88%) received at least 400 mg of fluconazole daily for a mean of 7. 1 months. Alopecia developed a median of 3 months after initiation of fluconazole therapy and involved the scalp in all patients. Other sites were involved in about one third of patients. Three patients required wigs because of extensive hair loss. Alopecia resolved within 6 months of discontinuation of fluconazole therapy or reduction of the daily dose by at least 50%. Conclusions: Alopecia appears to be a common adverse event associated with higher-dose (400 mg/d) fluconazole given for 2 months or longer. This effect may be severe but is reversed by discontinuing fluconazole therapy or substantially reducing the daily dose.	UNIV MICHIGAN, ANN ARBOR, MI USA; DUKE UNIV, MED CTR, DURHAM, NC USA; UNIV TEXAS, MED CTR, HOUSTON, TX USA; BAYLOR COLL MED, HOUSTON, TX USA; MED RES CTR, KANSAS CITY, MO USA; UNIV MISSOURI, KANSAS CITY, MO USA; UNIV TEXAS, SAN ANTONIO MED CTR, SAN ANTONIO, TX USA; UNIV MISSISSIPPI, JACKSON, MS USA; WAYNE STATE MED SCH, DETROIT, MI USA	University of Michigan System; University of Michigan; Duke University; University of Texas System; Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Mississippi; Wayne State University	PAPPAS, PG (corresponding author), UNIV ALABAMA, DEPT MED, DIV INFECT DIS, 1900 UNIV BLVD, 229 TINSLEY HARRISON TOWER, BIRMINGHAM, AL 35294 USA.		MOORE-MILLAR, KARENA/A-9015-2012; Bamberger, David/GYV-3403-2022		NIAID NIH HHS [N01-AI-15082] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRANT SM, 1990, DRUGS, V39, P877, DOI 10.2165/00003495-199039060-00006; Hay R J, 1988, Ann N Y Acad Sci, V544, P580, DOI 10.1111/j.1749-6632.1988.tb40456.x; JUSTNUBLING G, 1991, EUR J CLIN MICROBIOL, V10, P917, DOI 10.1007/BF02005444; PAPPAS PG, 1995, CLIN INFECT DIS, V20, P267, DOI 10.1093/clinids/20.2.267; PAPPAS PG, 1994, FLUCONAZOLE TREATMEN; PONT A, 1984, ARCH INTERN MED, V144, P2150, DOI 10.1001/archinte.144.11.2150; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; SUGAR AM, 1987, ANTIMICROB AGENTS CH, V31, P1874, DOI 10.1128/AAC.31.12.1874; VANCAUTEREN H, 1987, REV INFECT DIS, V9, pS43; WEINROTH SE, 1993, ANN INTERN MED, V119, P637, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00029; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003	15	46	46	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					354	357		10.7326/0003-4819-123-5-199509010-00006	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625624				2022-12-28	WOS:A1995RQ98800006
J	GUADAGNOLI, E; HAUPTMAN, PJ; AYANIAN, JZ; PASHOS, CL; MCNEIL, BJ; CLEARY, PD				GUADAGNOLI, E; HAUPTMAN, PJ; AYANIAN, JZ; PASHOS, CL; MCNEIL, BJ; CLEARY, PD			VARIATION IN THE USE OF CARDIAC PROCEDURES AFTER ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							Q-WAVE; PROGNOSTIC-SIGNIFICANCE; MEDICARE POPULATION; PATIENT POPULATION; SAMPLE SELECTION; UNITED-STATES; VALIDITY; ISCHEMIA; CARE; RELIABILITY	Background. There are large geographic differences in the frequency with which coronary angiography and revascularization are performed. We attempted to assess whether differences in case mix or in the treatment of specific groups of patients may explain this variability. We also assessed the consequences of various patterns of treatment. Methods. We studied patients covered by Medicare who were 65 to 79 years of age and were admitted to 478 hospitals with acute myocardial infarctions during 1990 in New York (1852 patients), where the rate of use of cardiac procedures is low, and in Texas (1837 patients), where the rate of use of such procedures is high. We compared the patterns of treatment of clinically similar groups of patients in the two states. We also compared mortality rates and measures of the health-related quality of life. Results. Coronary angiography was performed more often in Texas than in New York (45 percent vs. 30 percent, P<0.001). The frequency of use in Texas was significantly higher than that in New York for all the clinical subgroups of patients analyzed except those at greatest risk for reinfarction. Over a two-year period, the adjusted likelihood of death was lower in New York than in Texas (hazard ratio, 0.87; 95 percent confidence interval, 0.78 to 0.98). Patients from Texas were 41 percent more likely to report angina (P = 0.002) and 62 percent more likely to say they could not perform activities requiring energy expenditure of 5 or more metabolic equivalents than patients from New York approximately two years after infarction (P<0.001). Conclusions. Physicians in Texas were more likely to perform angiography than physicians in New York for patients whose conditions allowed more discretion in the use of cardiac procedures. On average, there appears to be no advantage with respect to mortality or health-related quality of life to performing the procedures at the higher rate used in Texas.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	GUADAGNOLI, E (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115, USA.		Cleary, Paul/AAF-7048-2019		AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P253, DOI 10.1016/S0735-1097(10)80043-9; BODEN WE, 1989, AM J CARDIOL, V64, P799, DOI 10.1016/0002-9149(89)90768-6; BOSCH X, 1987, CIRCULATION, V75, P988, DOI 10.1161/01.CIR.75.5.988; BRAUNWALD E, 1992, HEART DISEASE TXB CA; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CLEARY PD, 1991, MED CARE, V29, P939, DOI 10.1097/00005650-199110000-00001; CLEARY PD, 1991, CONTROL CLIN TRIALS, V12, pS189, DOI 10.1016/S0197-2456(05)80023-6; CLEARY PD, 1992, MED CARE, V30, P76; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GROTZINGER KM, 1994, MED CARE, V32, P989, DOI 10.1097/00005650-199410000-00002; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; HECKMAN JJ, 1976, ANN ECON SOC MEAS, V5, P475; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JETTE AM, 1986, J GEN INTERN MED, V1, P427; MAISEL AS, 1985, CIRCULATION, V71, P211, DOI 10.1161/01.CIR.71.2.211; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARMOR A, 1982, CIRCULATION, V66, P415, DOI 10.1161/01.CIR.66.2.415; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SCHUSTER EH, 1981, NEW ENGL J MED, V305, P1101, DOI 10.1056/NEJM198111053051901; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530	30	187	198	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					573	578		10.1056/NEJM199508313330908	http://dx.doi.org/10.1056/NEJM199508313330908			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623908				2022-12-28	WOS:A1995RQ75100008
J	NELSON, HS				NELSON, HS			DRUG-THERAPY - BETA-ADRENERGIC BRONCHODILATORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							METERED-DOSE INHALER; RECEPTOR MESSENGER-RNA; ASTHMATIC-PATIENTS; INDUCED BRONCHOCONSTRICTION; BRONCHIAL-ASTHMA; PARADOXICAL BRONCHOCONSTRICTION; PROLONGED THERAPY; SALMETEROL; SALBUTAMOL; AGONIST				NELSON, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, DENVER, CO 80206 USA.							ANDERSON GP, 1993, LIFE SCI, V52, P2145, DOI 10.1016/0024-3205(93)90729-M; ANDERSON GP, 1993, AGENT ACTION SUPPL, V43, P253; APPEL D, 1989, J ALLERGY CLIN IMMUN, V84, P90, DOI 10.1016/0091-6749(89)90182-6; ARNER B, 1970, ACTA MED SCAND, P45; BARNES PJ, 1992, TRENDS PHARMACOL SCI, V13, P20, DOI 10.1016/0165-6147(92)90011-T; BENGTSSON B, 1984, EUR J RESPIR DIS, V65, P231; BENTUR L, 1990, ANN ALLERGY, V65, P122; BONER AL, 1994, AM J RESP CRIT CARE, V149, P935, DOI 10.1164/ajrccm.149.4.7908246; BOOTH H, 1993, THORAX, V48, P1121, DOI 10.1136/thx.48.11.1121; BOWTON DL, 1992, CHEST, V101, P305, DOI 10.1378/chest.101.2.305; BRAMBILLA C, 1994, ALLERGY, V49, P421, DOI 10.1111/j.1398-9995.1994.tb00834.x; BRAUN SR, 1990, ARCH INTERN MED, V150, P1242; BRAUN SR, 1989, ARCH INTERN MED, V149, P544, DOI 10.1001/archinte.149.3.544; BRITTON MG, 1993, EUR RESPIR J, V6, P150; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; BUTCHERS PR, 1991, BRIT J PHARMACOL, V104, P672, DOI 10.1111/j.1476-5381.1991.tb12487.x; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHAIEB J, 1989, RESP MED, V83, P497, DOI 10.1016/S0954-6111(89)80134-9; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COLACONE A, 1993, CHEST, V104, P835, DOI 10.1378/chest.104.3.835; CONNER WT, 1989, PEDIATR PULM, V6, P263, DOI 10.1002/ppul.1950060410; DAHL R, 1991, EUR RESPIR REV, V1, P272; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; DAVIS B, 1979, AM REV RESPIR DIS, V120, P547; DEVALIA JL, 1992, PULM PHARMACOL, V5, P257, DOI 10.1016/0952-0600(92)90068-R; DOLOVICH M, 1981, CHEST, V80, P911; ERJEFALT I, 1991, AM REV RESPIR DIS, V143, P1008, DOI 10.1164/ajrccm/143.5_Pt_1.1008; FINNERTY JP, 1993, AM REV RESPIR DIS, V148, P512, DOI 10.1164/ajrccm/148.2.512; Fraser CM, 1993, ALLERGY PRINCIPLES P, V1, P778; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GEORGOPOULOS D, 1990, CHEST, V97, P280, DOI 10.1378/chest.97.2.280; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GRATZIOU C, 1992, EUR RESPIR J S15, V5, pS207; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; GUYATT GH, 1987, AM REV RESPIR DIS, V135, P1069; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P8415, DOI 10.1073/pnas.85.22.8415; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HARRIS L, 1972, J ALLERGY CLIN IMMUN, V49, P63, DOI 10.1016/0091-6749(72)90057-7; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; HINDLE M, 1993, THORAX, V48, P607, DOI 10.1136/thx.48.6.607; ISAWA T, 1990, AM REV RESPIR DIS, V141, P715, DOI 10.1164/ajrccm/141.3.715; JOAD JP, 1987, J ALLERGY CLIN IMMUN, V79, P78, DOI 10.1016/S0091-6749(87)80020-9; JOHNSON M, 1993, LIFE SCI, V52, P2131, DOI 10.1016/0024-3205(93)90728-L; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; KARPEL JP, 1991, CHEST, V99, P871, DOI 10.1378/chest.99.4.871; KELLY HW, 1992, ANN PHARMACOTHER, V26, P81, DOI 10.1177/106002809202600115; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612, DOI 10.1164/ajrccm.150.6.7952623; KESTEN S, 1991, AM REV RESPIR DIS, V144, P622, DOI 10.1164/ajrccm/144.3_Pt_1.622; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; LOTVALL J, 1993, LUNG, V171, P249; LUNDBACK B, 1993, THORAX, V48, P148, DOI 10.1136/thx.48.2.148; MACONOCHIE JG, 1994, BRIT J CLIN PHARMACO, V37, P199, DOI 10.1111/j.1365-2125.1994.tb04261.x; MANN RD, 1994, BRIT MED J, V309, P1018, DOI 10.1136/bmj.309.6960.1018b; MORLEY J, 1992, CLIN EXP ALLERGY, V22, P724, DOI 10.1111/j.1365-2222.1992.tb00197.x; MORTENSEN J, 1991, THORAX, V46, P817, DOI 10.1136/thx.46.11.817; NELSON HS, 1991, AM REV RESPIR DIS, V144, P249, DOI 10.1164/ajrccm/144.2.249; NELSON HS, 1983, J ALLERGY CLIN IMMUN, V72, P371, DOI 10.1016/0091-6749(83)90502-X; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NELSON HS, 1993, ALLERGY PRINCIPLES P, V1, P785; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; NICKLAS RA, 1990, J ALLERGY CLIN IMMUN, V85, P959, DOI 10.1016/0091-6749(90)90084-H; NOWAK D, 1992, EUR J CLIN PHARMACOL, V43, P591, DOI 10.1007/BF02284956; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; OCONNOR BJ, 1994, AM J RESP CRIT CARE, V150, P381, DOI 10.1164/ajrccm.150.2.8049819; PAGE C, 1992, RESP MED, V86, P477, DOI 10.1016/S0954-6111(96)80005-9; PAGE C, 1992, ANN ALLERGY, V69, P251; PALMER JBD, 1991, EUR RESPIR REV, V1, P297; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PEDERSEN B, 1993, ALLERGY, V48, P377, DOI 10.1111/j.1398-9995.1993.tb02410.x; RABE KF, 1993, AM REV RESPIR DIS, V147, P1436, DOI 10.1164/ajrccm/147.6_Pt_1.1436; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; RHODEN KJ, 1988, J APPL PHYSIOL, V65, P700, DOI 10.1152/jappl.1988.65.2.700; SCHATZ M, 1988, J ALLERGY CLIN IMMUN, V82, P686, DOI 10.1016/0091-6749(88)90984-0; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; SKORODIN MS, 1993, CHEST, V103, P1587, DOI 10.1378/chest.103.5.1587; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STEIN M, 1993, CLIN PHARMACOL THER, V54, P187, DOI 10.1038/clpt.1993.130; STILES GL, 1983, LIFE SCI, V33, P467, DOI 10.1016/0024-3205(83)90796-8; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TAYLOR IK, 1992, J ALLERGY CLIN IMMUN, V89, P575, DOI 10.1016/0091-6749(92)90325-V; TEULE GJJ, 1980, THORAX, V35, P536, DOI 10.1136/thx.35.7.536; THIRINGER G, 1977, SCAND J RESPIR DIS, P95; VANDEWALKER ML, 1986, CHEST, V90, P198, DOI 10.1378/chest.90.2.198; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; WAGNER PD, 1978, AM REV RESPIR DIS, V118, P511; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WILKINSON JRW, 1992, BRIT MED J, V305, P931, DOI 10.1136/bmj.305.6859.931; WILLIAMS SJ, 1981, THORAX, V36, P629, DOI 10.1136/thx.36.8.629; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156	99	187	192	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					499	506		10.1056/NEJM199508243330807	http://dx.doi.org/10.1056/NEJM199508243330807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623883				2022-12-28	WOS:A1995RP75900007
J	VALLESI, A; GIULI, G; BRADSHAW, RA; LUPORINI, P				VALLESI, A; GIULI, G; BRADSHAW, RA; LUPORINI, P			AUTOCRINE MITOGENIC ACTIVITY OF PHEROMONES PRODUCED BY THE PROTOZOAN CILIATE EUPLOTES-RAIKOVI	NATURE			English	Article							MATING PHEROMONE; STRUCTURAL CHARACTERIZATION; GROWTH-FACTOR; IDENTIFICATION; PURIFICATION; RECOGNITION; CELLS; ER-1	DIFFUSIBLE polypeptide pheromones (formerly referred to as mating-type factors, sex factors or gamones), which distinguish otherwise morphologically identical vegetative cell (mating) types from one another, are produced by some species of ciliates(1,2), Their most striking effect can be observed by exposing cells of one type to a pheromone secreted by another co-specific cell type(3). In the presence of this 'non-self' signal, these cells interrupt their vegetative life to unite temporarily in mating pairs, Thus ciliate pheromones have traditionally been associated only with mating induction(2,4), However, the identification of autocrine pheromone receptors(5,6) suggests a broader role, which is supported by the hypothesis that ciliates evolved their mating-type mechanism for pursuing self-recognition(1). We now report studies, in the cosmopolitan marine sand-dwelling protozoan ciliate Euplotes raikovi, demonstrating that these molecules promote the vegetative reproduction (mitogenic proliferation or growth) of the same cells from which they originate, As, understandably, such autocrine pheromone activity is primary to that of targeting and inducing a foreign cell to mate (paracrine functions), this finding provides an example of how the original function of a molecule can be obscured during evolution by the acquisition of a new one.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine	VALLESI, A (corresponding author), UNIV CAMERINO,DIPARTIMENTO BIOL MOLEC CELLULARE & ANIM,I-62032 CAMERINO MC,ITALY.		Vallesi, Adriana/I-9933-2016; Bradshaw, Ralph A/K-1515-2013	Vallesi, Adriana/0000-0002-4127-090X; 				BEALE G, 1990, TRENDS GENET, V6, P137, DOI 10.1016/0168-9525(90)90132-P; BROWN LR, 1993, J MOL BIOL, V231, P800, DOI 10.1006/jmbi.1993.1327; CONCETTI A, 1986, J BIOL CHEM, V261, P582; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KUHLMANN HW, 1989, J EXP ZOOL, V251, P316, DOI 10.1002/jez.1402510308; LUGINBUHL P, 1994, PROTEIN SCI, V3, P1537, DOI 10.1002/pro.5560030919; LUPORINI P, 1992, DEV GENET, V13, P9, DOI 10.1002/dvg.1020130103; LUPORINI P, 1994, ANN NY ACAD SCI, V712, P195, DOI 10.1111/j.1749-6632.1994.tb33573.x; LUPORINI P, 1986, P NATL ACAD SCI USA, V83, P2889, DOI 10.1073/pnas.83.9.2889; Luporini P., 1986, P263; MICELI C, 1991, EUR J BIOCHEM, V202, P759, DOI 10.1111/j.1432-1033.1991.tb16430.x; MICELI C, 1992, P NATL ACAD SCI USA, V89, P1988, DOI 10.1073/pnas.89.5.1988; Miyake A, 1981, BIOCH PHYSL PROTOZOA, P125; MRONGA S, 1994, PROTEIN SCI, V3, P1527, DOI 10.1002/pro.5560030918; OLINS DE, 1994, INT REV CYTOL, V153, P137, DOI 10.1016/S0074-7696(08)62190-7; ORTENZI C, 1990, J CELL BIOL, V111, P607, DOI 10.1083/jcb.111.2.607; ORTENZI C, 1995, J EUKARYOT MICROBIOL, V42, P242; OTTIGER M, 1994, PROTEIN SCI, V3, P1515, DOI 10.1002/pro.5560030917; PARFENOVA EV, 1989, ACTA PROTOZOOL, V28, P11; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P2071, DOI 10.1073/pnas.89.6.2071; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STEWART AE, 1992, PROTEIN SCI, V1, P777, DOI 10.1002/pro.5560010609; TAKAGI Y, 1994, ZOOL SCI, V10, P53; TANABE H, 1990, BIOCHEM BIOPH RES CO, V170, P786, DOI 10.1016/0006-291X(90)92160-2; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WHITBREAD JA, 1991, DEV GENET, V12, P78, DOI 10.1002/dvg.1020120114	26	64	66	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					522	524		10.1038/376522a0	http://dx.doi.org/10.1038/376522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637785	Green Submitted			2022-12-28	WOS:A1995RN62200047
J	DUPONT, HL; MARSHALL, GD				DUPONT, HL; MARSHALL, GD			HIV-ASSOCIATED DIARRHEA AND WASTING	LANCET			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; VIRUS-INFECTION; SYNDROME AIDS; DISEASE; HYPERSENSITIVITY; MICROSPORIDIA; LEUKOCYTES; RATS		UNIV TEXAS, SCH MED, DEPT INTERNAL MED, HOUSTON, TX USA	University of Texas System			DuPont, Herbert/AAH-6776-2021; Marshall, Gailen D./R-7459-2019					BAIRD AW, 1985, BRIT J PHARMACOL, V85, P787, DOI 10.1111/j.1476-5381.1985.tb11077.x; CASTRO GA, 1994, PHYSL GASTROINTESTIN, P707; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHACHOUA A, 1987, ANN INTERN MED, V107, P133, DOI 10.7326/0003-4819-107-2-133; DIETERICH DT, 1994, J INFECT DIS, V169, P178, DOI 10.1093/infdis/169.1.178; DJURIC VJ, 1990, INT J NEUROSCI, V51, P231, DOI 10.3109/00207459008999704; FRANCIS ND, 1989, J CLIN PATHOL, V42, P1055, DOI 10.1136/jcp.42.10.1055; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; KOTLER DP, 1990, ANN INTERN MED, V113, P444; MARSHALL GD, 1994, CLIN RES, V42, pA279; MATHEWSON JJ, 1995, J INFECT DIS, V171, P1636, DOI 10.1093/infdis/171.6.1636; MATHEWSON JJ, 1994, J INFECT DIS, V169, P614, DOI 10.1093/infdis/169.3.614; MORGAN DR, 1984, INFECT IMMUN, V46, P25, DOI 10.1128/IAI.46.1.25-33.1984; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PEDERSEN M, 1989, AGENTS ACTIONS, V27, P55, DOI 10.1007/BF02222197; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; RABENECK L, 1993, ANN INTERN MED, V119, P895, DOI 10.7326/0003-4819-119-9-199311010-00005; READ NW, 1987, SCAND J GASTROENTERO, V22, P7, DOI 10.3109/00365528709090994; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; YOLKEN RH, 1991, J INFECT DIS, V164, P61, DOI 10.1093/infdis/164.1.64; ZHANG S, 1990, INT ARCH ALLER A IMM, V93, P272, DOI 10.1159/000235313; ZHANG S, 1991, GASTROENTEROLOGY, V100, P922, DOI 10.1016/0016-5085(91)90265-M	27	35	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					352	356		10.1016/S0140-6736(95)92229-6	http://dx.doi.org/10.1016/S0140-6736(95)92229-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623535				2022-12-28	WOS:A1995RM71300012
J	MCCARRON, MO; WRIGHT, GD; ROBERTS, SD				MCCARRON, MO; WRIGHT, GD; ROBERTS, SD			WATER-INTOXICATION AFTER LOW-DOSE CYCLOPHOSPHAMIDE	BRITISH MEDICAL JOURNAL			English	Letter							HYPONATREMIA		MUSGRAVE PK HOSP,DEPT RHEUMATOL,BELFAST,ANTRIM,NORTH IRELAND		MCCARRON, MO (corresponding author), ROYAL VICTORIA HOSP,DEPT RHEUMATOL,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND.							ARIEFF AI, 1993, BRIT MED J, V307, P305, DOI 10.1136/bmj.307.6899.305; DEFONZA RA, 1974, CANCER, V33, P483; HARLOW PJ, 1979, CANCER, V44, P896, DOI 10.1002/1097-0142(197909)44:3<896::AID-CNCR2820440316>3.0.CO;2-9; WEBBERLEY MJ, 1989, POSTGRAD MED J, V65, P950, DOI 10.1136/pgmj.65.770.950	4	16	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					292	292		10.1136/bmj.311.7000.292	http://dx.doi.org/10.1136/bmj.311.7000.292			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633237	Green Published			2022-12-28	WOS:A1995RM71900023
J	PAUL, WE				PAUL, WE			CAN THE IMMUNE-RESPONSE CONTROL HIV-INFECTION	CELL			English	Review							IMMUNODEFICIENCY VIRUS TYPE-1; NEUTRALIZING ANTIBODIES; GLYCOPROTEIN; IMMUNIZATION; RECIPIENTS; INDUCTION; VACCINE				PAUL, WE (corresponding author), NIH,OFF AIDS RES,BETHESDA,MD 20892, USA.							ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; ANDINO R, 1994, SCIENCE, V265, P1448, DOI 10.1126/science.8073288; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLERICI M, 1994, AIDS, V8, P1391, DOI 10.1097/00002030-199410000-00004; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COX WI, 1993, VIROLOGY, V195, P845, DOI 10.1006/viro.1993.1442; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DULIEGE AM, 1994, 9 C CENT GARD, P301; FULTZ PN, 1994, 9 C CENT GARD, P257; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GROSSMAN Z, 1992, P NATL ACAD SCI USA, V89, P10365, DOI 10.1073/pnas.89.21.10365; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; MACKEWICZ CE, 1994, CELL IMMUNOL, V153, P329, DOI 10.1006/cimm.1994.1032; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PINTO L, 1995, IN PRESS J CLIN INVE; PLOTKIN S, 1994, 9 C CENT GARD, P309; PUTKONEN P, 1991, NATURE, V352, P436, DOI 10.1038/352436a0; ROBERTGUROFF M, 1988, AIDS RES HUM RETROV, V4, P343, DOI 10.1089/aid.1988.4.343; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAWYER LA, 1990, AIDS RES HUM RETROV, V6, P341, DOI 10.1089/aid.1990.6.341; SCHWARTZ DH, 1993, LANCET, V342, P69, DOI 10.1016/0140-6736(93)91283-R; SHIBATA R, 1995, IN PRESS J VIROLOGY; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; VAJDY M, 1992, IMMUNOLOGY, V75, P488; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WALKER BD, 1990, AIDS VACCINE RES CLI, P179; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISS R, 1984, RNA TUMOR VIRUSES	38	57	60	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					177	182		10.1016/0092-8674(95)90304-6	http://dx.doi.org/10.1016/0092-8674(95)90304-6			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628008	Bronze			2022-12-28	WOS:A1995RL76000004
J	SCHMIDT, B; SELMER, T; INGENDOH, A; VONFIGURA, K				SCHMIDT, B; SELMER, T; INGENDOH, A; VONFIGURA, K			A NOVEL AMINO-ACID MODIFICATION IN SULFATASES THAT IS DEFECTIVE IN MULTIPLE SULFATASE DEFICIENCY	CELL			English	Article							HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; STEROID-SULFATASE; NUCLEOTIDE-SEQUENCE; EXPRESSION; CLONING; GENE; COMPLEMENTATION; FIBROBLASTS	Multiple sulfatase deficiency (MSD) is a lysosomal storage disorder characterized by a decreased activity of all known sulfatases. The deficiency of sulfatases was proposed to result from the lack of a co- or posttranslational modification that is common to all sulfatases and required for their catalytic activity. Structural analysis of two catalytically active sulfatases revealed that a cysteine residue that is predicted from the cDNA sequence and conserved among ail known sulfatases is replaced by a 2-amino-3-oxopropionic acid residue, while in sulfatases derived from MSD cells, this cysteine residue is retained. It is proposed that the co- or posttranslational conversion of a cysteine to 5-amino-3-oxopropionic acid is required for generating catalytically active sulfatases and that deficiency of this protein modification is the cause of MSD.	UNIV GOTTINGEN,D-37073 GOTTINGEN,GERMANY; UNIV MUNSTER,D-48149 MUNSTER,GERMANY	University of Gottingen; University of Munster								ANSON DS, 1993, BIOCHEM J, V294, P657, DOI 10.1042/bj2940657; BALLABIO A, 1985, HUM GENET, V70, P315, DOI 10.1007/BF00295367; BALLABIO A, 1995, METABOLIC MOL BASES, P2999; CHANG PL, 1980, P NATL ACAD SCI-BIOL, V77, P6166, DOI 10.1073/pnas.77.10.6166; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; DEHOSTOS EL, 1989, MOL GEN GENET, V218, P229, DOI 10.1007/BF00331273; DEVER TE, 1989, J BIOL CHEM, V264, P20518; FEDDE K, 1984, AM J HUM GENET, V36, P623; FUJII T, 1992, BIOCHIM BIOPHYS ACTA, V1122, P93, DOI 10.1016/0167-4838(92)90132-W; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; HALLMANN A, 1994, EUR J BIOCHEM, V221, P143, DOI 10.1111/j.1432-1033.1994.tb18723.x; HORWITZ AL, 1979, P NATL ACAD SCI USA, V76, P6486; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; PETERS C, 1990, J BIOL CHEM, V265, P3374; ROBERTSON DA, 1988, BIOCHEM BIOPH RES CO, V157, P218, DOI 10.1016/S0006-291X(88)80035-4; ROMMERSKIRCH W, 1992, P NATL ACAD SCI USA, V89, P2561, DOI 10.1073/pnas.89.7.2561; ROY AB, 1978, BIOCHIM BIOPHYS ACTA, V526, P489, DOI 10.1016/0005-2744(78)90140-7; SASAKI H, 1988, EUR J BIOCHEM, V177, P9, DOI 10.1111/j.1432-1033.1988.tb14338.x; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; SOMMERLADE HJ, 1994, J BIOL CHEM, V269, P20977; STECKEL F, 1985, EUR J BIOCHEM, V151, P141, DOI 10.1111/j.1432-1033.1985.tb09078.x; STEIN C, 1989, J BIOL CHEM, V264, P13865; STEIN C, 1989, J BIOL CHEM, V264, P1252; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; WAHEED A, 1980, ARCH BIOCHEM BIOPHYS, V203, P11, DOI 10.1016/0003-9861(80)90149-6; WAHEED A, 1979, ARCH BIOCHEM BIOPHYS, V195, P248, DOI 10.1016/0003-9861(79)90348-5; WILSON PJ, 1990, P NATL ACAD SCI USA, V87, P8531, DOI 10.1073/pnas.87.21.8531; YANG Q, 1989, DEV BIOL, V135, P53, DOI 10.1016/0012-1606(89)90157-7; YEN PH, 1987, CELL, V49, P443, DOI 10.1016/0092-8674(87)90447-8	31	283	308	1	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					271	278		10.1016/0092-8674(95)90314-3	http://dx.doi.org/10.1016/0092-8674(95)90314-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628016	Bronze			2022-12-28	WOS:A1995RL76000014
J	DOODY, GM; JUSTEMENT, LB; DELIBRIAS, CC; MATTHEWS, RJ; LIN, JJ; THOMAS, ML; FEARON, DT				DOODY, GM; JUSTEMENT, LB; DELIBRIAS, CC; MATTHEWS, RJ; LIN, JJ; THOMAS, ML; FEARON, DT			A ROLE IN B-CELL ACTIVATION FOR CD22 AND THE PROTEIN-TYROSINE-PHOSPHATASE SHP	SCIENCE			English	Article							ANTIGEN RECEPTOR; ADHESION MOLECULE; MOTH-EATEN; EXPRESSION; CD40; MICE; LYMPHOCYTES; KINASES; DOMAINS; CD19	CD22 is a membrane immunoglobulin (mlg)-associated protein of B cells. CD22 is tyrosine-phosphorylated when mlg is ligated. Tyrosine-phosphorylated CD22 binds and activates SHP, a protein tyrosine phosphatase known to negatively regulate signaling through mlg. Ligation of CD22 to prevent its coaggregation with mlg lowers the threshold at which mlg activates the B cell by a factor of 100. In secondary lymphoid organs, CD22 may be sequestered away from mlg through interactions with counterreceptors on T cells. Thus, CD22 is a molecular switch for SHP that may bias mlg signaling to anatomic sites rich in T cells.	UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,WELLCOME TRUST IMMUNOL UNIT,CAMBRIDGE CB2 2SP,ENGLAND; UNIV TEXAS,MED BRANCH,DEPT MICROBIOL & IMMUNOL,GALVESTON,TX 77555; WASHINGTON UNIV,SCH MED,DEPT PATHOL,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	University of Cambridge; University of Texas System; University of Texas Medical Branch Galveston; Howard Hughes Medical Institute; Washington University (WUSTL)			Doody, Gina/AAN-8246-2021	Doody, Gina/0000-0003-0665-6759; Justement, Louis/0000-0001-7058-867X	NIGMS NIH HHS [GM-46524] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046524, R01GM046524] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOUE DR, 1988, J IMMUNOL, V140, P192; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; ENGEL P, 1993, J IMMUNOL, V150, P4719; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; LIN JJ, 1992, J IMMUNOL, V149, P1548; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POWELL LD, 1993, J BIOL CHEM, V268, P7019; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; TORRES RM, 1992, J IMMUNOL, V149, P2641; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	32	487	491	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					242	244		10.1126/science.7618087	http://dx.doi.org/10.1126/science.7618087			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618087				2022-12-28	WOS:A1995RJ02900046
J	ARHIN, D				ARHIN, D			HEALTH-INSURANCE IN RURAL AFRICA	LANCET			English	Editorial Material							PRICE; PAY				ARHIN, D (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH POLICY UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			/0000-0002-3624-1696				ARHIN DC, 1994, SOC SCI MED, V39, P861, DOI 10.1016/0277-9536(94)90048-5; ARHIN DC, 1993, INSTITUTIONALIZATION; Bennett S., 1989, LESOTHO EPIDEMIOLOGI, V4, P29; De Bethune X., 1989, Health Policy and Planning, V4, P76, DOI 10.1093/heapol/4.1.76; CHABOT J, 1984, COMMUNITY HLTH PROJE; FOSTER S, 1988, ALTERNATIVES DIRECT; Waddington C. J., 1989, International Journal of Health Planning and Management, V4, P17, DOI 10.1002/hpm.4740040104; YODER RA, 1989, SOC SCI MED, V29, P35, DOI 10.1016/0277-9536(89)90125-1; 1993, INVESTING HLTH	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					44	45		10.1016/S0140-6736(95)91160-X	http://dx.doi.org/10.1016/S0140-6736(95)91160-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QA290	7619111				2022-12-28	WOS:A1995QA29000018
J	LEROITH, D; BASERGA, R; HELMAN, L; ROBERTS, CT				LEROITH, D; BASERGA, R; HELMAN, L; ROBERTS, CT			INSULIN-LIKE GROWTH-FACTORS AND CANCER	ANNALS OF INTERNAL MEDICINE			English	Article							MESSENGER RIBONUCLEIC-ACID; NONISLET CELL TUMORS; HUMAN-BREAST CANCER; FACTOR-II GENE; WILMS-TUMOR; PROTEIN SECRETION; BINDING PROTEINS; IGF-I; EXPRESSION; RECEPTOR	The insulin-like growth factor (IGF) family of peptides, binding proteins, and receptors are important for normal human growth and development and are involved in the specialized functions of most physiologic systems. Most members of the IGF system are expressed by different cancer cells and may play an important role in the propagation of these malignancies. New therapies aimed at modulating various components of the IGF system could affect the progression and metastasis of cancer.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON CANC CTR, PHILADELPHIA, PA 19107 USA; NCI, PEDIAT BRANCH, MOLEC ONCOL SECT, BETHESDA, MD 20892 USA	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LEROITH, D (corresponding author), NIDDKD, DIABET BRANCH, MOLEC & CELLULAR PHYSIOL SECT, BLDG 10, ROOM 8S-239, BETHESDA, MD 20892 USA.		Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; BAXTER RC, 1991, J CLIN ENDOCR METAB, V73, P696, DOI 10.1210/jcem-73-4-696; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIN E, 1994, J CLIN ENDOCR METAB, V78, P156, DOI 10.1210/jc.78.1.156; CHIN E, 1992, J CLIN ENDOCR METAB, V75, P962, DOI 10.1210/jc.75.3.962; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; COLLETTI RB, 1989, CANCER RES, V49, P1882; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DICKSON RB, 1992, J STEROID BIOCHEM, V43, P69, DOI 10.1016/0960-0760(92)90189-P; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; GANSLER T, 1989, AM J PATHOL, V135, P961; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAPPEL CC, 1994, CANCER RES, V54, P2803; KELEBIC T, CANCER RES, V54, P5331; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LERNER LJ, 1990, CANCER RES, V50, P4177; LEROITH D, 1992, ANN INTERN MED, V116, P854, DOI 10.7326/0003-4819-116-10-854; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LOWE WL, 1989, J CLIN ENDOCR METAB, V69, P1153, DOI 10.1210/jcem-69-6-1153; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MCCUMBEE WD, 1980, ENDOCRINOLOGY, V106, P1930, DOI 10.1210/endo-106-6-1930; MEGYESI K, 1974, J CLIN ENDOCR METAB, V38, P931, DOI 10.1210/jcem-38-5-931; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PEYRAT JP, 1990, J STEROID BIOCHEM, V37, P823, DOI 10.1016/0960-0760(90)90426-L; POLLAK M, 1992, J NATL CANCER I, V84, P966, DOI 10.1093/jnci/84.12.966; POLLAK MN, 1990, J NATL CANCER I, V82, P301, DOI 10.1093/jnci/82.4.301; POLLAK MN, 1992, BREAST CANCER RES TR, V22, P91, DOI 10.1007/BF01833337; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; RESNICOFF M, 1994, IN PRESS CANCER RES; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SELL C, 1994, IN PRESS MOL CELL BI; SHAO ZM, 1992, CANCER RES, V52, P5100; TORRISI R, 1993, CANCER RES, V53, P4769; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WERNER H, 1991, INSULIN LIKE GROWTH, P17; WHITE MF, 1994, J BIOL CHEM, V269, P1; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; YUN K, 1993, CANCER RES, V53, P5166; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZUMKELLER W, 1993, EUR J CANCER, V29A, P1973, DOI 10.1016/0959-8049(93)90455-O	53	272	278	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1995	122	1					54	59		10.7326/0003-4819-122-1-199501010-00009	http://dx.doi.org/10.7326/0003-4819-122-1-199501010-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY502	7619109				2022-12-28	WOS:A1995PY50200009
J	KEOGH, A; SPRATT, P; MCCOSKER, G; MACDONALD, P; MUNDY, J; KAAN, A				KEOGH, A; SPRATT, P; MCCOSKER, G; MACDONALD, P; MUNDY, J; KAAN, A			KETOCONAZOLE TO REDUCE THE NEED FOR CYCLOSPORINE AFTER CARDIAC TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-TRANSPLANTATION; METABOLISM; INFECTIONS; RECIPIENTS; DILTIAZEM; TOXICITY; THERAPY; TRIAL; MICE	Background. Because ketoconazole can markedly reduce the need for cyclosporine and because it also has antimicrobial properties, it may offer benefits in the treatment of patients after cardiac transplantation. Methods. We randomly assigned 43 patients at the time of cardiac transplantation to receive ketoconazole (200 mg per day) (23 patients) or no ketoconazole (20 patients). The main end points were the dose of cyclosporine required and the incidence of cardiac rejection and infection. Results. Ketoconazole reduced the dose of cyclosporine needed to maintain target levels by 62 percent at one week and by 80 percent at one year. The cost savings per patient (in U.S. dollars, inclusive of the cost of ketoconazole) was about $5,200 in the first year and about $3,920 in each subsequent year. The mean (+/-SD) rate of rejection in the first month was lower in the ketoconazole group than in the controls (4.2+/-0.8 vs. 5.7+/-1.0 episodes per 100 patient-days, P<0.001), and the average number of days to the first rejection was higher (30+/-29 vs. 15+/-8, P=0.03). In the first year, 22 percent of the ketoconazole group required cytolytic therapy, as compared with 35 percent of the controls, and 9 percent of the ketoconazole group required total lymphoid irradiation, as compared with 15 percent of the controls (P=0.07). The incidence of infection was lower in ketoconazole-treated patients than in controls in the second month (1.4+/-0.5 vs. 2.8+/-0.7 episodes per 100 patient-days, P<0.001) and in the third month (0.8+/-0.3 vs. 2.3+/-0.6 episodes per 100 patient-days, P<0.001). Transient, asymptomatic cholestasis was observed in the ketoconazole group. Conclusions. After cardiac transplantation, ketoconazole greatly reduced the need for cyclosporine, resulting In substantial cost savings. Ketoconazole also reduced the rates of rejection and infection, without persistent toxic effects. We now use ketoconazole routinely in cardiac-transplant recipients.	ST VINCENTS HOSP,VICTOR CHANG RES INST,DARLINGHURST,NSW 2010,AUSTRALIA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute	KEOGH, A (corresponding author), ST VINCENTS HOSP,CARDIOPULM TRANSPLANT UNIT,DARLINGHURST,NSW 2010,AUSTRALIA.		Macdonald, Peter/Q-3188-2019; Mundy, Julie A/F-6551-2013					ANDERSON JE, 1987, TRANSPLANTATION, V43, P529, DOI 10.1097/00007890-198704000-00015; ANDERSON JE, 1986, J PHARMACOL EXP THER, V236, P671; Billingham M E, 1990, J Heart Transplant, V9, P587; BUTMAN SM, 1991, J HEART LUNG TRANSPL, V10, P351; CARLSON JA, 1983, AM J HOSP PHARM, V40, P1334, DOI 10.1093/ajhp/40.8.1334; CAUWENBERGH G, 1986, DRUG EXP CLIN RES, V12, P419; DANESHMEND TK, 1982, LANCET, V2, P1342; DIEPERINK H, 1986, CLIN NEPHROL, V25, pS137; EVANS RW, 1988, TRANSPL P, V20, P49; FERGUSON RM, 1982, LANCET, V2, P882; FIRST MR, 1993, TRANSPLANTATION, V55, P1000, DOI 10.1097/00007890-199305000-00009; GIRARDET RE, 1989, TRANSPLANTATION, V48, P887, DOI 10.1097/00007890-198911000-00039; GLYNN AM, 1986, CLIN PHARMACOL THER, V39, P654, DOI 10.1038/clpt.1986.114; KEOGH A, 1992, TRANSPLANT P, V24, P2263; KRAMER MR, 1990, ANN INTERN MED, V113, P327, DOI 10.7326/0003-4819-113-4-327; LINDGREN BW, 1976, STATISTICAL THEORY; MACDONALD P, 1992, TRANSPL P, V24, P2259; MCEVOY GK, 1991, AHFS DRUG INFORMATIO, P82; NASHAN D, 1989, ACTA ENDOCRINOL-COP, V120, P677, DOI 10.1530/acta.0.1200677; NIEMEGEERS CJE, 1981, ARCH INT PHARMACOD T, V251, P26; SCHROEDER JS, 1993, NEW ENGL J MED, V328, P164, DOI 10.1056/NEJM199301213280303; SCHROEDER T J, 1987, Journal of Heart Transplantation, V6, P84; SMITH J, 1983, EXP HEMATOL, V11, P176	23	114	118	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					628	633		10.1056/NEJM199509073331004	http://dx.doi.org/10.1056/NEJM199509073331004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637723				2022-12-28	WOS:A1995RR84000004
J	BESSON, I; INGRAND, P; PERSON, B; BOUTROUX, D; HERESBACH, D; BERNARD, P; HOCHAIN, P; LARRICQ, J; GOURLAOUEN, A; RIBARD, D; KARA, NM; LEGOUX, JL; PILLEGAND, B; BECKER, MC; DICOSTANZO, J; METREAU, JM; SILVAIN, C; BEAUCHANT, M				BESSON, I; INGRAND, P; PERSON, B; BOUTROUX, D; HERESBACH, D; BERNARD, P; HOCHAIN, P; LARRICQ, J; GOURLAOUEN, A; RIBARD, D; KARA, NM; LEGOUX, JL; PILLEGAND, B; BECKER, MC; DICOSTANZO, J; METREAU, JM; SILVAIN, C; BEAUCHANT, M			SCLEROTHERAPY WITH OR WITHOUT OCTREOTIDE FOR ACUTE VARICEAL BLEEDING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESOPHAGEAL-VARICES; CONTROLLED TRIAL; ENDOSCOPIC SCLEROTHERAPY; INJECTION SCLEROTHERAPY; PORTAL-HYPERTENSION; CIRRHOTIC-PATIENTS; EMERGENCY CONTROL; RANDOMIZED TRIAL; SOMATOSTATIN; HEMORRHAGE	Background. Sclerotherapy is considered the most effective way to stop bleeding from esophageal varices, but acute variceal bleeding is still associated with a high risk of rebleeding and death. We compared sclerotherapy alone with sclerotherapy and octreotide to control acute variceal bleeding and prevent early rebleeding in patients with cirrhosis. Methods. In a double-blind, prospective trial, 199 patients with cirrhosis and acute variceal bleeding who underwent emergency sclerotherapy were randomly assigned to receive a continuous infusion of octreotide (25 mu g per hour) or placebo for five days. The primary outcome measure was survival without rebleeding five days after sclerotherapy. Results. After five days, the proportion of patients who had survived without rebleeding was higher in the octreotide group (85 of 98 patients, or 87 percent) than in the placebo group (72 of 101, or 71 percent; 95 percent confidence interval for the difference, 4 to 27 percent; P = 0.009). The mean number of units of blood transfused within the first 24 hours after sclerotherapy was lower in the octreotide group (1.2 units; range, 0 to 7) than in the placebo group (2.0 units; range, 0 to 10; P=0.006). A logistic-regression analysis showed that the treatment assignment (P=0.003) and the number of blood units transfused before any other treatment was undertaken (P = 0.002) were the only two variables independently associated with survival without rebleeding. After adjustment for base-line differences between the two groups, the odds ratio for treatment failure in the placebo group, as compared with the octreotide group, was 3.3 (95 percent confidence interval, 1.5 to 7.3). The mean (+/-SD) 15-day cumulative survival rate (estimated by the Kaplan-Meier method) was 88+/-12 percent in both groups. Side effects were minor, and their incidence was similar in the two groups. Conclusions. In patients with cirrhosis, the combination of sclerotherapy and octreotide is more effective than sclerotherapy alone in controlling acute variceal bleeding, but there is no difference between the overall mortality rates associated with the two approaches to treatment.	CHU POITIERS,SERV HEPATOGASTROENTEROL,F-86021 POITIERS,FRANCE	CHU Poitiers; Universite de Poitiers								ALBILLOS A, 1993, GASTROENTEROLOGY, V104, P575, DOI 10.1016/0016-5085(93)90429-G; ARMITAGE P, 1987, STATISTICAL METHODS; AVGERINOS A, 1991, J HEPATOL, V13, P78, DOI 10.1016/0168-8278(91)90867-B; BARSOUM MS, 1982, BRIT J SURG, V69, P76, DOI 10.1002/bjs.1800690206; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; BURROUGHS AK, 1989, NEW ENGL J MED, V321, P857, DOI 10.1056/NEJM198909283211303; DEFRANCHIS R, 1992, J HEPATOL, V15, P256, DOI 10.1016/0168-8278(92)90044-P; DUDLEY FJ, 1992, GASTROENTEROLOGY, V103, P1973, DOI 10.1016/0016-5085(92)91459-H; FIACCADORI F, 1993, CURR THER RES CLIN E, V54, P519, DOI 10.1016/S0011-393X(05)80671-X; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; Huang C C, 1992, Changgeng Yi Xue Za Zhi, V15, P78; HWANG SJ, 1992, J HEPATOL, V16, P320, DOI 10.1016/S0168-8278(05)80663-4; MCCORMICK PA, 1990, EUR J GASTROEN HEPAT, V2, P489; MCKEE R, 1990, DIGESTION, V45, P60, DOI 10.1159/000200264; MOLLER S, 1992, J HEPATOL, V15, P184, DOI 10.1016/0168-8278(92)90034-M; PLANAS R, 1994, HEPATOLOGY, V20, P370, DOI 10.1016/0270-9139(94)90188-0; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SILVAIN C, 1993, HEPATOLOGY, V18, P61, DOI 10.1016/0270-9139(93)90507-J; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; THOMSEN BL, 1994, J HEPATOL, V21, P367, DOI 10.1016/S0168-8278(05)80315-0; 1987, SAS STAT GUIDE PERSO	23	212	219	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					555	560		10.1056/NEJM199508313330904	http://dx.doi.org/10.1056/NEJM199508313330904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623904	Bronze			2022-12-28	WOS:A1995RQ75100004
J	PILOTE, L; CALIFF, RM; SAPP, S; MILLER, DP; MARK, DB; WEAVER, WD; GORE, JM; ARMSTRONG, PW; OHMAN, EM; TOPOL, EJ				PILOTE, L; CALIFF, RM; SAPP, S; MILLER, DP; MARK, DB; WEAVER, WD; GORE, JM; ARMSTRONG, PW; OHMAN, EM; TOPOL, EJ			REGIONAL VARIATION ACROSS THE UNITED-STATES IN THE MANAGEMENT OF ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIALS; PLASMINOGEN-ACTIVATOR; CARDIAC PROCEDURES; MEDICAL-PRACTICE; ANGIOPLASTY; ASSOCIATION; ANGIOGRAPHY; CARE	Background. Differences in the management of acute myocardial infarction have been reported among countries, but few studies have investigated this issue in regions of the United States. Methods. We compared the management of acute myocardial infarction among census regions across the United States, using data from the first Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (GUSTO-1) comprising 21,772 patients, and from the American Hospital Association. Results. We found substantial regional variation in the management of acute myocardial infarction in the United States. Beta-blockers (prescribed for a range of 55 to 81 percent of patients in the various regions), nitrates (prescribed for 61 to 77 percent), and angiotensin-converting-enzyme inhibitors (prescribed for 18 to 23 percent) were used most often in New England, whereas calcium-channel blockers (31 to 42 percent) and lidocaine (14 to 43 percent) were used least often there. Similarly, the proportion of patients undergoing various cardiac procedures differed among regions (range for angiography, 52 to 81 percent of patients; angioplasty, 22 to 35 percent; and coronary-artery bypass surgery, 9 to 17 percent) and was lowest in New England. The regional use of cardiac procedures was closely related to their availability, except in New England. After the analysis was adjusted for clinical and hospital variables, patients in New England were found to be less likely to undergo angiography than patients in the other regions (odds ratio, 0.37; 95 percent confidence interval, 0.32 to 0.42). There was no apparent relation between the use of cardiac procedures and rates of recurrent infarction or death at 30 days or 1 year. Conclusions. There is substantial regional variation in the use of cardiac medications and procedures to manage acute myocardial infarction in the United States. The use and availability of cardiac procedures are closely related. The management of acute myocardial infarction in New England is atypical in that the relatively limited availability of cardiac procedures does not account for their relatively low use in that region.	CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA; DUKE UNIV, MED CTR, DURHAM, NC USA; UNIV WASHINGTON, SEATTLE, WA USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA USA; UNIV ALBERTA, EDMONTON, AB, CANADA	Cleveland Clinic Foundation; Duke University; University of Washington; University of Washington Seattle; University of Massachusetts System; University of Massachusetts Worcester; University of Alberta				Mark, Daniel/0000-0001-6340-8087; Armstrong, Paul/0000-0002-0460-3445; Miller, Dave/0000-0003-2947-152X; Pilote, Louise/0000-0002-6159-0628; Topol, Eric/0000-0002-1478-4729				AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; NETER J, 1990, APPLIED LINEAR STATI, P466; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; RESNEKOV L, 1989, CHEST, V95, pS52, DOI 10.1378/chest.95.2_Supplement.52S; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WINTERS WL, 1991, JAMA-J AM MED ASSOC, V265, P496, DOI 10.1001/jama.1991.03460040072032; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1990, CIRCULATION, V82, P117; 1991, JAMA-J AM MED ASSOC, V265, P482; 1993, AM HOSPITAL ASS GUID	28	317	320	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					565	572		10.1056/NEJM199508313330907	http://dx.doi.org/10.1056/NEJM199508313330907			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623907				2022-12-28	WOS:A1995RQ75100007
J	COLLIN, J				COLLIN, J			TRANSLUMINAL AORTIC-ANEURYSM REPLACEMENT	LANCET			English	Editorial Material											COLLIN, J (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.							Collin J, 1991, Eur J Vasc Surg, V5, P141, DOI 10.1016/S0950-821X(05)80678-4; MAY J, 1994, J VASC SURG, V19, P924, DOI 10.1016/S0741-5214(94)70020-6; MOORE WS, 1994, ANN SURG, V220, P331, DOI 10.1097/00000658-199409000-00009; NASIM A, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92444-9; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; PARODI JC, 1993, ADV VASC SURG, V1, P83; SCOTT RAP, 1993, LANCET, V342, P1395, DOI 10.1016/0140-6736(93)92756-J; SCOTT RAP, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91247-5; YUSUF SW, 1994, LANCET, V344, P650, DOI 10.1016/S0140-6736(94)92086-9; YUSUF SW, 1994, LANCET, V344, P1645, DOI 10.1016/S0140-6736(94)90443-X	10	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					457	458		10.1016/S0140-6736(95)91318-1	http://dx.doi.org/10.1016/S0140-6736(95)91318-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637477				2022-12-28	WOS:A1995RP85700006
J	FISHERHOCH, SP; KHAN, JA; REHMAN, S; MIRZA, S; KHURSHID, M; MCCORMICK, JB				FISHERHOCH, SP; KHAN, JA; REHMAN, S; MIRZA, S; KHURSHID, M; MCCORMICK, JB			CRIMEAN-CONGO HEMORRHAGIC-FEVER TREATED WITH ORAL RIBAVIRIN	LANCET			English	Article							HEMORRHAGIC-FEVER; NOSOCOMIAL OUTBREAK; LASSA FEVER; VIRUS; RISK; INFECTION; THERAPY	Crimean-Congo Haemorrhagic Fever (CCHF) is an often-lethal haemorrhagic fever caused by a tick-borne virus. There are no published data on ribavirin treatment of CCHF-infected patients, despite established in-vitro and in-vivo sensitivity. We report three health workers-two surgeons and a hospital worker-infected with CCHF Virus ill Pakistan who were treated with oral ribavirin 4 g/day for four days, then 2.4 g/day for six days. Intravenous ribavirin was unavailable. All three patients were severely ill with low platelet and white-cell counts, raised aspartate transaminase acid evidence of impaired haemostasis. Based on published reports, all had an estimated probability of death of 90% or more. The patients became afebrile, and their haematological and biochemical abnormalities returned to normal within 48 h of ribavirin treatment; all made a complete recovery, and developed IgG and IgM antibody to CCHF virus. Our experience with ribavirin treatment is encouraging, but does not constitute evidence of efficacy. Given the difficulties in gathering adequate treatment data, we propose a consensus protocol for both intravenous and oral treatment of CCHF. This protocol could be distributed to key medical personnel in areas endemic for CCHF and used to provide a firm basis for effective treatment recommendations.	AGA KHAN UNIV,DEPT COMMUNITY HLTH SCI,KARACHI 748000,PAKISTAN; SANDEMAN HOSP,DEPT SURG,QUETTA,PAKISTAN		FISHERHOCH, SP (corresponding author), AGA KHAN UNIV,DEPT PATHOL,POB 3500,STADIUM RD,KARACHI 748000,PAKISTAN.			McCormick, Joseph/0000-0002-5844-8102				ALTIKRITI SK, 1981, B WORLD HEALTH ORGAN, V59, P85; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; CANONICO PG, 1984, TOXICOL APPL PHARM, V74, P155, DOI 10.1016/0041-008X(84)90138-8; CHAPMAN LE, 1991, J INFECT DIS, V164, P686, DOI 10.1093/infdis/164.4.686; FISHERHOCH SP, 1985, LANCET, V2, P1227; FISHERHOCH SP, 1992, AM J TROP MED HYG, V47, P337, DOI 10.4269/ajtmh.1992.47.337; HOOGSTRAAL H, 1979, J MED ENTOMOL, V15, P307, DOI 10.1093/jmedent/15.4.307; HUGGINS JW, 1991, J INFECT DIS, V164, P1119, DOI 10.1093/infdis/164.6.1119; HUGGINS JW, 1989, REV INFECT DIS, V2, pS750; LASKIN OL, 1987, CLIN PHARMACOL THER, V41, P546, DOI 10.1038/clpt.1987.70; LESHCHINSKAYA EV, 1965, T I POLIO VIRUS ENTS, V7, P226; MARTINI G A, 1971, P1; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; SHEPHERD AJ, 1989, REV INFECT DIS, V11, pS801; SULEIMAN MNEH, 1980, LANCET, V2, P939; SWANEPOEL R, 1989, REV INFECT DIS, V11, pS794; SWANEPOEL R, 1990, 7TH P INT C VIR BERL; TIGNOR GH, 1993, ANTIVIR RES, V22, P309, DOI 10.1016/0166-3542(93)90040-P; VANDEWAL BW, 1985, S AFR MED J, V68, P729; VANEEDEN PJ, 1985, S AFR MED J, V68, P711; WATTS DM, 1989, AM J TROP MED HYG, V41, P591; WILSON SZ, 1984, ANTIMICROB AGENTS CH, V26, P200, DOI 10.1128/AAC.26.2.200; 1988, MMWR-MORBID MORTAL W, V37, pS1; 1980, RIBAVIRIN BROAD SPEC, P58	25	158	174	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					472	475		10.1016/S0140-6736(95)91323-8	http://dx.doi.org/10.1016/S0140-6736(95)91323-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637481	Bronze			2022-12-28	WOS:A1995RP85700011
J	MADHOK, R				MADHOK, R			TENIDAP	LANCET			English	Article							RHEUMATOID-ARTHRITIS; DISEASE; DRUGS; TOXICITY; THERAPY				MADHOK, R (corresponding author), GLASGOW ROYAL INFIRM UNIV NHS TRUST,CTR RHEUMAT DIS,84 CASTLE ST,GLASGOW E4 0SF,LANARK,SCOTLAND.							BEEDVELD F, 1994, SCAND J RHEUMAT S100, V23, P31; BLACKBURN WD, 1991, ARTHRITIS RHEUM, V34, P211, DOI 10.1002/art.1780340213; BLACKBURN WD, 1992, ARTHRITIS RHEUM, V35, pS97; CAPELL HA, 1993, ANN RHEUM DIS, V52, P423, DOI 10.1136/ard.52.6.423; CARTY T J, 1988, Arthritis and Rheumatism, V31, pS89; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; FELSON DT, 1994, ARTHRITIS RHEUM, V37, P1487, DOI 10.1002/art.1780371012; FRIES JF, 1993, ARTHRITIS RHEUM, V36, P297, DOI 10.1002/art.1780360303; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; KIRBY DS, 1993, ARTHRITIS RHEUM S9, V30, P112; KYANAUNG U, 1993, J RHEUMATOL, V20, P1014; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; LUBECK DP, 1994, RHEUMATOID ARTHRITIS, P247; MADHOK R, 1993, J RHEUMATOL, V20, P630; Martel-Pelletier J., 1994, Arthritis and Rheumatism, V37, pS309; PINCUS T, 1994, RHEUMATOID ARTHRITIS, P1; PROUDMAN KE, 1991, AGENTS ACTIONS, V34, P121, DOI 10.1007/BF01993255; PULLAR T, 1995, BR J CLIN PHARM S1, V39; SHARIF M, 1994, ARTHRITIS RHEUM S9, V37, P1008; SIPE JP, 1994, J IMMUNOL, V153, P2180; TUGWELL P, 1994, ARTHRITIS RHEUM S9, V37, P1198; VANLEEUWEN MA, 1994, J RHEUMATOL, V21, P425; WYLIE G, IN PRESS BR J RHEUMA	23	21	21	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					481	485		10.1016/S0140-6736(95)91326-2	http://dx.doi.org/10.1016/S0140-6736(95)91326-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637484				2022-12-28	WOS:A1995RP85700014
J	TAMURA, T; ISHIHARA, M; LAMPHIER, MS; TANAKA, N; OISHI, I; AIZAWA, S; MATSUYAMA, T; MAK, TW; TAKI, S; TANIGUCHI, T				TAMURA, T; ISHIHARA, M; LAMPHIER, MS; TANAKA, N; OISHI, I; AIZAWA, S; MATSUYAMA, T; MAK, TW; TAKI, S; TANIGUCHI, T			AN IRF-1-DEPENDENT PATHWAY OF DNA DAMAGE-INDUCED APOPTOSIS IN MITOGEN-ACTIVATED T-LYMPHOCYTES	NATURE			English	Article							REGULATORY FACTOR-I; PROGRAMMED CELL-DEATH; GENE CED-3; IRF-1; INDUCTION; HOMOLOG; ENZYME; SYSTEM; GROWTH; BCL-2	LYMPHOCYTES are particularly susceptible to DNA damage-induced apoptosis, a response which may serve as a form of 'altruistic suicide' to counter their intrinsic high potential for mutation and clonal expansion(1). The tumour suppressor p53 has been shown to regulate this type of apoptosis in thymocytes(2,3), but an as yet unknown, p53-independent pathway(s) appears to mediate the same event in mitogen-activated mature T lymphocytes(4). Here we show that DNA damage-induced apoptosis in these T lymphocytes is dependent on the antioncogenic transcription factor interferon regulatory factor (IRF)-1 (refs 5-7). Thus two different anti-oncogenic transcription factors, p53 and IRF-1, are required for distinct apoptotic pathways in T lymphocytes. We also show that mitogen induction of the interleukin-1 beta converting enzyme (ICE) gene(8-10), a mammalian homologue of the Caenorhabditis elegans cell death gene ced-3, is IRF-1-dependent. Ectopic overexpression of IRE-1 results in the activation of the endogenous gene for ICE and enhances the sensitivity of cells to radiation-induced apoptosis.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES EMBRYON SCI & TECHNOL,KYOTO 61902,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 860,JAPAN; AMGEN INST,TORONTO,ON M4X 1K9,CANADA	Osaka University; Japan Science & Technology Agency (JST); Kumamoto University	TAMURA, T (corresponding author), UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.		Oishi, Isao/L-8639-2018	Oishi, Isao/0000-0003-3682-5349; Tanaka, Nobuyuki/0000-0002-6373-2220; Taki, Shinsuke/0000-0001-5143-3496				CARRETTI DP, 1992, SCIENCE, V256, P97; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUKADA T, 1993, ONCOGENE, V8, P3313; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	414	422	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					596	599		10.1038/376596a0	http://dx.doi.org/10.1038/376596a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637809				2022-12-28	WOS:A1995RP75600052
J	NISHIMURA, S				NISHIMURA, S			CENSORSHIP OF THE ATOMIC-BOMB CASUALTY REPORTS IN OCCUPIED JAPAN - A COMPLETE BAN VS TEMPORARY DELAY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV TORONTO,INST HIST & PHILOSOPHY SCI & TECHNOL,TORONTO,ON,CANADA	University of Toronto								ARITOMI S, 1948, NAGASAKI IGAKKAI ZAS, V24, P153; BAUER AJ, 1948, COMMUNICATION   0826; BRAW M, 1991, ATOMIC BOMB SUPPRESS, P123; GROVES LR, 1946, COMMUNICATION   1209; HERSEY J, 1949, HIROSHIMA, P58; JOHNSON HG, 1946, COMMUNICATION   0102; KELLY HC, 1948, COMMUNICATION   0415; KELLY HC, 1948, COMMUNICATION   0127; KELLY HC, 1946, COMMUNICATION   1126; KELLY HC, 1948, COMMUNICATION   0610; MARQUAT WF, 1948, COMMUNICATION   0621; OSADA A, 1962, HEIWA MOTOMETE, P65; ROPER HM, 1948, COMMUNICATION   0907; SAMS CF, 1957, IMPACT HIROSHIMA NAG, P10; STONE WS, 1946, COMMUNICATION   1108; TSUZUKI M, 1954, IGAKU NO TACHIBA KAR, P35; TSUZUKI M, 1947, REPORT MED STUDIES E, P79; TSUZUKI M, 1945, NIHON IJI SHINP 1001, P4; TSUZUKI M, 1954, IGAKU NO TACHIBA KAR, P104; TSUZUKI M, 1947, SOGO IGAKU      0601, P21; TSUZUKI M, 1951, GENSHI BAKUDAN SAIGA, P11; TSUZUKI M, 1947, 1947 AT BOMB CAS COM, P79; TSUZUKI M, 1945, SOGO IGAKU, V2, P3; WILLOUGHBY CA, 1948, COMMUNICATION   0430; 1948, APR SCAP DOC C, P2; 1948, APR SCAP DOC C, P11; 1948, ESS1947 SCAP ACT REP, P1; 1968, NIHON KAGAKU GIJUTSU, V2, P426; 1947, ESS1947 SCAP ACT REP, P6; 1961, HIROSHIMA GENBAKU IR, P464; 1954, MAINICHI SHINBU 0730, P7; 1953, GENSHI BAKUDAN SAIGA, P285	32	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					520	522						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629965				2022-12-28	WOS:A1995RN46600003
J	STAMM, WE; HICKS, CB; MARTIN, DH; LEONE, P; HOOK, EW; COOPER, RH; COHEN, MS; BATTEIGER, BE; WORKOWSKI, K; MCCORMACK, WM; BOLAN, G; DOUGLAS, JM; WONG, ES; PAPPAS, PG; JOHNSON, RB				STAMM, WE; HICKS, CB; MARTIN, DH; LEONE, P; HOOK, EW; COOPER, RH; COHEN, MS; BATTEIGER, BE; WORKOWSKI, K; MCCORMACK, WM; BOLAN, G; DOUGLAS, JM; WONG, ES; PAPPAS, PG; JOHNSON, RB			AZITHROMYCIN FOR EMPIRICAL-TREATMENT OF THE NONGONOCOCCAL URETHRITIS SYNDROME IN MEN - A RANDOMIZED DOUBLE-BLIND-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHLAMYDIAL INFECTIONS; DOXYCYCLINE; THERAPY	Objective.-To evaluate the use of single-dose azithromycin for empirical treat Design.-Randomized, double-blind, multicenter trial comparing azithromycin vs doxycycline therapy, with a 2:1 randomization ratio. Patients were evaluated clinically and microbiologically for Chlamydia trachomatis and Ureaplasma urealyticum infection before therapy and at 2 and 5 weeks after study entry. Setting.-Eleven sexually transmitted disease clinics throughout the United States. Patients.-A total of 452 men aged 18 years or older with symptomatic nongonococcal urethritis of less than 14 days' duration. Intervention.-Patients were treated with either 1.0 g of azithromycin as a single oral dose or 100 mg of doxycycline taken orally twice daily for 7 days. Main Outcome Measures.-Clinical resolution of symptoms and signs of nongonococcal urethritis, microbiological cure of C trachomatis and U urealyticum, and occurrence of adverse experiences. Results.-Of the 452 patients enrolled, 248 in the azithromycin-treated group and 123 in the doxycycline-treated group were evaluable for clinical response. The two treatment groups were comparable in terms of age, weight, ethnic distribution, sexual preference, sexual activity, and history of prior nongonococcal urethritis or gonorrhea, Sixteen percent of the azithromycin group and 24% of the doxycycline group were culture positive for C trachomatis before therapy, while 38% and 28%, respectively, were culture positive for U urealyticum. The cumulative clinical cure rate was 81% (95% confidence interval [Cl], 75% to 85%) in the azithromycin-treated group and 77% (95% Cl, 69% to 84%) in the doxycycline-treated group. Clinical cure rates in the two groups were also comparable when patients were stratified by presence or absence of infection with C trachomatis or U urealyticum prior to therapy. Among those infected with C trachomatis, overall microbiological cure rates were 83% (95% Cl, 65% to 94%) for azithromycin-treated patients (n=30) and 90% (95% Cl, 68% to 98%) for doxycycline-treated patients (n=21). Among those infected with U urealyticum, overall microbiological cure rates were 45% (95% Cl, 34% to 57%) for azithromycin-treated patients (n=75) and 47% (95% Cl, 30% to 65%) for doxycycline-treated patients (n=32). Adverse reactions were generally mild to moderate and occurred in 23% of the azithromycin-treated group and 29% of the doxycycline-treated group. Conclusions.-For empirical treatment of the acute nongonococcal urethritis syndrome in men, a single oral dose of azithromycin was as effective as a standard 7-day course of doxycycline in achieving clinical cure. Further, clinical cure rates were comparable with either regimen, regardless of the presence or absence of Chlamydia or Ureaplasma infection.	DUKE UNIV, MED CTR, DURHAM, NC USA; LOUISIANA STATE UNIV, SCH MED, NEW ORLEANS, LA USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; UNIV ALABAMA, BIRMINGHAM, AL USA; MADIGAN ARMY MED CTR, TACOMA, WA 98431 USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA; SUNY COLL BUFFALO, BROOKLYN, NY USA; STD CONTROL PROGRAM, SAN FRANCISCO, CA USA; DENVER DEPT PUBL HLTH, DENVER, CO USA; HUNTER HOLMES MCGUIRE VET AFFAIRS MED CTR, RICHMOND, VA USA; PFIZER INC, PFIZER CENT RES, GROTON, CT 06340 USA	Duke University; Louisiana State University System; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham; Madigan Army Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; State University of New York (SUNY) System; Buffalo State College; Hunter Holmes McGuire Veterinary Affairs Medical Center; Pfizer	STAMM, WE (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR, ZA-89, 325 9TH AVE, SEATTLE, WA 98104 USA.							BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; BOWIE WR, 1989, SEXUALLY TRANSMITTED, P627; BRITTON TF, 1992, AM J GYNECOL HLTH, V6, P24; JONES RB, 1990, CHLAMYDIAL INFECTION, P490; LAUHARANTA J, 1993, J ANTIMICROB CHEMOTH, V31, P177, DOI 10.1093/jac/31.suppl_E.177; LISTER PJ, 1993, J ANTIMICROB CHEMOTH, V31, P185, DOI 10.1093/jac/31.suppl_E.185; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; Nuovo J, 1995, J Am Board Fam Pract, V8, P7; PIOT P, 1994, CHLAMYDIAL INFECTION, P7; STAMM WE, 1993, ANN INTERN MED, V119, P432, DOI 10.7326/0003-4819-119-5-199309010-00017; STAMM WE, 1991, AM J MED, V91, pS19, DOI 10.1016/0002-9343(91)90396-F; STAMM WE, 1989, SEXUALLY TRANSMITTED, P181; STEINGRIMSSON O, 1990, J ANTIMICROB CHEMOTH, V25, P109, DOI 10.1093/jac/25.suppl_A.109; WORKOWSKI KA, 1993, JAMA-J AM MED ASSOC, V270, P2071, DOI 10.1001/jama.270.17.2071; 1993, MMWR-MORBID M      S, V42, P47	15	104	112	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					545	549		10.1001/jama.274.7.545	http://dx.doi.org/10.1001/jama.274.7.545			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629982				2022-12-28	WOS:A1995RN46600024
J	CHENG, HJ; NAKAMOTO, M; BERGEMANN, AD; FLANAGAN, JG				CHENG, HJ; NAKAMOTO, M; BERGEMANN, AD; FLANAGAN, JG			COMPLEMENTARY GRADIENTS IN EXPRESSION AND BINDING OF ELF-1 AND MEK4 IN DEVELOPMENT OF THE TOPOGRAPHIC RETINOTECTAL PROJECTION MAP	CELL			English	Article							RETINAL AXONS; VISUAL-SYSTEM; CHICK; RECEPTOR; GUIDANCE; MOLECULE; POSITION; INVITRO; TECTUM; ORDER	Topographic maps with a defined spatial ordering of neuronal connections are a key feature of brain organization. Such maps are believed to develop in response to complementary position-specific labels in presynaptic and postsynaptic fields. However, the complementary labeling molecules are not known. In the well-studied visual map of retinal axons projecting to the tectum, the labels are hypothesized to be in gradients, without needing large numbers of cell-specific molecules. We recently cloned ELF-1 as a ligand for Eph family receptors. Here, RNA hybridization shows matching expression gradients for ELF-1 in the tectum and its receptor Mek4 in the retina. Binding activity detected with alkaline phosphatase fusions of ELF-1 and Mek4 also reveals gradients and provides direct evidence for molecular complementarity of gradients in reciprocal fields, ELF-1 and Mek4 may therefore play roles in retinotectal development and have properties predicted of topographic mapping labels.			CHENG, HJ (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Flanagan, John/AAM-2995-2020; Cheng, Hwai-Jong/AAY-5067-2021	Cheng, Hwai-Jong/0000-0003-0647-0567; Nakamoto, Masaru/0000-0001-9356-1189; Bergemann, Andrew/0000-0002-0027-7662	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD029417, R01HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, IN PRESS MOL CELL BI; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COX EC, 1990, NEURON, V2, P31; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEITCHER DL, 1994, J NEUROSCI, V14, P486; Descartes R., 1664, TREATISE MAN; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; ITASAKI N, 1992, NEURON, V8, P787, DOI 10.1016/0896-6273(92)90099-Y; Jacobson M., 1991, DEV NEUROBIOLOGY; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAVAIL JH, 1971, BRAIN RES, V28, P391, DOI 10.1016/0006-8993(71)90053-9; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MEY J, 1992, J HIRNFORSCH, V33, P673; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NIETO MA, 1992, DEVELOPMENT, V116, P1137; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; SOANS C, 1994, ONCOGENE, V9, P3353; Sperry RW, 1943, J COMP NEUROL, V79, P33, DOI 10.1002/cne.900790104; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SPIRA AW, 1987, J COMP NEUROL, V260, P526, DOI 10.1002/cne.902600406; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VONBOXBERG Y, 1993, NEURON, V10, P345; WALTER J, 1987, DEVELOPMENT, V101, P685; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	43	630	642	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					371	381		10.1016/0092-8674(95)90426-3	http://dx.doi.org/10.1016/0092-8674(95)90426-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634327	Bronze, Green Published			2022-12-28	WOS:A1995RP24200007
J	CHEUNG, AY; WANG, H; WU, HM				CHEUNG, AY; WANG, H; WU, HM			A FLORAL TRANSMITTING TISSUE-SPECIFIC GLYCOPROTEIN ATTRACTS POLLEN TUBES AND STIMULATES THEIR GROWTH	CELL			English	Article							PROLINE-RICH PROTEIN; ARABINOGALACTAN-PROTEINS; NICOTIANA-ALATA; GENE-EXPRESSION; DAUCUS-CAROTA; EXTENSIN; STIGMA; AXONS; IDENTIFICATION; CHEMOTROPISM	Pollen tubes elongate directionally in the extracellular matrix of pistil tissues to transport the male gametes from the apically located stigma to the basally located ovary for fertilization. The molecular mechanisms underlying directional pollen tube growth in the pistil are poorly understood. We have purified a glycoprotein, TTS, from tobacco stylar transmitting tissue, which supports pollen tube growth between the stigma and the ovary. TTS proteins belong to the arabinogalactan protein family, and they polymerize readily in vitro in a head-to-tail fashion into oligomeric forms. TTS proteins stimulate pollen tube growth in vitro and attract pollen tubes grown in a semi-in vivo culture system. In vivo, the pollen tube growth rate is reduced in transgenic plants that have significantly reduced levels of TTS proteins as a result of either antisense suppression or sense cosuppression. These results identify TTS protein as a pistil component that positively contributes to pollen tube growth.			CHEUNG, AY (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.			Wang, Hong/0000-0003-4130-8741				BALDWIN TC, 1993, PLANT PHYSIOL, V103, P115, DOI 10.1104/pp.103.1.115; CHEN CG, 1993, PLANT MOL BIOL, V21, P391, DOI 10.1007/BF00019955; CHEN CG, 1994, P NATL ACAD SCI USA, V91, P10305, DOI 10.1073/pnas.91.22.10305; CHEN CG, 1992, PLANT CELL, V4, P1053, DOI 10.1105/tpc.4.9.1053; CHEUNG AY, 1995, P NATL ACAD SCI USA, V92, P3077, DOI 10.1073/pnas.92.8.3077; CHEUNG AY, 1993, PLANT J, V3, P151, DOI 10.1111/j.1365-313X.1993.tb00018.x; CLARKE A, 1979, P NATL ACAD SCI USA, V76, P3358, DOI 10.1073/pnas.76.7.3358; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DU H, 1994, PLANT CELL, V6, P1643, DOI 10.1105/tpc.6.11.1643; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; GLEESON PA, 1980, PHYTOCHEMISTRY, V19, P1777, DOI 10.1016/S0031-9422(00)83812-1; GOLDMAN MHD, 1992, PLANT CELL, V4, P1041, DOI 10.1105/tpc.4.9.1041; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HEATH IB, 1990, TIP GROWTH PLANT FUN; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JEFFERIES CJ, 1974, STAIN TECHNOL, V49, P199, DOI 10.3109/10520297409116977; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; KANDASAMY MK, 1987, J PLANT PHYSIOL, V131, P495, DOI 10.1016/S0176-1617(87)80292-4; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIELISZEWSKI MJ, 1992, PLANT PHYSIOL, V99, P538, DOI 10.1104/pp.99.2.538; Knox R. B., 1984, Cellular interactions, P508; KREUGER M, 1993, PLANTA, V189, P243, DOI 10.1007/BF00195083; LABARCA C, 1973, PLANT PHYSIOL, V52, P87, DOI 10.1104/pp.52.2.87; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; MASCARENHAS JP, 1975, BOT REV, V41, P259, DOI 10.1007/BF02860839; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MASCARENHAS JP, 1962, AM J BOT, V49, P482, DOI 10.2307/2439418; MASCARENHAS JP, 1962, NATURE, V196, P292, DOI 10.1038/196292a0; Mulcahy G. B., 1982, J PALYNOL, V18, P61; READ SM, 1993, PROTOPLASMA, V177, P1, DOI 10.1007/BF01403393; REGER BJ, 1992, SEX PLANT REPROD, V5, P201, DOI 10.1007/BF00189812; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROSEN WG, 1961, AM J BOT, V48, P889, DOI 10.2307/2439530; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SHOWALTER AM, 1989, BIOCH PLANTS, V15, P485; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; SOMMERVILLE J, 1987, ELECTRON MICROSCOPY; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; Van Montagu M., 1986, METHOD ENZYMOL, V153, P277; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; VASIL IK, 1987, INT REV CYTOL, V107, P127, DOI 10.1016/S0074-7696(08)61075-X; WANG H, 1993, PLANT CELL, V5, P1639, DOI 10.1105/tpc.5.11.1639; WELK M, 1965, AM J BOT, V52, P774, DOI 10.2307/2439758; WU HM, 1995, CELL, V82, P395, DOI 10.1016/0092-8674(95)90428-X; YARIV J, 1967, BIOCHEM J, V105, P10; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	51	385	438	3	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					383	393		10.1016/0092-8674(95)90427-1	http://dx.doi.org/10.1016/0092-8674(95)90427-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634328	hybrid			2022-12-28	WOS:A1995RP24200008
J	STUTZ, F; NEVILLE, M; ROSBASH, M				STUTZ, F; NEVILLE, M; ROSBASH, M			IDENTIFICATION OF A NOVEL NUCLEAR PORE-ASSOCIATED PROTEIN AS A FUNCTIONAL TARGET OF THE HIV-1 REV PROTEIN IN YEAST	CELL			English	Article							VIRUS TYPE-1 REV; VIRAL MESSENGER-RNA; HTLV-I REX; TRANS-ACTIVATOR; MUTATIONAL ANALYSIS; COMPLEX PROTEINS; PREMESSENGER RNA; GENE; ENVELOPE; BINDING	The HIV-1 Rev protein increases the cytoplasm ic levels of unspliced and singly spliced target transcripts in metazoan systems. Based on experiments that indicate a similar function of Rev in the yeast S. cerevisiae, we have identified a yeast protein that interacts with the effector domain of Rev. The protein, Rip1p, is a novel small nucleoporin-like protein, some of which is associated with nuclear pores. Its closest known yeast relative is a nuclear pore component also implicated in mRNA transport from nucleus to cytoplasm. Analysis of strains that overexpress Rip1p or that are deleted for the RIP1 gene show that Rip1p is important for the effect of Rev on gene expression, indicating that the physical interaction is of functional significance in vivo. The results suggest that Rev directly promotes the cytoplasmic transport of suitable transcripts by targeting them to the nuclear pore.	BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA	Brandeis University	STUTZ, F (corresponding author), BRANDEIS UNIV, HOWARD HUGHES MED INST, WALTHAM, MA 02254 USA.		Stutz, Françoise C/N-4329-2017	Goodwin, Megan/0000-0001-8506-9944				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DINGWALL C, 1993, CURR BIOL, V3, P297, DOI 10.1016/0960-9822(93)90184-P; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P389; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LESSER CF, 1993, GENETICS, V133, P851; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Maniatis T., 1982, MOL CLONING; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	68	211	216	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					495	506		10.1016/0092-8674(95)90438-7	http://dx.doi.org/10.1016/0092-8674(95)90438-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634338	Bronze			2022-12-28	WOS:A1995RP24200019
J	GOLDENBERG, RL; TAMURA, T; NEGGERS, Y; COPPER, RL; JOHNSTON, KE; DUBARD, MB; HAUTH, JC				GOLDENBERG, RL; TAMURA, T; NEGGERS, Y; COPPER, RL; JOHNSTON, KE; DUBARD, MB; HAUTH, JC			THE EFFECT OF ZINC SUPPLEMENTATION ON PREGNANCY OUTCOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FETAL GROWTH-RETARDATION; LOW-INCOME WOMEN; MEXICAN DESCENT; ANTHROPOMETRIC MEASUREMENTS; ADOLESCENT PREGNANCY; BLOOD-CONSTITUENTS; NUTRITIONAL-STATUS; BIRTH-WEIGHT; SERUM; ASSOCIATION	Objective.-To evaluate whether zinc supplementation during pregnancy is associated with an increase in birth weight. Design.-A randomized double-blind placebo-controlled trial. Setting.-Outpatient clinic and delivery service at the University of Alabama at Birmingham. Patients.-Five hundred eighty medically indigent but otherwise healthy African-American pregnant women with plasma zinc levels below the median at enrollment in prenatal care, randomized at 19 weeks' gestational age. Women were subdivided by the population median body mass index of 26 kg/m(2) into two groups for additional analyses. Intervention.-Women who were taking a non-zinc-containing prenatal multivitamin/mineral tablet were randomized to receive either a daily dose of 25 mg of zinc or a placebo until delivery. Main Outcome Measures.-Birth weight, gestational age at birth, and head circumference at birth. Results.-In all women, infants in the zinc supplement group had a significantly greater birth weight (126 g, P=.03) and head circumference (0.4 cm, P=.02) than infants in the placebo group. In women with a body mass index less than 26 kg/m(2), zinc supplementation was associated with a 248-g higher infant birth weight (P=.005) and a 0.7-cm larger infant head circumference (P=.007). Plasma zinc concentrations were significantly higher in the zinc supplement group. Conclusions.-Daily zinc supplementation in women with relatively low plasma zinc concentrations in early pregnancy is associated with greater infant birth weights and head circumferences, with the effect occurring predominantly in women with a body mass index less than 26 kg/m(2).	UNIV ALABAMA,DEPT NUTR SCI,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT HUMAN NUTR,TUSCALOOSA,AL	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Tuscaloosa	GOLDENBERG, RL (corresponding author), UNIV ALABAMA,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,CTR OBSTET RES,ROOM 452,620 S 20TH ST,BIRMINGHAM,AL 35233, USA.				NICHD NIH HHS [HD28119, HD27289] Funding Source: Medline; PHS HHS [282-92-0055] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028119, R01HD027289] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APGAR J, 1985, ANNU REV NUTR, V5, P43, DOI 10.1146/annurev.nu.05.070185.000355; BASSIOUNI BA, 1979, EUR J OBSTET GYN R B, V9, P75, DOI 10.1016/0028-2243(79)90002-9; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P55; BRO S, 1988, SCAND J CLIN LAB INV, V48, P805, DOI 10.3109/00365518809088764; CHERRY FF, 1989, AM J CLIN NUTR, V50, P945, DOI 10.1093/ajcn/50.5.945; CHERRY FF, 1981, AM J CLIN NUTR, V34, P2367, DOI 10.1093/ajcn/34.11.2367; CLIVER SP, 1992, OBSTET GYNECOL, V80, P262; DREOSTI IE, 1993, ESSENTIAL TOXIC TRAC, P81; DUBARD MB, 1993, AM J OBSTET GYNECOL, V169, P1181, DOI 10.1016/0002-9378(93)90278-Q; Goldenberg R. L., 1993, American Journal of Obstetrics and Gynecology, V168, P383; GOLDENBERG RL, 1991, OBSTET GYNECOL, V78, P782; GOLDENBERG RL, 1993, AM J OBSTET GYNECOL, V168, P1197, DOI 10.1016/0002-9378(93)90369-T; HAMBIDGE KM, 1983, AM J CLIN NUTR, V37, P429, DOI 10.1093/ajcn/37.3.429; Hambridge KM., 1986, TRACE ELEMENTS HUM A, P1; HUNT IF, 1979, AM J CLIN NUTR, V32, P1511, DOI 10.1093/ajcn/32.7.1511; HUNT IF, 1984, AM J CLIN NUTR, V40, P508, DOI 10.1093/ajcn/40.3.508; HUNT IF, 1985, AM J CLIN NUTR, V42, P815, DOI 10.1093/ajcn/42.5.815; HUNT IF, 1983, AM J CLIN NUTR, V37, P572, DOI 10.1093/ajcn/37.4.572; HURLEY LS, 1966, P SOC EXP BIOL MED, V123, P692, DOI 10.3181/00379727-123-31578; JAMESON S, 1982, CLIN APPLICATIONS RE, P39; KING JC, 1990, J NUTR, V120, P1474, DOI 10.1093/jn/120.suppl_11.1474; KING JC, 1981, AM J CLIN NUTR, V34, P1049, DOI 10.1093/ajcn/34.6.1049; KREBS NF, 1984, AM J DIS CHILD, V138, P270, DOI 10.1001/archpedi.1984.02140410048015; KYNAST G, 1986, GYNECOL OBSTET INVES, V21, P117, DOI 10.1159/000298940; LAZEBNIK N, 1988, AM J OBSTET GYNECOL, V158, P161, DOI 10.1016/0002-9378(88)90802-2; MAHER JE, 1993, OBSTET GYNECOL, V81, P165; MAHOMED K, 1989, BRIT MED J, V299, P826, DOI 10.1136/bmj.299.6703.826; MEADOWS NJ, 1981, LANCET, V2, P1135; NEGGERS YH, 1990, AM J CLIN NUTR, V51, P678, DOI 10.1093/ajcn/51.4.678; PRASAD AS, 1991, AM J CLIN NUTR, V53, P403, DOI 10.1093/ajcn/53.2.403; PROHASKA JR, 1987, PHYSIOL REV, V67, P858, DOI 10.1152/physrev.1987.67.3.858; SCHOLL TO, 1993, AM J EPIDEMIOL, V137, P1115, DOI 10.1093/oxfordjournals.aje.a116615; SIMMER K, 1991, EUR J CLIN NUTR, V45, P139; SIMMER K, 1985, ACTA PAEDIATR SC   S, V319, P158; SWANSON CA, 1987, AM J CLIN NUTR, V46, P763, DOI 10.1093/ajcn/46.5.763; TAMURA T, 1994, BIOL TRACE ELEM RES, V41, P165, DOI 10.1007/BF02917226; TAMURA T, 1992, AM J CLIN NUTR, V56, P365, DOI 10.1093/ajcn/56.2.365; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WALRAVENS PA, 1976, AM J CLIN NUTR, V29, P1114, DOI 10.1093/ajcn/29.10.1114; WELLS JL, 1987, BRIT MED J, V294, P1054, DOI 10.1136/bmj.294.6579.1054; 1989, RECOMMENDED DIETARY, P205; 1994, PHYSICIANS DESK REFE; 1994, DRUG FACTS COMP; 1990, NUTRITION PREGNANCY, P66	45	263	272	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					463	468		10.1001/jama.274.6.463	http://dx.doi.org/10.1001/jama.274.6.463			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629954				2022-12-28	WOS:A1995RM69900025
J	LOZANO, P; CONNELL, FA; KOEPSELL, TD				LOZANO, P; CONNELL, FA; KOEPSELL, TD			USE OF HEALTH-SERVICES BY AFRICAN-AMERICAN CHILDREN WITH ASTHMA ON MEDICAID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD ASTHMA; UNITED-STATES; RACE; HOSPITALIZATIONS; PREVALENCE; MORTALITY; TRENDS; EVENTS; SODIUM	Objective.-To determine whether African-American children with asthma use more emergency department (ED) and inpatient medical services and fewer preventive services than white children with similar insurance coverage and family income. Design.-Historical cohort study using Medicaid claims data, Setting.-Aid to Families With Dependent Children enrollees aged 3 through 17 years in the Seattle-Tacoma, Wash, metropolitan area. Patients.-All 576 African-American children and 1369 white children receiving services for asthma between June 1988 and December 1992. Main Outcome Measures.-Utilization of asthma services (ED, inpatient, office visits, and pharmacy) and well-child services and associated Medicaid reimbursements, Results.-African-American children were more likely than white children to make ED visits or to be hospitalized for asthma; adjusted odds ratios (ORs) were 1.70 (95% confidence interval [CI], 1.34 to 2.15) and 1.42 (95% CI, 1.03 to 1.96), respectively, African-American children were less likely to have made an office visit for asthma; the adjusted OR was 0.48 (95% CI, 0.26 to 0.85). The two groups were similarly likely to have filled a prescription for an asthma medication and to have made a well-child visit. Per capita payments for asthma services were 24% higher for African-American children: $436 vs $350 per child-year. Conclusions.-Higher use of ED and inpatient services for asthma among African-American children using Medicaid (compared with white children) cannot be fully explained by poverty or inadequate health insurance. Furthermore, these children appear to make disproportionately few office visits for asthma, suggesting suboptimal use of preventive services for asthma. In contrast, the comparable use of well-child visits in the two groups suggests the problem may not be in access to care in general, but there may be specific problems in the successful management of chronic diseases such as asthma among African-American children.	UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LOZANO, P (corresponding author), GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,1730 MINOR AVE,SUITE 1600,SEATTLE,WA 98101, USA.		Lozano, Paula Maria/GPP-4090-2022		PHS HHS [MCJ-9043] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOSCO LA, 1993, CHEST, V104, P1727, DOI 10.1378/chest.104.6.1727; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARR W, 1989, SOC SCI MED, V29, P705, DOI 10.1016/0277-9536(89)90149-4; COGSWELL JJ, 1985, ARCH DIS CHILD, V60, P736, DOI 10.1136/adc.60.8.736; CONNELL FA, 1987, ANNU REV PUBL HEALTH, V8, P51, DOI 10.1146/annurev.publhealth.8.1.51; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; FITZPATRICK SB, 1992, J NATL MED ASSOC, V84, P233; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; KLEIN R, 1977, PEDIATRICS, V60, P7; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; ROBINSON JC, 1991, INQUIRY-J HEALTH CAR, V28, P107; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SLY RM, 1988, ANN ALLERGY, V60, P433; TAYLOR WR, 1992, PEDIATRICS, V90, P657; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1991, NIH PHS913042 NAT HE; 1992, STATE AM CHILDREN 19	27	162	163	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					469	473		10.1001/jama.274.6.469	http://dx.doi.org/10.1001/jama.274.6.469			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629955				2022-12-28	WOS:A1995RM69900026
J	MAJEED, AW; BROWN, S; WILLIAMS, N; HANNAY, DR; JOHNSON, AG				MAJEED, AW; BROWN, S; WILLIAMS, N; HANNAY, DR; JOHNSON, AG			VARIATIONS IN MEDICAL ATTITUDES TO POSTOPERATIVE RECOVERY PERIOD	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,DEPT GEN PRACTICE,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	MAJEED, AW (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT SURG,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.		brown, steve/AAG-2066-2019; brown, steven/D-5833-2012	brown, steven/0000-0002-0980-2793				BOURKE JB, 1981, LANCET, V2, P623; CANNON SR, 1982, BRIT J SURG, V69, P112, DOI 10.1002/bjs.1800690218; CHRISTENSEN T, 1985, BRIT J SURG, V72, P63, DOI 10.1002/bjs.1800720124; ROSS APJ, 1975, ANN ROY COLL SURG, V57, P326; SHULMAN AG, 1994, BRIT MED J, V309, P216, DOI 10.1136/bmj.309.6949.216	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					296	296		10.1136/bmj.311.7000.296	http://dx.doi.org/10.1136/bmj.311.7000.296			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633239	Green Published			2022-12-28	WOS:A1995RM71900027
J	SHORT, JA				SHORT, JA			HAS NURSING LOST ITS WAY - DUAL PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article											SHORT, JA (corresponding author), BARROW HOSP,BARROW GURNEY,BRISTOL BS19 3SG,AVON,ENGLAND.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					303	304		10.1136/bmj.311.7000.303	http://dx.doi.org/10.1136/bmj.311.7000.303			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633242	Green Published			2022-12-28	WOS:A1995RM71900030
J	DEWIND, N; DEKKER, M; BERNS, A; RADMAN, M; RIELE, HT				DEWIND, N; DEKKER, M; BERNS, A; RADMAN, M; RIELE, HT			INACTIVATION OF THE MOUSE MSH2 GENE RESULTS IN MISMATCH REPAIR DEFICIENCY, METHYLATION TOLERANCE, HYPERRECOMBINATION, AND PREDISPOSITION TO CANCER	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; BASE-PAIR MISMATCHES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GENOMIC INSTABILITY; ESCHERICHIA-COLI; DNA-DAMAGE; EXTRACTS; BINDING; MUTATIONS	To investigate the role of the presumed DNA mismatch repair (MMR) gene Msh2 in genome stability and tumorigenesis, we have generated cells and mice that are deficient for the gene. Msh2-deficient cells have lost mismatch binding and have acquired microsatellite instability, a mutator phenotype, and tolerance to methylating agents. Moreover, in these cells, homologous recombination has lost dependence on complete identity between interacting DNA sequences, suggesting that Msh2 is involved in safeguarding the genome from promiscuous recombination. Msh2-deficient mice display no major abnormalities, but a significant fraction develops lymphomas at an early age. Thus, Msh2 is involved in MMR, controlling several aspects of genome stability; loss of MMR-controlled genome stability predisposes to cancer.	NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS; INST JACQUES MONOD, MUTAGENESIS LAB, F-75251 PARIS 5, FRANCE	Netherlands Cancer Institute; UDICE-French Research Universities; Universite Paris Cite	DEWIND, N (corresponding author), NETHERLANDS CANC INST, DIV MOLEC CARCINOGENESIS, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.		; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148				AALTONEN LA, 1994, CANCER RES, V54, P1645; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; AQUILINA G, 1993, CARCINOGENESIS, V14, P2097, DOI 10.1093/carcin/14.10.2097; BEIJERSBERGEN RL, 1995, IN PRESS GENES DEV; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BOUFFLER S, 1993, BIOESSAYS, V15, P409, DOI 10.1002/bies.950150607; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROSIUS J, 1992, P NATL ACAD SCI USA, V89, P10706, DOI 10.1073/pnas.89.22.10706; CHONG JM, 1994, CANCER RES, V54, P4595; COHEN PR, 1991, AM J MED, V90, P606; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GRIFFIN S, 1993, BIOCHEMISTRY-US, V32, P13032, DOI 10.1021/bi00211a012; HAN HJ, 1993, CANCER RES, V53, P5087; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; JASS JR, 1994, MUTAT RES-FUND MOL M, V310, P125, DOI 10.1016/0027-5107(94)90016-7; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KOLODNER RD, 1995, CANCER RES, V55, P242; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LOEB LA, 1994, CANCER RES, V54, P5059; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MICHEJDA CJ, 1994, DNA ADDUCTS IDENTIFI, P323; MIRET JJ, 1993, J BIOL CHEM, V268, P3507; MIRONOV NM, 1994, CANCER RES, V54, P41; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PETIT MA, 1991, GENETICS, V129, P327; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; RISINGER JI, 1993, CANCER RES, V53, P5100; Sambrook J, 1989, MOL CLONING LABORATO; SELVA EM, 1995, GENETICS, V139, P1175; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SUZUKI H, 1994, CANCER RES, V54, P4841; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VARLET I, 1994, NUCLEIC ACIDS RES, V22, P5723, DOI 10.1093/nar/22.25.5723; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	88	693	720	0	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					321	330		10.1016/0092-8674(95)90319-4	http://dx.doi.org/10.1016/0092-8674(95)90319-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628020	Bronze			2022-12-28	WOS:A1995RL76000019
J	KATZ, WS; HILL, RJ; CLANDININ, TR; STERNBERG, PW				KATZ, WS; HILL, RJ; CLANDININ, TR; STERNBERG, PW			DIFFERENT LEVELS OF THE C-ELEGANS GROWTH-FACTOR LIN-3 PROMOTE DISTINCT VULVAR PRECURSOR FATES	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; POST-EMBRYONIC DEVELOPMENT; CELL LINEAGES; EXPRESSION; INDUCTION; AUTONOMY; ENCODES; MUTANTS; PATTERN; SIGNAL	An invariant spatial pattern of three cell fates (3 degrees-3 degrees 2 degrees-1 degrees-2 degrees-3 degrees) is generated from a field of multipotent precursor cells during C. elegans vulval development. We demonstrate that the epidermal growth factor-like domain of the LIN-3 protein can induce either of two distinct vulval cell fates: a high dose of LIN-3 induces a 1 degrees fate; a lower dose of LIN-3 induces a 2 degrees fate. A high dose of LIN-3 can also induce adjacent vulval precursor cells to assume 1 degrees fates; thus, high levels of LIN-3 can override the lateral signaling that normally inhibits formation of adjacent 1 degrees fates. We propose that the invariant pattern of vulval cell fates is generated by a graded distribution of LIN-3 that promotes different vulval fates according to local concentration and by a lateral signal that reinforces this initial bias.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	KATZ, WS (corresponding author), CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125, USA.			Sternberg, Paul/0000-0002-7699-0173; Katz, Wendy/0000-0003-3038-6314	NICHD NIH HHS [HD23690] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023690] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BRENNER S, 1974, GENETICS, V77, P71; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREYD G, 1991, THESIS MIT CAMBRIDGE; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAN M, 1990, GENETICS, V126, P899; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; JAN YN, 1994, ANNU REV GENET, V28, P373, DOI 10.1146/annurev.ge.28.120194.002105; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOGA M, 1995, IN PRESS DEVELOPMENT; KUNISCH M, 1994, P NATL ACAD SCI USA, V91, P10139, DOI 10.1073/pnas.91.21.10139; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, METHODS CELL BIOL C; PEIFER M, 1994, SCIENCE, V266, P192; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; Sambrook J, 1989, MOL CLONING LABORATO; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STJOHNSTON D, 1992, CELL, V68, P201; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1976, PHILOS T ROY SOC B, V275, P287, DOI 10.1098/rstb.1976.0084; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	49	167	177	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					297	307		10.1016/0092-8674(95)90317-8	http://dx.doi.org/10.1016/0092-8674(95)90317-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628018	Bronze			2022-12-28	WOS:A1995RL76000017
J	MOHRIG, JR; MOERKE, KA; CLOUTIER, DL; LANE, BD; PERSON, EC; ONASCH, TB				MOHRIG, JR; MOERKE, KA; CLOUTIER, DL; LANE, BD; PERSON, EC; ONASCH, TB			IMPORTANCE OF HISTORICAL CONTINGENCY IN THE STEREOCHEMISTRY OF HYDRATASE-DEHYDRATASE ENZYMES	SCIENCE			English	Article							STEREOSPECIFICITY; ANALOGS; EVOLUTION; FUMARASE	There are two stereochemical classes of hydratase-dehydratase enzymes. Those that catalyze the addition of water to alpha,beta-unsaturated thioesters give syn addition-elimination stereochemistry, whereas those that catalyze the addition of water to conjugated carboxylate substrates give anti stereochemistry. This dichotomy could reflect different adaptive advantages or contingencies of separate evolutionary histories. Determination of the nonenzymatic stereochemistry of deuterium oxide addition to fumarate and to S-crotonyl N-acetylcysteamine has provided direct evidence for the importance of the contingencies of evolutionary history, rather than chemical efficiency, in the pathways of these hydratase-dehydratase enzymes.			MOHRIG, JR (corresponding author), CARLETON COLL, DEPT CHEM, NORTHFIELD, MN 55057 USA.		Onasch, Tim/AAY-4998-2020; MOHRIG, JERRY/V-8908-2019	Onasch, Tim/0000-0001-7796-7840; 				AMYES TL, 1992, J AM CHEM SOC, V114, P10297, DOI 10.1021/ja00052a028; ANDERSON SR, 1994, BIOCHEMISTRY-US, V33, P10545, DOI 10.1021/bi00200a041; ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2779, DOI 10.1021/bi00307a038; BAHNSON BJ, 1991, BIOCHEMISTRY-US, V30, P5894, DOI 10.1021/bi00238a013; BAHNSON BJ, 1989, BIOCHEMISTRY-US, V28, P4173, DOI 10.1021/bi00436a008; BENNER SA, 1989, CHEM REV, V89, P789, DOI 10.1021/cr00094a004; BENNER SA, 1989, TOP STEREOCHEM, V19, P127; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; CLELAND WW, 1975, ACCOUNTS CHEM RES, V8, P145, DOI 10.1021/ar50089a001; CREIGHTON DJ, 1990, ENZYMES, V19, pCH7; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P14733, DOI 10.1021/bi00253a011; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; ERICKSON LE, 1959, J PHYS CHEM-US, V63, P705, DOI 10.1021/j150575a014; GAWRON O, 1961, J AM CHEM SOC, V83, P3634, DOI 10.1021/ja01478a021; GERIT JA, 1992, J AM CHEM SOC, V114, P5928; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GLASFELD A, 1990, J BIOL CHEM, V265, P11692; HANSON KR, 1975, ACCOUNTS CHEM RES, V8, P1, DOI 10.1021/ar50085a001; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MOHRIG JR, 1990, J AM CHEM SOC, V112, P3665, DOI 10.1021/ja00165a065; MOHRIG JR, 1981, J ORG CHEM, V46, P4655, DOI 10.1021/jo00336a003; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; SAUNDERS WH, 1973, MECHANISMS ELIMINATI, pCH3; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5304, DOI 10.1021/ja00277a040; SPEIR TW, 1971, BIOCHEM J, V125, P267, DOI 10.1042/bj1250267	28	54	54	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					527	529						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	RL495	7624773				2022-12-28	WOS:A1995RL49500023
J	MEHTA, M; SCHILLER, JH				MEHTA, M; SCHILLER, JH			PROGNOSIS WITH ASYMPTOMATIC PULMONARY NODULES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MEHTA, M (corresponding author), UNIV WISCONSIN,MADISON,WI 53706, USA.							BERLIN NI, 1984, AM REV RESPIR DIS, V30, P565; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; GINSBERG RJ, 1993, CANCER PRINCIPLES PR; HARVEY JC, 1993, SEMIN SURG ONCOL, V9, P32; SAAD R, 1989, REV ASSOC MED BRAS, V35, P23; STEELE JD, 1964, SOLITARY PULMONARY N	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					358	358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609270				2022-12-28	WOS:A1995RJ89800044
J	KIKKAWA, M; ISHIKAWA, T; WAKABAYASHI, T; HIROKAWA, N				KIKKAWA, M; ISHIKAWA, T; WAKABAYASHI, T; HIROKAWA, N			3-DIMENSIONAL STRUCTURE OF THE KINESIN HEAD-MICROTUBULE COMPLEX	NATURE			English	Article							CRYO-ELECTRON MICROSCOPY; SURFACE LATTICE; RECONSTRUCTION; DECORATION; TUBULIN; SYSTEM; IMAGES	KINESIN is a microtubule (MT)-associated 'motor' molecule fundamental to organelle transport(1,2). Recently, various kinesin superfamily members (KIFs) have also been identified and suggested as being responsible for the transport of specific organelles(3-5). Kinesin is a heterotetramer composed of two heavy chains and two light chains. The heavy chains form two globular heads, a rod and a fan-like tail completed by the light chains(6,7). The globular head, which is composed of approximately 340 amino-terminal residues of the heavy chain, includes both ATP-binding and MT-binding domains, and its recombinant protein also has these properties(8). To improve the understanding of the mechanism of force generation by an MT-based molecular motor, kinesin, we report here the three-dimensional structure of the complex of a recombinant kinesin head and MTs, as revealed by helical reconstruction from cryoelectron micrographs. A kinesin head is a globular teardrop-like structure binding to the ridge of one protofilament of MTs. We have determined the polarity of the structure of the complex of MTs and the kinesin head in relation to MT polarity.	UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC SCI, DEPT PHYS, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo			Ishikawa, Takashi/E-5023-2017; Kikkawa, Masahide/A-6692-2010	Ishikawa, Takashi/0000-0002-1976-7477; Kikkawa, Masahide/0000-0001-7656-8194				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; ISHIKAWA T, 1994, BIOCHEM BIOPH RES CO, V203, P951, DOI 10.1006/bbrc.1994.2274; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Vale Ronald D., 1993, P175; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	30	88	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					274	277		10.1038/376274a0	http://dx.doi.org/10.1038/376274a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617041				2022-12-28	WOS:A1995RK33100052
J	BARKER, DJP				BARKER, DJP			FETAL ORIGINS OF CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; GROWTH; HYPERTENSION; DEATH; INSULIN; BIRTH	The fetal origins hypothesis states that fetal undernutrition in middle to late gestation, which leads to disproportionate fetal growth, programmes later coronary heart disease. Animal studies have shown that undernutrition before birth programmes persisting changes in a range of metabolic, physiological, and structural parameters. Studies in humans have shown that men and women whose birth weights were at the lower end of the normal range, who were thin or short at birth, or who were small. in relation to placental size have increased rates of coronary heart disease. We are beginning to understand something of the mechanisms underlying these associations. The programming of blood pressure, insulin responses to glucose, cholesterol metabolism, blood coagulation, and hormonal settings are all areas of active research.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X				[Anonymous], MOTHERS BABIES DISEA; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1995, LANCET, V345, P1087, DOI 10.1016/S0140-6736(95)90821-8; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1995, BRIT MED J, V310, P703, DOI 10.1136/bmj.310.6981.703; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; DESAI M, 1994, DIABETIC MED, V11, P537; DICKE JM, 1987, CLIN OBSTETRICS, P421; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FOWDEN AL, 1989, J DEV PHYSIOL, V12, P173; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KLINE J, 1976, CONCEPTION BIRTH EPI; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LAW CM, 1994, DIABETIC MED, V12, P24; LEVENO KJ, 1979, AM J OBSTET GYNECOL, V135, P727, DOI 10.1016/0002-9378(79)90382-X; LUCAS A, 1991, CHILDHOOD ENV ADULT, P38; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; MARTYN CN, 1995, BRIT HEART J, V73, P116; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MCKEIGUE PM, 1994, DIABETIC MED, V11, pS17; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; Robinson JS, 1994, EARLY FETAL GROWTH D, P317; TAYLOR DJ, IN PRESS DIABETOLOGI; VAGERO D, 1994, LANCET, V343, P260, DOI 10.1016/S0140-6736(94)91112-6; WHEELER T, 1994, LANCET, V343, P511, DOI 10.1016/S0140-6736(94)91461-3; WIDDOWSON EM, 1975, PEDIATR RES, V9, P154, DOI 10.1203/00006450-197503000-00010; WIDDOWSON EM, 1974, P R SOC LOND, V185, P1; Wolpert L., 1991, TRIUMPH EMBRYO; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	38	2261	2341	2	155	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					171	174		10.1136/bmj.311.6998.171	http://dx.doi.org/10.1136/bmj.311.6998.171			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613432	Green Published			2022-12-28	WOS:A1995RK15900026
J	ROBINSON, R; HAYTER, P				ROBINSON, R; HAYTER, P			RELUCTANCE OF GENERAL-PRACTITIONERS TO BECOME FUNDHOLDERS	BRITISH MEDICAL JOURNAL			English	Article											ROBINSON, R (corresponding author), UNIV SOUTHAMPTON,INST HLTH POLICY STUDIES,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND.							GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; GLENNERSTER H, 1994, EMBEDDING PRIMARY CA; 1994, DEV NHS PURCHASING G	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					166	166		10.1136/bmj.311.6998.166	http://dx.doi.org/10.1136/bmj.311.6998.166			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613430	Green Published			2022-12-28	WOS:A1995RK15900024
J	QIAN, XQ; JEON, CJ; YOON, HS; AGARWAL, K; WEISS, MA				QIAN, XQ; JEON, CJ; YOON, HS; AGARWAL, K; WEISS, MA			STRUCTURE OF A NEW NUCLEIC-ACID-BINDING MOTIF IN EUKARYOTIC TRANSCRIPTIONAL ELONGATION-FACTOR TFIIS	NATURE			English	Article							RNA POLYMERASE-II; ZINC FINGER; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; DNA RECOGNITION; DOMAINS; PROTEIN; COMPLEX; SUBUNIT; BLOCK	TRANSCRIPTIONAL elongation involves dynamic interactions among RNA polymerase and single-stranded and double-stranded nucleic acids in the ternary complex1-4. In prokaryotes its regulation provides an important mechanism of genetic control1. Analogous eukaryotic mechanisms are not well understood5, but may control expression of proto-oncogenes6,7 and viruses, including the human immunodeficiency virus HIV-1 (ref. 8). The highly conserved eukaryotic transcriptional elongation factor TFIIS9 enables RNA polymerase II (RNAPII) to read though pause or termination sites, nucleosomes and sequence-specific DNA-binding proteins10-14 . Two distinct domains of human TFIIS, which bind RNAPII and nucleic acids, regulate read-through10 and possibly nascent transcript cleavage11-15. Here we describe the three-dimensional NMR16 structure of a Cys4 nucleic-acid-binding domain from human TFIIS9,10. Unlike previously characterized zinc modules17-21, which contain an alpha-helix, this structure consists of a three-stranded beta-sheet. Analogous Cys4, structural motifs may occur in other proteins involved in DNA or RNA transactions22-24, including RNAPII itself25. This new structure, designated the Zn ribbon, extends the repertoire of Zn-mediated peptide architectures26 and highlights the growing recognition of the beta-sheet as a motif of nucleic-acid recognition27,28.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114	University of Chicago; University of Chicago; Harvard University; Massachusetts General Hospital	QIAN, XQ (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.		Yoon, Ho Sup/A-2193-2011	Yoon, Ho Sup/0000-0002-8243-3904				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAMORSTEIN R, 1992, NATURE, V356, P408; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN X, IN PRESS BIOCHEMISTR; QIAN XQ, 1992, BIOCHEMISTRY-US, V31, P7463, DOI 10.1021/bi00148a006; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RENIES D, 1992, J BIOL CHEM, V267, P3795; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	30	111	118	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					277	279		10.1038/365277a0	http://dx.doi.org/10.1038/365277a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	7626141	Green Accepted			2022-12-28	WOS:A1993LX47100062
J	LEE, S; HAHN, S				LEE, S; HAHN, S			MODEL FOR BINDING OF TRANSCRIPTION FACTOR TFIIB TO THE TBP-DNA COMPLEX	NATURE			English	Article							RNA POLYMERASE-II; CRYSTAL-STRUCTURE; MINOR-GROOVE; TATA-BOX; FUNCTIONAL DOMAINS; ELEMENT	TRANSCRIPTION factor TFIIB is essential for the formation of RNA polymerase II initiation complexes where it binds to the TATA-binding protein (TBP) complex with DNA and recruits RNA polymerase II. TFIIB is probably a target for various activators(1-4). Several models have been proposed for the position of TFIIB in the TFIIB-TBP-DNA complex(1,3,5,6). Here we examine the structure of this Complex using gel mobility-shift assays and hydroxylradical footprinting. TFIIB requires at least seven base pairs of DNA on either side of the TATA box to form a stable TFIIB-TBP-DNA complex. The sugar residues protected from hydroxylradial cleavage by the TFIIB-TBP complex were mapped on the crystal-structure model of the TBP-DNA complex. This analysis suggests that TFIIB binds beneath the concave surface of TBP, contacting DNA both upstream and downstream of the TATA box. Our model predicts that TFIIB binds close to the C-terminal stirrup of TBP and provides one explanation for why TBP needs to bend DNA.			LEE, S (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Hahn, Steven/0000-0001-7240-2533				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HA L, 1991, NATURE, V352, P689; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIMBALL AS, 1993, BIOCHEMISTRY-US, V32, P4698, DOI 10.1021/bi00069a002; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TULLIUS TD, 1988, NATURE, V332, P663, DOI 10.1038/332663a0; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911	24	81	81	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					609	612		10.1038/376609a0	http://dx.doi.org/10.1038/376609a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637813				2022-12-28	WOS:A1995RP75600056
J	HENRARD, DR; PHILLIPS, JF; MUENZ, LR; BLATTNER, WA; WIESNER, D; EYSTER, ME; GOEDERT, JJ				HENRARD, DR; PHILLIPS, JF; MUENZ, LR; BLATTNER, WA; WIESNER, D; EYSTER, ME; GOEDERT, JJ			NATURAL-HISTORY OF HIV-1 CELL-FREE VIREMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; HOMOSEXUAL MEN; VIRAL BURDEN; INFECTION; AIDS; PLASMA; TYPE-1; BLOOD	Objective.-To characterize the natural history of viremia with human immunodeficiency virus type 1 (HIV-1) and its association with disease progression from infection to acquired immunodeficiency syndrome (AIDS). Design.-Prospective cohort study. Annual specimens were tested for quantitative virion-associated HIV-1 RNA, p24 antigen, and CD4(+) lymphocyte levels. Participants.-A total of 42 homosexual men who seroconverted to HIV-1 between 1982 and 1985. Main Outcome Measures.-Trends over time in serum HIV-1 RNA level, correlations between serum HIV-1 RNA and other markers, and prediction of AIDS using these markers. ResuIts.-HIV-1 RNA levels were stable overtime, increasing by 10-fold or more in only six (14%) of the 42 subjects during 3 to 11 years of follow-up. Mean HIV-1 RNA levels were 10(3.8) copies/mL if AIDS occurred in less than 4 years, 10(3.07) copies/mL if AIDS developed within 4 through 9 years, and 10(2.27) copies/mL if AIDS did not develop within 6 through 11 years. In both univariate and multivariate models, initial and subsequent HIV-1 RNA levels, p24 antigenemia, and percentage of CD4(+) lymphocytes were independently predictive of AIDS. Conclusions.-The stability of virion-associated HIV-1 RNA levels suggests that an equilibrium between HIV-1 replication rate and efficacy of immunologic response is established shortly after infection and persists throughout the asymptomatic period of the disease. Thus, defective immunologic control of HIV-1 infection may be as important as the viral replication rate for determining AIDS-free survival. Because individual steady-state levels of viremia were established soon after infection, HIV-1 RNA levels may be useful markers for predicting clinical outcome.	ABBOTT LABS, DEPT MED RES, N CHICAGO, IL 60064 USA; NCI, VIRAL EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT MED, DIV HEMATOL, HERSHEY, PA 17033 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				, M. Elaine Eyster/0000-0001-8248-6793	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095612] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-33060, N01-CP-40521, N01-CP-95612] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; COOMBS RW, 1993, J CLIN MICROBIOL, V31, P1980, DOI 10.1128/JCM.31.8.1980-1986.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARZADEGAN H, 1993, 1ST P NAT C HUM RETR; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; GARRY RF, 1993, NATURE, V365, P301, DOI 10.1038/365301b0; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JOLLERJEMELKA HI, 1994, J HEPATOL, V21, P269, DOI 10.1016/S0168-8278(05)80407-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARIM MR, SAS MACRO GENERALIZE; KOJIMA E, 1994, 10TH P INT C AIDS; KRONER BL, 1995, AIDS, V9, P275, DOI 10.1097/00002030-199509030-00009; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MCLEAN A, 1993, NATURE, V365, P301, DOI 10.1038/365301a0; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PETRICCIANI JC, 1992, AIDS RES HUM RETROV, V8, P1527, DOI 10.1089/aid.1992.8.1527; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRESTON DL, 1990, EPICURE RISK REGRESS; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	34	200	202	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					554	558						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629984				2022-12-28	WOS:A1995RN46600026
J	DOPPMAN, JL; CHANG, R; FRAKER, DL; NORTON, JA; ALEXANDER, HR; MILLER, DL; COLLIER, E; SKARULIS, MC; GORDEN, P				DOPPMAN, JL; CHANG, R; FRAKER, DL; NORTON, JA; ALEXANDER, HR; MILLER, DL; COLLIER, E; SKARULIS, MC; GORDEN, P			LOCALIZATION OF INSULINOMAS TO REGIONS OF THE PANCREAS BY INTRAARTERIAL STIMULATION WITH CALCIUM	ANNALS OF INTERNAL MEDICINE			English	Article						INSULINOMA; CALCIUM; HEPATIC VEINS; ANGIOGRAPHY; PANCREAS	SELECTIVE INTRAARTERIAL INJECTION; ZOLLINGER-ELLISON SYNDROME; INTRAOPERATIVE ULTRASONOGRAPHY; INFUSION; GASTRINOMAS; SECRETION; RELEASE	Objective: To determine the sensitivity of calcium injected into pancreatic arteries in localizing insulin-secreting tumors to regions of the pancreas. Design and Patients: To stimulate the release of insulin, 25 patients with surgically proven insulinomas (average diameter, 15 mm) had calcium gluconate (0.025 mEq Ca++/kg body weight) injected before surgery into the arteries supplying the pancreatic head (gastroduodenal and superior mesenteric arteries) and the body and tail (splenic artery) of the pancreas. Setting: Tertiary referral hospital. Measurements: Insulin levels were measured in samples taken from the right and left hepatic veins before and 30, 60, and 120 seconds after calcium injection. A twofold increase in insulin level in the sample taken from the right hepatic vein 30 or 60 seconds after injection localized the insulinoma to the segment of the pancreas supplied by the selectively injected artery. Localization done using calcium stimulation was compared with localization done using transcutaneous ultrasonography (n = 22), computed tomography (n = 23), magnetic resonance imaging (n = 21), arteriography (n = 25), and portal venous sampling (n = 9) Results: Calcium stimulation localized 22 of 25 insulinomas (sensitivity, 88% [95% CI, 68% to 97%]) to the correct region of the pancreas. The sensitivities of the other imaging methods were 9% for ultrasonography (CI, 1% to 23%), 17% for computed tomography (CI, 5% to 39%), 43% for magnetic resonance imaging (CI, 22% to 66%), 36% for arteriography (CI, 18% to 57%), and 67% for portal venous sampling (CI, 30% to 93%). Calcium stimulation added only a few minutes to the time needed for pancreatic arteriography and caused no morbid conditions. Conclusion: Intra-arterial calcium stimulation with right hepatic vein sampling for insulin gradients is the most sensitive preoperative test for localizing insulinomas.	NATL NAVAL MED CTR, BETHESDA, MD 20889 USA; WASHINGTON UNIV, ST LOUIS, MO USA	Walter Reed National Military Medical Center; Washington University (WUSTL)	DOPPMAN, JL (corresponding author), NIH, CTR CLIN,DEPT DIAGNOST RADIOL,BLDG 10,ROOM 1C660, 10 CTR DR, MSC 1182, BETHESDA, MD 20892 USA.							BRUNT LM, 1986, J CLIN ENDOCR METAB, V62, P210, DOI 10.1210/jcem-62-1-210; DEPALO C, 1981, J CLIN ENDOCR METAB, V52, P804, DOI 10.1210/jcem-52-4-804; DOHERTY GM, 1991, SURGERY, V110, P989; DOPPMAN JL, 1990, RADIOLOGY, V174, P25, DOI 10.1148/radiology.174.1.2294556; DOPPMAN JL, 1993, WORLD J SURG, V17, P439, DOI 10.1007/BF01655101; DOPPMAN JL, 1991, RADIOLOGY, V178, P237, DOI 10.1148/radiology.178.1.1984311; GAEKE RF, 1975, METABOLISM, V24, P1029, DOI 10.1016/0026-0495(75)90096-7; GALIBER AK, 1988, RADIOLOGY, V166, P405, DOI 10.1148/radiology.166.2.2827232; GRANT CS, 1988, ARCH SURG-CHICAGO, V123, P843; HARRISON TS, 1981, MIL MED, V146, P103; IMAMURA M, 1987, ANN SURG, V205, P230, DOI 10.1097/00000658-198703000-00003; KAKITA K, 1981, HORM METAB RES, V13, P237, DOI 10.1055/s-2007-1019231; KAPLAN EL, 1979, ANN SURG, V190, P501, DOI 10.1097/00000658-197910000-00009; KING CMP, 1994, CLIN RADIOL, V49, P295, DOI 10.1016/S0009-9260(05)81790-8; MILLER DL, 1992, RADIOLOGY, V182, P235, DOI 10.1148/radiology.182.1.1727289; MILLER JL, 1981, NEW ENGL J MED, V304, P1430; NORTON JA, 1990, ANN SURG, V212, P615, DOI 10.1097/00000658-199011000-00009; POINTEL JP, 1978, HORM METAB RES, V10, P572, DOI 10.1055/s-0028-1096158; ROY BK, 1979, METABOLISM, V28, P246, DOI 10.1016/0026-0495(79)90071-4; THOM AK, 1992, SURGERY, V112, P1002	20	207	216	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					269	273		10.7326/0003-4819-123-4-199508150-00004	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611592				2022-12-28	WOS:A1995RN66500004
J	BOGERD, HP; FRIDELL, RA; MADORE, S; CULLEN, BR				BOGERD, HP; FRIDELL, RA; MADORE, S; CULLEN, BR			IDENTIFICATION OF A NOVEL CELLULAR COFACTOR FOR THE REV/REX CLASS OF RETROVIRAL REGULATORY PROTEINS	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REV TRANS-ACTIVATOR; GENE-EXPRESSION REQUIRES; VIRAL MESSENGER-RNA; I REX; BINDING-SITE; NUCLEOLAR LOCALIZATION; TARGET SEQUENCE; DOMAIN; MUTANTS	HIV-1 Rev is the prototype of a class of retroviral regulatory proteins that induce the sequence-specific nuclear export of target RNAs. This function requires the Rev activation domain, which is believed to bind an essential cellular cofactor. We report the identification of a novel human gene product that binds to not only the HIV-1 Rev activation domain in vitro and in vivo but also to functionally equivalent domains in other Rev and Rex proteins. The Rev/Rex activation domain-binding (Rab) protein occupies a binding site on HIV-I Rev that precisely matches that predicted by genetic analysis. Rab binds the Rev activation domain when Rev is assembled onto its RNA target and can significantly enhance Rev activity when overexpressed. We conclude that Rab is the predicted activation domain-specific cofactor for the Rev/Rex class of RNA export factors.	DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710	Duke University	BOGERD, HP (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; FRIDELL RA, 1993, J VIROL, V67, P7317, DOI 10.1128/JVI.67.12.7317-7323.1993; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HARPER JW, 1993, CELL, V75, P805; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HUANG JK, 1993, MOL CELL BIOL, V13, P7476, DOI 10.1128/MCB.13.12.7476; IVEYHOYLE M, 1990, MOL CELL BIOL, V10, P6152, DOI 10.1128/MCB.10.12.6152; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; KJERNS J, 1992, EMBO J, V11, P1119; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANCUSO VA, 1994, J VIROL, V68, P1998, DOI 10.1128/JVI.68.3.1998-2001.1994; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; TILEY LS, 1991, J VIROL, V65, P3877, DOI 10.1128/JVI.65.7.3877-3881.1991; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992	41	285	294	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					485	494		10.1016/0092-8674(95)90437-9	http://dx.doi.org/10.1016/0092-8674(95)90437-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634337	Bronze			2022-12-28	WOS:A1995RP24200018
J	FARNSWORTH, CL; FRESHNEY, NW; ROSEN, LB; GHOSH, A; GREENBERG, ME; FEIG, LA				FARNSWORTH, CL; FRESHNEY, NW; ROSEN, LB; GHOSH, A; GREENBERG, ME; FEIG, LA			CALCIUM ACTIVATION OF RAS MEDIATED BY NEURONAL EXCHANGE FACTOR RAS-GRF	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; PROTEIN; GENE; EXPRESSION; DOMAIN; CDC25; IDENTIFICATION; ASSOCIATION; INHIBITION	TYROSINE kinase receptors stimulate the Ras signalling pathway by enhancing the activity of the SOS nucleotide-exchange factor(1) This occurs, at least in part, by the recruitment of an SOS-GRB2 complex to Ras in the plasma membrane. Here we describe a different signalling pathway to Ras that involves activation of the Ras-GRF exchange factor(2-4) in response to Ca2+-influx, In particular, se show that the ability of Ras-CRF to activate Ras in vivo is markedly enhanced by raised Ca2+ concentrations. Activation is mediated by calmodulin binding to an IQ motif(5) in Ras-GRF, because substitutions in conserved amino acids in this motif prevent both calmodulin binding to Ras-CRF and Ras-GRF activation in vivo, So far, full-length Ras-GRF has been detected only in brain neurons(2,6,7), Our findings implicate Ras-GRF in the regulation of neuronal functions that are influenced by Ca2+ signals.	HARVARD UNIV,CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA 02111; HARVARD UNIV,CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 01215	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	FARNSWORTH, CL (corresponding author), TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111, USA.		Farnsworth, Christine/Q-5617-2018	Farnsworth, Christine/0000-0001-7615-3749; Freshney, Norman/0000-0002-6342-341X				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1994, MOL CELL BIOL, V13, P7718; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cheney R. E., 1994, Molecular Biology of the Cell, V5, p21A; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D	28	379	386	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					524	527		10.1038/376524a0	http://dx.doi.org/10.1038/376524a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637786				2022-12-28	WOS:A1995RN62200048
J	LEVIN, ER				LEVIN, ER			MECHANISMS OF DISEASE - ENDOTHELINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMOOTH-MUSCLE CELLS; ANGIOTENSIN-II; RECEPTOR ANTAGONIST; MYOCARDIAL-INFARCTION; INDUCED HYPERTROPHY; VASCULAR-RESPONSES; GENE-EXPRESSION; BLOOD-PRESSURE; NITRIC-OXIDE; RELEASE		UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine	LEVIN, ER (corresponding author), LONG BEACH VET HOSP,MED SERV 111I,5901 E 7TH ST,LONG BEACH,CA 90822, USA.		Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50161] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BATTISTINI B, 1993, LAB INVEST, V68, P600; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BRANCH DW, 1991, LANCET, V337, P943, DOI 10.1016/0140-6736(91)91572-C; BRUNNER F, 1992, J MOL CELL CARDIOL, V24, P1291, DOI 10.1016/0022-2828(92)93095-2; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; CHAN L, 1994, AM J PHYSIOL, V266, pF135, DOI 10.1152/ajprenal.1994.266.1.F135; CLARKE JG, 1989, AM J PHYSIOL, V257, pH2033, DOI 10.1152/ajpheart.1989.257.6.H2033; CLAVELL AL, 1994, J AM COLL CARDIOL, pA172; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; COCEANI F, 1991, CAN J PHYSIOL PHARM, V69, P218, DOI 10.1139/y91-033; COZZA EN, 1992, AM J PHYSIOL, V262, pR85, DOI 10.1152/ajpregu.1992.262.1.R85; DENG AY, 1994, J CLIN INVEST, V93, P2701, DOI 10.1172/JCI117284; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; ENCABO A, 1992, GEN PHARMACOL-VASC S, V23, P263, DOI 10.1016/0306-3623(92)90022-C; FERRARIO RG, 1989, EUR J PHARMACOL, V171, P127, DOI 10.1016/0014-2999(89)90436-6; FILEP JG, 1991, J CARDIOVASC PHARM, V17, pS216, DOI 10.1097/00005344-199100177-00062; FOGO A, 1992, KIDNEY INT, V42, P770, DOI 10.1038/ki.1992.346; FRANK HJL, 1993, ENDOCRINOLOGY, V133, P1092, DOI 10.1210/en.133.3.1092; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1993, LANCET, V341, P1550; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; GOLIGORSKY MS, 1994, J CELL PHYSIOL, V158, P485, DOI 10.1002/jcp.1041580313; GROVER GJ, 1993, CARDIOVASC RES, V27, P1613, DOI 10.1093/cvr/27.9.1613; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; HICKEY KA, 1985, AM J PHYSIOL, V248, pC550, DOI 10.1152/ajpcell.1985.248.5.C550; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HU RM, 1994, J CLIN INVEST, V93, P1056, DOI 10.1172/JCI117055; HU RM, 1992, J BIOL CHEM, V267, P17384; HUNEIDI AHS, 1991, J CARDIOVASC PHARM, V17, pS492; INOUE A, 1989, J BIOL CHEM, V264, P14954; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; KANYICSKA B, 1991, BIOCHEM BIOPH RES CO, V174, P338, DOI 10.1016/0006-291X(91)90525-C; KOH E, 1990, BIOCHEM INT, V20, P375; KOHNO M, 1991, J CLIN INVEST, V87, P1999, DOI 10.1172/JCI115228; KON V, 1990, KIDNEY INT, V37, P1487, DOI 10.1038/ki.1990.139; KURIHARA H, 1989, LIFE SCI, V44, P1937, DOI 10.1016/0024-3205(89)90406-2; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LANESE DM, 1993, J CLIN INVEST, V91, P2144, DOI 10.1172/JCI116440; LEE ME, 1990, J BIOL CHEM, V265, P10446; LERMAN A, 1991, CIRCULATION, V83, P1808, DOI 10.1161/01.CIR.83.5.1808; LEVIN E R, 1991, Molecular and Cellular Neuroscience, V2, P189, DOI 10.1016/1044-7431(91)90044-O; LEVIN ER, 1992, J NEUROCHEM, V58, P659, DOI 10.1111/j.1471-4159.1992.tb09768.x; LOPEZ JAG, 1990, ARTERIOSCLEROSIS, V10, P1113, DOI 10.1161/01.ATV.10.6.1113; MACQUINMAVIER I, 1989, J PHARMACOL EXP THER, V250, P740; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; MIURA K, 1991, J PHARMACOL EXP THER, V256, P11; NAKAMURA S, 1990, HISTOCHEMISTRY, V94, P475, DOI 10.1007/BF00272609; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; OMLAND T, 1994, CIRCULATION, V89, P1573, DOI 10.1161/01.CIR.89.4.1573; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; OUCHI Y, 1989, AM J PHYSIOL, V256, pH1747, DOI 10.1152/ajpheart.1989.256.6.H1747; PACHER R, 1993, AM J CARDIOL, V71, P1293, DOI 10.1016/0002-9149(93)90543-L; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PRINS BA, 1994, J BIOL CHEM, V269, P11938; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROSOLOWSKY LJ, 1990, ENDOCRINOLOGY, V126, P1860, DOI 10.1210/endo-126-4-1860; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAMSON WK, 1993, AM J PHYSIOL, V265, pR1212; SCHIEBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119, DOI 10.1210/endo-127-1-119; SCHUMACHER WA, 1990, PROSTAGLANDINS, V40, P71, DOI 10.1016/0090-6980(90)90057-3; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; SHICHIRI M, 1989, BIOCHEM BIOPH RES CO, V163, P1332, DOI 10.1016/0006-291X(89)91124-8; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V164, P587, DOI 10.1016/0006-291X(89)91760-9; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SIMONSON MS, 1993, PHYSIOL REV, V73, P375, DOI 10.1152/physrev.1993.73.2.375; SUZUKI R, 1992, J NEUROSURG, V77, P96, DOI 10.3171/jns.1992.77.1.0096; TABUCHI Y, 1989, BIOCHEM BIOPH RES CO, V161, P803, DOI 10.1016/0006-291X(89)92671-5; THIEMERMANN C, 1989, J CARDIOVASC PHARM, V13, pS138, DOI 10.1097/00005344-198900135-00034; VIGNE P, 1994, J BIOL CHEM, V269, P19925; WATANABE T, 1990, NATURE, V344, P114, DOI 10.1038/344114a0; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580; WILLETTE RN, 1994, STROKE, V25, P2450, DOI 10.1161/01.STR.25.12.2450; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YAMAMOTO T, 1992, AM J PHYSIOL, V262, pE856, DOI 10.1152/ajpendo.1992.262.6.E856; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; YOSHIMOTO S, 1991, STROKE, V22, P378, DOI 10.1161/01.STR.22.3.378; ZIV I, 1992, STROKE, V23, P1014, DOI 10.1161/01.STR.23.7.1014	89	866	890	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					356	363		10.1056/NEJM199508103330607	http://dx.doi.org/10.1056/NEJM199508103330607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609754				2022-12-28	WOS:A1995RN08200007
J	GILSDORF, JR				GILSDORF, JR			BRAD MISSED THE MIRACLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629936				2022-12-28	WOS:A1995RM69900002
J	ROCKALL, TA; LOGAN, RFA; DEVLIN, HB; NORTHFIELD, TC				ROCKALL, TA; LOGAN, RFA; DEVLIN, HB; NORTHFIELD, TC			VARIATION IN OUTCOME AFTER ACUTE UPPER GASTROINTESTINAL HEMORRHAGE	LANCET			English	Article							HEMORRHAGE; MORTALITY; MANAGEMENT; UNITS; HEMATEMESIS; MELAENA; AUDIT; ULCER	Hospital mortality after acute upper gastrointestinal haemorrhage Varies widely. In a population-based, multicentre, prospective survey of the management and outcome of unselected cases of acute upper gastrointestinal haemorrhage, we have assessed the effect of risk standardisation on this variation. We collected data from 74 acute hospitals in four health regions in the UK on patients aged 16 years and over who presented with acute upper gastrointestinal haemorrhage during 4 months in 1993 (3981 cases) and 3 months in 1994 (1584 cases). The overall mortality was 14.3% (798/5565). Crude mortality in individual hospitals ranged from 0% to 29%, and differed significantly from the overall rate in eight. Risk-standardised mortality ratios were calculated with a risk score derived from well-established risk factors. Only two hospitals had standardised mortality ratios significantly different from the reference value. When hospitals were ranked in order of increasing mortality, risk standardisation for age, shook, and comorbidity resulted in 21 of the 74 hospitals changing ranks by ten or more places. After further standardisation for diagnosis, endoscopic stigmata of recent haemorrhage, and rebleeding, 32 hospitals moved ten or more places from their original rank; one hospital moved 45 places. Risk standardisation to correct for variation in case mix results in apparently significant differences in mortality rates becoming non-significant. The current state of routine data collection does not allow for anything but the most basic case-mix adjustment to be made. Simple league tables of crude mortality are misleading in this disorder and cannot be regarded as a reflection of the quality of health care.	UNIV NOTTINGHAM HOSP,NOTTINGHAM,ENGLAND; UNIV LONDON ST GEORGES HOSP,SCH MED,LONDON,ENGLAND	University of Nottingham; St Georges University London	ROCKALL, TA (corresponding author), ROYAL COLL SURGEONS ENGLAND,EPIDEMIOL & AUDIT UNIT,35-43 LINCOLNS INN FIELDS,LONDON WC2A 3PN,ENGLAND.							Berry A R, 1984, J R Coll Surg Edinb, V29, P134; Cleary R, 1994, Qual Health Care, V3, P3, DOI 10.1136/qshc.3.1.3; CLEMENTS D, 1991, J ROY COLL PHYS LOND, V25, P27; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; DRONFIELD MW, 1987, BRIT MED J, V294, P1308, DOI 10.1136/bmj.294.6583.1308-a; EMBERTON M, 1993, BRIT J HEALTHC COMP, V10, P32; EMBERTON M, 1994, BRIT J HEALTHC COMP, V11, P23; HOLMAN RAE, 1990, GUT, V31, P504, DOI 10.1136/gut.31.5.504; HUNT PS, 1979, BRIT MED J, V1, P1238, DOI 10.1136/bmj.1.6173.1238; HUNT PS, 1979, BRIT J SURG, V66, P633, DOI 10.1002/bjs.1800660911; JOHNSTON SJ, 1973, BRIT MED J, V3, P655, DOI 10.1136/bmj.3.5882.655; JONES F A, 1947, Br Med J, V2, P441; KATSCHINSKI BD, 1989, POSTGRAD MED J, V65, P913, DOI 10.1136/pgmj.65.770.913; LOGAN RFA, 1976, LANCET, V1, P1173; MAYBERRY JF, 1981, POSTGRAD MED J, V57, P627, DOI 10.1136/pgmj.57.672.627; McKee M, 1993, Qual Health Care, V2, P104, DOI 10.1136/qshc.2.2.104; ROCKALL TA, 1974, GUT S5, V35, pS47; SANDERSON JD, 1990, GUT, V31, pA1206; SANDERSON JD, 1990, POSTGRAD MED J, V66, P654, DOI 10.1136/pgmj.66.778.654; SCHILLER KF, 1970, BRIT MED J, V2, P7, DOI 10.1136/bmj.2.5700.7; SCHLUP M, 1984, NEW ZEAL MED J, V97, P511; Vickers N, 1993, Qual Health Care, V2, P170, DOI 10.1136/qshc.2.3.170; WHEATLEY KE, 1990, BRIT MED J, V301, P272, DOI 10.1136/bmj.301.6746.272; 1993, LANCET, V341, P1183	24	116	119	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					346	350		10.1016/S0140-6736(95)92227-X	http://dx.doi.org/10.1016/S0140-6736(95)92227-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623533				2022-12-28	WOS:A1995RM71300010
J	VANDAMME, W				VANDAMME, W			DO REFUGEES BELONG IN CAMPS - EXPERIENCES FROM GOMA AND GUINEA	LANCET			English	Editorial Material											VANDAMME, W (corresponding author), INST TROP MED, PUBL HLTH RES & TRAINING UNIT, NATL STR 155, B-2000 ANTWERP, BELGIUM.		Van Damme, Wim/F-7404-2011	Van Damme, Wim/0000-0002-6344-3007				[Anonymous], 1995, Lancet, V345, P339; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Bennett F J, 1968, East Afr Med J, V45, P229; BONNEUX L, 1994, LANCET, V344, P1689, DOI 10.1016/S0140-6736(94)90464-2; DETEMMERMAN E, 1994, DODEN ZIJN NIET DOOD, P1; FRAZER WM, 1948, TXB PUBLIC HLTH, P1; FREUND PJ, 1986, INT MIGR REV, V20, P299, DOI 10.2307/2546037; GARDNER P, 1972, LANCET, V1, P834; GOLDEN MHN, 1995, LANCET, V345, P918, DOI 10.1016/S0140-6736(95)90029-2; Harrell-Bond Barbara, 1986, IMPOSING AID EMERGEN, P1; HARRELLBOND B, 1994, NEW REPUBLIC, V211, P15; HARRELLBOND BE, 1991, PEOPLE, V18, P16; HILL AG, 1983, POPUL DEV REV, V9, P293, DOI 10.2307/1973054; LOWENSTEIN FW, 1962, B WORLD HEALTH ORGAN, V27, P751; MEARS C, 1994, HLTH CARE REFUGEES D, P1; PITTERMAN S, 1984, AFR TODAY, V31, P25; SEAMAN JA, 1972, LANCET, V2, P866; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; SIMMONDS S, 1983, REFUGEE COMMUNITY HL, P1; TOLLET D, 1988, ORG UN CAMP REFUGIES; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; VASSALADAMS G, 1994, AGENDA INT ACTION, P1; VIS HL, 1994, LANCET, V344, P957, DOI 10.1016/S0140-6736(94)92312-4; ZETTER R, 1992, J REF STUD, V5, P201; 1985, LANCET, V1, P673; 1991, MMWR-MORBID MORTAL W, V40, P209; 1994, AFRICAN RIGHTS RWAND, P1; 1995, LANCET, V345, P529; 1982, HDB EMERGENCIES 1, P1	30	41	41	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					360	362						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM713	7623537				2022-12-28	WOS:A1995RM71300014
J	MCEACHERN, MJ; BLACKBURN, EH				MCEACHERN, MJ; BLACKBURN, EH			RUNAWAY TELOMERE ELONGATION CAUSED BY TELOMERASE RNA GENE-MUTATIONS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HUMAN FIBROBLASTS; BINDING-PROTEIN; YEAST; DNA; SENESCENCE; RAP1; IDENTIFICATION; SEQUENCES; STABILITY	The ribonucleoprotein enzyme telomerase adds telomeric DNA onto chromosome ends and is normally regulated so that telomeric DNA lengths are kept within defined bounds. In the telomerase RNA gene from the yeast Kluyveromyces lactis, specific mutations that alter telomeric DNA sequences result in telomeres elongating to up to 100 times their normal length and Impair cell growth. Some mutations cause immediate elongation whereas others behave like genetic time bombs, causing elongation only after a latent period of hundreds of generations.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	MCEACHERN, MJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, BOX 0414, SAN FRANCISCO, CA 94143 USA.							BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1993, MOL CELL BIOL, V13, P551, DOI 10.1128/MCB.13.1.551; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PARDUE ML, 1994, CURR OPIN GENET DEV, V4, P845, DOI 10.1016/0959-437X(94)90069-8; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sambrook J, 1989, MOL CLONING; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHAY JW, 1993, ONCOGENE, V8, P1407; SHIPPEN DE, 1994, P NATL ACAD SCI USA, V91, P405, DOI 10.1073/pnas.91.1.405; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; VESELKOV AG, 1993, NATURE, V364, P496, DOI 10.1038/364496a0; WILLIAMSON JR, 1994, REV BIOPHYS BIOMOL S, V23, P703; WRAY LV, 1987, MOL CELL BIOL, V7, P1111, DOI 10.1128/MCB.7.3.1111; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	43	305	316	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					403	409		10.1038/376403a0	http://dx.doi.org/10.1038/376403a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630414				2022-12-28	WOS:A1995RM63900045
J	CERMERLIC, EZ; SCHALLER, JG				CERMERLIC, EZ; SCHALLER, JG			HUMAN WRONGS - A CHILDRENS-HOSPITAL DESTROYED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					386	386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616633				2022-12-28	WOS:A1995RL41600023
J	JOHNSON, S; THORNICROFT, G				JOHNSON, S; THORNICROFT, G			EMERGENCY PSYCHIATRIC-SERVICES IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, S (corresponding author), INST PSYCHIAT,PRISM,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010; Johnson, Sonia/A-5220-2008; Johnson, Sonia/ABF-1457-2020	Thornicroft, Graham/0000-0003-0662-0879; Johnson, Sonia/0000-0002-2219-1384; Johnson, Sonia/0000-0002-2219-1384				BURNS T, 1993, BRIT J PSYCHIAT, V163, P49, DOI 10.1192/bjp.163.1.49; HUXLEY P, IN PRESS PSYCHIAT B; JOHNSON S, 1993, SOC PSYCH PSYCH EPID, V28, P45, DOI 10.1007/BF00797833; Katschnig H., 1990, MENTAL HLTH CARE DEL, P85; Repper J., 1997, EXPERIENCING PSYCHIA	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					287	288		10.1136/bmj.311.7000.287	http://dx.doi.org/10.1136/bmj.311.7000.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM719	7633232	Green Published			2022-12-28	WOS:A1995RM71900019
J	CHEN, JJ; REID, CE; BAND, V; ANDROPHY, EJ				CHEN, JJ; REID, CE; BAND, V; ANDROPHY, EJ			INTERACTION OF PAPILLOMAVIRUS E6 ONCOPROTEINS WITH A PUTATIVE CALCIUM-BINDING PROTEIN	SCIENCE			English	Article							MAMMARY EPITHELIAL-CELLS; BOVINE PAPILLOMAVIRUS; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; P53 PROTEIN; HPV-16 E6; TYPE-16; DEGRADATION; DNA; TRANSACTIVATION	Human papillomaviruses (HPVs) are associated with the majority of cervical cancers and encode a transforming protein, E6, that interacts with the tumor suppressor protein p53. Because E6 has p53-independent transforming activity, the yeast two-hybrid system was used to search for other EG-binding proteins. One such protein, E6BP, interacted with cancer-associated HPV E6 and with bovine papillomavirus type 1 (BPV-1) E6. The transforming activity of BPV-1 E6 mutants correlated with their E6BP-binding ability. E6BP is identical to a putative calcium-binding protein, ERC-55, that appears to be localized in the endoplasmic reticulum.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT DERMATOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT RADIAT ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT BIOCHEM, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center				Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R29CA056803, R01CA044174] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA44174, R29CA56803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen J., UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DOSHI N, UNPUB; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KEEN N, 1994, ONCOGENE, V9, P1493; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIANG XH, 1993, ONCOGENE, V8, P2645; MANSUR CP, 1995, ONCOGENE, V10, P457; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, DNA TUMOR VIRUSES CO, P571; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHMITT A, 1994, ONCOGENE, V68, P7051; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; WEIS K, 1994, J BIOL CHEM, V269, P19142; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	40	245	255	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					529	531		10.1126/science.7624774	http://dx.doi.org/10.1126/science.7624774			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624774				2022-12-28	WOS:A1995RL49500024
J	KENYON, C				KENYON, C			A PERFECT VULVA EVERY TIME - GRADIENTS AND SIGNALING CASCADES IN C-ELEGANS	CELL			English	Review							CAENORHABDITIS-ELEGANS; CELL FATE; LIN-12; GENE; INDUCTION; ENCODES				KENYON, C (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KOGA M, 1995, IN PRESS DEVELOPMENT; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; TUCK S, 1995, GENE DEV, V9, P341, DOI 10.1101/gad.9.3.341; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	18	49	56	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					171	174		10.1016/0092-8674(95)90302-X	http://dx.doi.org/10.1016/0092-8674(95)90302-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628006	Bronze			2022-12-28	WOS:A1995RL76000002
J	FOSTER, S; BUVE, A				FOSTER, S; BUVE, A			BENEFITS OF HIV SCREENING OF BLOOD-TRANSFUSIONS IN ZAMBIA	LANCET			English	Article								Blood transfusion continues to be an important route of transmission of HIV in developing countries, especially for young children following the perinatal period, Testing for HIV is costly and reliable donor support for the purchase of test kits is often essential, yet difficult to secure. The costs of screening of transfusions for HIV and the financial benefits in terms of savings on treatment costs averted were calculated for a district hospital in Zambia where seroprevalence among donors was 15.9%. Financial benefits exceed costs by a factor of 2.7-3.5. In 1991, 1073 transfusions were given and an estimated 150 cases of transfusion-related AIDS were prevented by screening, of which 59% were in children aged 5 years or under and 31% were in women. The total cost of HIV screening was pound 3061 ($4745), and the cost per case of HIV infection prevented was pound 20.40 ($31.62); the cost of this protection for the population served by the hospital was pound 0.02 ($0.03) per person. An estimated 3625 undiscounted healthy years of life were saved, of which nearly 69% were in children under 6, at a cost of pound 0.85 ($1.32) per year of life saved. It is essential that financial and political support for HIV screening of blood for transfusion is maintained,	INST TROP MED,B-2000 ANTWERP,BELGIUM	Institute of Tropical Medicine (ITM)	FOSTER, S (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND.							BEAL R, 1992, SAFE BLOOD DEV COUNT; BUVE A, 1993, 9TH C AIDS BERL; EISENSTAEDT RS, 1988, AM J PUBLIC HEALTH, V78, P450, DOI 10.2105/AJPH.78.4.450; Gibbs WN, 1992, GUIDELINES ORG BLOOD; GUMODOKA B, 1993, AIDS, V7, P387, DOI 10.1097/00002030-199303000-00013; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; KASLOW RA, 1989, EPIDEMIOLOGY AIDS; MILLS A, 1993, COSTS HIV AIDS PREVE; OVER M, 1988, GLOBAL IMPACT AIDS; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SODERLUND N, 1993, B WORLD HEALTH ORGAN, V71, P595	11	37	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					225	227		10.1016/S0140-6736(95)91272-X	http://dx.doi.org/10.1016/S0140-6736(95)91272-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616804				2022-12-28	WOS:A1995RK41900014
J	WHITMARSH, AJ; SHORE, P; SHARROCKS, AD; DAVIS, RJ				WHITMARSH, AJ; SHORE, P; SHARROCKS, AD; DAVIS, RJ			INTEGRATION OF MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS AT THE SERUM RESPONSE ELEMENT	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; ETS-RELATED PROTEIN; FACTOR P62TCF; DNA-BINDING; ELK-1; PHOSPHORYLATION; EXPRESSION; GENE	The ternary complex factor (TCF) subfamily of ETS-domain transcription factors bind with serum response factor (SRF) to the serum response element (SRE) and mediate increased gene expression. The TCF protein Elk-1 is phosphorylated by the JNK and ERK groups of mitogen-activated protein (MAP) kinases causing increased DNA binding, ternary complex formation, and transcriptional activation. Activated SRE-dependent gene expression is induced by JNK in cells treated with interleukin-1 and by ERK after treatment with phorbol ester. The Elk-1 transcription factor therefore integrates MAP kinase signaling pathways in vivo to coordinate biological responses to different extracellular stimuli.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Newcastle University - UK				Whitmarsh, Alan/0000-0003-1184-6610; Shore, Paul/0000-0002-1832-5976				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BUSCHER M, 1988, ONCOGENE, V3, P301; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERLJARD B, 1994, CELL, V76, P1025; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1994, J BIOL CHEM, V269, P25699; SETH A, 1992, J BIOL CHEM, V267, P24796; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHARROCKS AD, IN PRESS FEBS LETT; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMARSH AJ, UNPUB; YAN MH, 1994, NATURE, V372, P798	43	887	904	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					403	407		10.1126/science.7618106	http://dx.doi.org/10.1126/science.7618106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618106				2022-12-28	WOS:A1995RK42700049
J	THOMAS, SM; SORIANO, P; IMAMOTO, A				THOMAS, SM; SORIANO, P; IMAMOTO, A			SPECIFIC AND REDUNDANT ROLES OF SRC AND FYN IN ORGANIZING THE CYTOSKELETON	NATURE			English	Article							TYROSINE PHOSPHORYLATION; CELLS; GENE; MICE; KINASES; IDENTIFICATION; OSTEOPETROSIS; DISRUPTION; SUBSTRATE; ENCODES	MOUSE embryos lacking Csk, a negative regulator of Src family kinases, exhibit defects in neurulation and die at mid-gestation(1,2). To determine the role of activated Src family kinases in the csk(-) phenotype, we have introduced mutations in the src and fyn genes(3,4) into the csk(-) mutant background. Genetic analysis reveals that src, but not fyn, is partly epistatic to the csk gene. Biochemical analysis indicates that several cytoskeletal proteins are hyperphosphorylated an tyrosine residues in csk(-) cells. Regulation of cortactin and tensin hyperphosphorylation is Src-dependent, whereas focal adhesion kinase and paxillin hyperphosphorylation is partly dependent on both Src and Fyn. Furthermore, the src(-) mutation can restore the normal distribution of cortactin and partly correct filamentous actin organization in csk(-) cells. Thus, Src family kinases have both specific and overlapping functions in regulation of the cytoskeleton. The disturbance of these functions may be a molecular basis for the phenotype exhibited by csk(-) mutants.			THOMAS, SM (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV MOLEC MED, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IMAMOTO A, 1994, CURR OPIN GENET DEV, V4, P40, DOI 10.1016/0959-437X(94)90089-2; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARTANEN J, 1991, ONCOGENE, V6, P2013; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TURNER CE, 1994, J CELL SCI, V107, P1583; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAGI T, 1994, ONCOGENE, V9, P2433; YANG JT, 1993, DEVELOPMENT, V119, P1093	30	301	302	1	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					267	271		10.1038/376267a0	http://dx.doi.org/10.1038/376267a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617039				2022-12-28	WOS:A1995RK33100050
J	YELAMOS, J; KLIX, N; GOYENECHEA, B; LOZANO, F; CHUI, YL; FERNANDEZ, AG; PANNELL, R; NEUBERGER, MS; MILSTEIN, C				YELAMOS, J; KLIX, N; GOYENECHEA, B; LOZANO, F; CHUI, YL; FERNANDEZ, AG; PANNELL, R; NEUBERGER, MS; MILSTEIN, C			TARGETING OF NON-LG SEQUENCES IN-PLACE OF THE V-SEGMENT BY SOMATIC HYPERMUTATION	NATURE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; IMMUNOGLOBULIN GENES; PASSENGER TRANSGENES; AFFINITY MATURATION; MUTATION; KAPPA; MUTAGENESIS; MECHANISM; PROMOTER	Affinity maturation of antibodies is characterized by localized hypermutation of the DNA around the V segment. Here we show, using mice containing single or multiple transgene constructs, that an immunoglobulin V-kappa segment can be replaced by human beta-globin or prokaryotic neo or gpt genes without affecting the rate of hypermutation; the V gene itself is not necessary for recruiting hypermutation. The ability to target hypermutation to heterologous genes in vivo could find more general applications in biology.			YELAMOS, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Yelamos, Jose/N-2842-2016; González-Fernández, África/E-2641-2012	González-Fernández, África/0000-0002-9226-4825; LOZANO, FRANCISCO/0000-0003-1119-4368; Yelamos, Jose/0000-0003-1195-1496; Chui, Yiu-Loon/0000-0002-3441-9729				AZUMA T, 1993, INT IMMUNOL, V5, P121, DOI 10.1093/intimm/5.2.121; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOTH GW, 1990, MOL CELL BIOL, V10, P5187, DOI 10.1128/MCB.10.10.5187; CHUI YL, 1995, J MOL BIOL, V249, P555, DOI 10.1006/jmbi.1995.0318; CLACKSON T, 1989, NUCLEIC ACIDS RES, V17, P10163, DOI 10.1093/nar/17.24.10163; Galfre G, 1981, Methods Enzymol, V73, P3; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; GONZALEZFERNAND.A, 1994, P NATL ACAD SCI USA, V91, P12614; GONZALEZFERNANDEZ, 1993, P NATL ACAD SCI USA, V90, P9862; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HACKETT J, 1992, J EXP MED, V176, P225, DOI 10.1084/jem.176.1.225; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KEPLER TB, 1993, IMMUNOL TODAY, V14, P412, DOI 10.1016/0167-5699(93)90145-B; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MACLENNAN ICM, 1992, IMMUNOL REV, V126, P143, DOI 10.1111/j.1600-065X.1992.tb00635.x; MANSER T, 1990, SOMATIC HYPERMUTATIO, P20; MOTOYAMA N, 1991, P NATL ACAD SCI USA, V88, P7933, DOI 10.1073/pnas.88.18.7933; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; OBRIEN RL, 1987, NATURE, V326, P405, DOI 10.1038/326405a0; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Pettersson S, 1989, Int Immunol, V1, P509, DOI 10.1093/intimm/1.5.509; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RADA C, 1994, EUR J IMMUNOL, V24, P1453, DOI 10.1002/eji.1830240632; ROGERSON B, 1991, EMBO J, V10, P4331, DOI 10.1002/j.1460-2075.1991.tb05011.x; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROTHENFLUH HS, 1993, EUR J IMMUNOL, V23, P2152, DOI 10.1002/eji.1830230916; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; STEELE EJ, 1992, IMMUNOL CELL BIOL, V70, P129, DOI 10.1038/icb.1992.18; UMAR A, 1991, P NATL ACAD SCI USA, V88, P4902, DOI 10.1073/pnas.88.11.4902; WEBER JS, 1991, J IMMUNOL, V146, P3652; WEBER JS, 1994, J IMMUNOL, V153, P3594; WEIGERT M, 1986, PROG IMMUNOL, V6, P139	40	208	247	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					225	229						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617031				2022-12-28	WOS:A1995RK33100038
J	THREADGILL, DW; DLUGOSZ, AA; HANSEN, LA; TENNENBAUM, T; LICHTI, U; YEE, D; LAMANTIA, C; MOURTON, T; HERRUP, K; HARRIS, RC; BARNARD, JA; YUSPA, SH; COFFEY, RJ; MAGNUSON, T				THREADGILL, DW; DLUGOSZ, AA; HANSEN, LA; TENNENBAUM, T; LICHTI, U; YEE, D; LAMANTIA, C; MOURTON, T; HERRUP, K; HARRIS, RC; BARNARD, JA; YUSPA, SH; COFFEY, RJ; MAGNUSON, T			TARGETED DISRUPTION OF MOUSE EGF RECEPTOR - EFFECT OF GENETIC BACKGROUND ON MUTANT PHENOTYPE	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; HAIR FOLLICLE; EXPRESSION; DIFFERENTIATION; ALPHA; SKIN; IMPLANTATION; ANTIBODIES; EMBRYOS; INVITRO	Gene targeting was used to create a null allele at the epidermal growth factor receptor locus (Egfr). The phenotype was dependent on genetic background. EGFR deficiency on a CF-1 background resulted in peri-implantation death due to degeneration of the inner cell mass. On a 129/Sv background, homozygous mutants died at mid-gestation due to placental defects; on a CD-1 background, the mutants lived for up to 3 weeks and showed abnormalities in skin, kidney, brain, liver, and gastrointestinal tract. The multiple abnormalities associated with EGFR deficiency indicate that the receptor is involved in a wide range of cellular activities.	CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,DEPT NEUROL,ALZHEIMER RES LAB,CLEVELAND,OH 44106; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University; Vanderbilt University; Vanderbilt University; Vanderbilt University			Threadgill, David W/N-4425-2013; Herrup, Karl/C-5313-2014	Threadgill, David W/0000-0003-3538-1635; Herrup, Karl/0000-0001-7786-5844	NICHD NIH HHS [HD26722, HD07104] Funding Source: Medline; NIGMS NIH HHS [GM14630] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014630] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON ED, 1990, MOL REPROD DEV, V27, P16, DOI 10.1002/mrd.1080270106; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; BRICE EC, 1993, DEV GENET, V14, P174, DOI 10.1002/dvg.1020140304; CAREY TE, 1992, MONOGR NATL CANCER I, V20, P75; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; PARIA BC, 1990, P NATL ACAD SCI USA, V87, P4756, DOI 10.1073/pnas.87.12.4756; POIRIER F, 1991, DEVELOPMENT, V113, P1105; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; SASSOON D, 1993, GUIDE TECHNIQUES MOU, P384; TENHAVEOPBROEK AAW, 1988, ANAT REC, V221, P846, DOI 10.1002/ar.1092210409; TENNENBAUM T, 1992, CANCER RES, V52, P2966; THREADGILL DW, UNPUB; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; WOOD SA, 1989, J REPROD FERTIL, V85, P575, DOI 10.1530/jrf.0.0850575; ZELLER R, 1989, CUR PROT MOL BIOL	25	1194	1217	1	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					230	234		10.1126/science.7618084	http://dx.doi.org/10.1126/science.7618084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618084				2022-12-28	WOS:A1995RJ02900042
J	FRASER, RC; FAROOQI, A; SORRIE, R				FRASER, RC; FAROOQI, A; SORRIE, R			USE OF VITAMIN-B-12 IN LEICESTERSHIRE PRACTICES - A SINGLE TOPIC AUDIT LED BY A MEDICAL AUDIT ADVISORY GROUP	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Objectives-To encourage active participation of Leicestershire general practitioners and their staff in audit; to examine the use of vitamin B-12 injections and to achieve a more appropriate use. Design-Implementation of an agreed audit protocol, with central analysis and feedback of anonymous and aggregated data by a medical audit advisory group. Setting-All 147 Leicestershire practices. Main outcome measures-Participation in the complete audit cycle, comparison of actual use of vitamin B-12 injections with agreed criteria of use, and assessment of improvement in use. Results-264 general practitioners (55% of all doctors from 49% of all Leicestershire practices) completed both phases of the audit cycle, and 321 (67%) completed phase 1 only. Twenty four (16%) practices failed to participate from the outset, and a further 58 (35%) dropped out at various stages. Only 10 of the 37 singlehanded practices completed the audit, although 34 initially agreed to participate. If singlehanded practices were excluded, 56% (61) of practices completed both phases of the audit cycle. In total 1714 patients received B-12 injections. Appropriate use increased from 62% in phase 1 to 72% in phase 2 of the audit; there was a 32% reduction in the number of patients inappropriately receiving B-12 (521 to 352), and the proportion of patients receiving B-12 at the correct frequency rose from 58% to 72%. The proportion of patients in whom all the diagnostic criteria for pernicious anaemia were established before treatment with B-12 was 27% in phase 1 and 28% in phase 2. Conclusion-Our study suggests that single topic audits organised by a medical audit advisory group can encourage large numbers of general practitioners to participate and can bring about changes in behaviour resulting in improvements in standards of care. Nevertheless, advisory groups will need to devise strategies to encourage even higher levels of involvement, most particularly from singlehanded practices.			FRASER, RC (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DEPT GEN PRACTICE,LEICESTERSHIRE MED AUDIT ADVISORY GRP,LEICESTER LE5 4PW,LEICS,ENGLAND.		Farooqi, Ammad Ahmad/AAF-5325-2021; Farooqi, Ammad A/H-1610-2016					BAKER R, 1995, BRIT MED J, V311, P31, DOI 10.1136/bmj.311.6996.31; COCHRANE AL, 1971, BRIT J PREV SOC MED, V25, P147; DERRY J, 1991, BRIT MED J, V303, P1247, DOI 10.1136/bmj.303.6812.1247; ELLIS FR, 1970, PRACTITIONER, V204, P838; FRASER RC, 1983, BRIT MED J, V287, P729, DOI 10.1136/bmj.287.6394.729; HOLDEN JD, 1994, FAM PRACT, V11, P358, DOI 10.1093/fampra/11.4.358; MIDDLETON J, 1985, BRIT MED J, V290, P1254, DOI 10.1136/bmj.290.6477.1254; WEBB SJ, 1991, BRIT MED J, V302, P390, DOI 10.1136/bmj.302.6773.390; WILSON A, 1994, AUDIT TRENDS, V2, P97; 1990, DOH HCFP908 DEP HLTH	10	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					28	30		10.1136/bmj.311.6996.28	http://dx.doi.org/10.1136/bmj.311.6996.28			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613320	Green Published			2022-12-28	WOS:A1995RG97500023
J	POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S				POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S			STROKE PATIENTS VIEWS ON THEIR ADMISSION TO HOSPITAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOME	Objective-To explore which components of care were valued by patients admitted to hospital following a stroke. Design-Qualitative study using in depth interviews 10 months after the stroke. Setting-Two adjacent districts in North Thames Regional Health Authority. Subjects-82 survivors of stroke taken consecutively from a stroke register, 40 of whom agreed to be interviewed. Results-Patients reported that during the acute stage of the stroke they wanted to put their faith in experienced and trusted experts who would help them make sense of the event, take all the actions necessary to ensure survival, and provide comfort and human warmth during the crisis. In addition to being reassured by the clinical tests and practical nursing help they received, patients valued feeling cared about by the staff, In most cases patients reported that their needs were met; however, the institutional nature of the hospital sometimes obstructed the fulfilment of their needs. Conclusion-Patients have important psychosocial needs during the acute stage of the stroke, which are often met by hospital admission. Patients gained benefits from their admission over and above those measurable in terms of morbidity or function. They used a combination of criteria to evaluate their care, focusing on the process as well as the outcome of care. Researchers and clinicians should do likewise.	UNIV LONDON, ROYAL HOLLOWAY & BEDFORD NEW COLL, DEPT SOCIAL POLICY & SOCIAL SCI, EGHAM TW20 0EX, SURREY, ENGLAND	University of London; Royal Holloway University London	POUND, P (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.							Anderson R., 1992, AFTERMATH STROKE EXP; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BENSIRA Z, 1980, J HEALTH SOC BEHAV, V21, P170, DOI 10.2307/2136736; BROCKLEHURST J C, 1978, Age and Ageing, V7, P100, DOI 10.1093/ageing/7.2.100; Bury M, 1994, Health Care Anal, V2, P240, DOI 10.1007/BF02251026; CHRISTIE D, 1978, SOC SCI MED, V12, P49; Fitzpatrick R, 1994, Qual Health Care, V3, P107; GOMPERTZ P, 1995, AGE AGEING, V24, P137, DOI 10.1093/ageing/24.2.137; HOFFMANN JE, 1974, URBAN LIFE CULT, V3, P50, DOI 10.1177/089124167400300103; Hunt SM, 1986, MEASURING HLTH STATU; ISAACS B, 1978, BRIT MED J, V2, P1640, DOI 10.1136/bmj.2.6152.1640; KAUFMAN SR, 1988, QUALITATIVE GERONTOL, P82; LUM O, 1982, CLIN GERONTOL, V1, P37; MAHONEY F I, 1965, Md State Med J, V14, P61; McKeown Thomas, 1979, ROLE MED; MULLEY G, 1978, BRIT MED J, V2, P1321, DOI 10.1136/bmj.2.6148.1321; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; Parker R., 1981, NEW LOOK PERSONAL SO, P17; Pound P, 1994, Qual Health Care, V3, P69, DOI 10.1136/qshc.3.2.69; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; WADE DT, 1987, BRIT J HOSP MED, V37, P200; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1983, LANCET, V1, P807; WADE DT, 1985, J EPIDEMIOL COMMUN H, V39, P347, DOI 10.1136/jech.39.4.347; WILLIAMS SJ, 1991, SOC SCI MED, V33, P707, DOI 10.1016/0277-9536(91)90025-8; YOUNG J, 1994, BRIT MED J, V309, P1356, DOI 10.1136/bmj.309.6965.1356	26	54	55	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					18	22		10.1136/bmj.311.6996.18	http://dx.doi.org/10.1136/bmj.311.6996.18			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613315	Green Published			2022-12-28	WOS:A1995RG97500019
J	ANDERSON, IM; TOMENSON, BM				ANDERSON, IM; TOMENSON, BM			TREATMENT DISCONTINUATION WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS COMPARED WITH TRICYCLIC ANTIDEPRESSANTS - A METAANALYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND MULTICENTER; COMPARATIVE TRIAL; CLINICAL-TRIAL; OUT-PATIENTS; FLUVOXAMINE MALEATE; GERIATRIC-PATIENTS; ELDERLY PATIENTS; GENERAL-PRACTICE; FLUOXETINE	Objective-To assess treatment discontinuation rates with selective serotonin reuptake inhibitors compared with tricyclic antidepressants. Design-Meta-analysis of 62 randomised controlled trials. Subjects-6029 patients with major unipolar depression. Main outcome measures-Pooled risk ratios for drop out rates with respect to all cases of discontinuation and those due to side effects and treatment failure. Results-The total discontinuation rate was 10% lower with selective serotonin reuptake inhibitors than with tricyclic antidepressants (risk ratio 0.90; 95% confidence interval 0.84 to 0.97) and the drop out rate due to side effects was 25% lower (risk ratio 0.75; 0.66 to 0.84). There was no significant difference between drug classes in the drop out rates for treatment failure. The risk ratios for drop out did not differ significantly between individual selective serotonin reuptake inhibitors. Conclusions-Selective serotonin reuptake inhibitors are better tolerated than tricyclic antidepressants as measured by total numbers of drop outs. The definite advantage to selective serotonin reuptake inhibitors is explained by fewer drop outs due to side effects. The overall difference, however, is comparatively small and may not be clinically relevant. Analyses of cost effectiveness should not overestimate the advantage to selective serotonin reuptake inhibitors.			ANDERSON, IM (corresponding author), UNIV MANCHESTER, MANCHESTER ROYAL INFIRM, DEPT PSYCHIAT, RAWNSLEY BLDG, MANCHESTER M13 9WL, LANCS, ENGLAND.			Anderson, Ian M/0000-0003-2205-9209				ALTAMURA AC, 1989, INT CLIN PSYCHOPHARM, V4, P103; Altman DG, 1991, PRACTICAL STATISTICS; AMIN MM, 1984, CLIN NEUROPHARMAC S1, V7, P580; AMORE M, 1989, CURR THER RES CLIN E, V46, P815; Andersen B, 1990, J AFFECT DISORDERS, V18, P289; ANDERSON IM, 1994, J PSYCHOPHARMACOL, V8, P238, DOI 10.1177/026988119400800407; ARMITAGE P, 1987, STATISTICAL METHODS; BALLINGER BR, 1983, BRIT MED J, V286, P1885, DOI 10.1136/bmj.286.6381.1885; BASCARA L, 1989, ACTA PSYCHIAT SCAND, V80, P141, DOI 10.1111/j.1600-0447.1989.tb07196.x; BATTEGAY R, 1985, NEUROPSYCHOBIOLOGY, V13, P31, DOI 10.1159/000118159; BIGNAMINI A, 1992, INT CLIN PSYCHOPHARM, V6, P37, DOI 10.1097/00004850-199206004-00008; BOYER WF, 1991, SELECTIVE SEROTONIN, P133; BRAMANTI P, 1988, CURR THER RES CLIN E, V43, P718; BREMNER JD, 1984, J CLIN PSYCHIAT, V45, P414; BRESSA GM, 1989, INT CLIN PSYCHOPHARM, V4, P69; BYERLEY WF, 1988, J CLIN PSYCHOPHARM, V8, P112; BYRNE MM, 1989, ACTA PSYCHIAT SCAND, V80, P138, DOI 10.1111/j.1600-0447.1989.tb07194.x; CHOUINARD G, 1985, J CLIN PSYCHIAT, V46, P32; CLAGHORN JL, 1993, J CLIN PSYCHOPHAR S2, V13, P23; COHN CK, 1990, J CLIN PSYCHIAT, V51, P28; COHN JB, 1990, PSYCHOPHARMACOL BULL, V26, P185; COHN JB, 1985, J CLIN PSYCHIAT, V46, P26; COLEMAN BS, 1982, PROG NEURO-PSYCHOPH, V6, P475, DOI 10.1016/S0278-5846(82)80132-2; CORNE SJ, 1989, INT CLIN PSYCHOPHARM, V4, P245, DOI 10.1097/00004850-198907000-00007; DEBUS JR, 1988, J CLIN PSYCHIAT, V49, P422; DEJONGHE F, 1991, PHARMACOPSYCHIATRY, V24, P21; DEJONGHE F, 1991, PHARMACOPSYCHIATRY, V24, P62, DOI 10.1055/s-2007-1014440; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEWILDE JE, 1983, BR J CLIN PHARM S, V15, P427; DEWILDE JEM, 1982, J AFFECT DISORDERS, V4, P9; DICK P, 1983, BR J CLIN PHARM, V15, P419; DOMINGUEZ RA, 1985, J CLIN PSYCHIAT, V46, P84; DORMAN T, 1992, INT CLIN PSYCHOPHARM, V6, P53; DUNBAR GC, 1991, BRIT J PSYCHIAT, V159, P394, DOI 10.1192/bjp.159.3.394; DUNNER DL, 1992, J CLIN PSYCHIAT, V53, P57; FABRE LF, 1991, J CLIN PSYCHIAT, V52, P62; Falk W E, 1989, J Geriatr Psychiatry Neurol, V2, P208, DOI 10.1177/089198878900200407; FAWCETT J, 1989, CURR THER RES CLIN E, V45, P821; FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P20; FEIGHNER JP, 1989, INT CLIN PSYCHOPHARM, V4, P127, DOI 10.1097/00004850-198904000-00004; FEIGHNER JP, 1989, INT CLIN PSYCHOPHARM, V4, P239, DOI 10.1097/00004850-198907000-00006; FEIGHNER JP, 1993, J AFFECT DISORDERS, V28, P71, DOI 10.1016/0165-0327(93)90035-I; FEIGHNER JP, 1991, J CLIN PSYCHIAT, V52, P329; FEIGHNER JP, 1989, ACTA PSYCHIAT SCAND, V80, P125, DOI 10.1111/j.1600-0447.1989.tb07190.x; FEIGHNER JP, 1992, INT CLIN PSYCHOPHARM, V6, P31, DOI 10.1097/00004850-199206004-00007; FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P369; FERRERI M, 1989, INT CLIN PSYCHOPHARM, V4, P97; FONTAINE R, 1991, EUR NEUROPSYCHOPHARM, V1, P75; GAGIANO CA, 1989, ACTA PSYCHIAT SCAND, V80, P130, DOI 10.1111/j.1600-0447.1989.tb07191.x; GARDNER MJ, 1989, STATISTICS CONFIDENC; GASPERINI M, 1992, NEUROPSYCHOBIOLOGY, V26, P186, DOI 10.1159/000118918; GINESTET D, 1989, INT CLIN PSYCHOPHARM, V4, P37; GONELLA G, 1990, CURR MED RES OPIN, V12, P177, DOI 10.1185/03007999009111499; GRAVEM A, 1987, ACTA PSYCHIAT SCAND, V75, P478, DOI 10.1111/j.1600-0447.1987.tb02821.x; GUELFI JD, 1983, BR J CLIN PHARM, V15, P411; GUILLIBERT E, 1989, ACTA PSYCHIAT SCAND, V80, P132, DOI 10.1111/j.1600-0447.1989.tb07192.x; GUY W, 1984, PSYCHOPHARMACOL BULL, V20, P73; HARRIS B, 1991, BRIT J CLIN RES, V2, P89; HARRISON G, 1994, BRIT MED J, V309, P1280, DOI 10.1136/bmj.309.6964.1280; Hutchinson D.R., 1991, BRIT J CLIN RES, V2, P43; HUTCHINSON DR, 1992, AM J CLIN RES, V1, P49; ITIL TM, 1983, BR J CLIN PHARM, V15, P433; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; JOHNSON DAW, 1981, ACTA PSYCHIAT SCAND, V63, P447, DOI 10.1111/j.1600-0447.1981.tb00751.x; JONSSON B, 1994, BRIT J PSYCHIAT, V164, P665, DOI 10.1192/bjp.164.5.665; JUDD F, 1991, J AM MED ASS SEA S, P31; JUDD FK, 1993, AUST NZ J PSYCHIAT, V27, P49, DOI 10.3109/00048679309072123; Kasper S, 1992, Drugs, V43 Suppl 2, P11; KEEGAN D, 1991, INT CLIN PSYCHOPHARM, V6, P117, DOI 10.1097/00004850-199100620-00007; KLOK CJ, 1981, ACTA PSYCHIAT SCAND, V64, P1, DOI 10.1111/j.1600-0447.1981.tb00756.x; KUHS H, 1989, ACTA PSYCHIAT SCAND, V80, P145, DOI 10.1111/j.1600-0447.1989.tb07198.x; LAAKMANN G, 1988, BRIT J PSYCHIAT, V153, P64, DOI 10.1192/S0007125000297316; LAPIERRE YD, 1987, J CLIN PSYCHIAT, V48, P65; LAURSEN AL, 1985, ACTA PSYCHIAT SCAND, V71, P249, DOI 10.1111/j.1600-0447.1985.tb01281.x; LEVINE S, 1989, INT CLIN PSYCHOPHARM, V4, P41; LEVINE S, 1987, BRIT J PSYCHIAT, V150, P653, DOI 10.1192/bjp.150.5.653; LOEB C, 1989, INT CLIN PSYCHOPHARM, V4, P75; LYDIARD RB, 1989, PSYCHOPHARMACOL BULL, V25, P68; MADDOX JC, 1994, J PSYCHOPHARMACOL, V8, P48, DOI 10.1177/026988119400800108; MANNA V, 1989, INT CLIN PSYCHOPHARM, V4, P81; MARCH JS, 1990, J CLIN PSYCHIAT, V51, P200; MASCO H L, 1985, Advances in Therapy, V2, P275; MERTENS C, 1988, ACTA PSYCHIAT SCAND, V77, P683, DOI 10.1111/j.1600-0447.1988.tb05188.x; MOLLER HJ, 1993, PHARMACOPSYCHIATRY, V26, P75, DOI 10.1055/s-2007-1014346; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008; MUIJEN M, 1988, ACTA PSYCHIAT SCAND, V78, P384, DOI 10.1111/j.1600-0447.1988.tb06353.x; MULLIN JM, 1988, BRIT J CLIN PRACT, V42, P51; NATHAN RS, 1990, J CLIN PSYCHIAT, V51, P367; NIELSEN BM, 1993, ACTA PSYCHIAT SCAND, V87, P269, DOI 10.1111/j.1600-0447.1993.tb03370.x; NIELSEN OA, 1991, ACTA PSYCHIAT SCAND, V84, P233, DOI 10.1111/j.1600-0447.1991.tb03136.x; NOGUERA R, 1991, J AFFECT DISORDERS, V22, P119, DOI 10.1016/0165-0327(91)90045-T; NORTON KRW, 1984, J AFFECT DISORDERS, V7, P297, DOI 10.1016/0165-0327(84)90051-X; OHRBERG S, 1992, ACTA PSYCHIAT SCAND, V86, P437, DOI 10.1111/j.1600-0447.1992.tb03294.x; OWENS D, 1994, BRIT MED J, V309, P1281, DOI 10.1136/bmj.309.6964.1281; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; PEREZ A, 1990, CURR MED RES OPIN, V12, P234, DOI 10.1185/03007999009111652; PERRY PJ, 1989, J CLIN PSYCHIAT, V50, P290; PESELOW ED, 1989, PSYCHOPHARMACOL BULL, V25, P267; PHANJOO AL, 1991, ACTA PSYCHIAT SCAND, V83, P476, DOI 10.1111/j.1600-0447.1991.tb05579.x; POELINGER W, 1989, INT CLIN PSYCHOPHARM, V4, P47; RAHMAN MK, 1991, BRIT J CLIN PRACT, V45, P255; REIMHERR FW, 1990, J CLIN PSYCHIAT, V51, P18; ROPERT R, 1989, INT CLIN PSYCHOPHARM, V4, P89; ROTH D, 1990, PROG NEURO-PSYCHOPH, V14, P929, DOI 10.1016/0278-5846(90)90078-U; SHAW DM, 1986, BRIT J PSYCHIAT, V149, P515, DOI 10.1192/bjp.149.4.515; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; STARK P, 1985, J CLIN PSYCHIAT, V46, P53; TAMMINEN TTA, 1989, INT CLIN PSYCHOPHARM, V4, P51; TANERI Z, 1989, INT CLIN PSYCHOPHARM, V4, P56; THOMPSON C, 1991, INT CONGR SER, V968, P863; WILSON A, 1992, MED J AUSTRALIA, V156, P173, DOI 10.5694/j.1326-5377.1992.tb139704.x; YOUNG JPR, 1987, BRIT J PSYCHIAT, V151, P337, DOI 10.1192/bjp.151.3.337; 1993, J PSYCHOPHARMACOL, V7, P19; 1988, INT CLIN PSYCHOPHARM, V3, P75; 1986, PSYCHOPHARMACOLOGY, V90, P131	116	261	263	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	1995	310	6992					1433	1438		10.1136/bmj.310.6992.1433	http://dx.doi.org/10.1136/bmj.310.6992.1433			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613276	Green Published			2022-12-28	WOS:A1995RC10500016
J	POJMAN, DV; TAXY, JB				POJMAN, DV; TAXY, JB			DOUBLE UTERUS WITH ADENOCARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											POJMAN, DV (corresponding author), LUTHERAN GEN HOSP,PARK RIDGE,IL 60068, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					709	709		10.1056/NEJM199509143331106	http://dx.doi.org/10.1056/NEJM199509143331106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637749				2022-12-28	WOS:A1995RV22700006
J	KENDALL, MJ; LYNCH, KP; HJALMARSON, A; KJEKSHUS, J				KENDALL, MJ; LYNCH, KP; HJALMARSON, A; KJEKSHUS, J			BETA-BLOCKERS AND SUDDEN CARDIAC DEATH	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; ARRHYTHMIA SUPPRESSION TRIAL; LEFT-VENTRICULAR HYPERTROPHY; ADRENERGIC BLOCKING-DRUGS; LOW-DENSITY-LIPOPROTEIN; QUALITY-OF-LIFE; ADRENOCEPTOR BLOCKADE; ANTIHYPERTENSIVE THERAPY; POSTINFARCTION PATIENTS	Objectives: To 1) consider the problem of sudden death from heart disease and the role of beta-blockers and other agents in preventing sudden death and 2) review perceived problems with beta-blocker therapy, such as effects on blood lipids, complications in diabetes, and adverse effects on heart failure and quality of life. Data Sources: MEDLINE and EMBASE searches done from July 1994 on, and recognized texts. Study Selection: More than 400 original and review articles were evaluated, of which the most relevant were selected. Data Extraction: Data were extracted and reviewed by two authors. Accuracy was confirmed, when necessary, by the other authors. Data Synthesis: Of all of the therapies currently available for-the prevention of sudden cardiac death, none is more established or more effective than beta-blockers. Indeed, the evidence that beta-blockers have a cardioprotective effect is compelling. They probably reduce the rate of atheroma formation; they reduce the risk for ventricular fibrillation in animal models of myocardial ischemia; they appear to reduce cardiac mortality in primary prevention trials; and they reduce mortality, particularly from sudden death, in patients who have had infarction. Moreover, withholding beta-blockers because of problems perceived to be associated with them is usually not warranted and may frequently prevent their use in those who will benefit most from them. Conclusion: Clinicians should reappraise the evidence for the significant effect of beta-blockers on morbidity and mortality, and they should recognize the importance of initiating and maintaining beta-blocker therapy when the less well-informed might suggest otherwise.	SAHLGRENS UNIV HOSP, GOTHENBURG, SWEDEN; NATL HOSP, OSLO, NORWAY; UNIV OSLO, OSLO, NORWAY	Sahlgrenska University Hospital; University of Oslo; National Hospital Norway; University of Oslo	KENDALL, MJ (corresponding author), QUEEN ELIZABETH HOSP, DEPT MED, CLIN PHARMACOL SECT, BIRMINGHAM M15 2TH, W MIDLANDS, ENGLAND.							ABLAD B, 1987, FASEB J, V46, P974; ABLAD B, 1991, J AM COLL CARDIOL, V17, P165; AMES RP, 1986, DRUGS, V32, P335, DOI 10.2165/00003495-198632040-00003; ANDERSON JL, 1990, J CLIN PHARMACOL, V30, P981, DOI 10.1002/j.1552-4604.1990.tb03582.x; ANDERSON JL, 1983, AM J CARDIOL, V51, P1196, DOI 10.1016/0002-9149(83)90368-5; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1986, Lancet, V2, P57; BAKER JW, 1991, ATHEROSCLEROSIS, V89, P209, DOI 10.1016/0021-9150(91)90062-8; BALL SG, 1993, LANCET, V342, P821; BASHIR Y, 1993, BRIT HEART J, V70, P8; BIGGER JT, 1993, J AM COLL CARDIOL, V21, P729, DOI 10.1016/0735-1097(93)90106-B; BLACK JW, 1962, LANCET, V2, P311; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAMEJO G, 1991, CIRCULATION, V84, P17; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COLLINS R, 1995, LANCET, V345, P669; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAHLOF C, 1991, CIRCULATION, V84, P108; DEBAKEY ME, 1985, ANN SURG, V201, P115; DELLSPERGER KC, 1990, CIRCULATION, V82, P941, DOI 10.1161/01.CIR.82.3.941; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; EICHHORN EJ, 1994, CIRCULATION, V90, P2153, DOI 10.1161/01.CIR.90.4.2153; ELWOOD PC, 1984, DRUGS, V28, P1, DOI 10.2165/00003495-198428010-00001; EWING DJ, 1976, LANCET, V1, P601, DOI 10.1016/S0140-6736(76)90413-X; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; FEARON RE, 1967, AM J CARDIOL, V20, P222, DOI 10.1016/0002-9149(67)90081-1; FLETCHER A, 1988, J HUM HYPERTENS, V2, P219; FOWLER MB, 1985, AM J CARDIOL, V55, pD120, DOI 10.1016/0002-9149(85)91066-5; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FURBERG CD, 1984, CIRCULATION, V69, P761, DOI 10.1161/01.CIR.69.4.761; FURUKAWA T, 1993, J CLIN INVEST, V91, P1521, DOI 10.1172/JCI116358; GOTTLIEB SS, 1994, CURR OPIN CARDIOL, V9, P295, DOI 10.1097/00001573-199405000-00006; GREEN KG, 1991, AM J HYPERTENS, V4, P723, DOI 10.1093/ajh/4.8.723; GULLESTAD L, 1992, Tidsskrift for den Norske Laegeforening, V112, P1016; GUNDERSEN T, 1983, DIABETES CARE, V6, P285, DOI 10.2337/diacare.6.3.285; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; HALLSTROM AP, 1991, AM J CARDIOL, V68, P1025, DOI 10.1016/0002-9149(91)90490-C; HANSTEEN V, 1982, BRIT MED J, V284, P155, DOI 10.1136/bmj.284.6310.155; HELD P, 1989, CARDIOLOGY, V76, P132, DOI 10.1159/000174484; HERLITZ J, 1984, AM J CARDIOL, V53, pD9; HERLITZ J, 1984, BRIT HEART J, V51, P539; HJALMARSON A, 1981, LANCET, V2, P823; HJALMARSON A, 1985, EUR HEART J, V6, P199; HJALMARSON A, 1994, DRUGS, V47, P31, DOI 10.2165/00003495-199400474-00006; HJALMARSON A, 1994, PACE, V17, P460, DOI 10.1111/j.1540-8159.1994.tb01413.x; HJEMDAHL P, 1992, J HYPERTENS, V10, P1437, DOI 10.1097/00004872-199210120-00001; HOFFMAN BB, 1990, GOODMAN GILMANS PHAR, P233; HOHNLOSER SH, 1994, NEW ENGL J MED, V331, P31; HUIKURI HV, 1989, AM J CARDIOL, V64, P1305, DOI 10.1016/0002-9149(89)90572-9; JULIAN DG, 1982, LANCET, V1, P1142; KAHN JK, 1988, J NUCL MED, V29, P1605; KANNEL WB, 1975, CIRCULATION, V51, P606, DOI 10.1161/01.CIR.51.4.606; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KANNEL WB, 1988, HYPERTENSION, V11, pS45; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KAPLAN NM, 1988, AM J HYPERTENS, V1, P428, DOI 10.1093/ajh/1.4.428; Kennedy Harold L., 1993, Journal of the American College of Cardiology, V21, p378A; KHAN MI, 1972, AM J CARDIOL, V30, P832, DOI 10.1016/0002-9149(72)90007-0; KJEKSHUS JK, 1986, AM J CARDIOL, V57, pF43, DOI 10.1016/0002-9149(86)90888-X; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLEINMAN JC, 1988, AM J EPIDEMIOL, V128, P389, DOI 10.1093/oxfordjournals.aje.a114979; LAGER I, 1979, LANCET, V1, P458; LEVY D, 1990, AM HEART J, V119, P712, DOI 10.1016/S0002-8703(05)80050-X; LICHSTEIN E, 1990, J AM COLL CARDIOL, V16, P1327, DOI 10.1016/0735-1097(90)90372-V; LINDQVIST P, 1988, ATHEROSCLEROSIS, V72, P163, DOI 10.1016/0021-9150(88)90077-9; MALMBERG K, 1989, EUR HEART J, V10, P423, DOI 10.1093/oxfordjournals.eurheartj.a059505; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; MORGANROTH J, 1990, AM J CARDIOL, V65, P40, DOI 10.1016/0002-9149(90)90023-T; MOSER M, 1989, ARCH INTERN MED, V149, P2174, DOI 10.1001/archinte.149.10.2174; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MYERBURG RJ, 1992, HEART DIS TXB CARDIO, P756; OLSSON G, 1992, EUR HEART J, V13, P28, DOI 10.1093/oxfordjournals.eurheartj.a060043; OLSSON G, 1991, AM J HYPERTENS, V4, P151, DOI 10.1093/ajh/4.2.151; OLSSON G, 1990, CARDIOVASCULAR DRUG, P497; OSTLUNDLINDQVIST AM, 1988, ARTERIOSCLEROSIS, V8, P40, DOI 10.1161/01.ATV.8.1.40; PARKER GW, 1990, CIRC RES, V66, P259, DOI 10.1161/01.RES.66.2.259; PASTERNAK RC, 1992, HEART DISEASE TXB CA, P1200; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PEDERSEN TR, 1994, LANCET, V344, P1383; PENTECOST BL, 1966, AM HEART J, V72, P790, DOI 10.1016/0002-8703(66)90162-1; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAJMAN I, 1993, POSTGRAD MED J, V69, P903, DOI 10.1136/pgmj.69.818.903; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; RUTHERFORD JD, 1992, HEART DIS TXB CARDIO, P1307; RYDEN L, 1983, NEW ENGL J MED, V308, P614, DOI 10.1056/NEJM198303173081102; SCHOENBERGER JA, 1990, AM J HYPERTENS, V3, P123, DOI 10.1093/ajh/3.2.123; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEINER SS, 1990, J HUM HYPERTENS, V4, P217; SURAWICZ B, 1987, RHYTHMOLOGY, V11, P3; TEGERNILSSON AC, 1990, J CLIN PHARMACOL, V30, pS132, DOI 10.1002/j.1552-4604.1990.tb03511.x; THIESSEN BQ, 1990, ARCH INTERN MED, V150, P2286, DOI 10.1001/archinte.150.11.2286; Thubrikar M. J., 1990, FASEB J, V4, pA1151; THUBRIKAR MJ, 1988, ARTERIOSCLEROSIS, V8, P410, DOI 10.1161/01.ATV.8.4.410; THUBRIKAR MJ, 1992, ATHEROSCLEROSIS, V97, P1, DOI 10.1016/0021-9150(92)90045-I; THUBRIKAR MJ, 1990, J BIOMECH, V23, P15, DOI 10.1016/0021-9290(90)90365-A; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Waldo AL, 1995, J AM COLL CARDIOL S, V25, p15A; WIKSTRAND J, 1992, EUR HEART J, V13, P111; WINTHER K, 1986, CEPHALALGIA, V6, P33, DOI 10.1177/03331024860060S504; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1987, Cardiovascular Drugs and Therapy, V1, P343, DOI 10.1007/BF02209073; YUSUF S, 1991, J CARDIOVASC ELECT S, V2, pS233; 1981, DHEW PHS NIH822035 P, P114	112	210	218	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					358	367		10.7326/0003-4819-123-5-199509010-00007	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625625				2022-12-28	WOS:A1995RQ98800007
J	ANNAS, GJ				ANNAS, GJ			MEDICINE, DEATH, AND THE CRIMINAL-LAW	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				BRAHAMS D, 1993, LANCET, V341, P1404, DOI 10.1016/0140-6736(93)90961-F; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CAPRON AM, 1995, HASTINGS CENT REP, V25, P26, DOI 10.2307/3562111; Glantz L H, 1987, Law Med Health Care, V15, P231; HARRINGTON MP, 1994, RUTGERS LJ, V26, P111; HOLLOWAY L, 1995, NY TIMES        0809, pA1; KOLATA G, 1995, NY TIMES        0413, pA16; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; NOSSITER A, 1995, NY TIMES        0905, pA1; VOELKER R, 1995, JAMA-J AM MED ASSOC, V273, P1559, DOI 10.1001/jama.273.20.1559; 1995, WASHINGTON POST 0418, pA16	11	14	14	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					527	530		10.1056/NEJM199508243330822	http://dx.doi.org/10.1056/NEJM199508243330822			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623900	Green Published			2022-12-28	WOS:A1995RP75900033
J	CARTLIDGE, PHT; STEWART, JH				CARTLIDGE, PHT; STEWART, JH			EFFECT OF CHANGING THE STILLBIRTH DEFINITION ON EVALUATION OF PERINATAL-MORTALITY RATES	LANCET			English	Article							PRETERM INFANTS; ATTITUDES; VIABILITY	The perinatal mortality rate is widely used as a summary statistic for evaluating the effectiveness of perinatal care. Since October, 1992, it has been a legal requirement in England and Wales to register fetal deaths at 24-27 completed weeks of gestation as stillbirths (in addition to those after 28 weeks), thereby altering the definition of perinatal death. In a cohort analysis of all babies born to women resident in Wales during 1993, we assessed whether the revised definition of perinatal mortality rate more appropriately measures effectiveness of care. There were 36 793 births and 313 perinatal deaths (221 stillbirths, 92 early neonatal deaths). At 24-27 weeks' gestation there were 59 (39%) survivors and 93 deaths (52 stillbirths, 36 neonatal deaths [28 early, eight late], and 5 postneonatal deaths). 119 babies had a birthweight below 500 g; one survived and 24 were perinatal deaths. Of the 36 late neonatal deaths all were attributed to perinatally related events. Increased survival of infants at 24-27 weeks' gestation emphasises the importance of including all these infants in the perinatal mortality rate, but it would be a more useful measure of the effectiveness of perinatal care if it excluded babies below 500 g, and included late neonatal deaths.			CARTLIDGE, PHT (corresponding author), UNIV WALES COLL MED,DEPT CHILD HLTH,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							[Anonymous], 1978, INT CLASSIFICATION D; [Anonymous], 1988, REGISTRATION MODERN; CARTLIDGE PHT, 1995, BRIT MED J, V310, P155, DOI 10.1136/bmj.310.6973.155; CLARKE M, 1993, BRIT MED J, V306, P824, DOI 10.1136/bmj.306.6881.824; FENTON AC, 1990, BRIT MED J, V300, P434, DOI 10.1136/bmj.300.6722.434; KEELING JW, 1989, ARCH DIS CHILD, V64, P1345, DOI 10.1136/adc.64.10_Spec_No.1345; MACFARLANE A, 1990, BRIT MED J, V300, P942, DOI 10.1136/bmj.300.6729.942-a; Macfarlane A, 1980, HLTH TRENDS, V12, P45; Mallett R, 1979, Community Med, V1, P6, DOI 10.1007/BF02548737; MUTCH LMM, 1981, BRIT MED J, V282, P119, DOI 10.1136/bmj.282.6258.119; SCOTT MJ, 1981, BRIT MED J, V282, P707, DOI 10.1136/bmj.282.6265.707; WIGGLESWORTH JS, 1980, LANCET, V2, P684; 1993, CONFIDENTIAL ENQUIRY; 1990, REGISTRATION PROPOSA; 1991, LANCET, V337, P331; 1990, LANCET, V336, P782	16	55	60	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					486	488		10.1016/S0140-6736(95)91327-0	http://dx.doi.org/10.1016/S0140-6736(95)91327-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637485				2022-12-28	WOS:A1995RP85700015
J	FENDRICK, AM; CHERNEW, ME; HIRTH, RA; BLOOM, BS				FENDRICK, AM; CHERNEW, ME; HIRTH, RA; BLOOM, BS			ALTERNATIVE MANAGEMENT STRATEGIES FOR PATIENTS WITH SUSPECTED PEPTIC-ULCER DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						PEPTIC ULCER; COST-BENEFIT ANALYSIS; HELICOBACTER PYLORI; HELICOBACTER INFECTIONS; ENDOSCOPY	HELICOBACTER-PYLORI INFECTION; DOUBLE-BLIND TRIAL; DUODENAL-ULCER; CAMPYLOBACTER-PYLORI; NONULCER DYSPEPSIA; BREATH TEST; GASTRIC-CARCINOMA; TRIPLE THERAPY; FOLLOW-UP; H-2-RECEPTOR ANTAGONISTS	Objective: To estimate the clinical and economic effects of available invasive and noninvasive management strategies for peptic ulcer and Helicobacter pylori in persons with symptoms suggesting peptic ulcer disease. Design: Cost-effectiveness analysis using a decision analytic model. Intervention: 2 immediate endoscopy and 3 noninvasive diagnostic and treatment strategies were evaluated: 1) immediate endoscopy for peptic ulcer and biopsy for H. pylori; 2) immediate endoscopy without biopsy; 3) serologic test for H. pylori; 4) empiric treatment with antisecretory therapy; and 5) empiric treatment with antisecretory therapy and antibiotic agents to eradicate H. pylori. Measurements: Cost per ulcer cured and cost per patient treated. Results: The estimated costs per ulcer cured by strategy were as follows: 1) endoscopy and biopsy for H. pylori, $8045; 2) endoscopy without biopsy, $6984; 3) serologic test for H. pylori, $4541; 4) empiric antisecretory therapy, $4835; and 5) empiric antisecretory and antibiotic therapy, $4155. The predicted costs per patient treated were as follows: 1) endoscopy and biopsy for H. pylori, $1584; 2) endoscopy without biopsy, $1375; 3) serologic test for H. pylori, $894; 4) empiric antisecretory therapy, $952; and 5) empiric antisecretory and antibiotic therapy, $818. The cost-effectiveness advantage of the noninvasive strategies diminished as the cost of endoscopy decreased or as the probability of recurrent symptoms increased in patients initially managed without endoscopy. Conclusion: Endoscopy, although costly, precisely guided diagnosis and treatment and thus potentially reduced the number of patients inappropriately treated. However, the safety and effectiveness of less expensive, less invasive diagnostic and treatment strategies strongly support initial noninvasive care of symptomatic persons thought to have peptic ulcer disease.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	FENDRICK, AM (corresponding author), UNIV MICHIGAN, MED CTR, DIV GEN MED, 3116 TAUBMAN CTR, ANN ARBOR, MI 48109 USA.							ARCHAMBAULT AP, 1988, GASTROENTEROLOGY, V94, P1130, DOI 10.1016/0016-5085(88)90003-0; BAMBERG P, 1992, J GASTROEN HEPATOL, V7, P577, DOI 10.1111/j.1440-1746.1992.tb01489.x; BANK S, 1992, AM J GASTROENTEROL, V87, P1365; BARDHAN KD, 1989, J CLIN GASTROENTEROL, V21, P408; BARNES RJ, 1974, BRIT MED J, V4, P214, DOI 10.1136/bmj.4.5938.214; BAYERDORFFER E, 1993, SCAND J GASTROENTERO, V28, P19, DOI 10.3109/00365529309098337; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; BELL GD, 1987, LANCET, V1, P1367; BELL GD, 1992, ALIMENT PHARM THERAP, V6, P427; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1993, INT J CANCER, V55, P799, DOI 10.1002/ijc.2910550518; BLOOM BS, 1989, J CLIN GASTROENTEROL, V11, P615, DOI 10.1097/00004836-198912000-00003; BLOOM BS, 1990, J CLIN GASTROENTEROL, V12, P100, DOI 10.1097/00004836-199002000-00026; BONNEVIE O, 1985, DIGEST DIS SCI, V30, pS8, DOI 10.1007/BF01309380; BORODY TJ, 1989, MED J AUSTRALIA, V151, P431, DOI 10.5694/j.1326-5377.1989.tb101251.x; BURETTE A, 1993, GASTROENTEROLOGY S, V4, pA49; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; CADY B, 1977, AM J SURG, V133, P423, DOI 10.1016/0002-9610(77)90126-X; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; COELHO LGV, 1991, AM J GASTROENTEROL, V86, P971; COGHLAN JG, 1987, LANCET, V2, P1109; COLINJONES DG, 1986, LANCET, V1, P1022; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P1359; DOBRILLA G, 1988, GUT, V29, P181, DOI 10.1136/gut.29.2.181; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DUPONT JB, 1978, CANCER-AM CANCER SOC, V41, P941, DOI 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M; ELASHOFF JD, 1983, J CLIN GASTROENTEROL, V5, P509, DOI 10.1097/00004836-198312000-00008; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FARUP PG, 1992, ALIMENT PHARM THERAP, V6, P179; FISHER JA, 1977, BRIT MED J, V2, P1199, DOI 10.1136/bmj.2.6096.1199; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; FORMAN D, 1993, LANCET, V341, P1359; GEAR MWL, 1980, BRIT MED J, V280, P1136, DOI 10.1136/bmj.280.6223.1136; GLISE H, 1987, AM J MED, V83, P105, DOI 10.1016/0002-9343(87)90838-2; GLUPCZYNSKI Y, 1988, AM J GASTROENTEROL, V83, P365; GOH KL, 1991, SCAND J GASTROENTERO, V26, P1123, DOI 10.3109/00365529108998603; GRAHAM DY, 1992, GASTROENTEROLOGY, V102, P1289; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GRAHAM DY, 1993, GASTROENTEROLOGY, V105, P279, DOI 10.1016/0016-5085(93)90038-E; GRAHAM DY, 1990, DIGEST DIS SCI, V35, P66, DOI 10.1007/BF01537225; GREENBERG RE, 1990, ARCH INTERN MED, V150, P2053, DOI 10.1001/archinte.150.10.2053; HANSSON LE, 1993, GASTROENTEROLOGY, V105, P1098, DOI 10.1016/0016-5085(93)90954-B; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOLCOMBE C, 1992, ALIMENT PHARM THERAP, V6, P119; HORROCKS JC, 1978, GUT, V19, P19, DOI 10.1136/gut.19.1.19; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; JENSEN DM, 1986, AM J MED, V81, P42, DOI 10.1016/0002-9343(86)90599-1; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; KAGEVI I, 1989, SCAND J GASTROENTERO, V24, P145, DOI 10.3109/00365528909093029; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; KLEIN PD, 1993, AM J GASTROENTEROL, V88, P1865; LABENZ J, 1993, AM J GASTROENTEROL, V88, P491; LABENZ J, 1993, GUT, V34, P1167, DOI 10.1136/gut.34.9.1167; LAMBERT JR, 1993, GASTROENTEROL CLIN N, V22, P141; LANE MR, 1988, LANCET, V1, P1147; LINDBERG G, 1987, SCAND J GASTROENTERO, V22, P190, DOI 10.3109/00365528709090990; LOGAN RPH, 1992, LANCET, V340, P239, DOI 10.1016/0140-6736(92)90502-T; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MALFERTHEINER P, 1993, SCAND J GASTROENTERO, V28, P34, DOI 10.3109/00365529309098341; MANSI C, 1990, DIGEST DIS SCI, V35, P1452, DOI 10.1007/BF01540561; MANSI C, 1993, J CLIN GASTROENTEROL, V16, P149, DOI 10.1097/00004836-199303000-00015; MARSHALL BJ, 1988, J NUCL MED, V29, P11; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1991, AM J GASTROENTEROL, V86, P438; MARSHALL RJ, 1985, MED J AUSTRALIA, V82, P192; MCNULTY CAM, 1989, GUT, V30, P1058, DOI 10.1136/gut.30.8.1058; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MOLLMANN KM, 1975, SCAND J GASTROENTERO, V10, P805; MORRISSEY JF, 1988, ANN INTERN MED, V109, P605, DOI 10.7326/0003-4819-109-8-605; MORRISSEY JF, 1976, GASTROINTEST ENDOSC, V23, P13, DOI 10.1016/S0016-5107(76)73567-3; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; OLEARCHYK AS, 1978, AM J GASTROENTEROL, V70, P25; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PATCHETT S, 1991, BMJ-BRIT MED J, V303, P1238, DOI 10.1136/bmj.303.6812.1238; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; RAUWS EAJ, 1989, GUT, V30, P798, DOI 10.1136/gut.30.6.798; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIPPONEN P, 1991, SCAND J GASTROENTERO, V26, P6, DOI 10.3109/00365529109103980; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; TALLEY NJ, 1993, GASTROENTEROL CLIN N, V22, P153; TALLEY NJ, 1992, J CLIN MICROBIOL, V30, P3146, DOI 10.1128/JCM.30.12.3146-3150.1992; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THIJS JC, 1993, SCAND J GASTROENTERO, V28, P934, DOI 10.3109/00365529309098287; VANDEVENTER GM, 1989, NEW ENGL J MED, V320, P1113, DOI 10.1056/NEJM198904273201704; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	96	183	183	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					260	268		10.7326/0003-4819-123-4-199508150-00003	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611591				2022-12-28	WOS:A1995RN66500003
J	WALSTON, J; SILVER, K; BOGARDUS, C; KNOWLER, WC; CELI, FS; AUSTIN, S; MANNING, B; STROSBERG, AD; STERN, MP; RABEN, N; SORKIN, JD; ROTH, J; SHULDINER, AR				WALSTON, J; SILVER, K; BOGARDUS, C; KNOWLER, WC; CELI, FS; AUSTIN, S; MANNING, B; STROSBERG, AD; STERN, MP; RABEN, N; SORKIN, JD; ROTH, J; SHULDINER, AR			TIME OF ONSET OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND GENETIC-VARIATION IN THE BETA(3)-ADRENERGIC-RECEPTOR GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BROWN ADIPOSE-TISSUE; BETA-3-ADRENERGIC RECEPTOR; GLUCOSE-TOLERANCE; METABOLIC-RATE; OBESITY; THERMOGENESIS; MUTATIONS; CHAIN; RISK	Background. The beta(3)-adrenergic receptor is expressed in visceral adipose tissue and is thought to contribute to the regulation of the resting metabolic rate and lipolysis. Methods. To investigate whether mutations in the gene for the beta(3)-adrenergic receptor predispose patients to obesity and non-insulin-dependent diabetes mellitus (NIDDM), we studied this gene in 10 Pima Indians by analysis of single-stranded conformational polymorphisms and dideoxy sequence analysis. Association studies were performed in 642 Pima subjects (390 with NIDDM and 252 without NIDDM). Results. A missense mutation was identified in the gene for the beta(3)-adrenergic receptor that results in the replacement of tryptophan by arginine (Trp64Arg) in the first intracellular loop of the receptor. This mutation was detected with allelic frequencies of 0.31 in Pima Indians, 0.13 in 62 Mexican Americans, 0.12 in 49 blacks, and 0.08 in 48 whites in the United States. Among Pimas, the frequency of the Trp64Arg mutation was similar in nondiabetic and diabetic subjects. However, in subjects homozygous for the mutation the mean (+/-SD) age at the onset of NIDDM was significantly lower (36+/-10 years) than in Trp64Arg heterozygotes (40+/-10 years) or normal homozygotes (41 +/- 11 years; P = 0.02). Furthermore, subjects with the mutation tended to have a lower adjusted resting metabolic rate (P = 0.14 by analysis of covariance). Conclusions. Pima subjects homozygous for the Trp64Arg beta(3)-adrenergic-receptor mutation have an earlier onset of NIDDM and tend to have a lower resting metabolic rate. This mutation may accelerate the onset of NIDDM by altering the balance of energy metabolism invisceral adipose tissue.	JOHNS HOPKINS UNIV, SCH MED, DIV GERIATR MED & GERONTOL, BALTIMORE, MD 21224 USA; JOHNS HOPKINS UNIV, SCH MED, DIV ENDOCRINOL & METAB, BALTIMORE, MD USA; NIDDKD, CLIN DIABET & NUTR SECT, PHOENIX, AZ 85016 USA; NIDDKD, DIABET & ARTHRITIS EPIDEMIOL SECT, PHOENIX, AZ 85016 USA; NIA, CLIN PHYSIOL LAB, BALTIMORE, MD 21224 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; INST COCHIN GENET MOLEC, IMMUNOPHARMACOL MOLEC LAB, F-75014 PARIS, FRANCE; UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV CLIN EPIDEMIOL, SAN ANTONIO, TX 78284 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; University of Texas Health San Antonio				Shuldiner, Alan/0000-0001-9921-4305	NATIONAL INSTITUTE ON AGING [T32AG000120] Funding Source: NIH RePORTER; NIA NIH HHS [5T32AG00120] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BOUCHARD C, 1989, METABOLISM, V38, P364, DOI 10.1016/0026-0495(89)90126-1; BOUCHARD C, 1993, WORLD REV NUTR DIET, V72, P68; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CIEMENT K, 1995, NEW ENGL J MED, V333, P352; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; CONNACHER AA, 1992, AM J CLIN NUTR, V55, P258; ELBEIN SC, 1994, DIABETES CARE, V17, P1523, DOI 10.2337/diacare.17.12.1523; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GRIFFITHS M, 1990, LANCET, V336, P76, DOI 10.1016/0140-6736(90)91592-X; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; KNOWLER WC, 1991, AM J CLIN NUTR, V53, pS1543, DOI 10.1093/ajcn/53.6.1543S; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; LIGGETT SB, 1992, DNA SEQUENCE, V2, P61; LYONS J, 1990, PCR PROTOCOLS GUIDE; MITCHELL BD, 1994, DIABETES CARE, V17, P567, DOI 10.2337/diacare.17.6.567; MITCHELL TH, 1989, INT J OBESITY, V13, P757; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PROCHAZKA M, 1993, DIABETES, V42, P514, DOI 10.2337/diabetes.42.4.514; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; ROTTER JI, 1990, ELLENBERG RIFKINS DI, P378; SHULDINER AR, 1993, HDB ENDOCRINE RES TE, P457; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUSULIC S, 1995, 77TH ANN M END SOC B, P36; TRAYHURN P, 1986, BIOCHEM SOC T, V14, P236, DOI 10.1042/bst0140236; TURNER RC, 1995, DIABETES, V44, P1, DOI 10.2337/diabetes.44.1.1; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; 1985, WHO TECH REP SER, V727, P7	35	566	594	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					343	347		10.1056/NEJM199508103330603	http://dx.doi.org/10.1056/NEJM199508103330603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609750				2022-12-28	WOS:A1995RN08200003
J	FRYATT, RJ				FRYATT, RJ			FOREIGN-AID AND TB CONTROL POLICY IN NEPAL	LANCET			English	Editorial Material											FRYATT, RJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON,ENGLAND.							Chan S. L., 1994, P141; 1995, STOP TB SOURCE WHO R; 1994, NATIONAL TUBERCULOSI; 1993, WORLD HLTH, V4, P2	4	7	7	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					328	328		10.1016/S0140-6736(95)92223-7	http://dx.doi.org/10.1016/S0140-6736(95)92223-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623529				2022-12-28	WOS:A1995RM71300006
J	KRIEGER, D; KRIEGER, S; JANSEN, O; GASS, P; THEILMANN, L; LICHTNECKER, H				KRIEGER, D; KRIEGER, S; JANSEN, O; GASS, P; THEILMANN, L; LICHTNECKER, H			MANGANESE AND CHRONIC HEPATIC-ENCEPHALOPATHY	LANCET			English	Article							CIRRHOTIC-PATIENTS; BRAIN; FAILURE; LESIONS; RATS	Clinical observations and animal studies have raised the hypothesis that increased concentrations of manganese (Mn) in whole blood might lead to accumulation of this metal within the basal ganglia in patients with end-stage liver disease. We studied ten patients with liver failure (and ten controls) by magnetic resonance imaging (MRI) and measurement of Mn in brain tissue of three patients who died of progressive liver failure (and three controls) was also done. Whole blood Mn concentrations in patients with liver cirrhosis were significantly increased (median 34.4 mu g/L vs 10.3 mu g/L in controls; p=0.0004) and pallidal signal intensity indices correlated with blood Mn (R(s)=0.8, p=0.0058). Brain tissue samples reveal highest Mn concentrations in the caudate nucleus, followed by the quadrigeminal plate and globus pallidus. Mn accumulates within the basal ganglia in liver cirrhosis. Similarities between Mn neurotoxicity and chronic hepatic encephalopathy suggest that this metal may have a role in the pathogenesis of chronic hepatic encephalopathy. Further studies are warranted because the use of chelating agents could prove to be a new therapeutic option to prevent or reverse this neuropsychiatric syndrome.	UNIV HEIDELBERG,DEPT GASTROENTEROL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT NEURORADIOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT NEUROPATHOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST & POLYCLIN OCCUPAT & SOCIAL MED,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	KRIEGER, D (corresponding author), UNIV HEIDELBERG,KOPFKLIN,DEPT NEUROL,400 NEUENHEIMER FELD,D-69120 HEIDELBERG,GERMANY.		Jansen, Olav/D-2547-2010					ASHNER M, 1992, J NEUROCHEM, V58, P730; BROUILLET EP, 1993, EXP NEUROL, V120, P89, DOI 10.1006/exnr.1993.1042; BRUNBERG JA, 1991, AM J NEURORADIOL, V12, P909; COTZIAS GC, 1958, PHYSIOL REV, V38, P503, DOI 10.1152/physrev.1958.38.3.503; DEVENYI AG, 1994, GASTROENTEROLOGY, V106, P1068, DOI 10.1016/0016-5085(94)90769-2; DRAYER BP, 1986, RADIOLOGY, V159, P493, DOI 10.1148/radiology.159.2.3961182; ERIKSSON H, 1992, ARCH TOXICOL, V66, P403, DOI 10.1007/BF02035130; KOSENKO E, 1994, J NEUROCHEM, V62, P2172; KRIEGER D, 1995, NEUROLOGY S4, V45; LAI JCK, 1992, NEUROCHEM RES, V17, P841, DOI 10.1007/BF00993259; MENA I, 1967, NEUROLOGY, V17, P128, DOI 10.1212/WNL.17.2.128; METHA R, 1990, J PARENT ENTERAL NUT, V14, P428; MIROWITZ SA, 1992, RADIOLOGY, V185, P535, DOI 10.1148/radiology.185.2.1410368; MOUSSEAU DD, 1993, NEUROSCI LETT, V162, P192, DOI 10.1016/0304-3940(93)90593-A; NELSON K, 1993, BRIT J IND MED, V50, P510; NEWLAND MC, 1989, EXP NEUROL, V106, P251, DOI 10.1016/0014-4886(89)90157-X; NORENBERG MD, 1992, PROG BRAIN RES, V94, P261; PUJOL A, 1993, NEUROLOGY, V43, P65, DOI 10.1212/WNL.43.1_Part_1.65; RAO VLR, 1993, BRAIN RES, V621, P349, DOI 10.1016/0006-8993(93)90126-8; SCHRAMM VL, 1986, FASEB J, V45, P2817; SLOOT WN, 1994, J NEUROCHEM, V62, P205; SRIVASTAVA RS, 1989, BIOCHEM INT, V18, P903; VERSIECK J, 1974, CLIN CHEM, V20, P1141; Wedler F C, 1993, Prog Med Chem, V30, P89, DOI 10.1016/S0079-6468(08)70376-X; WEDLER FC, 1984, CURR TOP CELL REGUL, V24, P153; WEDLER FC, 1986, MANGANESE METABOLISM, P221; YAMADA M, 1986, ACTA NEUROPATHOL, V70, P273, DOI 10.1007/BF00686083	27	358	373	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					270	274		10.1016/S0140-6736(95)92164-8	http://dx.doi.org/10.1016/S0140-6736(95)92164-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630246				2022-12-28	WOS:A1995RL75700009
J	SASAI, Y; LU, B; STEINBEISSER, H; DEROBERTIS, EM				SASAI, Y; LU, B; STEINBEISSER, H; DEROBERTIS, EM			REGULATION OF NEURAL INDUCTION BY THE CHD AND BMP-4 ANTAGONISTIC PATTERNING SIGNALS IN XENOPUS	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL PATTERN; MESODERM INDUCTION; DROSOPHILA EMBRYO; GENE-EXPRESSION; PLATE; LAEVIS	IN Drosophila the amount of neurogenic ectoderm, from which the central nervous system (CNS) derives, is regulated by a dorsal-ventral system of positional information in which two secreted molecules of antagonistic functions, decapentaplegic (dpp) and short-gastrulation (sog), play fundamental roles(1-4). The vertebrate homologue of dpp is either bmp-4 or bmp-2 (ref. 5), and the homologue of sog is chd(4,6,7) (s-chordin). In Xenopus the CNS is induced by signals emanating from the organizer(8), and two proteins secreted by the organizer, noggin(9) and follistatin(10), have been shown to induce neural tissue in animal-cap assays. Here we report that Chd, another organizer-specific secreted factor(6), has neuralizing activity and that this activity can be antagonized by Bmp-4. Inhibition of the function of the endogenous Bmp-4 present in the animal cap(1)1 also leads to neural differentiation. We suggest that conserved molecular mechanisms involving chd/sog and bmp-4/dpp gene products pattern the ectoderm in Xenopus and in Drosophila.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869				ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JAMRICH M, 1989, DEVELOPMENT, V105, P779; JONES CM, 1992, DEVELOPMENT, V115, P639; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; PADGETT RW, 1994, P NATL ACAD SCI USA, V90, P2905; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHARPE CR, 1989, DEVELOPMENT, V107, P701; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; ZARAISKY AG, 1992, DEV BIOL, V152, P373, DOI 10.1016/0012-1606(92)90144-6	28	542	566	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					333	336		10.1038/376333a0	http://dx.doi.org/10.1038/376333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630399				2022-12-28	WOS:A1995RL44300045
J	CAMPBELL, LM; SULLIVAN, F; MURRAY, TS				CAMPBELL, LM; SULLIVAN, F; MURRAY, TS			VIDEOTAPING OF GENERAL-PRACTICE CONSULTATIONS - EFFECT ON PATIENT SATISFACTION	BRITISH MEDICAL JOURNAL			English	Article									WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW,LANARK,SCOTLAND		CAMPBELL, LM (corresponding author), UNIV GLASGOW,DEPT POSTGRAD MED,GLASGOW G12 8QQ,LANARK,SCOTLAND.		Sullivan, Frank/L-8286-2019; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; 				BAIN JE, 1993, BRIT MED J, V307, P504, DOI 10.1136/bmj.307.6902.504-b; BAKER R, 1990, BRIT J GEN PRACT, V40, P487; MARTIN E, 1984, J ROY COLL GEN PRACT, V34, P607; PRINGLE M, 1984, BRIT MED J, V288, P1659, DOI 10.1136/bmj.288.6431.1659; PRINGLE M, 1990, BRIT J GEN PRACT, V40, P455	5	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					236	236		10.1136/bmj.311.6999.236	http://dx.doi.org/10.1136/bmj.311.6999.236			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627043	Green Published			2022-12-28	WOS:A1995RL44100026
J	WALTER, MR; WINDSOR, W; NAGABHUSHAN, TL; LUNDELL, DJ; LUNN, CA; ZAUODNY, PJ; NARULA, SK				WALTER, MR; WINDSOR, W; NAGABHUSHAN, TL; LUNDELL, DJ; LUNN, CA; ZAUODNY, PJ; NARULA, SK			CRYSTAL-STRUCTURE OF A COMPLEX BETWEEN INTERFERON-GAMMA AND ITS SOLUBLE HIGH-AFFINITY RECEPTOR	NATURE			English	Article							EXTRACELLULAR DOMAIN; ACCESSORY FACTOR; C-TERMINUS; HUMAN CD4; PROTEIN; EXPRESSION; RESOLUTION; FRAGMENT; CLONING	The crystal structure of interferon-gamma bound to the extracellular fragment of its high-affinity cell-surface receptor reveals the first view of a class-2 cytokine receptor-ligand complex. In the complex, one interferon-gamma homodimer binds two receptor molecules. Unlike the class-1 growth hormone receptor complex, the two interferon-gamma receptors do not interact with one another and are separated by 27 Angstrom. Upon receptor binding, the flexible As loop of interferon-gamma undergoes a conformational change that includes the formation of a 3(10) helix.	UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, BIRMINGHAM, AL 35294 USA; SCHERING PLOUGH CORP, RES INST, KENILWORTH, NJ 07033 USA	University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering Plough Corporation	WALTER, MR (corresponding author), UNIV ALABAMA, DEPT PHARMACOL, BIRMINGHAM, AL 35294 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GRIGGS ND, 1992, J IMMUNOL, V149, P517; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; JARPE MA, 1993, J INTERFERON RES, V13, P99, DOI 10.1089/jir.1993.13.99; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LUNDELL D, 1994, J BIOL CHEM, V269, P16159; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; LUNN CA, 1992, PROTEIN ENG, V5, P253, DOI 10.1093/protein/5.3.253; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	49	337	353	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					230	235		10.1038/376230a0	http://dx.doi.org/10.1038/376230a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617032				2022-12-28	WOS:A1995RK33100039
J	JOHNSTONE, P				JOHNSTONE, P			WORK IN A DEVELOPING-COUNTRY	BRITISH MEDICAL JOURNAL			English	Article								Some health professionals seek the exciting challenge of working for a time in a developing country. Uncertainties about taking this step, however, may have to be addressed. It is important to understand your reasons for wanting to work overseas-it is ill advised, for example, to go abroad just to escape job dissatisfaction in Britain. Skills needed for international aid work nowadays centre on low tech community based programmes, and enabling, facilitating, and managing skills are more important than clinical skills. Further training may be necessary. Careful planning both for the work abroad and for a return to work in Britain is advisable; full health insurance cover, for example, is important. Although working in a developing country is largely unrecognised as an asset to a professional career in Britain, attitudes are slowly changing. A spell overseas can be very relevant to a career plan and the NHS.			JOHNSTONE, P (corresponding author), INT HLTH EXCHANGE,LONDON WC2E 9NA,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					113	115		10.1136/bmj.311.6997.113	http://dx.doi.org/10.1136/bmj.311.6997.113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ030	7613364	Green Published			2022-12-28	WOS:A1995RJ03000029
J	MURRAY, SA; GRAHAM, LJC				MURRAY, SA; GRAHAM, LJC			PRACTICE-BASED HEALTH NEEDS ASSESSMENT - USE OF 4 METHODS IN A SMALL NEIGHBORHOOD	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective-To explore the use of four methods to define health needs in a community, with a view to formulating guidelines for practice based assessment of health needs. Design-Collection of data on health needs for a specific neighbourhood with four complementary methods: rapid participatory appraisal, postal survey, analysis of routinely available small area statistics, and collation of practice held information. Setting-Council estate of 670 homes in Edinburgh. Main outcome measures-Description and comparison of health needs found by the different methods. Results-Each method yielded particular insights into both health and health care needs. Conclusions-An extended primary care team with public health support can assess health and health care needs in a neighbourhood by means of a mixture of quantitative and qualitative methods. Different methods may be more suitable to assess different health needs or to explore potential service provision in the community or in primary or secondary care. A composite method may be most informative.	LOTHIAN HLTH,DEPT PUBL HLTH,EDINBURGH EH8 9RS,MIDLOTHIAN,SCOTLAND		MURRAY, SA (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							ANNETT H, 1988, GUIDELINES RAPID APP; CHARLTON BG, 1994, BRIT MED J, V308, P1019, DOI 10.1136/bmj.308.6935.1019; GILLAM SJ, 1992, BRIT J GEN PRACT, V42, P404; HANNAY DR, 1993, BRIT MED J, V307, P516, DOI 10.1136/bmj.307.6903.516; Hart, 1988, NEW KIND DOCTOR; HOPTON JL, 1995, BRIT MED J, V310, P1237, DOI 10.1136/bmj.310.6989.1237; KENNEDY A, 1994, PRACTISING HLTH ALL; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; PAYNE JN, 1994, J EPIDEMIOL COMMUN H, V48, P74, DOI 10.1136/jech.48.1.74; Pickles WN, 1939, EPIDEMIOLOGY COUNTRY; RECORD MC, 1994, BRIT MED J, V309, P849, DOI 10.1136/bmj.309.6958.849; SHANKS J, 1995, BRIT MED J, V310, P480, DOI 10.1136/bmj.310.6978.480; SINGER R, 1994, COMMISSIONING CARE D, P13; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; TWINN S, 1992, PROCESS HLTH PROFILI; WILKIN D, 1992, MEASURES NEED OUTCOM; 1992, LOCAL VOICES VIEWS L; 1993, GP PRACTICE POPULATI	18	51	51	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1443	1448		10.1136/bmj.310.6992.1443	http://dx.doi.org/10.1136/bmj.310.6992.1443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613279	Green Published			2022-12-28	WOS:A1995RC10500020
J	TIPLADY, B; CROMPTON, GK; BRACKENRIDGE, D				TIPLADY, B; CROMPTON, GK; BRACKENRIDGE, D			ELECTRONIC DIARIES FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Letter									WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; PA CONSULTING GRP,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	TIPLADY, B (corresponding author), ASTRA PHARMACEUT LTD,CLIN RES UNIT,EDINBURGH EH7 4HG,MIDLOTHIAN,SCOTLAND.							CHOWIENCZYK PJ, 1994, BRIT MED J, V309, P1618, DOI 10.1136/bmj.309.6969.1618; HYLAND ME, 1993, BRIT MED J, V306, P487, DOI 10.1136/bmj.306.6876.487	2	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1469	1469		10.1136/bmj.310.6992.1469	http://dx.doi.org/10.1136/bmj.310.6992.1469			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613295	Green Published			2022-12-28	WOS:A1995RC10500054
J	VONMUHLENDAHL, E; HERKENHOFF, H				VONMUHLENDAHL, E; HERKENHOFF, H			LONG-TERM COURSE OF NEONATAL DIABETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-FUNCTION; BIRTH-WEIGHT; MELLITUS	Background. Neonatal diabetes mellitus defined here as hyperglycemia occurring within the first month of life that lasts for at least two weeks and requires insulin therapy - is a very rare form of the disease. Little is known about it, particularly with respect to its long-term course. Methods. We studied two brothers who had neonatal diabetes and obtained follow-up information on 34 patients described in the literature as well as information on 21 additional patients. Forty-seven of the patients had neonatal diabetes, as defined above, and in 10 others the onset was between the first and third month of life. Results. Twenty-six of the 57 infants had permanent diabetes, 18 had transient diabetes, and 13 had transient diabetes that recurred when they were 7 to 20 years old. Neonatal diabetes was associated with the Wolcott-Rallison syndrome in six infants, hyperuricemia due to phosphoribosyl-ATP pyrophosphatase hyperactivity in two, and celiac disease in two. Forty-one of 45 neonates in whom the duration of gestation and birth weight were known were small for their gestational ages. There were two pairs of affected twins and four other families with two or more infants with neonatal diabetes, but only three parents had diabetes. The incidence of neonatal diabetes mellitus in Germany has been estimated to be 1 in 500,000 neonates. Conclusions. Neonatal diabetes differs from insulin-dependent diabetes in that its course is highly variable. Some patients have permanent diabetes, but others have transient or lasting remissions.			VONMUHLENDAHL, E (corresponding author), KINDERHOSP, IBURGER STR 187, D-49082 OSNABRUCK, GERMANY.							BELMONTE MM, 1985, INFODIABETE, V3, P1; BRIGGS JR, 1986, SCOT MED J, V31, P41, DOI 10.1177/003693308603100113; BRUGSCH H, 1962, Z ARZTL FORTBILD, V51, P439; BURLAND WL, 1964, J PEDIATR-US, V65, P122, DOI 10.1016/S0022-3476(64)80591-6; CAMPBELL IW, 1978, BMJ-BRIT MED J, V2, P174, DOI 10.1136/bmj.2.6131.174; CHRISTEN HJ, 1992, LANCET, V340, P1167, DOI 10.1016/0140-6736(92)93202-X; COFFEY JD, 1967, AM J DIS CHILD, V113, P480, DOI 10.1001/archpedi.1967.02090190126016; COMBLATH M, 1992, DISORDERS CARBOHYDRA, P225; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; DETTMAN C, 1972, J PEDIATR-US, V80, P292, DOI 10.1016/S0022-3476(72)80596-1; DORCHY H, 1992, EUR J PEDIATR, V151, P151, DOI 10.1007/BF01958969; DORCHY H, 1975, Z KINDERHEILKD, V118, P271, DOI 10.1007/BF00492333; FRANCOIS R, 1972, ARCH FR PEDIATR, V29, P941; GEFFNER ME, 1993, LANCET, V341, P1095, DOI 10.1016/0140-6736(93)92454-2; GOUMY P, 1980, ARCH FR PEDIATR, V37, P323; HANSSLER H, 1984, THERAPIEWOCHE, V34, P1487; HASCHKE F, 1978, HELV PAEDIATR ACTA, V33, P385; HATTEVIG G, 1982, J PEDIATR-US, V101, P955, DOI 10.1016/S0022-3476(82)80018-8; HESSE H, 1963, Kinderarztl Prax, V31, P333; HUTCHISON JH, 1962, BRIT MED J, P436, DOI 10.1136/bmj.2.5302.436; KNIP M, 1983, ACTA PAEDIATR SCAND, V72, P303, DOI 10.1111/j.1651-2227.1983.tb09718.x; KUNA P, 1979, AM J DIS CHILD, V133, P65, DOI 10.1001/archpedi.1979.02130010071012; LAWRENCE RD, 1962, BRIT MED J, P671; MATTERN H, 1964, Arch Kinderheilkd, V170, P243; NIELSEN F, 1989, ACTA PAEDIATR SCAND, V78, P469, DOI 10.1111/j.1651-2227.1989.tb11114.x; Nivelon J L, 1970, Pediatrie, V25, P887; SCHIFF D, 1972, NEW ENGL J MED, V287, P119, DOI 10.1056/NEJM197207202870304; SEQUEL A, 1982, AM J DIS CHILD, V136, P626, DOI 10.1001/archpedi.1982.03970430058015; SHIELD JPH, 1993, LANCET, V341, P693, DOI 10.1016/0140-6736(93)90461-O; SODOYEZGOFFAUX F, 1977, J PEDIATR-US, V91, P395, DOI 10.1016/S0022-3476(77)81306-1; STEIGENBERGER H, 1986, MONATSSCHR KINDERH, V134, P207; STOSS H, 1982, EUR J PEDIATR, V138, P120, DOI 10.1007/BF00441137; WEIMERSKIRCH D, 1993, J PEDIATR-US, V122, P598, DOI 10.1016/S0022-3476(05)83544-9; WELLER U, 1993, MONATSSCHR KINDERH, V141, P665; WIDNESS JA, 1982, J PEDIATR-US, V100, P926, DOI 10.1016/S0022-3476(82)80517-9; WYLIE MES, 1953, ARCH DIS CHILD, V28, P297, DOI 10.1136/adc.28.140.297	36	154	156	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					704	708		10.1056/NEJM199509143331105	http://dx.doi.org/10.1056/NEJM199509143331105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637748	Bronze			2022-12-28	WOS:A1995RV22700005
J	ALBERTSEN, PC; FRYBACK, DG; STORER, BE; KOLON, TF; FINE, J				ALBERTSEN, PC; FRYBACK, DG; STORER, BE; KOLON, TF; FINE, J			LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION-ANALYSIS; CO-MORBIDITY; COMORBIDITY; OUTCOMES; DISEASE	Objective.-To determine age-specific, all-cause mortality, disease-specific mortality, and life expectancy for men aged 65 to 75 years who are treated only with immediate or delayed hormonal therapy for newly diagnosed, clinically localized prostate cancer. Design.-A population-based, retrospective cohort study. Setting.-Patient records were abstracted from 37 acute care hospitals and two Veterans Affairs medical centers in Connecticut. Original pathology slides were sent to a referee pathologist who was blinded to case outcomes. Subjects.-All men identified by the Connecticut Tumor Registry with clinically localized prostate cancer diagnosed in 1971 to 1976 who were aged 65 to 75 years at the time of diagnosis and were untreated or treated with immediate or delayed hormonal therapy. Main Outcome Measures.-Parametric proportional hazards models incorporating tumor histologic findings, comorbidity, and age at the time of diagnosis to compare cohort survival with that of men in the general population. Results.-After a mean follow-up of 15.5 years, the age-adjusted survival for men with Gleason score 2 to 4 tumors was not significantly different from that of the general population. Maximum estimated lost life expectancy for men with Gleason score 5 to 7 tumors was 4 to 5 years and for men with Gleason score 8 to 10 tumors was 6 to 8 years. Tumor histologic findings and patient comorbidities were powerful independent predictors of survival. Conclusions.-Compared with the general population, men aged 65 to 75 years with conservatively treated low-grade prostate cancer incur no loss of life expectancy. Men with higher-grade tumors (Gleason scores 5 to 10) experience a progressively increasing loss of life expectancy. Case series reports of survival/ mortality experienced by men with clinically localized prostate cancer that fail to control for age, tumor histologic features, and comorbidities risk significant bias.	UNIV WISCONSIN,DEPT PREVENT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOSTAT,MADISON,WI 53706; YALE UNIV,CTR CANC,NEW HAVEN,CT	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Yale University	ALBERTSEN, PC (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT SURG,DIV UROL,263 FARMINGTON AVE,FARMINGTON,CT 06030, USA.			Kolon, Thomas/0000-0002-8740-5021	AHRQ HHS [HS06770] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CATALONA WJ, 1989, J UROLOGY, V142, P1302, DOI 10.1016/S0022-5347(17)39066-3; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; COWEN ME, 1994, J CLIN EPIDEMIOL, V47, P3, DOI 10.1016/0895-4356(94)90029-9; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; Fleming C, 1993, JAMA, V269, P2650; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KAPLAN MH, 1974, J CHRON DIS, V27, P387, DOI 10.1016/0021-9681(74)90017-4; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; MOLD JW, 1992, J FAM PRACTICE, V34, P561; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487	21	369	374	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					626	631		10.1001/jama.274.8.626	http://dx.doi.org/10.1001/jama.274.8.626			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637143				2022-12-28	WOS:A1995RP70200030
J	HAYWARD, RSA; WILSON, MC; TUNIS, SR; BASS, EB; GUYATT, G				HAYWARD, RSA; WILSON, MC; TUNIS, SR; BASS, EB; GUYATT, G			USERS GUIDES TO THE MEDICAL LITERATURE .8. HOW TO USE CLINICAL-PRACTICE GUIDELINES .A. ARE THE RECOMMENDATIONS VALID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MCMASTER UNIV, HLTH SCI CTR, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA; JOHNS HOPKINS UNIV, SCH MED, DIV INTERNAL MED, BALTIMORE, MD USA; US CONGRESS, OFF TECHNOL ASSESSMENT, HLTH PROGRAM, WASHINGTON, DC 20510 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, WINSTON SALEM, NC 27103 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; Johns Hopkins University; Wake Forest University; Wake Forest Baptist Medical Center								[Anonymous], 1990, CLIN PRACTICE GUIDEL; [Anonymous], 1992, MANUAL ASSESSING HLT; BASINSKI ASH, 1992, CAN MED ASSOC J, V146, P833; Braunwald E, 1994, UNSTABLE ANGINA DIAG; DIAMOND GA, 1993, ANN INTERN MED, V118, P455, DOI 10.7326/0003-4819-118-6-199303150-00010; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; Gottlieb L K, 1990, QRB Qual Rev Bull, V16, P80; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Hayward R S, 1993, Ann Intern Med, V118, P731; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HAYWARD RSA, 1993, CAN MED ASSOC J, V148, P507; Kanouse DE, 1989, CHANGING MED PRACTIC; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MATCHAR DB, 1994, ANN INTERN MED, V121, P54; MERRICK JN, 1986, INDICATIONS SELECTED, P41; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Moy J G, 1993, J Am Board Fam Pract, V6, P153; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Sackman H, 1975, DELPHI CRITIQUE EXPE; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Wallace W A, 1993, J R Coll Surg Edinb, V38, P58; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; 1986, INT J GYNECOL OBSTET, V41, P291; 1990, ATTRIBUTES GUIDE DEV; 1992, GUIDELINES CLIN PRAC; 1989, STANDARDS OBSTETRICS, P97; 1993, CATARACT ADULTS MANA; 1986, CLIN EFFICACY ASSESS	30	343	354	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					570	574		10.1001/jama.274.7.570	http://dx.doi.org/10.1001/jama.274.7.570			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629987				2022-12-28	WOS:A1995RN46600029
J	BOYCE, TG; SWERDLOW, DL; GRIFFIN, PM				BOYCE, TG; SWERDLOW, DL; GRIFFIN, PM			CURRENT CONCEPTS - ESCHERICHIA-COLI O157-H7 AND THE HEMOLYTIC-UREMIC SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMORRHAGIC COLITIS; RISK-FACTORS; 0157-H7 INFECTIONS; CANADIAN CHILDREN; WASHINGTON-STATE; NURSING-HOME; OUTBREAK; EPIDEMIOLOGY; DIARRHEA		CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	BOYCE, TG (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA.							ASHKENAZI S, 1993, ANNU REV MED, V44, P11, DOI 10.1146/annurev.med.44.1.11; BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BELLBP, 1994, JAMA-J AM MED ASSOC, V272, P1349; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BITZAN M, 1993, EPIDEMIOL INFECT, V110, P183, DOI 10.1017/S0950268800068102; BITZAN M, 1991, J PEDIATR-US, V119, P380, DOI 10.1016/S0022-3476(05)82049-9; BOKETE TN, 1993, GASTROENTEROLOGY, V105, P1724, DOI 10.1016/0016-5085(93)91069-T; BRANDT JR, 1994, J PEDIATR-US, V125, P519, DOI 10.1016/S0022-3476(94)70002-8; BRYANT HE, 1989, J INFECT DIS, V160, P858, DOI 10.1093/infdis/160.5.858; BUJAK J, 1993, 93RD GEN M AM SOC MI, P524; CAHOON FE, 1987, CAN J MICROBIOL, V33, P914, DOI 10.1139/m87-158; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; Centers for Disease Control and Prevention. (CDC), 1995, MMWR-MORBID MORTAL W, V44, P157; CIESLAK PR, 1993, LANCET, V342, P367, DOI 10.1016/0140-6736(93)91509-K; CIMOLAI N, 1992, PEDIATRICS, V90, P616; CIMOLAI N, 1990, J PEDIATR-US, V116, P589, DOI 10.1016/S0022-3476(05)81609-9; GRANSDEN WR, 1986, J INFECT DIS, V154, P522, DOI 10.1093/infdis/154.3.522; Griffin Patricia M., 1995, P739; GRIFFIN PM, 1990, GASTROENTEROLOGY, V99, P142, DOI 10.1016/0016-5085(90)91241-W; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; KARCH H, 1986, FEMS MICROBIOL LETT, V35, P141, DOI 10.1016/0378-1097(86)90080-7; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KEENE WE, 1994, NEW ENGL J MED, V331, P579, DOI 10.1056/NEJM199409013310904; LOPEZ EL, 1992, J PEDIATR-US, V120, P210, DOI 10.1016/S0022-3476(05)80429-9; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MARCH SB, 1989, J CLIN MICROBIOL, V27, P1675, DOI 10.1128/JCM.27.7.1675-1677.1989; MARSHALL WF, 1990, MAYO CLIN PROC, V65, P787, DOI 10.1016/S0025-6196(12)62567-1; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; NEILL MA, 1987, PEDIATRICS, V80, P37; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; PAI CH, 1984, ANN INTERN MED, V101, P738, DOI 10.7326/0003-4819-101-6-738; PAI CH, 1988, J INFECT DIS, V157, P1054, DOI 10.1093/infdis/157.5.1054; PARK CH, 1994, AM J CLIN PATHOL, V101, P91, DOI 10.1093/ajcp/101.1.91; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; PICKERING LK, 1994, PEDIATR INFECT DIS J, V13, P459, DOI 10.1097/00006454-199406000-00001; PROULX F, 1992, J PEDIATR-US, V121, P299, DOI 10.1016/S0022-3476(05)81209-0; RATNAM S, 1986, CAN MED ASSOC J, V134, P43; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Robson W L, 1993, Curr Probl Pediatr, V23, P16, DOI 10.1016/0045-9380(93)90027-A; ROBSON WLM, 1989, CHILD NEPHROL UROL, V9, P203; ROBSON WLM, 1993, PEDIATR INFECT DIS J, V12, P699; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; ROWE PC, 1993, EPIDEMIOL INFECT, V110, P1, DOI 10.1017/S0950268800050615; RUGGENENTI P, 1990, HEMATOL ONCOL CLIN N, V4, P219, DOI 10.1016/S0889-8588(18)30514-8; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SALMON RL, 1989, EPIDEMIOL INFECT, V103, P249, DOI 10.1017/S0950268800030600; SIEGLER RL, 1994, PEDIATRICS, V94, P35; SIEGLER RL, 1994, J PEDIATR-US, V125, P511, DOI 10.1016/S0022-3476(94)70001-X; SIEGLER RL, 1988, J PEDIATR-US, V112, P1014, DOI 10.1016/S0022-3476(88)80239-7; SIEGLER RL, 1993, PEDIATRICS, V91, P666; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; STROCKBINE NA, 1986, INFECT IMMUN, V53, P135, DOI 10.1128/IAI.53.1.135-140.1986; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TARR PI, 1989, AM J EPIDEMIOL, V129, P582, DOI 10.1093/oxfordjournals.aje.a115170; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; 1994, MMWR-MORBID MORTAL W, V43, P192; 1994, NEW ENGL J MED, V330, P1811	60	441	450	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					364	368		10.1056/NEJM199508103330608	http://dx.doi.org/10.1056/NEJM199508103330608			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609755				2022-12-28	WOS:A1995RN08200008
J	GLICKMAN, R; DALEY, J				GLICKMAN, R; DALEY, J			A 35-YEAR-OLD MAN WITH EPIGASTRIC PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER DISEASE; DUODENAL-ULCER; RECURRENCE; RISK		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School								ADAMI HO, 1987, SCAND J GASTROENTERO, V22, P889, DOI 10.3109/00365528708991931; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; CHIBA N, 1992, AM J GASTROENTEROL, V12, P1716; DELUCA VA, 1981, J CLIN GASTROENTEROL, V3, P17; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; ELTA GH, 1994, GASTROENTEROLOGY, V105, P1563; FELDMAN M, 1994, JAMA-J AM MED ASSOC, V272, P70; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; FRY J, 1964, BMJ-BRIT MED J, V2, P809, DOI 10.1136/bmj.2.5412.809; GRAHAM DY, 1993, NEW ENGL J MED, V328, P349, DOI 10.1056/NEJM199302043280512; GRAHAM DY, 1993, GASTROENTEROLOGY, V105, P279, DOI 10.1016/0016-5085(93)90038-E; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GREIBE J, 1992, BRIT MED J, V2, P1572; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; ISENBERG JI, 1991, TXB GASTROENTEROLO 1, V61, P1241; LOFFELD RJLF, 1993, DIGEST DIS, V11, P173, DOI 10.1159/000171409; MOHAMED AH, 1994, GASTROENTEROLOGY, V106, pA142; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PETERSEN H, 1988, SCAND J GASTROENTERO, V23, P30, DOI 10.3109/00365528809096278; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; RAWS EAJ, 1988, GASTROENTEROLOGY, V94, P33; STEMMERMANN GN, 1989, GASTROENTEROLOGY, V96, P1419, DOI 10.1016/0016-5085(89)90507-6; SUNG JJY, 1995, NEW ENGL J MED, V332, P139, DOI 10.1056/NEJM199501193320302; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; 1994, JAMA-J AM MED ASSOC, V272, P65	27	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					495	500		10.1001/jama.274.6.495	http://dx.doi.org/10.1001/jama.274.6.495			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629961				2022-12-28	WOS:A1995RM69900032
J	LEMPP, H				LEMPP, H			HAS NURSING LOST ITS WAY - NURSING - NO REGRETS	BRITISH MEDICAL JOURNAL			English	Article											LEMPP, H (corresponding author), MERTON SUTTON & WANDSWORTH HLTH COMMISS,LONDON SW15 2SW,ENGLAND.		Lempp, Heidi/E-4959-2010; Lempp, Heidi/T-2914-2017	Lempp, Heidi/0000-0003-2509-3656				Black D., 1980, INEQUALITIES HLTH; Castledine G, 1995, Br J Nurs, V4, P45; FAWCETT HA, 1995, NURS TIMES, V91, P40; Fox P, 1995, Nurs Stand, V9, P30; ILLICH J, 1976, LIMITS MED MED NEMES; LEDDY S, 1993, CONCEPTUAL BASES PRO; LEININGER MC, 1984, CARE ESSENCES NURSIN; LEMPP H, 1987, SENIOR NURSE, V7, P24; LEMPP H, 1990, NURSING TIEMS S, V86, P11; MARSH GN, 1995, BRIT MED J, V310, P778, DOI 10.1136/bmj.310.6982.778; MCKEOWN T, 1976, ROLE MED; 1992, SCOPE PROFESSIONAL P; [No title captured]; 1992, LONDON HLTH CARE 201; 1992, REPORT ENQUIRY LONDO	15	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					307	308		10.1136/bmj.311.7000.307	http://dx.doi.org/10.1136/bmj.311.7000.307			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633245	Green Published			2022-12-28	WOS:A1995RM71900033
J	NEUMANN, H; CAVALIE, A; JENNE, DE; WEKERLE, H				NEUMANN, H; CAVALIE, A; JENNE, DE; WEKERLE, H			INDUCTION OF MHC CLASS-I GENES IN NEURONS	SCIENCE			English	Article							EXPRESSION; ANTIGENS; CELLS	Whether neurons express major histocompatibility complex (MHC) class I genes has not been firmly established. The techniques of confocal laser microscopy, patch clamp electrophysiology, and reverse transcriptase-polymerase chain reaction were combined here to directly examine the inducibility of MHC class I genes in individual cultured rat hippocampal neurons. Transcription of MHC class I genes was very rare in neurons with spontaneous action potentials. In electrically silent neurons, transcription was noted, with expression of beta(2)-microglobulin under tighter control than in class I heavy chain molecules. Surface expression of class I molecules occurred only in electrically silent neurons treated with interferon gamma. Immunosurveillance by cytotoxic T cells may be focused on functionally impaired neurons.	MAX PLANCK INST PSYCHIAT,DEPT NEUROIMMUNOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Neumann, Harald/A-9718-2010; Jenne, Dieter Erich/AAP-1414-2020	Neumann, Harald/0000-0002-5071-5202; 				BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; HAMILL OP, 1991, PFLUEGERS ARCH, V391, P85; JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MASSA PT, 1993, GLIA, V8, P201, DOI 10.1002/glia.440080307; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	10	354	360	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					549	552		10.1126/science.7624779	http://dx.doi.org/10.1126/science.7624779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624779				2022-12-28	WOS:A1995RL49500031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW INFORMATION ADDED TO THEOPHYLLINE LABELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					292	292						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609246				2022-12-28	WOS:A1995RJ89800009
J	MORRELL, J; ROBERTS, A				MORRELL, J; ROBERTS, A			HOW TO DO IT - MAKE AN APPLICATION FOR FLEXIBLE (PART-TIME) TRAINING	BRITISH MEDICAL JOURNAL			English	Article							WOMEN DOCTORS	Part time training posts are advertised in the BMJ each year in August or September in an advertisement placed by the Department of Health. Although the advertisement is placed by the department and manpower approvals are allocated centrally, each region runs its own scheme, and the first person to approach is the regional postgraduate dean (most regions have an assistant dean responsible for flexible training). If an application is successful then part time trainees are interviewed by the same appointments committee as full time applicants and they are judged by the same criteria, Manpower approval is granted to applicants who reach the same standard as full time applicants, but there may be a waiting list if there are more suitable applicants than training places available. The next stage is to gain educational approval from the relevant higher training committee for the proposed training programme, followed by funding from the region.	TAVISTOCK CLIN,DEPT CHILD & FAMILY,LONDON NW2,ENGLAND		MORRELL, J (corresponding author), CHILD & FAMILY CONSULTAT UNIT,LONDON W6 7DQ,ENGLAND.							BOLTONMAGGS PH, 1988, BRIT J HOSP MED, V39, P413; GATH A, 1988, B ROYAL COLLEGE PSYC, V12, P368; MORRELL JE, 1992, BRIT MED J, V305, P1411, DOI 10.1136/bmj.305.6866.1411; PROCTOR S, 1987, MED EDUC, V21, P260, DOI 10.1111/j.1365-2923.1987.tb00700.x; WARREN VJ, 1989, J ROY SOC MED, V82, P528, DOI 10.1177/014107688908200907; 1993, HOSPITAL DOCTORS TRA	6	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					242	244		10.1136/bmj.311.6999.242	http://dx.doi.org/10.1136/bmj.311.6999.242			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627045	Green Published			2022-12-28	WOS:A1995RL44100028
J	COHN, M; BLACKBURN, EH				COHN, M; BLACKBURN, EH			TELOMERASE IN YEAST	SCIENCE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; PRIMER SPECIFICITY; DNA-SEQUENCES; TETRAHYMENA; IDENTIFICATION; SENESCENCE; RNA; RIBONUCLEOPROTEIN; CHROMOSOMES; ELONGATION	The ribonucleoprotein enzyme telomerase synthesizes telomeric DNA by copying an internal RNA template sequence. The telomerase activities of the yeasts Saccharomyces castellii and Saccharomyces cerevisiae-with regular and irregular telomeric sequences, respectively-have now been identified and characterized. The S. cerevisiae activity required the telomerase RNA gene TLC1 but not the EST1 gene, both of which are required for normal telomere maintenance in vivo. This activity exhibited low processivity and produced no regularly repeated products. An inherently high stalling frequency of the S. cerevisiae telomerase may account for its in vitro properties and for the irregular telomeric sequences of this yeast.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Cohn, Marita/0000-0002-3370-2864	NIGMS NIH HHS [GM26259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; COHN M, UNPUB; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; GILLEY D, IN PRESS GENES DEV; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1990, CELL, V60, P529; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MCEACHERN MJ, IN PRESS NATURE; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	30	251	261	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					396	400		10.1126/science.7618104	http://dx.doi.org/10.1126/science.7618104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618104				2022-12-28	WOS:A1995RK42700047
J	GRAHAM, T				GRAHAM, T			THE BROWN-AND-WILLIAMSON DOCUMENTS - THE COMPANY RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GRAHAM, T (corresponding author), TRIVALLEY HERALD,4770 WILLOW RD,PLEASANTON,CA 94588, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					254	255						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609235				2022-12-28	WOS:A1995RH93700032
J	MARSDEN, AK; NG, GA; DALZIEL, K; COBBE, SM				MARSDEN, AK; NG, GA; DALZIEL, K; COBBE, SM			WHEN IS IT FUTILE FOR AMBULANCE PERSONNEL TO INITIATE CARDIOPULMONARY-RESUSCITATION	BRITISH MEDICAL JOURNAL			English	Article							HEARTSTART-SCOTLAND PROJECT; HOSPITAL DEFIBRILLATION; DECISION-MAKING; CARDIAC-ARREST; TECHNICIANS	Objective-To determine whether patients with unexpected prehospital cardiac arrest could be identified in whom ambulance resuscitation attempts would be futile. Design-Review of ambulance and hospital records; detailed review of automated external defibrillator rhythm strips of patients in whom no shock was advised. Setting-Scottish Ambulance Service; all cardiopulmonary resuscitation attempts after cardiorespiratory arrest during 1988-94 included in the Heartstart Scotland database. Subjects-414 cardiorespiratory arrest patients with no pulse or breathing on arrival of ambulance personnel, no bystander cardiopulmonary resuscitation performed, and more than 15 minutes from time of arrest to arrival of ambulance. Patients were stratified into those with ''shockable'' and ''nonshockable'' rhythms. Main outcome measures-Return of spontaneous circulation, or survival to reach hospital alive, or survival to discharge, or all three. Results-No patient with a non-shockable rhythm who met the entry criteria for analysis survived a resuscitation attempt. Review of the defibrillator rhythm strips of these patients failed to find any case in which the tracing was deemed compatible with survival. Conclusions-On the basis that it would be inappropriate to initiate vigorous resuscitation in patients who can be identified as ''dead'' and beyond help an algorithm was prepared to guide ambulance personnel.	ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G4 0SF,LANARK,SCOTLAND	Royal Infirmary of Edinburgh	MARSDEN, AK (corresponding author), SCOTTISH AMBULANCE SERV,NATL HEADQUARTERS,EDINBURGH EH10 5UU,MIDLOTHIAN,SCOTLAND.			Ng, G. Andre/0000-0001-5965-0671				APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; JOHNSON DR, 1993, AM J EMERG MED, V11, P139, DOI 10.1016/0735-6757(93)90107-M; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; 1993, JAMA-J AM MED ASSOC, V270, P1471; 1992, JAMA-J AM MED ASSOC, V268, P2171	10	35	35	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					49	51		10.1136/bmj.311.6996.49	http://dx.doi.org/10.1136/bmj.311.6996.49			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613330	Green Published			2022-12-28	WOS:A1995RG97500032
J	BRENNAN, JA; MAO, L; HRUBAN, RH; BOYLE, JO; EBY, YJ; KOCH, WM; GOODMAN, SN; SIDRANSKY, D				BRENNAN, JA; MAO, L; HRUBAN, RH; BOYLE, JO; EBY, YJ; KOCH, WM; GOODMAN, SN; SIDRANSKY, D			MOLECULAR ASSESSMENT OF HISTOPATHOLOGICAL STAGING IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPH-NODE INVOLVEMENT; PROGNOSTIC FACTORS; ORAL CAVITY; POSITIVE MARGINS; GENE-MUTATIONS; P53 MUTATIONS; CANCER; OROPHARYNX; DISSECTION; TUMORS	Background. Surgical oncologists rely heavily on the histopathological assessment of surgical margins to ensure total excision of the tumor in patients with head and neck cancer. However, current techniques may not detect small numbers of cancer cells at the margins of resection or in cervical lymph nodes. Methods. We used molecular techniques to determine whether clonal populations of infiltrating tumor cells harboring mutations of the p53 gene could be detected in histopathologically negative surgical margins and cervical lymph nodes of patients with squamous-cell carcinoma of the head and neck. Results. We identified 25 patients with primary squamous-cell carcinoma of the head and neck containing a p53 mutation who appeared to have had complete tumor resection on the basis of a negative histopathological assessment. In 13 of these 25 patients, molecular analysis was positive for a p53 mutation in at least one tumor margin. In 5 of 13 patients with positive margins by this method (38 percent), the carcinoma has recurred locally, as compared with none of 12 patients with negative margins (P=0.02 by the log-rank test). Furthermore, molecular analysis identified neoplastic cells in 6 of 28 lymph nodes (21 percent) that were initially negative by histopathological assessment. Conclusions. Among specimens initially believed to be negative on light microscopy, a substantial percentage of the surgical margins and lymph nodes from patients with squamous-cell carcinoma of the head and neck contained p53 mutations specific for the primary tumor. Patients with these positive margins appear to have a substantially increased risk of local recurrence. Molecular analysis of surgical margins and lymph nodes can augment standard histopathological assessment and may improve the prediction of local tumor recurrence.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,DIV BIOSTAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358; Goodman, Steven/0000-0002-3872-5723	NCI NIH HHS [CA-58184-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARANY F, 1991, PCR METH APPL, V1, P5; Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN CT, 1991, LARYNGOSCOPE, V101, P1175; BUCHMAN GW, 1992, FOCUS, V14, P41; BYERS RM, 1978, AM J SURG, V136, P525, DOI 10.1016/0002-9610(78)90275-1; CHEN TY, 1987, INT J RADIAT ONCOL, V13, P833, DOI 10.1016/0360-3016(87)90095-2; CLOSE LG, 1989, ARCH OTOLARYNGOL, V115, P1304; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; DAVIDSON TM, 1984, ARCH OTOLARYNGOL, V110, P193; DAVIDSON TM, 1988, LARYNGOSCOPE, V98, P1078; EIBAND JD, 1989, AM J SURG, V158, P314, DOI 10.1016/0002-9610(89)90123-2; FARRAR WB, 1988, AM J SURG, V156, P173, DOI 10.1016/S0002-9610(88)80058-8; FEINMESSER R, 1992, HEAD NECK-J SCI SPEC, V14, P173, DOI 10.1002/hed.2880140302; FIELDING LP, 1992, CANCER, V70, P2367, DOI 10.1002/1097-0142(19921101)70:9<2367::AID-CNCR2820700927>3.0.CO;2-B; GANDOUREDWARDS RF, 1993, HEAD NECK-J SCI SPEC, V15, P373, DOI 10.1002/hed.2880150502; GHOURI AF, 1993, OTOLARYNG HEAD NECK, V108, P225, DOI 10.1177/019459989310800304; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; JONES KR, 1992, ARCH OTOLARYNGOL, V118, P483; KALNINS IK, 1977, AM J SURG, V134, P450, DOI 10.1016/0002-9610(77)90376-2; KOWALSKI LP, 1993, ARCH OTOLARYNGOL, V119, P958; Lee JG, 1974, T AM ACAD OPHTHALMOL, V78, pORL49; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; LOOSER KG, 1978, HEAD NECK SURG, V1, P107, DOI 10.1002/hed.2890010203; MAESTRO R, 1992, ONCOGENE, V7, P1159; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MAO L, 1994, CANCER RES, V54, P1634; NAWROZ H, 1994, CANCER RES, V54, P1152; NEES M, 1993, CANCER RES, V53, P4189; OBRIEN CJ, 1987, CANCER, V59, P994, DOI 10.1002/1097-0142(19870301)59:5<994::AID-CNCR2820590524>3.0.CO;2-E; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PRADIER R, 1993, CANCER, V71, P2472, DOI 10.1002/1097-0142(19930415)71:8<2472::AID-CNCR2820710808>3.0.CO;2-Y; SCHOLL P, 1986, AM J SURG, V152, P354, DOI 10.1016/0002-9610(86)90304-1; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SNOW GB, 1982, CLIN OTOLARYNGOL, V7, P185, DOI 10.1111/j.1365-2273.1982.tb01581.x; Snow GB, 1989, CANC HEAD NECK, P17; SNYDERMAN CH, 1992, AM J OTOLARYNG, V13, P373, DOI 10.1016/0196-0709(92)90079-9; SOO KC, 1988, AM J SURG, V156, P281, DOI 10.1016/S0002-9610(88)80292-7; SUAREZ C, 1993, OTOLARYNG HEAD NECK, V109, P3, DOI 10.1177/019459989310900102; TADA M, 1993, CANCER RES, V53, P2472; TOBI M, 1994, J NATL CANCER I, V86, P1007; YOO GH, 1994, CANCER RES, V54, P4603; ZATTERSTROM UK, 1991, HEAD NECK-J SCI SPEC, V13, P477, DOI 10.1002/hed.2880130603; ZIESKE LA, 1986, ARCH OTOLARYNGOL, V112, P863	47	596	623	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					429	435		10.1056/NEJM199502163320704	http://dx.doi.org/10.1056/NEJM199502163320704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7619114				2022-12-28	WOS:A1995QF77000004
J	PATHMANATHAN, R; PRASAD, U; SADLER, R; FLYNN, K; RAABTRAUB, N				PATHMANATHAN, R; PRASAD, U; SADLER, R; FLYNN, K; RAABTRAUB, N			CLONAL PROLIFERATIONS OF CELLS INFECTED WITH EPSTEIN-BARR-VIRUS IN PREINVASIVE LESIONS RELATED TO NASOPHARYNGEAL CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EBV GENE-EXPRESSION; LYMPHOPROLIFERATIVE DISEASE; EPITHELIAL-CELLS; TRANSCRIPTION; INSITU; DNA; RNA; TRANSFORMATION; SPECIMENS; BIOPSIES	Background. The Epstein-Barr virus (EBV) is consistently detected in patients with nasopharyngeal carcinoma. To determine whether EBV infection is an early, initiating event in the development of this malignant tumor, we screened nasopharyngeal-biopsy samples, most of which were archival, for preinvasive lesions, including dysplasia and carcinoma in situ, Preinvasive lesions were found in 11 samples, which were tested for the presence of EBV. Methods. EBV infection was detected with in situ hybridization for EBV-encoded RNAs (EBERs) and by immunohistochemical staining for latent membrane protein 1 (LMP-1). The larger samples were also tested for the EBV genome with the use of Southern blotting. The expression of specific EBV RNAs was determined by the amplification of complementary DNA with the polymerase chain reaction. Results. Evidence of EBV infection was detected in all 11 tissue samples with dysplasia or carcinoma in situ, EBERs were identified in all eight samples tested, and LMP-1 was detected in all six of the tested samples. Six of the seven samples tested for the EBV termini contained clonal EBV DNA. Transcription of the latent EBV gene products, EBV nuclear antigen 1, LMP-1, LMP-2A, and the BamHI-A fragment, was detected in most of the samples. Viral proteins characteristic of lytic lesions were not detected. Conclusions. Preinvasive lesions of the nasopharynx are infected with EBV. The EBV DNA is clonal, indicating that the lesions represent a focal cellular growth that arose from a single EBV-infected cell and that EBV infection is an early, possibly initiating event in the development of nasopharyngeal carcinoma. Preinvasive lesions contain EBV RNAs that are characteristic of latent infection but not the viral proteins that are characteristic of lytic infection. The detection of the EBV-transforming gene, LMP-1, in all the neoplastic cells suggests that its expression is essential for preinvasive epithelial proliferations associated with nasopharyngeal carcinoma.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL,CHAPEL HILL,NC 27599; UNIV MALAYA,DEPT PATHOL,KUALA LUMPUR,MALAYSIA; UNIV MALAYA,DEPT OTORHINOLARYNGOL,KUALA LUMPUR,MALAYSIA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Universiti Malaya; Universiti Malaya			Rajadurai, Pathmanathan A/ L A/W-1817-2019		NCI NIH HHS [CA32979] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032979] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MC, 1987, HAINES TAYLOR OBSTET, P225; ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; CRISSMAN JD, 1989, AM J SURG PATHOL, V13, P5; de-The G., 1982, HERPESVIRUSES, P25; DESGRANGES C, 1975, INT J CANCER, V16, P7, DOI 10.1002/ijc.2910160103; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GILLIGAN KJ, 1991, J VIROL, V65, P6252, DOI 10.1128/JVI.65.11.6252-6259.1991; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; LEE ES, 1995, NEW ENGL J MED, V332, P19, DOI 10.1056/NEJM199501053320104; LI ZQ, 1983, NASOPHARYNGEAL CARCI, P17; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RANDHAWA PS, 1992, NEW ENGL J MED, V327, P1710, DOI 10.1056/NEJM199212103272403; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SAM CK, 1993, INT J CANCER, V53, P957; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SUN Y, 1993, ONCOGENE, V8, P791; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WU TC, 1991, AM J PATHOL, V138, P1461; YEUNG WM, 1993, INT J CANCER, V53, P746, DOI 10.1002/ijc.2910530507; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	36	458	480	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					693	698		10.1056/NEJM199509143331103	http://dx.doi.org/10.1056/NEJM199509143331103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637746				2022-12-28	WOS:A1995RV22700003
J	ANDREASEN, NC				ANDREASEN, NC			SYMPTOMS, SIGNS, AND DIAGNOSIS OF SCHIZOPHRENIA	LANCET			English	Article							NEGATIVE SYMPTOMS; LOBE				ANDREASEN, NC (corresponding author), UNIV IOWA HOSP & CLIN, MHCRC, 2911 JPP, 200 HAWKINS DR, IOWA CITY, IA 52242 USA.				NIMH NIH HHS [MH40856, MH31593, MHCRC 43271] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH031593, R01MH040856, P30MH043271, P50MH043271, R01MH031593] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASEN NC, 1995, PSYCHOPATHOLOGY, V28, P7, DOI 10.1159/000284894; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; ANDREASEN NC, 1995, ARCH GEN PSYCHIAT, V52, P341; ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P615; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ANDREASEN NC, 1994, ACTA PSYCHIAT SCAND, V90, P51, DOI 10.1111/j.1600-0447.1994.tb05891.x; ANDREASEN NC, 1986, CAN SCHIZOPHRENIA LO; ANDREASEN NC, 1990, MODERN PROBLEMS PHAR, P1; ARNDT S, 1991, ARCH GEN PSYCHIAT, V52, P340; BARTA PE, 1990, SCHIZOPHR RES, V3, P22; BILDER RM, 1985, SCHIZOPHRENIA BULL, V11, P409, DOI 10.1093/schbul/11.3.409; BLACK DW, 1986, SCHIZO RES, V7, P109; Bleuler E., 1950, DEMENTIA PRAECOX; BRAFF DL, 1993, SCHIZOPHRENIA BULL, V19, P233, DOI 10.1093/schbul/19.2.233; CARLSSON M, 1990, SCHIZOPHRENIA BULL, V16, P425, DOI 10.1093/schbul/16.3.425; CARPENTER WT, 1985, SCHIZOPHRENIA BULL, V11, P440, DOI 10.1093/schbul/11.3.440; CROW TJ, 1980, BRIT J PSYCHIAT, V137, P383, DOI 10.1192/S0007125000071919; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; FLAUM M, 1995, AM J PSYCHIAT, V152, P704; FLAUM M, 1990, SCHIZOPHR B, V17, P27; FLAUM M, IN PRESS J PSYCHIATR; GOLDMAN HH, 1987, PSYCHIAT ANN, V17, P580, DOI 10.3928/0048-5713-19870901-06; GREDEN JF, 1990, NEGATIVE SCHIZOPHREN; Jackson J. H., 1931, SELECTED WRITINGS JH; KENDELL RE, 1971, ARCH GEN PSYCHIAT, V25, P123, DOI 10.1001/archpsyc.1971.01750140027006; Kraepelin E., 1919, CUTTING SHEPHERD; KREITMAN N, 1961, J MENT SCI, V107, P887, DOI 10.1192/bjp.107.450.887; LIDDLE PF, 1987, BRIT J PSYCHIAT, V151, P145, DOI 10.1192/bjp.151.2.145; LIDDLE PF, 1990, BRIT J PSYCHIAT, V157, P558, DOI 10.1192/bjp.157.4.558; LIDDLE PF, 1991, BRIT J PSYCHIAT, V158, P340, DOI 10.1192/bjp.158.3.340; Marneros A., 1991, NEGATIVE VERSUS POSI; MELTZER HY, 1986, J CLIN PSYCHOPHARM, V6, P329; MESULAM MM, 1978, J PSYCHIATR RES, V14, P249, DOI 10.1016/0022-3956(78)90027-4; PAKKENBERG B, 1993, NEUROPATH APPL NEURO, V19, P373, DOI 10.1111/j.1365-2990.1993.tb00457.x; PEARLSON GD, 1993, PSYCHIATRY APAARO, V12, P347; SATORIUS N, 1986, PSYCHOL MED, V16, P909; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; Spitzer RL, 1990, STRUCTURED CLIN INTE; Willick Martin S., 1994, P5; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WYATT RJ, 1987, PSYCHIAT ANN, V17, P586, DOI 10.3928/0048-5713-19870901-07; 1980, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC; 1994, INT CLASSIFICATION D; 1994, COMPOSITE INT DIAGNO	48	232	244	1	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	1995	346	8973					477	481		10.1016/S0140-6736(95)91325-4	http://dx.doi.org/10.1016/S0140-6736(95)91325-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RP857	7637483				2022-12-28	WOS:A1995RP85700013
J	CORTI, MC; GURALNIK, JM; SALIVE, ME; HARRIS, T; FIELD, TS; WALLACE, RB; BERKMAN, LF; SEEMAN, TE; GLYNN, RJ; HENNEKENS, CH; HAVLIK, RJ				CORTI, MC; GURALNIK, JM; SALIVE, ME; HARRIS, T; FIELD, TS; WALLACE, RB; BERKMAN, LF; SEEMAN, TE; GLYNN, RJ; HENNEKENS, CH; HAVLIK, RJ			HDL CHOLESTEROL PREDICTS CORONARY HEART-DISEASE MORTALITY IN OLDER PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DENSITY LIPOPROTEIN; HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; RISK-FACTORS; FOLLOW-UP; FRAMINGHAM; PREVALENCE; HEALTH	Objectives.-To examine the relationship of total cholesterol and high-density lipoprotein cholesterol (HDL-C) with coronary heart disease (CHD) mortality and with occurrence of new CHD events in persons aged 71 years and older. Design.-Prospective cohort study with a median of 4.4 years of follow-up. Setting.-East Boston, Mass; New Haven, Conn; and Iowa and Washington counties, Iowa. Participants.-A total of 2527 women and 1377 men who completed an interview, had serum lipid determinations, and survived at least 1 year. New CHD events were evaluated in persons with no CHD history or hospitalization. Main Outcome Measures.-Death due to CHD (ICD-9 codes 410 through 414 as underlying cause of death); new occurrence of CHD events (fatal CHD or hospitalization with CHD [ICD-9 codes 410 through 414]). Results.-After adjustment for established CHD risk factors, the relative risk (RR) of death due to CHD for those with low HDL-C (<0.90 mmol/L [<35 mg/dL]) compared with the reference group (HDL-C greater than or equal to 1.55 mmol/L [greater than or equal to 60 mg/dL]) was 2.5 (95% confidence interval [Cl], 1.6 to 4.0). Elevated risk was present in subgroups aged 71 through 80 years (RR, 4.1; 95% Cl, 1.9 to 8.8) and over 80 years (RR, 1.8; 95% Cl, 0.99 to 3.4), and in men and women. Low HDL-C predicted an increased risk of occurrence of new CHD events (RR, 1.4, 95% Cl, 1.1 to 2.0), with similar but nonsignificant results in subgroups of men and women. Total cholesterol was less consistently associated with CHD mortality than HDL-C. When we compared individuals with total cholesterol of at least 6.20 mmol/L (240 mg/dL) with the reference group with total cholesterol of 4.16 to 5.19 mmol/L (161 to 199 mg/dL), a significant risk of CHD mortality was seen for women (RR, 1.8; 95% Cl, 1.03 to 3.0) but not for men (RR, 1.0; 95% Cl, 0.5 to 2.0). In the total population, for each 1-unit increase in the total cholesterol/HDL-C ratio there was a 17% increase in the risk of CHD death that was statistically significant. Conclusions.-Low HDL-C predicts CHD mortality and occurrence of new CHD events in persons older than 70 years. Elevated total cholesterol was not found to be associated with CHD mortality in older men, but may be a risk factor for CHD in older women.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; UNIV IOWA, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06510 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Iowa; Yale University; Harvard University; Harvard T.H. Chan School of Public Health	CORTI, MC (corresponding author), NIA, EPIDEMIOL DEMOG & BIOMETRY PROGRAM, 7201 WISCONSIN AVE, ROOM 3C309, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE ON AGING [N01AG002105, N01AG002106, N01AG002107] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02105, N01-AG-02106, N01-AG-02107] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGNER E, 1983, ACTA MED SCAND, V214, P33; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1994, CIRCULATION, V89, P1329; Barrett-Connor E, 1992, Ann Epidemiol, V2, P77, DOI 10.1016/1047-2797(92)90040-W; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; BRAY GA, 1978, INT J OBESITY, V2, P99; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; JACKSON R, 1988, NEW ZEAL MED J, V101, P658; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LACROIX AZ, 1991, NEW ENGL J MED, V325, P1586; MALENKA DJ, 1988, ARCH INTERN MED, V148, P2247, DOI 10.1001/archinte.148.10.2247; MANOLIO TA, 1992, ANN INTERN MED, V116, P641, DOI 10.7326/0003-4819-116-8-641; MILLERBASS K, 1993, ARCH INTERN MED, V153, P2209; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1994, AM J EPIDEMIOL, V139, P155, DOI 10.1093/oxfordjournals.aje.a116977; Reed D, 1992, Ann Epidemiol, V2, P29, DOI 10.1016/1047-2797(92)90034-N; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHURTLEFF D, 1974, US DHEW NIH74599 PUB; Sorkin J D, 1992, Ann Epidemiol, V2, P59, DOI 10.1016/1047-2797(92)90038-R; STAESSEN J, 1990, J HYPERTENS, V8, P755, DOI 10.1097/00004872-199008000-00010; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Wallace R B, 1992, Ann Epidemiol, V2, P15, DOI 10.1016/1047-2797(92)90032-L; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1991, P217 SAS I INC TECHN; [No title captured]; 1977, JAMA-J AM MED ASSOC, V237, P2385	42	210	214	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					539	544		10.1001/jama.274.7.539	http://dx.doi.org/10.1001/jama.274.7.539			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629981				2022-12-28	WOS:A1995RN46600023
J	LIU, LX; CHI, J; UPTON, MP; ASH, LR				LIU, LX; CHI, J; UPTON, MP; ASH, LR			EOSINOPHILIC COLITIS ASSOCIATED WITH LARVAE OF THE PINWORM ENTEROBIUS-VERMICULARIS	LANCET			English	Note								Various helmintic parasites, most of which are uncommon in economically developed countries, can cause abdominal pain end eosinophilic inflammation of the bowel. A homosexual man presented with severe abdominal pain and haemorrhagic colitis, eosinophilic inflammation of the ileum and colon, and numerous unidentifiable larval nematodes in diarrhoeal stool. His symptoms resolved with anthelmintic treatment alone. Using comparative morphology and molecular cloning of nematode ribosomal RNA genes, we identified the parasites as larvae of the pinworm Enterobius vermicularis, which are rarely observed or associated with disease. Occult enterobiasis is widely prevalent and may be a cause of unexplained eosinophilic enterocolitis.	BETH ISRAEL HOSP, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT PATHOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles	LIU, LX (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV INFECT DIS, DANA 617, BOSTON, MA 02215 USA.							BIJLMER J, 1946, J PARASITOL, V32, P359, DOI 10.2307/3272867; CHO S-Y, 1985, Korean Journal of Parasitology, V23, P7, DOI 10.3347/kjp.1985.23.1.7; COOK GC, 1994, GUT, V35, P1159, DOI 10.1136/gut.35.9.1159; COOPER ES, 1991, LANCET, V338, P1104, DOI 10.1016/0140-6736(91)91964-V; HULINSKA D., 1968, FOLIA PARASITOL, V15, P15; LIU LX, 1993, INFECT DIS CLIN N AM, V7, P655; PROCIV P, 1990, LANCET, V335, P1299, DOI 10.1016/0140-6736(90)91186-E; SYMMERS WS, 1950, AMA ARCH PATHOL, V50, P475; TALLEY NJ, 1993, GASTROINTESTINAL DIS, P1224; WALKER NI, 1995, AM J SURG PATHOL, V19, P328, DOI 10.1097/00000478-199503000-00011	10	46	47	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					410	412		10.1016/S0140-6736(95)92782-4	http://dx.doi.org/10.1016/S0140-6736(95)92782-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623572	hybrid			2022-12-28	WOS:A1995RN65600011
J	DEBERG, JC; PATTYNAMA, PMT; OBERMANN, WR; BODE, PJ; VIELVOYE, GJ; TAMINIAU, AHM				DEBERG, JC; PATTYNAMA, PMT; OBERMANN, WR; BODE, PJ; VIELVOYE, GJ; TAMINIAU, AHM			PERCUTANEOUS COMPUTED-TOMOGRAPHY-GUIDED THERMOCOAGULATION FOR OSTEOID OSTEOMAS	LANCET			English	Note							ELECTRODE	Current treatment for osteoid osteomas is usually surgical excision of the nidus. We treated 18 patients with osteoid osteoma by percutaneous thermocoagulation of the nidus under computed-tomography guidance. The procedure was technically successful in all cases and there were no complications. Patients were discharged on the following morning and resumed normal activities immediately. Air patients but one remained pain free during follow-up (range 3-15 months). A second thermocoagulation treatment relieved the recurrent symptoms in this patient. Percutaneous thermocoagulation appears to be effective for osteoid osteomas, and is a minimally invasive alternative to surgical resection.	UNIV LEIDEN HOSP,DEPT ORTHOPAED SURG,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	DEBERG, JC (corresponding author), UNIV LEIDEN HOSP,DEPT RADIOL,2333 AA LEIDEN,NETHERLANDS.							MARCOVE RC, 1991, CLIN ORTHOP RELAT R, V267, P197; MAZOYER JF, 1991, RADIOLOGY, V181, P269, DOI 10.1148/radiology.181.1.1887046; MULDER JD, 1993, RADIOLOGIC ATLAS BON, P385; NORMAN A, 1975, CLIN ORTHOP RELAT R, V110, P233; Picci P, 1989, BONE TUMORS CLIN RAD, P226; ROSENTHAL DI, 1992, RADIOLOGY, V183, P29, DOI 10.1148/radiology.183.1.1549690; TILLOTSON CL, 1989, INVEST RADIOL, V24, P888, DOI 10.1097/00004424-198911000-00009	7	103	107	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					350	351		10.1016/S0140-6736(95)92228-8	http://dx.doi.org/10.1016/S0140-6736(95)92228-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623534				2022-12-28	WOS:A1995RM71300011
J	RICE, P; MIZUUCHI, K				RICE, P; MIZUUCHI, K			STRUCTURE OF THE BACTERIOPHAGE-MU TRANSPOSASE CORE - A COMMON STRUCTURAL MOTIF FOR DNA TRANSPOSITION AND RETROVIRAL INTEGRATION	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; RIBONUCLEASE-H; ESCHERICHIA-COLI; STRAND TRANSFER; CRYSTAL-STRUCTURE; B-PROTEIN; 3-DIMENSIONAL STRUCTURE; INVITRO TRANSPOSITION; ANGSTROM RESOLUTION	The crystal structure of the core domain of bacteriophage Mu transposase, MuA, has been determined at 2.4 Angstrom resolution. The first of two subdomains contains the active site and, despite very limited sequence homology, exhibits a striking similarity to the core domain of HIV-1 integrase, which carries out a similar set of biochemical reactions. It also exhibits more limited similarity to other nucleases, RNase fl and RuvC. The second, a beta barrel, connects to the first subdomain through several contacts. Three independent determinations of the monomer structure from two crystal forms all show the active site held in a similar, apparently inactive configuration. The enzymatic activity of MuA is known to be activated by formation of a DNA-bound tetramer of the protein. We propose that the connections between the two subdomains may be involved in the cross-talk between the active site and the other domains of the transposase that controls the activity of the protein.			RICE, P (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ARTYMIUK PJ, 1993, FEBS LETT, V324, P15, DOI 10.1016/0014-5793(93)81523-3; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DESMET L, 1989, MOL MICROBIOL, V3, P1145, DOI 10.1111/j.1365-2958.1989.tb00265.x; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NAMGOONG S, 1994, J MOL BIOL, V238, P514, DOI 10.1006/jmbi.1994.1311; Nicholls A.J., 1993, GRASP MANUAL; ODA Y, 1993, NUCLEIC ACIDS RES, V21, P4690, DOI 10.1093/nar/21.20.4690; ODA Y, 1993, J BIOL CHEM, V268, P88; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; ROWLAND SJ, 1995, EMBO J, V14, P196, DOI 10.1002/j.1460-2075.1995.tb06990.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; YANG W, 1991, THESIS COLUMBIA U NE; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; ZOU A, 1991, J BIOL CHEM, V266, P20476; 1979, CCP4 SERC COLL COMP	76	187	191	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					209	220		10.1016/0092-8674(95)90308-9	http://dx.doi.org/10.1016/0092-8674(95)90308-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628012	Bronze			2022-12-28	WOS:A1995RL76000008
J	BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A				BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A			PREVENTABLE HOSPITALIZATIONS AND ACCESS TO HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CITY; POOR	Objective. To examine whether the higher hospital admission rates for chronic medical conditions such as asthma, hypertension, congestive heart failure, chronic obstructive pulmonary disease, and diabetes in low-income communities resulted from community differences in access to care, prevalence of the diseases, propensity to seek care, or physician admitting style. Design.-Analysis of California hospital discharge data. We calculated the hospitalization rates for these five chronic conditions for the 250 ZIP code clusters that define urban California. We performed a random-digit telephone survey among adults residing in a random sample of 41 of these urban ZIP code clusters stratified by admission rates and a mailed survey of generalist and emergency physicians who practiced in the same 41 areas. Setting.-Community based. Participants.-A total of 6674 English- and Spanish-speaking adults aged 18 through 64 years residing in the 41 areas were asked about their access to care, their chronic medical conditions, and their propensity to seek health care. Physician admitting style was measured with written clinical vignettes among 723 generalist and emergency physicians practicing in the same communities. Main Outcome Measures.-We compared respondents' reports of access to medical care in an area with the area's cumulative admission rate for these five chronic conditions. We then tested whether access to medical care remained independently associated with preventable hospitalization rates after controlling for the prevalence of the conditions, health care seeking, and physician practice style. Results.-Access to care was inversely associated with the hospitalization rates for the five chronic medical conditions (R(2)=0.50; P<.001). In a multivariate analysis that included a measure of access, the prevalence of conditions, health care seeking, and physician practice style to predict cumulative hospitalization rates for chronic medical conditions, both self-rated access to care (P<.002) and the prevalence of the conditions (P<.03) remained independent predictors. Conclusion.-Communities where people perceive poor access to medical care have higher rates of hospitalization for chronic diseases. Improving access to care is more likely than changing patients' propensity to seek health care or eliminating variation in physician practice style to reduce hospitalization rates for chronic conditions.	SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH & AGING,SAN FRANCISCO,CA 94143; UNIV MINNESOTA,SCH MED,HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; NYU,ROBERT F WAGNER GRAD SCH PUBL SERV,NEW YORK,NY 10003	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; New York University	BINDMAN, AB (corresponding author), SAN FRANCISCO GEN HOSP,PRIMARY CARE RES CTR,WARD 95,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.		Grumbach, Kevin/L-9222-2016		AHRQ HHS [HSO7373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; CAPER P, 1993, HEALTH AFFAIR, V12, P174, DOI 10.1377/hlthaff.12.1.174; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GRISWOLD PR, 1992, HLTH CARE COSTS MASS; GRUMBACH K, 1995, CALIFORNIA POLICY SE; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; KLEINMAN JC, 1981, MED CARE, V19, P1011, DOI 10.1097/00005650-198110000-00004; Komaromy Miriam, 1995, JGIM, V10, P70; MEUX E, 1994, HEALTH SERV RES, V29, P247; MEUX EF, 1990, REPORT RESULTS OSHPD; NEWACHECK PW, 1988, HEALTH SERV RES, V23, P401; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SMELOFF EA, 1981, PUBLIC HEALTH REP, V96, P310; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; 1993, CD ROM SERIES 10, V4; 1990, STATISTICAL ANAL SAM; 1992, US DEPT HLTH HUMA 10, V4; 1992, 1990 CALIFORNIA HOSP	20	687	692	0	54	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					305	311		10.1001/jama.274.4.305	http://dx.doi.org/10.1001/jama.274.4.305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ898	7609259				2022-12-28	WOS:A1995RJ89800032
J	BEREK, JS				BEREK, JS			OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME	LANCET			English	Editorial Material							TUMORS				BEREK, JS (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET & GYNAECOL,LOS ANGELES,CA 90024, USA.							CHILDERS JM, 1994, OBSTET GYNECOL, V84, P765; DEMBO AJ, 1990, OBSTET GYNECOL, V75, P263; GLEESON NC, 1993, AM J OBSTET GYNECOL, V169, P522, DOI 10.1016/0002-9378(93)90611-L; GRANBERG S, 1990, GYNECOL ONCOL, V37, P224, DOI 10.1016/0090-8258(90)90337-K; HERRMANN UJ, 1987, OBSTET GYNECOL, V69, P777; HULKA J, 1992, J REPROD MED, V7, P599; MAIMAN M, 1991, OBSTET GYNECOL, V77, P563; PARKER WH, 1990, AM J OBSTET GYNECOL, V163, P1574, DOI 10.1016/0002-9378(90)90630-P; PARKER WH, 1994, J AM COLL SURGEONS, V179, P733; SEVELDA P, 1989, GYNECOL ONCOL, V35, P321, DOI 10.1016/0090-8258(89)90071-1; SJOVALL K, 1994, INT J GYNECOL CANCER, V4, P333, DOI 10.1046/j.1525-1438.1994.04050333.x; WEBB MJ, 1973, AM J OBSTET GYNECOL, V116, P222, DOI 10.1016/0002-9378(73)91054-5	12	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					200	200		10.1016/S0140-6736(95)91264-9	http://dx.doi.org/10.1016/S0140-6736(95)91264-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616797				2022-12-28	WOS:A1995RK41900006
J	VANDERWIELEN, RPJ; LOWIK, MRH; VANDENBERG, H; DEGROOT, LCPGM; HALLER, J; MOREIRAS, O; VANSTAVEREN, WA				VANDERWIELEN, RPJ; LOWIK, MRH; VANDENBERG, H; DEGROOT, LCPGM; HALLER, J; MOREIRAS, O; VANSTAVEREN, WA			SERUM VITAMIN-D CONCENTRATIONS AMONG ELDERLY PEOPLE IN EUROPE	LANCET			English	Article							POSTMENOPAUSAL WOMEN; NUTRITIONAL-STATUS; RELATIVE CONTRIBUTIONS; PARATHYROID-HORMONE; D DEFICIENCY; 25-HYDROXYVITAMIN-D; SUNLIGHT; POPULATION; EXPOSURE; DIET	Vitamin D status decreases with age, mainly as a result of restricted sunlight exposure, reduced capacity of the skin to produce vitamin D, and reduced dietary Vitamin D intake. We measured wintertime serum 25-hydroxyvitamin D [25(OH)D] concentrations in 824 elderly people from 11 European countries. 36% of men and 47% of women had 25(OH)D concentrations below 30 nmol/L. Users of Vitamin D supplements and/or sunlamps had higher 25(OH)D (median 54 nmol/L) than non users (median 31 nmol/L). Surprisingly, lowest mean 25(OH)D concentrations were seen in southern European countries. Low 25(OH)D concentrations could largely be explained by attitudes towards sunlight exposure and factors of physical health status, after exclusion of users of vitamin D supplements or sunlamps. Problems with daily living activities and wearing clothes with long sleeves during periods of sunshine were strong predictors of low wintertime serum 25(OH)D concentrations. These findings show that free-living elderly Europeans, regardless of geographical location, are at substantial risk of inadequate Vitamin D status during winter and that dietary enrichment or supplementation with vitamin D should be seriously considered during this season.	TNO, NUTR & FOOD RES INST, ZEIST, NETHERLANDS; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; CSIC, INST NUTR, MADRID, SPAIN	Netherlands Organization Applied Science Research; Roche Holding; Consejo Superior de Investigaciones Cientificas (CSIC)	VANDERWIELEN, RPJ (corresponding author), AGR UNIV WAGENINGEN, DEPT HUMAN NUTR, POB 8129, 6700 EV WAGENINGEN, NETHERLANDS.			de Groot, Lisette/0000-0003-2778-2789				BERGSTEIN I, 1988, NED T DIETISTEN, V43, P169; CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0; CRUZ JAA, 1991, EUR J CLIN NUTR, V45, P121; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DEGROOT CPG, 1988, 11 EUR REP; DELVIN EE, 1988, AM J CLIN NUTR, V48, P373, DOI 10.1093/ajcn/48.2.373; DUBBELMAN R, 1993, AM J CLIN NUTR, V58, P106, DOI 10.1093/ajcn/58.1.106; JUTTMANN JR, 1981, BRIT MED J, V282, P1349, DOI 10.1136/bmj.282.6273.1349; KHAW KT, 1992, BRIT MED J, V305, P273, DOI 10.1136/bmj.305.6848.273; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P419; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LAMBERG-ALLARDT C, 1984, ANN NUTR METAB, V28, P144, DOI 10.1159/000176796; LAWSON DEM, 1979, BRIT MED J, V2, P303, DOI 10.1136/bmj.2.6185.303; LESTER E, 1977, LANCET, V1, P979; LIPS P, 1987, AM J CLIN NUTR, V46, P1005, DOI 10.1093/ajcn/46.6.1005; LOWIK MRH, 1990, J AM COLL NUTR, V9, P18; MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134; MCKENNA MJ, 1985, AM J CLIN NUTR, V41, P101, DOI 10.1093/ajcn/41.1.101; NES M, 1991, EUR J CLIN NUTR, V45, P97; OMDAHL JL, 1982, AM J CLIN NUTR, V36, P1225, DOI 10.1093/ajcn/36.6.1225; OOMS ME, 1994, THESIS AMSTERDAM, P69; OSLER M, 1991, EUR J CLIN NUTR, V45, P139; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; SALAMONE LM, 1994, AM J CLIN NUTR, V59, P80, DOI 10.1093/ajcn/59.1.80; STAMP TCB, 1974, NATURE, V247, P563, DOI 10.1038/247563a0; VANDENBERG H, 1993, INT J VITAM NUTR RES, V63, P257; VANDENBERG H, 1991, NUTRITIONAL STATUS A, P203; VANTHOF MA, 1991, EUR J CLIN NUTR, V45, P5; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075; WEBB AR, 1988, ANNU REV NUTR, V8, P375, DOI 10.1146/annurev.nu.08.070188.002111	31	616	630	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	1995	346	8969					207	210		10.1016/S0140-6736(95)91266-5	http://dx.doi.org/10.1016/S0140-6736(95)91266-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616799				2022-12-28	WOS:A1995RK41900008
J	HOLLEY, SA; JACKSON, PD; SASAI, Y; LU, B; DEROBERTIS, EM; HOFFMANN, FM; FERGUSON, EL				HOLLEY, SA; JACKSON, PD; SASAI, Y; LU, B; DEROBERTIS, EM; HOFFMANN, FM; FERGUSON, EL			A CONSERVED SYSTEM FOR DORSAL-VENTRAL PATTERNING IN INSECTS AND VERTEBRATES INVOLVING SOG AND CHORDIN	NATURE			English	Article							DROSOPHILA EMBRYO; XENOPUS; GRADIENT; POLARITY; DOMINANT; GENES; TOLL	DORSAL-VENTRAL patterning within the ectoderm of the Drosophila embryo requires seven zygotic genes, including short gastrulation (sog)(1). Here we demonstrate that sog, which is expressed in the ventrolateral region of the embryo that gives rise to the nerve cord(2), is functionally homologous to the chordin gene of Xenopus, which is expressed in the dorsal blastopore lip of the embryo and in dorsal mesoderm, in particular the notochord(3). We show by injections of messenger RNA that both sog and chordin can promote ventral development in Drosophila, and that sog, like chordin(3), can promote dorsal development in Xenopus. In Drosophila, sog antagonizes the dorsalizing effects of decapentaplegic (dpp)(1,2,4), member of the transforming growth factor-beta family. One of the dpp homologues in vertebrates, bmp-4, is expressed ventrally in Xenopus(5) and promotes ventral development(6,7). We show that dpp can promote ventral fates in Xenopus, and that injection of sog mRNA counteracts the ventralizing effects of dpp. These results suggest the molecular conservation of dorsoventral patterning mechanisms during evolution.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,GENET LAB,MADISON,WI 53706; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	HOLLEY, SA (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Ferguson, Edwin/0000-0003-4125-4253; Hoffmann, F. Michael/0000-0002-2770-9656				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Geoffroy Saint-Hilaire E., 1822, MEMOIRES DU MUSEUM D, V9, P89; JONES CM, 1992, DEVELOPMENT, V115, P39; LACALLI TC, 1995, NATURE, V373, P110, DOI 10.1038/373110c0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; PETERSON KJ, 1995, NATURE, V373, P112; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEWART RM, 1991, ROUX ARCH DEV BIOL, V199, P341, DOI 10.1007/BF01705927; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WHARTON KA, 1993, DEVELOPMENT, V117, P807; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	24	363	371	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					249	253		10.1038/376249a0	http://dx.doi.org/10.1038/376249a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617035				2022-12-28	WOS:A1995RK33100045
J	HODGKINSON, DW; GRAY, AJ; DALAL, B; WILSON, P; SZAWARSKI, Z; SENSKY, T; GILLETT, G; YATES, DW				HODGKINSON, DW; GRAY, AJ; DALAL, B; WILSON, P; SZAWARSKI, Z; SENSKY, T; GILLETT, G; YATES, DW			DOCTORS LEGAL POSITION IN TREATING TEMPORARILY INCOMPETENT PATIENTS - DISCUSSION	BRITISH MEDICAL JOURNAL			English	Discussion									UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND; DEPT LAW,NOTTINGHAM NG7 2RD,ENGLAND; UNIV COLL SWANSEA,CTR PHILOSOPHY & HLTH CARE,SWANSEA SA2 8PP,W GLAM,WALES; W MIDDLESEX UNIV HOSP,DEPT PSYCHIAT,ISLEWORTH TW7 6AF,MIDDX,ENGLAND; UNIV OTAGO,DEPT NEUROSURG,DUNEDIN,NEW ZEALAND; HOPE HOSP,SALFORD ROYAL J HOSP,NHS TRUST,SALFORD M6 8HD,LANCS,ENGLAND	University of Nottingham; Swansea University; Imperial College London; University of Otago; Salford Royal NHS Foundation Trust; Salford Royal Hospital	HODGKINSON, DW (corresponding author), STOCKPORT INFIRM,STOCKPORT ACUTE SERV NHS TRUST,STOCKPORT SK1 3UJ,ENGLAND.							JONES R, 1994, MENTAL HLTH ACT MANU; 1993, RIGHTS RESPONSIBILIT	2	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					115	118		10.1136/bmj.311.6997.115a	http://dx.doi.org/10.1136/bmj.311.6997.115a			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613365	Green Published			2022-12-28	WOS:A1995RJ03000030
J	PETCHEY, R				PETCHEY, R			COLLINGS REPORT ON GENERAL-PRACTICE IN ENGLAND IN 1950 - UNRECOGNIZED, PIONEERING PIECE OF BRITISH SOCIAL-RESEARCH	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FAMILY	Collings's grim description of postwar general practice in England and his sombre analysis of its prospects created an immediate sensation. In addition to its value as a historical document, the report is also regarded as a turning point in the postwar history of British general practice. The study is also interesting for another reason, which has not been acknowledged: Collings merits recognition as a pioneer of ethnographic research at a time when it was largely unknown elsewhere in British social research.			PETCHEY, R (corresponding author), QUEENS MED CTR, SCH MED, DEPT GEN PRACTICE, NOTTINGHAM NG7 2UH, ENGLAND.							[Anonymous], 1966, WAGES WORK ALLOCATIO; BAZERMAN C., 1988, SHAPING WRITTEN KNOW; COLLINGS JS, 1950, LANCET, V258, P555; DINGWALL R, 1979, SOCIOLOGY HLTH ILLNE, V3, P348; Frankenberg R., 1957, VILLAGE BORDER; GRAY DP, 1992, 40 YEARS STORY 1ST 4; Hannerz Ulf, 1980, EXPLORING CITY INQUI; HARRISSON Tom, 1947, PILOT PAPERS, VII, P10; Hart, 1988, NEW KIND DOCTOR; HONIGSBAUM F, 1979, DIVISION BRIT MED; Honigsbaum F, 1989, HLTH HAPPINESS SECUR; Hunt J H, 1973, J R Coll Gen Pract, V23, P5; HUNT JH, 1955, LANCET, V2, P681; LOUDON I, 1984, B HIST MED, V58, P347; LUPTON T, 1963, SHOP FLOOR; McLachlan G., 1992, HIST NUFFIELD PROVIN; MURPHY E, 1992, FAM PRACT, V9, P85, DOI 10.1093/fampra/9.1.85; PAYNE G, 1981, SOCIOLOGY SOCIAL RES; Roethlisberger F. J., 1939, MANAGEMENT WORKER; SMITH HV, 1950, LANCET, V259, P275; Stacey Margaret, 1960, TRADITION CHANGE STU; TAYLOR S, 1954, GOOD GENERAL PRACTIC; Webster C., 1988, HLTH SERVICES WAR; Williams W. M., 1956, SOCIOLOGY ENGLISH VI; 1945, HOSPITAL SURVEYS DOM; 1951, 2ND NUFF PROV HOSP T; 1950, BRIT MED J, V1, P709	27	8	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					40	42		10.1136/bmj.311.6996.40	http://dx.doi.org/10.1136/bmj.311.6996.40			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613328	Green Published			2022-12-28	WOS:A1995RG97500028
J	RUPP, ME				RUPP, ME			RHINOCEREBRAL MUCORMYCOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											RUPP, ME (corresponding author), UNIV NEBRASKA,MED CTR,OMAHA,NE 68198, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					564	564		10.1056/NEJM199508313330906	http://dx.doi.org/10.1056/NEJM199508313330906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623906				2022-12-28	WOS:A1995RQ75100006
J	ROSEN, FS; COOPER, MD; WEDGWOOD, RJP				ROSEN, FS; COOPER, MD; WEDGWOOD, RJP			MEDICAL PROGRESS - THE PRIMARY IMMUNODEFICIENCIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WISKOTT-ALDRICH SYNDROME; COMMON VARIABLE IMMUNODEFICIENCY; X-LINKED AGAMMAGLOBULINEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTOR GAMMA-CHAIN; HYPER-IGM SYNDROME; PROMOTER BINDING-PROTEIN; B-CELL-DIFFERENTIATION; II GENE-EXPRESSION; T-CELLS		HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA; UNIV ALABAMA,SCH MED,DEPT PEDIAT,BIRMINGHAM,AL; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA	Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle								ALDRICH RA, 1954, PEDIATRICS, V13, P133; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Asherson GL, 1980, DIAGNOSIS TREATMENT, P7; ASHMAN RF, 1992, J CLIN IMMUNOL, V12, P406, DOI 10.1007/BF00918852; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BASILE GD, 1987, P NATL ACAD SCI USA, V84, P7576; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; Blaese R M, 1992, Immunodefic Rev, V3, P329; BLAESE RM, 1968, LANCET, V1, P1056; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; CASTIGLI E, 1993, P NATL ACAD SCI USA, V90, P4728, DOI 10.1073/pnas.90.10.4728; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHATILA T, 1989, NEW ENGL J MED, V320, P696, DOI 10.1056/NEJM198903163201104; CHU ET, 1984, P NATL ACAD SCI-BIOL, V81, P4945, DOI 10.1073/pnas.81.15.4945; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; CUNNINGHAMRUNDL.C, 1987, J CLIN IMMUNOL, V7, P294; CUNNINGHAMRUNDL.C, 1989, J CLIN IMMUNOL, V9, P22; DELASALLE H, 1994, SCIENCE, V266, P1464; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DEPREVAL C, 1988, NEW ENGL J MED, V318, P1295, DOI 10.1056/NEJM198805193182003; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DERRY JMJ, 1994, CELL, V79, P923; DESAINTBASILE G, 1991, ANN HEMATOL, V63, P107, DOI 10.1007/BF01707282; DESCHENES SM, 1994, GENOMICS, V23, P62, DOI 10.1006/geno.1994.1459; DEWEERS M, 1994, HUM MOL GENET, V3, P161, DOI 10.1093/hmg/3.1.161; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; DISANTO JP, 1994, NEW ENGL J MED, V330, P969, DOI 10.1056/NEJM199404073301404; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DONNER M, 1988, BLOOD, V72, P1849; EISENSTEIN EM, 1993, J CLIN IMMUNOL, V13, P247, DOI 10.1007/BF00919383; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; FEARON ER, 1988, BLOOD, V72, P1735; FISCHER MB, 1993, J ALLERGY CLIN IMMUN, V92, P340, DOI 10.1016/0091-6749(93)90178-I; FRIEDMAN JM, 1977, CLIN EXP IMMUNOL, V28, P375; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GATTI RA, 1968, LANCET, V2, P1366; GEALY WJ, 1980, LANCET, V1, P63; GEHA RS, 1979, J CLIN INVEST, V64, P385, DOI 10.1172/JCI109473; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOODMAN MG, 1991, CLIN IMMUNOL IMMUNOP, V59, P26, DOI 10.1016/0090-1229(91)90079-P; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GREER WL, 1989, GENOMICS, V4, P60, DOI 10.1016/0888-7543(89)90315-7; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HENTHORN PS, 1994, GENOMICS, V23, P69, DOI 10.1006/geno.1994.1460; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HINZ CF, 1963, NEW ENGL J MED, V269, P1329, DOI 10.1056/NEJM196312192692501; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; HOWE HS, 1991, CLIN EXP IMMUNOL, V83, P387; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JAFFE JS, 1993, PEDIATR RES, V33, pS24; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KENNEY D, 1986, BLOOD, V68, P1329; KHAN WN, IN PRESS IMMUNITY; KINCADE PW, 1994, P NATL ACAD SCI USA, V91, P2888, DOI 10.1073/pnas.91.8.2888; KINLEN LJ, 1985, LANCET, V1, P263; KNOXMACAULAY HHM, 1993, J MED GENET, V30, P968, DOI 10.1136/jmg.30.11.968; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KWAN SP, 1991, GENOMICS, V10, P29, DOI 10.1016/0888-7543(91)90480-3; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; KWAN SP, 1990, GENOMICS, V6, P238, DOI 10.1016/0888-7543(90)90562-9; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LEVITT D, 1983, J CLIN INVEST, V72, P1650, DOI 10.1172/JCI111124; LING ZD, 1993, J CLIN IMMUNOL, V13, P302, DOI 10.1007/BF00920238; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; MILILI M, 1993, J CLIN INVEST, V91, P1616, DOI 10.1172/JCI116369; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MULLEN CA, 1993, BLOOD, V82, P2961; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NONOYAMA S, 1993, J CLIN INVEST, V92, P1282, DOI 10.1172/JCI116701; NORTH ME, 1991, CLIN EXP IMMUNOL, V85, P198; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; NOTARANGELO LD, 1991, BLOOD, V77, P1125; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; OCHS HD, 1980, BLOOD, V55, P243; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OLERUP O, 1992, P NATL ACAD SCI USA, V89, P10653, DOI 10.1073/pnas.89.22.10653; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PANDOLFI F, 1992, CLIN EXP IMMUNOL, V89, P198; PARKMAN R, 1978, NEW ENGL J MED, V298, P921; PEARL ER, 1978, J IMMUNOL, V120, P1169; PRCHAL JT, 1980, BLOOD, V56, P1048; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; PUCK JM, 1993, AM J HUM GENET, V53, P176; PUCK JM, 1989, AM J HUM GENET, V44, P724; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROSEN FS, 1963, NEW ENGL J MED, V269, P1336, DOI 10.1056/NEJM196312192692502; Rosen FS, 1993, IMMUNODEFICIENCIES, P141; RUMP JA, 1992, CLIN EXP IMMUNOL, V89, P204; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SAXON A, 1992, CELL IMMUNOL, V144, P169, DOI 10.1016/0008-8749(92)90234-G; SCHWABER J, 1988, J CLIN INVEST, V81, P514, DOI 10.1172/JCI113349; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; SMITH CIE, 1994, J IMMUNOL, V152, P557; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SNELLER MC, 1993, ANN INTERN MED, V188, P720; SPICKETT GP, 1992, DIS MARKERS, V10, P67; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V364, P362, DOI 10.1038/364362a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOLANAKIS JE, 1992, J CLIN INVEST, V89, P1914, DOI 10.1172/JCI115797; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; WENGLER G, 1995, BLOOD, V85, P2471, DOI 10.1182/blood.V85.9.2471.bloodjournal8592471; WENGLER GS, 1993, J IMMUNOL, V150, P700; WILTON AN, 1985, IMMUNOGENETICS, V21, P333, DOI 10.1007/BF00430799; WISKOTT A, 1937, MONATSSCHR KINDERH, V68, P212; WOLLHEIM FA, 1964, ACTA MED SCAND, V176, P1; YANG Z, 1988, EMBO J, V7, P1965, DOI 10.1002/j.1460-2075.1988.tb03034.x; ZHU QL, 1994, J EXP MED, V180, P461, DOI 10.1084/jem.180.2.461; ZHU QL, 1994, HUM MOL GENET, V3, P1899, DOI 10.1093/hmg/3.10.1899; 1995, CLIN EXP IMMUNOL  S1, V99, P1	140	298	313	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					431	440		10.1056/NEJM199508173330707	http://dx.doi.org/10.1056/NEJM199508173330707			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616993				2022-12-28	WOS:A1995RP24300007
J	SILVERSTEIN, FE; GRAHAM, DY; SENIOR, JR; DAVIES, HW; STRUTHERS, BJ; BITTMAN, RM; GEIS, GS				SILVERSTEIN, FE; GRAHAM, DY; SENIOR, JR; DAVIES, HW; STRUTHERS, BJ; BITTMAN, RM; GEIS, GS			MISOPROSTOL REDUCES SERIOUS GASTROINTESTINAL COMPLICATIONS IN PATIENTS WITH RHEUMATOID-ARTHRITIS RECEIVING NONSTEROIDAL ANTIINFLAMMATORY DRUGS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						MISOPROSTOL; ARTHRITIS, RHEUMATOID; ANTIINFLAMMATORY AGENTS, NONSTEROIDAL; GASTRIC OUTLET OBSTRUCTION; GASTROINTESTINAL HEMORRHAGE	INDUCED GASTRIC-ULCER; PEPTIC-ULCER; HELICOBACTER-PYLORI; ANTIINFLAMMATORY DRUGS; GASTRODUODENAL INJURY; ELDERLY PERSONS; CHRONIC ASPIRIN; MUCOSAL DAMAGE; GASTROPATHY; PREVENTION	Objective: To investigate whether concurrent administration of misoprostol reduces the occurrence of serious upper gastrointestinal complications, such as perforation, gastric outlet obstruction, or bleeding, in patients with rheumatoid arthritis who are receiving nonsteroidal anti-inflammatory drugs (NSAIDs). Design: 6-month randomized, double-blind, placebo-controlled trial. Setting: 664 clinical practices of family medicine, internal medicine, or rheumatology in the United States and Canada. Patients: 8843 men and women (mean age, 68 years) receiving continuous therapy with any of 10 specified NSAIDs for control of symptoms of rheumatoid arthritis. Patients were enrolled between July 1991 and August 1993. Intervention: Patients were randomly assigned to receive 200 mu g of misoprostol or placebo four times a day. Measurements: Development of serious upper gastrointestinal complications detected by clinical symptoms or findings (not by scheduled endoscopy). Results: Serious upper gastrointestinal complications were reduced by 40% (odds ratio, 0.598 [95% CI, 0.364 to 0.982; P = 0.049]) among patients receiving misoprostol (25 of 4404 patients) compared with those receiving placebo (42 of 4439 patients). During the first month, more patients receiving misoprostol (20%) than placebo (15%) withdrew from the study, primarily because of diarrhea and related problems (P < 0.001). Risk factors for serious upper gastrointestinal complications were increasing age, history of peptic ulcer or bleeding, and cardiovascular disease. Patients with all four risk factors would have a 9% risk for a major complication in 6 months. Conclusions: In older patients with rheumatoid arthritis, misoprostol reduced serious NSAID-induced upper gastrointestinal complications by 40% compared with placebo.	GD SEARLE & CO, SKOKIE, IL 60077 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV PENN, GASTROENTEROL SECT, PHILADELPHIA, PA 19104 USA; QUINTILES TRANSNATL CORP, RES TRIANGLE PK, NC 27709 USA	Pfizer; University of Washington; University of Washington Seattle; Baylor College of Medicine; University of Pennsylvania; IQVIA			Graham, David/AAL-2165-2021					AGRAWAL NM, 1991, ANN INTERN MED, V115, P195, DOI 10.7326/0003-4819-115-3-195; ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; CALDWELL JR, 1987, AM J MED, V83, P74, DOI 10.1016/0002-9343(87)90832-1; CARUSO I, 1980, BRIT MED J, V280, P75, DOI 10.1136/bmj.280.6207.75; COLES LS, 1983, AM J MED, V74, P820, DOI 10.1016/0002-9343(83)91073-2; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; FARAH D, 1988, ANN RHEUM DIS, V47, P478, DOI 10.1136/ard.47.6.478; FELDMAN M, 1993, ANN INTERN MED, V119, P337, DOI 10.7326/0003-4819-119-4-199308150-00015; FRIES JF, 1991, J RHEUMATOL, V18, P6; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GABRIEL SE, 1993, ARTHRITIS RHEUM-US, V36, P447, DOI 10.1002/art.1780360404; GEIS GS, 1991, J RHEUMATOL, V18, P11; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; GRAHAM DY, 1993, ANN INTERN MED, V119, P257, DOI 10.7326/0003-4819-119-4-199308150-00001; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GUDJONSSON H, 1990, Scandinavian Journal of Gastroenterology Supplement, V25, P24; HILLMAN AL, 1989, ARCH INTERN MED, V149, P2061, DOI 10.1001/archinte.149.9.2061; JANSSEN M, 1994, DIGEST DIS SCI, V39, P362, DOI 10.1007/BF02090209; JASZEWSKI R, 1990, J CLIN GASTROENTEROL, V12, P10, DOI 10.1097/00004836-199002000-00004; JIRANEK GC, 1989, GASTROENTEROLOGY, V96, P656, DOI 10.1016/S0016-5085(89)80062-9; Kim Jong G., 1994, American Journal of Gastroenterology, V89, P203; KNILLJONES R, 1990, POSTGRAD MED J, V66, P639, DOI 10.1136/pgmj.66.778.639; LAINE L, 1992, AM J GASTROENTEROL, V87, P1398; LANGMAN MJS, 1989, GASTROENTEROLOGY, V96, P640, DOI 10.1016/S0016-5085(89)80060-5; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; LEE M, 1994, ANN INTERN MED, V120, P184, DOI 10.7326/0003-4819-120-3-199402010-00002; LICHTENSTEIN DR, 1995, ARTHRITIS RHEUM, V38, P5, DOI 10.1002/art.1780380103; LLEWELLYN JG, 1988, J RHEUMATOL, V15, P691; LOEB DS, 1992, GASTROENTEROLOGY, V102, P1899, DOI 10.1016/0016-5085(92)90311-L; ODDSSON E, 1990, SCAND J GASTROENTERO, V25, P231, DOI 10.1080/00365521.1990.12067096; PAULUS HE, 1988, ARTHRITIS RHEUM, V31, P1450, DOI 10.1002/art.1780311118; PHILP I, 1987, J CLIN EXP GERONTOL, V9, P179; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; Roth S. H., 1994, Practical Gastroenterology, V18, P14; ROTH SH, 1987, ARCH INTERN MED, V147, P2093, DOI 10.1001/archinte.147.12.2093; ROTH SH, 1987, ARCH INTERN MED, V147, P1798, DOI 10.1001/archinte.147.10.1798; SHORROCK C J, 1992, Gastroenterology, V102, pA165; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; SPECTOR TD, 1988, CLIN RHEUMATOL, V7, P315, DOI 10.1007/BF02239187; WALT RP, 1992, NEW ENGL J MED, V327, P1575; 1992, STATISTICS B, V73, P25	45	894	926	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					241	249		10.7326/0003-4819-123-4-199508150-00001	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611589				2022-12-28	WOS:A1995RN66500001
J	TATARA, K				TATARA, K			ON PUTTING LIFE FIRST	LANCET			English	Editorial Material											TATARA, K (corresponding author), OSAKA UNIV,SCH MED,DEPT PUBL HLTH,OSAKA,JAPAN.							MIZUNO H, 1991, BRAIN DEATH ORGAN TR	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					327	328		10.1016/S0140-6736(95)92222-9	http://dx.doi.org/10.1016/S0140-6736(95)92222-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623528				2022-12-28	WOS:A1995RM71300005
J	MAKIN, AJ; FITT, S; WILLIAMS, R; DUNCAN, JS				MAKIN, AJ; FITT, S; WILLIAMS, R; DUNCAN, JS			FULMINANT HEPATIC-FAILURE INDUCED BY LAMOTRIGINE	BRITISH MEDICAL JOURNAL			English	Letter									UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	MAKIN, AJ (corresponding author), INST LIVER STUDIES, LONDON SE5 9PJ, ENGLAND.			opoku, anita/0000-0001-7243-8157; Duncan, John S/0000-0002-1373-0681				BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; PESSAYRE D, 1988, BAILLIERE CLIN GASTR, V2, P385, DOI 10.1016/0950-3528(88)90009-7; POWELLJACKSON PR, 1984, GUT, V25, P673, DOI 10.1136/gut.25.6.673; SCHAUB JEM, 1994, LANCET, V344, P481, DOI 10.1016/S0140-6736(94)91818-X; YUEN AWC, 1992, LANCET, V340, P618, DOI 10.1016/0140-6736(92)92159-D	5	53	54	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					292	292		10.1136/bmj.311.7000.292b	http://dx.doi.org/10.1136/bmj.311.7000.292b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633236	Green Published			2022-12-28	WOS:A1995RM71900025
J	RICHARDSON, R; HURWITZ, B				RICHARDSON, R; HURWITZ, B			DONORS ATTITUDES TOWARDS BODY DONATION FOR DISSECTION	LANCET			English	Article								We report a survey in the UK of potential whole-body donors for dissection. 218 people (age range 19-97 years) answered a postal questionnaire, giving information about themselves, their reasons for donation, attitudes towards the dead body, funeral preferences and medical giving and receiving. In addition to altruism, motives included the wish to avoid funeral ceremonies, to avoid waste, and in a few cases, to evade the expense of a funeral. 44% understood that their bodies would be used as teaching material, 42% for experiments. Whilst 69% believed in one or more supernatural phenomena, only 39% said they were religious. 69% requested cremation after dissection; 2% wanted to be buried. The notion of money incentives to promote donation was overwhelmingly rejected.	ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON, ENGLAND	Imperial College London	RICHARDSON, R (corresponding author), UCL, DEPT ANAT, LONDON WC1 6BT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Dooley D, 1973, Ann R Coll Surg Engl, V53, P13; Druce M, 1994, CLIN ANAT, V7, P42, DOI [DOI 10.1002/CA.980070108, 10.1002/ca.980070108]; FENNELL S, 1992, NEW ZEAL MED J, V105, P472; HORNE DJD, 1990, ACAD MED, V65, P645, DOI 10.1097/00001888-199010000-00011; HUMPHREY DC, 1973, B NEW YORK ACAD MED, V49, P819; MURRAY TH, 1994, JAMA-J AM MED ASSOC, V272, P814, DOI 10.1001/jama.272.10.814; MURRAY TH, 1987, HASTINGS CENT REP, V17, P30, DOI 10.2307/3562041; RICHARDSON R, 1989, DEATH DISSECTION DES, P95	8	86	86	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 29	1995	346	8970					277	279		10.1016/S0140-6736(95)92166-4	http://dx.doi.org/10.1016/S0140-6736(95)92166-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630248				2022-12-28	WOS:A1995RL75700011
J	HANAUER, P; SLADE, J; BARNES, DE; BERO, L; GLANTZ, SA				HANAUER, P; SLADE, J; BARNES, DE; BERO, L; GLANTZ, SA			LAWYER CONTROL OF INTERNAL SCIENTIFIC-RESEARCH TO PROTECT AGAINST PRODUCTS-LIABILITY LAWSUITS - THE BROWN-AND-WILLIAMSON DOCUMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To understand how attorneys for the tobacco industry in general, and Brown and Williamson Tobacco Corporation (B&W) in particular, have responded to the threat of products liability litigation arising from smoking-induced diseases. Data Sources.-Documents from B&W, the British American Tobacco Company (BAT), and other tobacco interests provided by an anonymous source, obtained from Congress, or received from the private papers of a former BAT officer. Study Selection.-All available materials, including confidential reports regarding research and internal memoranda exchanged between tobacco industry lawyers. Conclusions.-She documents demonstrate that the tobacco industry in general, and B&W in particular, were very concerned about the threat of products liability lawsuits, and they illustrate some of the steps taken by lawyers at one company to avoid the discovery of documents that might be useful to a plaintiff in such a lawsuit, These steps included efforts to control the language of scientific discourse on issues related to smoking and health, to bring all potentially damaging internal scientific documents under attorney work product and attorney-client privilege to avoid discovery, to remove ''deadwood'' documents, and to insulate B&W from knowledge of potentially damaging scientific information from other BAT companies.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ST PETERS MED CTR,DEPT MED,NEW BRUNSWICK,NJ	University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center					NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; RABIN RL, 1992, STANFORD LAW REV, V44, P853, DOI 10.2307/1229002; Taylor Peter, 1984, SMOKE RING TOBACCO M; WAGNER S, 1971, CIGARETTE COUNTRY TO	4	40	40	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					234	240						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH937	7609232				2022-12-28	WOS:A1995RH93700029
J	SIBILIA, M; WAGNER, EF				SIBILIA, M; WAGNER, EF			STRAIN-DEPENDENT EPITHELIAL DEFECTS IN MICE LACKING THE EGF RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; EMBRYONIC STEM-CELLS; FACTOR-ALPHA; TGF-ALPHA; MOUSE DEVELOPMENT; NULL MUTATION; SELF-RENEWAL; DIFFERENTIATION; PLACENTA; CULTURE	Mice and cells lacking the epidermal growth factor receptor (EGFR) were generated to examine its physiological role in vivo. Mutant fetuses are retarded in growth and die at mid-gestation in a 129/Sv genetic background, whereas in a 129/Sv x C57BL/6 cross some survive until birth and even to postnatal day 20 in a 129/Sv x C57BL/6 x MF1 background. Death in utero probably results from a defect in the spongiotrophoblast layer of the placenta. Newborn mutant mice have open eyes, rudimentary whiskers, immature lungs, and defects in the epidermis, correlating with the expression pattern of the EGFR as monitored by beta-galactosidase activity, These defects are probably cell-autonomous because chimeric mice generated with EGFR(-/-) embryonic stem cells contribute small amounts of mutant cells to some organs. These results indicate that the EGFR regulates epithelial proliferation and differentiation and that the genetic background influences the resulting phenotype.			SIBILIA, M (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Sibilia, Maria/0000-0001-6129-5613; Wagner, Erwin F/0000-0001-7872-0196				Adamson E D, 1990, Curr Top Dev Biol, V24, P1, DOI 10.1016/S0070-2153(08)60082-4; AVIVI A, 1991, ONCOGENE, V6, P673; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BREIER G, IN PRESS DEV DYNAMIC; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DAS SK, 1994, DEVELOPMENT, V120, P1071; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONDACCI C, 1994, J CLIN INVEST, V93, P1149, DOI 10.1172/JCI117067; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P407; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LESCISIN KR, 1989, GENE DEV, V2, P1639; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; MUNTENER M, 1977, ACTA ANAT, V98, P241; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROSSANT J, 1985, J EMBRYOL EXP MORPH, V86, P177; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIBILIA M, UNPUB; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VONRUDEN T, 1992, BLOOD, V12, P3145; WILEY LM, 1992, DEV BIOL, V149, P247, DOI 10.1016/0012-1606(92)90282-L; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	41	818	829	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					234	238		10.1126/science.7618085	http://dx.doi.org/10.1126/science.7618085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618085				2022-12-28	WOS:A1995RJ02900043
J	BARKER, DJP; WINTER, PD; OSMOND, C; PHILLIPS, DIW; SULTAN, HY				BARKER, DJP; WINTER, PD; OSMOND, C; PHILLIPS, DIW; SULTAN, HY			WEIGHT-GAIN IN INFANCY AND CANCER OF THE OVARY	LANCET			English	Note								The geographic association between ovarian cancer and tall stature suggests a link with rapid growth in early childhood. Among 5585 women born in Hertfordshire, UK, 41 who died from ovarian cancer had had a high rate of weight in infancy. Whereas their mean birthweight was the same as that of the other women, their mean weight at 1 year was higher (22.3 pounds [10.1 kg] vs 21.4 pounds [9.7 kg], p=0.01). These observations are consistent with the hypothesis that ovarian cancer is linked to altered patterns of gonadotropin release established in utero when the fetal hypothalamus is imprinted.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; BALASCH J, 1993, HUM REPROD, V8, P990, DOI 10.1093/oxfordjournals.humrep.a138215; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BERAL V, 1978, LANCET, V1, P1083; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Pfeiffer CA, 1936, AM J ANAT, V58, P195, DOI 10.1002/aja.1000580112; VONSAAL FS, 1980, SCIENCE, V208, P597; WHITTEMORE AS, 1989, CANCER RES, V49, P4047	10	35	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1087	1088		10.1016/S0140-6736(95)90821-8	http://dx.doi.org/10.1016/S0140-6736(95)90821-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7619123				2022-12-28	WOS:A1995QV41100013
J	JOHNS, DR				JOHNS, DR			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - MITOCHONDRIAL-DNA AND DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEREDITARY OPTIC NEUROPATHY; EXTERNAL OPHTHALMOPLEGIA; MUTATION; DELETIONS; SEQUENCES; DEAFNESS; THERAPY; GENOME; MTDNA		BETH ISRAEL HOSP,DEPT NEUROL,DIV NEUROMUSCULAR DIS,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center	JOHNS, DR (corresponding author), HARVARD UNIV,SCH MED,B1-242,220 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL EYE INSTITUTE [R01EY010864] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY10864] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AUSTIN SG, 1994, NEUROLOGY, V44, pA403; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CLAYTON DA, 1992, J INHERIT METAB DIS, V15, P439, DOI 10.1007/BF01799602; CULLOM ME, 1993, ARCH OPHTHALMOL-CHIC, V111, P1482, DOI 10.1001/archopht.1993.01090110048021; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOWELL N, 1994, CLIN NEUROSCI, V2, P130; HOWELL N, 1994, AM J HUM GENET, V55, P219; Johns Donald R., 1993, P329; JOHNS DR, 1989, GENOMICS, V5, P623, DOI 10.1016/0888-7543(89)90032-3; JOHNS DR, 1989, P NATL ACAD SCI USA, V86, P8059, DOI 10.1073/pnas.86.20.8059; JOHNS DR, 1991, ANN NEUROL, V30, P234; JOHNS DR, 1993, AM J HUM GENET, V53, P916; JOHNS DR, 1993, AM J OPHTHALMOL, V115, P108, DOI 10.1016/S0002-9394(14)73533-0; JOHNS DR, 1993, BIOCHEM BIOPH RES CO, V196, P810, DOI 10.1006/bbrc.1993.2321; JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5; JOHNS DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P1491, DOI 10.1001/archopht.1993.01090110057023; JOHNS DR, 1994, CLIN NEUROSCI, V2, P146; JOHNS DR, 1994, ANN NEUROL, V36, P315; JOHNS DR, 1995, MOL GENETICS OCULAR, P201; JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q; NEWMAN NJ, 1993, ARCH NEUROL-CHICAGO, V50, P540, DOI 10.1001/archneur.1993.00540050082021; NIKOSKELAINEN EK, 1987, ARCH OPHTHALMOL-CHIC, V105, P665, DOI 10.1001/archopht.1987.01060050083043; POULTON J, 1992, J INHERIT METAB DIS, V15, P487, DOI 10.1007/BF01799607; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299; SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200; SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; ZEVIANI M, 1992, J INHERIT METAB DIS, V15, P456, DOI 10.1007/BF01799604	47	337	352	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					638	644		10.1056/NEJM199509073331007	http://dx.doi.org/10.1056/NEJM199509073331007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637726				2022-12-28	WOS:A1995RR84000007
J	DEFRONZO, RA; GOODMAN, AM; ABELOVE, W; REID, E; PITA, J; CALLAHAN, M; JOHNSON, D; PELAYO, E; PUGH, J; SHANK, M; GARZA, P; HAAG, B; KORFF, J; ANGELO, A; IZENSTEIN, B; VANDERLEEDEN, M; CATHCART, H; TIERNEY, M; BIGGS, D; KARAM, J; NOLTE, M; GAVIN, L; ELDER, MA; CORBOY, J; THWAITE, D; WONG, S; DAVIDSON, M; PETERS, A; DUNCAN, T; KERCHER, S; FISCHER, J; KIPNES, M; RADNICK, BJ; ROURA, M; ROQUE, J; MONTGOMERY, C; COLLUM, P; RUST, M; POHL, S; PFEIFER, M; ALLWEISS, P; LEICHTER, S; LEACH, P; GALLINA, D; MUSEY, V; BERKOWITZ, K; EASTMAN, R; TAYLOR, T; DELAPENA, MS; ZAWADSKI, J; GRIMES, P; TANENBERG, R; VIGERSKY, R; PHILLIPS, G; BROWNING, S; FLOOD, T; FLOOD, J; SELTZER, H; DAVIDSON, J; ROSENSTOCK, J; ROBERTS, V; FLANDERS, D; CLARK, C; ALEXANDER, C; STEINKELER, S; FISHER, C; FINEBERG, S; BRIDGES, J; BLEVINS, V; SAUDEK, C; GEORGOPOULOS, K; MONAKIL, M; COOPPAN, R; BEASER, R; GANDA, O; ROSENZWEIG, J; WOLFSDORF, J; WRAY, M; KILO, C; DUDLEY, J; OJILE, J; WHITSETT, M; PALUMBO, PJ; KENNEDY, F; KUBLY, M; GARBER, A; HUFFMAN, D; GANDY, S; KELLY, L; TUCKER, W; MILLER, E; HINSHAW, H; KLEINMANN, R; BECK, J; BLONDE, L; ZIMMERMAN, R; MURRAY, J; REDDY, S; MIRANDA, E; MURRAY, J; FAESSLER, V; FALKO, J; RAO, M; JEFFERS, L; BROWN, J; LARSON, L; FLOYD, J; KNOPF, R; VANAPPLEDORN, S; GERICH, J; JOHNSTON, J; SALATA, R; CONSOLI, A; EVRON, W; KORYTKOWSKI, M; MOKAN, M; DERISO, L; VIGNATI, L; GOLDSTEIN, H; HUDSON, M; SHEEHAN, R; GRUNBERGER, G; VANDENBERG, M				DEFRONZO, RA; GOODMAN, AM; ABELOVE, W; REID, E; PITA, J; CALLAHAN, M; JOHNSON, D; PELAYO, E; PUGH, J; SHANK, M; GARZA, P; HAAG, B; KORFF, J; ANGELO, A; IZENSTEIN, B; VANDERLEEDEN, M; CATHCART, H; TIERNEY, M; BIGGS, D; KARAM, J; NOLTE, M; GAVIN, L; ELDER, MA; CORBOY, J; THWAITE, D; WONG, S; DAVIDSON, M; PETERS, A; DUNCAN, T; KERCHER, S; FISCHER, J; KIPNES, M; RADNICK, BJ; ROURA, M; ROQUE, J; MONTGOMERY, C; COLLUM, P; RUST, M; POHL, S; PFEIFER, M; ALLWEISS, P; LEICHTER, S; LEACH, P; GALLINA, D; MUSEY, V; BERKOWITZ, K; EASTMAN, R; TAYLOR, T; DELAPENA, MS; ZAWADSKI, J; GRIMES, P; TANENBERG, R; VIGERSKY, R; PHILLIPS, G; BROWNING, S; FLOOD, T; FLOOD, J; SELTZER, H; DAVIDSON, J; ROSENSTOCK, J; ROBERTS, V; FLANDERS, D; CLARK, C; ALEXANDER, C; STEINKELER, S; FISHER, C; FINEBERG, S; BRIDGES, J; BLEVINS, V; SAUDEK, C; GEORGOPOULOS, K; MONAKIL, M; COOPPAN, R; BEASER, R; GANDA, O; ROSENZWEIG, J; WOLFSDORF, J; WRAY, M; KILO, C; DUDLEY, J; OJILE, J; WHITSETT, M; PALUMBO, PJ; KENNEDY, F; KUBLY, M; GARBER, A; HUFFMAN, D; GANDY, S; KELLY, L; TUCKER, W; MILLER, E; HINSHAW, H; KLEINMANN, R; BECK, J; BLONDE, L; ZIMMERMAN, R; MURRAY, J; REDDY, S; MIRANDA, E; MURRAY, J; FAESSLER, V; FALKO, J; RAO, M; JEFFERS, L; BROWN, J; LARSON, L; FLOYD, J; KNOPF, R; VANAPPLEDORN, S; GERICH, J; JOHNSTON, J; SALATA, R; CONSOLI, A; EVRON, W; KORYTKOWSKI, M; MOKAN, M; DERISO, L; VIGNATI, L; GOLDSTEIN, H; HUDSON, M; SHEEHAN, R; GRUNBERGER, G; VANDENBERG, M			EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; NIDDM; SULFONYLUREAS; BIGUANIDES; THERAPY; RETINOPATHY; PREVALENCE; RESISTANCE; MECHANISM; PLASMA	Background. Sulfonylurea drugs have been the only oral therapy available for patients with non-insulin-dependent diabetes mellitus (NIDDM) in the United States, Recently, however, metformin has been approved for the treatment of NIDDM. Methods. We performed two large, randomized, parallel-group, double-blind, controlled studies in which metformin or another treatment was given for 29 weeks to moderately obese patients with NIDDM whose diabetes was inadequately controlled by diet (protocol 1: metformin vs. placebo; 289 patients), or diet plus glyburide (protocol 2: metformin and glyburide vs, metformin vs. glyburide; 632 patients). To determine efficacy we measured plasma glucose (while the patients were fasting and after the oral administration of glucose), lactate, lipids, insulin, and glycosylated hemoglobin before, during, and at the end of the study. Results. In protocol 1, at the end of the study the 143 patients in the metformin group, as compared with the 146 patients in the placebo group, had lower mean (+/-SE) fasting plasma glucose concentrations (189+/-5 vs. 244+/-6 mg per deciliter [10.6+/-0.3 vs. 13.7+/-0.3 mmol per liter], P<0.001) and glycosylated hemoglobin values (7.1+/-0.1 percent vs. 8.6+/-0.2 percent, P<0.001). In protocol 2, the 213 patients given metformin and glyburide, as compared with the 209 patients treated with glyburide alone, had lower mean fasting plasma glucose concentrations (187+/-4 vs. 261+/-4 mg per deciliter [10.5+/-0.2 vs. 14.6+/-0.2 mmol per liter], P<0.001) and glycosylated hemoglobin values (7.1+/-0.1 percent vs. 8.7+/-0.1 percent, P<0.001). The effect of metformin alone was similar to that of glyburide alone. Eighteen percent of the patients given metformin and glyburide had symptoms compatible with hypoglycemia, as compared with 3 percent in the glyburide group and 2 percent in the metformin group. In both protocols the patients given metformin had statistically significant decreases in plasma total and low-density lipoprotein cholesterol and triglyceride concentrations, whereas the values in the respective control groups did not change. There were no significant changes in fasting plasma lactate concentrations in any of the groups. Conclusions. Metformin monotherapy and combination therapy with metformin and sulfonylurea are well tolerated and improve glycemic control and lipid concentrations in patients with NIDDM whose diabetes is poorly controlled with diet or sulfonylurea therapy alone.	LIPHA PHARMACEUT, NEW YORK, NY USA; ARIZONA HLTH SCI CTR, TUCSON, AZ USA; AUDIE L MURPHY VET AFFAIRS HOSP, SAN ANTONIO, TX USA; BAYSTATE MED CTR, SPRINGFIELD, MA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA USA; CEDARS SINAI MED CTR, LOS ANGELES, CA USA; DIABET EDUC & RES CTR, PHILADELPHIA, PA USA; DIABET & GLANDULAR DIS CLIN, SAN ANTONIO, TX USA; MEM HOSP, CTR DIABET & THYROID, JACKSONVILLE, FL USA; DIABET RES & ANAL ASSOC, LEXINGTON, KY USA; EMORY UNIV, SCH MED, ATLANTA, GA USA; GEORGETOWN UNIV HOSP, WASHINGTON, DC USA; GEORGIA CTR DIABET, ATLANTA, GA USA; HUMANA MED CITY DALLAS HOSP, DALLAS, TX USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; JOSLIN DIABET CTR, BOSTON, MA USA; KILO DIABET & VASC RES FDN, ST LOUIS, MO USA; MAYO CLIN, ROCHESTER, MN USA; METHODIST HOSP, HOUSTON, TX USA; NALLE CLIN, CHARLOTTE, NC USA; OCHSNER CLIN & ALTON OCHSNER MED FDN, NEW ORLEANS, LA USA; OHIO STATE UNIV, COLL MED, COLUMBUS, MS USA; UNIV IOWA, IOWA CITY, IA USA; UNIV MICHIGAN HOSP, CLIN RES CTR, ANN ARBOR, MI USA; UNIV PITTSBURGH, PRESBYTERIAN UNIV HOSP, PITTSBURGH, PA USA; WALTHAM WESTERN HOSP & MED CTR, WALTHAM, MA USA; WAYNE STATE UNIV, SCH MED, DETROIT, MI USA	University of Arizona Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Baystate Medical Center; University of California System; University of California San Francisco; Cedars Sinai Medical Center; Emory University; Georgetown University; Medical City Dallas Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; Johns Hopkins University; Harvard University; Joslin Diabetes Center, Inc.; Mayo Clinic; The Methodist Hospital System; The Methodist Hospital - Houston; Ochsner Health System; University System of Ohio; Ohio State University; University of Iowa; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Wayne State University	DEFRONZO, RA (corresponding author), UNIV TEXAS, HLTH SCI CTR, DIV DIABET, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78229 USA.							[Anonymous], 1994, DIABETES CARE, V17, P519; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; BERGER W, 1985, HORM METAB RES, V15, P111; CAMPBELL IW, 1985, HORM METAB RES, V15, P105; CHARLES BG, 1981, CLIN CHEM, V27, P434; COHEN RD, 1979, RES CLIN FORUMS, V1, P125; CUSI K, 1994, DIABETES, V43, pA258; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; GROOP LC, 1992, DIABETES CARE, V15, P737, DOI 10.2337/diacare.15.6.737; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Hermann LS, 1992, INT TXB DIABETES MEL, V1, P773; HOTHERNIELSEN O, 1989, ACTA ENDOCRINOL-COP, V120, P257, DOI 10.1530/acta.0.1200257; JOHNSON AB, 1993, METABOLISM, V42, P1217, DOI 10.1016/0026-0495(93)90284-U; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLIP A, 1990, DIABETES CARE, V13, P696, DOI 10.2337/diacare.13.6.696; LANDIN K, 1991, J INTERN MED, V229, P181, DOI 10.1111/j.1365-2796.1991.tb00328.x; LUCIS OJ, 1983, CAN MED ASSOC J, V128, P24; NAGI DK, 1993, DIABETES CARE, V16, P621, DOI 10.2337/diacare.16.4.621; NATHAN DM, 1986, DIABETES, V35, P797, DOI 10.2337/diabetes.35.7.797; NETER J, 1985, APPL LINEAR STAT MOD, P517; NOSADINI R, 1987, DIABETES CARE, V10, P62, DOI 10.2337/diacare.10.1.62; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; REAVEN GM, 1992, J CLIN ENDOCR METAB, V74, P1020, DOI 10.1210/jc.74.5.1020; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; SCHAFER G, 1983, DIABETES METAB, V9, P148; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHANK ML, 1995, DIABETES, V44, P165, DOI 10.2337/diabetes.44.2.165; WIDEN EIM, 1992, DIABETES, V41, P354, DOI 10.2337/diabetes.41.3.354; WIHOLM BE, 1993, EUR J CLIN PHARMACOL, V44, P589, DOI 10.1007/BF02440866; WOLLEN N, 1988, BIOCHEM PHARMACOL, V37, P4353, DOI 10.1016/0006-2952(88)90617-X; 1988, SAS LANGUAGE PROCEDU	32	977	1012	2	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					541	549		10.1056/NEJM199508313330902	http://dx.doi.org/10.1056/NEJM199508313330902			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623902	Bronze			2022-12-28	WOS:A1995RQ75100002
J	STONE, MM; VANNIER, AM; STORCH, SK; PETERSON, C; NITTA, AT; ZHANG, YS				STONE, MM; VANNIER, AM; STORCH, SK; PETERSON, C; NITTA, AT; ZHANG, YS			BRIEF REPORT - MENINGITIS DUE TO LATROGENIC BCG INFECTION IN 2 IMMUNOCOMPROMISED CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							BACILLUS-CALMETTE-GUERIN; SUPERFICIAL BLADDER-CANCER; IMMUNOTHERAPY; COMPLICATIONS; VACCINATION; ABSCESS; SAFETY	VACCINATION with bacille Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, has been used extensively throughout the world as immunoprophylaxis against tuberculosis. Since 1976, intravesical administration of BCG has been used to treat superficial transitional-cell carcinoma of the bladder.(1) In both uses the complications of therapy have been rare, and the majority of serious side effects have occurred in immunocompromised persons.(2-5) In this report we describe two children with leukemia treated at our institution in whom BCG-associated meningitis developed. Neither child was receiving BCG as part of the immunotherapy for leukemia, and neither had a history of BCG vaccination. We speculate that both infections may have been caused by the accidental inoculation of BCG during the administration of intrathecal chemotherapy. Although proof is lacking, we believe that the contamination occurred in or near the biologic-safety cabinet in the hospital pharmacy, where both the chemotherapeutic agents used to treat these patients and the BCG used to treat patients with bladder cancer were prepared.	KAISER PERMANENTE REG LABS, DEPT PATHOL, N HOLLYWOOD, CA USA; LOS ANGELES CTY DEPT HLTH SERV, ACUTE COMMUN DIS CONTROL, LOS ANGELES, CA USA; LOS ANGELES CTY DEPT HLTH SERV, TB CONTROL UNIT, LOS ANGELES, CA USA; UNIV TEXAS, CTR HLTH, CTR PULM INFECT DIS CONTROL, TYLER, TX USA	Kaiser Permanente; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	STONE, MM (corresponding author), KAISER PERMANENTE MED CTR, DEPT PEDIAT, WOODLAND HILLS, CA USA.							BESNARD M, 1993, PEDIATR INFECT DIS J, V12, P993, DOI 10.1097/00006454-199312000-00006; BUTLER WR, 1991, J CLIN MICROBIOL, V29, P2468, DOI 10.1128/JCM.29.11.2468-2472.1991; COPPES MJ, 1992, CLIN INFECT DIS, V14, P662, DOI 10.1093/clinids/14.3.662; GLICKMAN SE, 1994, J CLIN MICROBIOL, V32, P740, DOI 10.1128/JCM.32.3.740-745.1994; GUPTA RC, 1988, CHEST, V94, P1296, DOI 10.1378/chest.94.6.1296; HAKIM S, 1993, J UROLOGY, V150, P188, DOI 10.1016/S0022-5347(17)35432-0; LALLEMANTLECOEUR S, 1991, AIDS, V5, P195, DOI 10.1097/00002030-199102000-00010; LAMM DL, 1992, J UROLOGY, V147, P596, DOI 10.1016/S0022-5347(17)37316-0; LAMM DL, 1992, UROL CLIN N AM, V19, P565; Lotte A, 1984, Adv Tuberc Res, V21, P107; MCPARLAND C, 1992, AM REV RESPIR DIS, V146, P1330, DOI 10.1164/ajrccm/146.5_Pt_1.1330; MORALES A, 1992, UROL CLIN N AM, V19, P549; PEDERSEN FK, 1978, ACTA PAEDIATR SCAND, V67, P519, DOI 10.1111/j.1651-2227.1978.tb16363.x; RYDER RW, 1993, J PEDIATR-US, V122, P697, DOI 10.1016/S0022-3476(06)80007-7; SHOPE TR, 1994, PEDIATRICS, V93, P835; SMITH RL, 1993, CANCER, V71, P1846, DOI 10.1002/1097-0142(19930301)71:5<1846::AID-CNCR2820710521>3.0.CO;2-O; SPARKS FC, 1976, MED CLIN N AM, V60, P499, DOI 10.1016/S0025-7125(16)31894-6; TARDIEU M, 1988, LANCET, V1, P440; WELTMAN AC, 1993, AIDS, V7, P149, DOI 10.1097/00002030-199302000-00001; ZHANG Y, 1995, TUBERCLE LUNG DIS, V76, P43, DOI 10.1016/0962-8479(95)90579-0; ZHANG YS, 1992, J CLIN MICROBIOL, V30, P1551, DOI 10.1128/JCM.30.6.1551-1556.1992; 1988, MMWR-MORBID MORTAL W, V37, P669; 1991, MMWR-MORBID MORTAL W, V40, P833; 1988, MMWR-MORBID MORTAL W, V37, P663	24	23	24	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					561	563		10.1056/NEJM199508313330905	http://dx.doi.org/10.1056/NEJM199508313330905			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623905	Bronze			2022-12-28	WOS:A1995RQ75100005
J	MOHLEBOETANI, JC; MILLER, B; HALPERN, M; TRIVEDI, A; TESSLER, J; SOLOMON, SL; FENSTERSHEIB, M				MOHLEBOETANI, JC; MILLER, B; HALPERN, M; TRIVEDI, A; TESSLER, J; SOLOMON, SL; FENSTERSHEIB, M			SCHOOL-BASED SCREENING FOR TUBERCULOUS INFECTION - A COST-BENEFIT-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION-ANALYSIS; PROGNOSIS; CHILDREN; REACTORS	Objective.-To compare tuberculin screening of all kindergartners and high school entrants (screen-all strategy) vs screening limited to high-risk children (targeted screening). Design.-Decision, cost-effectiveness, and cost-benefit analyses. Setting and Subjects.-Students in a large urban and rural county. Definitions.-High risk of tuberculous infection was defined as birth in a country with a high prevalence of tuberculosis. Low risk was defined as birth in the United States. Outcome Measures.-Tuberculosis cases prevented per 10 000 children screened. Net costs, net cost per case prevented, benefit-cost ratio, and incremental cost-effectiveness. Results.-The screen-all strategy would prevent 14.9 cases per 10 000 children screened; targeted screening would prevent 84.9 cases per 10 000 children screened. The screen-all strategy is more costly than no screening; the benefit-cost ratio is 0.58. Targeted screening would result in a net savings; the benefit-cost ratio is 1.2. Screening all children is cost saving only if the reactor rate is 20% or greater. The cost per additional case prevented for screening all children compared with targeted screening ($34 666) is more than twice as high as treatment and contact tracing for a case of tuberculosis ($16 392). Conclusions.-Targeted screening of schoolchildren is much less costly than mass screening and is more efficient in prevention of tuberculosis.	CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,CLIN RES BRANCH,PREVENT EFFECTIVENESS STUDIES UNIT,ATLANTA,GA 30333; CTY SANTA CLARA PUBL HLTH DEPT,DIV DIS CONTROL & PREVENT,SAN JOSE,CA; CTR DIS CONTROL & PREVENT,PREVENT MED RESIDENCY,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,SPECIAL STUDIES ACT,ATLANTA,GA 30333; BATTELLE CTR PUBL HLTH RES & EVALUAT,ARLINGTON,VA; BATTELLE CTR PUBL HLTH RES & EVALUAT,DURHAM,NC	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Mohle-Boetani, Janet/AAH-4221-2019					BARRY MA, 1990, AM J PUBLIC HEALTH, V80, P439, DOI 10.2105/AJPH.80.4.439; BASS JB, 1993, TUBERCULOSIS COMPREH, P139; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; COMSTOCK GW, 1986, JAMA-J AM MED ASSOC, V256, P2729, DOI 10.1001/jama.256.19.2729; COMSTOCK GW, 1975, AM REV RESPIR DIS, V11, P573; DAVIDSON P T, 1990, American Review of Respiratory Disease, V141, pA336; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GRZYBOWSKI S, 1964, AM REV RESPIR DIS, V90, P707; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; KOPLAN JP, 1980, JAMA-J AM MED ASSOC, V2442, P736; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; SCHECHTER Y, 1990, DIABETES, V39, P1; SHAW BV, 1993, PROFESSIONAL SOFTWAR; SNIDER DE, 1984, AM J PUBLIC HEALTH, V74, P1353, DOI 10.2105/AJPH.74.12.1353; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; 1991, LOTUS 1 2 3 DOS; 1993, ADV REPORT FINAL MOR, V41, P22; 1993, DATA MATTERS; 1982, B WORLD HEALTH ORGAN, V60, P555; 1988, MMWR-MORBID MORTAL W, V37, P663; 1994, AM J RESP CRIT CARE, V149, P1359; 1990, MMWR-MORBID MORTAL W, V39, P10; 1989, CDC898322 US DEP HLT; 1990, PERSONS AGE PLACE BI; 1994, PEDIATRICS, V93, P131; 1991, REPORT COMMITTEE INF, P487	34	78	78	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					613	619						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637141				2022-12-28	WOS:A1995RP70200028
J	WYNN, TA; CHEEVER, AW; JANKOVIC, D; POINDEXTER, RW; CASPAR, P; LEWIS, FA; SHER, A				WYNN, TA; CHEEVER, AW; JANKOVIC, D; POINDEXTER, RW; CASPAR, P; LEWIS, FA; SHER, A			AN IL-12-BASED VACCINATION METHOD FOR PREVENTING FIBROSIS INDUCED BY SCHISTOSOME INFECTION	NATURE			English	Article							TUMOR NECROSIS FACTOR; MURINE SCHISTOSOMIASIS; IMMUNE-RESPONSE; MESSENGER-RNA; MANSONI; MICE; INFLAMMATION; INDUCTION; INVIVO; BETA	THE harmful fibrosis which often occurs in the context of infectious. disease involves the excessive deposition of connective tissue matrix, particularly collagen, and is mostly resistant to pharmacological and immunological intervention(1). In schistosomiasis, fibrosis is associated with the granulomatous response to parasite eggs trapped in the liver(2). We have previously shown that interleukin (IL)-12 administered peritoneally with eggs prevents subsequent pulmonary granuloma formation on intravenous challenge with eggs(3). Here we show that sensitization with eggs plus IL-12 partly inhibits granuloma formation and dramatically reduces the tissue fibrosis induced by natural infection with Schistosoma mansoni worms. These results are an example of a vaccine against parasites which acts by preventing pathology rather than infection. IL-12, is known to favour the priming of Th1 rather than Th2 cells, and the effects on fibrosis are accompanied by replacement of the Th2-dominated pattern of cytokine expression characteristic of S. mansoni infection with one dominated by Th1 cytokines. Elevated Th2 cytokine expression and fibrosis are common manifestations of a wide variety of infectious diseases and atopic disorders which might be ameliorated by vaccination with antigen and IL-12.	NIAID,PARASIT DIS LAB,HOST PARASITE SECT,BETHESDA,MD 20892; BIOMED RES INST,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	WYNN, TA (corresponding author), NIAID,PARASITOL LAB,IMMUNOBIOL SECT,BETHESDA,MD 20892, USA.		Wynn, Thomas A/AAO-3523-2021; Wynn, Thomas A/C-2797-2011	Wynn, Thomas A/0000-0002-7244-8731; 				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; BERGQUIST NR, 1994, IMMUNOLOGIST, V2, P131; BUTTERWORTH AE, 1992, T ROY SOC TROP MED H, V86, P1, DOI 10.1016/0035-9203(92)90411-5; CAPRON AR, 1992, CURR OPIN IMMUNOL, V4, P419, DOI 10.1016/S0952-7915(06)80033-6; CHEEVER AW, 1992, J IMMUNOL, V148, P3244; CHEEVER AW, 1994, J IMMUNOL, V153, P753; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; DOMINGO EO, 1968, AM J PATHOL, V52, P369; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HENDERSON GS, 1992, J IMMUNOL, V148, P2261; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; OSWALD IP, 1994, J IMMUNOL, V153, P1707; PEARCE EJ, 1995, MOL APPROACHES PARAS, V12, P497; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; PLAYFAIR JHL, 1991, ACT LEIDENS, V60, P157; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SHER A, 1991, J IMMUNOL, V147, P2713; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; WYNN TA, 1993, J IMMUNOL, V151, P1430; WYNN TA, 1995, J IMMUNOL, V154, P4701; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551; YAMASHITA T, 1992, J IMMUNOL, V149, P3659; ZWINGENBERGER K, 1990, SCAND J IMMUNOL, V31, P205, DOI 10.1111/j.1365-3083.1990.tb02761.x	27	356	376	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					594	596		10.1038/376594a0	http://dx.doi.org/10.1038/376594a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637808				2022-12-28	WOS:A1995RP75600051
J	ANH, NTN; TRAM, TT				ANH, NTN; TRAM, TT			INTEGRATION OF PRIMARY HEALTH-CARE CONCEPTS IN A CHILDRENS-HOSPITAL WITH LIMITED RESOURCES	LANCET			English	Article								After nearly 30 years of war, health services in Vietnam were devastated. Pediatric Hospital Number 1 (PH1) in Ho Chi Minh City was severely overloaded, mortality rates for readily treatable diseases were high, and staff competence and motivation were low. In 1988, PH1 introduced primary health care (PHC) concepts into the policy of the hospital. The approach included identification of priority diseases that are most easily treatable (diarrhoea, acute respiratory infections, Dengue haemorrhagic fever, malnutrition, and common paediatric emergencies including malaria); establishment of training programmes through paediatric priority training units for medical staff of PH1 and health centres (district and commune services), and health education for the patients' carers; promotion of outpatient treatment to avoid unnecessary admissions; use of appropriate technology such as essential drugs and application of WHO guidelines; support for health centres; transfer of responsibility for decision-making from one central authority to each department; and community participation, by which we sought small contributions from families who could afford to pay. Since the new approach was implemented, the numbers of admissions have fallen substantially. Mortality rates have decreased greatly (diarrhoea by 80%, Dengue fever by 64%, and acute respiratory infections by 41%). Support from foreign non-governmental organisations has enabled training and research to enhance staff skill and knowledge and supply of necessary equipment. Fund mobilisation from patients is unlikely to be substantial in developing countries, but budget should not be regarded as the sole factor that affects mortality rates. Better use of the limited resources available has enabled us to achieve our objective of decreasing the hospital mortality rates.	PEDIAT HOSP 1, DEPT PEDIAT, HO CHI MINH CITY, VIETNAM; UNIV TRAINING CTR, HO CHI MINH CITY, VIETNAM									BREWER H, 1992, FAR E HLTH, P14; MILLS A, HLTH P0OLICY PLANNIN, V5, P203; 1993, AGENDA ACTION; 1988, DIARRHOEA TRAINING U; 1993, EVALUATION RECENT CH, P37; 1978, 1978 INT C PRIM HLTH	6	7	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					421	424		10.1016/S0140-6736(95)92785-9	http://dx.doi.org/10.1016/S0140-6736(95)92785-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623575				2022-12-28	WOS:A1995RN65600014
J	STOLLERMAN, GH				STOLLERMAN, GH			RHEUMATIC CARDITIS	LANCET			English	Editorial Material									BOSTON UNIV,SCH MED,DEPT PUBL HLTH,BOSTON,MA 02215	Boston University	STOLLERMAN, GH (corresponding author), BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02215, USA.							ALBERT DA, 1995, MEDICINE, V74, P1, DOI 10.1097/00005792-199501000-00001; [Anonymous], 1965, CIRCULATION, V32, P457; DORFMAN A, 1961, PEDIATRICS, V27, P692; FEINSTEIN AR, 1959, NEW ENGL J MED, V260, P1001, DOI 10.1056/NEJM195905142602002; MRKOWITZ M, 1972, RHEUMATIC FEVER; STOLLERMAN GH, 1988, HEART DISEASE TXB CA, P1706; STOLLERMAN GH, 1975, RHEUMATIC FEVER STRE; STOLZER BL, 1955, ARCH INTERN MED, V95, P677, DOI 10.1001/archinte.1955.00250110047006; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; 1960, CIRCULATION, V22, P503; 1965, NEW ENGL J MED, V272, P63; 1960, NEW ENGL J MED, V262, P895	12	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					390	392		10.1016/S0140-6736(95)92776-X	http://dx.doi.org/10.1016/S0140-6736(95)92776-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623566	Bronze			2022-12-28	WOS:A1995RN65600005
J	FRANKLIN, WH; HICKEY, RW				FRANKLIN, WH; HICKEY, RW			LONG-QT SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											FRANKLIN, WH (corresponding author), CHILDRENS HOSP,700 CHILDRENS DR,COLUMBUS,OH 43205, USA.								0	5	5	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					355	355		10.1056/NEJM199508103330606	http://dx.doi.org/10.1056/NEJM199508103330606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609753				2022-12-28	WOS:A1995RN08200006
J	MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO				MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO			BLUNT IMPACT TO THE CHEST LEADING TO SUDDEN-DEATH FROM CARDIAC-ARREST DURING SPORTS ACTIVITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-QT SYNDROME; COMMOTIO-CORDIS; MYOCARDIAL-INFARCTION; YOUNG-ADULTS	Background. Sudden death from cardiac arrest in a young person may occur during sports play after a blunt blow to the chest in the absence of structural cardiovascular disease or traumatic injury (cardiac concussion or commotio cordis). We studied the clinical features of this apparently uncommon but important phenomenon. Methods. We identified cases from the registries of relevant agencies and organizations, as well as news-media accounts, and developed a clinical profile of 25 children and young adults, 3 to 19 years of age. Results. Each victim collapsed with cardiac arrest immediately after an unexpected blow to the chest, which was usually inflicted by a projectile (such as a baseball or hockey puck), Incidents took place during organized competitive sports in 16 cases and in recreational settings at home, at school, or on the playground in 9, in each instance, the impact to the chest was not judged to be extraordinary for the sport involved and did not appear to have sufficient force to cause death. Twelve victims collapsed virtually instantaneously on impact, whereas 13 remained conscious and physically active for a brief time before cardiac arrest. Cardiopulmonary resuscitation was administered within about three minutes to 19 victims, but normal cardiac rhythm could be restored in only 2 (both incurred irreversible brain damage and died shortly thereafter), Seven victims (28 percent) were wearing some form of protective chest padding. Conclusions. We speculate that most sudden deaths related to impact to the chest (not associated with traumatic injury) are due to ventricular dysrhythmia induced by an abrupt, blunt precordial blow, presumably delivered at an electrically vulnerable phase of ventricular excitability. This profile of blunt chest impact leading to cardiac arrest adds to our understanding of the range of causes of sudden death on the athletic field and may help in the development of preventive measures.	DARTMOUTH COLL SCH MED,DEPT PATHOL,LEBANON,NH; OFF NEW HAMPSHIRE STATE MED EXAMINER,LEBANON,NH; NATL CTR CATASTROPH SPORTS INJURY RES,CHAPEL HILL,NC; UNIV N CAROLINA,CHAPEL HILL,NC 27515	Dartmouth College; University of North Carolina; University of North Carolina Chapel Hill	MARON, BJ (corresponding author), MINNEAPOLIS HEART INST FDN,DIV CARDIOVASC RES,920 E 28TH ST,SUITE 40,MINNEAPOLIS,MN 55407, USA.							ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; COHN PF, 1977, CIRCULATION, V56, P598, DOI 10.1161/01.CIR.56.4.598; Cooper G J, 1989, J R Army Med Corps, V135, P58; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; FERSTLE J, 1978, PHYSICIAN SPORTSMED, V6, P21; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; GROSSFELD PD, 1993, MED SCI SPORT EXER, V25, P901; JAMES TN, 1967, ANN INTERN MED, V67, P1013, DOI 10.7326/0003-4819-67-5-1013; Janda DH., 1992, CLIN J SPORT MED, V2, P172; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KING AI, 1986, CPSCC841170 CONS PRO; KULBS F, 1909, MITT GRENZGEB MED CH, V19, P678; LOWN B, 1969, AM J MED, V46, P705, DOI 10.1016/0002-9343(69)90022-9; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1993, CIRCULATION, V88, P50; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; PRINGLE SD, 1987, BRIT HEART J, V57, P375; RAGOSTA M, 1984, MED SCI SPORT EXER, V16, P339; RUTHERFORD G, 1981, OVERVIEW SPORTS RELA; SMIRK FH, 1960, AM J CARDIOL, V6, P620, DOI 10.1016/0002-9149(60)90265-4; SWIFT EM, 1993, SPORTS ILLUSTRA 1206, P66; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; VIANO DC, 1978, J TRAUMA, V18, P452, DOI 10.1097/00005373-197806000-00010; Viano DC, 1992, CLIN J SPORT MED, V2, P166; VIANO DC, 1992, CLIN J SPORT MED, V2, P161; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; ZOLL PM, 1976, NEW ENGL J MED, V294, P1274, DOI 10.1056/NEJM197606032942307	36	223	231	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					337	342		10.1056/NEJM199508103330602	http://dx.doi.org/10.1056/NEJM199508103330602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609749	Green Submitted			2022-12-28	WOS:A1995RN08200002
J	CHOW, WH; FINKLE, WD; MCLAUGHLIN, JK; FRANKL, H; ZIEL, HK; FRAUMENI, JF				CHOW, WH; FINKLE, WD; MCLAUGHLIN, JK; FRANKL, H; ZIEL, HK; FRAUMENI, JF			THE RELATION OF GASTROESOPHAGEAL REFLUX DISEASE AND ITS TREATMENT TO ADENOCARCINOMAS OF THE ESOPHAGUS AND GASTRIC CARDIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BARRETTS-ESOPHAGUS; CIMETIDINE; CANCER	Objective.-To examine the relationship of gastrointestinal disorders and their treatment to the risk of adenocarcinomas of the esophagus and gastric cardia (AEC). Design.-A medical record-based case-control study, with data collected on a standardized form by a trained abstractor, blind to the case-control status. Setting.-A large prepaid health plan. Subjects.-Case patients were plan members newly diagnosed with histologically confirmed AEC from 1986 to 1992. For each of the 196 eligible case patients, one control was selected who matched for membership at time of diagnosis, sex, year of birth, and duration of membership. Main Outcome Measures.-Association between AEC and history of gastroesophageal conditions and their treatment. Conditional logistic regression procedures were used for calculation of odds ratios (ORs) and corresponding 95% confidence intervals (Cls), with adjustment for race, smoking status, and body mass index. Medications were grouped into H-2 antagonists (cimetidine, ranitidine, famotidine, and nizatidine) and anticholinergics (propantheline bromide, dicyclomine hydrochloride, Donnatal [combination of atropine sulfate, hyoscyamine sulfate, phenobarbital, and scopolamine hydrobromide], and Librax [combination of chlordiazepoxide hydrochloride and clidinium bromide]). Results.-Significant twofold or greater risks of AEC were associated with a history of esophageal reflux, hiatal hernia, esophagitis/esophageal ulcer, and difficulty swallowing. The ORs increased with increasing number of these conditions. Although a fourfold risk was linked to four or more prescriptions for H-2 antagonists, the risk was reduced to 1.5 (95% CI, 0.4 to 5.4) after adjusting for the predisposing conditions. Further analysis revealed that the excess risk was restricted to persons with a history of gastroesophageal reflux and related conditions. No association was observed for overall use of anticholinergics. However, after adjustment for predisposing conditions, ORs decreased with increasing number of prescriptions for anticholinergics (P for trend=.08). Conclusions.-This study provides reassuring findings that use of H-2 antagonists and anticholinergics does not increase AEC risk. It also quantifies the elevated risk of AEC associated with gastroesophageal reflux disease. Further research into reflux disease and the production of premalignant epithelial changes may help elucidate carcinogenic mechanisms and measures aimed at early detection and prevention of AEC.	INT EPIDEMIOL INST,ROCKVILLE,MD 20850; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892; SO CALIF PERMANENTE MED GRP,DEPT MED,LOS ANGELES,CA 90027; SO CALIF PERMANENTE MED GRP,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90027	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups					NCI NIH HHS [N01 CP 95680] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095680] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BROWN LM, 1994, CANCER CAUSE CONTROL, V5, P333, DOI 10.1007/BF01804984; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; COLINJONES DG, 1991, Q J MED, V78, P13; ELDER JB, 1979, LANCET, V1, P1005, DOI 10.1016/S0140-6736(79)92757-0; GAREWAL HS, 1989, PREV MED, V18, P749, DOI 10.1016/0091-7435(89)90046-7; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; Harrison S L, 1992, Eur J Cancer Prev, V1, P271, DOI 10.1097/00008469-199204000-00009; KABAT GC, 1993, CANCER CAUSE CONTROL, V4, P123, DOI 10.1007/BF00053153; LAVECCHIA C, 1992, NUTRITION, V8, P177; MACDONALD WC, 1987, CANCER, V60, P1094, DOI 10.1002/1097-0142(19870901)60:5<1094::AID-CNCR2820600529>3.0.CO;2-4; Moller H, 1992, Eur J Cancer Prev, V1, P159; MOLLER H, 1992, GUT, V33, P1166, DOI 10.1136/gut.33.9.1166; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; REED PI, 1979, LANCET, V1, P1234; REID BJ, 1991, GASTROENTEROL CLIN N, V20, P817; Schumacher M C, 1990, Epidemiology, V1, P251, DOI 10.1097/00001648-199005000-00012; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; VAUGHAN TL, 1992, RECENT ADV BIOL PREV; WANG HH, 1986, HUM PATHOL, V17, P482, DOI 10.1016/S0046-8177(86)80038-7; WANG HH, 1994, CANCER CAUSE CONTROL, V5, P573, DOI 10.1007/BF01831386; [No title captured]	25	291	297	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					474	477		10.1001/jama.274.6.474	http://dx.doi.org/10.1001/jama.274.6.474			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629956				2022-12-28	WOS:A1995RM69900027
J	WORLD, MJ				WORLD, MJ			TOXIC GAS TRAUMA	LANCET			English	Editorial Material											WORLD, MJ (corresponding author), ROYAL ARMY MED COLL,DEPT MIL MED,LONDON,ENGLAND.							VANBIEMA D, 1995, TIME, V145, P21	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					260	261		10.1016/S0140-6736(95)92158-3	http://dx.doi.org/10.1016/S0140-6736(95)92158-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630240				2022-12-28	WOS:A1995RL75700003
J	WELLBERY, CE				WELLBERY, CE			ROUTINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					297	297						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609249				2022-12-28	WOS:A1995RJ89800012
J	NICHOLL, JP; BRAZIER, JE; SNOOKS, HA				NICHOLL, JP; BRAZIER, JE; SNOOKS, HA			EFFECTS OF LONDON HELICOPTER EMERGENCY MEDICAL-SERVICE ON SURVIVAL AFTER TRAUMA	BRITISH MEDICAL JOURNAL			English	Article							INJURY SEVERITY; SCORE; CARE	Objective-To assess the effect of the London helicopter emergency medical service on survival after trauma. Design-Prospective comparison of outcomes in cohorts of seriously injured patients attended by the helicopter and attended by London ambulance service land ambulances crewed by paramedics. Setting-Greater London. Subjects-337 patients attended by helicopter and 466 patients attended by ambulance who sustained traumatic injuries and died, stayed in hospital three or more nights, or had other evidence of severe injury and who were taken to any one of 20 primary receiving hospitals. Main outcome measure-Survival at six months after the incident. Results-After differences in the nature and severity of the injuries in the two cohorts were accounted for the estimated survival rates were the same (relative risk of death with helicopter=1.0; 95% confidence interval 0.7 to 1.4). An analysis with trauma and injury severity scores (TRISS) found 16% more deaths than predicted in the helicopter cohort but only 2% more in the ambulance cohort. There was no evidence of a difference in survival for patients with head injury but a little evidence that patients with major trauma (injury severity score greater than or equal to 16) were more likely to survive if attended by the helicopter. An estimated 13 (-5 to 39) extra patients with major trauma could survive each year if attended by the helicopter. Conclusion-Any benefit in survival is restricted to patients with very severe injuries and amounts to an estimated one additional survivor of major trauma each month. Over all the helicopter caseload, however, there is no evidence that it improves the chance of survival in trauma.			NICHOLL, JP (corresponding author), UNIV SHEFFIELD,MED CARE RES UNIT,REGENT COURT,SHEFFIELD S1 4DA,S YORKSHIRE,ENGLAND.		Nicholl, Jon/B-8257-2008; brazier, john e/B-1936-2008; Snooks, Helen A/N-2165-2014	Snooks, Helen A/0000-0003-0173-8843; Brazier, John/0000-0001-8645-4780				[Anonymous], 1990, ABBREVIATED INJURY S; BAXT WG, 1985, ANN EMERG MED, V14, P859, DOI 10.1016/S0196-0644(85)80634-X; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BURNEY RE, 1985, ANN EMERG MED, V14, P927, DOI 10.1016/S0196-0644(85)80650-8; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Good P., 1993, PERMUTATION TESTS PR; HARVIEL JD, 1989, J TRAUMA, V29, P766, DOI 10.1097/00005373-198906000-00012; HOLLIS S, IN PRESS J TRAUMA; JONES JM, 1995, J TRAUMA, V38, P118, DOI 10.1097/00005373-199501000-00028; NICHOLL JP, 1994, COSTS EFFECTIVENESS; WALSH S, 1993, REPORT EFFECTS LONDO; WISNER DH, 1992, ARCH SURG-CHICAGO, V127, P111	13	103	104	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					217	222		10.1136/bmj.311.6999.217	http://dx.doi.org/10.1136/bmj.311.6999.217			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627033	Green Published			2022-12-28	WOS:A1995RL44100016
J	LEAN, MEJ; HAN, TS; MORRISON, CE				LEAN, MEJ; HAN, TS; MORRISON, CE			WAIST CIRCUMFERENCE AS A MEASURE FOR INDICATING NEED FOR WEIGHT MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article							BODY-FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; OBESE WOMEN; ADIPOSE-TISSUE; RISK-FACTORS; FOLLOW; PARTICIPANTS; CHOLESTEROL; OVERWEIGHT; REDUCTION	Objective-To test the hypothesis that a single measurement, waist circumference, might be used to identify people at health risk both from being overweight and from having a central fat distribution. Design-A community derived random sample of men and women and a second, validation sample. Setting-North Glasgow. Subjects-904 men and 1014 women (first sample); 86 men and 202 women (validation sample). Main outcome measures-Waist circumference, body mass index, waist:hip ratio. Results-Waist circumference greater than or equal to 94 cm for men and greater than or equal to 80 cm for women identified subjects with high body mass index (greater than or equal to 25 kg/m(2)) and those with lower body mass index but high waist:hip ratio (greater than or equal to 0.95 for men, greater than or equal to 0.80 women) with a sensitivity of > 96% and specificity > 97.5%. Waist circumference greater than or equal to 102 cm for men or greater than or equal to 88 cm for women identified subjects with body mass index greater than or equal to 30 and those with lower body mass index but high waist:hip ratio with a sensitivity of > 96% and specificity > 98%, with only about 2% of the sample being misclassified. Conclusions-Waist circumference could be used in health promotion programmes to identify individuals who should seek and be offered weight management. Men with waist circumference greater than or equal to 94 cm and women with waist circumference greater than or equal to 80 cm should gain no further weight; men with waist circumference greater than or equal to 102 cm and women with waist circumference greater than or equal to 88 cm should reduce their weight.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW,LANARK,SCOTLAND	University of Glasgow	LEAN, MEJ (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT HUMAN NUTR,GLASGOW G31 2ER,LANARK,SCOTLAND.			Han, Thang/0000-0003-2570-0938				Bennett N, 1995, HLTH SURVEY ENGLAND; BJORNTORP P, 1987, AM J CLIN NUTR, V45, P1120, DOI 10.1093/ajcn/45.5.1120; CASIMIRRI F, 1989, ANN NUTR METAB, V33, P79, DOI 10.1159/000177524; CHAN JM, 1994, DIABETES CARE, V9, P961; DENBESTEN C, 1988, AM J CLIN NUTR, V47, P840, DOI 10.1093/ajcn/47.5.840; DENNIS KE, 1993, ARTERIOSCLER THROMB, V13, P1487, DOI 10.1161/01.ATV.13.10.1487; FLODMARK CE, 1994, ACTA PAEDIATR, V83, P941, DOI 10.1111/j.1651-2227.1994.tb13177.x; Gregory F., 1990, DIETARY NUTR SURVEY; HANSON P, 1988, RESOURCE MANUAL GUID; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; HOUMARD JA, 1994, INT J OBESITY, V18, P243; KANALEY JA, 1993, AM J CLIN NUTR, V57, P20, DOI 10.1093/ajcn/57.1.20; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NORUSIS MJ, 1993, BASE SYSTEM USERS GU; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; SEIDELL JC, 1989, INFUSIONSTHERAPIE, V16, P276; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SONNICHSEN AC, 1992, METABOLISM, V41, P1035, DOI 10.1016/0026-0495(92)90134-V; VANDERKOOY K, 1993, AM J CLIN NUTR, V58, P853, DOI 10.1093/ajcn/58.6.853; VANGAAL LF, 1990, BODY FAT DISTRIBUTIO; WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086; YUDKIN JS, 1993, BMJ-BRIT MED J, V306, P1313, DOI 10.1136/bmj.306.6888.1313; 1992, SCOTLANDS HLTH CHALL; 1989, WHO UD EURICPNUT125; 1991, OBESITY OVERWEIGHT; 1994, NUTRITIONAL ASPECTS; 1991, CM1583	31	1082	1141	0	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					158	161		10.1136/bmj.311.6998.158	http://dx.doi.org/10.1136/bmj.311.6998.158			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613427	Green Published			2022-12-28	WOS:A1995RK15900021
J	IRIBARREN, C; SHARP, DS; BURCHFIEL, CM; PETROVITCH, H				IRIBARREN, C; SHARP, DS; BURCHFIEL, CM; PETROVITCH, H			ASSOCIATION OF WEIGHT-LOSS AND WEIGHT FLUCTUATION WITH MORTALITY AMONG JAPANESE-AMERICAN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; BODY-WEIGHT; METABOLIC-RATE; HEALTH; RISK; VARIABILITY; LONGEVITY; STROKE; HAWAII	Background. Weight loss and fluctuations in weight have been associated with increased risks of death from cardiovascular disease and from all causes. The clinical and public health implications of these associations are unclear. Methods. We examined the long-term relation of weight change and fluctuation in weight with mortality over a 6-year period in 6537 middle-aged Japanese American men enrolled in the Honolulu Heart Program, a prospective study (mean follow-up, 14.5 years). Results. Men who had a weight loss of 4.5 kg or more or who had large fluctuations in weight (or both) over a six-year period were, on average, in poorer health than their peers whose weight was more stable. After the exclusion of subjects who died during the first five years of follow-up and after adjustment for confounding factors, a weight loss of more than 4.5 kg was associated with the risk of death from all causes, with the exception of death from cancer. The subjects whose weight fluctuated the most had a significantly higher risk of death from cardiovascular causes (relative risk, 1.41; 95 percent confidence interval, 1.03 to 1.93), death from noncardiovascular and noncancerous causes (relative risk, 1.53; 95 percent confidence interval, 1.12 to 2.10), and death from all causes (relative risk, 1.25; 95 percent confidence interval, 1.05 to 1.48). However, the associations of weight loss and variation in weight with death from cardiovascular causes and from noncardiovascular and noncancerous causes were not found among healthy men who had never smoked. Conclusions. The associations between weight loss or fluctuation and mortality were partially explained by confounding factors and by the presence of preexisting disease. However, weight loss and weight fluctuation were unrelated to death among healthy men who had never smoked. Thus, concern about the health hazards of weight loss and variation may not be applicable to otherwise healthy people.	NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, HONOLULU EPIDEMIOL RES UNIT, BETHESDA, MD 20892 USA; UNIV HAWAII MANOA, JOHN A BURNS SCH MED, DEPT MED, HONOLULU, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Hawaii System; University of Hawaii Manoa	IRIBARREN, C (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.				NHLBI NIH HHS [N01-HV-02901, N01-HC-02901] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC002901] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; ARCHAMBAULT CM, 1989, PHYSIOL BEHAV, V46, P417, DOI 10.1016/0031-9384(89)90013-9; BELSKY JL, 1971, 1271 AT BOMB CAS COM; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; BROWNELL KD, 1986, PHYSIOL BEHAV, V38, P459, DOI 10.1016/0031-9384(86)90411-7; COX DR, 1972, J R STAT SOC B, V34, P187; DRAPER NR, 1981, APPLIED REGRESSION A, P19; FRENCH SA, 1995, INT J OBESITY, V19, P22; GORDON T, 1975, AM J CLIN NUTR, V28, P304, DOI 10.1093/ajcn/28.4.304; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS TB, 1993, AM J EPIDEMIOL, V137, P1318, DOI 10.1093/oxfordjournals.aje.a116641; HO SC, 1994, J GERONTOL, V49, pM269, DOI 10.1093/geronj/49.6.M269; JEBB SA, 1991, INT J OBESITY, V15, P367; JEFFERY RW, 1992, AM J CLIN NUTR, V55, P641, DOI 10.1093/ajcn/55.3.641; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KRAEMER H C, 1990, Annals of Behavioral Medicine, V12, P119, DOI 10.1207/s15324796abm1203_4; KULLER L, 1993, ANN INTERN MED, V119, P630, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00015; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; Reed G W, 1993, Obes Res, V1, P392; RHOADS GG, 1983, LANCET, V1, P492; Rumpel C, 1993, Ann Epidemiol, V3, P343, DOI 10.1016/1047-2797(93)90060-H; RUMPEL C, 1994, INT J OBESITY, V18, P179; SCHOTTE DE, 1990, HEALTH PSYCHOL, V9, P599, DOI 10.1037/0278-6133.9.5.599; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STEVENS J, 1990, INT J OBESITY, V14, P385; TAYLOR CB, 1995, AM J EPIDEMIOL, V141, P461, DOI 10.1093/oxfordjournals.aje.a117448; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WATT BK, 1963, DEP AGR HDB, V8; Wing R R, 1993, Obes Res, V1, P390; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; 1994, JAMA-J AM MED ASSOC, V272, P1196; 1987, SAS STAT SOFTWARE VE; 1971, 1970 CENSUS POPULATI	41	109	109	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					686	692		10.1056/NEJM199509143331102	http://dx.doi.org/10.1056/NEJM199509143331102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637745				2022-12-28	WOS:A1995RV22700002
J	REID, MC; LACHS, MS; FEINSTEIN, AR				REID, MC; LACHS, MS; FEINSTEIN, AR			USE OF METHODOLOGICAL STANDARDS IN DIAGNOSTIC-TEST RESEARCH - GETTING BETTER BUT STILL NOT GOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DEEP-VEIN THROMBOSIS; PNEUMOCYSTIS-CARINII PNEUMONIA; POLYMERASE CHAIN-REACTION; CORTICOTROPIN-RELEASING HORMONE; LIQUID-CRYSTAL THERMOGRAPHY; PROSTATIC ACID-PHOSPHATASE; URINARY-TRACT INFECTION; VENOUS THROMBOSIS; RAPID DIAGNOSIS; TUBERCULOUS MENINGITIS	Objective.-To determine the frequency and temporal changes in application of seven accepted methodological standards for the evaluation of diagnostic tests. Data Sources.-A search of the MEDLINE database yielded 1302 articles about diagnostic test studies, during a 16-year secular interval, 1978 through 1993, in four prominent general medical journals. Study Selection.-In the 112 eligible studies, the test was intended for clinical use, indexes of accuracy (sensitivity and specificity or likelihood ratios) were provided, and more than 10 patients were enrolled. Data Extraction.-Although each study was critically reviewed by one primary observer, a subset was independently evaluated for interrater consistency. Data Synthesis.-The percentage of studies that fulfilled criteria for each of the seven methodological standards are as follows: (1) specify spectrum of evaluated patients, 27%; (2) report test indexes for clinical subgroups, 8%; (3) avoid workup bias, 46%; (4) avoid review bias, 38%; (5) provide numerical precision for test indexes, 11%, (6) report frequency and management of indeterminate results when calculating test indexes, 22%; and (7) specify test reproducibility, 23%. Secular increases were found for six of the seven standards in ranges of use from 14% to 31% during 1978-1981 to 1990-1993. Nevertheless, only one standard, avoidance of workup bias, was fulfilled by more than 50% of studies in the most recent secular interval. Conclusions.-These results indicate that most diagnostic tests are still inadequately appraised. The routine demand for methodological standards could raise the quality of diagnostic test information, and the careful predissemination evaluation of diagnostic tests could eliminate useless tests before they receive widespread application.	YALE UNIV, SCH MED, ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL, NEW HAVEN, CT 06520 USA; CORNELL UNIV, NEW YORK HOSP, SCH MED, DIV GEN INTERNAL MED, NEW YORK, NY USA	Yale University; Yale University; Yale University; Cornell University; NewYork-Presbyterian Hospital				Reid, Cary/0000-0001-8117-662X	PHS HHS [K0800580] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN AP, 1981, BRIT MED J, V283, P97, DOI 10.1136/bmj.283.6284.97; AMOUYAL P, 1989, LANCET, V2, P1195; ANDERSON GH, 1980, LANCET, V2, P821; ARROLL B, 1988, J GEN INTERN MED, V3, P443, DOI 10.1007/BF02595920; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BAKKER AJ, 1993, LANCET, V342, P1220, DOI 10.1016/0140-6736(93)92192-V; BARAKAT MH, 1984, LANCET, V1, P656; BATES AS, 1993, J PEDIATR-US, V122, P585, DOI 10.1016/S0022-3476(05)83540-1; BECKER DM, 1989, ARCH INTERN MED, V149, P1731, DOI 10.1001/archinte.149.8.1731; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; BEGG CB, 1986, J CHRON DIS, V39, P575; BERCHE P, 1990, LANCET, V335, P624, DOI 10.1016/0140-6736(90)90411-W; BERGER LA, 1979, LANCET, V1, P633; BESWICK W, 1979, BRIT MED J, V1, P82, DOI 10.1136/bmj.1.6156.82; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; BUNKER SR, 1982, JAMA-J AM MED ASSOC, V247, P789, DOI 10.1001/jama.247.6.789; CARSON JL, 1985, JAMA-J AM MED ASSOC, V253, P665, DOI 10.1001/jama.253.5.665; CHOU S, 1983, NEW ENGL J MED, V308, P921, DOI 10.1056/NEJM198304213081603; COOPER GL, 1985, NEW ENGL J MED, V312, P1142, DOI 10.1056/NEJM198505023121802; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; COULDEN RA, 1990, LANCET, V336, P273, DOI 10.1016/0140-6736(90)91804-J; CUSICK EL, 1990, BMJ-BRIT MED J, V301, P318, DOI 10.1136/bmj.301.6747.318; DANIEL WG, 1991, NEW ENGL J MED, V324, P795, DOI 10.1056/NEJM199103213241203; DEMETRIOU E, 1984, JAMA-J AM MED ASSOC, V252, P247, DOI 10.1001/jama.252.2.247; DIAMOND GA, 1992, MED DECIS MAKING, V12, P22, DOI 10.1177/0272989X9201200105; DIAMOND GA, 1990, J AM COLL CARDIOL, V16, P1017, DOI 10.1016/S0735-1097(10)80356-0; DOWN RHL, 1979, LANCET, V2, P1094; DUNCAN MW, 1988, NEW ENGL J MED, V319, P136, DOI 10.1056/NEJM198807213190303; ELVIN KM, 1988, BRIT MED J, V297, P381, DOI 10.1136/bmj.297.6645.381; ERBEL R, 1989, LANCET, V1, P457; EZEKOWITZ MD, 1982, NEW ENGL J MED, V306, P1509, DOI 10.1056/NEJM198206243062502; FEDAIL SS, 1978, LANCET, V1, P181; FINEBERG HV, 1979, NEW ENGL J MED, V301, P1086, DOI 10.1056/NEJM197911153012004; FLANAGAN PG, 1989, LANCET, V1, P1117, DOI 10.1016/S0140-6736(89)92392-1; FLANIGAN DP, 1978, LANCET, V2, P331; Fleiss JL, 1981, STAT METHODS RATES P; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; FREITAS JE, 1980, JAMA-J AM MED ASSOC, V244, P1585, DOI 10.1001/jama.244.14.1585; FRENCH GL, 1987, LANCET, V2, P117; GARCIA HH, 1991, LANCET, V338, P549; GOKA AKJ, 1986, LANCET, V2, P184; GOLIGHTLY MG, 1993, AM J CLIN PATHOL, V99, P168, DOI 10.1093/ajcp/99.2.168; GOWLAND M, 1981, LANCET, V2, P190; GRAHAM DY, 1987, LANCET, V1, P1174; GRASBECK R, 1982, LANCET, V1, P1330; GREENES RA, 1985, INVEST RADIOL, V20, P751, DOI 10.1097/00004424-198510000-00018; GUYATT GH, 1986, CAN MED ASSOC J, V134, P587; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEINSIMER JA, 1987, JAMA-J AM MED ASSOC, V257, P3266; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HODSON ME, 1983, BMJ-BRIT MED J, V286, P1381, DOI 10.1136/bmj.286.6375.1381; HOLZEL W, 1991, SCAND J CLIN LAB INV, V51, P113, DOI 10.3109/00365519109104609; HORROCKS PM, 1982, BRIT MED J, V285, P1302, DOI 10.1136/bmj.285.6351.1302; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; ISOMAKI O, 1989, LANCET, V1, P1411; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JOBST KA, 1992, LANCET, V340, P1179; KAUL S, 1986, JAMA-J AM MED ASSOC, V255, P508, DOI 10.1001/jama.255.4.508; KEMPSTER PA, 1987, LANCET, V1, P769; KENT DL, 1992, INVEST RADIOL, V27, P245, DOI 10.1097/00004424-199203000-00014; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KOVACS JA, 1986, LANCET, V2, P1; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; KRAMBOVITIS E, 1984, LANCET, V2, P1229, DOI 10.1016/S0140-6736(84)92792-2; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; LAHAV M, 1987, JAMA-J AM MED ASSOC, V257, P39, DOI 10.1001/jama.257.1.39; LAKEBAKAAR G, 1979, LANCET, V2, P878; LAMAS AM, 1984, JAMA-J AM MED ASSOC, V252, P2999, DOI 10.1001/jama.252.21.2999; LANDESMAN S, 1991, JAMA-J AM MED ASSOC, V266, P3443, DOI 10.1001/jama.266.24.3443; LEICESTER RJ, 1983, BRIT MED J, V286, P673, DOI 10.1136/bmj.286.6366.673; LENSING AWA, 1993, THROMB HAEMOSTASIS, V69, P2; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEWIT EM, 1982, JAMA-J AM MED ASSOC, V247, P321, DOI 10.1001/jama.247.3.321; LIMBERG B, 1990, LANCET, V335, P144, DOI 10.1016/0140-6736(90)90012-T; LIMBERG B, 1992, NEW ENGL J MED, V327, P65, DOI 10.1056/NEJM199207093270201; LINDHOLM GR, 1980, JAMA-J AM MED ASSOC, V244, P2071, DOI 10.1001/jama.244.18.2071; LIPSCHIK GY, 1992, LANCET, V340, P203, DOI 10.1016/0140-6736(92)90469-J; LOFFELD RJLF, 1989, LANCET, V1, P1182; LOFT DE, 1990, LANCET, V335, P1293, DOI 10.1016/0140-6736(90)91183-B; LU CZ, 1990, LANCET, V336, P10, DOI 10.1016/0140-6736(90)91519-G; MALHOTRA AS, 1981, JAMA-J AM MED ASSOC, V246, P1113, DOI 10.1001/jama.246.10.1113; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; MANSON JC, 1980, LANCET, V1, P330; MARCHAND A, 1980, JAMA-J AM MED ASSOC, V243, P1909, DOI 10.1001/jama.243.19.1909; MORTIMER MJ, 1990, LANCET, V335, P75, DOI 10.1016/0140-6736(90)90541-C; MUSHLIN AI, 1993, JAMA-J AM MED ASSOC, V269, P3146, DOI 10.1001/jama.269.24.3146; NAHASS GT, 1992, JAMA-J AM MED ASSOC, V268, P2541, DOI 10.1001/jama.268.18.2541; NI HL, 1992, LANCET, V340, P1432, DOI 10.1016/0140-6736(92)92622-M; NICHOLS AB, 1978, NEW ENGL J MED, V299, P279, DOI 10.1056/NEJM197808102990604; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; NIERENBERG AA, 1988, JAMA-J AM MED ASSOC, V259, P1699, DOI 10.1001/jama.259.11.1699; NOE DA, 1994, LABORATORY MED SELEC; NORMAN RJ, 1985, LANCET, V1, P19; NORMAN RJ, 1986, BRIT MED J, V292, P590, DOI 10.1136/bmj.292.6520.590; OCONNOR DT, 1983, JAMA-J AM MED ASSOC, V249, P383; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; PODOLSKY DK, 1981, NEW ENGL J MED, V304, P1313, DOI 10.1056/NEJM198105283042201; POWER EJ, 1994, ANNU REV PUBL HEALTH, V15, P561; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; RAFFO JA, 1979, BRIT MED J, V2, P295, DOI 10.1136/bmj.2.6185.295; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RAPOZA PA, 1986, JAMA-J AM MED ASSOC, V255, P3369; RICKMAN LS, 1989, LANCET, V1, P68; ROSE SR, 1988, NEW ENGL J MED, V319, P201, DOI 10.1056/NEJM198807283190403; RUDDELL WSJ, 1981, BRIT MED J, V283, P1429, DOI 10.1136/bmj.283.6304.1429; RYDER REJ, 1988, LANCET, V1, P1303, DOI 10.1016/S0140-6736(88)92120-4; SANDLER DA, 1985, LANCET, V1, P665; SANDLER DA, 1984, LANCET, V2, P716; SAVAGE COS, 1987, LANCET, V1, P1389; SCHAPIRA RM, 1993, JAMA-J AM MED ASSOC, V270, P731, DOI 10.1001/jama.270.6.731; SCHINDLER JM, 1990, BRIT MED J, V301, P1369, DOI 10.1136/bmj.301.6765.1369; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SETHABUTR O, 1985, LANCET, V2, P1095; SHANKAR P, 1991, LANCET, V337, P5, DOI 10.1016/0140-6736(91)93328-7; SHAW ST, 1985, JAMA-J AM MED ASSOC, V253, P1596, DOI 10.1001/jama.253.11.1596; SHEPS SB, 1984, JAMA-J AM MED ASSOC, V252, P2418, DOI 10.1001/jama.252.17.2418; SHULTZ T, 1979, JAMA-J AM MED ASSOC, V242, P439, DOI 10.1001/jama.242.5.439; SIMEL DL, 1987, MED DECIS MAKING, V7, P107, DOI 10.1177/0272989X8700700208; SIMPSON FG, 1980, LANCET, V1, P331; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STENMAN UH, 1983, LANCET, V2, P647; TAYLOR KJW, 1978, LANCET, V1, P83; TEARE JP, 1993, LANCET, V342, P895, DOI 10.1016/0140-6736(93)91946-J; TEMPERO MA, 1982, JAMA-J AM MED ASSOC, V248, P1329, DOI 10.1001/jama.248.11.1329; THIBONNIER M, 1984, JAMA-J AM MED ASSOC, V251, P56, DOI 10.1001/jama.251.1.56; THOMAS EA, 1989, BRIT MED J, V299, P951, DOI 10.1136/bmj.299.6705.951; TSANG RSW, 1981, BRIT MED J, V282, P1505, DOI 10.1136/bmj.282.6275.1505; TULASSAY Z, 1988, BRIT MED J, V297, P297; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9; VOIGT MD, 1989, LANCET, V1, P751; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WAKEFIELD AE, 1991, LANCET, V337, P1378, DOI 10.1016/0140-6736(91)93062-E; WARNKE RA, 1983, NEW ENGL J MED, V309, P1275, DOI 10.1056/NEJM198311243092102; WEGNER DL, 1992, JAMA-J AM MED ASSOC, V267, P695, DOI 10.1001/jama.267.5.695; WEISS N, 1978, LANCET, V2, P1231; WOLSON AH, 1978, JAMA-J AM MED ASSOC, V240, P2073, DOI 10.1001/jama.240.19.2073; YANOVSKI JA, 1993, JAMA-J AM MED ASSOC, V269, P2232, DOI 10.1001/jama.269.17.2232; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	142	565	575	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					645	651		10.1001/jama.274.8.645	http://dx.doi.org/10.1001/jama.274.8.645			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637146				2022-12-28	WOS:A1995RP70200033
J	STROES, ESG; KOOMANS, HA; DEBRUIN, TWA; RABELINK, TJ				STROES, ESG; KOOMANS, HA; DEBRUIN, TWA; RABELINK, TJ			VASCULAR FUNCTION IN THE FOREARM OF HYPERCHOLESTEROLEMIC PATIENTS OFF AND ON LIPID-LOWERING MEDICATION	LANCET			English	Article							ENDOTHELIUM-DEPENDENT VASODILATION; RESISTANCE VESSELS; CORONARY-ARTERIES; NITRIC-OXIDE; L-ARGININE; RELEASE; CHOLESTEROL; HUMANS	To study whether vascular dysfunction in hypercholesterolaemia is reversible, we investigated patients without overt arterial disease who were taking maintenance treatment for hypercholesterolaemia. Medication was stopped for 2 weeks, reinstituted for 12 weeks, and again stopped for 6 weeks. During both maintenance treatment and the 12 weeks of step-up medication the lipid profile was improved but did not return to normal. Dose-response curves for serotonin-induced vasodilatation, an index of nitric oxide-dependent vasodilatation, showed a comparable and significant rightward shift. after a medication-free period of 2 and 6 weeks compared with control subjects, indicating endothelial dysfunction, which was already maximum after 2 weeks. After 12 weeks of lipid-lowering medication, the difference in endothelial function between controls and patients had disappeared. Go-infusion of L-arginine, the substrate for nitric oxide synthase, returned the impaired serotonin response during hypercholesterolaemia to normal, but had no effect on this response in controls or in patients while on lipid-lowering medication. Neither endothelium-independent vasorelaxation, assessed by sodium nitroprusside infusion, nor vasoconstriction induced by the nitric oxide blocker L-NMMA, were different between controls and patients, whether the latter were on or off lipid-lowering medication. Our results show an L-arginine-sensitive, impaired nitric-oxide-mediated vascular relaxation of forearm resistance vessels in hypercholesterolaemia which is reproducible, and reversible after short-term lipid-lowering therapy. Demonstration of such changes in this readily accessible vascular bed will allow larger trials assessing vascular function during lipid-lowering therapy to be done.	UNIV UTRECHT HOSP,DEPT MED,LIPID CLIN,3584 CX UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,DEPT HYPERTENS & NEPHROL,3584 CX UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center			Rabelink, Ton J./A-5316-2008	Rabelink, Ton J./0000-0001-6780-5186				ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BRUNING TA, 1994, J CARDIOVASC PHARM, V24, P454, DOI 10.1097/00005344-199409000-00014; BRUNING TA, 1994, CIRC RES, V74, P912, DOI 10.1161/01.RES.74.5.912; BUSSE R, 1993, CIRCULATION, V87, P18; CALVER A, 1992, J CLIN INVEST, V90, P2448; CASINO PR, 1993, CIRCULATION, V88, P2541, DOI 10.1161/01.CIR.88.6.2541; CHANG PC, 1988, COMPUT BIOL MED, V18, P157, DOI 10.1016/0010-4825(88)90042-X; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; CHOWIENCZYK PJ, 1995, CLIN SCI, V88, P111, DOI 10.1042/cs0880111; CHOWIENCZYK PJ, 1994, LANCET, V344, P305, DOI 10.1016/S0140-6736(94)91342-0; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DUBOISRANDE JL, 1992, J CARDIOVASC PHARM, V20, pA211; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; EGASHIRA K, 1993, J CLIN INVEST, V91, P29, DOI 10.1172/JCI116183; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Goldstein JL, 1983, METABOLIC BASIS INHE, P672; HARRISON DG, 1995, AM J CARDIOL, V75, pB75, DOI 10.1016/0002-9149(95)80018-N; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; PRITCHARD KA, 1995, ENDOTHELIUM S, V2, pS19; RABELINK AJ, 1988, LANCET, V2, P1335; SHIMOKAWA H, 1991, CIRCULATION, V83, P652, DOI 10.1161/01.CIR.83.2.652; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801	28	373	380	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					467	471		10.1016/S0140-6736(95)91322-X	http://dx.doi.org/10.1016/S0140-6736(95)91322-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637480				2022-12-28	WOS:A1995RP85700010
J	VENANCE, L; PIOMELLI, D; GLOWINSKI, J; GIAUME, C				VENANCE, L; PIOMELLI, D; GLOWINSKI, J; GIAUME, C			INHIBITION BY ANANDAMIDE OF GAP-JUNCTIONS AND INTERCELLULAR CALCIUM SIGNALING IN STRIATAL ASTROCYTES	NATURE			English	Article							SINGLE-CHANNEL CURRENTS; CANNABINOID RECEPTOR; COMMUNICATION; WAVES; PROTEIN; BINDS; CELLS	ANANDAMIDE, an endogenous arachidonic acid derivative that is released from neurons and activates cannabinoid receptors(1), may act as a transcellular cannabimimetic messenger in the central nervous system(2-4). The biological actions of anandamide and the identity of its target cells are, however, still poorly documented(5). Here we show that anandamide is a potent inhibitor of gap-junction conductance and dye permeability in striatal astrocytes. This inhibitory effect is specific for anandamide as compared to coreleased congeners(4) or structural analogues, is sensitive to pertussis toxin and to protein-alkylating agents, and is neither mimicked by cannabinoid-receptor agonists nor prevented by a cannabinoid-receptor antagonist. Glutamate released from neurons evokes calcium waves in astrocytes(6) that propagate via gap junctions(7-9), and may, in turn, activate neurons distant from their initiation sites in astrocytes(10-12). We find that anandamide blocks the propagation of astrocyte calcium waves generated by either mechanical stimulation or local glutamate application. Thus, by regulating gap-junction permeability, anandamide may control intercellular communication in astrocytes and therefore neuron-glial interactions.	COLL FRANCE,INSERM,U114,F-75231 PARIS 05,FRANCE; INST NEUROSCI,LA JOLLA,CA 92037	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			Venance, Laurent/E-5840-2016	Venance, Laurent/0000-0003-0738-1662				CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; COMELLBELL AH, 1990, SCIENCE, V247, P470; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DEVANE WA, 1994, TRENDS PHARMACOL SCI, V15, P40, DOI 10.1016/0165-6147(94)90106-6; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIAUME C, 1991, P NATL ACAD SCI USA, V88, P5577, DOI 10.1073/pnas.88.13.5577; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MURPHY NP, 1994, EUR J NEUROSCI, V6, P854, DOI 10.1111/j.1460-9568.1994.tb00995.x; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0	28	310	316	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					590	594		10.1038/376590a0	http://dx.doi.org/10.1038/376590a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637807	Green Submitted			2022-12-28	WOS:A1995RP75600050
J	ALPERS, A; LO, B				ALPERS, A; LO, B			PHYSICIAN-ASSISTED SUICIDE IN OREGON - A BOLD EXPERIMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT; LIFE; CARE		UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALPERS, A (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM MED ETH,521 PARNASSUS AVE,ROOM C 126,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P474; BELKIN L, 1993, NY TIMES MAGAZI 1114, P75; BELKIN L, 1993, NY TIMES MAGAZI 1114, P74; BELKIN L, 1993, NY TIMES MAGAZI 1114, P63; Belkin Lisa, 1993, N Y Times Mag, P48; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; CHRISTAKIS N, 1993, J GEN INTERN MED, V9, P314; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Doyle D., 1993, OXFORD TXB PALLIATIV; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; LO B, 1995, RESOLVING ETHICAL DI, P168; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	22	55	55	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					483	487		10.1001/jama.274.6.483	http://dx.doi.org/10.1001/jama.274.6.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629958				2022-12-28	WOS:A1995RM69900029
J	ASAI, A; FUKUHARA, S; LO, B				ASAI, A; FUKUHARA, S; LO, B			ATTITUDES OF JAPANESE AND JAPANESE-AMERICAN PHYSICIANS TOWARDS LIFE-SUSTAINING TREATMENT	LANCET			English	Article								Doctors in different countries have different approaches to bioethical problems. We studied how attitudes to life-sustaining treatment for terminally ill patients differ in Japan and the USA by administering a questionnaire to Japanese (136) and Japanese-American (77) physicians. In a series of clinical scenarios the questionnaire asked what life-sustaining interventions the doctors would recommend to a patient with metastatic gastric cancer. Most Japanese physicians would recommend blood for transfusions for gastrointestinal bleeding (74%) total parenteral nutrition for malnutrition (67%) and vasopressors for life-threatening hypotension (61%) when the patient did not know of his diagnosis and outlook. Significantly fewer Japanese physicians would want these interventions for themselves: 29% would want transfusion, 36% would want total parenteral nutrition, and 25% would want vasopressors. 36% of Japanese physicians would override the explicit request of a competent moribund cancer patient to withdraw all life-support. By contrast, among Japanese-American physicians only 42% would recommend blood transfusions, 33% total parenteral nutrition, and 34% vasopressors to a terminally ill cancer patient who did not know of his diagnosis or outlook. Cross-cultural studies in medical ethics can help physicians and the public in different countries to take a fresh took at accepted practices and the ethical reasons behind them.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT GEN INTERNAL MED,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV TOKYO,FAC MED,DIV INTERNAL HLTH,TOKYO,JAPAN	University of California System; University of California San Francisco; University of Tokyo					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRAMPTON MW, 1987, J GEN INTERN MED, V2, P394, DOI 10.1007/BF02596364; HADFIELD P, 1993, LANCET, V341, P1141, DOI 10.1016/0140-6736(93)93144-P; LO B, 1995, RESOLVING ETHICAL DI, P141; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; 1994, REPORT SURVEY JAPANE	7	81	83	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					356	359		10.1016/S0140-6736(95)92230-X	http://dx.doi.org/10.1016/S0140-6736(95)92230-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM713	7623536				2022-12-28	WOS:A1995RM71300013
J	STEEL, KP				STEEL, KP			HAIR-CELL REGENERATION - CURE FOR DEAFNESS	LANCET			English	Editorial Material							ACOUSTIC TRAUMA; INNER-EAR				STEEL, KP (corresponding author), MRC, INST HEARING RES, UNIV PK, NOTTINGHAM, ENGLAND.							CORWIN JT, 1991, CIBA F SYMP, V160, P103; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; FORGE A, 1993, SCIENCE, V259, P1616, DOI 10.1126/science.8456284; KESSLER J, 1995, CIBA F S, V196; LEFEBVRE PP, 1993, SCIENCE, V260, P692, DOI 10.1126/science.8480180; LEWIS J, 1991, CIBA F SYMP, V160, P25, DOI 10.4171/RMI/104; RUBEL EW, 1995, SCIENCE, V267, P701, DOI 10.1126/science.7839150; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; STAECKER H, 1995, SCIENCE, V267, P709, DOI 10.1126/science.267.5198.709; WARCHOL ME, 1993, SCIENCE, V259, P1619, DOI 10.1126/science.8456285	10	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					325	326		10.1016/S0140-6736(95)92220-2	http://dx.doi.org/10.1016/S0140-6736(95)92220-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623526				2022-12-28	WOS:A1995RM71300003
J	WATTERS, JK				WATTERS, JK			HIV TEST-RESULTS, PARTNER NOTIFICATION, AND PERSONAL CONDUCT	LANCET			English	Editorial Material							INFECTION		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143, USA.							BAYER R, 1992, AM J PUBLIC HEALTH, V82, P1158, DOI 10.2105/AJPH.82.8.1158; GREEN J, 1995, LANCET, V345, P1508; HOFFMAN RE, 1995, J ACQ IMMUN DEF SYND, V8, P406; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; MASON HRC, 1995, HEALTH PSYCHOL, V14, P6, DOI 10.1037/0278-6133.14.1.6; NORTH RL, 1993, NEW ENGL J MED, V329, P1194, DOI 10.1056/NEJM199310143291612; PAVIA AT, 1993, AM J PUBLIC HEALTH, V83, P1418, DOI 10.2105/AJPH.83.10.1418; SIGNORILE M, 1995, NY TIMES        0226, V15; TEMMERMAN M, 1995, LANCET, V345, P969, DOI 10.1016/S0140-6736(95)90707-6; 1995, MMWR-MORBID MORTAL W, V44, P202; 1994, HIV AIDS SURVEILLANC, V6, P17; 1995, MMWR-MORBID MORTAL W, V44, P401	14	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					326	327		10.1016/S0140-6736(95)92221-0	http://dx.doi.org/10.1016/S0140-6736(95)92221-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623527				2022-12-28	WOS:A1995RM71300004
J	STOYANOV, B; VOLINIA, S; HANCK, T; RUBIO, I; LOUBTCHENKOV, M; MALEK, D; STOYANOVA, S; VANHAESEBROECK, B; DHAND, R; NURNBERG, B; GIERSCHIK, P; SEEDORF, K; HSUAN, JJ; WATERFIELD, MD; WETZKER, R				STOYANOV, B; VOLINIA, S; HANCK, T; RUBIO, I; LOUBTCHENKOV, M; MALEK, D; STOYANOVA, S; VANHAESEBROECK, B; DHAND, R; NURNBERG, B; GIERSCHIK, P; SEEDORF, K; HSUAN, JJ; WATERFIELD, MD; WETZKER, R			CLONING AND CHARACTERIZATION OF A G-PROTEIN-ACTIVATED HUMAN PHOSPHOINOSITIDE-3 KINASE	SCIENCE			English	Article							PHOSPHOLIPASE-C ISOZYMES; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATED ACCUMULATION; BINDING-SITE; YEAST; CELLS	Phosphoinositide-3 kinase activity is implicated in diverse cellular responses triggered by mammalian cell surface receptors and in the regulation of protein sorting in yeast. Receptors with intrinsic and associated tyrosine kinase activity recruit heterodimeric phosphoinositide-3 kinases that consist of p110 catalytic subunits and p85 adaptor molecules containing Src homology 2 (SH2) domains. A phosphoinositide-3 kinase isotype, p110 gamma, was cloned and characterized. The p110 gamma enzyme was activated in vitro by both the alpha and beta gamma subunits of heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins) and did not interact with p85. A potential pleckstrin homology domain is located near its amino terminus. The p110 gamma isotype may link signaling through G protein-coupled receptors to the generation of phosphoinositide second messengers phosphorylated in the D-3 position.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON WCE 6BT, ENGLAND; UNIV JENA, FAC MED, MAX PLANCK RES UNIT GROWTH FACTOR SIGNAL TRANSDUC, D-07747 JENA, GERMANY; UNIV ULM, DEPT PHARMACOL & TOXICOL, D-89069 ULM, GERMANY; UNIV JENA, FAC MED, INST BIOCHEM 2, D-07747 JENA, GERMANY; FREE UNIV BERLIN, INST PHARMACOL, D-14195 BERLIN, GERMANY; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Ludwig Institute for Cancer Research; University of London; University College London; Friedrich Schiller University of Jena; Max Planck Society; Ulm University; Friedrich Schiller University of Jena; Free University of Berlin; Max Planck Society			Volinia, Stefano/A-3029-2010; Volinia, Stefano/AAA-9264-2019; Hsuan, Justin/C-8825-2009; Wetzker, Reinhard/AAD-8713-2019	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Hsuan, Justin/0000-0001-6083-7564; Nurnberg, Bernd/0000-0002-5995-6555				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIERSCHIK P, 1994, METHOD ENZYMOL, V238, P181; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; NURNBERG B, 1994, BIOCHEM J, V300, P387; OKADA T, 1994, J BIOL CHEM, V269, P3568; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; VOLINIA S, IN PRESS EMBO J; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YANO H, 1993, J BIOL CHEM, V268, P25846	32	633	675	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					690	693		10.1126/science.7624799	http://dx.doi.org/10.1126/science.7624799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624799				2022-12-28	WOS:A1995RM70200034
J	SHIGEMATSU, I; MENDELSOHN, ML				SHIGEMATSU, I; MENDELSOHN, ML			THE RADIATION-EFFECTS-RESEARCH-FOUNDATION-OF-HIROSHIMA-AND-NAGASAKI - PAST, PRESENT, AND FUTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									RADIAT EFFECTS RES FDN,NAGASAKI,JAPAN	Radiation Effects Research Foundation - Japan	SHIGEMATSU, I (corresponding author), RADIAT EFFECTS RES FDN,MINAMI KU,5-2 HIJIYAMA PK,HIROSHIMA 732,JAPAN.							Neel J V, 1991, CHILDREN ATOMIC BOMB; PUTNAM FW, 1994, PERSPECT BIOL MED, V37, P515; ROESCH WE, 1987, US JAPAN REASSESSMEN, V1; SHIGEMATSU I, 1995, EFFECT A BOMB RAD HU; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; YOSHIMOTO Y, 1994, LANCET, V344, P345, DOI 10.1016/S0140-6736(94)91389-7; 1995, R95096 US DEP EN	7	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					425	426						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616640				2022-12-28	WOS:A1995RL41600031
J	WEINBERG, AD; KRIPALANI, S; MCCARTHY, PL; SCHULL, WJ				WEINBERG, AD; KRIPALANI, S; MCCARTHY, PL; SCHULL, WJ			CARING FOR SURVIVORS OF THE CHERNOBYL DISASTER - WHAT THE CLINICIAN SHOULD KNOW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW TRANSPLANTATION; A-BOMB SURVIVORS; POST-CHERNOBYL; NUCLEAR ACCIDENTS; INDUCED ABORTIONS; BIRTH-DEFECTS; CANCER; CONSEQUENCES; MORTALITY; RADIATION	The health status of approximately 1 million immigrants in the United States and Israel may have been adversely affected by radiation exposure as a result of the Chernobyl nuclear power plant disaster and cleanup efforts. Many of these immigrants suffer from significant psychological distress, fearing that they have a radiation-induced illness. Based on a review of the literature and our experience from the US National Chernobyl Registry Coordinating Center, we recommend that medical management of these immigrants include routine physical examination, with particular attention to the thyroid gland. Adults should receive regular cancer screening as well as routine blood chemistry tests, thyroid function tests, complete blood cell count, and urinalysis. Children should be examined regularly, with attention to the thyroid and overall body growth. It is reasonable for children to undergo thyroid studies, a complete blood cell count, or neuropsychiatric testing if there is clinical suspicion of a disorder. Given the long latency period for disease induction by radiation exposure, it is still too early to fully assess and draw conclusions concerning the possible health effects of the Chernobyl disaster, and long-term follow-up of all potentially affected individuals is important.	UNIV TEXAS, HLTH SCI CTR, CTR HUMAN GENET, SCH PUBL HLTH, HOUSTON, TX USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	WEINBERG, AD (corresponding author), BAYLOR COLL MED, CTR CANC CONTROL RES, DEPT MED, 1 BAYLOR PLAZA, ST924, HOUSTON, TX 77030 USA.							ABELIN T, 1994, SOZ PRAVENTIV MED, V39, P189, DOI 10.1007/BF01309218; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1991, INT CHERNOBYL PROJEC; AUVINEN A, 1994, BRIT MED J, V309, P151, DOI 10.1136/bmj.309.6948.151; BARANOV A, 1989, NEW ENGL J MED, V321, P205, DOI 10.1056/NEJM198907273210401; Baverstock K F, 1993, World Health Stat Q, V46, P204; BEHAR A, 1990, Journal of Environmental Pathology Toxicology and Oncology, V10, P281; BERTOLLINI R, 1990, SCAND J WORK ENV HEA, V16, P96, DOI 10.5271/sjweh.1803; BOICE J, 1994, BRIT MED J, V309, P139, DOI 10.1136/bmj.309.6948.139; BOLSHOVA EV, 1993, ACTA ENDOCRINOL-COP, V129, P594, DOI 10.1530/acta.0.1290594; BONTE FJ, 1988, SEMIN NUCL MED, V18, P16, DOI 10.1016/S0001-2998(88)80016-3; BUTTURINI A, 1994, BRIT MED J, V309, P1299; CASTRONOVO FP, 1987, J NUCL MED, V28, P535; CHAMPLIN R, 1987, SEMIN HEMATOL, V24, P1; CHAMPLIN RE, 1988, ANN INTERN MED, V109, P730, DOI 10.7326/0003-4819-109-9-730; DERUIG WG, 1992, ANALYST, V117, P545, DOI 10.1039/an9921700545; DEWALS P, 1988, INT J EPIDEMIOL, V17, P230, DOI 10.1093/ije/17.1.230; EMERIT I, 1994, J CANCER RES CLIN, V120, P558, DOI 10.1007/BF01221035; ERICSON A, 1994, ENVIRON RES, V67, P149, DOI 10.1006/enrs.1994.1070; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GALE RP, 1987, JAMA-J AM MED ASSOC, V258, P625, DOI 10.1001/jama.258.5.625; GEIGER HJ, 1986, JAMA-J AM MED ASSOC, V256, P609, DOI 10.1001/jama.256.5.609; GINZBURG HM, 1993, PUBLIC HEALTH REP, V108, P184; GOLD SJ, 1994, AM JEWISH YB, V94, P3; GUVENC H, 1993, J EPIDEMIOL COMMUN H, V47, P40, DOI 10.1136/jech.47.1.40; HAEUSLER MCH, 1992, AM J OBSTET GYNECOL, V167, P1025, DOI 10.1016/S0002-9378(12)80032-9; HARJULEHTO T, 1989, BRIT MED J, V298, P995, DOI 10.1136/bmj.298.6679.995; HARJULEHTOMERVAALA T, 1992, MUTAT RES, V275, P81, DOI 10.1016/0921-8734(92)90011-D; HJALMARS U, 1994, BRIT MED J, V309, P154, DOI 10.1136/bmj.309.6948.154; HOLOWINSKY IZ, 1993, MENT RETARD, V31, P35; JENSEN RH, 1995, RADIAT RES, V141, P129, DOI 10.2307/3579040; KAMPMANN B, 1994, BRIT MED J, V309, P1299; KATO H, 1982, RADIAT RES, V91, P243, DOI 10.2307/3575833; KATO H, 1982, RADIAT RES, V90, P395, DOI 10.2307/3575716; KNUDSEN LB, 1991, BIOMED PHARMACOTHER, V45, P229, DOI 10.1016/0753-3322(91)90022-L; KUCHUK AA, 1994, TOXICOL LETT, V72, P213, DOI 10.1016/0378-4274(94)90031-0; LIE RT, 1992, AM J EPIDEMIOL, V136, P377, DOI 10.1093/oxfordjournals.aje.a116510; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; LIKHTAREV IA, 1994, RADIAT ENVIRON BIOPH, V33, P149, DOI 10.1007/BF01219338; LINNEMANN RE, 1987, JAMA-J AM MED ASSOC, V258, P637; LITTELL FH, 1993, HOLOCAUST GENOCIDE S, V7, P121, DOI 10.1093/hgs/7.1.121; Mettler FA, 1995, MED EFFECTS IONIZING; Mould R F, 1987, Br J Radiol, V60, pB29; Nazarov A. N., 1992, Problemy Endokrinologii, V38, P58; Neel J V, 1991, CHILDREN ATOMIC BOMB; NENOT JC, 1990, INT J RADIAT BIOL, V57, P1073, DOI 10.1080/09553009014551201; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; PARAZZINI F, 1988, BRIT MED J, V296, P136, DOI 10.1136/bmj.296.6615.136-a; PARKIN DM, 1993, EUR J CANCER, V29A, P87, DOI 10.1016/0959-8049(93)90582-Z; Perry A R, 1990, Radiol Technol, V61, P290; PETER RU, 1994, J AM ACAD DERMATOL, V30, P719, DOI 10.1016/S0190-9622(08)81501-0; PETRIDOU E, 1994, SCAND J SOC MED, V22, P127, DOI 10.1177/140349489402200208; RAYMOND L, 1991, SOZ PRAVENTIV MED, V36, P304, DOI 10.1007/BF01359163; RON E, 1992, NATURE, V360, P113, DOI 10.1038/360113a0; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SJOBERG L, 1987, MED ONCOL TUMOR PHAR, V4, P259; SOUCHKEVITCH G, 1995, PARTICIPANTS CLEAN U; SPERLING K, 1994, BRIT MED J, V309, P158, DOI 10.1136/bmj.309.6948.158; STOLL C, 1990, AM J MED GENET, P79; TAJTAKOVA M, 1993, HORM METAB RES, V25, P644, DOI 10.1055/s-2007-1002197; TRICHOPOULOS D, 1987, BRIT MED J, V295, P1100, DOI 10.1136/bmj.295.6606.1100; YARILIN AA, 1993, INT J RADIAT BIOL, V63, P519, DOI 10.1080/09553009314550681; 1977, 5 NAT COUNC RAD PROT; 1995, CANCER FACTS FIGURES; 1988, 37TH SESS ANN VIENN; 1985, 35TH SESS UNSCEAR NE; 1988, PAEDIATR PERINAT EP, V2, P253	67	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					408	412		10.1001/jama.274.5.408	http://dx.doi.org/10.1001/jama.274.5.408			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616637				2022-12-28	WOS:A1995RL41600027
J	HORTON, R				HORTON, R			US SCIENCE ON THE SLIDE	LANCET			English	Editorial Material																		Ahrens E.H., 1992, CRISIS CLIN RES OVER; GIBBONS JH, 1995, SCIENCE, V269, P143, DOI 10.1126/science.269.5221.143; MANDEL HG, 1994, SCIENCE, V266, P1789, DOI 10.1126/science.7997868; MANDEL HG, 1995, SCIENCE, V269, P13, DOI 10.1126/science.7604271	4	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					260	260		10.1016/S0140-6736(95)92157-5	http://dx.doi.org/10.1016/S0140-6736(95)92157-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630239				2022-12-28	WOS:A1995RL75700002
J	SMITH, N; WILSON, A; WEEKES, T				SMITH, N; WILSON, A; WEEKES, T			USE OF READ CODES IN DEVELOPMENT OF A STANDARD DATA SET	BRITISH MEDICAL JOURNAL			English	Article								General practice has a wealth of data that could be used for purposes such as assessing health needs, planning, and audit. If this potential is to be realised appropriate data must be easily accessible and of high quality. This article describes the experience of an information project team in developing and coding a standard data set, with the aim of meeting the needs of commissioners, public health, and general practitioners. The Read coding classification seemed the logical choice for the standard data set because Read codes are the basis of a standard classification of general practice data. However, the coding structure has several weaknesses that were difficult to resolve, and the standard data set had to be changed to match available codes. This paper may prove helpful to similar project teams attempting to develop and use a standard data set.	WAKEFIELD HEALTHCARE,WAKEFIELD WF1 1LT,W YORKSHIRE,ENGLAND		SMITH, N (corresponding author), UNIV LEEDS,CTR RES PRIMARY CARE,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.							ANDERSON P, 1988, ALCOHOL PROBLEMS; PRINGLE M, 1990, BRIT MED J, V301, P827, DOI 10.1136/bmj.301.6756.827; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284; 1990, NEW CLIN CLASSIFICAT; 1993, REQUIREMENTS ACCREDI; 1988, CLASSIFICATION GENER; 1993, COMPUTERISATION GP P; 1992, HLTH NATION; 1994, GP              0513, P90; 1992, ALLIED DUNBAR NATION; 1993, READ CODES TERMS PRO	12	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					313	315		10.1136/bmj.311.7000.313	http://dx.doi.org/10.1136/bmj.311.7000.313			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633247	Green Published			2022-12-28	WOS:A1995RM71900035
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEM RULE TO PROTECT IDENTITIES OF REPORTERS OF ADVERSE EVENTS AND PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					292	292						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609246				2022-12-28	WOS:A1995RJ89800008
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - GETTING YOUR THOUGHTS ON PAPER	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,HILLINGDON,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER,ENGLAND	Gloucestershire Royal Hospital	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					245	249		10.1136/bmj.311.6999.245	http://dx.doi.org/10.1136/bmj.311.6999.245			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627046	Green Published			2022-12-28	WOS:A1995RL44100029
J	SHELLEY, WB; SHELLEY, ED; TALANIN, NY				SHELLEY, WB; SHELLEY, ED; TALANIN, NY			HYPERSENSITIVITY TO RETINOL PALMITATE INJECTION	BRITISH MEDICAL JOURNAL			English	Letter							VITAMIN-A				SHELLEY, WB (corresponding author), MED COLL OHIO,DEPT MED,POB 10008,TOLEDO,OH 43699, USA.							BATES CJ, 1995, LANCET, V345, P31, DOI 10.1016/S0140-6736(95)91157-X; BLONDEEL A, 1984, CONTACT DERMATITIS, V11, P191, DOI 10.1111/j.1600-0536.1984.tb00976.x; DANILOV L N, 1977, Klinicheskaya Meditsina (Moscow), V55, P122; MCCORMICK PA, 1990, BRIT MED J, V301, P924, DOI 10.1136/bmj.301.6757.924; Nagano T, 1965, Wakayama Med Rep, V10, P105	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					232	232		10.1136/bmj.311.6999.232	http://dx.doi.org/10.1136/bmj.311.6999.232			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627039	Green Published			2022-12-28	WOS:A1995RL44100022
J	RIVERAPOMAR, R; LU, XG; PERRIMON, N; TAUBERT, H; JACKLE, H				RIVERAPOMAR, R; LU, XG; PERRIMON, N; TAUBERT, H; JACKLE, H			ACTIVATION OF POSTERIOR GAP DENE EXPRESSION IN THE DROSOPHILA BLASTODERM	NATURE			English	Article							CAUDAL GENE; PATTERN; PROTEIN; EMBRYO; GRADIENT; RNA; EMBRYOGENESIS; LOCALIZATION	THE process of body prepatterning during Drosophila blastoderm formation relies on the localized activities of zygotic segmentation genes, which are controlled by asymmetrically distributed maternal determinants(1,2). The anterior determinant bicoid, a homeodomain transcription factor(3,4), forms an anterior-to-posterior concentration gradient(1-4). It interacts with the maternal transcription factor hunchback(5) to activate the anterior zygotic patterning genes, including the central gap gene Kruppel (Kr)(6). In contrast, the posterior maternal system(1,2) does not provide such a decisive transcription factor, but rather prevents the repressor hunchback from acting in the posterior half so that the gap genes giant (gt) and knirps (kni) are activated by an as yet unknown transcription factor(2,7). Here we show that caudal, a conserved homeodomain protein that forms a posterior-to-anterior concentration gradient(8,9), and the anterior determinant bicoid cooperate to form a partly redundant activator system in the posterior region of the embryo.	HARVARD UNIV, SCH MED, DEPT GENET, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66045 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Kansas	RIVERAPOMAR, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ENTWICKLUNGSBIOL ABT, POSTFACH 2841, D-37018 GOTTINGEN, GERMANY.			Perrimon, Norbert/0000-0001-7542-472X				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HOUS XS, 1995, CELL, V81, P63; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LEHMANN R, 1988, DEVELOPMENT, V104, P17; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MIODZIK M, 1987, DEVELOPMENT, V101, P421; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; Pankratz Michael J., 1993, P467; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1992, CELL, V68, P201; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; XU X, 1994, DEVELOPMENT, V120, P277	29	153	153	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 20	1995	376	6537					253	256		10.1038/376253a0	http://dx.doi.org/10.1038/376253a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617036				2022-12-28	WOS:A1995RK33100046
J	LASPADA, A; SKALHEGG, BS; HENDERSON, R; SCHMER, G; PIERCE, R; CHANDLER, W				LASPADA, A; SKALHEGG, BS; HENDERSON, R; SCHMER, G; PIERCE, R; CHANDLER, W			BRIEF REPORT - FATAL HEMORRHAGE IN A PATIENT WITH AN ACQUIRED INHIBITOR OF HUMAN THROMBIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							BOVINE THROMBIN; ANTITHROMBIN; ANTIBODIES; SURGERY; PROTHROMBIN; MECHANISM		UNIV WASHINGTON,MED CTR,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	LASPADA, A (corresponding author), UNIV WASHINGTON,MED CTR,DEPT LAB MED,BOX 357110,1959 NE PACIFIC ST,SEATTLE,WA 98195, USA.		Skålhegg, Bjørn Steen/AAZ-2976-2021; La Spada, Albert/AAG-8809-2020	Skålhegg, Bjørn Steen/0000-0002-3481-8084; 				ARNAUD E, 1994, BLOOD, V84, P1843; BAJAJ SP, 1985, BLOOD, V65, P1538, DOI 10.1182/blood.V65.6.1538.bloodjournal6561538; BANNINGER H, 1993, BRIT J HAEMATOL, V85, P528; BARTHELS M, 1985, HAEMOSTASIS, V15, P395; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; COSTA JM, 1992, THROMB HAEMOSTASIS, V67, P193; CRADDOCK CG, 1953, J LAB CLIN MED, V42, P847; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; FEINSTEIN DI, 1991, HEMATOLOGY BASIC PRI, P1380; FLAHERTY MJ, 1989, ANN INTERN MED, V111, P631, DOI 10.7326/0003-4819-111-8-631; FLECK RA, 1988, BLOOD, V72, P512; FRICK PG, 1955, AM J CLIN PATHOL, V25, P1263; FURIE B, 1991, HEMATOLOGY BASIC PRI, P1213; GABRIEL DA, 1987, AM J HEMATOL, V25, P85, DOI 10.1002/ajh.2830250109; GALANAKIS DK, 1978, JAMA-J AM MED ASSOC, V239, P1873, DOI 10.1001/jama.239.18.1873; HAWIGER J, 1964, Acta Med Pol, V5, P53; HOYER LW, 1994, HEMOSTASIS THROMBOSI, P109; LAWSON JH, 1990, BLOOD, V76, P2249; LOELIGER A, 1957, THROMB DIATH HAEMOST, V1, P499, DOI 10.1055/s-0038-1656216; Mann KG., 1994, HEMOSTASIS THROMBOSI, P184; NICHOLS WL, 1993, BLOOD, V82, pA59; PERKINS HA, 1970, BLOOD-J HEMATOL, V35, P695, DOI 10.1182/blood.V35.5.695.695; RAPAPORT SI, 1960, BLOOD, V15, P212, DOI 10.1182/blood.V15.2.212.212; SCULLY MF, 1982, BRIT J HAEMATOL, V50, P655, DOI 10.1111/j.1365-2141.1982.tb01966.x; SIE P, 1991, J CLIN INVEST, V88, P290, DOI 10.1172/JCI115290; STRICKER RB, 1988, BLOOD, V72, P1375	26	30	30	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					494	497						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623881				2022-12-28	WOS:A1995RP75900005
J	HOFFMAN, RS; GOLDFRANK, LR				HOFFMAN, RS; GOLDFRANK, LR			THE POISONED PATIENT WITH ALTERED CONSCIOUSNESS - CONTROVERSIES IN THE USE OF A COMA COCKTAIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIGH-DOSE NALOXONE; TRICYCLIC ANTIDEPRESSANT OVERDOSE; INDUCED RESPIRATORY DEPRESSION; WERNICKE-KORSAKOFF SYNDROME; INDUCED PULMONARY-EDEMA; CENTRAL NERVOUS-SYSTEM; ISCHEMIC BRAIN-DAMAGE; BLOOD-GLUCOSE LEVELS; SPINAL-CORD INJURY; BENZODIAZEPINE ANTAGONIST	Objective.-In the assessment and management of the potentially poisoned patient with altered consciousness, the most consequential and controversial interventions occur during the first 5 minutes of care. In this review article, the risks and benefits of standard diagnostic and therapeutic interventions are presented to guide clinicians through this critical period of decision making. Data Sources.-Data for discussion were obtained from a search of English-language publications referenced on MEDLINE for the years 1966 to 1994. Older literature was included when pertinent. Search terms included poisoning, overdose, toxicity, naloxone, glucose, thiamine, and flumazenil. Study Selection.-Only large trials were used for determinations of diagnostic utility and efficacy. Small trials, case series, and case reports were reviewed extensively for adverse effects. Data Extraction and Synthesis.-Trials were reviewed for overall methodology, inclusion and exclusion criteria, sources of bias, and outcome. Conclusion.-Analysis favors empirical administration of hypertonic dextrose and thiamine hydrochloride to patients with altered consciousness. Although rapid reagent test strips can be used to guide this therapy, they are not infallible, and they fail to recognize clinical hypoglycemia that may occur without numerical hypoglycemia. Administration of naloxone hydrochloride should be reserved for patients with signs and symptoms of opioid intoxication. Flumazenil is best left for reversal of therapeutic conscious sedation and rare select cases of benzodiazepine overdose.	NYU, MED CTR,BELLEVUE HOSP CTR, NEW YORK CITY POISON CONTROL CTR,BUR LABS, NEW YORK, NY 10016 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	Bellevue Hospital Center; New York University; New York City Department of Health & Mental Hygiene				Hoffman, Robert/0000-0002-0091-9573				ADLER PM, 1986, AM J EMERG MED, V4, P504, DOI 10.1016/S0735-6757(86)80004-3; ALBERTO G, 1989, ANN EMERG MED, V18, P889, DOI 10.1016/S0196-0644(89)80220-3; AMMON RA, 1978, ANN INTERN MED, V89, P349, DOI 10.7326/0003-4819-89-3-349; AMREIN R, 1987, MED TOXICOL ADV DRUG, V2, P411, DOI 10.1007/BF03259876; ANDREE RA, 1980, ANESTH ANALG, V59, P782; ASSEM ESK, 1973, PRACTITIONER, V211, P565; AZAR I, 1979, ANESTH ANALG, V58, P524; BAKER H, 1976, J NUTR SCI VITAMINOL, V22, P63, DOI 10.3177/jnsv.22.Supplement_63; BARREAU PB, 1987, MED J AUSTRALIA, V147, P286, DOI 10.5694/j.1326-5377.1987.tb133457.x; BASKIN DS, 1981, LANCET, V2, P272; BELSEY R, 1987, JAMA-J AM MED ASSOC, V258, P1634, DOI 10.1001/jama.258.12.1634; BLASS JP, 1977, NEW ENGL J MED, V297, P1367, DOI 10.1056/NEJM197712222972503; BONNET F, 1985, CRIT CARE MED, V13, P972, DOI 10.1097/00003246-198511000-00039; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BREHENY FX, 1992, CRIT CARE MED, V20, P736, DOI 10.1097/00003246-199206000-00006; BRIMACOMBE J, 1991, ANAESTH INTENS CARE, V19, P578, DOI 10.1177/0310057X9101900418; BROGDEN RN, 1991, DRUGS, V42, P1061, DOI 10.2165/00003495-199142060-00010; BROWNING RG, 1990, ANN EMERG MED, V19, P683, DOI 10.1016/S0196-0644(05)82479-5; BURR W, 1989, BRIT MED J, V298, P1713, DOI 10.1136/bmj.298.6689.1713-a; BUTTERWORTH RF, 1991, METAB BRAIN DIS, V6, P207, DOI 10.1007/BF00996920; BYCK R, 1982, Psychopharmacology Bulletin, V18, P214; CALLAHAM M, 1988, J PHARMACOL EXP THER, V245, P216; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; CARAVATI EM, 1991, ANN EMERG MED, V20, P147, DOI 10.1016/S0196-0644(05)81213-2; CARTER AS, 1990, ACTA ANAESTH SCAND, V34, P59, DOI 10.1111/j.1399-6576.1990.tb03186.x; CENTERWALL BS, 1978, NEW ENGL J MED, V299, P285, DOI 10.1056/NEJM197808102990605; CHEELEY RD, 1990, AM J EMERG MED, V8, P11, DOI 10.1016/0735-6757(90)90286-9; CHERN TL, 1993, AM J EMERG MED, V11, P122, DOI 10.1016/0735-6757(93)90103-I; CHIANG W K, 1990, Emergency Medicine Clinics of North America, V8, P613; CLEMMESEN C, 1961, CLIN PHARMACOL THER, V2, P220; COHEN MR, 1982, LIFE SCI, V30, P2025, DOI 10.1016/0024-3205(82)90443-X; COHEN MR, 1983, ARCH GEN PSYCHIAT, V40, P613; CUSS FM, 1984, BMJ CLIN RED ED, V4, P363; DALECY LG, 1986, SURGERY, V100, P505; DECOURTENMYERS G, 1988, STROKE, V19, P623, DOI 10.1161/01.STR.19.5.623; DOBOS JK, 1961, JAMA-J AM MED ASSOC, V176, P268, DOI 10.1001/jama.1961.03040170014004; DOLE VP, 1982, ALCOHOL CLIN EXP RES, V6, P275, DOI 10.1111/j.1530-0277.1982.tb04974.x; Dunton A W, 1988, Eur J Anaesthesiol Suppl, V2, P81; ECKENHOFF JE, 1960, CLIN PHARMACOL THER, V1, P483; EVANS CJ, 1988, OPIATE RECEPTORS, P23; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FINKEL AS, 1994, 1994 RED BOOK, P164; FINKEL AS, 1994, 1994 RED BOOK, P383; FINKLE BS, 1979, JAMA-J AM MED ASSOC, V242, P429, DOI 10.1001/jama.242.5.429; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; FLACKE JW, 1977, ANESTHESIOLOGY, V47, P376, DOI 10.1097/00000542-197710000-00009; FLAMM ES, 1985, J NEUROSURG, V63, P390, DOI 10.3171/jns.1985.63.3.0390; GADDIS GM, 1992, ANN PHARMACOTHER, V26, P196, DOI 10.1177/106002809202600211; GELLER E, 1991, EUR NEUROL, V31, P241, DOI 10.1159/000116684; GODINE JE, 1986, AM J MED, V80, P803, DOI 10.1016/0002-9343(86)90619-4; GOLDFARB S, 1976, ANN INTERN MED, V84, P426, DOI 10.7326/0003-4819-84-4-426; GOLDFRANK L, 1986, ANN EMERG MED, V15, P566, DOI 10.1016/S0196-0644(86)80994-5; GRAZAITIS DM, 1980, PEDIATRICS, V66, P221; GREENBLATT DJ, 1977, CLIN PHARMACOL THER, V21, P497; GROEGER JS, 1987, CRIT CARE MED, V15, P751, DOI 10.1097/00003246-198708000-00008; GROEGER JS, 1983, CRIT CARE MED, V11, P650, DOI 10.1097/00003246-198308000-00013; GROSS JB, 1991, ANESTHESIOLOGY, V75, P179, DOI 10.1097/00000542-199108000-00002; GURLL NJ, 1982, J PHARMACOL EXP THER, V220, P621; HADDAD LM, 1990, CLIN MANAGEMENT POIS, P2; Harrington L W, 1988, Crit Care Nurse, V8, P69; HOFFMAN JR, 1991, ANN EMERG MED, V20, P246, DOI 10.1016/S0196-0644(05)80933-3; HOFFMAN JR, 1992, ANN EMERG MED, V21, P20, DOI 10.1016/S0196-0644(05)82231-0; HOFFMAN RS, 1992, NEW YORK STATE J MED, V92, P127; HOGYA PT, 1989, PREHOSP DISASTER MED, V4, P109; HOJER J, 1988, ACTA MED SCAND, V224, P357; Jones Jonathan L., 1992, Journal of Emergency Medicine, V10, P679, DOI 10.1016/0736-4679(92)90524-W; KAPLAN JL, 1993, ANN EMERG MED, V22, P187, DOI 10.1016/S0196-0644(05)80200-8; KATZ JA, 1991, REGION ANESTH, V16, P247; KERR D, 1993, ANN INTERN MED, V119, P799, DOI 10.7326/0003-4819-119-8-199310150-00005; KIRKEGAARD L, 1986, ANAESTHESIA, V41, P1184, DOI 10.1111/j.1365-2044.1986.tb13001.x; KRAUSS S, 1971, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.5761.591-c; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; LANGLEY LL, 1971, PHYSL MAN, P710; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; LAVERY RF, 1991, AM J EMERG MED, V9, P304, DOI 10.1016/0735-6757(91)90046-M; LEVIN ER, 1985, AM J MED SCI, V290, P70, DOI 10.1097/00000441-198508000-00005; LHEUREUX P, 1992, AM J EMERG MED, V10, P184, DOI 10.1016/0735-6757(92)90205-C; Liebaldt G P, 1977, Monogr Gesamtgeb Psychiatr Psychiatry Ser, V14, P37; LIM AG, 1989, BRIT MED J, V299, P858, DOI 10.1136/bmj.299.6703.858-c; LINAKIS JG, 1993, ANN EMERG MED, V22, P1822, DOI 10.1016/S0196-0644(05)80408-1; LITOVITZ TL, 1994, AM J EMERG MED, V12, P546, DOI 10.1016/0735-6757(94)90276-3; LOPEZ A, 1990, CRIT CARE MED, V18, P1480, DOI 10.1097/00003246-199012000-00032; MALOUF R, 1985, ANN NEUROL, V17, P421, DOI 10.1002/ana.410170502; MARIANI PJ, 1989, AM J EMERG MED, V7, P127, DOI 10.1016/0735-6757(89)90119-8; MARTENS F, 1990, J TOXICOL-CLIN TOXIC, V28, P341, DOI 10.3109/15563659008994435; MARTIN WR, 1976, ANN INTERN MED, V85, P765, DOI 10.7326/0003-4819-85-6-765; MATCHAR DB, 1992, ANN INTERN MED, V117, P449, DOI 10.7326/0003-4819-117-6-449; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MERIGIAN KS, 1993, AM J EMERG MED, V11, P96, DOI 10.1016/0735-6757(93)90074-L; Michaelis L L, 1974, Ann Thorac Surg, V18, P608; MORA CT, 1989, ANESTH ANALG, V68, P473; MORDEL A, 1992, CRIT CARE MED, V20, P1733, DOI 10.1097/00003246-199212000-00022; NAKADA T, 1984, MED CLIN N AM, V68, P121, DOI 10.1016/S0025-7125(16)31245-7; OLINGER CP, 1990, STROKE, V21, P721, DOI 10.1161/01.STR.21.5.721; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1014, DOI 10.1136/bmj.291.6501.1014-a; OSULLIVAN GF, 1987, CLIN PHARMACOL THER, V42, P254, DOI 10.1038/clpt.1987.143; PARTRIDGE BL, 1986, ANESTHESIOLOGY, V65, P709, DOI 10.1097/00000542-198612000-00037; PENTEL P, 1980, ANN EMERG MED, V9, P588, DOI 10.1016/S0196-0644(80)80232-0; PERSSON A, 1989, Human Psychopharmacology, V4, P21, DOI 10.1002/hup.470040105; PROUGH DS, 1984, ANESTHESIOLOGY, V60, P485, DOI 10.1097/00000542-198405000-00018; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RADO JP, 1977, CHEM PATHOL PHARM, V18, P365; RALL T W, 1990, P345; RAPPOLT RT, 1980, ANN EMERG MED, V9, P357, DOI 10.1016/S0196-0644(80)80112-0; REULER JB, 1985, NEW ENGL J MED, V312, P1035, DOI 10.1056/NEJM198504183121606; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROCK P, 1985, CRIT CARE MED, V13, P28, DOI 10.1097/00003246-198501000-00008; Schiff L., 1941, JOUR AMER MED ASSOC, V117, P609; SCHWARTZ JA, 1987, ANN EMERG MED, V16, P1294, DOI 10.1016/S0196-0644(87)80244-5; SEIBERT DG, 1985, AM J MED, V78, P1036, DOI 10.1016/0002-9343(85)90229-3; SERFATY M, 1993, BRIT J PSYCHIAT, V163, P386, DOI 10.1192/bjp.163.3.386; SHALANSKY SJ, 1993, CLIN PHARMACY, V12, P483; SHORT TG, 1988, BRIT MED J, V296, P1070, DOI 10.1136/bmj.296.6628.1070-e; SIEMKOWICZ E, 1980, ACTA PHYSIOL SCAND, V110, P225, DOI 10.1111/j.1748-1716.1980.tb06658.x; SPIVEY WH, 1992, CLIN THER, V14, P292; SPIVEY WH, 1993, ANN EMERG MED, V22, P1813, DOI 10.1016/S0196-0644(05)80407-X; STAUTER RL, 1986, ANN EMERG MED, V15, P1121, DOI 10.1016/S0196-0644(86)80148-2; STILES MERRITT H., 1941, JOUR ALLERGY, V12, P507, DOI 10.1016/S0021-8707(41)90232-0; TAFF RH, 1983, ANESTHESIOLOGY, V59, P576, DOI 10.1097/00000542-198312000-00019; TANAKA GY, 1974, JAMA-J AM MED ASSOC, V228, P25, DOI 10.1001/jama.1974.03230260019008; TANAKA K, 1976, NEW ENGL J MED, V295, P461, DOI 10.1056/NEJM197608262950901; TATE JR, 1987, ANAL BIOCHEM, V160, P78, DOI 10.1016/0003-2697(87)90616-6; THOMSON AD, 1970, J LAB CLIN MED, V76, P34; TOLKSDORF W, 1990, ANESTH ANALG, V70, pS409; TURKINGTON RW, 1977, ARCH INTERN MED, V137, P1082, DOI 10.1001/archinte.137.8.1082; VANCE MV, 1992, EMERGENCY MED COMPRE, P545; VARON J, 1991, ANN EMERG MED, V20, P1125, DOI 10.1016/S0196-0644(05)81389-7; VIBERTI GC, 1978, LANCET, V1, P690; Victor M, 1953, METABOLIC TOXIC DISE, P526; VOLL CL, 1988, ANN NEUROL, V24, P638, DOI 10.1002/ana.410240508; VOTEY SR, 1991, ANN EMERG MED, V20, P181, DOI 10.1016/S0196-0644(05)81219-3; WALLIS WE, 1985, ANN NEUROL, V18, P510, DOI 10.1002/ana.410180415; WASSERBERGER J, 1988, ANN EMERG MED, V17, P557, DOI 10.1016/S0196-0644(88)80287-7; WATSON AJS, 1981, IRISH J MED SCI, V150, P301, DOI 10.1007/BF02938260; WEDIN GP, 1989, AM J EMERG MED, V7, P343, DOI 10.1016/0735-6757(89)90190-3; WEIGAND C G, 1950, Geriatrics, V5, P274; WEINBROUM A, 1991, Intensive Care Medicine, V17, pS32, DOI 10.1007/BF01731152; WEINBRUM A, 1990, ACTA ANAESTH SCAND, V34, P65, DOI 10.1111/j.1399-6576.1990.tb03187.x; WEISMAN RS, 1991, J TOXICOL-CLIN TOXIC, V29, P553, DOI 10.3109/15563659109025754; WEISMAN RS, 1990, GOLDFRANKS TOXICOLOG, P444; WILKINS BH, 1982, ARCH DIS CHILD, V57, P948, DOI 10.1136/adc.57.12.948; WILSON JD, 1980, HARRISONS PRINCIPLES, P425; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; WRENN KD, 1989, ANN EMERG MED, V18, P867, DOI 10.1016/S0196-0644(89)80215-X; WRIDE SRN, 1989, ANAESTH INTENS CARE, V17, P374, DOI 10.1177/0310057X8901700327; YEALY DM, 1990, ANN EMERG MED, V19, P902, DOI 10.1016/S0196-0644(05)81566-5	148	83	85	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					562	569		10.1001/jama.274.7.562	http://dx.doi.org/10.1001/jama.274.7.562			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629986				2022-12-28	WOS:A1995RN46600028
J	KITZINGER, J				KITZINGER, J			QUALITATIVE RESEARCH - INTRODUCING FOCUS GROUPS	BRITISH MEDICAL JOURNAL			English	Article							NEEDS	This paper introduces focus group methodology, gives advice on group composition, running the groups, and analysing the results. Focus groups have advantages for researchers in the field of health and medicine: they do not discriminate against people who cannot read or write and they can encourage participation from people reluctant to be interviewed on their own or who feel they have nothing to say.			KITZINGER, J (corresponding author), UNIV GLASGOW,DEPT SOCIOL,GLASGOW UNIV MEDIA GRP,GLASGOW G12 8LF,LANARK,SCOTLAND.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				BARKER GK, 1992, STUD FAMILY PLANN, V23, P199, DOI 10.2307/1966728; BASCH CE, 1987, HEALTH EDUC QUART, V14, P411, DOI 10.1177/109019818701400404; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; BROWN JB, 1993, J FAM PRACTICE, V36, P185; DENNING JD, 1993, CHILD WELFARE, V72, P569; DIMATTEO MR, 1993, BIRTH-ISS PERINAT C, V20, P204, DOI 10.1111/j.1523-536X.1993.tb00228.x; DUKE SS, 1994, HEALTH EDUC RES, V9, P331, DOI 10.1093/her/9.3.331; GEIS SB, 1986, DEATH STUD, V10, P43, DOI 10.1080/07481188608252798; Gregory S, 1991, Nurs Stand, V5, P32; HUGHES D, 1993, AM J COMMUN PSYCHOL, V21, P775, DOI 10.1007/BF00942247; KHAN ME, 1992, HEALTH POLICY PLANN, V7, P56, DOI 10.1093/heapol/7.1.56; Kitzinger J, 1990, Nurs Times, V86, P38; KITZINGER J, 1990, SOCIOL HEALTH ILL, V12, P319, DOI 10.1111/1467-9566.ep11347258; KITZINGER J, 1994, SOCIOL HEALTH ILL, V16, P103, DOI 10.1111/1467-9566.ep11347023; Kitzinger J., 1993, GETTING MESSAGE NEWS, P271; KITZINGER J, 1994, CHALLENGE INNOVATION, P159; LEDERMAN L, 1983, COMMUNICATION Q, V31, P233, DOI DOI 10.1080/01463378309369509; MAYS N, 1995, BRIT MED J, V311, P182, DOI 10.1136/bmj.311.6998.182; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Merton R., 1956, FOCUSED INTERVIEW RE; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; NIAHS J, 1994, BRIT MED J, V309, P1126; OBrien K., 1993, SUCCESSFUL FOCUS GRO, P105, DOI 10.4135/9781483349008.n7; Powney J., 1988, RES INTELLIGENCE J B, V28, P10; RITCHIE JE, 1994, HEALTH EDUC RES, V9, P95, DOI 10.1093/her/9.1.95; Watts M., 1987, BRIT EDUC RES J, V13, P25, DOI DOI 10.1080/0141192870130103; ZIMMERMAN M, 1990, STUD FAMILY PLANN, V21, P92, DOI 10.2307/1966670	27	3343	3386	7	439	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					299	302		10.1136/bmj.311.7000.299	http://dx.doi.org/10.1136/bmj.311.7000.299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM719	7633241	Green Published			2022-12-28	WOS:A1995RM71900029
J	JUNGNICKEL, B; RAPOPORT, TA				JUNGNICKEL, B; RAPOPORT, TA			A POSTTARGETING SIGNAL SEQUENCE RECOGNITION EVENT IN THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							PROTEIN TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; NASCENT POLYPEPTIDES; SUPPRESSOR MUTATIONS; MICROSOMAL-MEMBRANES; PARTICLE RECEPTOR; ESCHERICHIA-COLI; ER MEMBRANE; COMPONENTS; PEPTIDES	We have analyzed early phases of the cotranslational transport of the secretory protein preprolactin through the mammalian endoplasmic reticulum (ER) membrane. Following recognition of the signal sequence of the nascent polypeptide chain in the cytosol by the SRP, the chain is transferred into the membrane, where a second signal sequence recognition step takes place for which the presence in the lipid bilayer of the Sec61p complex is essential and sufficient. This step leads to a tight junction between the ribosome-nascent chain complex and the Sec61p complex, and to the productive insertion of the nascent chain into the translocation site, These results show that a translocation substrate is subjected to two recognition events before being allowed to cross the ER membrane.	MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine	JUNGNICKEL, B (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.							ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1992, J CELL BIOL, V95, P470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J BIOL CHEM, V268, P26745; JUNGNICKEL B, 1993, FEBS LETT, V329, P268, DOI 10.1016/0014-5793(93)80235-M; KALLES KU, 1994, J CELL BIOL, V126, P925; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PREHN S, 1980, EUR J BIOCHEM, V107, P185, DOI 10.1111/j.1432-1033.1980.tb04639.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; [No title captured]	30	232	234	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					261	270		10.1016/0092-8674(95)90313-5	http://dx.doi.org/10.1016/0092-8674(95)90313-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628015	Bronze			2022-12-28	WOS:A1995RL76000013
J	MING, M; EWEN, ME; PEREIRA, MEA				MING, M; EWEN, ME; PEREIRA, MEA			TRYPANOSOME INVASION OF MAMMALIAN-CELLS REQUIRES ACTIVATION OF THE TGF-BETA SIGNALING PATHWAY	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; II RECEPTOR; CRUZI; INHIBITION; PROTEIN; KINASE; TRYPOMASTIGOTES; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION	Trypanosoma cruzi invades most nucleated mammalian cells by as yet unknown mechanisms, We report here that while T. cruzi attaches to epithelial cells lacking signaling transforming growth factor beta (TGF beta) receptor I or II, the adherent parasites cannot penetrate and replicate inside the mutant cells, as they do in parental cells, Invasion of the mutants is restored by transfection with the TGF beta receptor genes, as are biological responses to TGF beta. Similar rescue of both TGF beta antiproliferative response and T. cruzi invasion was demonstrated in a hybrid of TGF beta-resistant bladder and colon carcinoma cells. In addition, T. cruzi did not efficiently invade epithelial cells with dysfunction of the intracellular signaling cascade caused by the constitutive expression of the cyclin-dependent kinase cdk4 or of the oncogene H-ras. Treatment with TGF beta, but not with other antiproliferative agents of nonphagocytic cells, greatly enhances T. cruzi invasion. Moreover, infective, but not noninfective, trypanosomes strongly induce a TGF beta-responsive reporter gene in TGF beta-sensitive, but not in TGF beta-insensitive, cell lines. Thus, T. cruzi itself may directly trigger activation of the TGF beta signaling pathway required for parasite entry into the mammalian cells.	TUFTS UNIV,NEW ENGLAND MED CTR,TUPPER RES INST,DIV GEOG MED & INFECT DIS,TROP DIS RES UNIT,BOSTON,MA 02111; HARVARD UNIV,SCH MED,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute								ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ANDRADE Z, 1983, CYTOPATHOLOGY PARASI, P228; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; Brener Z., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P247; CAVALLESCO R, 1988, J IMMUNOL, V140, P617; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DVORAK JA, 1981, SCIENCE, V214, P1034, DOI 10.1126/science.7029713; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FILMUS J, 1992, ONCOGENE, V7, P521; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOODING LR, 1992, CELL, V71, P5; HENRIQUEZ D, 1981, MOL BIOCHEM PARASIT, V2, P359, DOI 10.1016/0166-6851(81)90087-6; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MING M, 1993, MOL BIOCHEM PARASIT, V59, P243, DOI 10.1016/0166-6851(93)90222-J; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; Pereira M. E. A., 1990, Modern parasite biology: cellular, immunological, and molecular aspects., P64; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PEREIRA MEA, 1994, BAILLIERE CLIN INF D, V1, P305; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROWIN KS, 1983, P NATL ACAD SCI-BIOL, V80, P6390, DOI 10.1073/pnas.80.20.6390; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCUDDER P, 1993, J BIOL CHEM, V268, P9886; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; TARDIEUX I, 1994, J EXP MED, V179, P1017, DOI 10.1084/jem.179.3.1017; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; WAHL SM, 1988, J IMMUNOL, V140, P3026; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAKUBU MA, 1994, MOL BIOCHEM PARASIT, V66, P119, DOI 10.1016/0166-6851(94)90042-6	50	128	132	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					287	296		10.1016/0092-8674(95)90316-X	http://dx.doi.org/10.1016/0092-8674(95)90316-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628017	Bronze			2022-12-28	WOS:A1995RL76000016
J	PELLEYMOUNTER, MA; CULLEN, MJ; BAKER, MB; HECHT, R; WINTERS, D; BOONE, T; COLLINS, F				PELLEYMOUNTER, MA; CULLEN, MJ; BAKER, MB; HECHT, R; WINTERS, D; BOONE, T; COLLINS, F			EFFECTS OF THE OBESE GENE-PRODUCT ON BODY-WEIGHT REGULATION IN OB/OB MICE	SCIENCE			English	Article								C57BL/6J mice with a mutation in the obese (ob) gene are obese, diabetic, and exhibit reduced activity, metabolism, and body temperature. Daily intraperitoneal injection of these mice with recombinant OB protein lowered their body weight, percent body fat, food intake, and serum concentrations of glucose and insulin. In addition, metabolic rate, body temperature, and activity levels were increased by this treatment. None of these parameters was altered beyond the level observed in lean controls, suggesting that the OB protein normalized the metabolic status of the ob/ob mice. Lean animals injected with OB protein maintained a smaller weight loss throughout the 28-day study and showed no changes in any of the metabolic parameters. These data suggest that the OB protein regulates body weight and fat deposition through effects on metabolism and appetite.	AMGEN INC,DEPT RECOVERY PROC DEV,THOUSAND OAKS,CA 91320	Amgen	PELLEYMOUNTER, MA (corresponding author), AMGEN INC,DEPT NEUROBIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRITTON DR, 1989, PHARMACOL BIOCHEM BE, V34, P779, DOI 10.1016/0091-3057(89)90274-8; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; LESHNER AI, 1972, PHYSIOL BEHAV, V9, P281, DOI 10.1016/0031-9384(72)90251-X; LU H, 1993, PROTEIN FOLDING IN V, V526, pCH15; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	7	3681	3891	3	239	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					540	543		10.1126/science.7624776	http://dx.doi.org/10.1126/science.7624776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624776				2022-12-28	WOS:A1995RL49500028
J	REILLY, JT; TOH, CH				REILLY, JT; TOH, CH			SHEAR-STRESS AND PLATELET-FUNCTION - A THERAPEUTIC CHALLENGE	LANCET			English	Editorial Material							AGGREGATION				REILLY, JT (corresponding author), NO GEN HOSP,DEPT HAEMATOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							BEURLINGHARBURY C, 1978, BLOOD, V52, P13; CAPPELL MS, 1986, ANN INTERN MED, V105, P54, DOI 10.7326/0003-4819-105-1-54; DARDIK R, 1993, THROMB HAEMOSTASIS, V70, P522; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; MOAKE JL, 1988, BLOOD, V71, P1366; OBRIEN JR, 1992, THROMB RES, V65, P821, DOI 10.1016/0049-3848(92)90121-P; OBRIEN JR, 1995, PLATELETS, V6, P242, DOI 10.3109/09537109509078461; OBRIEN JR, 1994, THROMB RES, V76, P103, DOI 10.1016/0049-3848(94)90212-7; ROTH GJ, 1991, BLOOD, V77, P5	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					196	197		10.1016/S0140-6736(95)91261-4	http://dx.doi.org/10.1016/S0140-6736(95)91261-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616794				2022-12-28	WOS:A1995RK41900003
J	ROCKALL, TA; LOGAN, RFA; DEVLIN, HB; NORTHFIELD, TC				ROCKALL, TA; LOGAN, RFA; DEVLIN, HB; NORTHFIELD, TC			INCIDENCE OF AND MORTALITY FROM ACUTE UPPER GASTROINTESTINAL HEMORRHAGE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							HEMATEMESIS; HEMORRHAGE; MANAGEMENT; MELAENA	Objective-To describe the current epidemiology of acute upper gastrointestinal haemorrhage, Design-Population based, unselected, multicentre, prospective survey, Setting-74 hospitals receiving emergency admissions in four health regions in the United Kingdom, Subjects-4185 cases of acute upper gastrointestinal haemorrhage in which patients were aged over 16 years identified over four months, Outcome measures-Incidence and mortality. Results-The overall incidence of acute upper gastrointestinal haemorrhage in the United Kingdom is 103/100 000 adults per year, The incidence rises from 23 in those aged under 30 to 485 in those aged over 75. At all ages incidence in men was more than double that in women except in elderly patients, 14% of the haemorrhages occurred in inpatients already in hospital for some other reason, In 27% of cases (37% female, 19% male) patients were aged over 80. Overall mortality was 14% (11% in emergency admissions and 33% in haemorrhage in inpatients), In the emergency admissions, 65% of deaths in those aged under 80 were associated with malignancy or organ failure at presentation, Mortality for patients under 60 in the absence of malignancy or organ failure at presentation was 0.8%. Conclusions-The incidence of acute upper gastrointestinal haemorrhage is twice that previously reported in England and similar to that reported in Scotland, The incidence increases appreciably with age, Although the proportion of elderly patients continues to rise and mortality increases steeply with age, age standardised mortality is lower than in earlier studies, Deaths occurred almost exclusively in very old patients or those with severe comorbidity.	QUEENS MED CTR,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND; UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT BIOCHEM MED,LONDON SW17 0RE,ENGLAND	University of Nottingham; St Georges University London	ROCKALL, TA (corresponding author), ROYAL COLL SURGEONS ENGLAND,LONDON WC2A 3PN,ENGLAND.							Berry A R, 1984, J R Coll Surg Edinb, V29, P134; CUTLER JA, 1981, DIG DIS SCI S, V26, P90; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; EMBERTON M, 1993, BRIT J HEALTHC COMP, V10, P32; GARDNER MJ, 1989, STATISTICS CONFIDENC; HOLMAN RAE, 1990, GUT, V31, P504, DOI 10.1136/gut.31.5.504; HUNT PS, 1979, BRIT MED J, V1, P1238, DOI 10.1136/bmj.1.6173.1238; JAGGER C, 1991, INT J EPIDEMIOL, V20, P234, DOI 10.1093/ije/20.1.234; JOHNSTON SJ, 1973, BRIT MED J, V3, P655, DOI 10.1136/bmj.3.5882.655; JONES F A, 1947, Br Med J, V2, P441; KATSCHINSKI BD, 1989, POSTGRAD MED J, V65, P913, DOI 10.1136/pgmj.65.770.913; MADDEN MV, 1986, J ROY COLL PHYS LOND, V20, P212; MAYBERRY JF, 1981, POSTGRAD MED J, V57, P627, DOI 10.1136/pgmj.57.672.627; MORGAN AG, 1984, SCAND J GASTROENTERO, V19, P41; NEEDHAM CD, 1950, BMJ-BRIT MED J, V2, P133, DOI 10.1136/bmj.2.4671.133; SCHILLER KF, 1970, BRIT MED J, V2, P7, DOI 10.1136/bmj.2.5700.7; SCHLUP M, 1984, NEW ZEAL MED J, V97, P511; SUSSER M, 1982, J CHRON DIS, V35, P29, DOI 10.1016/0021-9681(82)90027-3; 1991, KEY POPULATION VITAL; 1993, ADV STATISTICS	20	660	683	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					222	226		10.1136/bmj.311.6999.222	http://dx.doi.org/10.1136/bmj.311.6999.222			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627034	Green Published			2022-12-28	WOS:A1995RL44100017
J	HENSEL, M; SHEA, JE; GLEESON, C; JONES, MD; DALTON, E; HOLDEN, DW				HENSEL, M; SHEA, JE; GLEESON, C; JONES, MD; DALTON, E; HOLDEN, DW			SIMULTANEOUS IDENTIFICATION OF BACTERIAL VIRULENCE GENES BY NEGATIVE SELECTION	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; MUTANTS; AVIRULENT; CELLS; MICE	An insertional mutagenesis system that uses transposons carrying unique DNA sequence tags was developed for the isolation of bacterial virulence genes. The tags from a mixed population of bacterial mutants representing the inoculum and bacteria recovered from infected hosts were detected by amplification, radiolabeling, and hybridization analysis. When applied to a murine model of typhoid fever caused by Salmonella typhimurium, mutants with attenuated virulence were revealed by use of tags that were present in the inoculum but not in bacteria recovered from infected mice. This approach resulted in the identification of new virulence genes, some of which are related to, but functionally distinct from, the inv/spa family of S. typhimurium.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London				Hensel, Michael/0000-0001-6604-6253; Dalton, Emma/0000-0002-3517-0742				BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x; CARTER PB, 1974, J EXP MED, V139, P1189, DOI 10.1084/jem.139.5.1189; Davis R., 1980, ADV BACTERIAL GENETI; DELORENZO V, 1994, METHOD ENZYMOL, V264, P386; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; GROISMAN EA, 1990, TRENDS BIOCHEM SCI, V15, P30, DOI 10.1016/0968-0004(90)90128-X; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; Groisman Eduardo A., 1994, Trends in Microbiology, V2, P289, DOI 10.1016/0966-842X(94)90006-X; HENSEL M, UNPUB; HOLDEN DW, 1989, EMBO J, V8, P1927, DOI 10.1002/j.1460-2075.1989.tb03596.x; LEE JC, 1987, J INFECT DIS, V156, P741, DOI 10.1093/infdis/156.5.741; LU SW, 1994, P NATL ACAD SCI USA, V91, P12649, DOI 10.1073/pnas.91.26.12649; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MILLER I, 1989, INFECT IMMUN, V57, P2758, DOI 10.1128/IAI.57.9.2758-2763.1989; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; REED L. J., 1938, AMER JOUR HYG, V27, P493; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8	22	957	1136	1	78	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					400	403		10.1126/science.7618105	http://dx.doi.org/10.1126/science.7618105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618105				2022-12-28	WOS:A1995RK42700048
J	SCRIVENER, G; LLOYD, DCEF				SCRIVENER, G; LLOYD, DCEF			ALLOCATING CENSUS-DATA TO GENERAL-PRACTICE POPULATIONS - IMPLICATIONS FOR STUDY OF PRESCRIBING VARIATION AT PRACTICE LEVEL	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assign census data to general practice populations and to test accuracy of different procedures for estimating the proportion of patients aged over 64. Design-Patients' postcodes from patient register of one family health services authority and the directory linking postcodes to census enumeration districts were used to locate patients in their census area of residence. With different levels of census geography and four different allocation procedures, proportion of patients aged over 64 in each area was used to predict proportion of patients aged over 64 in each general practice. Predicted figures were compared with real figures from each practice register to assess accuracy of allocation methods. Setting-Data from 1991 census and from 73 practices administered by one family health services authority. Main outcome measures-Actual and predicted proportions of patients aged over 64 in general practice populations. Results-Correlations between actual and predicted proportions of patients aged over 64 were significant for all four allocation procedures-values of 0.66, 0.7, 0.84, and 0.84 were achieved (P < 0.0005). Predicted ranges of proportions of patients aged over 64, however, were well short of those that actually existed, and significant differences existed between predicted percentages and actual figures for all four methods. Conclusion-Although predicted values correlated with actual values, the failure of the allocation procedures to correctly predict values, especially at the extremes, casts doubt on the validity of similar techniques for allocating census variables to general practice populations.			SCRIVENER, G (corresponding author), UNIV LEEDS,ACAD UNIT GEN PRACTICE,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND.							Dale A, 1993, 1991 CENSUS USERS GU; Gatrell A. C., 1989, International Journal of Geographical Information Systems, V3, P335, DOI 10.1080/02693798908941520; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; WARD P, 1994, PUBLIC HEALTH, V108, P279, DOI 10.1016/S0033-3506(94)80007-3	4	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					163	165		10.1136/bmj.311.6998.163	http://dx.doi.org/10.1136/bmj.311.6998.163			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613429	Green Published			2022-12-28	WOS:A1995RK15900023
J	WYATT, JC				WYATT, JC			HOSPITAL INFORMATION MANAGEMENT - THE NEED FOR CLINICAL LEADERSHIP	BRITISH MEDICAL JOURNAL			English	Article							SYSTEMS	On 12 July the Audit Commission published For Your Information, a well researched report about information and its management in acute hospitals in Britain, how and why it is failing, and steps that clinicians, managers, and the NHS should take to correct this. This article discusses why information management matters to clinicians and considers the problems identified by the Audit Commission-most of which will strike chords with doctors-and possible remedies. Finally, it decribes possible routes to adminsiter these remedies and the proposal, recently supported by the BMA Council, for a national centre for health informatics with the goals of educating and enthusing clinicians about informatics, empowering them to participate in local and national information management decisions; exploring how information can be used to improve patient care and outcomes; and evaluating clinical information systems and helping to realise their benefits.			WYATT, JC (corresponding author), IMPERIAL CANC RES FUND,BIOMED INFORMAT UNIT,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				ANDERSON C, 1994, SCIENCE, V263, P1080, DOI 10.1126/science.8108722; ANDERSON R, 1995, BRIT MED J, V311, P5, DOI 10.1136/bmj.311.6996.5; BEINLICH I, 1993, DRUG RES, V43, P399; BLEICH HL, 1985, NEW ENGL J MED, V312, P756, DOI 10.1056/NEJM198503213121205; BYAR DP, 1980, BIOMETRICS, V36, P337, DOI 10.2307/2529989; CARTMILL RSV, 1992, LANCET, V339, P1520, DOI 10.1016/0140-6736(92)91275-D; COIERA E, 1995, BRIT MED J, V310, P1381, DOI 10.1136/bmj.310.6991.1381; DEAN M, 1993, LANCET, V341, P1269, DOI 10.1016/0140-6736(93)91161-E; HEATHFIELD H, 1994, 17TH P ANN S COMP AP, V129, P33; HEATHFIELD HA, 1993, METHOD INFORM MED, V32, P1; JONES R, 1995, BRIT MED J, V311, P2, DOI 10.1136/bmj.311.6996.2; LEANING MS, 1993, BRIT MED J, V307, P217, DOI 10.1136/bmj.307.6898.217; LUCAS RW, 1976, BMJ-BRIT MED J, V2, P623, DOI 10.1136/bmj.2.6036.623; MOORMAN PW, 1995, LANCET, V345, P865, DOI 10.1016/S0140-6736(95)93004-3; NORTON SL, 1981, COMPUT BIOMED RES, V14, P179, DOI 10.1016/0010-4809(81)90035-5; ONEIL M, 1995, METHOD INFORM MED, V34, P187; RECTOR AL, 1991, METHOD INFORM MED, V30, P179; SHORTLIFFE E, 1990, MED INFORM, P656; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P412, DOI 10.1136/jamia.1994.95153429; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; WYATT J, 1991, LANCET, V3381, P1368; WYATT JC, 1994, LANCET, V344, P1682, DOI 10.1016/S0140-6736(94)90463-4; WYATT JC, 1994, LANCET, V344, P1609, DOI 10.1016/S0140-6736(94)90409-X; WYATT JC, 1994, LANCET, V344, P1513; YEOH C, 1993, BRIT MED J, V306, P972, DOI 10.1136/bmj.306.6883.972; 1995, SETTING RECORDS STRA; 1993, RECOMMENDATIONS UNDE, P3; 1995, INFORMATION STUDY IN; 1995, 4 OFF SCI TECHN REP	31	44	44	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					175	178		10.1136/bmj.311.6998.175	http://dx.doi.org/10.1136/bmj.311.6998.175			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613433	Green Published			2022-12-28	WOS:A1995RK15900027
J	TAIT, N; LITTLE, JM				TAIT, N; LITTLE, JM			FORTNIGHTLY REVIEW - THE TREATMENT OF GALL-STONES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHOCK-WAVE LITHOTRIPSY; GALLSTONE FORMATION; GALLBLADDER CANCER; LAPAROSCOPIC CHOLECYSTECTOMY; CHOLESTEROL GALLSTONES; SYMPTOMATIC GALLSTONES; COMPUTED-TOMOGRAPHY; ACUTE-PANCREATITIS; DISEASE; BILE				TAIT, N (corresponding author), UNIV SYDNEY, WESTMEAD HOSP, DEPT SURG, WESTMEAD, NSW 2145, AUSTRALIA.							AGARWAL DK, 1993, SCAND J GASTROENTERO, V28, P613, DOI 10.3109/00365529309096098; AHMED AF, 1993, J ROY SOC HEALTH, V113, P57; ANDRENSANDBERG A, 1985, ANN SURG, V201, P328; AUCOTT JN, 1993, ARCH INTERN MED, V153, P1053, DOI 10.1001/archinte.153.9.1053; BOBBS JS, 1868, T INDIANA STATE MED, V18, P10; BROWN TH, 1989, AM J SURG, V157, P58, DOI 10.1016/0002-9610(89)90420-0; CAREY MC, 1993, AM J SURG, V165, P410, DOI 10.1016/S0002-9610(05)80932-8; CHIJIIWA K, 1993, SURG GYNECOL OBSTET, V177, P279; CHIJIIWA K, 1993, DIGEST DIS SCI, V38, P161, DOI 10.1007/BF01296790; CLAIR DG, 1993, SURGERY, V113, P355; DELORIO T, 1993, SURG ENDOSC-ULTRAS, V7, P404; DIEHL AK, 1993, AM J MED SCI, V305, P383, DOI 10.1097/00000441-199306000-00005; DOWNIE GH, 1993, CHEST, V103, P616, DOI 10.1378/chest.103.2.616; DUARTE I, 1993, CANCER-AM CANCER SOC, V72, P1878, DOI 10.1002/1097-0142(19930915)72:6<1878::AID-CNCR2820720615>3.0.CO;2-2; Etspuler H K, 1993, Ther Umsch, V50, P535; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; FRIEDMAN GD, 1993, AM J SURG, V165, P399, DOI 10.1016/S0002-9610(05)80930-4; FU XB, 1993, CHINESE MED J-PEKING, V106, P734; FUNABIKI T, 1993, SURG TODAY, V23, P350, DOI 10.1007/BF00309054; Giangrande M, 1993, Minerva Ginecol, V45, P159; GIBNEY EJ, 1990, BRIT J SURG, V77, P368, DOI 10.1002/bjs.1800770405; GOLDSCHMID S, 1993, MED CLIN N AM, V77, P413, DOI 10.1016/S0025-7125(16)30260-7; Gordon-Taylor G, 1937, BRIT J SURG, V25, P241, DOI 10.1002/bjs.1800259802; GRIMALDI CH, 1993, ANN INTERN MED, V118, P185, DOI 10.7326/0003-4819-118-3-199302010-00005; Hanis Craig L., 1993, Ethnicity and Disease, V3, P32; HARDY KJ, 1994, MED J AUSTRALIA, V160, P58, DOI 10.5694/j.1326-5377.1994.tb126514.x; HATSUSHIKA S, 1993, SCAND J GASTROENTERO, V28, P131, DOI 10.3109/00365529309096059; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HEATON KW, 1993, LANCET, V341, P8, DOI 10.1016/0140-6736(93)92479-D; HERMANN RE, 1976, SURGERY, V79, P609; Heuer GJ, 1934, ANN SURG, V99, P881, DOI 10.1097/00000658-193499060-00001; HONDA A, 1993, GASTROENTEROL JPN, V28, P406; JOHNSON AG, 1972, BRIT J SURG, V59, P449, DOI 10.1002/bjs.1800590611; JOHNSON CD, 1993, POSTGRAD MED J, V69, P509, DOI 10.1136/pgmj.69.813.509; KALSER SC, 1993, AM J SURG, V165, P390; Langenbuch, 1882, BERL KLIN WOCHENSCHR, V19, P725; LITTLE JM, 1991, LANCET, V337, P1135, DOI 10.1016/0140-6736(91)92796-5; LOWELL JA, 1993, SURGERY, V114, P858; LUND J, 1960, ANN SURG, V151, P153, DOI 10.1097/00000658-196002000-00001; MCSHERRY CK, 1980, ANN SURG, V191, P271, DOI 10.1097/00000658-198003000-00003; MCSHERRY CK, 1989, AM J SURG, V158, P174, DOI 10.1016/0002-9610(89)90246-8; METS TF, 1993, J TROP MED HYG, V96, P291; MOERMAN CJ, 1993, SCAND J GASTROENTERO, V28, P482, DOI 10.3109/00365529309098253; MOODY FG, 1993, AM J SURG, V165, P479, DOI 10.1016/S0002-9610(05)80945-6; MORI K, 1993, HEPATO-GASTROENTEROL, V40, P56; MORI T, 1993, SURG TODAY, V23, P387, DOI 10.1007/BF00309494; Mutsukura T, 1993, Nihon Rinsho, V51, P1870; NAHRWOLD DL, 1993, AM J SURG, V165, P431, DOI 10.1016/S0002-9610(05)80935-3; NALLY C, 1994, CAN J SURG, V37, P243; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; NEOPTOLEMOS JP, 1993, GASTROENTEROL CLIN N, P1732; OHYA T, 1993, GASTROENTEROLOGY, V104, P527, DOI 10.1016/0016-5085(93)90423-A; PETIT JL, 1743, MEM ACAD ROY CHIR PA, V1, P155; RANSOHOFF DF, 1993, ANN INTERN MED, V119, P606, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00010; RUDDELL WSJ, 1980, LANCET, V1, P444; RUNZI M, 1993, GASTROENTEROLOGY, V105, P157; SASAKI H, 1993, SCAND J GASTROENTERO, V28, P495, DOI 10.3109/00365529309098255; SCHIBAMOTO Y, 1993, NIPPON RINSHO, V51, P1731; SCHOENFIELD LJ, 1993, AM J SURG, V165, P427, DOI 10.1016/S0002-9610(05)80934-1; SCOTT LD, 1992, GASTROENTEROL CLIN N, V21, P803; SHIFFMAN ML, 1993, GASTROENTEROLOGY, V105, P1200, DOI 10.1016/0016-5085(93)90968-I; SIMON JA, 1993, MED HYPOTHESES, V40, P81, DOI 10.1016/0306-9877(93)90132-A; STEWART J, 1994, MINIM INVASIV THER, V3, P153, DOI 10.1080/0961625X.1994.11665545; STRASBERG SM, 1993, AM J SURG, V165, P420, DOI 10.1016/S0002-9610(05)80933-X; SUC B, 1992, ANN CHIR, V46, P219; Swobodnik W, 1993, Ther Umsch, V50, P564; TERATOLA SO, 1993, RADIOLOGY, V188, P419; THAYSEN EH, 1976, GUT, V17, P965, DOI 10.1136/gut.17.12.965; THORWALD J, 1960, TRIUMPH SURGERY, P152; THUDICHUM JLW, 1859, BRIT MED J, V2, P935; THUDICUM JLW, 1985, SILVERGIRLS SURGERY, P4; TURSI JP, 1993, OBSTET GYNECOL, V82, P653; TURUNEN MJ, 1981, ANN SURG, V194, P639, DOI 10.1097/00000658-198111000-00014; UPADHYA GA, 1993, J BIOL CHEM, V268, P5193; VALDIVIESO V, 1993, HEPATOLOGY, V17, P1; VELLAR ID, 1993, MED J AUSTRALIA, V158, P94, DOI 10.5694/j.1326-5377.1993.tb137532.x; WINSLET MC, 1991, BAILLIERE CLIN GASTR, V5, P99, DOI 10.1016/0950-3528(91)90008-O	77	27	27	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	1995	311	6997					99	105		10.1136/bmj.311.6997.99	http://dx.doi.org/10.1136/bmj.311.6997.99			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613411	Green Published			2022-12-28	WOS:A1995RJ03000025
J	CERLETTY, JM				CERLETTY, JM			DIAGNOSING AT THE MALL	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CERLETTY, JM (corresponding author), JOHN L DOYNE HOSP, MED COLL WISCONSIN, DEPT MED, 8700 W WISCONSIN AVE, MILWAUKEE, WI 53226 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					387	387		10.7326/0003-4819-123-5-199509010-00011	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625629				2022-12-28	WOS:A1995RQ98800011
J	MORRIS, JG; SHAY, DK; HEBDEN, JN; MCCARTER, RJ; PERDUE, BE; JARVIS, W; JOHNSON, JA; DOWLING, TC; POLISH, LB; SCHWALBE, RS				MORRIS, JG; SHAY, DK; HEBDEN, JN; MCCARTER, RJ; PERDUE, BE; JARVIS, W; JOHNSON, JA; DOWLING, TC; POLISH, LB; SCHWALBE, RS			ENTEROCOCCI RESISTANT TO MULTIPLE ANTIMICROBIAL AGENTS, INCLUDING VANCOMYCIN - ESTABLISHMENT OF ENDEMICITY IN A UNIVERSITY MEDICAL-CENTER	ANNALS OF INTERNAL MEDICINE			English	Article						VANCOMYCIN; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; DRUG RESISTANCE, MICROBIAL; ORGAN TRANSPLANTATION	HIGH-LEVEL RESISTANCE; ANTIBIOTIC SYNERGISM; FAECIUM; INFECTIONS; GENTAMICIN; TRENDS	Objectives: To determine the distribution of and risk factors for colonization and infection with vancomycin-resistant enterococci; to evaluate the molecular epidemiology of these strains; and to assess the effect of interventions, including 1) strict adherence to infection control procedures and 2) restricted use of vancomycin. Design: Problem identification based on descriptive studies, point-prevalence surveys, and case-control studies and followed by specific interventions and evaluation of the response to these interventions. Setting: University medical center. Participants: All patients hospitalized between May 1992 and June 1994 (59 196 admissions). Main Results: 75 active infections attributed to vancomycin-resistant enterococci were identified. Thirty-one patients (41%) had bloodstream infections and 6 (8%) died. The incidence of active infection was highest in the organ transplantation unit (13.2 infections/1000 admissions). In the point-prevalence studies, vancomycin-resistant enterococci were isolated from 20% of a random sample of hospitalized patients in July, August, and September 1993 (adjusted prevalence, 16.9%). Case-control studies showed significant associations between colonization and infection and 1) receipt of antimicrobial agents, particularly vancomycin, and 2) severity of illness. Although several small case clusters had isolates with identical banding patterns on pulsed-field gel electrophoresis, at least 45 different banding patterns were noted among medical center isolates. Interventions took place in November and December 1993. Vancomycin restriction policies resulted in a 59% decrease in intravenous vancomycin use and an 85% decrease in oral vancomycin use. Point-prevalence surveys done in April, May, and June 1994 showed a consistent 20% level of colonization with vancomycin-resistant enterococci strains (adjusted prevalence, 18.7%). No significant changes were seen in rates of vancomycin-resistant enterococci infection. Conclusions: Vancomycin-resistant enterococci are an important cause of illness and death in the study institution, particularly among organ transplant recipients and other seriously ill persons; they have also become a common intestinal colonizer among hospitalized patients. The diversity of isolates (based on molecular typing studies) suggests that resistant organisms have been introduced from multiple sources. Interventions that effectively lower the overall level of colonization with vancomycin-resistant enterococci must still be identified.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; UNIV MARYLAND, MED CTR, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	MORRIS, JG (corresponding author), VET AFFAIRS MED CTR, INFECT DIS SECT, 10 N GREENE ST, BALTIMORE, MD 21201 USA.		Dowling, Thomas/D-2147-2013	Dowling, Thomas/0000-0003-3214-9283; Shay, David/0000-0001-9619-4820				[Anonymous], 1993, METHODS DILUTION ANT; [Anonymous], 1993, PERFORMANCE STANDARD; ARDUINO RC, 1994, PRINCIPLES PRACTICE; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BATES J, 1993, LANCET, V342, P490, DOI 10.1016/0140-6736(93)91613-Q; BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; CHADWICK PR, 1994, LANCET, V344, P685, DOI 10.1016/S0140-6736(94)92119-9; DEAN AG, 1991, EPIINFO VERSION 5 WO; DEAN J, 1994, 94TH GEN M AM SOC MI; DONABEDIAN SM, 1992, J CLIN MICROBIOL, V30, P2757, DOI 10.1128/JCM.30.11.2757-2761.1992; FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P731, DOI 10.1128/JCM.27.4.731-734.1989; FRIEDEN TR, 1993, LANCET, V342, P76, DOI 10.1016/0140-6736(93)91285-T; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOERING RV, 1994, 3RD INT M BACT EP MA; GREEN M, 1993, 33RD INT C ANT AG CH; HARIHARAN R, 1993, 33RD INT C ANT AG CH; HERDEN J, 1994, 34TH INT C ANT AG CH; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; JONES R, 1993, 33RD INT C ANT AG CH; JORDENS JZ, 1994, J ANTIMICROB CHEMOTH, V34, P515, DOI 10.1093/jac/34.4.515; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LINDEN P, 1993, 33RD INT C ANT AG CH; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; MOELLERI.RC, 1971, J CLIN INVEST, V50, P2580, DOI 10.1172/JCI106758; MOELLERING RC, 1971, J INFECT DIS, V124, pS207, DOI 10.1093/infdis/124.Supplement_1.S207; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; PRATTRIPIN K, 1992, CLIN MICROBIOLOGY PR; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHWALBE RE, 1991, 91ST ANN M AM SOC MI; SMITH SM, 1994, 34TH INT C ANT AG CH; SPERA RV, 1992, JAMA-J AM MED ASSOC, V268, P2563, DOI 10.1001/jama.268.18.2563; STANDIFORD HD, 1970, ARCH INTERN MED, V126, P255, DOI 10.1001/archinte.126.2.255; STROUD L, 1993, SOC HOSPITAL EPIDEMI; UTTLEY AHC, 1988, LANCET, V1, P57; VENUTI E, 1994, 94TH GEN M AM SOC MI; VERMA P, 1994, 94TH GEN M AM SOC MI; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075; 1995, INFECT CONT HOSP EP, V16, P105; 1993, MMWR-MORBID MORTAL W, V42, P5947; 1992, STANDARD METHODS EXA, P69	45	395	404	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					250	259		10.7326/0003-4819-123-4-199508150-00002	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611590				2022-12-28	WOS:A1995RN66500002
J	CARROLL, SB				CARROLL, SB			HOMEOTIC GENES AND THE EVOLUTION OF ARTHROPODS AND CHORDATES	NATURE			English	Review							BITHORAX-COMPLEX; HOMEOBOX GENES; LIMB DEVELOPMENT; FOSSIL RECORD; DISTAL-LESS; HOX GENES; WNT GENE; DROSOPHILA; ANTENNAPEDIA; ORIGIN	Clusters of homeotic genes sculpt the morphology of animal body plans and body parts. Different body patterns may evolve through changes in homeotic gene number, regulation or function. Recent evidence suggests that homeotic gene clusters were duplicated early in vertebrate evolution, but the generation of arthropod and tetrapod diversity has largely involved regulatory changes in the expression of conserved arrays of homeotic genes and the evolution of interactions between homeotic proteins and the genes they regulate.			CARROLL, SB (corresponding author), UNIV WISCONSIN, HOWARD HUGHES MED INST, RM BOCK LABS, 1525 LINDEN DR, MADISON, WI 53706 USA.							AHLBERG PE, 1991, NATURE, V354, P298, DOI 10.1038/354298a0; AKAM M, 1994, DEVELOPMENT, P209; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEEMAN RW, 1993, BIOESSAYS, V15, P439, DOI 10.1002/bies.950150702; BIRKETSMITH SJR, 1984, PROLEGS LEGS WINGS I; Bonner JT., 1988, EVOLUTION COMPLEXITY; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; Brusca R.C., 1990, INVERTEBRATES; BURKE AC, 1995, DEVELOPMENT, V121, P333; Carroll RL, 1988, VERTEBRATE PALEONTOL; CARROLL SB, 1995, NATURE, V375, P58, DOI 10.1038/375058a0; CARTWRIGHT P, 1993, MOL PHYLOGENET EVOL, V2, P185, DOI 10.1006/mpev.1993.1019; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; DICKINSON WJ, 1991, EVOLUTIONARY BIOL, P127; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GANS C, 1975, AM ZOOL, V15, P455; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GINDHART JG, 1995, GENETICS, V139, P781; GOLDSCHMIDT RB, 1940, MATERIAL BASIS EVOLU; Gould S. J., 1977, ONTOGENY PHYLOGENY; GRAHAM A, 1994, CURR BIOL, V4, P1135, DOI 10.1016/S0960-9822(00)00256-6; HOGAN BLM, 1994, DEVELOPMENT, P53; HOLLAND PWH, 1994, DEVELOPMENT, P125; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JACOBS DK, 1990, P NATL ACAD SCI USA, V87, P4406, DOI 10.1073/pnas.87.11.4406; KAUFMAN T, 1990, GENETIC REGULATORY H; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOSTRIKEN R, 1992, DEV BIOL, V151, P225, DOI 10.1016/0012-1606(92)90229-A; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANN RS, 1994, DEVELOPMENT, V120, P3205; MASTICK GS, 1995, GENETICS, V139, P349; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1994, SCI AM, V270, P58, DOI 10.1038/scientificamerican0294-58; MCGINNIS W, 1994, GENETICS, V137, P607; MISOF B, 1995, CCE24 YAL U TECH REP; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; Ohno S., 1970, EVOLUTION GENE DUPLI; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; Raff R.A., 1983, EMBRYOS GENES EVOLUT; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RUDDLE FH, 1994, DEVELOPMENT, P155; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SHANKLAND M, 1991, DEVELOPMENT, P29; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WALLACE B, 1985, Q REV BIOL, V60, P31, DOI 10.1086/414172; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; WHEELER WC, 1993, CLADISTICS, V9, P1, DOI 10.1111/j.1096-0031.1993.tb00207.x; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WILSON AC, 1985, SCI AM, V253, P164, DOI 10.1038/scientificamerican1085-164; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	76	528	545	4	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 10	1995	376	6540					479	485		10.1038/376479a0	http://dx.doi.org/10.1038/376479a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637779				2022-12-28	WOS:A1995RN62200036
J	NISHIMURA, S				NISHIMURA, S			CENSORSHIP OF MEDICAL JOURNALS IN OCCUPIED JAPAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV TORONTO,INST HIST & PHILOSOPHY SCI & TECHNOL,TORONTO,ON,CANADA	University of Toronto								HIROTA K, 1947, SHIKAI TENBO, V4, P25; KOBIKICHO D, 1947, NIHON IJI SHINP 0811, P22; OJIMA N, 1946, RINSHO FUJINKA SANKA, V1, P82; OKUIZUMI E, 1983, ANN M ASS ASIAN STUD; SPAULDING RM, 1984, OCCUPATION JAPAN ART, P5; SPAULDING RM, 1984, 6TH S OCC JAP ARTS C; UMEHARA N, 1945, NIHON BYORI GAK 0115; 1947, TEIKOKU SHINKYU  MAR, P1; 1945, ASAKI SHINBUN   0908, P1; 1952, NIHON IJI SHINP 0614, P62; 1945, NIHON IRYODANPO 1210, P15; 1945, MAINICHI SHINBU 0912, P1; 1947, TOKYOTO YAKUZAI 0430, P7; 1946, SOGO IGAKU      1115, P29; 1946, NIHON NAIKA GAK 0310, P33; 1986, BESSATSU SHINBUN KEN, V21, P77; 1954, NIHON IJI SHINP 0206, P101	17	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					454	456		10.1001/jama.274.6.454	http://dx.doi.org/10.1001/jama.274.6.454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629944				2022-12-28	WOS:A1995RM69900010
J	PAGANO, M; TAM, SW; THEODORAS, AM; BEERROMERO, P; DELSAL, G; CHAU, V; YEW, PR; DRAETTA, GF; ROLFE, M				PAGANO, M; TAM, SW; THEODORAS, AM; BEERROMERO, P; DELSAL, G; CHAU, V; YEW, PR; DRAETTA, GF; ROLFE, M			ROLE OF THE UBIQUITIN-PROTEASOME PATHWAY IN REGULATING ABUNDANCE OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P27	SCIENCE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; DEGRADATION; ASSOCIATION; PROTEIN; CLONING; SYSTEM; YEAST; GENE; P53	The p27 mammalian cell cycle protein is an inhibitor of cyclin-dependent kinases. Both in vivo and in vitro, p27 was found to be degraded by the ubiquitin-proteasome pathway. The human ubiquitin-conjugating enzymes Ubc2 and Ubc3 were specifically involved in the ubiquitination of p27. Compared with proliferating cells, quiescent cells exhibited a smaller amount of p27 ubiquitinating activity, which accounted for the marked increase of p27 half-life measured in these cells. Thus, the abundance of p27 in cells is regulated by degradation. The specific proteolysis of p27 may represent a mechanism for regulating the activity of cyclin-dependent kinases.	WAYNE STATE UNIV, DEPT PHARMACOL, DETROIT, MI 48201 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Wayne State University; Harvard University; Harvard Medical School	PAGANO, M (corresponding author), MITOTIX INC, 1 KENDALL SQ, BLDG 600, CAMBRIDGE, MA 02139 USA.			pagano, michele/0000-0003-3210-2442; DEL SAL, GIANNINO/0000-0003-2185-6003				CHAU V, UNPUB; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KAISER P, 1994, J BIOL CHEM, V269, P8797; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; LIU Z, 1992, J BIOL CHEM, V267, P15829; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; Murray A, 1993, CELL CYCLE INTRO; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1995, CELL CYCLE MATERIALS, pCH24; PAGANO M, UNPUB; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TAM SC, UNPUB; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	34	1723	1771	3	67	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					682	685		10.1126/science.7624798	http://dx.doi.org/10.1126/science.7624798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624798				2022-12-28	WOS:A1995RM70200031
J	SKEATH, JB; ZHANG, Y; HOLMGREN, R; CARROLL, SB; DOE, CQ				SKEATH, JB; ZHANG, Y; HOLMGREN, R; CARROLL, SB; DOE, CQ			SPECIFICATION OF NEUROBLAST IDENTITY IN THE DROSOPHILA EMBRYONIC CENTRAL-NERVOUS-SYSTEM BY GOOSEBERRY-DISTAL	NATURE			English	Article							GENES; EXPRESSION; ACHAETE; SEGREGATION; COMPLEX; REGION	THE Drosophila central nervous system develops from a segmentally reiterated array of 30 unique neural precursors, called neuroblasts. Each neuroblast goes through a stereotyped cell lineage to produce an invariant clone of neural progeny. It is critical to identify the genes that specify neuroblast identity as these genes control the time of formation, gene expression profile, and cell lineage characteristics of each neuroblast. Here we show that the Pax-type gooseberry-distal gene specifies row 5 neuroblast identity. Initially, four rows of neuroblasts form per segment (1, 3, 5, 7) and gooseberry-distal is expressed in row 5 neuroblasts(1-3). By using 10 molecular markers, and by following the number and orientation of neuroblast divisions, we show that lack of gooseberry-distal transforms row 5 neuroblasts into row 3 neuroblasts, whereas ubiquitous gooseberry-distal generates the reciprocal transformation. Thus, gooseberry-distal is necessary and sufficient to specify row 5 neuroblast identity autonomously, The 10 genes coordinately regulated by gooseberry-distal are prime candidates for controlling specific aspects of neuroblast identity.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI	University of Illinois System; University of Illinois Urbana-Champaign; Northwestern University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	SKEATH, JB (corresponding author), UNIV ILLINOIS,HOWARD HUGHES MED INST,URBANA,IL 61801, USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DOE CQ, 1988, SCIENCE, V239, P190; DOE CQ, 1992, DEVELOPMENT, V119, P855; Goodman Corey S., 1993, P1131; GUTJAHR T, 1993, DEVELOPMENT, V119, P21; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; MARTINBERMUDO MD, 1991, DEVELOPMENT, V119, P1003; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; SKEATH JB, 1992, DEVELOPMENT, V114, P939; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; ZHANG Y, 1994, DEVELOPMENT, V120, P1151	18	81	81	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					427	430		10.1038/376427a0	http://dx.doi.org/10.1038/376427a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630418				2022-12-28	WOS:A1995RM63900052
J	BREARLEY, S				BREARLEY, S			HARMONIZATION OF SPECIALIST TRAINING IN EUROPE - IS IT A MIRAGE	BRITISH MEDICAL JOURNAL			English	Article								For the past 18 years there has been a proliferation of European committees, boards, associations, colleges, and working groups set up to promote the harmonisation of specialist training in Europe. It has been taken as read that this objective is desirable. The fact that these bodies have achieved remarkably little is telling, and it is time to question their activity. There are good practical reasons behind the evolution of Europe's disparate training schemes, and the arguments for retaining diversity rather than continuing to strive for homogeneity are persuasive.			BREARLEY, S (corresponding author), WHIPPS CROSS HOSP & CHEST CLIN,LONDON E11 1NR,ENGLAND.							BREARLEY S, 1994, BRIT MED J, V309, P1245, DOI 10.1136/bmj.309.6964.1245; BREARLEY S, 1989, MED EDUC, V23, P339; 1983, 2ND ADV COMM MED TRA; 1993, HOSPITAL DOCTORS TRA; 1994, UEMS D9426 UN EUR ME; 1992, UEMS D9367 UN EUR ME; 1992, COMPENDIUM MED SPECI	7	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					297	299		10.1136/bmj.311.7000.297	http://dx.doi.org/10.1136/bmj.311.7000.297			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633240	Green Published			2022-12-28	WOS:A1995RM71900028
J	BAKER, SM; BRONNER, CE; ZHANG, L; PLUG, AW; ROBATZEK, M; WARREN, G; ELLIOTT, EA; YU, JA; ASHLEY, T; ARNHEIM, N; FLAVELL, RA; LISKAY, RM				BAKER, SM; BRONNER, CE; ZHANG, L; PLUG, AW; ROBATZEK, M; WARREN, G; ELLIOTT, EA; YU, JA; ASHLEY, T; ARNHEIM, N; FLAVELL, RA; LISKAY, RM			MALE-MICE DEFECTIVE IN THE DNA MISMATCH REPAIR GENE PMS2 EXHIBIT ABNORMAL CHROMOSOME SYNAPSIS IN MEIOSIS	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; MEIOTIC SYNAPSIS; ESCHERICHIA-COLI; RECOMBINATION; CONVERSION; YEAST; INITIATION; MUTATIONS; SEQUENCE	Using gene targeting in embryonic stem cells, we have derived mice with a null mutation in a DNA mismatch repair gene homolog, PMS2. We observed microsatellite instability in the male germline, in tail, and in tumor DNA of PMS2-deficient animals. We therefore conclude that PMS2 is involved in DNA mismatch repair in a variety of tissues. PMS2-deficient animals appear prone to sarcomas and lymphomas, PMS2-deficient males are infertile, producing only abnormal spermatozoa. Analysis of axial element and synaptonemal complex formation during prophase of meiosis I indicates abnormalities in chromosome synapsis. These observations suggest links among mismatch repair, genetic recombination, and chromosome synapsis in meiosis.	OREGON HLTH SCI UNIV, DEPT MOLEC MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; UNIV SO CALIF, PROGRAM MOLEC BIOL, LOS ANGELES, CA 90089 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; AGR UNIV WAGENINGEN, DEPT GENET, 6703 HA WAGENINGEN, NETHERLANDS	Oregon Health & Science University; University of Southern California; Yale University; Howard Hughes Medical Institute; Yale University; Wageningen University & Research	BAKER, SM (corresponding author), OREGON HLTH SCI UNIV, DEPT MED & MOLEC GENET, PORTLAND, OR 97201 USA.		Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Arnheim, Norman/0000-0003-1247-1347	NIGMS NIH HHS [GM45413-05, GM32741-14, GM49779] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049779, R01GM045413, R01GM032741, R37GM032741] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1994, GENETICS, V137, P19; ASHLEY T, 1988, GENETICS, V118, P307; ASHLEY T, 1990, GENETICA, V83, P1; AU KG, 1992, J BIOL CHEM, V267, P12142; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Boer P. de, 1989, Fertility and chromosome pairing: recent studies in plants and animals., P37; BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; DETLOFF P, 1992, GENETICS, V132, P113; DIETRICH W, 1992, GENETICS, V131, P423; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOREJT J, 1985, EXP CLIN IMMUNOGENET, V2, P106; GOETZ P, 1984, J CELL SCI, V65, P249; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HOEKSTRA MF, 1991, METHOD ENZYMOL, V194, P329; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEEFLANG PE, 1994, CURRENT PROTOCOLS HU, V1; LI FP, 1988, CANCER RES, V48, P5358; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Moses MJ, 1980, ANIMAL MODELS HUMAN, P169; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; PETIT MA, 1991, GENETICS, V129, P327; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SELVA EM, 1995, GENETICS, V139, P1175; SHERMAN JD, 1992, GENOME, V35, P907, DOI 10.1139/g92-140; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; Speed R.M., 1989, FERTILITY CHROMOSOME, P1; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WILLIAMSON MS, 1985, GENETICS, V110, P609; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	52	469	494	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					309	319		10.1016/0092-8674(95)90318-6	http://dx.doi.org/10.1016/0092-8674(95)90318-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628019	hybrid			2022-12-28	WOS:A1995RL76000018
J	TRONO, D				TRONO, D			HIV ACCESSORY PROTEINS - LEADING ROLES FOR THE SUPPORTING CAST	CELL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; VPU PROTEIN; INFECTED-CELLS; NEF PROTEIN; T-CELLS; INDUCTION; GENE; LYMPHOCYTES; VIF				TRONO, D (corresponding author), SALK INST BIOL STUDIES,INFECT DIS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BORMAN AM, 1995, J VIROL, V69, P2058, DOI 10.1128/JVI.69.4.2058-2067.1995; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6692; VOUR S, 1995, J VIROL, V69, P1510; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WU XY, 1994, J VIROL, V68, P6161, DOI 10.1128/JVI.68.10.6161-6169.1994; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	33	240	250	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					189	192		10.1016/0092-8674(95)90306-2	http://dx.doi.org/10.1016/0092-8674(95)90306-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628010	Bronze			2022-12-28	WOS:A1995RL76000006
J	PERL, TM; DVORAK, LA; HWANG, T; WENZEL, RP				PERL, TM; DVORAK, LA; HWANG, T; WENZEL, RP			LONG-TERM SURVIVAL AND FUNCTION AFTER SUSPECTED GRAM-NEGATIVE SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREDICTOR; PROGNOSIS; ANTIBODY; DISTRESS	Objective.-To determine the long-term (>3 months) survival of septic patients, to develop mathematical models that predict patients likely to survive long-term, and to measure the health and functional status of surviving patients. Setting.-A large tertiary care university hospital and an associated Veterans Affairs Medical Center. Design.-From December 1986 to December 1990, a total of 103 patients with suspected gram-negative sepsis entered a double-blind, placebo-controlled efficacy trial of monoclonal antiendotoxin antibody. Of these, we followed up 100 patients for 7667 patient-months. Beginning in May 1992, we reviewed hospital records and contacted all known survivors. We measured the health status of all surviving patients. Main Outcome Measures.-The determinants of long-term survival (up to 6 years) were identified through two Cox proportional hazard regression models: one that included patient characteristics identified at the time of sepsis (bedside model) and another that included bedside, infection-related, and treatment characteristics (overall model). Results.-Of the 60 patients in the cohort who died at a median interval of 30.5 days after sepsis, 32 died within the first month of the septic episode, seven died within 3 months, and four more died within 6 months. In the bedside multivariate model constructed to predict long-term survival, large hazard ratios (HRs) were associated with severity of underlying illness as classified by McCabe and Jackson criteria (for rapidly fatal disease, HR=30.4, P<.001; for ultimately fatal disease, HR=7.6, P<.001) and the use of vasopressors (HR=2.5; P=.001). In the overall model for long-term survival, severity of underlying illness (rapidly fatal disease, HR=23.7, P<.001; ultimately fatal disease, HR=6.5, P<.001), number of active comorbid illnesses (HR=1.3; P=.04), use of vasopressors at the time of sepsis (HR=2.0; P=.02), and development of adult respiratory distress syndrome (HR=2.3; P=.02) predicted patients most likely to die, The Acute Physiology and Chronic Health Evaluation II score was not a significant predictor of outcome when either model included the simpler McCabe and Jackson classification of underlying disease severity. We compared the health status scores with norms for the general population and found that patients with resolved sepsis reported more physical dysfunction (P<.001), including problems with work and activities of daily living (P=.02), and more poorly perceived general health (P<.01). In contrast, patients' scores for perceived emotional health were higher than those in the general population (P=.004). The mean Barthel score of our patients was 85 (100=total independence) and the mean Eastern Cooperative Oncology Group score was 0.7 (0=normal, 4=100% bedridden), suggesting that the patient's physical function was not normal. Conclusions.-At the onset of suspected gram-negative sepsis, severity of underlying illness and in-hospital use of vasopressors are strong and consistent predictors of short- and long-term survival. Our data validate the McCabe and Jackson severity of illness scoring system for predicting long-term survival after sepsis. Physical dysfunction and more poorly perceived general health occur commonly after sepsis.	UNIV IOWA,COLL MED,DEPT PREVENT MED,IOWA CITY,IA 52242	University of Iowa	PERL, TM (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,C41 GH,IOWA CITY,IA 52242, USA.							ALBERTS WM, 1983, CHEST, V84, P272, DOI 10.1378/chest.84.3.272; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; Cox D. R., 1984, ANAL SURVIVAL DATA; ELLIOTT CG, 1981, AM REV RESPIR DIS, V123, P492; GREEMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P197; GROSS PA, 1988, INFECT CONT HOSP EP, V9, P497, DOI 10.2307/30146545; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAKSHMINARAYAN S, 1981, SEMIN RESPIR MED, V11, P160; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin M A, 1991, Infect Dis Clin North Am, V5, P739; MASANARI RM, 1993, INFECT CONT HOSP EP, V14, P430; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MINNA JD, 1989, CANCER PRINCIPLES PR; PERL TM, 1992, CLIN RES, V40, pA286; PITTET D, 1993, INTENS CARE MED, V19, P265, DOI 10.1007/BF01690546; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; ROBERTS FJ, 1991, REV INFECT DIS, V13, P34; SOMERVELL PD, 1989, AM J EPIDEMIOL, V130, P1013, DOI 10.1093/oxfordjournals.aje.a115402; Ware J. E., 1993, SF36 HLTH SURVEY MAN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WU AW, 1995, ANN INTERN MED, V122, P342, DOI 10.7326/0003-4819-122-5-199503010-00004; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1990, MMWR-MORBID MORTAL W, V39, P31; 1992, CHEST, V101, P1644	32	220	229	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					338	345		10.1001/jama.274.4.338	http://dx.doi.org/10.1001/jama.274.4.338			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609265				2022-12-28	WOS:A1995RJ89800038
J	SILBER, JH; ROSENBAUM, PR; SCHWARTZ, JS; ROSS, RN; WILLIAMS, SV				SILBER, JH; ROSENBAUM, PR; SCHWARTZ, JS; ROSS, RN; WILLIAMS, SV			EVALUATION OF THE COMPLICATION RATE AS A MEASURE OF QUALITY OF CARE IN CORONARY-ARTERY BYPASS GRAFT-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-HOSPITAL MORTALITY; SURGICAL-PROCEDURES; ADMISSION SEVERITY; ADVERSE EVENTS; DATA-BASES; ILLNESS; MEDISGROUPS; DEATH; RISK; VOLUME	Objective.-To determine whether hospital rankings based on complication rates provide the same information as hospital rankings based on mortality rates. Design.-A retrospective study of in-hospital death, complication, and death following complication (failure to rescue). Hospitals were ranked using residuals based on the difference between the observed and the expected number of events (from logistic regression models); rankings were compared using Spearman rank correlations. Setting.-Hospitals performing coronary artery bypass graft (CABG) surgery in the 1991 and 1992 MedisGroups National Comparative Data Bases. Patients and Data Sets,-Record abstraction data for 16 673 patients who underwent CABG procedures at 57 hospitals, linked with data from the 1991 American Hospital Association Annual Survey. Results.-After adjusting for patient admission severity of illness, there were low correlations between hospital rankings based on death or failure to rescue and those rankings based on complication (death vs complication, r=0.07, P=.58; failure to rescue vs complication, r=-0.22, P=.11). In addition, many hospital characteristics that are generally associated with a higher quality of care were associated with higher complication rates but with expected or lower-than-expected mortality rates. Conclusions.-HospitaI rankings based on complication rates provide different information than those based on mortality rates. Until more is known about these differences, complication rates should not be used to judge hospital quality of care in CABG surgery.	UNIV PENN, SCH MED, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DIV GEN INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, DEPT STAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Rosenbaum, Paul R/H-8687-2012		AHRQ HHS [R01-HS06560] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; DESHARNAIS S, 1991, HEALTH SERV RES, V26, P425; FLOOD AF, 1987, HOSPITAL STRUCTURE P, P174; HABERMAN SJ, 1976, 9TH P INT BIOM C BOS, P104; HABERMAN SJ, 1974, ANAL FREQUENCY DATA, P138; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HANNAN EL, 1989, AM J PUBLIC HEALTH, V79, P430, DOI 10.2105/AJPH.79.4.430; Hartz A J, 1992, Int J Technol Assess Health Care, V8, P524; HARTZ AJ, 1994, AM J PUBLIC HEALTH, V84, P1609, DOI 10.2105/AJPH.84.10.1609; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HARTZ AJ, 1992, AM J PUBLIC HEALTH, V82, P1631, DOI 10.2105/AJPH.82.12.1631; HARTZ AJ, 1993, HEALTH SERV RES, V27, P765; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; IEZZONI LI, 1993, MED CARE, V31, P277, DOI 10.1097/00005650-199303000-00009; IEZZONI LI, 1994, INQUIRY-J HEALTH CAR, V31, P40; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; KRAKAUER H, 1993, INQUIRY-J HEALTH CAR, V30, P115; KUHN EM, 1991, MED CARE, V29, P1028, DOI 10.1097/00005650-199110000-00008; LUFT HS, 1993, JAMA-J AM MED ASSOC, V270, P331, DOI 10.1001/jama.270.3.331; LUFT HS, 1986, JAMA-J AM MED ASSOC, V255, P2780, DOI 10.1001/jama.255.20.2780; Mosteller F, 1977, DATA ANAL REGRESSION, P299; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; ROSEN AK, 1992, MED CARE, V30, P753, DOI 10.1097/00005650-199209000-00001; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004; SILBER JH, 1995, J AM STAT ASSOC, V90, P7, DOI 10.2307/2291124; SILBER JH, 1993, CLIN RES, V41, pA181; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; THOMAS JW, 1989, INQUIRY-J HEALTH CAR, V26, P483; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39; WEISBERG S, 1985, APPL LINEAR REGRESSI, P179; WRIGHT JG, 1987, CHEST, V91, P394, DOI 10.1378/chest.91.3.394	41	250	252	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					317	323		10.1001/jama.274.4.317	http://dx.doi.org/10.1001/jama.274.4.317			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ898	7609261				2022-12-28	WOS:A1995RJ89800034
J	FRIEDMAN, E				FRIEDMAN, E			THE COMPROMISE AND THE AFTERTHOUGHT - MEDICARE AND MEDICAID AFTER 30 YEARS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-DISEASE PROGRAM											CAMPION FD, 1984, AMA US HLTH POLICY 1; COHEN W, 1979, MEDICAID EXPERIENCE; DELEW N, 1995, JAMA-J AM MED ASSOC, V274, P262; FISHBEIN M, 1932, JAMA-J AM MED ASSOC, V99, P1950; FOX R, 1978, COURAGE FAIL; FRIEDMAN E, 1990, HOSPITALS, V64, P38; FRIEDMAN E, 1985, HOSPITALS, V59, P41; FRIEDMAN E, 1984, HOSPITALS, V58, P102; FRIEDMAN E, 1981, HOSPITALS, V55, P65; FRIEDMAN E, 1995, 1994 NAT HLTH POL FO; FRIEDMAN E, 1977, PROBLEMS PROMISES ME; FRIEDMAN E, 1984, HOSPITALS, V58, P68; Harris Richard, 1966, SACRED TRUST; LEVINSKY NG, 1991, NEW ENGL J MED, V324, P1143, DOI 10.1056/NEJM199104183241628; LEVINSKY NG, 1993, NEW ENGL J MED, V329, P1395, DOI 10.1056/NEJM199311043291907; ROWLAND D, 1995, JAMA-J AM MED ASSOC, V274, P271, DOI 10.1001/jama.274.3.271; ROWLAND D, 1991, MEDICAID BUILDING HL; SANAZARO P, 1973, HLTHS ERVICES RES R; Starr P, 1982, SOCIAL TRANSFORMATIO; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P259, DOI 10.1001/jama.274.3.259; WILLIAMSON K, 1965, HOSPITALS, V39, P30; [No title captured]	22	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					278	282		10.1001/jama.274.3.278	http://dx.doi.org/10.1001/jama.274.3.278			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RH937	7609243				2022-12-28	WOS:A1995RH93700040
J	PARSONS, R; LI, GM; LONGLEY, M; MODRICH, P; LIU, B; BERK, T; HAMILTON, SR; KINZLER, KW; VOGELSTEIN, B				PARSONS, R; LI, GM; LONGLEY, M; MODRICH, P; LIU, B; BERK, T; HAMILTON, SR; KINZLER, KW; VOGELSTEIN, B			MISMATCH REPAIR DEFICIENCY IN PHENOTYPICALLY NORMAL HUMAN-CELLS	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; CARCINOGENESIS; MUTATIONS; LOCUS; MEMORIAL; HOMOLOG; LECTURE	Tumor cells in patients with hereditary nonpolyposis colorectal cancer (HNPCC) are characterized by a genetic hypermutability caused by defects in DNA mismatch repair. A subset of HNPCC patients was found to have widespread mutations not only in their tumors, but also in their non-neoplastic cells. Although these patients had numerous mutations in all tissues examined, they had very few tumors. The hypermutability was associated with a profound defect in mismatch repair at the biochemical level. These results have implications for the relation between mutagenesis and carcinogenesis, and they suggest that mismatch repair deficiency is compatible with normal human development.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; MT SINAI HOSP,FAMILIAL GI CANC REGISTRY,TORONTO,ON M5G 1X5,CANADA; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Duke University; Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Johns Hopkins University; Johns Hopkins University			Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885; Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA35494, CA62924] Funding Source: Medline; NIGMS NIH HHS [GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, R37CA035494, P50CA062924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1992, GUT, V33, P783, DOI 10.1136/gut.33.6.783; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KNUDSON AG, 1985, CANCER RES, V45, P1437; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PARSONS R, UNPUB; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	33	301	326	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					738	740		10.1126/science.7632227	http://dx.doi.org/10.1126/science.7632227			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7632227				2022-12-28	WOS:A1995QW60300054
J	PALLARES, R; LINARES, J; VADILLO, M; CABELLOS, C; MANRESA, F; VILADRICH, PF; MARTIN, R; GUDIOL, F				PALLARES, R; LINARES, J; VADILLO, M; CABELLOS, C; MANRESA, F; VILADRICH, PF; MARTIN, R; GUDIOL, F			RESISTANCE TO PENICILLIN AND CEPHALOSPORIN AND MORTALITY FROM SEVERE PNEUMOCOCCAL PNEUMONIA IN BARCELONA, SPAIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; SYSTEMIC INFECTIONS; BACTEREMIA; CHLORAMPHENICOL; SUSCEPTIBILITY; DIAGNOSIS; DISEASE; THERAPY	Background. Penicillin-resistant strains of Streptococcus pneumoniae are now found worldwide, and strains with resistance to cephalosporin are being reported. The appropriate antibiotic therapy for pneumococcal pneumonia due to resistant strains remains controversial. Methods. To examine the effect of resistance to penicillin and cephalosporin on mortality, we conducted a 10-year, prospective study in Barcelona of 504 adults with culture-proved pneumococcal pneumonia. Results. Among the 504 patients, 145 (29 percent) had penicillin-resistant strains of S. pneumoniae (minimal inhibitory concentration [MIG] of penicillin G, 0.12 to 4.0 mu g per milliliter), and 31 patients (6 percent) had cephalosporin-resistant strains (MIG of ceftriaxone or cefotaxime, 1.0 to 4.0 mu g per milliliter). Mortality was 38 percent in patients with penicillin-resistant strains, as compared with 24 percent in patients with penicillin-sensitive strains (P = 0.001). However, after the exclusion of patients with polymicrobial pneumonia and adjustment for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1.0 (95 percent confidence interval, 0.5 to 1.9; P = 0.84). Among patients treated with penicillin G or ampicillin, the mortality was 25 percent in the 24 with penicillin-resistant strains and 19 percent in the 126 with penicillin-sensitive strains (P = 0.51). Among patients treated with ceftriaxone or cefotaxime, the mortality was 22 percent in the 59 with penicillin-resistant strains and 25 percent in the 127 with penicillin-sensitive strains (P = 0.64), The frequency of resistance to cephalosporin increased from 2 percent in 1984-1988 to 9 percent in 1989-1993 (P = 0.002). Mortality was 26 percent in patients with cephalosporin-resistant S. pneumoniae and 28 percent in patients with susceptible organisms (P = 0.89), Among patients treated with ceftriaxone or cefotaxime, mortality was 22 percent in the 18 with cephalosporin-resistant strains and 24 percent in the 168 with cephalosporin-sensitive organisms (P = 0.64). Conclusions. Current levels of resistance to penicillin and cephalosporin by S. pneumoniae are not associated with increased mortality in patients with pneumococcal pneumonia, Hence, these antibiotics remain the therapy of choice for this disease.	HOSP BELLVITGE PRINCEPS ESPANYA, INFECT DIS SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, MICROBIOL SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, INTERNAL MED SERV, BARCELONA, SPAIN; HOSP BELLVITGE PRINCEPS ESPANYA, PULM DIS SERV, BARCELONA, SPAIN; UNIV BARCELONA, BARCELONA, SPAIN	University of Barcelona			PALLARES, Roman/B-5710-2008; Liñares, Josefina/N-9450-2014; Cabellos, Carmen/AAO-3784-2021	PALLARES, Roman/0000-0003-3262-8508; Cabellos, Carmen/0000-0001-7392-7382				AMSDEN GW, 1995, PRINCIPLES PRACTICE, P492; APPELBAUM PC, 1977, LANCET, V2, P995; APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; FENOLL A, 1991, REV INFECT DIS, V13, P56; FINKELSTEIN MS, 1983, J AM GERIATR SOC, V31, P19, DOI 10.1111/j.1532-5415.1983.tb06283.x; FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GARCIALEONI ME, 1992, CLIN INFECT DIS, V14, P427, DOI 10.1093/clinids/14.2.427; GARCIALEONI ME, 1992, ARCH INTERN MED, V152, P1808, DOI 10.1001/archinte.152.9.1808; GRANSDEN WR, 1985, BRIT MED J, V290, P505, DOI 10.1136/bmj.290.6467.505; GRUER LD, 1984, Q J MED, V53, P259; HANSMAN D, 1971, NEW ENGL J MED, V284, P175, DOI 10.1056/NEJM197101282840403; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; JACOBS MR, 1979, ANTIMICROB AGENTS CH, V16, P190, DOI 10.1128/AAC.16.2.190; JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JOHN CC, 1994, CLIN INFECT DIS, V18, P188, DOI 10.1093/clinids/18.2.188; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KRAMER MR, 1987, ISRAEL J MED SCI, V23, P174; LINARES J, 1992, CLIN INFECT DIS, V15, P99, DOI 10.1093/clinids/15.1.99; MANRESA F, 1991, THORAX, V46, P601, DOI 10.1136/thx.46.8.601; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; MYLOTTE JM, 1981, AM REV RESPIR DIS, V123, P265; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; SANCHEZ C, 1992, LANCET, V339, P988, DOI 10.1016/0140-6736(92)91560-U; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; TAN TQ, 1992, PEDIATRICS, V90, P928; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; VILADRICH PF, 1988, AM J MED, V84, P839, DOI 10.1016/0002-9343(88)90061-7; WATANAKUNAKORN C, 1993, CHEST, V103, P1152, DOI 10.1378/chest.103.4.1152; 1994, NCCLS M100S5 NAT COM	40	628	642	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	1995	333	8					474	480		10.1056/NEJM199508243330802	http://dx.doi.org/10.1056/NEJM199508243330802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP759	7623879	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1995RP75900002
J	WAGNER, A				WAGNER, A			2ND CHILDHOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					606	606						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637134				2022-12-28	WOS:A1995RP70200009
J	WIERENGA, KJJ; PATTISON, JR; BRINK, N; GRIFFITHS, M; MILLER, M; SHAH, DJ; WILLIAMS, W; SERJEANT, BE; SERJEANT, GR				WIERENGA, KJJ; PATTISON, JR; BRINK, N; GRIFFITHS, M; MILLER, M; SHAH, DJ; WILLIAMS, W; SERJEANT, BE; SERJEANT, GR			GLOMERULONEPHRITIS AFTER HUMAN PARVOVIRUS INFECTION IN HOMOZYGOUS SICKLE-CELL DISEASE	LANCET			English	Note							MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS	Glomerulonephritis with proteinuria of sufficient degree to manifest the nephrotic syndrome followed aplastic crises induced by human parvovirus (B19) in seven patients with homozygous sickle-cell disease, within 7 days in five patients and 6-7 weeks in two. Segmental proliferative glomerulosclerosis was found in the fifth patient who had a biopsy 4 months later. One patient recovered completely, one died in chronic renal failure after 3 months, and the others had impaired creatinine clearance, four with continuing proteinuria.	UCL, SCH MED, DIV VIROL, LONDON WC1E 6BJ, ENGLAND; UNIV W INDIES, MRC LABS, KINGSTON 7, JAMAICA; UNIV W INDIES, DEPT MED, KINGSTON 7, JAMAICA; UNIV W INDIES, DEPT CHILD HLTH, KINGSTON 7, JAMAICA; UNIV W INDIES, DEPT PATHOL, KINGSTON 7, JAMAICA	University of London; University College London; UCL Medical School; University West Indies Mona Jamaica; University West Indies Mona Jamaica; University West Indies Mona Jamaica; University West Indies Mona Jamaica								BERRY PL, 1981, CLIN NEPHROL, V16, P101; COHEN BJ, 1983, J HYG-CAMBRIDGE, V91, P113, DOI 10.1017/S0022172400060095; FINKEL TH, 1994, LANCET, V343, P1255, DOI 10.1016/S0140-6736(94)92152-0; ISKANDAR SS, 1991, CLIN NEPHROL, V35, P47; MARKENSON AL, 1978, AM J MED, V64, P719, DOI 10.1016/0002-9343(78)90596-X; STEVENS MCG, 1986, PEDIATRICS, V78, P124	6	68	73	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 19	1995	346	8973					475	476		10.1016/S0140-6736(95)91324-6	http://dx.doi.org/10.1016/S0140-6736(95)91324-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637482				2022-12-28	WOS:A1995RP85700012
J	COWEN, PJ; CLIFFORD, EM; WILLIAMS, C; WALSH, AES; FAIRBURN, CG				COWEN, PJ; CLIFFORD, EM; WILLIAMS, C; WALSH, AES; FAIRBURN, CG			WHY IS DIETING SO DIFFICULT	NATURE			English	Letter											COWEN, PJ (corresponding author), UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND.		Fairburn, Christopher/AAG-6234-2019; Fairburn, Christopher/AAM-9792-2020	Fairburn, Christopher/0000-0002-9673-9795; Cowen, Philip/0000-0001-5518-6138				ANDERSON IM, 1990, PSYCHOL MED, V20, P785, DOI 10.1017/S0033291700036473; BROWNELL KD, 1994, AM PSYCHOL, V49, P781, DOI 10.1037/0003-066X.49.9.781; COOPER Z, 1995, EATING DISORDERS OBE, P199; COWEN PJ, 1993, CLIN NEUROPHARMACOL, V16, pS6; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0	5	9	10	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					557	557		10.1038/376557a0	http://dx.doi.org/10.1038/376557a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP756	7637801				2022-12-28	WOS:A1995RP75600031
J	WHITCOMB, ME				WHITCOMB, ME			CORRECTING THE OVERSUPPLY OF SPECIALISTS BY LIMITING RESIDENCIES FOR GRADUATES OF FOREIGN MEDICAL-SCHOOLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WHITCOMB, ME (corresponding author), ASSOC AMER MED COLL,WASHINGTON,DC 20037, USA.							ALTMAN DF, 1994, AM J MED, V97, P407, DOI 10.1016/0002-9343(94)90319-0; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; MULLAN F, 1994, MILBANK Q, V72, P385, DOI 10.2307/3350263; STODDARD JJ, 1994, JAMA-J AM MED ASSOC, V272, P53, DOI 10.1001/jama.272.1.53; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITCOMB ME, 1986, NEW ENGL J MED, V314, P710, DOI 10.1056/NEJM198603133141111; 1994, MED ED RES INFORMATI; 1994, ACAD MED, V69, P508; 1992, 3RD REPORT IMPROVING; 1980, SUMMARY REPORT GRADU, V1; 1993, ANN REPORT C	11	36	36	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					454	456		10.1056/NEJM199508173330712	http://dx.doi.org/10.1056/NEJM199508173330712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616998				2022-12-28	WOS:A1995RP24300012
J	LAINE, L; COOK, D				LAINE, L; COOK, D			ENDOSCOPIC LIGATION COMPARED WITH SCLEROTHERAPY FOR TREATMENT OF ESOPHAGEAL VARICEAL BLEEDING - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							INJECTION SCLEROTHERAPY; RANDOMIZED TRIAL; HEMORRHAGE; TAMPONADE	Purpose: To compare the effect of endoscopic ligation with that of sclerotherapy in the treatment of patients with bleeding esophageal varices. Data Sources: Strategies to identify published and unpublished research included searches of computerized bibliographic and scientific citations, review of citations in relevant primary articles, searches of services providing information on unpublished studies, contact with primary investigators and the ligation equipment manufacturer, and review of proceedings from pertinent scientific meetings. Study Selection: From 158 potentially relevant articles, duplicate independent review identified 7 relevant randomized trials that compared endoscopic ligation with sclerotherapy for the treatment of patients with bleeding esophageal varices. Data Abstraction: Independent, duplicate data abstraction of the population, intervention, outcome, and methodologic quality of the trials was done. Data Synthesis: Ligation therapy compared with sclerotherapy reduced the rebleeding rate (odds ratio, 0.52 [95% CI, 0.37 to 0.74]), the mortality rate (odds ratio, 0.67 [CI, 0.46 to 0.98]), and the rate of death due to bleeding (odds ratio, 0.49 [CI, 0.24 to 0.996]). Four patients would need to be treated with ligation instead of sclerotherapy to avert one rebleeding episode, and 10 would need to be treated with ligation instead of sclerotherapy to prevent one death. Esophageal strictures occurred less frequently with ligation (odds ratio, 0.10 [CI, 0.03 to 0.29]), but no significant differences were seen between treatments for pulmonary infections or bacterial peritonitis. Additionally, the number of endoscopic treatment sessions required to achieve variceal obliteration was lower with ligation than with sclerotherapy. Conclusions: On the basis of lower rates of rebleeding, mortality, and complications and the need for fewer endoscopic treatments, ligation should be considered the endoscopic treatment of choice for patients with esophageal variceal bleeding.	MCMASTER UNIV, HAMILTON, ON, CANADA	McMaster University	LAINE, L (corresponding author), UNIV SO CALIF, SCH MED,DEPT MED,DIV GASTROENTEROL,LAC 12-137, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA.							AVGERINOS A, 1994, GASTROENTEROLOGY, V106, pA861; BARSOUM MS, 1982, BRIT J SURG, V69, P76, DOI 10.1002/bjs.1800690206; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Fleiss JL, 1981, STAT METHODS RATES P; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; HASHIZUME M, 1993, GASTROINTEST ENDOSC, V39, P123, DOI 10.1016/S0016-5107(93)70050-4; JENSEN DM, 1993, GASTROINTEST ENDOSC, V39, P279; LAINE L, 1993, ALIMENT PHARM THER, V7, P207; LAINE L, 1991, WESTERN J MED, V155, P274; LAINE L, 1993, ANN INTERN MED, V119, P1, DOI 10.7326/0003-4819-119-1-199307010-00001; LARSON AW, 1986, JAMA-J AM MED ASSOC, V255, P497, DOI 10.1001/jama.255.4.497; LO GH, 1994, GASTROENTEROLOGY, V106, pA933; MORETO M, 1988, SURG GYNECOL OBSTET, V167, P331; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; MUNDO F, 1993, AM J GASTROENTEROL, V88, P1493; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PAQUET KJ, 1985, HEPATOLOGY, V5, P580, DOI 10.1002/hep.1840050409; SILVERSTEIN FE, 1981, GASTROINTEST ENDOSC, V27, P80, DOI 10.1016/S0016-5107(81)73156-0; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; STIEGMANN GV, 1989, GASTROINTEST ENDOSC, V35, P431, DOI 10.1016/S0016-5107(89)72850-9; VANSTIEGMANN G, 1986, GASTROINTEST ENDOSC, V32, P230, DOI 10.1016/S0016-5107(86)71815-4; WALTER SD, 1991, BIOMETRICS, V47, P795, DOI 10.2307/2532640; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; YOUNG MF, 1993, GASTROINTEST ENDOSC, V39, P119, DOI 10.1016/S0016-5107(93)70049-8	25	496	513	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					280	287		10.7326/0003-4819-123-4-199508150-00007	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611595				2022-12-28	WOS:A1995RN66500007
J	FANKHAUSER, C; REYMOND, A; CERUTTI, L; UTZIG, S; HOFMANN, K; SIMANIS, V				FANKHAUSER, C; REYMOND, A; CERUTTI, L; UTZIG, S; HOFMANN, K; SIMANIS, V			THE S-POMBE CDC15 GENE IS A KEY ELEMENT IN THE REORGANIZATION OF F-ACTIN AT MITOSIS	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-DIVISION CYCLE; CYTOKINESIS; PROTEIN; CYTOSKELETON; COMPONENTS; SEPTATION; CLEAVAGE; DEFECTS; MYOSIN	The S. pombe cdc15 gene is essential for cell division, cdcl5(ts) mutants do not form a septum, but growth and nuclear division continue, leading to formation of multinucleate cells, The earliest step in septum formation and cytokinesis, rearrangement of actin to the center of the cell, is associated with appearance of hypophosphorylated cdc15p and formation of a cdc15p ring, which colocalizes with actin, Loss of cdc15p function impairs formation of the actin ring, The abundance of cdcl5 mRNA varies through the cell division cycle, peaking in early mitosis before septation, Expression of cdcl5 in G2-arrested cells induces actin rearrangement to the center of the cell, These data implicate cdc15p as a key element in mediating the cytoskeletal rearrangements required for cytokinesis.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND	Swiss Institute Experimental Cancer Research			Hofmann, Kay/D-6714-2011; Fankhauser, Christian/C-4291-2018; Fankhauser, Christian/ABE-8757-2021	Hofmann, Kay/0000-0002-2289-9083; Fankhauser, Christian/0000-0003-4719-5901; Fankhauser, Christian/0000-0003-4719-5901; Reymond, Alexandre/0000-0003-1030-8327				BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; FANKHAUSER C, 1993, MOL BIOL CELL, V4, P531, DOI 10.1091/mbc.4.5.531; Fankhauser Christian, 1994, Trends in Cell Biology, V4, P96, DOI 10.1016/0962-8924(94)90182-1; Fantes P.A., 1989, MOL BIOL FISSION YEA, P127; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; KANBE T, 1989, J CELL SCI, V94, P647; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KOHLI J, 1977, GENETICS, V87, P471; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARGOLIS RL, 1993, BIOESSAYS, V15, P201, DOI 10.1002/bies.950150310; MARKS J, 1992, J CELL SCI, V101, P801; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MARKS J, 1986, J CELL SCI, P229; MARKS J, 1987, SPEC PUBL SOC GEN MI, V23, P119; MCCOLLUM D, 1995, IN PRESS J CELL BIOL; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; NAKATSURU S, 1994, BIOCHEM BIOPH RES CO, V202, P82, DOI 10.1006/bbrc.1994.1896; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Robinow C, 1989, MOL BIOL FISSION YEA, P273; Sambrook J, 1989, MOL CLONING; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SIMANIS V, 1995, SEMIN CELL BIOL, V6, P79, DOI 10.1016/1043-4682(95)90004-7; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; WOODS A, 1989, J CELL SCI, V93, P491	44	218	221	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					435	444		10.1016/0092-8674(95)90432-8	http://dx.doi.org/10.1016/0092-8674(95)90432-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634333	Bronze			2022-12-28	WOS:A1995RP24200013
J	LOWN, B; CHAZOV, EI				LOWN, B; CHAZOV, EI			PHYSICIAN RESPONSIBILITY IN THE NUCLEAR-AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH PUBL HLTH,BOSTON,MA; CARDIOL RES CTR,MOSCOW,RUSSIA	Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health; National Medical Research Center of Cardiology	LOWN, B (corresponding author), LOWN CARDIOVASC CTR,21 LONGWOOD AVE,BROOKLINE,MA 02146, USA.							[Anonymous], 1987, PERESTROIKA; ARONOW S, 1962, NEW ENGL J MED, V266, P1145, DOI 10.1056/NEJM196205312662206; CASSEL C, 1982, ANN INTERN MED, V97, P426, DOI 10.7326/0003-4819-97-3-426; EISENBERG L, 1984, AM J MED, V77, P524, DOI 10.1016/0002-9343(84)90114-1; ELDERS MJ, 1994, LANCET, V343, P41; ERIKSON K, 1994, NY TIMES MAGAZI 0306, P34; ERVIN FR, 1962, NEW ENGL J MED, V266, P1127, DOI 10.1056/NEJM196205312662204; EVANGELISTA M, 1995, INT ORGAN, V49, P1, DOI 10.1017/S0020818300001569; GARLAND J, 1962, NEW ENGL J MED, V266, P1126; GREENE W, 1992, BOSTON GLOBE    0506, P13; HIATT HH, 1981, JAMA-J AM MED ASSOC, V244, P2314; Hu Howard, 1992, PLUTONIUM DEADLY GOL; LEIDERMAN P. HERBERT, 1962, NEW ENGLAND JOUR MED, V266, P1149, DOI 10.1056/NEJM196205312662207; LOWN B, 1985, JAMA-J AM MED ASSOC, V254, P655, DOI 10.1001/jama.254.5.655; LOWN B, 1981, NEW ENGL J MED, V304, P726, DOI 10.1056/NEJM198103193041210; LOWN B, 1985, LANCET, V2, P1285; LOWN B, 1981, JAMA-J AM MED ASSOC, V246, P2331, DOI 10.1001/jama.246.20.2331; LOWN B, 1995, BRIT MED J, V310, P993, DOI 10.1136/bmj.310.6985.993; LOWN B, 1984, IPPNW REP, V2, P2; NORIS RS, 1994, B ATOM SCI, V50, P58; Osler W., 1891, BOSTON MED SURG J, V125, P425; ROBBINS A, 1991, RAD HEAVEN EARTH HLT; SCHRAG PG, 1992, GLOBAL ACTION NUCLEA, P47; SIDEL VW, 1962, NEW ENGL J MED, V266, P1137, DOI 10.1056/NEJM196205312662205; Sidel VW, 1993, PSR Q, V3, P18; Specter Michael, 1995, NEW YORK TIMES  0722, p1 5; WHITNEY C, 1995, NY TIMES        0218, P2	27	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					416	419		10.1001/jama.274.5.416	http://dx.doi.org/10.1001/jama.274.5.416			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616639				2022-12-28	WOS:A1995RL41600029
J	MAEDA, T; TAKEKAWA, M; SAITO, H				MAEDA, T; TAKEKAWA, M; SAITO, H			ACTIVATION OF YEAST PBS2 MAPKK BY MAPKKKS OR BY BINDING OF AN SH3-CONTAINING OSMOSENSOR	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PATHWAY; ALLELE	The role of mitogen-activated protein (MAP) kinase cascades in integrating distinct upstream signals was studied in yeast. Mutants that were not able to activate PBS2 MAP kinase kinase (MAPKK; Pbs2p) at high osmolarity were characterized. Pbs2p was activated by two independent signals that emanated from distinct cell-surface osmosensors. Pbs2p was activated by MAP kinase kinase kinases (MAPKKKs) Ssk2p and Ssk22p that are under the control of the SLN1-SSK1 two-component osmosensor. Alternatively, Pbs2p was activated by a mechanism that involves the binding of its amino terminal proline-rich motif to the Src homology 3 (SH3) domain of a putative transmembrane osmosensor Sho1p.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Saito, Haruo/AAF-6113-2019; Maeda, Tatsuya/L-5540-2019	Saito, Haruo/0000-0001-7891-1689; Takekawa, Mutsuhiro/0000-0002-8027-3847				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, UNPUB; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; VOFTEK AB, 1993, CELL, V74, P205	23	537	565	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					554	558		10.1126/science.7624781	http://dx.doi.org/10.1126/science.7624781			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624781				2022-12-28	WOS:A1995RL49500033
J	WILSON, PA; HEMMATIBRIVANLOU, A				WILSON, PA; HEMMATIBRIVANLOU, A			INDUCTION OF EPIDERMIS AND INHIBITION OF NEURAL FATE BY BMP-4	NATURE			English	Article							XENOPUS-LAEVIS; MESODERM INDUCTION; DROSOPHILA EMBRYO; EARLY RESPONSE; EXPRESSION; ECTODERM; HOMOLOG; PATTERN; NOGGIN; RNA	DURING gastrulation in vertebrates, ectodermal cells choose between two fates, neural and epidermal. The nervous system forms in response to signals from the Spemann organizer(1,2); ectoderm that does not receive these signals becomes epidermis. Unexpectedly, however, in Xenopus, neural tissue also forms when cell-cell communication within the ectoderm is disrupted by cell dissociation(3,4) or by antagonists of the growth factor activin(5-7). These observations suggest that epidermal specification depends on local signalling, by activin or a close relative, and that neural tissue forms when this communication is blocked(6). Here we report that bone morphogenesis protein 4 (Bmp-4), a relative of activin that is expressed in the embryo at the time of ectodermal fate determination(8,9), is a potent epidermal inducer and neural inhibitor, the first reported in any vertebrate. Activin can inhibit neuralization by inducing mesoderm, but does not induce epidermis. Moreover, the dominant-negative activin receptor, which stimulates neuralization when expressed in the embryo(5,6), blocks Bmp-4 in our assay. Our findings demonstrate that epidermal fate can be induced, and thus provide further evidence that neural specification is under inhibitory control in vertebrates.			WILSON, PA (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							AKERS RM, 1986, SCIENCE, V231, P613, DOI 10.1126/science.3945801; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GODSAVE SF, 1989, DEV BIOL, V134, P486, DOI 10.1016/0012-1606(89)90122-X; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, IN PRESS DEV GENET; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; RAO Y, 1994, GENE DEV, V8, P939, DOI 10.1101/gad.8.8.939; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WITTA SE, 1995, DEVELOPMENT, V121, P721; YAMADA T, 1950, BIOL BULL-US, V98, P98, DOI 10.2307/1538572	31	629	655	4	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					331	333		10.1038/376331a0	http://dx.doi.org/10.1038/376331a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630398				2022-12-28	WOS:A1995RL44300044
J	HIRSCH, DR; INGENITO, EP; GOLDHABER, SZ				HIRSCH, DR; INGENITO, EP; GOLDHABER, SZ			PREVALENCE OF DEEP VENOUS THROMBOSIS AMONG PATIENTS IN MEDICAL INTENSIVE GALE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							VEIN-THROMBOSIS	Objective.-To determine the frequency of deep venous thrombosis (DVT) in medical intensive care unit (MICU) patients. Design.-Prospective ultrasound case series. Setting.-An MICU in a large tertiary care hospital in Boston, Mass. Subjects.-Patients older than 18 years of age admitted to the MICU with an anticipated stay of more than 48 hours. Main Outcome Measure.-Deep venous thrombosis as detected by ultrasonography with color Doppler imaging performed twice weekly in the MICU and once within 1 week of discharge from the MICU. Results.-Deep venous thrombosis was detected in 33% (95% confidence interval, 24% to 43%) of 100 eligible patients during the 8-month study period. Forty-eight percent (16/33) were proximal lower extremity DVT, and 15% (5/33) were upper extremity DVT associated with central venous catheters, with one patient having both upper and proximal lower extremity DVT. Ultrasound examination results led to inferior vena cava filter placement in three patients, initiation of full-dose anticoagulation in four patients, initiation or continuation of low-dose subcutaneous heparin in 10 patients, follow-up ultrasound studies in three patients, central line removal in one patient, and no intervention in 10 patients due to active bleeding, prior filter, or heparin-induced thrombocytopenia. Two patients remained anticoagulated for other reasons. In this series, there was no difference in age, gender, body mass index, diagnosis of cancer, recent surgery, duration of hospitalization prior to DVT detection, and DVT prophylaxis between patients with DVT and those without. Conclusions.-An unexpectedly high rate of DVT was detected by ultrasound in these MICU patients despite prophylaxis in 61%. Traditionally recognized DVT risk factors failed to identify patients who developed DVT. Routine ultrasound surveillance or more intensive prophylaxis regimens may be warranted in this patient population if these DVT rates are confirmed in other settings.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR02635] Funding Source: Medline; NHLBI NIH HHS [HL 02663] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; BICK RL, 1992, SEMIN THROMB HEMOST, V18, P267, DOI 10.1055/s-2007-1002434; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DIEBOLD J, 1991, PATHOL RES PRACT, V187, P260; GARDNER MJ, 1989, BRIT MED J CONFIDENC; Hirst D., 1993, PREVENTION VENOUS TH, P51; IBARRAPEREZ C, 1988, ANGIOLOGY, V39, P505, DOI 10.1177/000331978803900603; KEANE MG, 1994, CHEST, V106, P13, DOI 10.1378/chest.106.1.13; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; POLAK JF, 1992, PERIPHERAL VASCULAR, P162; SIMONS GR, 1995, AM J MED, V99, P1; SIOSON ER, 1988, ARCH PHYS MED REHAB, V69, P183; 1991, EPI INFO VERSION 5 0	15	223	238	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					335	337		10.1001/jama.274.4.335	http://dx.doi.org/10.1001/jama.274.4.335			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609264				2022-12-28	WOS:A1995RJ89800037
J	FORSTER, A; YOUNG, J				FORSTER, A; YOUNG, J			INCIDENCE AND CONSEQUENCES OF FALLS DUE TO STROKE - A SYSTEMATIC INQUIRY	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PEOPLE; NUMBER; HOME; RISK	Objective-To undertake a systematic inquiry into the incidence and consequences of falls in a cohort of elderly patients with stroke after discharge from hospital. Design-Administration of a questionnaire to patients and main carers at discharge from hospital and eight weeks and six months later. Setting-Bradford Metropolitan District. Subjects-108 patients recruited to the Bradford community stroke trial. Patients were recruited to the trial if they were 60 years or over and resident at home with some residual disability. Main outcome measures-Number of falls, motor club assessment, Barthel index, Frenchay activities index, and Nottingham health profile. Stress in carers was indicated by the general health questionnaire. Results-Of 108 patients, 79 (73%) fell in the six months after discharge from hospital with a total of 270 falls reported. Patients who fell in hospital were significantly more likely to fall at least twice at home after discharge (chi(2)=8.16; P=0.004). ''Fallers'' (two or more falls) were less socially active at six months and more had depressed mood. Carers of these patients were significantly more stressed at six months (53% v 18%; chi(2)=8.5; P=0.003). Conclusion-Stroke is associated with a risk of falling at home and affects the lives of patients with stroke and their carers. Falling and fear of falling is an important issue which needs to be dealt with by the multidisciplinary team.			FORSTER, A (corresponding author), ST LUKES HOSP,DEPT HLTH CARE ELDERLY,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.			young, john/0000-0003-4085-9306; Forster, Anne/0000-0001-7466-4414				Ashburn A, 1982, Physiotherapy, V68, P109; Askham J, 1990, HOME LEISURE ACCIDEN; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; EBRAHIM S, 1986, J EPIDEMIOL COMMUN H, V40, P166, DOI 10.1136/jech.40.2.166; EVANS JG, 1990, AGE AGEING, V19, P268, DOI 10.1093/ageing/19.4.268; FULLERTON KJ, 1986, LANCET, V1, P430; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Hunt SM, 1986, MEASURING HLTH STATU; Isaacs B, 1985, Clin Geriatr Med, V1, P513; MAHONEY F I, 1965, Md State Med J, V14, P61; Obonyo T, 1983, Int Rehabil Med, V5, P157; OVERSTALL PW, 1992, REV CLIN GERONTOLOGY, V2, P31; SIMPSON JM, 1993, AGE AGEING, V22, P294, DOI 10.1093/ageing/22.4.294; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TUTUARIMA JA, 1993, J ADV NURS, V18, P1101, DOI 10.1046/j.1365-2648.1993.18071101.x; VLAVHOV D, 1990, ARCH PHYS MED REHAB, V71, P8; Wade D T, 1985, Int Rehabil Med, V7, P176; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WILD D, 1981, J EPIDEMIOL COMMUN H, V35, P200, DOI 10.1136/jech.35.3.200; WOODHOUSE P, 1983, J CLIN EXPT GERONTOL, V54, P309; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	26	411	426	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					83	86		10.1136/bmj.311.6997.83	http://dx.doi.org/10.1136/bmj.311.6997.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613406	Green Published			2022-12-28	WOS:A1995RJ03000018
J	TEMMERMAN, M; NDINYAACHOLA, J; AMBANI, J; PLOT, P				TEMMERMAN, M; NDINYAACHOLA, J; AMBANI, J; PLOT, P			THE RIGHT NOT TO KNOW HIV-TEST RESULTS	LANCET			English	Article							WOMEN; ZAIRE	Large numbers of pregnant women in Africa have been invited to participate in studies on HIV infection. Study protocols adhere to guidelines on voluntary participation after pre-test and post-test counselling and informed consent; nevertheless, women may consent because they have been asked to do so without fully understanding the implications of being tested for HIV. Our studies in Nairobi, Kenya, show that most women informed consent did not actively results, less than one third informed their partner, and violence against women because of a positive HIV-antibody test was common. It is important to have carefully designed protocols weighing the benefits against the potential harms for women participating in a study. Even after having consented to HIV testing, women should have the right not to be told their result.	UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; INST TROP MED,DEPT MED MICROBIOL,ANTWERP,BELGIUM	University of Nairobi; Institute of Tropical Medicine (ITM)								ALLEN S, 1993, AM J PUBLIC HEALTH, V83, P705, DOI 10.2105/AJPH.83.5.705; HEYWARD WL, 1993, AIDS, V7, P1633, DOI 10.1097/00002030-199312000-00014; RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016; TEMMERMAN M, 1992, AIDS, V6, P1181, DOI 10.1097/00002030-199210000-00019; TEMMERMAN M, 1990, AIDS Care, V2, P247, DOI 10.1080/09540129008257737; TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002; TEMMERMAN M, IN PRESS AM J OBSTET; 1989, WHOGPAESR892; 1990, WHO AIDS SERIES, V8	9	164	167	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					969	970						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT919	7619122				2022-12-28	WOS:A1995QT91900017
J	LEIBEL, RL; ROSENBAUM, M; HIRSCH, J				LEIBEL, RL; ROSENBAUM, M; HIRSCH, J			CHANGES IN ENERGY-EXPENDITURE RESULTING FROM ALTERED BODY-WEIGHT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESTING METABOLIC-RATE; OBESE PATIENTS; SET-POINT; WOMEN; REQUIREMENTS; GENETICS; HUMANS; MASS; MEN	Background. No current treatment for obesity reliably sustains weight loss, perhaps because compensatory metabolic processes resist the maintenance of the altered body weight, We examined the effects of experimental perturbations of body weight on energy expenditure to determine whether they lead to metabolic changes and whether obese subjects and those who have never been obese respond similarly. Methods. We repeatedly measured 24-hour total energy expenditure, resting and nonresting energy expenditure, and the thermic effect of feeding in 18 obese subjects and 23 subjects who had never been obese. The subjects were studied at their usual body weight and after losing 10 to 20 percent of their body weight by underfeeding or gaining 10 percent by overfeeding. Results. Maintenance of a body weight at a level 10 percent or more below the initial weight was associated with a mean (+/-SD) reduction in total energy expenditure of 6+/-3 kcal per kilogram of fat-free mass per day in the subjects who had never been obese (P<0.001) and 8+/-5 kcal per kilogram per day in the obese subjects (P<0.001), Resting energy expenditure and nonresting energy expenditure each decreased 3 to 4 kcal per kilogram of fat-free mass per day in both groups of subjects, Maintenance of body weight at a level 10 percent above the usual weight was associated with an increase in total energy expenditure of 9+/-7 kcal per kilogram of fat-free mass per day in the subjects who had never been obese (P<0.001) and 8+/-4 kcal per kilogram per day in the obese subjects (P<0.001). The thermic effect of feeding and nonresting energy expenditure increased by approximately 1 to 2 and 8 to 9 kcal per kilogram of fat-free mass per day, respectively, after weight gain, These changes in energy expenditure were not related to the degree of adiposity or the sex of the subjects. Conclusions. Maintenance of a reduced or elevated body weight is associated with compensatory changes in energy expenditure, which oppose the maintenance of a body weight that is different from the usual weight. These compensatory changes may account for the poor longterm efficacy of treatments for obesity.			LEIBEL, RL (corresponding author), ROCKEFELLER UNIV,HUMAN BEHAV & METAB LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NCRR NIH HHS [GCRCRR00102] Funding Source: Medline; NIDDK NIH HHS [DK30583] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030583] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATRUDA JM, 1993, J CLIN INVEST, V92, P1236, DOI 10.1172/JCI116695; ASTRUP A, 1992, AM J PHYSIOL, V262, pE282, DOI 10.1152/ajpendo.1992.262.3.E282; BELANGER A, 1988, NIH882970 PUBL; Benedict FG, 1925, J BIOL CHEM, V66, P783; BLONDHEIM SH, 1987, RECENT ADV OBESITY R, V5, P151; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; DEBOER JO, 1986, AM J CLIN NUTR, V44, P585, DOI 10.1093/ajcn/44.5.585; DORE C, 1982, HUM NUTR-CLIN NUTR, V36, P41; ELLIOT DL, 1989, AM J CLIN NUTR, V49, P93, DOI 10.1093/ajcn/49.1.93; Epstein FH, 1992, OBESITY, P330; Faust I M, 1984, Res Publ Assoc Res Nerv Ment Dis, V62, P97; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; FORBES GB, 1983, INT J OBESITY, V7, P99; FROIDEVAUX F, 1993, AM J CLIN NUTR, V57, P35, DOI 10.1093/ajcn/57.1.35; GEISSLER CA, 1987, AM J CLIN NUTR, V45, P914, DOI 10.1093/ajcn/45.5.914; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; HEYMSFIELD SB, 1989, AM J CLIN NUTR, V50, P1282, DOI 10.1093/ajcn/50.6.1282; JIMENEZ J, 1987, J CLIN ENDOCR METAB, V64, P661, DOI 10.1210/jcem-64-4-661; Keesey R E, 1984, Res Publ Assoc Res Nerv Ment Dis, V62, P87; KNITTLE JL, 1979, J CLIN INVEST, V63, P239, DOI 10.1172/JCI109295; LEIBEL RL, 1984, METABOLISM, V33, P164, DOI 10.1016/0026-0495(84)90130-6; LEIBEL RL, 1977, J THEOR BIOL, V66, P297, DOI 10.1016/0022-5193(77)90173-4; LEIBEL RL, 1990, WESTERN J MED, V153, P429; MAZESS RB, 1984, AM J CLIN NUTR, V40, P834, DOI 10.1093/ajcn/40.4.834; NORGAN NG, 1980, AM J CLIN NUTR, V33, P978, DOI 10.1093/ajcn/33.5.978; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; RAVUSSIN E, 1989, AM J CLIN NUTR, V49, P968, DOI 10.1093/ajcn/49.5.968; RAVUSSIN E, 1982, AM J CLIN NUTR, V35, P566, DOI 10.1093/ajcn/35.3.566; Ravussin E, 1993, OBESITY THEORY THERA, P97; SCHOELLER DA, 1982, J APPL PHYSIOL, V53, P955, DOI 10.1152/jappl.1982.53.4.955; Sims E A, 1973, Recent Prog Horm Res, V29, P457; TREMBLAY A, 1992, AM J CLIN NUTR, V56, P857, DOI 10.1093/ajcn/56.5.857; Weigle D S, 1990, Int J Obes, V14 Suppl 1, P69; WEIGLE DS, 1988, METABOLISM, V37, P930, DOI 10.1016/0026-0495(88)90149-7; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; WEIGLE DS, 1988, INT J OBESITY, V12, P567; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1990, SAS STAT USERS GUIDE; 1963, USDA AGR HDB, V8, P159	41	1400	1441	1	95	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					621	628		10.1056/NEJM199503093321001	http://dx.doi.org/10.1056/NEJM199503093321001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7632212				2022-12-28	WOS:A1995QK06600001
J	ONEILL, WW; CHANDLER, JG; GORDON, RE; BAKALYAR, DM; ABOLFATHI, AH; CASTELLANI, MD; HIRSCH, JL; WIETING, DW; BASSETT, JS; BEATTY, KC; SOLTIS, MA; TIMMIS, GC; GRINES, CL				ONEILL, WW; CHANDLER, JG; GORDON, RE; BAKALYAR, DM; ABOLFATHI, AH; CASTELLANI, MD; HIRSCH, JL; WIETING, DW; BASSETT, JS; BEATTY, KC; SOLTIS, MA; TIMMIS, GC; GRINES, CL			RADIOGRAPHIC DETECTION OF STRUT SEPARATIONS IN BJORK-SHILEY CONVEXOCONCAVE MITRAL-VALVES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVULAR HEART-DISEASE; PROPHYLACTIC REPLACEMENT; PROSTHETIC VALVES; FRACTURE; MANAGEMENT; SURGERY; RISK	Background. The outlet struts of Bjork-Shiley convexo-concave heart valves can occasionally fracture. By December 31, 1994, 564 complete strut fractures had been reported to the manufacturer, approximately two thirds of which were fatal. There are no reliable diagnostic methods to detect waives that may be at risk for strut fracture. The outlet strut has two legs, and one leg often appears to break before the other, potentially permitting detection of the single-leg separation while the valve is still functionally intact. Methods. We used high-resolution cineradiography and defined valve profiles to evaluate 315 patients selected on the basis of their having mitral convexo-concave valves with an estimated fracture rate of 0.46 percent or higher per year. Two examinations were scheduled six months apart, with early reimaging performed when initial ratings were indeterminate. Results. Three patients had unsatisfactory studies, the most recent examinations in 277 patients were rated as apparently normal, 23 had findings considered minimally suspicious, and 1 had findings termed suspicious. The number of false negative results in this study group is unknown. Eleven cineradiograms were rated as showing probable or definite single-leg separations. All five ''definite'' ratings and five of the six ''probable'' ratings were confirmed by removal of the valves. One valve with a ''probable'' rating was intact. Two complete outlet-strut fractures occurred three and seven months after apparently normal radiographic examinations. Unsuspected new positive findings were not found at six months among 288 patients who completed the examination cycle. Conclusions. Cineradiographic imaging can detect some single-leg separations in mitral convexo-concave valves and may help the estimated 47,000 patients with these valves worldwide and their physicians decide about elective valve removal.	SHILEY HEART VALVE RES CTR,IRVINE,CA		ONEILL, WW (corresponding author), WILLIAM BEAUMONT HOSP,DEPT INTERNAL MED,DIV CARDIOL,3601 W 13 MILE RD,ROYAL OAK,MI 48073, USA.							BAKALYAR DM, 1994, CATHET CARDIOVASC DI, V32, P94; BIRKMEYER JD, 1992, LANCET, V340, P520, DOI 10.1016/0140-6736(92)91717-M; BJORK VO, 1977, J THORAC CARDIOV SUR, V73, P563; BJORK VO, 1970, J THORAC CARDIOV SUR, V60, P355; Blackstone E H, 1992, J Heart Valve Dis, V1, P3; BLACKSTONE EH, 1993, J HEART VALVE DIS, V2, P249; BLOOMFIELD P, 1991, NEW ENGL J MED, V324, P573, DOI 10.1056/NEJM199102283240901; COPANS H, 1980, CIRCULATION, V61, P169, DOI 10.1161/01.CIR.61.1.169; DEMOL BA, 1994, LANCET, V343, P9, DOI 10.1016/S0140-6736(94)90874-5; ERICSSON A, 1992, EUR J CARDIO-THORAC, V6, P339, DOI 10.1016/1010-7940(92)90169-X; Fleiss J. L., 1981, STATISTICAL METHODS, P1; FRIEDLI B, 1971, AM HEART J, V81, P702, DOI 10.1016/0002-8703(71)90015-9; Hollander M., 1973, NONPARAMETRIC STAT, P114; HUSEBYE DG, 1983, J THORAC CARDIOV SUR, V86, P543; IBARRA F, 1984, J THORAC CARDIOV SUR, V87, P315; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; KIRKLIN JW, 1973, NEW ENGL J MED, V288, P194, DOI 10.1056/NEJM197301252880407; KIRKLIN JW, 1973, NEW ENGL J MED, V288, P133, DOI 10.1056/NEJM197301182880307; LINDBLOM D, 1992, BRIT HEART J, V68, P249; MARRIN CAS, 1993, ANN THORAC SURG, V55, P1361, DOI 10.1016/0003-4975(93)91071-T; MCENANY MT, 1979, J THORAC CARDIOV SUR, V78, P136; SACKS SH, 1986, THORAX, V41, P142, DOI 10.1136/thx.41.2.142; Schondube F A, 1994, J Heart Valve Dis, V3, P247; SETHIA B, 1986, J THORAC CARDIOV SUR, V91, P350; SHRIMPTON PC, 1984, PHYS MED BIOL, V29, P1199, DOI 10.1088/0031-9155/29/10/003; TREASURE T, 1991, BRIT HEART J, V66, P333; VANDERGRAAF Y, 1992, LANCET, V339, P257, DOI 10.1016/0140-6736(92)91328-6; VANDERMEULEN JHP, 1993, CIRCULATION, V88, P156, DOI 10.1161/01.CIR.88.1.156; WILLERSON JT, 1972, BRIT HEART J, V34, P561	29	47	47	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					414	419		10.1056/NEJM199508173330703	http://dx.doi.org/10.1056/NEJM199508173330703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616990				2022-12-28	WOS:A1995RP24300003
J	SCHACTER, DL; REIMAN, E; UECKER, A; POLSTER, MR; YUN, LS; COOPER, LA				SCHACTER, DL; REIMAN, E; UECKER, A; POLSTER, MR; YUN, LS; COOPER, LA			BRAIN-REGIONS ASSOCIATED WITH RETRIEVAL OF STRUCTURALLY COHERENT VISUAL INFORMATION	NATURE			English	Article							MEMORY; OBJECTS; RECOGNITION; MECHANISMS; ACTIVATION; IMPLICIT	AN object's global, three-dimensional structure may be represented by a specialized brain system involving regions of inferior temporal cortex(1-3). This system's role in object representation can be understood by experiments in which people study drawings of novel objects with possible or impossible three-dimensional structures, and later make either possible/impossible object decisions or old/new recognition decisions about briefly flashed studied and nonstudied objects. Although object decisions about possible objects are facilitated by prior study, there is no corresponding facilitation for impossible objects, thereby implicating a system that is specifically involved in the representation of structurally coherent visual objects(4). Here we show, by positron emission tomography (PET), that increases in blood flow in inferior temporal regions are associated with object decisions about possible but not impossible objects, and that there are increases in the vicinity of the hippocampal formation associated with episodic recognition of possible objects.	UNIV ARIZONA,DEPT PSYCHIAT,TUCSON,AZ 85721; GOOD SAMARITAN REG MED CTR,CTR POSITRON EMISS TOMOG,PHOENIX,AZ 85006; UNIV ARIZONA,DIV NEURAL SYST MEMORY & AGING,TUCSON,AZ 85721; UNIV VICTORIA,DEPT PSYCHOL,WELLINGTON,NEW ZEALAND; ARIZONA STATE UNIV,DEPT COMP SCI & ENGN,TEMPE,AZ 85287; COLUMBIA UNIV,DEPT PSYCHOL,NEW YORK,NY 10027	University of Arizona; University of Arizona; Victoria University Wellington; Arizona State University; Arizona State University-Tempe; Columbia University	SCHACTER, DL (corresponding author), HARVARD UNIV,DEPT PSYCHOL,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.			Schacter, Daniel/0000-0002-2460-6061				ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; BUCKNER RL, 1995, J NEUROSCI, V15, P12; BUCKNER RL, 1995, HDB NEUROPSYCHOLOGY, P439; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; COOPER LA, 1992, J EXP PSYCHOL LEARN, V18, P43, DOI 10.1037/0278-7393.18.1.43; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; FRISTON KJ, 1991, J CEREB BLOOD FLOW M, V10, P458; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; Gray JA, 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; GROSS CG, 1992, PHIL T R SOC B, V335, P245; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Jones-Gotman M., 1993, Society for Neuroscience Abstracts, V19, P1002; KOSSLYN SM, IN PRESS BRAIN; MINTUN MA, 1991, J NUCL MED, V31, P816; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; SCHACTER DL, 1993, J EXP PSYCHOL LEARN, V19, P995, DOI 10.1037/0278-7393.19.5.995; SCHACTER DL, 1990, J EXP PSYCHOL GEN, V119, P5, DOI 10.1037/0096-3445.119.1.5; SCHACTER DL, 1991, J COGNITIVE NEUROSCI, V3, P118; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; STEM C, 1994, SOC NEUR ABSTR, V20, P530; Talairach J., 1988, COPLANAR STEREOTAXIC; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; VINOGRADA OS, 1978, HIPPOCAMPUS, V2	29	261	261	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					587	590		10.1038/376587a0	http://dx.doi.org/10.1038/376587a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637806				2022-12-28	WOS:A1995RP75600049
J	LAU, JYN; SIMMONDS, P; URDEA, MS				LAU, JYN; SIMMONDS, P; URDEA, MS			IMPLICATIONS OF VARIATIONS OF CONSERVED REGIONS OF HEPATITIS-C VIRUS GENOME	LANCET			English	Editorial Material									UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; CHIRON CORP,EMERYVILLE,CA	University of Edinburgh; Novartis	LAU, JYN (corresponding author), UNIV FLORIDA,DEPT MED,DIV GASTROENTEROL HEPATOL & NUTR,HEPATOBILIARY DIS SECT,GAINESVILLE,FL 32610, USA.			Simmonds, Peter/0000-0002-7964-4700				BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; HAYASHI J, 1995, J INFECTION, V30, P235, DOI 10.1016/S0163-4453(95)90785-8; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LAU JYN, IN PRESS ANN INTERN; ORITO E, 1994, J MED VIROL, V44, P410, DOI 10.1002/jmv.1890440418; POZZATO G, 1995, J MED VIROL, V45, P445, DOI 10.1002/jmv.1890450416; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; TKOHARA K, 1992, J VIROL, V66, P1476; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; YAMADA G, IN PRESS HEPATOLOGY	14	96	96	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					425	426		10.1016/S0140-6736(95)92786-7	http://dx.doi.org/10.1016/S0140-6736(95)92786-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623576				2022-12-28	WOS:A1995RN65600015
J	TERASAKI, PI; CECKA, JM; GJERTSON, DW; TAKEMOTO, S				TERASAKI, PI; CECKA, JM; GJERTSON, DW; TAKEMOTO, S			HIGH SURVIVAL RATES OF KIDNEY-TRANSPLANTS FROM SPOUSAL AND LIVING UNRELATED DONORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANTATION	Background. In the United States, increasing numbers of persons are donating kidneys to their spouses, Despite greater histoincompatibility, the survival rates of these kidneys are higher than those of cadaveric kidneys. We examined the factors influencing the high survival rates of spousal-donor kidneys. Methods. Kidney-transplant data from the United Network for Organ Sharing Renal Transplant Registry were used to calculate graft-survival rates with Kaplan-Meier analysis. Results. The three-year survival rates were 85 percent for kidneys from 368 spouses, 81 percent for kidneys from 129 living unrelated donors who were not married to the recipients, 82 percent for kidneys from 3368 parents, and 70 percent for 43,341 cadaveric kidneys. The three-year survival rate for wife-to-husband grafts was 87 percent, which was the same as for husband-to-wife grafts if the wife had never been pregnant. If the wife had previously been pregnant, the three-year graft-survival rate was 76 percent (P = 0.40). The three-year graft-survival rate among recipients of spousal grafts who did not receive transfusions preoperatively was 81 percent, as compared with 90 percent for recipients who received 1 to 10 transfusions preoperatively (P = 0.008). The superior survival rate of grafts from unrelated donors could not be attributed to better HLA matching, white race, younger donor age, or shorter cold-ischemia times, but might be explained by damage due to shock before removal in 10 percent of the cadaveric kidneys. Conclusions. Spouses are an important source of living-donor kidney grafts because, despite poor HLA matching, the graft-survival rate is similar to that of parental-donor kidneys. This high rate of survival is attributed to the fact that the kidneys were uniformly healthy.			TERASAKI, PI (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,950 VET AVE,LOS ANGELES,CA 90095, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM002375] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM02375-36] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cecka J M, 1994, Clin Transpl, P1; CECKA JM, 1987, TRANSPLANT P, V19, P4507; GEFFNER SR, 1995, CLIN TRANSPLANTS 199, P197; GJERTSON DW, 1993, CLIN TRANSPLANTS 199, P299; HABERAL M, 1992, WORLD J SURG, V16, P1183, DOI 10.1007/BF02067097; HEEMANN UW, 1994, TRANSPLANTATION, V58, P1317; JONES J, 1993, TRANSPLANT REV, V7, P115; NAJARIAN JS, 1994, TRANSPLANTATION, V57, P812, DOI 10.1097/00007890-199403270-00007; PARK K, 1993, CLIN TRANSPLANTS 199, P249; PIRSCH JD, 1988, AM J KIDNEY DIS, V12, P499, DOI 10.1016/S0272-6386(88)80101-X; RIEHLE RA, 1990, J UROLOGY, V144, P845, DOI 10.1016/S0022-5347(17)39606-4; SESSO R, 1992, ANN INTERN MED, V117, P983, DOI 10.7326/0003-4819-117-12-983; SIMMONS RG, 1983, PSYCHONEPHROLOGY, V2, P275; TANABE K, 1995, TRANSPLANT P, V27, P1020; TERASAKI PI, 1994, TRANSPLANTATION, V57, P1450, DOI 10.1097/00007890-199405270-00008; WYNER LM, 1993, J UROLOGY, V149, P706, DOI 10.1016/S0022-5347(17)36188-8; YOON YS, 1994, CLIN TRANSPLANTS 199, P275	17	954	985	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					333	336		10.1056/NEJM199508103330601	http://dx.doi.org/10.1056/NEJM199508103330601			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609748	Bronze			2022-12-28	WOS:A1995RN08200001
J	AVEROF, M; AKAM, M				AVEROF, M; AKAM, M			HOX GENES AND THE DIVERSIFICATION OF INSECT AND CRUSTACEAN BODY PLANS	NATURE			English	Article							DROSOPHILA EMBRYO; HOMEOTIC GENES; EXPRESSION; COMPLEX; SEGMENT; ARTEMIA	CRUSTACEANS and insects share a common origin of segmentation(1,2), but the specialization of trunk segments appears to have arisen independently in insects and various crustacean subgroups(3'4). Such macroevolutionary changes in body architecture may be investigated by comparative studies of conserved genetic markers(5-7). The Hox genes are well suited for this purpose, as they determine positional identity along the body axis in a wide range of animals. Here we examine the expression of four Hox genes in the branchiopod crustacean Artemia franciscana, and compare this with Hox expression patterns from insects. In Artemia the three 'trunk' genes Antp, Ubx and abdA are expressed in largely overlapping domains in the uniform thoracic region, whereas in insects they specify distinct segment types within the thorax and abdomen. Our comparisons suggest a multistep process for the diversification of these Hox gene functions, involving early differences in tissue specificity and the later acquisition of a role in defining segmental differences within the trunk. We propose that the branchiopod thorax may be homologous to the entire pregenital (thoracic and abdominal) region of the insect trunk.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE,ENGLAND	University of Cambridge	AVEROF, M (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			Averof, Michalis/0000-0002-6803-7251	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1988, DEVELOPMENT, V104, P123; AKAM M, 1994, DEVELOPMENT S, V120, P209; ANDERSON D. T., 1967, AUST J ZOOL, V15, P47, DOI 10.1071/ZO9670047; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; BEEMAN RW, 1993, BIOESSAYS, V15, P439, DOI 10.1002/bies.950150702; CALMAN WT, 1909, CRUSTACEA; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; DOHLE W, 1988, DEVELOPMENT, V104, P147; DOHLE W, 1988, MYRIAPODA ANCESTRY I; Jurgens G., 1993, DEV DROSOPHILA MELAN, P687; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P567; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; MAHAFFEY JW, 1989, DEVELOPMENT, V105, P167; MANZANARES M, 1993, DEVELOPMENT, V118, P1209; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCNAMARA KJ, 1993, PALAEONTOLOGY, V36, P319; PATEL NH, 1989, DEVELOPMENT, V107, P201; RIEK E F, 1968, Records of the Australian Museum, V27, P313; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; Scourfield DJ, 1926, PHILOS T R SOC LON B, V214, P153, DOI 10.1098/rstb.1926.0005; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Snodgrass R. E., 1951, COMP STUDIES HEAD MA; TEAR G, 1990, DEVELOPMENT, V110, P915; UENO K, 1992, DEVELOPMENT, V114, P555; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Walossek Dieter, 1993, Fossils and Strata, V32, P1; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0	30	211	223	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					420	423		10.1038/376420a0	http://dx.doi.org/10.1038/376420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630416				2022-12-28	WOS:A1995RM63900050
J	MORITA, H; YANAGISAWA, N; NAKAJIMA, T; SHIMIZU, M; HIRABAYASHI, H; OKUDERA, H; NOHARA, M; MIDORIKAWA, Y; MIMURA, S				MORITA, H; YANAGISAWA, N; NAKAJIMA, T; SHIMIZU, M; HIRABAYASHI, H; OKUDERA, H; NOHARA, M; MIDORIKAWA, Y; MIMURA, S			SARIN POISONING IN MATSUMOTO, JAPAN	LANCET			English	Article							MOUSE DIAPHRAGM; SOMAN; EXPOSURE; ORGANOPHOSPHATE; RAT; ELECTROENCEPHALOGRAM; TOXICITY	A presumed terrorist attack with sarin occurred in a residential area of the city of Matsumoto, Japan, on June 27, 1994. About 600 residents and rescue staff were poisoned; 58 were admitted to hospitals, and 7 died. We examined clinical and laboratory findings of 264 people who sought treatment and the results of health examinations on 155 residents done 3 weeks after the poisoning. Findings for severely poisoned people were decreases in serum cholinesterase, acetylcholinesterase in erythrocytes, serum triglyceride, serum potassium and chloride; and increases in serum creatine kinase, leucocytes, and ketones in urine. Slight fever and epileptiform abnormalities on electroencephalogram were present for up to 30 days. Examination revealed no persisting abnormal physical findings in any individual. Acetylcholinesterase returned to normal within 3 months in all people examined. Although subclinical miosis and neuropathy were present 30 days after exposure, almost all symptoms of sarin exposure disappeared rapidly and left no sequelae in most people.	SHINSHU UNIV,SCH MED,DEPT HYG,MATSUMOTO,NAGANO 390,JAPAN; SHINSHU UNIV,SCH MED,DIV INTENS & CRIT CARE MED,MATSUMOTO,NAGANO 390,JAPAN; NAGANO PREFECTURAL HOSP EMERGENCY MED,MATSUMOTO,NAGANO,JAPAN; SHINSHU UNIV,SCH MED,DEPT OPHTHALMOL,MATSUMOTO,NAGANO 390,JAPAN; MATSUMOTO HLTH CTR,MATSUMOTO,NAGANO,JAPAN; MATSUMOTO MED ASSOC,MATSUMOTO,NAGANO,JAPAN	Shinshu University; Shinshu University; Shinshu University	MORITA, H (corresponding author), SHINSHU UNIV,SCH MED,DEPT MED NEUROL,ASAHI 3-1-1,MATSUMOTO,NAGANO 390,JAPAN.			Okudera, Hiroshi/0000-0003-0153-6352				ANZUETO A, 1990, FUND APPL TOXICOL, V14, P676, DOI 10.1016/0272-0590(90)90293-S; BAJGAR J, 1992, BRIT J IND MED, V49, P648; BLACK RM, 1994, J CHROMATOGR A, V662, P301, DOI 10.1016/0021-9673(94)80518-0; BOKONJIC D, 1991, Arhiv za Higijenu Rada i Toksikologiju, V42, P359; BRIGHT JE, 1991, HUM EXP TOXICOL, V10, P9, DOI 10.1177/096032719101000102; BURCHFIEL JL, 1982, NEUROBEH TOXICOL TER, V4, P767; CROWELL JA, 1989, J BIOCHEM TOXICOL, V4, P15, DOI 10.1002/jbt.2570040104; DUFFY FH, 1979, TOXICOL APPL PHARM, V47, P161, DOI 10.1016/0041-008X(79)90083-8; GAZZARD MF, 1975, EXP EYE RES, V20, P15, DOI 10.1016/0014-4835(75)90104-9; GOLDSTEIN BD, 1987, TOXICOL APPL PHARM, V91, P55, DOI 10.1016/0041-008X(87)90193-1; GUPTA RC, 1991, FUND APPL TOXICOL, V16, P449, DOI 10.1016/0272-0590(91)90085-I; HUGHES JN, 1991, INT J EXP PATHOL, V72, P195; HUSAIN K, 1993, J APPL TOXICOL, V13, P143, DOI 10.1002/jat.2550130212; INNS RH, 1990, HUM EXP TOXICOL, V9, P245, DOI 10.1177/096032719000900407; KAWABUCHI M, 1991, SYNAPSE, V8, P218, DOI 10.1002/syn.890080308; KLEIN AK, 1987, TOXICOL LETT, V38, P239, DOI 10.1016/0378-4274(87)90004-X; LAU WM, 1991, J APPL TOXICOL, V11, P411, DOI 10.1002/jat.2550110606; LITTLE PJ, 1988, DRUG METAB DISPOS, V16, P515; LIU DD, 1986, J TOXICOL ENV HEALTH, V19, P23, DOI 10.1080/15287398609530903; MACILWAIN C, 1993, NATURE, V363, P3, DOI 10.1038/363003b0; RENGSTORFF RH, 1994, J APPL TOXICOL, V14, P115, DOI 10.1002/jat.2550140213; RENGSTORFF RH, 1985, ARCH TOXICOL, V56, P201, DOI 10.1007/BF00333427; SINGER AW, 1987, TOXICOL LETT, V36, P243, DOI 10.1016/0378-4274(87)90192-5; WARNICK JE, 1993, ARCH TOXICOL, V67, P302, DOI 10.1007/BF01973699; YANAGISAWA N, 1995, REPORT TOXIC GAS ATT	25	225	227	1	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					290	293						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630252				2022-12-28	WOS:A1995RL75700015
J	NOLAN, M				NOLAN, M			HAS NURSING LOST ITS WAY - TOWARDS AN ETHOS OF INTERDISCIPLINARY PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											NOLAN, M (corresponding author), UNIV WALES,FAC HLTH STUDIES,BANGOR LL57 2EF,GWYNEDD,WALES.							ADAMSON BJ, 1995, J ADV NURS, V21, P172, DOI 10.1046/j.1365-2648.1995.21010172.x; CASTLEDINE G, 1995, BRIT J SPECIALIST NU, V1, P264; CASTLEDINE G, 1994, BRIT J NURSING, V3, P621; Denner S, 1995, Nurs Times, V91, P27; Hay R, 1994, Nurs Stand, V8, P42; HUNTER S, 1993, RES POLICY PLANNING, V11, P2; KAPLUN A, 1992, HLTH PROMOTION CHRON; KING PM, 1994, J ADV NURS, V20, P209, DOI 10.1046/j.1365-2648.1994.20020209.x; NOLAN M, 1994, J ADV NURS, V20, P989, DOI 10.1046/j.1365-2648.1994.20060989.x; Ovretveit J, 1993, COORDINATING COMMUNI; PARKIN PAC, 1995, J ADV NURS, V21, P561, DOI 10.1111/j.1365-2648.1995.tb02741.x; POTT E, 1992, HLTH PROMOTION CHRON; REED J, 1994, INT J NURS STUD, V31, P57, DOI 10.1016/0020-7489(94)90007-8; REED S, 1994, REDUCTION JUNIOR DOC; SMITH J, 1995, ADV NURS, V21, P815; 1994, ENSURING EQUITY QUAL; 1994, CHALLENGE NURSING MI; 1995, NURS TIMES, V91, P18; 1994, GERIATRIC DAY HOSPIT	19	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					305	307		10.1136/bmj.311.7000.305	http://dx.doi.org/10.1136/bmj.311.7000.305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM719	7633244	Green Published			2022-12-28	WOS:A1995RM71900032
J	STERN, RC; DOERSHUK, CF; DRUMM, MI				STERN, RC; DOERSHUK, CF; DRUMM, MI			3849+10 KB C-]T MUTATION AND DISEASE SEVERITY IN CYSTIC-FIBROSIS	LANCET			English	Article							GENE; FORM; DNA	50% of patients with cystic fibrosis (CF) are homozygous for the Delta F508 mutation, but the remainder have at least one of many other less common mutations. The 3849+10 kb C-->T splice mutation seems to be associated with less severe disease. We report ten CF patients who are hemizygous for this mutation. Three male patients do not have azoospermia (sperm counts 12, 53, and 198x10(6)/mL). Another boy died before CF was diagnosed; his genital tract appeared normal at necropsy. All patients had clinically sufficient exocrine pancreatic function. Pulmonary disease was delayed in onset in most of these patients (range <1 to 16; median 9 years), but then became severe in some, progressing to death (in two) and need for transplantation in one. Sweat chloride concentration was abnormal (80 mmol/L) in one patient but in others was in the intermediate range (45-65 mmol/L). There was substantial variation in pulmonary disease severity within sibships. These observations suggest some dissociation in genetically determined severity between different organs. There was some evidence among these patients of a tendency for disease of the genital tract to become progressively more severe. Perhaps sperm banking should be offered to male patients. We speculate that some normal CF transmembrane conductance regulator is made in patients with this splice abnormality.	CASE WESTERN RESERVE UNIV,LEROY W MATTHEWS CYST FIBROSIS CTR,DEPT PEDIAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,LEROY W MATTHEWS CYST FIBROSIS CTR,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University	STERN, RC (corresponding author), UNIV CLEVELAND HOSP,RAINBOW BABIES & CHILDRENS HOSP,11100 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; DEAN M, 1994, HUM GENET, V93, P364; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KEREM BS, 1989, AM J HUM GENET, V44, P827; LANDING BH, 1969, ARCH PATHOL, V88, P569; LIEBERMAN J, 1990, INTERNAL MED, V11, P105; MERCIER B, 1995, AM J HUM GENET, V56, P272; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHUBER AP, 1993, HUM MOL GENET, V2, P153, DOI 10.1093/hmg/2.2.153; STERN RC, 1982, LANCET, V1, P1401; TAMAGNINI GP, 1983, BRIT J HAEMATOL, V54, P189, DOI 10.1111/j.1365-2141.1983.tb02087.x; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; 1994, HUM MUTAT, V4, P167	16	44	45	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					274	276		10.1016/S0140-6736(95)92165-6	http://dx.doi.org/10.1016/S0140-6736(95)92165-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630247				2022-12-28	WOS:A1995RL75700010
J	CLARKE, RJ; TOBIAS, PV				CLARKE, RJ; TOBIAS, PV			STERKFONTEIN-MEMBER-2 FOOT BONES OF THE OLDEST SOUTH-AFRICAN HOMINID	SCIENCE			English	Article							AUSTRALOPITHECUS-AFARENSIS; TARSOMETATARSAL JOINT; HADAR FORMATION; MORPHOLOGY; BIPEDALITY; EVOLUTION; TARSAL	Four articulating hominid foot bones have been recovered from Sterkfontein Member 2, near Johannesburg, South Africa. They have human features in the hindfoot and strikingly apelike traits in the forefoot. While the foot is manifestly adapted for bipedalism, its most remarkable characteristic is that the great toe (hallux) is appreciably medially diverged (varus) and strongly mobile, as in apes. Possibly as old as 3.5 million years, the foot provides the first evidence that bipedal hominids were in southern Africa more than 3.0 million years ago. The bones probably belonged to an early member of Australopithecus africanus or another early hominid species.	UNIV WITWATERSRAND,SCH MED,DEPT ANAT & HUMAN BIOL,PALAEO ANTHROPOL RES UNIT,JOHANNESBURG 2193,SOUTH AFRICA	University of Witwatersrand								Aiello L, 1990, INTRO HUMAN EVOLUTIO; BAMFORD M, 1994, 28TH ANN REP PARU, P12; CHRISTIE PW, 1977, AM J PHYS ANTHROPOL, V47, P123; CLARKE RJ, 1995, HOMINID EVOLUTION PA, P287; COPPENS Y, 1991, ORIGINES BIPEDIE CHE, P37; DAY MH, 1968, MAN, V3, P440, DOI 10.2307/2798879; DELOISON Y, 1984, CR ACAD SCI III-VIE, V299, P115; DELOISON Y, 1993, THESIS U PARIS; GOMBERG DN, 1984, AM J PHYS ANTHROPOL, V63, P164; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P403, DOI 10.1002/ajpa.1330570403; LATIMER B, 1987, AM J PHYS ANTHROPOL, V74, P155, DOI 10.1002/ajpa.1330740204; LATIMER B, 1989, AM J PHYS ANTHROPOL, V78, P369, DOI 10.1002/ajpa.1330780306; LATIMER B, 1990, AM J PHYS ANTHROPOL, V82, P125, DOI 10.1002/ajpa.1330820202; LATIMER BM, 1982, AM J PHYS ANTHROPOL, V57, P701, DOI 10.1002/ajpa.1330570412; LEAKEY MD, 1979, NATURE, V278, P317, DOI 10.1038/278317a0; LEWIS OJ, 1980, J ANAT, V131, P275; LEWIS OJ, 1972, AM J PHYS ANTHROPOL, V37, P13, DOI 10.1002/ajpa.1330370104; LEWIS OJ, 1980, J ANAT, V130, P527; MCKEE JK, 1993, J HUM EVOL, V25, P363, DOI 10.1006/jhev.1993.1055; PARTRIDGE T C, 1991, Palaeontologia Africana, V28, P35; PARTRIDGE TC, 1978, NATURE, V275, P282, DOI 10.1038/275282a0; Rose M.D., 1984, P509; Senut B., 1985, P193; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P270; Susman R.L., 1993, SWARTKRANS CAVES CHR, P117; SUSMAN RL, 1982, SCIENCE, V217, P931, DOI 10.1126/science.217.4563.931; SUSMAN RL, 1984, FOLIA PRIMATOL, V43, P113, DOI 10.1159/000156176; TOBIAS PV, 1979, S AFR J SCI, V75, P161; VRBA ES, 1982, C INT PALAEONTOLOGIE, V2, P707; 1975, NATTURE, V254, P301	30	183	193	1	44	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					521	524		10.1126/science.7624772	http://dx.doi.org/10.1126/science.7624772			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RL495	7624772				2022-12-28	WOS:A1995RL49500021
J	MCCUNE, JM				MCCUNE, JM			VIRAL LATENCY IN HIV DISEASE	CELL			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; PERIPHERAL-BLOOD CELLS; NF-KAPPA-B; T-CELL; INSITU HYBRIDIZATION; GENE-EXPRESSION; INFECTED INDIVIDUALS; PROVIRAL INTEGRATION; TYPE-1 INFECTION				MCCUNE, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141, USA.							ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3852; BAGASRA O, 1993, AIDS RES HUM RETROV, V9, P69, DOI 10.1089/aid.1993.9.69; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DUAN LX, 1994, VIROLOGY, V199, P474, DOI 10.1006/viro.1994.1148; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GENDELMAN HE, 1985, P NATL ACAD SCI USA, V82, P7086, DOI 10.1073/pnas.82.20.7086; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KASHANCHI F, 1994, VIROLOGY, V201, P95, DOI 10.1006/viro.1994.1269; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KIRCHHOFF R, 1995, NEW ENGL J MED, V332, P228; KITANO K, 1993, BLOOD, V82, P2742; LEBARGY F, 1994, AM J RESP CELL MOL, V10, P72, DOI 10.1165/ajrcmb.10.1.8292383; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCCUNE JM, 1995, HUMAN HEMATOPOIESIS, P133; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLI G, 1992, PATHOBIOLOGY, V60, P246, DOI 10.1159/000163729; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SAKSELA K, 1993, J VIROL, V67, P7423, DOI 10.1128/JVI.67.12.7423-7427.1993; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WAINHOBSON S, 1995, NATURE, V373, P102, DOI 10.1038/373102a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WINSLOW BJ, 1993, VIROLOGY, V196, P849, DOI 10.1006/viro.1993.1545; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	70	67	67	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					183	188		10.1016/0092-8674(95)90305-4	http://dx.doi.org/10.1016/0092-8674(95)90305-4			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628009	Bronze			2022-12-28	WOS:A1995RL76000005
J	PETRIJ, F; GILES, RH; DAUWERSE, HG; SARIS, JJ; HENNEKAM, RCM; MASUNO, M; TOMMERUP, N; VANOMMEN, GJB; GOODMAN, RH; PETERS, DJM; BREUNING, MH				PETRIJ, F; GILES, RH; DAUWERSE, HG; SARIS, JJ; HENNEKAM, RCM; MASUNO, M; TOMMERUP, N; VANOMMEN, GJB; GOODMAN, RH; PETERS, DJM; BREUNING, MH			RUBINSTEIN-TAYBI SYNDROME CAUSED BY MUTATIONS IN THE TRANSCRIPTIONAL COACTIVATOR CBP	NATURE			English	Article							DENOVO RECIPROCAL TRANSLOCATION; PAIRED BOX GENE; CYCLIC-AMP; SHORT ARM; PROTEIN; DNA; 16P13.3	THE Rubinstein-Taybi syndrome (RTS) is a well-defined syndrome with facial abnormalities, broad thumbs, broad big toes and mental retardation as the main clinical features(1-3). Many patients with RTS have been shown to have breakpoints in, and microdeletions of, chromosome 16p13.3 (refs 4-8). Here we report that all these breakpoints are restricted to a region that contains the gene for the human CREB binding protein (CBP), a nuclear protein participating co-activator in cyclic-AMP-regulated gene expression(9-12). We show that RTS results not only from gross chromosomal rearrangements of chromosome 16p, but also from point mutations in the CBP gene itself. Because the patients are heterozygous for the mutations, we propose that the loss of one functional copy of the CBP gene underlies the developmental abnormalities in RTS and possibly the propensity for malignancy.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,1105 AZ AMSTERDAM,NETHERLANDS; KANAGAWA CHILDRENS MED CTR,DIV MED GENET,YOKOHAMA,KANAGAWA,JAPAN; JOHN F KENNEDY INST,DANISH CTR HUMAN GENOME RES,DK-2600 GLOSTRUP,DENMARK; ULLEVAL UNIV HOSP,DEPT MED GENET,OSLO,NORWAY; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Aarhus University; University of Oslo; Oregon Health & Science University	PETRIJ, F (corresponding author), LEIDEN UNIV,SYLVIUS LABS,DEPT HUMAN GENET,LEIDEN,NETHERLANDS.		Peters, Dorien/AFH-8507-2022; Breuning, Martijn H/E-3429-2010; Tommerup, Niels/T-8776-2017	Peters, Dorien/0000-0001-6974-7143; Tommerup, Niels/0000-0003-2304-0112; Giles, Rachel/0000-0001-9133-2008				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BREUNING MH, 1993, AM J HUM GENET, V52, P249; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAUWERSE JG, 1992, BLOOD, V79, P1299; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GFIBBONS RJ, 1995, CELL, V80, P837; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HENNEKAM RCM, 1990, AM J MED GENET S, V6, P17; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOTH CF, 1993, AM J HUM GENET, V52, P455; IMAIZUMI K, 1991, AM J MED GENET, V38, P636, DOI 10.1002/ajmg.1320380430; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LACOMBE D, 1992, AM J MED GENET, V44, P126; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MASUNO M, 1994, AM J MED GENET, V53, P352, DOI 10.1002/ajmg.1320530409; MICHAIL J, 1957, Rev Chir Orthop Reparatrice Appar Mot, V43, P142; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; RUBINSTEIN JH, 1963, AM J DIS CHILD, V105, P588, DOI 10.1001/archpedi.1963.02080040590010; SIRAGANIAN PA, 1989, MED PEDIATR ONCOL, V17, P485; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TOMMERUP N, 1992, AM J MED GENET, V44, P237, DOI 10.1002/ajmg.1320440223; WESSELS JW, 1991, BLOOD, V77, P1555	28	929	964	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					348	351		10.1038/376348a0	http://dx.doi.org/10.1038/376348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630403				2022-12-28	WOS:A1995RL44300049
J	SIVARAJASINGAM, V; LASZLO, J; OGDEN, GR				SIVARAJASINGAM, V; LASZLO, J; OGDEN, GR			EXTENT OF HEPATITIS-B IMMUNIZATION AMONG MEDICAL AND DENTAL STUDENTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,DEPT DENT SURG & PERIODONTOL,DUNDEE DD1 4HR,SCOTLAND	University of Dundee			Ogden, Graham/U-6774-2019	Ogden, Graham/0000-0003-3394-4537				KINGMAN S, 1994, BRIT MED J, V308, P876, DOI 10.1136/bmj.308.6933.876; OATES BC, 1993, BRIT MED J, V307, P301, DOI 10.1136/bmj.307.6899.301; TONKS A, 1993, BRIT MED J, V307, P522; 1992, IMMUNISATION INFECTI, P110	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					231	231		10.1136/bmj.311.6999.231	http://dx.doi.org/10.1136/bmj.311.6999.231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627037	Green Published			2022-12-28	WOS:A1995RL44100020
J	COCKS, BG; CHANG, CCJ; CARBALLIDO, JM; YSSEL, H; DEVRIES, JE; AVERSA, G				COCKS, BG; CHANG, CCJ; CARBALLIDO, JM; YSSEL, H; DEVRIES, JE; AVERSA, G			A NOVEL RECEPTOR INVOLVED IN T-CELL ACTIVATION	NATURE			English	Article							MONOCLONAL-ANTIBODIES; B-CELLS; PROLIFERATION; CLONES; CD28; CD4+; ANTIGEN; CLONING; CTLA-4; GAMMA	OPTIMAL T-cell activation and T-cell expansion require triggering by T-cell antigen receptors and co-stimulatory signals provided by accessory cells(1-3). A major co-stimulatory pathway involves crosslinking the CD28 molecule on T cells by its ligands CD80 or CD86 expressed on antigen-presenting cells(4-7). But recent studies(8,9) on CD28-deficient mice have indicated that CD28 is not required for all T-cell responses and that additional T-cell costimulatory pathways exist. Here we describe a novel glycoprotein, of relative molecular mass 70,000 (M(r) 70K), designated SLAM, that belongs to the immunoglobulin gene superfamily, which is involved in T-cell stimulation. SLAM is constitutively expressed on peripheral-blood CD45RO(high) memory T cells, T-cell clones, immature thymocytes, and a proportion of B cells, and is rapidly induced on naive T cells after activation. Engagement of SLAM enhances antigen-specific proliferation and cytokine production by T cells carrying the CD4 antigen (CD4(+)). Particularly, the production of interferon-gamma (IFN-gamma) is strongly upregulated, even in T helper type 2 (Th2) CD4(+) T-cell clones, whereas no induction of interleukin(IL)-4 or IL-5 production was observed in Th1 clones. In addition, the engagement of SLAM induces directly the proliferation of CD4(+) T-cell clones and preactivated T cells, in the absence of any other stimuli, and without CD28 involvement. Thus SLAM is a novel receptor on T cells that, when engaged, potentiates T-cell expansion in a CD28-independent manner and induces a Th0/Th1 cytokine production profile.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yssel, Hans/AFV-2907-2022; Yssel, Hans/C-6406-2009	Yssel, Hans/0000-0001-7454-1836; Yssel, Hans/0000-0001-7454-1836				AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; AZUMA M, 1909, J EXP MED, V177, P845; BACCHETTA R, 1990, J IMMUNOL, V144, P902; Bierer B E, 1993, Semin Immunol, V5, P249, DOI 10.1006/smim.1993.1029; CHRETIEN I, 1989, J IMMUNOL METHODS, V117, P67, DOI 10.1016/0022-1759(89)90120-8; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; FAVRE C, 1989, MOL IMMUNOL, V26, P17, DOI 10.1016/0161-5890(89)90015-1; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; HAANEN JBAG, 1991, J EXP MED, V174, P583, DOI 10.1084/jem.174.3.583; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MATHEW PA, 1993, J IMMUNOL, V151, P5328; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; Sambrook J., 1989, MOL CLONING; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STAUNTON DE, 1989, J EXP MED, V169, P187; YSSEL H, 1992, J IMMUNOL, V148, P738; YSSEL H, 1984, J IMMUNOL METHODS, V72, P21; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	416	448	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					260	263		10.1038/376260a0	http://dx.doi.org/10.1038/376260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617038				2022-12-28	WOS:A1995RK33100048
J	COLLINS, JJ; CHOW, CC; IMHOFF, TT				COLLINS, JJ; CHOW, CC; IMHOFF, TT			STOCHASTIC RESONANCE WITHOUT TUNING	NATURE			English	Article							BISTABLE SYSTEMS; NOISE; INFORMATION; SIMULATION; DYNAMICS; NEURONS	STOCHASTIC resonance(1-4) (SR) is a phenomenon wherein the response of a nonlinear system to a weak periodic input signal is optimized by the presence of a particular, non-zero level of noises(5-7). SR has been proposed as a means for improving signal detection in a wide variety of systems, including superconducting quantum interference devices(8), and may be used in some natural systems such as sensory neurons(9-15). But for SR to be effective in a single-unit system (such as a sensory neuron or a single ion channel), the optimal intensity of the noise must be adjusted as the nature of the signal to be detected changes(15). This has been thought to impose a limitation on the practical and natural uses of SR. Here we show that the ability of a summing network of excitable units to detect a range of weak (sub-threshold) signals (either periodic or aperiodic) can be optimized by a fixed level of noise, irrespective of the nature of the input signal. We also show that this noise does not significantly degrade the ability of the network to detect suprathreshold signals. Thus, large nonlinear networks do not suffer from the limitations of SR in single units, and might be able to use a single noise level, such as that provided by the intrinsic noise of the individual components, to enhance the system's sensitivity to weak inputs. This suggests a functional role for neuronal noise(14,16-18) in sensory systems.	BOSTON UNIV, DEPT BIOMED ENGN, BOSTON, MA 02215 USA	Boston University	COLLINS, JJ (corresponding author), BOSTON UNIV, NEUROMUSCULAR RES CTR, 44 CUMMINGTON ST, BOSTON, MA 02215 USA.		Chow, Carson C/A-7970-2009					BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; BULSARA AR, 1993, PHYS REV E, V47, P3734, DOI 10.1103/PhysRevE.47.3734; CHIALVO DR, 1993, J STAT PHYS, V70, P375, DOI 10.1007/BF01053974; COLLINS JJ, UNPUB PHYS REV LETT; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DE LUCA CJ, 1982, J PHYSIOL-LONDON, V329, P113, DOI 10.1113/jphysiol.1982.sp014293; DENK W, 1989, PHYS REV LETT, V63, P207, DOI 10.1103/PhysRevLett.63.207; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GINGL Z, 1995, EUROPHYS LETT, V29, P191, DOI 10.1209/0295-5075/29/3/001; HIBBS AD, 1995, J APPL PHYS, V77, P2582, DOI 10.1063/1.358720; INCHIOSA ME, 1995, PHYS LETT A, V200, P283, DOI 10.1016/0375-9601(95)00198-C; INCHIOSA ME, IN PRESS 3RD P TECHN; INCHIOSA ME, IN PRESS PHYS REV E; JUNG P, 1992, PHYS REV A, V46, pR1709, DOI 10.1103/PhysRevA.46.R1709; JUNG P, 1993, PHYS REP, V234, P175, DOI 10.1016/0370-1573(93)90022-6; KISS LB, 1993, J STAT PHYS, V70, P451, DOI 10.1007/BF01053981; KISS LB, 3RD P TECHN C NONL D; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LINDNER JF, IN PRESS PHYS REV LE; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; LONGTIN A, 1993, J STAT PHYS, V70, P309, DOI 10.1007/BF01053970; MANNELLA R, 1989, PHYS REV A, V40, P3381, DOI 10.1103/PhysRevA.40.3381; MOSS F, 1993, ANN NY ACAD SCI, V706, P26, DOI 10.1111/j.1749-6632.1993.tb24679.x; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; NEIMAN A, 1995, PHYS LETT A, V197, P379, DOI 10.1016/0375-9601(94)01008-I; PANTAZELOU E, 1993, AIP CONF PROC, P549, DOI 10.1063/1.44658; SHEPHERD GM, 1988, NEUROBIOLOGHY; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	35	670	693	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					236	238		10.1038/376236a0	http://dx.doi.org/10.1038/376236a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617033				2022-12-28	WOS:A1995RK33100040
J	SOWDEN, AJ; DEEKS, JJ; SHELDON, TA				SOWDEN, AJ; DEEKS, JJ; SHELDON, TA			VOLUME AND OUTCOME IN CORONARY-ARTERY BYPASS GRAFT-SURGERY - TRUE ASSOCIATION OR ARTIFACT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURGICAL VOLUME; HOSPITAL VOLUME; INHOSPITAL MORTALITY; CLINICAL-TRIALS; RISK-FACTORS; QUALITY; OPERATIONS; CATEGORIES; PERFECT	Objectives-To examine the evidence for relation between volume of coronary artery bypass graft surgery and hospital death rates, and to assess the degree to which this could be due to confounding because of differences in case mix. Subjects-People receiving coronary artery bypass graft surgery in the United States. Design-A systematic review of empirical studies examining the relation between volume and outcome of coronary artery bypass graft surgery. Studies were scored according to degree of adjustment for case mix. Above 200 procedures a year was regarded as high volume. Results-Fifteen studies were identified, all of which used observational data from the United States for 1972-92. Six were included in the analysis, one was included in a sensitivity analysis, and eight were excluded because of duplicate analyses of data sources and methods of reporting results. The seven studies analysed reported a reduced mortality with increased volume. Studies with better adjustment for case mix, however, indicated less reduction in mortality with increased volume (P = 0.04). The apparent advantages of higher volume also decreased over time (P < 0.001). Conclusions-The evidence for reduced mortality in hospitals with a high volume of coronary artery bypass graft surgery is based entirely on observational studies. These studies may have overestimated the benefit of increased volume because of poor adjustment for case mix. It signals the need for caution in interpreting the results of observational studies that examine the relation between volume and outcome.			SOWDEN, AJ (corresponding author), UNIV YORK, NHS CTR REVIEWS & DISSEMINAT, YORK YO1 5DD, N YORKSHIRE, ENGLAND.		Deeks, Jon/AAV-5745-2020; Sheldon, Trevor/AAK-7088-2021	Deeks, Jon/0000-0002-8850-1971; Sheldon, Trevor/0000-0002-7479-5913				ADAYY LA, 1993, EVALUATING MED CARE, P55; AITKIN M, 1989, STATISTICAL MODELLIN, P213; Baker R. J, 1985, GLIM 3 77 REFERENCE; BANTA D, 1991, HEALTH POLICY, V18, P1, DOI 10.1016/0168-8510(91)90139-O; Black N, 1990, Health Serv Manage Res, V3, P108; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; ELLWOOD M, 1988, CAUSAL RELATIONSHIPS; FARLEY DE, 1992, MED CARE, V30, P77, DOI 10.1097/00005650-199201000-00009; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; GARNICK DW, 1989, JAMA-J AM MED ASSOC, V262, P547, DOI 10.1001/jama.262.4.547; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HARNAIS SIL, 1990, MED CARE, V28, P1127; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; JOHANSSON SR, 1991, CORONARY ARTERY BYPA; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; Riley G, 1985, Health Care Financ Rev, V7, P37; ROSENFELD K, 1987, AM J PUBLIC HEALTH, V77, P498, DOI 10.2105/AJPH.77.4.498; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SLOAN FA, 1986, SURGERY, V99, P446; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WILLIAMS SV, 1991, JAMA-J AM MED ASSOC, V266, P810, DOI 10.1001/jama.266.6.810; ZELEN J, 1991, NEW YORK STATE J MED, V91, P290; 1994, TERTIARY SERVICES RE; 1988, QUALITY MED CARE INF	39	81	82	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 15	1995	311	6998					151	155		10.1136/bmj.311.6998.151	http://dx.doi.org/10.1136/bmj.311.6998.151			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613425	Green Published			2022-12-28	WOS:A1995RK15900019
J	STUMVOLL, M; NURJHAN, N; PERRIELLO, G; DAILEY, G; GERICH, JE				STUMVOLL, M; NURJHAN, N; PERRIELLO, G; DAILEY, G; GERICH, JE			METABOLIC EFFECTS OF METFORMIN IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RAT HEPATOCYTES; SKELETAL-MUSCLE; MECHANISM; GLUCONEOGENESIS; OXIDATION; TURNOVER; LACTATE; BIGUANIDES; THERAPY; ALANINE	Background. The metabolic effects and mechanism of action of metformin are still poorly understood, despite the fact that it has been used to treat patients with non-insulin-dependent diabetes mellitus (NIDDM) for more than 30 years. Methods. In 10 obese patients with NIDDM, we used a combination of isotope dilution, indirect calorimetry, bioimpedance, and tissue-balance techniques to assess the effects of metformin on systemic lactate, glucose, and free-fatty-acid turnover, lactate oxidation and the conversion of lactate to glucose; skeletal-muscle glucose and lactate metabolism; body composition; and energy expenditure before and after four months of treatment. Results. Metformin treatment decreased the mean (+/-SD) glycosylated hemoglobin value from 13.2+/-2.2 percent to 10.5+/-1.6 percent (P<0.001) and reduced fasting plasma glucose concentrations from 220+/-41 to 155+/-28 mg per deciliter (12.2+/-0.7 to 8.6+/-0.5 mmol per liter) (P<0.001). Although resting energy expenditure did not change, the patients lost 2.7+/-1.3 kg of weight (P<0.001:), 88 percent of which was adipose tissue. The mean (+/-SE) rate of plasma glucose turnover (hepatic glucose output and systemic glucose disposal) decreased from 2.8+/-0.2 to 2.0+/-0.2 mg per kilogram of body weight per minute (15.3+/-0.9 to 10.8+/-0.9 mu mol per kilogram per minute) (P<0.001), as a result of a decrease in hepatic glucose output; systemic glucose clearance did not change. The rate of conversion of lactate to glucose (gluconeogenesis) decreased by 37 percent (P<0.001), whereas lactate oxidation increased by 25 percent (P<0.001). There were no changes in the plasma lactate concentration, plasma lactate turnover, muscle lactate release, plasma free-fatty-acid turnover or uptake of glucose by muscle. Conclusions. Metformin acts primarily by decreasing hepatic glucose output, largely by inhibiting gluconeogenesis, It also seems to induce weight toss, preferentially involving adipose tissue.	UNIV ROCHESTER,SCH MED,ROCHESTER,NY 14642; SCRIPPS CLIN & RES FDN,DIV ENDOCRINOL & METAB,LA JOLLA,CA	University of Rochester; Scripps Research Institute			Stumvoll, Michael/ABE-1121-2021	Stumvoll, Michael/0000-0001-6225-8240	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020411, R01DK020411] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1-RR 00044, 5MO1-RR 000954] Funding Source: Medline; NIDDK NIH HHS [DK-20411] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALENGRIN F, 1987, DIABETES METAB, V13, P591; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; CIGOLINI M, 1984, DIABETES METAB, V10, P311; CONSOLI A, 1990, J CLIN INVEST, V86, P2038, DOI 10.1172/JCI114940; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CONSOLI A, 1990, AM J PHYSIOL, V259, pE677, DOI 10.1152/ajpendo.1990.259.5.E677; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; DINNEEN S, 1992, NEW ENGL J MED, V327, P707, DOI 10.1056/NEJM199209033271007; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GERICH JE, 1993, BAILLIERE CLIN ENDOC, V7, P551, DOI 10.1016/S0950-351X(05)80207-1; HENDLER R, 1990, INT J OBESITY, V14, P927; HEYMSFIELD SB, 1982, AM J CLIN NUTR, V35, P1192, DOI 10.1093/ajcn/35.5.1192; JACKSON RA, 1987, DIABETES, V36, P632, DOI 10.2337/diabetes.36.5.632; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; KLIP A, 1990, DIABETES CARE, V13, P696, DOI 10.2337/diacare.13.6.696; KREISBERG RA, 1970, DIABETES, V19, P64, DOI 10.2337/diab.19.1.64; LESLIE P, 1987, CLIN SCI, V73, P41, DOI 10.1042/cs0730041; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; LUKE A, 1992, METABOLISM, V41, P450, DOI 10.1016/0026-0495(92)90083-M; MILES JM, 1987, AM J PHYSIOL, V252, pE431, DOI 10.1152/ajpendo.1987.252.3.E431; NOSADINI R, 1987, DIABETES CARE, V10, P62, DOI 10.2337/diacare.10.1.62; PERRIELLO G, 1994, DIABETES, V43, P920, DOI 10.2337/diabetes.43.7.920; SCHAFER G, 1980, PHARMACOL THERAPEUT, V8, P275, DOI 10.1016/0163-7258(80)90049-2; SEARLE GL, 1975, DIABETES, V24, P741, DOI 10.2337/diabetes.24.8.741; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; VIGNERI R, 1987, DIABETES CARE, V10, P118, DOI 10.2337/diacare.10.1.118; WILLIAMS RH, 1959, METABOLISM, V8, P548; WILLIAMS RH, 1975, ANN INTERN MED, V83, P567, DOI 10.7326/0003-4819-83-4-567; WING RR, 1994, DIABETES CARE, V17, P30, DOI 10.2337/diacare.17.1.30; Wolfe RR, 1992, RADIOACTIVE STABLE I; WOLLEN N, 1988, BIOCHEM PHARMACOL, V37, P4353, DOI 10.1016/0006-2952(88)90617-X; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415	34	884	901	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					550	554		10.1056/NEJM199508313330903	http://dx.doi.org/10.1056/NEJM199508313330903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623903				2022-12-28	WOS:A1995RQ75100003
J	VINCENT, JL; BIHARI, DJ; SUTER, PM; BRUINING, HA; WHITE, J; NICOLASCHANOIN, MH; WOLFF, M; SPENCER, RC; HEMMER, M				VINCENT, JL; BIHARI, DJ; SUTER, PM; BRUINING, HA; WHITE, J; NICOLASCHANOIN, MH; WOLFF, M; SPENCER, RC; HEMMER, M			THE PREVALENCE OF NOSOCOMIAL INFECTION IN INTENSIVE-CARE UNITS IN EUROPE - RESULTS OF THE EUROPEAN PREVALENCE OF INFECTION IN INTENSIVE-CARE (EPIC) STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL-ACQUIRED INFECTIONS; PNEUMONIA; EPIDEMIOLOGY; STATES	Objective.-To determine the prevalence of intensive care unit (ICU)-acquired infections and the risk factors for these infections, identify the predominant infecting organisms, and evaluate the relationship between IOU-acquired infection and mortality. Design.-A 1-day point-prevalence study. Setting.-Intensive care units in 17 countries in Western Europe, excluding coronary care units and pediatric and special care infant units. Patients.-All patients (>10 years of age) occupying an IOU bed over a 24-hour period. A total of 1417 ICUs provided 10 038 patient case reports. Main Outcome Measures.-Rates of ICU-acquired infection, prescription of antimicrobials, resistance patterns of microbiological isolates, and potential risk factors for IOU-acquired infection and death. Results.-A total of 4501 patients (44.8%) were infected, and 2064 (20.6%) had ICU-acquired infection. Pneumonia (46.9%), lower respiratory tract infection (17.8%), urinary tract infection (17.6%), and bloodstream infection (12%) were the most frequent types of ICU infection reported. Most frequently reported microorganisms were Enterobacteriaceae (34.4%), Staphylococcus aureus (30.1%; [60% resistant to methicillin]), Pseudomonas aeruginosa (28.7%), coagulase-negative staphylococci (19.1%), and fungi (17.1%). Seven risk factors for ICU-acquired infection were identified: increasing length of ICU stay (>48 hours), mechanical ventilation, diagnosis of trauma, central venous, pulmonary artery, and urinary catheterization, and stress ulcer prophylaxis. ICU-acquired pneumonia (odds ratio [OR], 1.91; 95% confidence interval [CI], 1.6 to 2.29), clinical sepsis (OR, 3.50; 95% CI, 1.71 to 7.18), and bloodstream infection (OR, 1.73; 95% CI, 1.25 to 2.41) increased the risk of ICU death. Conclusions.-ICU-acquired infection is common and often associated with microbiological isolates of resistant organisms. The potential effects on outcome emphasize the importance of specific measures for infection control in critically ill patients.	UNITED MED & DENT SCH,GUYS HOSP,INTENS CARE SERV,LONDON SE1 9RT,ENGLAND; UNIV GENEVA,HOP CANTONAL,DEPT ANAESTHESIOL,CH-1211 GENEVA,SWITZERLAND; ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT SURG,3015 GD ROTTERDAM,NETHERLANDS; MED ACT COMMUN,LONDON,ENGLAND; HOP AMBROISE PARE,SERV BACTERIOL,BOULOGNE,FRANCE; HOP BICHAT,SERV REANIMAT MED,PARIS,FRANCE; ROYAL HALLAMSHIRE HOSP,DEPT BACTERIOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; CTR HOP LUXEMBOURG,ANESTHESIOL SERV,LUXEMBOURG,LUXEMBOURG	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Geneva; Erasmus University Rotterdam; Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; University of Sheffield	VINCENT, JL (corresponding author), ERASME UNIV HOSP,DEPT INTENS CARE,ROUTE DELENNIK 808,B-1070 BRUSSELS,BELGIUM.			Vincent, Jean-Louis/0000-0001-6011-6951				BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247; BERNANDER S, 1978, SCAND J INFECT DIS, V10, P66, DOI 10.3109/inf.1978.10.issue-1.15; BRACHMAN PS, 1981, REV INFECT DIS, V3, P640; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; CRAVEN DE, 1988, ARCH INTERN MED, V149, P1161; CRUSE PJE, 1980, SURG CLIN N AM, V60, P27; DASCHNER FD, 1982, INTENS CARE MED, V8, P5; FRENCH GL, 1987, J HOSP INFECT, V9, P132, DOI 10.1016/0195-6701(87)90051-X; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990; Jepsen O B, 1980, J Hosp Infect, V1, P237, DOI 10.1016/0195-6701(80)90061-4; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARTONE WJ, 1992, HOSP INFECT, P577; Meers PD, 1981, J HOSPITAL INFECTI S, V2, P1, DOI DOI 10.1016/S0195-6701(81)80003-5; MERTENS R, 1987, J HOSP INFECT, V9, P219, DOI 10.1016/0195-6701(87)90117-4; MORO ML, 1986, J HOSP INFECT, V8, P72, DOI 10.1016/0195-6701(86)90107-6; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; WENZEL RP, 1983, INFECT CONT HOSP EP, V4, P371, DOI 10.1017/S0195941700059774	20	1813	1911	4	135	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					639	644		10.1001/jama.274.8.639	http://dx.doi.org/10.1001/jama.274.8.639			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637145				2022-12-28	WOS:A1995RP70200032
J	MEJIA, RE; POLLACK, MM				MEJIA, RE; POLLACK, MM			VARIABILITY IN BRAIN-DEATH DETERMINATION PRACTICES IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES	Objective.-To investigate variability in practices for determining brain death and organ procurement results in pediatric intensive care units (PICUs). Design.-Prospective cohort study. Setting.-Pediatric ICUs. Patients.-Children undergoing brain death evaluations selected from 5415 consecutive PICU admissions. Main Outcome Measures.-Data from children undergoing brain death evaluations including number of coma examinations, number and duration of apnea tests, Pco(2) measurements at the end of the apnea test, ancillary tests used to confirm brain death, organ procurement, and reasons for nonprocurement. Results.-A total of 93 (37%) of 248 deaths were brain deaths. Compared with the other deaths, children who were classified as brain dead were sicker on admission (mean Pediatric Risk of Mortality [PRISM] score+/-SD: 31+/-11 vs 23+/-12, P<,001; pre-ICU cardiopulmonary resuscitation, 72% vs 40%, P<.001), and had more traumatic injuries (42% vs 12%, P<.001). Variability in apnea testing included lack of apnea testing in 23 patients (25%) and controversial apnea testing practices in 20 patients (22%). Three patients (3%) had brain death evaluations within hours of discontinuing barbiturate infusions, and four of 30 patients younger than 1 year did not have a confirmatory test, Solid organ procurement was successful in 32%, Reasons for nonprocurement included parental refusal (12%), disease state (12%), and medical examiner's case (22%). Conclusions.-Substantial variability exists in the criteria used by clinicians for the diagnosis of brain death. Some practices are contradictory to the Guidelines for the Determination of Brain Death in Children and to recommendations for apnea testing. Organ procurement could be improved by increased medical examiner cooperation.	CHILDRENS NATL MED CTR,DEPT CRIT CARE MED,WASHINGTON,DC 20010; CHILDRENS NATL MED CTR,CHILRENS RES INST,CTR HLTH SERV & CLIN RES,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC	Children's National Health System; Children's National Health System; George Washington University					PHS HHS [MCH-110584] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALJUMAH M, 1992, CRIT CARE MED, V20, P1564; ASHWAL S, 1993, J HEART LUNG TRANSPL, V12, pS176; Ashwal S, 1991, Adv Pediatr, V38, P181; DRAKE B, 1986, PEDIATRICS, V78, P107; EDMONDS JF, 1989, PEDIAT BRAIN DEATH O, P89; FACKLER JC, 1988, AM J DIS CHILD, V142, P999, DOI 10.1001/archpedi.1988.02150090097034; FREEMAN JM, 1988, PEDIATRICS, V81, P301; GONNELLA JS, 1986, DISEASE STAGING CLIN; Hauser J E, 1969, J Forensic Sci, V14, P501; KAUFMAN HH, 1989, NEUROSURGERY, V25, P275, DOI 10.1227/00006123-198908000-00019; KOHRMAN MH, 1990, PEDIATR NEUROL, V6, P47, DOI 10.1016/0887-8994(90)90078-F; LEVETOWN M, 1994, JAMA-J AM MED ASSOC, V272, P1271, DOI 10.1001/jama.272.16.1271; NARKEWICZ RM, 1989, PEDIATRICS, V83, P629; POLLACK MM, 1993, CRIT CARE MED, V21, P607, DOI 10.1097/00003246-199304000-00023; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; POWNER DJ, 1976, JAMA-J AM MED ASSOC, V236, P1123, DOI 10.1001/jama.236.10.1123; RIVIELLO JJ, 1988, PEDIATR NEUROL, V4, P213, DOI 10.1016/0887-8994(88)90033-1; SCHAFER JA, 1984, CRIT CARE MED, V12, P357; SHAFER T, 1994, JAMA-J AM MED ASSOC, V272, P1607, DOI 10.1001/jama.272.20.1607; SHERIDAN F, 1993, J HEART LUNG TRANSPL, V12, pS179; SHEWMON DA, 1988, ANN NEUROL, V24, P789; SHEWMON DA, 1988, NEUROLOGY, V38, P1813, DOI 10.1212/WNL.38.11.1813-b; SQUIRES S, 1993, WASHINGTON POST 1118; SQUIRES S, 1994, WASHINGTON POST 0729; STAWORN D, 1994, CRIT CARE MED, V22, P1301, DOI 10.1097/00003246-199408000-00014; 1984, PEDIATRICS, V74, P505; 1981, JAMA-J AM MED ASSOC, V246, P2184	28	61	63	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					550	553		10.1001/jama.274.7.550	http://dx.doi.org/10.1001/jama.274.7.550			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629983				2022-12-28	WOS:A1995RN46600025
J	WU, HY; TAN, JY; FANG, M				WU, HY; TAN, JY; FANG, M			LONG-RANGE INTERACTION BETWEEN 2 PROMOTERS - ACTIVATION OF THE LEU-500 PROMOTER BY A DISTANT UPSTREAM PROMOTER	CELL			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; TOPOISOMERASE-I; DNA TOPOISOMERASES; TRANSCRIPTION; GENE; EXPRESSION; MUTATIONS; TEMPLATE; PLASMID	The leu-500 mutation can be suppressed in S. typhimurium topA. Previous studies have demonstrated that the plasmid-borne leu-500 minimal promoter cannot be activated in topA mutants unless adjacent (<250 bp) transcription occurs away from the leu-500 promoter (short-range promoter interaction). To search for a potential upstream promoter responsible for activation of leu-500 in the chromosomal context, we have identified the ilvlH promoter, located 1.9 kb upstream of leu-500 (long-range promoter interaction). Different from short-range promoter interaction, which is abolished by DNA sequence insertions, the long-range promoter interaction is mediated by the intervening DNA sequence. These studies suggest that the long-range interaction between a pair of divergently arrayed promoters is probably mediated by a complex process involving relay of DNA supercoiling by the DNA sequence located between the two promoters.			WU, HY (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201, USA.							BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; CALVO JM, 1969, J BACTERIOL, V97, P1272, DOI 10.1128/JB.97.3.1272-1282.1969; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CHEN DR, 1993, BIOCHEMISTRY-US, V32, P13162, DOI 10.1021/bi00211a027; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUBANAU E, 1972, MOL GEN GENET, V117, P91; ECCLES MR, 1994, ONCOGENE, V9, P2059; FRANCO RJ, 1989, J BACTERIOL, V171, P6573, DOI 10.1128/jb.171.12.6573-6579.1989; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GEMMILL RM, 1983, J MOL BIOL, V170, P39, DOI 10.1016/S0022-2836(83)80226-5; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MARGOLIN P, 1963, GENETICS, V48, P441; McKenney K, 1981, Gene Amplif Anal, V2, P383; MENZEL R, 1987, J BACTERIOL, V169, P1272, DOI 10.1128/jb.169.3.1272-1278.1987; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUKAI FH, 1963, P NATL ACAD SCI USA, V50, P140, DOI 10.1073/pnas.50.1.140; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; PLATKO JV, 1990, J BACTERIOL, V172, P4563, DOI 10.1128/jb.172.8.4563-4570.1990; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SHINYA E, 1994, NUCLEIC ACIDS RES, V22, P2143, DOI 10.1093/nar/22.11.2143; SMITH GR, 1981, CELL, V24, P599, DOI 10.1016/0092-8674(81)90085-4; SQUIRES CH, 1983, J BACTERIOL, V154, P1054, DOI 10.1128/JB.154.3.1054-1063.1983; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; TRUCKSIS M, 1981, J BACTERIOL, V147, P679, DOI 10.1128/JB.147.2.679-681.1981; UMBARGER HE, 1987, ESCHERICHIA COLI SAL, V1, P352; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	37	42	43	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					445	451		10.1016/0092-8674(95)90433-6	http://dx.doi.org/10.1016/0092-8674(95)90433-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634334	Bronze			2022-12-28	WOS:A1995RP24200014
J	CAI, H; LEVINE, V				CAI, H; LEVINE, V			MODULATION OF ENHANCER-PROMOTER INTERACTIONS BY INSULATORS IN THE DROSOPHILA EMBRYO	NATURE			English	Article							DOMAIN BOUNDARIES; PROTEIN; REPRESSION; EXPRESSION; CONVERSION; SILENCER; ELEMENT; ASSAY; GENE	INSULATOR DNAs, or boundary elements, functionally isolate neighbouring genes by blocking interactions between distal enhancers and inappropriate target promoters(1-5). The best-characterized insulators in Drosophila correspond to a 340-base-pair (bp) fragment from the gypsy retrotransposon(3), and the scs and scs' sequences flanking the 87A1 hsp70 locus(1,2). Here we demonstrate that both insulators block the interaction of defined even-skipped (eve) stripe enhancers(6,7) when positioned between the enhancer and the target promoter. The simultaneous use of two stripe enhancers (eve stripes 2 and 3) provides evidence that enhancers lying distal to the insulator are selectively blocked. The insertion of stripe- insulator-stripe sequences between two divergently transcribed promoters indicates that enhancers barred from acting on one basal promoter are fully accessible to appropriate regulatory factors for activating the other promoter. These results suggest that insulators do not propagate changes in chromatin structure. Finally, we present evidence that the gypsy insulator does not block interactions between a silencer element and a basal promoter, Taken together, these results suggest that insulators might not be restricted to the functional isolation of neighbouring genetic loci. Rather, they might function as flexible regulatory elements that modulate enhancer-promoter interactions within complex promoters and complex genetic loci.			CAI, H (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,PACIFIC HALL,LA JOLLA,CA 92093, USA.			Levine, Michael/0000-0001-7629-0081				CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GINDHART JG, 1995, GENETICS, V139, P781; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SMALL S, 1993, DEVELOPMENT, V119, P767; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1	16	188	190	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					533	536		10.1038/376533a0	http://dx.doi.org/10.1038/376533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637789				2022-12-28	WOS:A1995RN62200051
J	EMANUEL, L				EMANUEL, L			STRUCTURED ADVANCE PLANNING - IS IT FINALLY TIME FOR PHYSICIAN ACTION AND REIMBURSEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DIRECTIVES; CARE				EMANUEL, L (corresponding author), HARVARD UNIV,SCH MED,DIV MED ETH,641 HUNTINGTON AVE,BOSTON,MA 02115, USA.							DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Dresser R, 1989, ADV DIRECTIVES MED, P155; EISENDRATH SJ, 1983, JAMA-J AM MED ASSOC, V249, P2054, DOI 10.1001/jama.249.15.2054; EMANUEL EJ, 1991, JAMA-J AM MED ASSOC, V266, P2563, DOI 10.1001/jama.1991.03470180063038; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 1994, MED CARE, V32, P95, DOI 10.1097/00005650-199402000-00001; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EMANUEL LL, 1994, HASTINGS CENT REP, V24, pS27, DOI 10.2307/3563480; EMANUEL LL, IN PRESS HASTINGS CT; EMANUEL LL, IN PRESS CONT INTERN; JECKER NS, 1995, HASTINGS CENT REP, V25, P6, DOI 10.2307/3562484; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LOEWY EH, 1988, J GEN INTERN MED, V3, P54, DOI 10.1007/BF02595757; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SCHMERLING RH, 1988, J GEN INTERN MED, V3, P317; 1994, CAMB Q HLTH ETHICS, V3, P405	21	27	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					501	503		10.1001/jama.274.6.501	http://dx.doi.org/10.1001/jama.274.6.501			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629962				2022-12-28	WOS:A1995RM69900033
J	PELLIZZER, G; SARGENT, P; GEORGOPOULOS, AP				PELLIZZER, G; SARGENT, P; GEORGOPOULOS, AP			MOTOR CORTICAL ACTIVITY IN A CONTEXT-RECALL TASK	SCIENCE			English	Article							SINGLE CELL; DIRECTION; CORTEX; VISUOMOTOR; MOVEMENTS	A monkey was trained to respond on the basis of the serial position of a test stimulus in a sequence. First, three stimuli were presented successively on a circle. Then one of them (except the last) changed color (test stimulus) and served as the go signal: The monkey was required to produce a motor response in the direction of the stimulus that followed the test stimulus. When the test stimulus was the second in the sequence, there was a change in motor cortical activity from a pattern reflecting the direction of this stimulus to the pattern associated with the direction of the motor response. This change was abrupt, occurred 100 to 150 milliseconds after the go signal, and was evident both in the activity of single cells and in the time-varying neuronal population vector. These findings identify the neural correlates of a switching process that is different from a mental rotation described previously.	VET AFFAIRS MED CTR,CTR BRAIN SCI,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,SCH MED,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Pellizzer, Giuseppe/B-7540-2017	Pellizzer, Giuseppe/0000-0002-9254-5555	NINDS NIH HHS [NS17413] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017413] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; GAZZANIGA MS, 1995, COGNITIVE NEUROSCLEN; GEORGOPOULOS AP, 1991, EXP BRAIN RES, V83, P453; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1993, SCIENCE, V260, P47, DOI 10.1126/science.8465199; Kosslyn S. M., 1992, FRONTIERS COGNITIVE; LURITO JT, 1991, EXP BRAIN RES, V87, P562; MARDIA KV, 1972, STATISTICS DIRECTION; PELLIZZER G, 1993, EXP BRAIN RES, V93, P165; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; Snedecor G. W, 1989, STAT METHODS, V8th; STERNBERG S, 1969, AM SCI, V57, P421; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; Zar JH., 1999, BIOSTAT ANAL	16	55	55	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					702	705		10.1126/science.7624802	http://dx.doi.org/10.1126/science.7624802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624802				2022-12-28	WOS:A1995RM70200038
J	CHARNOV, EL; DOWNHOWER, JF				CHARNOV, EL; DOWNHOWER, JF			A TRADE-OFF-INVARIANT LIFE-HISTORY RULE FOR OPTIMAL OFFSPRING SIZE	NATURE			English	Article							NUMBER	OPTIMIZATION models have been widely and successfully used in evolutionary ecology to predict the attributes of organisms(1-6) Most such models maximize darwinian fitness (or a component of fitness) in the face of trade-offs and constraints; the numerical results usually depend on the exact form of the trade-offs/constraints. Here we report the first (to our knowledge) numerical optimum for life-history evolution which is independent of the details of the underlying trade-off, for a large array for trade-off forms. The rule is that at small litter sizes, the range in offspring size is inversely proportional to the size of the litter. Details of the offspring-survival/offspring-size trade-off(7-10) set the value of the proportionality constant, but the -1 exponent, the inverse proportionality itself, is universal. Studies of life histories have yielded many empirical examples of universality for various scaling exponents (for example, adult lifespan scales as approximate to 0.25 with adult body mass within many taxa); this is an example of the numerical value of an exponent (here -1) emerging from a life-history model as independent of all but a few general features of the underlying economic structure.	OHIO STATE UNIV, DEPT ZOOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University	CHARNOV, EL (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.							BEVERTON RJH, 1992, J FISH BIOL, V41, P137, DOI 10.1111/j.1095-8649.1992.tb03875.x; Bulmer M., 1994, THEORETICAL EVOLUTIO; CHARNOV E L, 1982; CHARNOV EL, 1995, EVOL ECOL, V9, P57, DOI 10.1007/BF01237697; CHARNOV EL, 1990, EVOL ECOL, V4, P273, DOI 10.1007/BF02214335; Charnov Eric L., 1993, P1; Clutton-Brock T, 1991, EVOLUTION PARENTAL C, DOI [10.1515/9780691206981, DOI 10.1515/9780691206981]; Gadgil M., 1975, ECOLOGY EVOLUTION CO, P142; GODFRAY HCJ, 1994, PARASITOIDS; LLOYD DG, 1987, AM NAT, V129, P800, DOI 10.1086/284676; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; SHINE R, 1995, OIKOS, V72, P343, DOI 10.2307/3546119; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Stearns S.C., 1992, pi; Stephens D.W., 1986, pi; WOOTTON RJ, 1994, J FISH BIOL, V45, P1067	16	60	61	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	1995	376	6539					418	419		10.1038/376418a0	http://dx.doi.org/10.1038/376418a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630415	Green Submitted			2022-12-28	WOS:A1995RM63900049
J	FLEMING, DM; CHAKRAVERTY, P; SADLER, C; LITTON, P				FLEMING, DM; CHAKRAVERTY, P; SADLER, C; LITTON, P			COMBINED CLINICAL AND VIROLOGICAL SURVEILLANCE OF INFLUENZA IN WINTERS OF 1992-3 AND 1993-4	BRITISH MEDICAL JOURNAL			English	Article									CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,LONDON NW9 5EQ,ENGLAND	Public Health England	FLEMING, DM (corresponding author), ROYAL COLL GEN PRACTITIONERS,BIRMINGHAM RES UNIT,BIRMINGHAM B17 9DB,W MIDLANDS,ENGLAND.							DAISY JA, 1979, J CLIN MICROBIOL, V5, P688; HANNOUN C, 1989, EUR J EPIDEMIOL, V5, P285, DOI 10.1007/BF00144828; VANCASTEREN V, 1992, METHOD INFORM MED, V31, P147; WEBSTER RG, 1994, BRIT MED J, V309, P1179, DOI 10.1136/bmj.309.6963.1179; 1977, J R COLL GEN PRACT, V27, P544	5	47	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					290	291		10.1136/bmj.311.7000.290	http://dx.doi.org/10.1136/bmj.311.7000.290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633235	Green Published			2022-12-28	WOS:A1995RM71900022
J	JOHNSON, RE; KOVVALI, GK; PRAKASH, L; PRAKASH, S				JOHNSON, RE; KOVVALI, GK; PRAKASH, L; PRAKASH, S			REQUIREMENT OF THE YEAST RTH1 5' TO 3' EXONUCLEASE FOR THE STABILITY OF SIMPLE REPETITIVE DNA	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; INSTABILITY; MUTATIONS; REPLICATION; MECHANISM; PROTEINS; HOMOLOG; HISTORY	Simple repetitive DNA sequences are unstable in human colorectal cancers and a variety of other cancers. Mutations in the DNA mismatch repair genes MSH2, MLH1, and PMS1 result in elevated rates of spontaneous mutation and cause a marked increase in the instability of simple repeats. Compared with the wild type, a null mutation in the yeast RTH1 gene, which encodes a 5' to 3' exonuclease, was shown to increase the rate of instability of simple repetitive DNA by as much as 280 times and to increase the spontaneous mutation rate by 30 times. Epistasis analyses were consistent with the hypothesis that this RTH1-encoded nuclease has a role in the MSH2-MLH1-PMS1 mismatch repair pathway.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41261] Funding Source: Medline; NIGMS NIH HHS [GM 19261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GLEBOV OK, 1994, CANCER RES, V54, P3703; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HAN HJ, 1993, CANCER RES, V53, P5087; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KIM HG, 1994, AM J PATHOL, V145, P148; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P975; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WAGA S, 1994, J BIOL CHEM, V269, P10923; WALMSLEY RM, 1983, NATURE, V302, P84, DOI 10.1038/302084a0	38	172	181	1	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					238	240		10.1126/science.7618086	http://dx.doi.org/10.1126/science.7618086			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618086				2022-12-28	WOS:A1995RJ02900044
J	ROBERGE, JY; BEEBE, X; DANISHEFSKY, SJ				ROBERGE, JY; BEEBE, X; DANISHEFSKY, SJ			A STRATEGY FOR A CONVERGENT SYNTHESIS OF N-LINKED GLYCOPEPTIDES ON A SOLID SUPPORT	SCIENCE			English	Article							OLIGOSACCHARIDES; GLYCOBIOLOGY; GLYCALS; ROUTE	Oligosaccharides and glycopeptides are of considerable importance in molecular biology and pharmacology. However, their synthesis is complicated by the large number of different linking sites between each saccharide unit, the need for stereochemical control, the chemical sensitivity of the glycopeptide bonds, and the need to harmonize diverse protecting groups. Here, an efficient solid-phase synthesis of three N-linked glycopeptides based on glycal assembly is presented. The peptide domain can be extended while the ensemble remains bound to the polymer. The glycopeptides synthesized here are among the largest M-linked glycopeptides ever accessed by either solution- or solid-phase synthesis.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University	ROBERGE, JY (corresponding author), SLOAN KETTERING INST CANC RES,BIOORGAN CHEM LAB,1275 YORK AVE,BOX 106,NEW YORK,NY 10021, USA.		Roberge, Jacques Y./B-2412-2013	Roberge, Jacques Y./0000-0002-7810-4139	NCI NIH HHS [T32 CA62948] Funding Source: Medline; NIAID NIH HHS [AI 16943] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA062948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016943] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANISFELD ST, 1990, J ORG CHEM, V55, P5560, DOI 10.1021/jo00308a009; BAHL OP, 1992, GLYCOCONJUGATES COMP, P1; BERKOWITZ DB, 1992, J AM CHEM SOC, V114, P4518, DOI 10.1021/ja00038a011; BLACKBURN GM, 1990, NUCLEIC ACIDS CHEM B; BRAY AM, 1994, J ORG CHEM, V59, P2197, DOI 10.1021/jo00087a041; COHENANISFELD ST, 1993, J AM CHEM SOC, V115, P10531, DOI 10.1021/ja00076a010; DANISHEFSKY J, IN PRESS GLYCOPEPTID; Danishefsky S.J., 1989, CHEMTRACTS ORG CHEM, P273; DANISHEFSKY SJ, 1993, SCIENCE, V260, P1307, DOI 10.1126/science.8493573; DANISHEFSKY SJ, 1995, SCHERING LECTURE SER; DANISHEFSKY SJ, 1994, POLYM PREPR, V35, P977; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; FEIZI T, 1994, CURR OPIN STRUC BIOL, V4, P673, DOI 10.1016/S0959-440X(94)90164-3; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; JONES D A JR, 1977, Tetrahedron Letters, V33, P2853; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KOBATA A, 1993, ACCOUNTS CHEM RES, V26, P319, DOI 10.1021/ar00030a004; KUNZ H, 1992, SYNLETT, P591; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEHRMAN MA, 1993, Patent No. 5272070; LEMIEUX RU, 1964, CAN J CHEM, V42, P1473, DOI 10.1139/v64-222; MATSUURA S, 1976, J CHEM SOC CHEM COMM, P451, DOI 10.1039/c39760000451; MCDONALD FE, 1992, J ORG CHEM, V57, P7001, DOI 10.1021/jo00052a001; McPherson M. J., 1991, PCR PRACTICAL APPROA; MELDAL M, 1994, CURR OPIN STRUC BIOL, V4, P710, DOI 10.1016/S0959-440X(94)90169-4; Meldal Morten, 1994, P145; NESTLER HP, 1994, J ORG CHEM, V59, P4723, DOI 10.1021/jo00096a008; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; PAULSEN H, 1985, LIEBIGS ANN CHEM, P2028; RANDOLPH JT, 1994, ANGEW CHEM INT EDIT, V33, P1470, DOI 10.1002/anie.199414701; ROBINSON AJ, 1993, TETRAHEDRON, V49, P11329, DOI 10.1016/S0040-4020(01)81815-9; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; UNVERZAGT C, 1993, BIOORGAN MED CHEM, V3, P197; VETTER D, 1995, ANGEW CHEM INT EDIT, V34, P60, DOI 10.1002/anie.199500601; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227	36	84	188	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					202	204		10.1126/science.7618080	http://dx.doi.org/10.1126/science.7618080			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618080				2022-12-28	WOS:A1995RJ02900032
J	BAKER, R; ROBERTSON, N; FAROOQI, A				BAKER, R; ROBERTSON, N; FAROOQI, A			AUDIT IN GENERAL-PRACTICE - FACTORS INFLUENCING PARTICIPATION	BRITISH MEDICAL JOURNAL			English	Article								Objective-To identify the factors influencing participation in a single topic audit initiated by a medical audit advisory group. Design-Interview and questionnaire survey of general practitioners who had been invited to take part in an audit of vitamin B-12. Setting-All 147 general practices in Leicestershire. Main outcome measures-Aspects of structure, attitude, and behaviour that influenced participation or non-participation. Results-75 practices completed the audit, 49 withdrew after initial agreement, and 23 refused to take part at the outset. Participants were more likely than those who refused to view the advisory group as useful or a threat and to have positive thoughts about audit but less likely to have previously undertaken audit entailing implementation of change. Participants were more likely than those who withdrew to have positive thoughts about audit and to have discussed whether to take part within the practice but were less likely to view the advisory group as useful. The most common reason given for withdrawal was lack of time. Conclusions-Participation was influenced by attitudes towards audit in general and the advisory group in particular and by aspects of behaviour such as communication within the practice. Practical support and resources may help some practices undertake audit, but advisory groups must also deal with attitudes and unsatisfactory communication in practice teams.			BAKER, R (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DEPT GEN PRACTICE,ELI LILLY NATL CLIN AUDIT CTR,LEICESTER LE5 4PW,LEICS,ENGLAND.		Farooqi, Ammad A/H-1610-2016; Farooqi, Ammad Ahmad/AAF-5325-2021	Robertson, Noelle/0000-0003-1178-9230				BAKER R, 1992, BRIT J GEN PRACT, V42, P415; BAPNA G, 1994, AUDIT TRENDS, V2, P49; CHAMBERS R, 1993, EVALUATION QUALITY M; CLAYTON D, 1993, STATISTICAL MODELS E; CLIFFORD R, 1994, AUDIT TRENDS, V2, P3; COOPER A, 1994, ILLUSTRATIVE EXAMPLE; FOXALL M, 1993, AUDIT TRENDS, V1, P99; FRASER RC, 1985, BRIT MED J, V291, P1473, DOI 10.1136/bmj.291.6507.1473; FRASER RC, 1995, BRIT MED J, V311, P28, DOI 10.1136/bmj.311.6996.28; Hearnshaw H M, 1994, Qual Health Care, V3, P164, DOI 10.1136/qshc.3.3.164; JARMAN B, 1985, MED ANN, P224; JOHNSON R, 1994, BRIT MED J, V309, P98, DOI 10.1136/bmj.309.6947.98; LEAH C, 1979, INTRO STATISTICS NON; LERVY B, 1994, BRIT J GEN PRACT, V44, P311; Rogers EM., 1983, DIFFUSION INNOVATION; STEWART A, 1994, AUDIT TRENDS, V2, P80; VOISEY J, 1993, AUDIT TRENDS, V1, P175; WEBB SJ, 1991, BRIT MED J, V302, P390, DOI 10.1136/bmj.302.6773.390; WEST MA, 1991, EUR J SOC PSYCHOL, V21, P303, DOI 10.1002/ejsp.2420210404; WILSON A, 1994, AUDIT TRENDS, V2, P97; 1990, HCFP908 DEP HLTH	21	24	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					31	34		10.1136/bmj.311.6996.31	http://dx.doi.org/10.1136/bmj.311.6996.31			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613323	Green Published			2022-12-28	WOS:A1995RG97500024
J	KRAVITZ, RL; LAOURI, M; KAHAN, JP; GUZY, P; SHERMAN, T; HILBORNE, L; BROOK, RH				KRAVITZ, RL; LAOURI, M; KAHAN, JP; GUZY, P; SHERMAN, T; HILBORNE, L; BROOK, RH			VALIDITY OF CRITERIA USED FOR DETECTING UNDERUSE OF CORONARY REVASCULARIZATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APPROPRIATENESS; SURGERY; CARE	Objective.-To assess criteria used for detecting underuse of coronary artery revascularization procedures in terms of patient outcomes. Design.-Retrospective cohort study using medical records supplemented by a telephone survey and review of county death records. Setting.-Four public hospitals and two academically affiliated private hospitals in Los Angeles County, California. Participants.-A total of 671 patients who had coronary angiography between June 1, 1990, and September 30, 1991, and who met explicit clinical criteria for the necessity of coronary artery bypass graft (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA). Main Outcome Measures.-For all patients (n=671), we estimated the association between receipt of necessary revascularization and mortality (median follow-up after angiography, 797 days) after adjusting for potential confounders. For the patients completing the telephone interview (n=374), we examined the relationship between receipt of necessary revascularization and frequency of chest pain. Results.-Patients who received necessary revascularization within 1 year of angiography had tower mortality than those who did not (8.7% vs 15.8%, P=.01), and this association persisted after adjustment for extent of coronary artery disease, clinical symptom complex, ejection fraction, and cardiac surgical risk index (adjusted odds ratio=0.49; 95% confidence interval, 0.28 to 0.86). The same general results were obtained whether revascularization was received within 1 year or within 30 days of the catheterization, whether panelists' ratings or individual clinical variables were entered as covariates, and whether the statistical procedure used was logistic regression or Cox proportional hazards analysis. In addition, among patients responding to the telephone survey, those receiving necessary revascularization had less chest pain at follow-up (P=.03). Conclusions.-Among patients meeting criteria for the necessity of revascularization, those receiving a revascularization procedure within I year had lower mortality than those treated medically. These results support the validity of the RAND/UCLA criteria for detecting underuse of these procedures, but more research is needed to confirm the findings and to determine the validity of guidelines for other procedures.	UNIV CALIF LOS ANGELES,SCH MED,DEPT HLTH SERV,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA; RAND CORP,SANTA MONICA,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation	KRAVITZ, RL (corresponding author), UNIV CALIF DAVIS,SCH MED,CTR PRIMARY CARE,DEPT MED,ROOM 3107,2221 STOCKTON BLVD,SACRAMENTO,CA 95817, USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; CHASSIN MR, 1989, APPROPRIATENESS SELE; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; HILBORNE LH, 1991, RAND JRA01; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LEAPE LL, 1991, RAND JRA02; PARSONNET V, 1989, CIRCULATION, V79, P3; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P332; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; 1993, STATA 3 1 REFERENCE	14	139	139	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					632	638		10.1001/jama.274.8.632	http://dx.doi.org/10.1001/jama.274.8.632			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637144				2022-12-28	WOS:A1995RP70200031
J	SCHEINBERG, DA				SCHEINBERG, DA			ADULT LEUKEMIA IN 1995 - NEW DIRECTIONS	LANCET			English	Editorial Material							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS RETINOIC ACID				SCHEINBERG, DA (corresponding author), MEM SLOAN KETTERING CANC CTR, LEUKEMIA SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							ANTIN JH, 1993, BLOOD, V82, P2273; BAKER MA, 1986, LANCET, V1, P786; BERMAN E, 1992, NEW ENGL J MED, V326, P156, DOI 10.1056/NEJM199201163260303; BOCCHIA M, 1995, BLOOD, V85, P2680, DOI 10.1182/blood.V85.10.2680.bloodjournal85102680; CASTAIGNE S, 1990, BLOOD, V76, P1704; CLARKSON B, 1990, UCLA SYM BI, V134, P239; FOA R, 1993, J CLIN ONCOL, V11, P1817, DOI 10.1200/JCO.1993.11.9.1817; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; HERNANDEZ JA, 1995, CANCER, V75, P381, DOI 10.1002/1097-0142(19950101)75:1+<381::AID-CNCR2820751320>3.0.CO;2-B; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JURCIC JG, 1995, LEUKEMIA, V9, P238; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; 1994, CA, V44, P323	15	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 19	1995	346	8973					455	456		10.1016/S0140-6736(95)91315-7	http://dx.doi.org/10.1016/S0140-6736(95)91315-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637474	Bronze			2022-12-28	WOS:A1995RP85700003
J	WILLIAMS, GV; GOLDMANRAKIC, PS				WILLIAMS, GV; GOLDMANRAKIC, PS			MODULATION OF MEMORY FIELDS BY DOPAMINE D1 RECEPTORS IN PREFRONTAL CORTEX	NATURE			English	Article							PRIMATE CEREBRAL-CORTEX; WORKING MEMORY; PARKINSONS-DISEASE; TARGET-CELLS; NEURONS; RAT; SCHIZOPHRENIA; AMPHETAMINE; INVOLVEMENT; STIMULATION	Dopamine has been implicated in the cognitive process of working memory but the cellular basis of its action has yet to be revealed. By combining iontophoretic analysis of dopamine receptors with single-cell recording during behaviour, we found that D1 antagonists can selectively potentiate the 'memory fields' of prefrontal neurons which subserve working memory. The precision shown for D1 receptor modulation of mnemonic processing Indicates a direct gating of selective excitatory synaptic inputs to prefrontal neurons during cognition.			WILLIAMS, GV (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA.							Amsten A. F., 1995, J NEUROSCI, V15, P3429; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; BAUER RH, 1978, PHARMACOL BIOCHEM BE, V8, P243, DOI 10.1016/0091-3057(78)90311-8; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BERGSON C, 1994, SOC NEUR ABSTR, V20, P275; BRADLEY VA, 1989, J NEUROL NEUROSUR PS, V52, P1228, DOI 10.1136/jnnp.52.11.1228; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; BUSHNELL PJ, 1983, PHARM BIOCH BEHAV, V45, P765; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; CEPEDA C, 1992, SYNAPSE, V11, P330, DOI 10.1002/syn.890110408; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster JM, 1989, PREFRONTAL CORTEX, P51; GODBOUT R, 1991, J PHARMACOL EXP THER, V258, P728; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; GOLDSTEIN LE, 1994, J NEUROSCI, V14, P4937; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; MILLAR J, 1988, J NEUROSCI METH, V25, P59, DOI 10.1016/0165-0270(88)90120-3; MILLAR J, 1989, J COMP NEUROL, V287, P119, DOI 10.1002/cne.902870109; OSCALAIDHE SP, 1993, SOC NEUR ABSTR, V19, P800; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; SABATER R, 1993, EUR J PHARMACOL, V242, P205, DOI 10.1016/0014-2999(93)90082-S; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SEGUELA P, 1988, BRAIN RES, V442, P11, DOI 10.1016/0006-8993(88)91427-8; SHURTLEFF D, 1994, PHARMACOL BIOCHEM BE, V47, P935, DOI 10.1016/0091-3057(94)90299-2; SMILEY JF, 1994, P NATL ACAD SCI USA, V91, P5720, DOI 10.1073/pnas.91.12.5720; TAYLOR LA, 1991, LIFE SCI, V49, P1505, DOI 10.1016/0024-3205(91)90051-C; THIERRY AM, 1988, ANN NY ACAD SCI, V537, P101, DOI 10.1111/j.1749-6632.1988.tb42099.x; VANEDEN CG, 1987, NEUROSCIENCE, V22, P849, DOI 10.1016/0306-4522(87)92964-2; WILSON FAW, 1994, P NATL ACAD SCI USA, V91, P4009, DOI 10.1073/pnas.91.9.4009; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4	45	1296	1312	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	1995	376	6541					572	575		10.1038/376572a0	http://dx.doi.org/10.1038/376572a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637804				2022-12-28	WOS:A1995RP75600044
J	SHELHAMER, JH; LEVINE, SJ; WU, T; JACOBY, DB; KALINER, MA; RENNARD, SI				SHELHAMER, JH; LEVINE, SJ; WU, T; JACOBY, DB; KALINER, MA; RENNARD, SI			AIRWAY INFLAMMATION	ANNALS OF INTERNAL MEDICINE			English	Discussion							BRONCHIAL EPITHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; PULMONARY PARASYMPATHETIC NERVES; INTERLEUKIN-8 GENE-EXPRESSION; TACHYKININ-INDUCED INCREASE; COLONY-STIMULATING FACTOR; M2 MUSCARINIC RECEPTORS; CHALLENGED GUINEA-PIGS; CILIARY BEAT FREQUENCY; NEUTRAL ENDOPEPTIDASE	Diseases characterized by airway inflammation, excessive airway secretion, and airway obstruction affect a substantial proportion of the population. These diseases include asthma, chronic bronchitis, bronchiectasis, and cystic fibrosis. Asthma and chronic bronchitis may affect 25 million persons in the United States. Much progress has been made in the last decade toward an understanding of the mechanisms underlying chronic airway inflammation; recent work has resulted in several new concepts of the initiation and maintenance of airway inflammation. Airway production of chemokines, cytokines, and growth factors in response to irritants, infectious agents, and inflammatory mediators may play an important role in the modulation of acute and chronic airway inflammation. Lipid mediators may be produced by resident airway cells and by inflammatory cells; production of these mediators may also be altered by inflammatory cytokines. Increased airway obstruction may be related to intercurrent viral respiratory infection and to the induction of airway inflammation and airway hyperreactivity that results from such infection. Furthermore, several models exist to explain the processes by which airway inflammation is perpetuated in diseases such as asthma and chronic bronchitis. These include neurogenic inflammation, the perpetuation of the acute inflammatory response, and cycles of airway epithelial cell-mediated and inflammatory cell-mediated recruitment and activation of inflammatory cells. An understanding of these mechanisms of airway inflammation may provide the clinician with new therapeutic approaches to the treatment of these common and chronic diseases.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; INST ASTHMA & ALLERGY, WASHINGTON, DC 20010 USA; UNIV NEBRASKA, SCH MED, DEPT MED, OMAHA, NE 68198 USA	Johns Hopkins University; University of Nebraska System	SHELHAMER, JH (corresponding author), NIH, CTR CLIN, DEPT CRIT CARE MED, BLDG 10, ROOM 7-D-43, BETHESDA, MD 20892 USA.			Jacoby, David/0000-0003-2195-9512				ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; ADELROTH E, 1994, ASTHMA RHINITIS, P1067; ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ALBAZZAZ FJ, 1985, AM REV RESPIR DIS, V131, P86; ANDERSON GP, 1994, TRENDS PHARMACOL SCI, V15, P324, DOI 10.1016/0165-6147(94)90027-2; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAILEY JM, 1991, BIOFACTORS, V3, P97; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1989, EXPERIENTIA        S, V56, P317; BASBAUM C, 1994, TXB RESP MED, P323; BECKER S, 1994, AM J PHYSIOL, V266, pL278, DOI 10.1152/ajplung.1994.266.3.L278; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; BEDARD M, 1993, AM J RESP CELL MOL, V9, P455, DOI 10.1165/ajrcmb/9.4.455; BELLINI A, 1993, J ALLERGY CLIN IMMUN, V92, P412, DOI 10.1016/0091-6749(93)90120-5; Benson V, 1994, Vital Health Stat 10, P1; BORSON DB, 1987, EXP LUNG RES, V12, P21, DOI 10.3109/01902148709068812; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; CAPRI S, 1994, CHEST, V106, P1532; CARILLI AD, 1964, NEW ENGL J MED, V270, P123, DOI 10.1056/NEJM196401162700303; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; CHRISTENSEN TG, 1977, J CLIN INVEST, V59, P397, DOI 10.1172/JCI108652; CHUNG KF, 1990, EUR RESPIR J, V3, P329; CHURCHILL L, 1993, AM REV RESPIR DIS, V148, pS83, DOI 10.1164/ajrccm/148.6_Pt_2.S83; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; COSTELLO RW, 1995, AM J RESP CRIT CARE, V151, pA818; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVLIN RB, 1994, AM J PHYSIOL, V266, pL612, DOI 10.1152/ajplung.1994.266.6.L612; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Drumm M L, 1993, Mol Genet Med, V3, P33; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DUSSER DJ, 1989, J APPL PHYSIOL, V67, P1504, DOI 10.1152/jappl.1989.67.4.1504; DUSSER DJ, 1988, J PHARMACOL EXP THER, V244, P531; DUSSER DJ, 1989, J CLIN INVEST, V84, P900, DOI 10.1172/JCI114251; ELIAS JA, 1994, J BIOL CHEM, V269, P22261; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ENDO T, 1992, BIOCHEM BIOPH RES CO, V186, P1594, DOI 10.1016/S0006-291X(05)81590-6; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; FINKBEINER WE, 1994, TXB RESPIRATORY MED, P419; Floreani Anthony A., 1994, P149; FRICK WE, 1988, CLIN CHEST MED, V9, P539; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FRYER AD, 1992, J CLIN INVEST, V90, P2292, DOI 10.1172/JCI116116; FRYER AD, 1984, BRIT J PHARMACOL, V83, P973, DOI 10.1111/j.1476-5381.1984.tb16539.x; FRYER AD, 1991, BRIT J PHARMACOL, V102, P267, DOI 10.1111/j.1476-5381.1991.tb12164.x; FRYER AD, 1990, EUR J PHARMACOL, V181, P51, DOI 10.1016/0014-2999(90)90244-Z; FRYER AD, 1987, EUR J PHARMACOL, V139, P187, DOI 10.1016/0014-2999(87)90251-2; FRYER AD, 1994, BRIT J PHARMACOL, V112, P588, DOI 10.1111/j.1476-5381.1994.tb13115.x; GOLDSTEIN IM, 1994, TXB RESPIRATORY MED, P402; GUMP DW, 1976, AM REV RESPIR DIS, V113, P465; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HIRAYAMA Y, 1993, BRIT J PHARMACOL, V108, P844, DOI 10.1111/j.1476-5381.1993.tb12888.x; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; INASE N, 1993, AM J RESP CELL MOL, V9, P526, DOI 10.1165/ajrcmb/9.5.526; IRWIN RS, 1994, TXB RESPIRATORY MED, P529; IWAMOTO I, 1989, INT ARCH ALLER A IMM, V88, P288, DOI 10.1159/000234808; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; JACOBY DB, 1988, J APPL PHYSIOL, V64, P2653, DOI 10.1152/jappl.1988.64.6.2653; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JOHNSTON S, 1992, EUR RESPIR J, V5, pS109; KAHN RM, 1994, AM J RESP CRIT CARE, V149, pA899; KALINER M, 1987, JAMA-J AM MED ASSOC, V258, P2851, DOI 10.1001/jama.258.20.2851; KALINER M, 1976, TXB IMMUNOPATHOLOGY, P387; KAY AB, 1994, J ROY COLL PHYS LOND, V28, P325; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KNOBIL K, 1995, AM J RESP CRIT CARE, V151, pA543; KOHROGI H, 1989, J CLIN INVEST, V84, P781, DOI 10.1172/JCI114236; KONDO M, 1990, AM REV RESPIR DIS, V142, P403, DOI 10.1164/ajrccm/142.2.403; KWON OJ, 1994, IMMUNOLOGY, V81, P389; LEE RM, 1991, LUNG SCI F, P169; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEI YH, 1992, BRIT J PHARMACOL, V105, P261, DOI 10.1111/j.1476-5381.1992.tb14243.x; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEVINE SJ, 1993, AM REV RESPIR DIS, V147, pA437; Levine SJ, 1994, AM J RESP CRIT CARE, V149, pA27; LEVINE SJ, 1995, IN PRESS AM J RESPIR; LEVINE SJ, 1993, AM J PHYSL 1, V265, pL3608; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; LOGAN C, 1994, AM J RESPIR CELL CRI, V149, pA990; MARASCO WA, 1981, BIOCHEM BIOPH RES CO, V99, P1065, DOI 10.1016/0006-291X(81)90727-0; MARINI M, 1992, PULM PHARMACOL, V5, P61, DOI 10.1016/0952-0600(92)90019-D; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MATTOLI S, 1990, AM J PHYSIOL, V259, pL320, DOI 10.1152/ajplung.1990.259.4.L320; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MCCAIN RW, 1994, AM J RESP CELL MOL, V10, P651, DOI 10.1165/ajrcmb.10.6.8003341; MCDONALD DM, 1988, AM REV RESPIR DIS, V137, P1432, DOI 10.1164/ajrccm/137.6.1432; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MINETTE PA, 1988, J APPL PHYSIOL, V64, P2532, DOI 10.1152/jappl.1988.64.6.2532; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461, DOI 10.1152/jappl.1989.67.6.2461; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MOSSBERG B, 1982, EUR J RESPIR DIS, V63, P570; MULLOL J, 1992, J ALLERGY CLIN IMMUN, V89, P584, DOI 10.1016/0091-6749(92)90326-W; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PAYAN DG, 1983, J IMMUNOL, V131, P1613; PERSSON CGA, 1988, LUNG, V166, P1, DOI 10.1007/BF02714025; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; PIEDIMONTE G, 1990, J APPL PHYSIOL, V68, P754, DOI 10.1152/jappl.1990.68.2.754; PITALE ML, 1993, AM REV RESPIR DIS, V147, pA18; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; RAMSAY AJ, 1994, SCIENCE, V264, P561, DOI 10.1126/science.8160012; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413, DOI 10.1152/ajplung.1993.264.4.L413; RIEVES RD, 1991, AM J PHYSIOL, V261, pL415, DOI 10.1152/ajplung.1991.261.6.L415; ROSSI GA, 1990, AM J RESP CELL MOL, V3, P431, DOI 10.1165/ajrcmb/3.5.431; RUEF C, 1993, EUR RESPIR J, V6, P1429; RUFF MR, 1985, PEPTIDES, V6, P107, DOI 10.1016/0196-9781(85)90142-1; SABAN R, 1987, AM REV RESPIR DIS, V136, P586, DOI 10.1164/ajrccm/136.3.586; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; SARIA A, 1987, ACTA PHYSIOL HUNG, V69, P421; SATOH M, 1991, RESP PHYSIOL, V84, P379, DOI 10.1016/0034-5687(91)90131-2; SAUNDERS NA, 1994, AM J RESP CELL MOL, V11, P147, DOI 10.1165/ajrcmb.11.2.8049075; SCHULTHEIS AH, 1994, J APPL PHYSIOL, V76, P1088, DOI 10.1152/jappl.1994.76.3.1088; SEKIZAWA K, 1987, J PHARMACOL EXP THER, V243, P1211; SHOJI S, 1989, AM J RESP CELL MOL, V1, P13, DOI 10.1165/ajrcmb/1.1.13; SIGAL E, 1993, J LIPID MEDIATOR, V6, P75; SNIDER GL, 1994, TXB RESP MED, P1331; SOBONYA RE, 1989, TXB PULMONARY DISEAS; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; SPERBER K, 1992, AM REV RESPIR DIS, V146, P1589, DOI 10.1164/ajrccm/146.6.1589; SPURZEM JR, 1991, CHEST, V100, P389, DOI 10.1378/chest.100.2.389; SUBAUSTE MC, 1995, IN PRESS J CLIN INVE; TAKAHASHI T, 1994, AM J RESP CRIT CARE, V150, P1640, DOI 10.1164/ajrccm.150.6.7952627; TAKIZAWA H, 1992, BIOCHEM BIOPH RES CO, V187, P596, DOI 10.1016/0006-291X(92)91236-J; TAMAOKI J, 1989, AM REV RESPIR DIS, V140, P430, DOI 10.1164/ajrccm/140.2.430; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; THOMPSON AB, 1993, CHEST, V103, P1482, DOI 10.1378/chest.103.5.1482; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; ULICH TR, 1994, CLIN IMMUNOL IMMUNOP, V72, P137, DOI 10.1006/clin.1994.1117; ULICH TR, 1993, AM J PATHOL, V142, P1335; UMENO E, 1990, J APPL PHYSIOL, V69, P2131, DOI 10.1152/jappl.1990.69.6.2131; VANOOSTERHOUT AJM, 1995, AM J RESP CRIT CARE, V151, P177, DOI 10.1164/ajrccm.151.1.7812550; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; VASSALLO CL, 1970, AM REV RESPIR DIS, V101, P245; WATSON ML, 1993, AM J RESP CELL MOL, V8, P365, DOI 10.1165/ajrcmb/8.4.365; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WRIGHT JL, 1983, AM REV RESPIR DIS, V127, P474, DOI 10.1164/arrd.1983.127.4.474; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; WU T, 1993, AM J RESP CELL MOL, V8, P282, DOI 10.1165/ajrcmb/8.3.282; WU T, 1991, EXP LUNG RES, V17, P1079, DOI 10.3109/01902149109064336; WU T, 1994, AM J RESP CRIT CARE, V149, pA1069; XING Z, 1992, AM J RESP CELL MOL, V6, P212, DOI 10.1165/ajrcmb/6.2.212; 1991, NIH913042A US DEP HL	162	99	101	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					288	304		10.7326/0003-4819-123-4-199508150-00008	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00008			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611596				2022-12-28	WOS:A1995RN66500008
J	TESSIERLAVIGNE, M				TESSIERLAVIGNE, M			EPH RECEPTOR TYROSINE KINASES, AXON REPULSION, AND THE DEVELOPMENT OF TOPOGRAPHIC MAPS	CELL			English	Review							DIRECTIONAL CUES; RETINAL AXONS; GROWTH; GRADIENTS; GUIDANCE; NEURITES; COLLAPSE; CONTACT				TESSIERLAVIGNE, M (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.							BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BONHOEFFER F, 1985, NATURE, V315, P408, DOI 10.1038/315409a0; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; GIERER A, 1987, DEVELOPMENT, V101, P479; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRIFFIN CG, 1980, J CELL BIOL, V86, P156, DOI 10.1083/jcb.86.1.156; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; JOHNSTON AR, 1991, DEVELOPMENT, V113, P409; Kennedy Timothy E., 1995, Current Opinion in Neurobiology, V5, P83, DOI 10.1016/0959-4388(95)80091-3; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; RAPER JA, 1990, EXP NEUROL, V109, P70, DOI 10.1016/S0014-4886(05)80009-3; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, COLD SPRING HARB SYM, V55, P351; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6	23	183	188	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					345	348		10.1016/0092-8674(95)90421-2	http://dx.doi.org/10.1016/0092-8674(95)90421-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634322	Bronze			2022-12-28	WOS:A1995RP24200002
J	MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE				MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE			THE INACCESSIBILITY OF ADVANCE DIRECTIVES ON TRANSFER FROM AMBULATORY TO ACUTE-CARE SETTINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATTITUDES	Objective.-To investigate the accessibility of patients' previously executed advance directives during an acute hospitalization. Design.-Retrospective chart review. Setting.-A large metropolitan teaching hospital, a 514-bed skilled nursing facility, a geriatrics ambulatory care clinic, and a geriatrics group practice office. Patients.-One hundred fourteen geriatric patients who had previously executed an advance directive. Main Outcome Measures.-The medical records of 180 admissions over 3 years, 1991 through 1993, were reviewed for documentation of patients' advance directive status. Results.-Twenty-six percent of patients who had previously executed advance directives had their directives recognized during their hospitalization. Of the subgroup of patients who were judged not to have the capacity to make medical decisions during their admissions, 26% (14/53) had their directives recognized. When the advance directive was recognized, it appeared to influence treatment decisions in 12 (86%) of 14 cases. Conclusions.-Previously executed advance directives are not accessible when patients are admitted to hospitals for acute illness. When such directives are recognized, they are used to influence medical treatment decisions. Further research is needed to define and overcome barriers to this inaccessibility.	JEWISH HOME & HOSP AGED NEW YORK,NEW YORK,NY		MORRISON, RS (corresponding author), MT SINAI MED CTR,DEPT GERIATR & ADULT DEV,BOX 1070,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.							DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; GHUSIN HF, 1993, J AM GERIATR SOC S, V41; HIGH DM, 1994, GERONTOLOGIST, V24, P409; LIBOW LS, 1978, GERIATRICS, V33, P92; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LYNN J, 1993, HASTINGS CENT REP, V23, P20, DOI 10.2307/3562275; MILLER MB, 1976, J AM GERIATR SOC, V24, P108, DOI 10.1111/j.1532-5415.1976.tb04281.x; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; OUSLANDER J, 1990, PRINCIPLES GERIATRIC, P331; PARIS B, 1992, J AM GERIATR SOC, V40, pA129; PARIS BEC, 1993, ARCH INTERN MED, V153, P1689, DOI 10.1001/archinte.153.14.1689; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SCHMERLING RH, 1988, J GEN INTERN MED, V3, P317; SUGARMAN J, 1994, J CLIN ETHIC, V5, P60; TENO JM, 1994, J CLIN ETHIC, V5, P23; 1992, Q PROGR REPORT ADV D	20	139	139	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					478	482		10.1001/jama.274.6.478	http://dx.doi.org/10.1001/jama.274.6.478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629957				2022-12-28	WOS:A1995RM69900028
J	CAMPFIELD, LA; SMITH, FJ; GUISEZ, Y; DEVOS, R; BURN, P				CAMPFIELD, LA; SMITH, FJ; GUISEZ, Y; DEVOS, R; BURN, P			RECOMBINANT MOUSE OB PROTEIN - EVIDENCE FOR A PERIPHERAL SIGNAL LINKING ADIPOSITY AND CENTRAL NEURAL NETWORKS	SCIENCE			English	Article							DIABETES-OBESITY SYNDROMES; MICE; RODENTS; ANIMALS	The recent positional cloning of the mouse ob gene and its human homolog has provided the basis to investigate the potential role of the ob gene product in body weight regulation. A biologically active form of recombinant mouse OB protein was overexpressed and purified to near homogeneity from a bacterial expression system. Peripheral and central administration of microgram doses of OB protein reduced food intake and body weight of ob/ob and diet-induced obese mice but not in db/db obese mice. The behavioral effects after brain administration suggest that OB protein can act directly on neuronal networks that control feeding and energy balance.	ROCHE RES GENT,B-9000 GHENT,BELGIUM		CAMPFIELD, LA (corresponding author), HOFFMANN LA ROCHE INC,DEPT METAB DIS,NUTLEY,NJ 07110, USA.							BJORNTORP P, 1992, OBESITY; BOGARDUS C, 1986, NEW ENGL J MED, V315, P96, DOI 10.1056/NEJM198607103150205; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRAY GA, 1975, METABOLISM, V24, P99, DOI 10.1016/0026-0495(75)90011-6; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; Coleman D L, 1981, Prog Clin Biol Res, V45, P145; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1982, DIABETES, V31, P1; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; COLEMAN DL, 1982, DIABETES, V31, P24, DOI 10.2337/diab.31.1.S24; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GUISEZ Y, UNPUB; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; INGALS AM, 1950, J HERED, V17, P317; KEESEY RE, 1989, MED CLIN N AM, V73, P15, DOI 10.1016/S0025-7125(16)30689-7; Le Magnen J, 1992, NEUROBIOLOGY FEEDING; LEIBEL RL, 1993, CRIT REV FOOD SCI, V33, P351, DOI 10.1080/10408399309527632; LEIBEL RL, 1995, NEW ENGL J MED, V232, P621; MOKHTARIAN A, 1993, PHYSIOL BEHAV, V54, P895, DOI 10.1016/0031-9384(93)90298-T; MORLEY JE, 1987, AM J PHYSIOL, V253, pR516, DOI 10.1152/ajpregu.1987.253.3.R516; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; Schwartz MW, 1994, ENDOCR REV, V2, P109; Snedecor G. W, 1989, STAT METHODS, V8th; Thomas PR, 1995, WEIGHING OPTIONS CRI; WEST DB, 1994, MAMM GENOME, V5, P546, DOI 10.1007/BF00354928; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	2909	3049	4	136	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					546	549		10.1126/science.7624778	http://dx.doi.org/10.1126/science.7624778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624778				2022-12-28	WOS:A1995RL49500030
J	YANG, W; STEITZ, TA				YANG, W; STEITZ, TA			CRYSTAL-STRUCTURE OF THE SITE-SPECIFIC RECOMBINASE GAMMA-DELTA RESOLVASE COMPLEXED WITH A 34 BP CLEAVAGE SITE	CELL			English	Article							DNA-BINDING DOMAIN; TN3 RESOLVASE; RES-SITES; STRAND EXCHANGE; CROSSOVER POINT; MINOR-GROOVE; PROTEIN; RESOLUTION; MUTANTS; IDENTIFICATION	The structure of gamma delta resolvase complexed with a 34 bp substrate DNA has been determined at 3.0 Angstrom resolution. The DNA is sharply bent by 60 degrees toward the major groove and away from the resolvase catalytic domains at the recombination crossover point. The C-terminal one third of resolvase, which was disordered in the absence of DNA, forms an arm and a 3-helix DNA-binding domain on the opposite side of the DNA from the N-terminal domain. The arms wrap around the minor groove of the central 16 bp, and the DNA-binding domains interact with the major grooves near the outer boundaries of the binding site. The resolvase dimer is asymmetric, particularly in the arm region, implying a conformational adaptability that may be important for resolvase binding to different DNA sites in the synaptosome. It also raises the possibility of a sequential single-strand cleavage mechanism.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Yale University; Howard Hughes Medical Institute; Yale University	YANG, W (corresponding author), YALE UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW HAVEN,CT 06520, USA.		Yang, Wei/D-4926-2011; Steitz, Thomas A./C-6559-2009; Yang, Wei/ABB-4785-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195	NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; BEDNARZ AL, 1990, GENE DEV, V4, P2366, DOI 10.1101/gad.4.12b.2366; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FALVEY E, 1988, NATURE, V332, P861, DOI 10.1038/332861a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; GRINDLEY NDF, 1993, SCIENCE, V262, P738, DOI 10.1126/science.8235593; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; GRINDLEY NDF, 1994, NUCLEIC ACIDS MOL BI, V8, P236; HATFULL GF, 1989, J MOL BIOL, V208, P661, DOI 10.1016/0022-2836(89)90156-3; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HATFULL GF, 1988, S SOC GEN MICROBIOL, V43, P149; HUGHES RE, 1993, EMBO J, V12, P1447, DOI 10.1002/j.1460-2075.1993.tb05788.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LESCHZINER AE, 1995, J MOL MICROBIOL, V15, P865; NEWMAN BJ, 1984, CELL, V38, P463, DOI 10.1016/0092-8674(84)90501-4; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REED RR, 1984, COLD SPRING HARB SYM, V49, P245, DOI 10.1101/SQB.1984.049.01.028; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; RICE PA, 1994, EMBO J, V13, P1514, DOI 10.1002/j.1460-2075.1994.tb06413.x; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; RIMPHANITCHAYAK.V, 1990, EMBO J, V9, P719; RIMPHANITCHAYAK.V, 1989, NUCLEIC ACIDS RES, V17, P1035; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; STARK WM, 1994, J MOL BIOL, V239, P25, DOI 10.1006/jmbi.1994.1348; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	49	220	225	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					193	207		10.1016/0092-8674(95)90307-0	http://dx.doi.org/10.1016/0092-8674(95)90307-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628011	hybrid			2022-12-28	WOS:A1995RL76000007
J	TERADA, Y; TATSUKA, M; JINNO, S; OKAYAMA, H				TERADA, Y; TATSUKA, M; JINNO, S; OKAYAMA, H			REQUIREMENT FOR TYROSINE PHOSPHORYLATION OF CDK4 IN G1 ARREST INDUCED BY ULTRAVIOLET-IRRADIATION	NATURE			English	Article							ATAXIA TELANGIECTASIA; DNA-REPLICATION; PROTEIN-KINASE; CELLS; MITOSIS; INDUCTION; MUTATION; GENE	EXPOSURE to ultraviolet light arrests the function of mammalian fibroblasts in the G1 phase of the cell cycle, as well as the S and G2 phases. Although p21, an inhibitor of cyclin-dependent kinase (Cdk) that is induced by DNA damage mag partly account for the arrest in G1 (ref. 1), the mechanism is little understood. Here we show that tyrosine phosphorylation of Cdk4 is required for this arrest. In rat fibroblast, Cdk4 is tyrosine-phosphorylated during G1 progression, and its dephosphorylation is required for S phase. When cells are ultraviolet-irradiated, their arrest in G1 is accompanied by an increase in phosphorylation level. Conversely, cells expressing unphosphorylatable Cdk4(F17) fail to arrest in G1, and suffer significantly elevated chromosomal aberrations and cell death.	KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN; UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Kanazawa University; University of Tokyo	TERADA, Y (corresponding author), RES DEV CORP JAPAN, ERATO, OKAYAMA CELL SWITCHING PROJECT, SAKYO KU, KYOTO 606, JAPAN.			Terada, Yasuhiko/0000-0003-4784-5273				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NAGATA A, 1991, NEW BIOL, V3, P959; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TATSUKA M, 1989, MUTAT RES, V214, P321; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	27	169	169	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 27	1995	376	6538					358	362		10.1038/376358a0	http://dx.doi.org/10.1038/376358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630405				2022-12-28	WOS:A1995RL44300052
J	GUNNELL, DJ; PETERS, TJ; KAMMERLING, RM; BROOKS, J				GUNNELL, DJ; PETERS, TJ; KAMMERLING, RM; BROOKS, J			RELATION BETWEEN PARASUICIDE, SUICIDE, PSYCHIATRIC ADMISSIONS, AND SOCIOECONOMIC DEPRIVATION	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; UNEMPLOYMENT; EPIDEMIOLOGY; INEQUALITIES; TRENDS	Objective-To examine the relations between parasuicide, suicide, psychiatric inpatient admissions, and socioeconomic deprivation. Design-Ecological analysis with data from routine information systems and the 1991 census. Setting-24 localities in the area covered by the Bristol and District Health Authority (population 817 000), consisting of aggregations of neighbouring wards, with an average population of 34 000. Subjects-6089 subjects aged over 10 years admitted to hospital after parasuicide between April 1990 and March 1994; 997 suicides occurring 1982-91; 4763 subjects aged 10-64 years admitted with acute psychiatric illness between April 1990 and March 1994. Results-Localities varied significantly in standardised admission ratios for parasuicide and standardised mortality ratios for suicide (P<0.001). Spearman's rank correlation coefficient between the standardised mortality ratio for suicide and standardised admission ratio for parasuicide was 0.73 (95% confidence interval 0.46 to 0.88). Correlation between parasuicide and Townsend score was 0.86 (0.70 to 0.94) and between suicide and Townsend score 0.73 (0.46 to 0.88). The partial correlation coefficient between suicide and parasuicide after the Townsend score was adjusted for was 0.29 (-0.13 to 0.62). The correlation between standardised admission ratio for parasuicide and standardised admission ratio for psychiatric illness was 0.76 (0.51 to 0.89) and between standardised mortality ratio for suicide and standardised admission ratio for psychiatric illness was 0.72 (0.45 to 0.87). Conclusion-A strong ecological association exists between suicide and parasuicide, with socioeconomic deprivation accounting for much of this relation. This strong association provides supporting evidence for the importance of social policy measures in attaining Health of the Nation targets on mental health.	AVON HLTH,BRISTOL BS2 8EE,AVON,ENGLAND		GUNNELL, DJ (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,CANYANGE HALL,BRISTOL BS8 2PR,AVON,ENGLAND.		Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Peters, Tim/0000-0003-2881-4180				BECK P, 1994, BRIT MED J, V308, P789, DOI 10.1136/bmj.308.6931.789; BLOOR M, 1987, SOCIOL HEALTH ILL, V9, P231, DOI 10.1111/1467-9566.ep10957568; Breslow NE, 1987, STATISTICAL METHODS, V2, P96; BUGLASS D, 1977, PARASUICIDE, P158; Charlton J., 1992, Population Trends, P10; Charlton J., 1993, POPULATION TRENDS, V71, P34; CROMBIE IK, 1989, BMJ-BRIT MED J, V298, P782, DOI 10.1136/bmj.298.6676.782; DELAMOTHE T, 1991, BRIT MED J, V303, P1046, DOI 10.1136/bmj.303.6809.1046; FARMER RDT, 1988, BRIT J PSYCHIAT, V153, P16, DOI 10.1192/bjp.153.1.16; GOLDBERG EM, 1963, BRIT J PSYCHIAT, V109, P785, DOI 10.1192/bjp.109.463.785; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; INEICHEN B, 1984, BRIT J PSYCHIAT, V145, P600, DOI 10.1192/bjp.145.6.600; KAMMERLING RM, 1993, BRIT MED J, V307, P1536, DOI 10.1136/bmj.307.6918.1536; MCCARTHY J, 1994, BRIT MED J, V309, P58, DOI 10.1136/bmj.309.6946.58b; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; MORGAN HG, 1975, BRIT J PSYCHIAT, V126, P319, DOI 10.1192/bjp.126.4.319; OVENSTON.IM, 1974, BRIT J PSYCHIAT, V124, P336, DOI 10.1192/bjp.124.4.336; PAYNE JN, 1994, J EPIDEMIOL COMMUN H, V48, P74, DOI 10.1136/jech.48.1.74; PLATT S, 1984, BMJ-BRIT MED J, V289, P1029, DOI 10.1136/bmj.289.6451.1029; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; STARK C, 1994, BRIT MED J, V308, P1569, DOI 10.1136/bmj.308.6943.1569a; TODD CJ, 1992, J PSYCHOPHARMACOL, V6, P318, DOI 10.1177/0269881192006002061; Townsend PP., 1988, HLTH DEPRIVATION INE; 1992, HLTH NATION STRATEGY	25	168	170	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					226	230		10.1136/bmj.311.6999.226	http://dx.doi.org/10.1136/bmj.311.6999.226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL441	7627035	Green Published			2022-12-28	WOS:A1995RL44100018
J	HOENGER, A; SABLIN, EP; VALE, RD; FLETTERICK, RJ; MILLIGAN, RA				HOENGER, A; SABLIN, EP; VALE, RD; FLETTERICK, RJ; MILLIGAN, RA			3-DIMENSIONAL STRUCTURE OF A TUBULIN-MOTOR-PROTEIN COMPLEX	NATURE			English	Article							ELECTRON-MICROSCOPY; 3-DIMENSIONAL STRUCTURE; MICROTUBULE DYNAMICS; SURFACE LATTICE; DROSOPHILA; KINESIN; RECONSTRUCTION; SEGREGATION; MOLECULE; CRYSTALS	THE kinesin superfamily is a class of microtubule-based mechanoenzymes involved in intracellular transport and chromosome movements. Molecules that move towards either the plus end or the minus end of microtubules are represented within the family. The motor domains of these molecules exhibit considerable sequence homology and contain both the ATP- and microtubule-binding sites (reviewed in refs 1, 2). Here we focus on non-claret disjunctional (ncd), a minus-end-directed motor involved in chromosome segregation in meiosis and early mitosis in Drosophila(3-6). We have calculated a three-dimensional map of tubulin sheets decorated with monomeric recombinant ncd motor domains(7) by negative-stain electron microscopy and image analysis. Comparisons with a control structure of tubulin alone reveal that each motor domain binds to the crest of a single protofilament, making extensive contacts with both the alpha and beta tubulin monomers. Binding of the motor domain results in significant conformational changes in both of the tubulin monomers.	UNIV CALIF SAN FRANCISCO, DEPT BIOPHYS & BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	HOENGER, A (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Hoenger, Andreas/0000-0001-9176-6658				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CREPEAU RH, 1978, P NATL ACAD SCI USA, V75, P5006, DOI 10.1073/pnas.75.10.5006; CREPEAU RH, 1977, J MOL BIOL, V116, P301, DOI 10.1016/0022-2836(77)90218-2; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ERICKSON HP, 1974, J CELL BIOL, V60, P153, DOI 10.1083/jcb.60.1.153; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HEUSER JE, 1986, J CELL BIOL, V103, P2209, DOI 10.1083/jcb.103.6.2209; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SABLIN EP, 1995, PROTEINS, V21, P68, DOI 10.1002/prot.340210108; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; SHIMIZU T, 1993, METHOD CELL BIOL, V39, P167, DOI 10.1016/S0091-679X(08)60169-7; SIMON JR, 1990, J CELL SCI, V96, P571; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; TAMM LK, 1979, J MOL BIOL, V130, P473, DOI 10.1016/0022-2836(79)90435-2; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	27	100	100	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					271	274		10.1038/376271a0	http://dx.doi.org/10.1038/376271a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7617040				2022-12-28	WOS:A1995RK33100051
J	DELEW, N				DELEW, N			THE FIRST 30 YEARS OF MEDICARE AND MEDICAID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; ACCESS; CARE		US DEPT HHS,HLTH CARE FINANCING ADM,SPECIAL ANAL STAFF,OFF DIRECTOR,WASHINGTON,DC									[Anonymous], 1993, ACCESS HLTH CARE AM; DAVIS K, 1991, MILBANK Q, V69, P253, DOI 10.2307/3350204; Gornick M, 1985, Health Care Financ Rev, VSuppl, P13; GORNICK M, 1976, SOC SECUR B     0703, P3; GRAD S, 1994, INCOME POPULATION 55; HOLAHAN J, 1995, CHANGING COMPOSITION; Howell E M, 1991, Health Care Financ Rev, V12, P1; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MOON M, 1993, MEDICARE NOW FUTURE; Waldo D R, 1989, Health Care Financ Rev, V10, P111; WOOD DL, 1990, PEDIATRICS, V86, P666; 1994, ANN REPORT C MONITOR; HLTH NEEDS MEDICAID, P95; 1995, P60188 CURR POP REP; 1995, 1995 DATA COMPENDIUM; 1993, CURRENT POPULATION P, V60; 1995, HLTH CARE FINANC FEB	18	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					262	267						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609238				2022-12-28	WOS:A1995RH93700035
J	PERNIS, A; GUPTA, S; GOLLOB, KJ; GARFEIN, E; COFFMAN, RL; SCHINDLER, C; ROTHMAN, P				PERNIS, A; GUPTA, S; GOLLOB, KJ; GARFEIN, E; COFFMAN, RL; SCHINDLER, C; ROTHMAN, P			LACK OF INTERFERON-GAMMA RECEPTOR-BETA CHAIN AND THE PREVENTION OF INTERFERON-GAMMA SIGNALING IN T(H)1 CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; LYMPHOCYTE-T CLONES; IFN-GAMMA; TRANSCRIPTION FACTOR; IMMUNE REGULATION; TH1; PHOSPHORYLATION; ACTIVATION; SUBSETS; ANTIBODIES	The ability of interferon gamma (IFN-gamma) to inhibit the proliferation of type 2 T helper cells (T(H)2), but not that of type 1 (T(H)1) cells, suggests that helper cell subsets might differ in their activation of the IFN-gamma signaling pathway. The IFN-gamma-inducible signal transducing factor (STF-IFN gamma) was activated in murine T(H)2 but not in T(H)1 cell clones, because in the latter the second chain of the IFN-gamma receptor (accessory factor 1 or IFN-gamma R beta) was absent. Thus, T(H)1 cells use receptor modification to prevent the activation of STF-IFN gamma and achieve an IFN-gamma-resistant state.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Columbia University; Columbia University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Gollob, Kenneth J/C-1341-2008; Gollob, Kenneth J/GPX-8434-2022	Gollob, Kenneth J/0000-0003-4184-3867; 				BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK JR, 1994, J BIOL CHEM, V269, P7013; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LECLAIRE RD, 1992, J LEUKOCYTE BIOL, V51, P507, DOI 10.1002/jlb.51.5.507; LEDERER JA, 1994, J IMMUNOL, V152, P77; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PERNIS A, UNPUB; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YANG XJ, 1993, J NEUROSCI, V13, P3006	42	265	269	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					245	247		10.1126/science.7618088	http://dx.doi.org/10.1126/science.7618088			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7618088				2022-12-28	WOS:A1995RJ02900047
J	MIDDLETON, JF				MIDDLETON, JF			ASKING PATIENTS TO WRITE LISTS - FEASIBILITY STUDY	BRITISH MEDICAL JOURNAL			English	Article											MIDDLETON, JF (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DEPT GEN PRACTICE,LEICESTER LE5 4PW,LEICS,ENGLAND.							MIDDLETON J, 1994, BRIT J GEN PRACT, V44, P309; MIDDLETON JF, 1989, J ROY COLL GEN PRACT, V39, P383; MIDDLETON JF, 1991, MODERN MED       APR, P183; Stewart M A, 1975, J Fam Pract, V2, P411; Tuckett D., 1985, M EXPERTS APPROACH S	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					34	34		10.1136/bmj.311.6996.34	http://dx.doi.org/10.1136/bmj.311.6996.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613324	Green Published			2022-12-28	WOS:A1995RG97500025
J	DREW, WL; IVES, D; LALEZARI, JP; CRUMPACKER, C; FOLLANSBEE, SE; SPECTOR, SA; BENSON, CA; FRIEDBERG, DN; HUBBARD, L; STEMPIEN, MJ; SHADMAN, A; BUHLES, W				DREW, WL; IVES, D; LALEZARI, JP; CRUMPACKER, C; FOLLANSBEE, SE; SPECTOR, SA; BENSON, CA; FRIEDBERG, DN; HUBBARD, L; STEMPIEN, MJ; SHADMAN, A; BUHLES, W			ORAL GANCICLOVIR AS MAINTENANCE TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY SYNDROME; ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS RETINITIS; OCULAR MANIFESTATIONS; FOSCARNET; THERAPY; INFECTION; DISEASE	Background. Cytomegalovirus retinitis, a sight threatening infection associated with the acquired immunodeficiency syndrome (AIDS), currently requires lifelong intravenous treatment. An effective oral treatment would bean important advance. Methods. We compared oral with intravenous ganciclovir in an open-label, randomized study in patients with AIDS and newly diagnosed, stable cytomegalovirus retinitis (the disease was stabilized by three weeks of treatment with intravenous ganciclovir). Sixty subjects were randomly assigned to maintenance therapy with intravenous ganciclovir at a dose of 5 mg per kilogram of body weight daily, and 63 to maintenance therapy with oral ganciclovir at a dose of 3000 mg daily. The subjects were followed for up to 20 weeks, with photography of the fundi conducted every other week. The photographs were evaluated at the completion of the study by an experienced grader who was unaware of the subjects' treatment assignments. Results. Efficacy could be evaluated in 117 subjects; photographs were ungradable for 2 of the 117. On the basis of the masked assessment of photographs from 115 subjects, the mean time to the progression of retinitis was 62 days in those given intravenous ganciclovir and 57 days in those given oral ganciclovir (P=0.63; relative risk [oral vs. intravenous], 1.08; 95 percent confidence interval for the difference in means, -22 to +12 days). On the basis of funduscopy by ophthalmologists who were aware of the subjects' treatment assignments, the mean time to progression was 96 days in subjects given intravenous ganciclovir and 68 days in subjects given oral ganciclovir (P=0.03; relative risk [oral vs. intravenous], 1.68; 95 percent confidence interval for the difference in means, -45 to -11 days). Survival, changes in visual acuity, the incidence of viral shedding, and the incidence of adverse gastrointestinal events were similar in the two groups. Neutropenia, anemia, intravenous-catheter-related adverse events, and sepsis were more common in the group given intravenous ganciclovir. Conclusions. Oral ganciclovir is safe and effective as maintenance therapy for cytomegalovirus retinitis and is more convenient for patients to take than intravenous ganciclovir.	BETH ISRAEL HOSP,BOSTON,MA 02215; DAVIES MED CTR,SAN FRANCISCO,CA 94114; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103; RUSH MED COLL,CHICAGO,IL 60612; NYU,MED CTR,NEW YORK,NY; UNIV WISCONSIN,MADISON,WI; SYNTEX INC,DEV RES,PALO ALTO,CA 94304	Harvard University; Beth Israel Deaconess Medical Center; California Pacific Medical Center; University of California System; University of California San Diego; Rush University; New York University; University of Wisconsin System; University of Wisconsin Madison; Syntex Corporation	DREW, WL (corresponding author), UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,POB 7921,SAN FRANCISCO,CA 94120, USA.							ANDERSON RD, 1995, CLIN THER, V17, P425, DOI 10.1016/0149-2918(95)80107-3; Drew W L, 1993, Clin Diagn Virol, V1, P179; DREW WL, 1988, J INFECT DIS, V158, P449, DOI 10.1093/infdis/158.2.449; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; FLETCHER CV, 1989, DICP ANN PHARMAC, V23, P5, DOI 10.1177/106002808902300101; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; HOLLAND GN, 1987, OPHTHALMOLOGY, V94, P815; JABS DA, 1989, OPHTHALMOLOGY, V96, P1092; JABS DA, 1987, OPHTHALMOLOGY, V94, P824; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; JACOBSON MA, 1993, J INFECT DIS, V168, P444, DOI 10.1093/infdis/168.2.444; JACOBSON MA, 1988, J MED VIROL, V25, P339, DOI 10.1002/jmv.1890250311; LEHOANG P, 1989, OPHTHALMOLOGY, V96, P865; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; ORELLANA J, 1987, OPHTHALMOLOGY, V94, P831; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; PLOTKIN SA, 1985, J INFECT DIS, V152, P833, DOI 10.1093/infdis/152.4.833; SPECTOR SA, 1995, J INFECT DIS, V171, P1431, DOI 10.1093/infdis/171.6.1431; WALMSLEY SL, 1988, J INFECT DIS, V157, P569, DOI 10.1093/infdis/157.3.569; 1994, OPHTHALMOLOGY, V101, P1250; 1992, NEW ENGL J MED, V326, P213	23	240	245	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					615	620		10.1056/NEJM199509073331002	http://dx.doi.org/10.1056/NEJM199509073331002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637721	Bronze			2022-12-28	WOS:A1995RR84000002
J	PHELPS, WC; ALEXANDER, KA				PHELPS, WC; ALEXANDER, KA			ANTIVIRAL THERAPY FOR HUMAN PAPILLOMAVIRUSES - RATIONALE AND PROSPECTS	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; E2F TRANSCRIPTION FACTOR; EPIDERMAL GROWTH-FACTOR; STRUCTURE-BASED DESIGN; DNA-BINDING DOMAIN; RETINOBLASTOMA SUPPRESSOR PROTEIN; COTTONTAIL RABBIT PAPILLOMAVIRUS; PURINE NUCLEOSIDE PHOSPHORYLASE; EPITHELIAL-CELL DIFFERENTIATION	Objective: To review the basic virology of human papillomavirus (HPV) and the natural history of HPV infection and to discuss current and potential therapies. Data Sources: The MEDLINE database (1966 to 1994) was searched to identify English-language articles and abstracts on HPV biology and antiviral chemotherapy. Study Selection: Peer-reviewed basic science and clinical research studies on the molecular, cellular, and human biology of HPV infection. Data Extraction: Summaries of data from research studies on the biology of papillomavirus infection and information from review articles on the basic and applied pharmacology of antiviral agents. Data Synthesis: Papillomavirus infections are very common. Human papillomavirus infections may be asymptomatic or may be manifested in various benign or malignant lesions, most notably anogenital condyloma and anogenital carcinoma. Currently, therapeutic options for HPV infection are limited, expensive, and often ineffective. By understanding the basic virology and natural history of HPV infection, potential sites for pharmacologic intervention can be identified. Although currently available antiviral compounds are inactive against HPV, they serve as models for the rational design of HPV antiviral drugs. Conclusions: Although HPV infection causes substantial morbidity and expense, uniformly effective therapy for HPV infection is not currently available. Several processes in the HPV infection cycle are appropriate targets for the development of antiviral agents. The development of compounds active against HPV could prevent the benign and malignant diseases associated with HPV infection.	DUKE UNIV, MED CTR, DURHAM, NC USA	Duke University	PHELPS, WC (corresponding author), BURROUGHS WELLCOME CO, DIV VIROL, RC2, 3030 CORNWALLIS RD, POB 12700, RES TRIANGLE PK, NC 27709 USA.							AGARWAL C, 1991, CANCER RES, V51, P3982; ALLOUB MI, 1989, BMJ-BRIT MED J, V298, P153, DOI 10.1136/bmj.298.6667.153; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; ASSELINEAU D, 1984, BRIT J DERMATOL, V111, P219, DOI 10.1111/j.1365-2133.1984.tb15608.x; BADGER J, 1988, P NATL ACAD SCI USA, V85, P3304, DOI 10.1073/pnas.85.10.3304; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BAKER CC, 1987, PAPOVAVIRIDAE, P321; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARR BBB, 1989, LANCET, V1, P124; BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BECKER TM, 1987, OBSTET GYN CLIN N AM, V14, P389; Bernard Bruno A., 1993, P207; BEUTNER KR, 1989, J AM ACAD DERMATOL, V20, P114, DOI 10.1016/S0190-9622(89)80004-0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLEUL C, 1991, J CLIN MICROBIOL, V29, P1579, DOI 10.1128/JCM.29.8.1579-1588.1991; BLITZ IL, 1991, J VIROL, V65, P649, DOI 10.1128/JVI.65.2.649-656.1991; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BRANDSMA JL, 1992, J VIROL, V66, P6204, DOI 10.1128/JVI.66.10.6204-6207.1992; BREAM GL, 1993, J VIROL, V67, P2655, DOI 10.1128/JVI.67.5.2655-2663.1993; BUNNEY MH, 1982, VIRAL WARTS BIOL TRE; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BYRNE JC, 1987, NEW ENGL J MED, V317, P873, DOI 10.1056/NEJM198710013171406; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; COHEN KA, 1991, J BIOL CHEM, V266, P14670; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; COOK TA, 1973, ANN OTO RHINOL LARYN, V82, P649, DOI 10.1177/000348947308200507; COOPER KD, 1990, J INVEST DERMATOL, V94, P769, DOI 10.1111/1523-1747.ep12874631; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Crumpacker C. S., 1984, CLIN APPLICATIONS RI, P33; DARMANN K, 1986, VIROLOGY, V151, P124, DOI 10.1016/0042-6822(86)90110-8; DECLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963, DOI 10.1016/0006-2952(91)90276-B; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DEVILLIERS EM, 1981, J VIROL, V40, P932, DOI 10.1128/JVI.40.3.932-935.1981; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DIMAIO D, 1994, SEMIN VIROL, V5, P369, DOI 10.1006/smvy.1994.1041; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EALICK SE, 1991, P NATL ACAD SCI USA, V88, P11540, DOI 10.1073/pnas.88.24.11540; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FRAZER IH, 1986, LANCET, V2, P657; FURMAN PA, 1984, J BIOL CHEM, V259, P9575; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; FYFE JA, 1978, J BIOL CHEM, V253, P8721; GASSENMAIER A, 1985, ARCH DERMATOL RES, V278, P79, DOI 10.1007/BF00412502; GHOSH AK, 1993, INT J CANCER, V53, P591, DOI 10.1002/ijc.2910530411; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GISSMANN L, 1980, INT J CANCER, V25, P605, DOI 10.1002/ijc.2910250509; GISSMANN L, 1982, J VIROL, V44, P393, DOI 10.1128/JVI.44.1.393-400.1982; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GLEW SS, 1992, CANCER RES, V52, P4009; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HALPERT R, 1986, OBSTET GYNECOL, V68, P251; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; HAUSEN HZ, 1986, LANCET, V2, P489; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HOWLEY PM, 1990, VIROLOGY, P1625; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUGHES RG, 1988, J CLIN PATHOL, V41, P253, DOI 10.1136/jcp.41.3.253; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JABLONSKA S, 1972, CANCER RES, V32, P583; JOCHMUS I, 1993, HUM PATHOL, V24, P519, DOI 10.1016/0046-8177(93)90164-C; JOCHMUSKUDIELKA I, 1989, J NATL CANCER I, V81, P1698, DOI 10.1093/jnci/81.22.1698; JONES RE, 1992, J BIOL CHEM, V267, P908; JONES RE, 1990, J BIOL CHEM, V265, P12782; KANDA T, 1992, VIROLOGY, V190, P724, DOI 10.1016/0042-6822(92)90910-H; KASHIMA HK, 1992, LARYNGOSCOPE, V102, P9; KATO N, 1969, VIROLOGY, V37, P632, DOI 10.1016/0042-6822(69)90281-5; KIRNBAUER R, 1993, J VIROL, V67, P6929, DOI 10.1128/JVI.67.12.6929-6936.1993; KIRSI JJ, 1983, ANTIMICROB AGENTS CH, V24, P353, DOI 10.1128/AAC.24.3.353; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KOCHEL HG, 1991, INT J CANCER, V48, P682, DOI 10.1002/ijc.2910480509; KOHLER M, 1989, ANTICANCER RES, V9, P1537; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; KRAUS SJ, 1990, REV INFECT DIS, V12, pS620; KREBS HB, 1989, CLIN OBSTET GYNECOL, V32, P200, DOI 10.1097/00003081-198903000-00024; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LOWY DR, 1994, P NATL ACAD SCI USA, V91, P2436, DOI 10.1073/pnas.91.7.2436; LUTZNER MA, 1978, B CANCER, V65, P169; MAJEWSKI S, 1990, J AM ACAD DERMATOL, V22, P423, DOI 10.1016/0190-9622(90)70058-P; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATSUKURA T, 1986, J VIROL, V58, P979, DOI 10.1128/JVI.58.3.979-982.1986; MATSUKURA T, 1989, VIROLOGY, V172, P63, DOI 10.1016/0042-6822(89)90107-4; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MCGLENNEN RC, 1993, HEAD NECK-J SCI SPEC, V15, P504, DOI 10.1002/hed.2880150605; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEISELS A, 1976, ACTA CYTOL, V20, P505; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MONINI P, 1991, J VIROL, V65, P2124, DOI 10.1128/JVI.65.4.2124-2130.1991; MOSCICKI A, 1992, PEDIATR RES, V28, P507; MOSKALUK C, 1987, P NATL ACAD SCI USA, V84, P1215, DOI 10.1073/pnas.84.5.1215; MOSKALUK CA, 1988, J VIROL, V62, P1925, DOI 10.1128/JVI.62.6.1925-1931.1988; MOSKALUK CA, 1989, VIROLOGY, V169, P236, DOI 10.1016/0042-6822(89)90062-7; MOUNTS P, 1982, P NATL ACAD SCI-BIOL, V79, P5425, DOI 10.1073/pnas.79.17.5425; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MULLER M, 1992, VIROLOGY, V187, P508; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; NAHMIAS AJ, 1970, AM J EPIDEMIOL, V91, P547, DOI 10.1093/oxfordjournals.aje.a121166; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NEVINS JR, 1992, SCIENCE, V258, P424; NUOVO GJ, 1990, OBSTET GYNECOL, V75, P1006; ONDA T, 1993, INT J CANCER, V54, P624, DOI 10.1002/ijc.2910540417; ORTH G, 1987, PAPOVAVIRIDAE, V2, P199; ORTH G, 1980, COLD SPRING HARBOR C, V7, P259; OSTROW RS, 1982, P NATL ACAD SCI-BIOL, V79, P1634, DOI 10.1073/pnas.79.5.1634; OSTROW RS, 1992, ANTIVIR RES, V17, P99, DOI 10.1016/0166-3542(92)90045-7; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PFISTER H, 1983, CANCER RES, V43, P1436; PHELPS WC, 1987, J VIROL, V61, P1630, DOI 10.1128/JVI.61.5.1630-1638.1987; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; PIM D, 1992, ONCOGENE, V7, P27; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PIRISI L, 1992, CANCER RES, V52, P187; PUROLA E, 1977, ACTA CYTOL, V21, P26; QUICK CA, 1980, ANN OTO RHINOL LARYN, V89, P467, DOI 10.1177/000348948008900521; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; RAWLS WE, 1968, SCIENCE, V161, P1255, DOI 10.1126/science.161.3847.1255; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RICHMAN DD, 1986, VIROLOGY, V151, P200, DOI 10.1016/0042-6822(86)90042-5; RIOU G, 1990, LANCET, V335, P1171; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSSMANN MG, 1989, ANTIVIR RES, V11, P3, DOI 10.1016/0166-3542(89)90016-8; ROSSMANN MG, 1988, P NATL ACAD SCI USA, V85, P4625, DOI 10.1073/pnas.85.13.4625; RUDLINGER R, 1988, DERMATOLOGICA, V176, P277, DOI 10.1159/000248735; RUDLINGER R, 1989, LANCET, V1, P1132; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHEFFNER M, 1994, CURR TOP MICROBIOL, P83; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SCULLY C, 1988, ORAL SURG ORAL MED O, V65, P526, DOI 10.1016/0030-4220(88)90134-X; SECRIST JA, 1993, J MED CHEM, V36, P1847, DOI 10.1021/jm00065a007; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SHAH K, 1986, OBSTET GYNECOL, V68, P795; SHAH KV, 1990, VIROLOGY, P1651; Sidwell R. W., 1984, CLIN APPLICATIONS RI, P19; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSA R, 1990, BIOCHIM BIOPHYS ACTA, V1032, P19, DOI 10.1016/0304-419X(90)90010-X; SPALHOLZ BA, 1993, VIROLOGY, V193, P201, DOI 10.1006/viro.1993.1116; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STAGNO S, 1985, NEW ENGL J MED, V313, P1270, DOI 10.1056/NEJM198511143132006; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; STRIDH S, 1983, ARCH VIROL, V77, P223, DOI 10.1007/BF01309269; STRONG MS, 1977, LARYNGOTRACHEAL PROB, P88; SUGRUE MF, 1990, CURR EYE RES, V9, P607, DOI 10.3109/02713689008999600; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; TAGAMI H, 1974, BRIT J DERMATOL, V90, P147, DOI 10.1111/j.1365-2133.1974.tb06378.x; TAY SK, 1987, BRIT J OBSTET GYNAEC, V94, P1094, DOI 10.1111/j.1471-0528.1987.tb02296.x; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; TINDLE RW, 1991, P NATL ACAD SCI USA, V88, P5887, DOI 10.1073/pnas.88.13.5887; TINDLE RW, 1990, AUST NZ J OBSTET GYN, V30, P370, DOI 10.1111/j.1479-828X.1990.tb02033.x; TROFATTER KF, 1991, DERMATOL CLIN, V9, P343; TYRING SK, 1988, SEMIN ONCOL, V15, P35; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006; VIAC J, 1993, IMMUNOBIOLOGY, V188, P392, DOI 10.1016/S0171-2985(11)80222-6; VIAC J, 1990, IMMUNOBIOLOGY, V180, P328, DOI 10.1016/S0171-2985(11)80296-2; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Vousden K H, 1990, Semin Cancer Biol, V1, P415; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WERNESS BA, 1991, IMPORTANT ADV ONCOLO, P2; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WILSON WD, 1993, BIOCHEMISTRY-US, V32, P4098, DOI 10.1021/bi00066a035; WRAY SK, 1985, ANTIVIR RES, V5, P29, DOI 10.1016/0166-3542(85)90012-9; YABE Y, 1989, INT J CANCER, V43, P1022, DOI 10.1002/ijc.2910430611; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; YEUDALL WA, 1991, J GEN VIROL, V72, P173, DOI 10.1099/0022-1317-72-1-173; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; ZHOU J, 1993, J GEN VIROL, V74, P763, DOI 10.1099/0022-1317-74-4-763; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245; ZURHAUSEN H, 1977, BEHRING I MITT, V61, P23; 1993, JAMA-J AM MED ASSOC, V270, P2975; 1983, MMWR MORTAL WKLY REP, V32, P306; 1993, MMWR-MORBID MORTAL W, V42, P816	229	47	51	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					368	382		10.7326/0003-4819-123-5-199509010-00008	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00008			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625626				2022-12-28	WOS:A1995RQ98800008
J	ARCHER, JE; VEGA, LR; SOLOMON, F				ARCHER, JE; VEGA, LR; SOLOMON, F			RBL2P, A YEAST PROTEIN THAT BINDS TO BETA-TUBULIN AND PARTICIPATES IN MICROTUBULE FUNCTION IN-VIVO	CELL			English	Article							CONDITIONAL-LETHAL MUTATIONS; SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; ALPHA-TUBULIN; GAMMA-TUBULIN; ASPERGILLUS-NIDULANS; GENETIC-ANALYSIS; MESSENGER-RNAS; ACTIN; INHIBITION	Genetic configurations resulting in high ratios of beta-tubulin to alpha-tubulin are toxic in S. cerevisiae, causing microtubule disassembly and cell death, We identified three non-tubulin yeast genes that, when overexpressed, rescue cells from excess beta-tubulin, One, RBL2, rescues beta-tubulin lethality as efficiently as does alpha-tubulin. Rbl2p binds to beta-tubulin in vivo, Deficiencies or excesses of either Rbl2p or alpha-tubulin affect microtubule-dependent functions in a parallel fashion, Rbl2p has functional homology with murine cofactor A, a protein important for in vitro assays of beta-tubulin folding. The results suggest that Rbl2p participates in microtubule morphogenesis but not in the assembled polymer.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	ARCHER, JE (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		Vega, Leticia/AAF-4981-2021; Vega, Leticia/G-1984-2017	Vega, Leticia/0000-0001-7605-1048; 				ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; ADAMS AEM, 1989, GENETICS, V121, P675; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; FLOOR E, 1970, Journal of Molecular Biology, V47, P293, DOI 10.1016/0022-2836(70)90303-7; FULLER MT, 1987, J CELL BIOL, V104, P385, DOI 10.1083/jcb.104.3.385; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KATZ W, 1990, MOL CELL BIOL, V10, P2730; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; LIU HP, 1992, GENETICS, V132, P665; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PASQUALONE D, 1994, J CELL BIOL, V127, P1973, DOI 10.1083/jcb.127.6.1973; ROUT MP, 1991, COLD SH Q B, V56, P687; SCHATZ PJ, 1988, GENETICS, V120, P681; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SHERMAN F, 1986, LABORATOORY COURSE M; SKOUFIAS DA, 1992, BIOCHEMISTRY-US, V31, P738, DOI 10.1021/bi00118a015; SOLOMON F, 1992, METHODS STUDYING YEA; STERNBERG N, 1976, VIROLOGY, V71, P568, DOI 10.1016/0042-6822(76)90382-2; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WEINSTEIN B, 1992, MOL MICROBIOL, V6, P677, DOI 10.1111/j.1365-2958.1992.tb01515.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	38	76	79	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					425	434		10.1016/0092-8674(95)90431-X	http://dx.doi.org/10.1016/0092-8674(95)90431-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634332	Bronze			2022-12-28	WOS:A1995RP24200012
J	HAJNOCZKY, G; ROBBGASPERS, LD; SEITZ, MB; THOMAS, AP				HAJNOCZKY, G; ROBBGASPERS, LD; SEITZ, MB; THOMAS, AP			DECODING OF CYTOSOLIC CALCIUM OSCILLATIONS IN THE MITOCHONDRIA	CELL			English	Article							MAMMALIAN MITOCHONDRIA; HEPATOCYTES; METABOLISM; CHANNELS; RECEPTOR; CELLS; IONS	Frequency-modulated oscillations of cytosolic Ca2+ ([Ca2+](c)) are believed to be important in signal transduction, but it has been difficult to correlate [Ca2+](c) oscillations directly with the activity of Ca2+-regulated targets. We have studied the control of Ca2+-sensitive mitochondrial dehydrogenases (CSMDHs) by monitoring mitochondrial Ca2+ ([Ca2+](m)) and the redox state of flavoproteins and pyridine nucleotides simultaneously with [Ca2+](c) in single hepatocytes. Oscillations of [Ca2+](c) induced by IP3-dependent hormones were efficiently transmitted to the mitochondria as [Ca2+](m) oscillations. Each [Ca2+](m) spike was sufficient to cause a maximal transient activation of the CSMDHs and [Ca2+](m) oscillations at frequencies above 0.5 per minute caused a sustained activation of mitochondrial metabolism. By contrast, sustained [Ca2+](c) increases yielded only transient CSMDH activation, and slow or partial [Ca2+](c) elevations were ineffective in increasing [Ca2+](m) or stimulating CSMDHs. We conclude that the mitochondria are tuned to oscillating [Ca2+](c) signals, the frequency of which can control the CSMDHs over the full range of potential activities.			HAJNOCZKY, G (corresponding author), THOMAS JEFFERSON UNIV, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA.		Thomas, Andrew/C-6755-2013; Gaspers, Lawrence/W-8766-2019	Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA00180, AA07215] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWER MS, 1994, HEPATOLOGY, V20, P1309, DOI 10.1016/0270-9139(94)90773-0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; DENTON RM, 1980, FEBS LETT, V119, P1, DOI 10.1016/0014-5793(80)80986-0; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HOEK JB, 1995, IN PRESS BIOCH BIOPH; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MIX TCH, 1994, BIOPHYS J, V66, pA97; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NICHOLS BJ, 1994, BIOCHEM J, V303, P461, DOI 10.1042/bj3030461; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; RAPP PE, 1981, J EXP BIOL, V93, P119; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHOLZ R, 1969, J BIOL CHEM, V244, P2317; TAKEI K, 1992, J NEUROSCI, V12, P489; Thomas Andrew P., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P225; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	32	927	945	3	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 11	1995	82	3					415	424		10.1016/0092-8674(95)90430-1	http://dx.doi.org/10.1016/0092-8674(95)90430-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634331	Bronze			2022-12-28	WOS:A1995RP24200011
J	JOSEPH, AM; KNAPP, JM; NICHOL, KL; PIRIE, PL				JOSEPH, AM; KNAPP, JM; NICHOL, KL; PIRIE, PL			DETERMINANTS OF COMPLIANCE WITH A NATIONAL SMOKE-FREE HOSPITAL STANDARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FREE POLICY; UNIT; BAN	Objective.-To determine the extent of compliance with the new Joint Commission on Accreditation of Healthcare Organizations (JCAHO) standard requiring acute care hospitals to be smoke-free, and to identify predictors of adoption of smoke-free hospital policies. Design.-We conducted a survey of a national sample of acute care hospitals and developed a predictive model for implementation of smoke-free policies using multiple logistic regression. We examined numerous factors that might predict adoption of smoke-free policies, such as hospital characteristics, patient care services, and experience with smoke-free initiatives. Setting and Participants.-A systematic 20% sample of JCAHO-accredited hospitals in the United States (n=1278). Military, Department of Veterans Affairs, Indian Health Service, psychiatric, substance abuse treatment, and children's hospitals were excluded. Main Outcome Measure.-Compliance with the JCAHO standard. Results.-The response rate was 85%. Sixty-five percent of hospitals were in compliance with the standard 16 months after it was introduced. Factors that were independently and positively associated with implementation of smoke-free policies were administrative support (odds ratio [OR], 7.82; 95% confidence interval [CI], 2.05 to 29.65) and inpatient smoking cessation services (OR, 1.24; 95% Cl, 1.02 to 1.52). Factors negatively associated with implementation of smoke-free policy were the number of psychiatric treatment beds (OR, 0.57; 95% Ct, 0.41 to 0.81), number of substance abuse treatment beds (OR, 0.17; 95% CI, 0.11 to 0.26), and presence of an active task force to address smoking policy (OR, 0.56; 95% GI, 0.40 to 0.77). Conclusions.-The majority of acute care hospitals are in compliance with the JCAHO national smoke-free policy initiative. The standard is well accepted by most patients and employees. It is critical to address the challenges presented by special populations, such as psychiatry patients, to accomplish the goal of completely smoke-free hospitals.	UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455; MINNESOTA COALIT SMOKE FREE SOC 2000,MINNEAPOLIS,MN	University of Minnesota System; University of Minnesota Twin Cities	JOSEPH, AM (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT 1110,1 VET DR,MINNEAPOLIS,MN 55417, USA.			Joseph, Anne/0000-0002-3440-2679				BAILE WF, 1991, ADDICT BEHAV, V16, P419, DOI 10.1016/0306-4603(91)90050-R; BATTLE E, 1991, BR J ADDICT, V86, P709; BRONAUGH TA, 1990, HOSP COMMUNITY PSYCH, V41, P1303; DAUGHTON DM, 1992, PREV MED, V21, P670, DOI 10.1016/0091-7435(92)90073-Q; Davis L, 1991, AARN News Lett, V47, P20; FIORE MC, 1992, CHEST, V102, P1317, DOI 10.1378/chest.102.5.1317; FISHMAN ML, 1993, J SUBST ABUSE TREAT, V10, P133, DOI 10.1016/0740-5472(93)90037-3; GOLDSMITH JR, 1993, J SUBST ABUSE TREAT, V10, P107; HURT RD, 1989, JAMA-J AM MED ASSOC, V261, P91; JOSEPH AM, 1990, JAMA-J AM MED ASSOC, V263, P3043; JOSEPH AM, 1992, JAMA-J AM MED ASSOC, V267, P87; KALES SN, 1993, CHEST, V104, P1589, DOI 10.1378/chest.104.5.1589; KARAN LD, 1993, J SUBST ABUSE TREAT, V10, P117, DOI 10.1016/0740-5472(93)90035-Z; KNAPP JM, 1989, MINN MED, V72, P713; KNAPP JM, 1991, ARCH INTERN MED, V151, P32, DOI 10.1001/archinte.151.1.32; LONGO DR, 1995, JAMA-J AM MED ASSOC, V274, P488, DOI 10.1001/jama.274.6.488; OFFORD KP, 1992, CHEST, V102, P1531, DOI 10.1378/chest.102.5.1531; RESNICK MP, 1989, HOSP COMMUNITY PSYCH, V40, P525; SMITH WR, 1989, HOSP COMMUNITY PSYCH, V40, P497; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; Thompson J R, 1993, J Ky Med Assoc, V91, P48; WELTY TK, 1987, MMWR-MORBID MORTAL W, V36, P348; 1993, ACCREDITATION MANUAL	23	24	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					491	494		10.1001/jama.274.6.491	http://dx.doi.org/10.1001/jama.274.6.491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629960				2022-12-28	WOS:A1995RM69900031
J	TATEISHI, J; BROWN, P; KITAMOTO, T; HOQUE, ZM; ROOS, R; WOLLMAN, R; CERVENAKOVA, L; GAJDUSEK, DC				TATEISHI, J; BROWN, P; KITAMOTO, T; HOQUE, ZM; ROOS, R; WOLLMAN, R; CERVENAKOVA, L; GAJDUSEK, DC			FIRST EXPERIMENTAL TRANSMISSION OF FATAL FAMILIAL INSOMNIA	NATURE			English	Article							CREUTZFELDT-JAKOB DISEASE; PRION PROTEIN ACCUMULATION; CODON-178; GENE; MICE	ORIGINALLY described by Lugaresi et al, in 1986 (ref. 1), fatal familial insomnia (FFI) is a rare inherited neurological disease characterized by the subacute progression of intractable insomnia and other autonomic abnormalities, cerebellar and pyramidal signs; myoclonus and dementia; neuropathologically, the major feature is severe neuronal loss with associated gliosis in the ventral and mediodorsal thalamic nuclei. The disease has been related to the group of spongiform encephalopathies by virtue of the presence of low levels of proteinase-resistant amyloid protein (PrPres) in the brain(2-4), and of a pathogenic single-allele mutation at codon 178 of the PRNP gene that encodes PrPres (refs 2, 5). Here rye report the successful transmission of the disease to experimental animals, placing FFI within the group of infectious cerebral amyloidoses.	NINCDS,CNS STUDIES LAB,BETHESDA,MD 20892; UNIV CHICAGO,MED CTR,DEPT NEUROL,CHICAGO,IL 60637; UNIV CHICAGO,MED CTR,DEPT PATHOL,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	TATEISHI, J (corresponding author), KYUSHU UNIV,INST NEUROL,DEPT NEUROPATHOL,FUKUOKA 812,JAPAN.							BOSQUE PJ, 1992, NEUROLOGY, V42, P1864, DOI 10.1212/WNL.42.10.1864; BROWN P, 1995, ANN NEUROL, V38, P245, DOI 10.1002/ana.410380218; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; LITTLE BW, 1986, ANN NEUROL, V20, P231, DOI 10.1002/ana.410200209; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; MURAMOTO T, 1992, BRAIN RES, V599, P309, DOI 10.1016/0006-8993(92)90406-Y; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; TATEISHI J, 1981, ACTA NEUROPATHOL, V53, P161, DOI 10.1007/BF00689997	12	110	111	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					434	435		10.1038/376434a0	http://dx.doi.org/10.1038/376434a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630420				2022-12-28	WOS:A1995RM63900054
J	LAND, CE				LAND, CE			STUDIES OF CANCER AND RADIATION-DOSE AMONG ATOMIC-BOMB SURVIVORS - THE EXAMPLE OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IONIZING-RADIATION; MORTALITY; THERAPY; WOMEN; RISK	A comprehensive program of medical follow-up of survivors of the atomic bombings of Hiroshima and Nagasaki, Japan, by the Radiation Effects Research Foundation (RERF) has produced quantitative estimates of cancer risk from exposure to ionizing radiation. For breast cancer in women, in particular, the strength of the radiation dose response and the generally low level of population risk in the absence of radiation exposure have led to a clear description of excess risk and its variation by age at exposure and over time following exposure. Comparisons of RERF data with data from medically irradiated populations have yielded additional information on the influence of population and underlying breast cancer rates on radiation-related risk. Epidemiological investigations of breast cancer cases and matched controls among atomic bomb survivors have clarified the role of reproductive history as a modifier of the carcinogenic effects of radiation exposure. Finally, a pattern of radiation-related risk by attained age among the survivors exposed during childhood or adolescence suggests the possible existence of a radiation-susceptible subgroup. The hypothetical existence of such a group is lent plausibility by the results of recent family studies suggesting that heritable mutations in certain genes are associated with familial aggregations of breast cancer. The recent isolation and cloning of one such gene, BRCA1, makes it likely that the hypothesis can be tested using molecular assays of archival and other tissue obtained from atomic bomb survivor cases and controls.			LAND, CE (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EPN 408,6130 EXECUT BLVD,MS 7362,BETHESDA,MD 20892, USA.							BOICE JD, 1990, RADIAT RES, V125, P214; CLIFTON KH, 1975, J NATL CANCER I, V55, P485; CLIFTON KH, 1978, CANCER RES, V38, P1507; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HANCOCK SL, 1993, J NATL CANCER I, V181, P25; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; LAND CE, 1993, LANCET, V342, P237, DOI 10.1016/0140-6736(93)92324-M; LAND CE, 1980, SCIENCE, V209, P1197, DOI 10.1126/science.7403879; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P157, DOI 10.1007/BF01830262; LAND CE, 1980, J NATL CANCER I, V65, P353; MABUCHI K, 1994, RADIAT RES, V137, P51; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Neel J V, 1991, CHILDREN ATOMIC BOMB; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PUTNAM FW, 1994, PERSPECT BIOL MED, V37, P515; RALL JE, 1985, NIH852748 PUBL; Roesch WC, 1987, US JAPAN JOINT REASS; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SHORE RE, 1986, J NATL CANCER I, V77, P689, DOI 10.1093/jnci/77.3.689; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; THOMPSON DE, 1994, RADIAT RES, V137, P517; TOKUNAGA M, 1987, RADIAT RES, V112, P243, DOI 10.2307/3577254; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; ZIEGLER RG, 1993, J NATL CANCER I, V22, P1819; 1994, SOURCES EFFECTS IONI, P115	33	92	97	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					402	407						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616636				2022-12-28	WOS:A1995RL41600026
J	BALTIMORE, D				BALTIMORE, D			THE ENIGMA OF HIV-INFECTION - OVERVIEW	CELL			English	Editorial Material											BALTIMORE, D (corresponding author), MIT,WHITEHEAD INST,CAMBRIDGE,MA 02139, USA.								0	17	19	2	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					175	176		10.1016/0092-8674(95)90303-8	http://dx.doi.org/10.1016/0092-8674(95)90303-8			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628007	Bronze			2022-12-28	WOS:A1995RL76000003
J	WAGNER, JE; KERNAN, NA; STEINBUCH, M; BROXMEYER, HE; GLUCKMAN, E				WAGNER, JE; KERNAN, NA; STEINBUCH, M; BROXMEYER, HE; GLUCKMAN, E			ALLOGENEIC SIBLING UMBILICAL-CORD-BLOOD TRANSPLANTATION IN CHILDREN WITH MALIGNANT AND NONMALIGNANT DISEASE	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; VERSUS-HOST DISEASE; HEMATOPOIETIC STEM; RISK-FACTORS; APLASTIC-ANEMIA; CELLS; LEUKEMIA; PATIENT; RECONSTITUTION; ENGRAFTMENT	Allogeneic bone marrow transplantation is limited by the availability of suitable marrow donors and risk of graft-versus-host disease (GVHD) and opportunistic infection. In an attempt to ameliorate these limitations, umbilical cord blood has been postulated as an alternative source of allogeneic haemopoietic stem cells for transplantation. From September, 1994, umbilical cord blood from sibling donors has been used to reconstitute haemapoiesis in 44 children with acquired or congenital lympho-haemapoietic disorders, neuroblastoma, or metabolic diseases. Patients who had HLA-identical and HLA-1 antigen disparate grafts, had a probability of engraftment at 50 days after transplantation of 85%. No patient had late graft failure. The probability of grade II-IV GVHD at 100 days was 3% and the probability of chronic GVHD at one year was 6%. With a median follow-up of 1.6 years, the probability of survival for recipients of HLA-identical or HLA-1 antigen disparate grafts is 72%. We conclude that umbilical cord blood is a sufficient source of transplantable haemopoietic stem cells for children with HLA-identical or HLA-1 antigen disparate sibling donors with very low risk of acute or extensive chronic GVHD. The feasibility of umbilical-cord-blood transplantation with HLA-2 and HLA-3 antigen disparate sibling donors remains to be determined.	UNIV MINNESOTA,SCH MED,DIV EPIDEMIOL & CLIN RES,MINNEAPOLIS,MN 55455; MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,BONE MARROW TRANSPLANTAT SERV,NEW YORK,NY 10021; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MICROBIOL,INDIANAPOLIS,IN; INDIANA UNIV,SCH MED,DEPT IMMUNOL,INDIANAPOLIS,IN; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; HOP ST LOUIS,SERV GREFE MOELLE,FEDERAT HEMATOL,PARIS,FRANCE	University of Minnesota System; University of Minnesota Twin Cities; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	WAGNER, JE (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PEDIAT,DIV BONE MARROW TRANSPLANTAT,MINNEAPOLIS,MN 55455, USA.				NATIONAL CANCER INSTITUTE [P01CA021737, P01CA023766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI032918] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA21737, P01-CA23766] Funding Source: Medline; NIAID NIH HHS [P01-AI32918] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; BENSUSSAN A, 1994, P NATL ACAD SCI USA, V91, P9136, DOI 10.1073/pnas.91.19.9136; Bertolini F, 1995, J Hematother, V4, P29, DOI 10.1089/scd.1.1995.4.29; BOGDANIC V, 1993, TRANSPLANTATION, V56, P477; BROXMEYER HE, 1992, P NATL ACAD SCI USA, V89, P4109, DOI 10.1073/pnas.89.9.4109; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; BROXMEYER HE, 1991, BLOOD CELLS, V17, P313; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHANG RS, 1979, LANCET, V2, P201; CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377; DEACOCK SJ, 1992, TRANSPLANTATION, V53, P1128, DOI 10.1097/00007890-199205000-00028; GALE RP, 1987, BRIT J HAEMATOL, V67, P397, DOI 10.1111/j.1365-2141.1987.tb06160.x; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1993, BONE MARROW TRANSPL, V11, P199; HALL J, 1994, BLOOD, V84, pA97; ISSARAGRISIL S, 1995, NEW ENGL J MED, V332, P367, DOI 10.1056/NEJM199502093320605; KALIA A, 1988, TRANSPLANTATION, V46, P70, DOI 10.1097/00007890-198807000-00012; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOHLIKUMAR M, 1993, BRIT J HAEMATOL, V85, P419, DOI 10.1111/j.1365-2141.1993.tb03192.x; LINCH DC, 1989, NATURE, V340, P676, DOI 10.1038/340676a0; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; NATHAN DG, 1989, NEW ENGL J MED, V321, P1190, DOI 10.1056/NEJM198910263211710; PAHWA RN, 1994, P NATL ACAD SCI USA, V91, P4485, DOI 10.1073/pnas.91.10.4485; RISDON G, 1994, CELL IMMUNOL, V154, P14, DOI 10.1006/cimm.1994.1053; RONCAROLO MG, 1994, BLOOD CELLS, V20, P573; RUBINSTEIN P, 1993, BLOOD, V81, P1679; SOCIE G, 1994, BLOOD, V83, P340; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; STORB R, 1983, BRIT J HAEMATOL, V55, P573, DOI 10.1111/j.1365-2141.1983.tb02839.x; THIERRY D, 1992, BONE MARROW TRANSPL, V9, P101; Traineau R, 1993, J Hematother, V2, P231, DOI 10.1089/scd.1.1993.2.231; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; VILMER E, 1992, TRANSPLANTATION, V53, P1155; VOWELS MR, 1993, NEW ENGL J MED, V329, P1623, DOI 10.1056/NEJM199311253292205; Wagner J E, 1992, J Hematother, V1, P167, DOI 10.1089/scd.1.1992.1.167; WAGNER JE, 1992, BLOOD, V79, P1874; WEISDORF D, 1991, TRANSPLANTATION, V51, P1197, DOI 10.1097/00007890-199106000-00010	37	511	524	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					214	219		10.1016/S0140-6736(95)91268-1	http://dx.doi.org/10.1016/S0140-6736(95)91268-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616801				2022-12-28	WOS:A1995RK41900010
J	RILEY, T				RILEY, T			MEDICAID - THE ROLE OF THE STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											RILEY, T (corresponding author), NATL ACAD STATE HLTH POLICY,50 MONUMENT SQ,SUITE 502,PORTLAND,ME 04101, USA.							BLENDON J, 1993, HLTH AFF MILLWOO SPR, V12, P136; BUTLER M, 1993, CHIDLRENS HLTH PLANS; DEAN H, 1994, AUG ANN M NAT AC STA; HORVATH J, 1995, MEDICAID MANAGED CAR; HORVATH J, 1992, INTERGOVERNMENTA SPR, V18, P12; 1993, MEDICAID STATES TURN, P39; 1994, ACCESS CARE IS HLTH; 1994, OVERVIEW ENTITLEMENT, P787; 1994, 1994 EXPENDITURE REP; 1991, 914 PHYS PAYM REV CO, P38; 1993, MEDICAID SOURCE BOOK, P488; 1994, ANN REPORT C, P10	12	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					267	270		10.1001/jama.274.3.267	http://dx.doi.org/10.1001/jama.274.3.267			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609239				2022-12-28	WOS:A1995RH93700036
J	STARK, P				STARK, P			THE POLITICS OF MEDICARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											STARK, P (corresponding author), US HOUSE REPRESENTATIVES,239 CANNON HOUSE OFF BLDG,WASHINGTON,DC 20515, USA.							FREUDENHEIM M, 1995, NY TIMES        0411, pD1; MANN J, 1995, HLTH AFFAIRS     SPR, P263; STARK P, 1995, MEDICARE MONITO 0512, V1; STARK P, 1995, C RECORD        0210; 1995, CONCURRENT RESOLUTIO, P87; 1995, RECENT DEV MEDICARE, P2; 1995, MEDICARE FACT SHEET; 1994, COMMITTEE WAYS MEANS; 1994, TV GUIDE        1022, V42; 1995, HOUSE REPUBLICAN BUD, P13; 1965, 89TH C C Q SERV, V21, P252; 1994, HMO IND PROFILE 1994; 1994, ANN REPORT C 1994, P445; 1995, AARP PUBLIC POLICY A, P147; 1995, MEDICARE AM HLTH CAR, P79	15	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					274	276		10.1001/jama.274.3.274	http://dx.doi.org/10.1001/jama.274.3.274			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609241				2022-12-28	WOS:A1995RH93700038
J	DAVENPORT, RJ; STARKEY, IR; RUCKLEY, CV; DENNIS, MS; SANDERCOCK, PAG; WARLOW, CP				DAVENPORT, RJ; STARKEY, IR; RUCKLEY, CV; DENNIS, MS; SANDERCOCK, PAG; WARLOW, CP			A DIFFICULT CASE - HOW SHOULD A PATIENT PRESENTING WITH UNSTABLE ANGINA AND A RECENT STROKE BE MANAGED - CASE-REPORT	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL EDINBURGH INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	DAVENPORT, RJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135					0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1449	1449		10.1136/bmj.310.6992.1449a	http://dx.doi.org/10.1136/bmj.310.6992.1449a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613280	Green Published			2022-12-28	WOS:A1995RC10500022
J	HOPE, T; LOCKWOOD, G; LOCKWOOD, M				HOPE, T; LOCKWOOD, G; LOCKWOOD, M			AN ETHICAL DEBATE - SHOULD OLDER WOMEN BE OFFERED IN-VITRO FERTILIZATION - THE INTERESTS OF THE POTENTIAL CHILD	BRITISH MEDICAL JOURNAL			English	Article								In most discussions of the ethics of fertility treatment it is claimed that the interests of the potential child are of major if not paramount importance. The practical significance of this consideration has been grossly grossly overestimated. Contrary to conventional wisdom, the interests of the potential child hardly ever constitute an adequate reason for withholding fertility treatment.	UNIV OXFORD,GREEN COLL,OXFORD,ENGLAND	University of Oxford	HOPE, T (corresponding author), JOHN RADCLIFFE HOSP,SCH MED,OXFORD OX3 9DU,ENGLAND.			bewley, susan/0000-0001-8064-652X				LAURANCE J, 1994, TIMES           0103; MIHILL C, 1993, GUARDIAN        0720	2	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1455	1456		10.1136/bmj.310.6992.1455	http://dx.doi.org/10.1136/bmj.310.6992.1455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RC105	7613283	Green Published			2022-12-28	WOS:A1995RC10500029
J	LAROSA, JC				LAROSA, JC			HAS HRT COME OF AGE	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; HORMONE-THERAPY; DISEASE				LAROSA, JC (corresponding author), TULANE UNIV,MED CTR,NEW ORLEANS,LA, USA.							BAR J, 1993, OBSTET GYNECOL, V81, P261; CLARKSON RB, 1994, DRUGS S2, V47, P42; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KUSHWAHA RS, 1992, CURR OPIN LIPIDOL, V3, P167; MENDOZA S, 1994, J LAB CLIN MED, V123, P837; SPAGNOLI LG, 1980, ATHEROSCLEROSIS, V82, P27; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; VANDERMOOREN MJ, 1994, METABOLISM, V43, P799, DOI 10.1016/0026-0495(94)90256-9; WAGNER JD, 1992, ARTERIOSCLER THROMB, V12, P717, DOI 10.1161/01.ATV.12.6.717; WHITCROFT SI, 1994, OBSTET GYNECOL, V84, P222; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; 1985, VITAL STATISTICS US, V2, P258	15	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					76	77		10.1016/S0140-6736(95)90056-X	http://dx.doi.org/10.1016/S0140-6736(95)90056-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7632206				2022-12-28	WOS:A1995QB80400003
J	KEUNEN, JEE; ROTHOVA, A				KEUNEN, JEE; ROTHOVA, A			CYTOMEGALOVIRUS RETINITIS IN AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											KEUNEN, JEE (corresponding author), ACAD ZIEKEHUIS UTRECHT,3584 CX UTRECHT,NETHERLANDS.		Keunen, J.E.E./H-8061-2014						0	1	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					637	637		10.1056/NEJM199509073331006	http://dx.doi.org/10.1056/NEJM199509073331006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637725				2022-12-28	WOS:A1995RR84000006
J	KOCK, HJ; SCHMITNEUERBURG, KP; HANKE, J; RUDOFSKY, G; HIRCHE, H				KOCK, HJ; SCHMITNEUERBURG, KP; HANKE, J; RUDOFSKY, G; HIRCHE, H			THROMBOPROPHYLAXIS WITH LOW-MOLECULAR-WEIGHT HEPARIN IN OUTPATIENTS WITH PLASTER-CAST IMMOBILIZATION OF THE LEG	LANCET			English	Article							THROMBOEMBOLISM PROPHYLAXIS; THROMBOSIS-PROPHYLAXIS; SURGERY	Deep-vein thrombosis is common after plaster-cast immobilisation for traumatic injury. We did a randomised prospective study of the effect of low-molecular-weight heparin on the incidence of deep-vein thrombosis in patients with minor injuries treated with plaster-cast immobilisation of the leg. A control group (n=163) received no prophylaxis, the prophylaxis group received low-molecular-weight heparin once daily (n=176). The incidence of deep-vein thrombosis in the prophylaxis group was 0% (one tailed p<0.006) vs 4.3% in the control group. No severe side-effects of low-molecular-weight heparin were observed. Thromboprophylaxis with low-molecular-weight heparin once dairy is effective in reducing the risk of deep-vein thrombosis in outpatients with plaster-cast immobilisation of the leg.	UNIV HOSP ESSEN,INST MED INFORMAT,D-45122 ESSEN,GERMANY; UNIV HOSP ESSEN,ANGIOL UNIT,D-45122 ESSEN,GERMANY	University of Duisburg Essen; University of Duisburg Essen	KOCK, HJ (corresponding author), UNIV HOSP ESSEN,DEPT TRAUMA SURG,HUFELANDSTR 55,D-45122 ESSEN,GERMANY.							BARROWCLIFFE TW, 1992, LOW MOL WEIGHT HEPAR, P125; Bauer G, 1944, ACTA CHIR SCAND, V90, P229; BERGQUIST D, 1983, POSTOPERATIVE THROMB; ENCKE A, 1992, CHIRURG, V63, P264; HAAS S, 1992, CHIRURG, V63, P271; Haas S, 1989, HAEMOSTASIOLOGIE, V9, P237; HABSCHEID W, 1991, BILDGEBENDE SONOGRAP; HJELMSTEDT A, 1968, ACTA CHIR SCAND, V134, P209; Kakkar VV, 1994, HAEMOSTASIS THROMBOS, P1361; KANNUS P, 1991, J BONE JOINT SURG AM, V73A, P305, DOI 10.2106/00004623-199173020-00021; KIKRA MJ, 1993, SURGERY, V114, P705; KOCK HJ, 1993, CHIRURG, V64, P483; KUJATH P, 1992, DEUT MED WOCHENSCHR, V117, P6, DOI 10.1055/s-2008-1062272; NICOLAIDES AN, 1971, BRIT J RADIOL, V44, P653, DOI 10.1259/0007-1285-44-525-653; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PRINS MH, 1994, HAEMOSTASIS THROMBOS, P1381; SPANNAGEL U, 1993, SEMIN THROMB HEMOST, V19, P131; SPIELER U, 1972, SCHWEIZ MED WSCHR, V102, P1535; Thomas D, 1994, HAEMOSTASIS THROMBOS, P1335; ZAGRODNIK J, 1990, UNFALLCHIRURG, V92, P331; 1990, CHIRURG, V63, P853; 1992, INT ANGIOL, V11, P151	22	140	145	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					459	461		10.1016/S0140-6736(95)91320-3	http://dx.doi.org/10.1016/S0140-6736(95)91320-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637478	Bronze			2022-12-28	WOS:A1995RP85700008
J	LONDON, NJ; FARMERY, SM; WILL, EJ; DAVISON, AM; LODGE, JPA				LONDON, NJ; FARMERY, SM; WILL, EJ; DAVISON, AM; LODGE, JPA			RISK OF NEOPLASIA IN RENAL-TRANSPLANT PATIENTS	LANCET			English	Article							MALIGNANT-TUMORS; RECIPIENTS; CANCER; CYCLOSPORINE; FAILURE	Renal allograft recipients are at an increased risk of neoplasia, although the extent of the problem has not been established in a typical European transplant population. To assess this risk we did a comprehensive, retrospective study of 918 patients transplanted at one centre over 24 years. The centre (Leeds) serves Yorkshire and Humberside, a region in northern England with a population of 3.6 million. The search, which made use of six sources of information, revealed 70 patients (7.6%) who had developed a neoplastic lesion, 10 patients having more than one type. More than half (42) were cutaneous lesions (mostly squamous cell carcinomas). The risk of developing neoplasia in the first 10 years after transplantation was calculated to be 14%. By 20 years this had risen to 40% compared with a 6% cumulative risk of neoplasia in an age-matched control population (p<0.005). The full extent of this problem in the European transplant population has been underestimated and, now that recipients are surviving longer, there is a clear need for both lifelong surveillance and closer investigation of these patients.	ST JAMES UNIV HOSP, ACAD SURG UNIT, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; ST JAMES UNIV HOSP, DEPT RENAL MED, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND	Saint James's University Hospital; Saint James's University Hospital								ARMITAGE P, 1971, STATISTICAL METHODS, P414; BIRKELAND SA, 1983, CANCER, V51, P1571, DOI 10.1002/1097-0142(19830501)51:9<1571::AID-CNCR2820510903>3.0.CO;2-S; BLOHME I, 1984, TRANSPLANTATION, V37, P165, DOI 10.1097/00007890-198402000-00010; BROYER M, 1985, P EUR DIAL TRANS, V21, P2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIDDINGTON M, 1989, BRIT J SURG, V76, P1002, DOI 10.1002/bjs.1800761005; LONDON NJ, 1994, THESIS U CAMBRIDGE C; MATAS AJ, 1975, LANCET, V1, P883; PECQUEUX JC, 1990, UROL INT, V45, P290, DOI 10.1159/000281722; PENN I, 1991, TRANSPLANT P, V23, P1101; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; PENN I, 1994, TRANSPLANT P, V26, P1; PENN I, 1969, TRANSPLANT P, V1, P106; SHEIL AGR, 1977, TRANSPLANT P, V9, P1133; SHEIL AGR, 1993, TRANSPLANT P, V25, P1383; VILARDELL J, 1992, TRANSPLANT P, V24, P1948; WALZ MK, 1992, DTS MED WSCHR, V119, P927	17	297	307	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					403	406		10.1016/S0140-6736(95)92780-8	http://dx.doi.org/10.1016/S0140-6736(95)92780-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623570				2022-12-28	WOS:A1995RN65600009
J	ROTMAN, M; PAJAK, TF; CHOI, K; CLERY, M; MARCIAL, V; GRIGSBY, PW; COOPER, J; JOHN, M				ROTMAN, M; PAJAK, TF; CHOI, K; CLERY, M; MARCIAL, V; GRIGSBY, PW; COOPER, J; JOHN, M			PROPHYLACTIC EXTENDED-FIELD IRRADIATION OF PARAAORTIC LYMPH-NODES IN STAGE-IIB AND BULKY STAGE-IB AND STAGE-IIA CERVICAL CARCINOMAS - 10-YEAR TREATMENT RESULTS OF RTOG-79-20	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To investigate whether irradiation to the standard pelvic field only improves the response rate and survival in comparison with pelvic plus para-aortic irradiation in patients with high-risk cervical carcinoma, and to investigate patterns of failure and treatment-related toxicity. Design.-Randomized controlled trial from November 1979 to October 1986, with stratification by histology, para-aortic nodal status, and International Federation of Gynecology and Obstetrics (FIGO) stage. Setting.-Radiation Therapy Oncology Group (RTOG) multicenter clinical trial. Patients.-A total of 367 patients with FIGO stage IB or IIA primary cervical cancers measuring 4 cm or greater in lateral diameter or with FIGO stage IIB cervical cancers were randomized to RTOG protocol 79-20 to receive either standard pelvic only irradiation or pelvic plus para-aortic irradiation. Intervention.-Pelvic only irradiation consisted of a midplane pelvic dose of 40 to 50 Gy in 4.5 to 6.5 weeks with daily fractions of 1.6 to 1.8 Gy for 5 d/wk. Pelvic plus para-aortic irradiation delivered 44 to 45 Gy in 4.5 to 6.5 weeks with daily fractions of 1.6 to 1.8 Gy for 5 d/wk. A total dose of 4000 to 5000 mg/h of radium equivalent or 30 to 40 Gy was provided by intracavitary brachytherapy to point A. Main Outcome Measures.-Response rate, overall and disease-free survival, patterns of failure, and treatment-related toxicities. Results.-Ten-year overall survival was 44% for the pelvic only irradiation arm and 55% for the pelvic plus para-aortic irradiation arm (P=.02). Cumulative incidence of death due to cervical cancer was estimated as significantly higher in the pelvic only arm at 10 years (P=.01). Disease-free survival was similar in both arms; 40% for the pelvic only arm and 42% for the pelvic plus para-aortic arm. Locoregional failures were similar at 10 years for both arms (pelvic only, 35%; pelvic plus para-aortic, 31%; P=.44). In complete responders, the patterns of locoregional failures were the same for both arms, but there was a lower cumulative incidence for first distant failure in the pelvic plus para-aortic irradiation arm (P=.053). Survival following first failure was significantly higher in the pelvic plus para-aortic arm (P=.007). A higher percentage of local failures were salvaged long-term on the pelvic plus para-aortic arm compared with the pelvic only arm (25% vs 8%). The cumulative incidence of grade 4 and 5 toxicities at 10 years in the pelvic plus para-aortic arm was 8%, compared with 4% in the pelvic only arm (P=.06). The death rate due to radiotherapy complications was higher in the pelvic plus para-aortic arm (four [2%] of 170) compared with the pelvic only arm (one [1%] of 167) (P=.38). The proportion of deaths due to radiotherapy complications in the pelvic plus para-aortic arm was higher than in the pelvic only arm (four [6%] of 67 vs one [1%] of 85; P=.24). If the patient had abdominal surgery prior to para-aortic irradiation, the estimated cumulative incidence of grade 4 and 5 complications was 11%, compared with 2% in the pelvic only arm. Conclusions.-The statistically significant difference in overall survival at 10 years for the pelvic plus para-aortic irradiation arm, without a difference in disease-free survival, can be explained by the following two factors: (1) a lower incidence of distant failure in complete responders and (2) a better salvage in the complete responders who later failed locally.	RADIAT THERAPY ONCOL GRP HEADQUARTERS, PHILADELPHIA, PA USA; RADIAT ONCOL CTR, SAN JUAN, PR USA; WASHINGTON UNIV, MALLINCKRODT INST RADIOL, ST LOUIS, MO 63110 USA; NYU, TISCH HOSP, NEW YORK, NY USA; KAWEAH DELTA CANC CARE CTR, VISALIA, CA USA	Radiation Therapy Oncology Group (RTOG); Washington University (WUSTL); New York University	ROTMAN, M (corresponding author), SUNY HLTH SCI CTR, DEPT RADIAT ONCOL, 450 CLARKSON AVE, BOX 1211, BROOKLYN, NY 11203 USA.				NATIONAL CANCER INSTITUTE [U10CA021661, U10CA032115] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COX DR, 1972, J R STAT SOC B, V34, P187; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; GRISBY PW, 1984, INT J RADIAT ONCOL, V28, P451; HAIE C, 1988, RADIOTHER ONCOL, V11, P101, DOI 10.1016/0167-8140(88)90245-9; JAMPOLIS S, 1975, RADIOLOGY, V115, P681, DOI 10.1148/15.3.681; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PAUNIER JP, 1967, RADIOLOGY, V88, P555, DOI 10.1148/88.3.555; ROTMAN M, 1979, INT J RADIAT ONCOL, V5, P2139, DOI 10.1016/0360-3016(79)90972-6; ROTMAN M, 1978, INT J RADIAT ONCOL, V4, P795, DOI 10.1016/0360-3016(78)90038-X; ROTMAN M, 1990, INT J RADIAT ONCOL, V19, P513, DOI 10.1016/0360-3016(90)90475-Y; ROTMAN M, 1981, CANCER-AM CANCER SOC, V48, P560, DOI 10.1002/1097-0142(19810715)48:1+<560::AID-CNCR2820481320>3.0.CO;2-T; ROTMAN M, 1994, SEMIN RADIAT ONCOL, V1, P23; RUTLEDGE FN, 1958, AM J OBSTET GYNECOL, V76, P321, DOI 10.1016/0002-9378(58)90221-7; SOTTO LSJ, 1960, AM J OBSTET GYNECOL, V80, P791, DOI 10.1016/0002-9378(60)90591-3; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	20	276	284	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					387	393		10.1001/jama.274.5.387	http://dx.doi.org/10.1001/jama.274.5.387			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616634				2022-12-28	WOS:A1995RL41600024
J	JONES, JK; GORKIN, L; LIAN, JF; STAFFA, JA; FLETCHER, AP				JONES, JK; GORKIN, L; LIAN, JF; STAFFA, JA; FLETCHER, AP			DISCONTINUATION OF AND CHANGES IN TREATMENT AFTER START OF NEW COURSES OF ANTIHYPERTENSIVE DRUGS - A STUDY OF A UNITED-KINGDOM POPULATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; HYPERTENSION	Objective-To evaluate the incidence of discontinuation of and changes in treatment after newly prescribed courses of antihypertensive drugs of the four primary therapeutic classes: beta blocker, calcium channel blocker, and angiotensin converting enzyme inhibitor. Design-A retrospective analysis of patients on an automated database of 1.2 million patients was conducted on visits between 1 October 1992 and 30 September 1993. Setting-General practices in the United Kingdom. Subjects-37 643 patients with hypertension receiving a relevant drug in the time period were identified. A new course of treatment in at least one of the four therapeutic classes, defined as a drug not prescribed in the previous four months, was observed in 10 222 patients aged greater than or equal to 40 years. Main outcome measures-Patients changing to other treatment or discontinuing after initiating a new course of treatment, defined as the absence of a refill prescription for the new drug or another in its category within a six month observation period. Results-Changes in or discontinuation of treatment were frequently observed, and by month six continuation rates ranged between 40% to 50% for all four classes of drugs. Conclusion-Low rates of continuation with a newly prescribed antihypertensive drug exist regardless of which drug is prescribed.	IMS INT, LONDON, ENGLAND		JONES, JK (corresponding author), DEGGE GRP, 1616 N FT MYER DR, SUITE 1430, ARLINGTON, VA 22209 USA.							[Anonymous], 1991, JAMA, V265, P3255; BLACK DM, 1987, J GERONTOL, V42, P552, DOI 10.1093/geronj/42.5.552; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAVIS CE, 1990, HDB HLTH BEHAVIOR CH; GORKIN L, 1990, HDB HLTH BEHAVIOR CH; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; MARONDE RF, 1989, MED CARE, V27, P1159, DOI 10.1097/00005650-198912000-00007; MCCOMBS JS, 1994, MED CARE, V32, P214, DOI 10.1097/00005650-199403000-00003; MOSS AJ, 1989, CIRCULATION, V80, P102; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; SHULMAN N, 1982, CONTROL CLIN TRIALS, V3, P13, DOI 10.1016/0197-2456(82)90016-2; SWALES JD, 1994, LANCET, V344, P380; 1979, JAMA-J AM MED ASSOC, V22, P2562	15	226	231	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 29	1995	311	7000					293	295		10.1136/bmj.311.7000.293	http://dx.doi.org/10.1136/bmj.311.7000.293			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633238	Green Published			2022-12-28	WOS:A1995RM71900026
J	DHAWAN, S				DHAWAN, S			BIRTH WEIGHTS OF INFANTS OFF FIRST GENERATION ASIAN WOMEN IN BRITAIN COMPARED WITH 2ND GENERATION ASIAN WOMEN	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To compare birth weights of infants of first generation Asian women (women born in the Indian subcontinent) with those of infants of second generation Asian women (born in the United Kingdom). Design-Retrospective case note study. Setting-Bolton District General Hospital. Subjects-331 Asian women who gave birth between January 1989 and December 1989: 220 of these women were first generation Asians and 111 were second generation Asians. Main outcome measure-Birth weights of babies born to first and second generation Asian women. Results-At all gestational ages at delivery, babies born to second generation Asian women were heavier than those born to first generation women. The mean birth weight for babies of second generation women was 3196 g, 249 g more than the mean birth weight of 2946 g of babies of first generation women (P<0.001). After a stepwise multiple regression analysis was carried out the adjusted difference in birth weights was 280 g, greater than the crude difference. Conclusion-Birth weights are important in relation to perinatal mortality, which is notoriously high among Asians. The results of this study indicate that there is hope for lowering of perinatal mortality and improving postnatal growth in babies of second generation Asians.			DHAWAN, S (corresponding author), HULL MATERN HOSP,KINGSTON HULL HU9 5LX,N HUMBERSIDE,ENGLAND.							AITKIN M, 1978, J ROY STAT SOC A STA, V141, P195, DOI 10.2307/2344453; BHARGAVA SK, 1986, ANN TROP PAEDIATR, V6, P225, DOI 10.1080/02724936.1986.11748446; BROOKE OG, 1980, J HUM NUTR, V34, P355; CAMPBELLBROWN M, 1983, J OBSTET GYNAECOL, V4, P2, DOI 10.3109/01443618309071212; DAVIES DP, 1982, EARLY HUM DEV, V6, P257, DOI 10.1016/0378-3782(82)90119-0; DAWSON I, 1982, BRIT J OBSTET GYNAEC, V89, P896, DOI 10.1111/j.1471-0528.1982.tb05053.x; TERRY PB, 1980, BRIT MED J, V281, P1307, DOI 10.1136/bmj.281.6251.1307; TUCK SM, 1983, BRIT J OBSTET GYNAEC, V90, P892, DOI 10.1111/j.1471-0528.1983.tb06759.x; 1989, BIRTHS ENGLAND WALES	9	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					86	88		10.1136/bmj.311.6997.86	http://dx.doi.org/10.1136/bmj.311.6997.86			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613407	Green Published			2022-12-28	WOS:A1995RJ03000019
J	GOWDA, R; RAZVI, FM; SUMMERFIELD, GP				GOWDA, R; RAZVI, FM; SUMMERFIELD, GP			RISK OF PNEUMOCOCCAL SEPTICEMIA IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE MALIGNANCIES	BRITISH MEDICAL JOURNAL			English	Article									MIDDLESBROUGH GEN HOSP,DEPT HAEMATOL,MIDDLESBROUGH TS5 5AZ,CLEVELAND,ENGLAND									CONE L, 1964, J CLIN INVEST, V43, P2241, DOI 10.1172/JCI105098; FRIEDEN TR, 1990, JAMA-J AM MED ASSOC, V264, P1438, DOI 10.1001/jama.264.11.1438; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069; IN PRESS GUIDELINES; 1988, NEW ENGL J MED, V319, P902	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					26	27		10.1136/bmj.311.6996.26	http://dx.doi.org/10.1136/bmj.311.6996.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613318	Green Published			2022-12-28	WOS:A1995RG97500021
J	FARRINGTON, P; PUGH, S; COLVILLE, A; FLOWER, A; NASH, J; MORGANCAPNER, P; RUSH, M; MILLER, E				FARRINGTON, P; PUGH, S; COLVILLE, A; FLOWER, A; NASH, J; MORGANCAPNER, P; RUSH, M; MILLER, E			A NEW METHOD FOR ACTIVE SURVEILLANCE OF ADVERSE EVENTS FROM DIPHTHERIA-TETANUS-PERTUSSIS AND MEASLES MUMPS RUBELLA VACCINES	LANCET			English	Article							IMMUNIZATION; RISK; VACCINATION; CHILDREN; SEIZURES	We describe a new method for active post-marketing surveillance of vaccine safety based on patient records. We studied the association between diphtheria/tetanus/pertussis (DTP) vaccination and febrile convulsion, and between measles/mumps/rubella (MMR) vaccination and febrile convulsion and idiopathic thrombocytopenic purpura (ITP) in five district health authorities in England by linking vaccination records with computerised hospital admission records. We found an increased relative incidence for convulsions 0-3 days after DTP vaccination. The effect was limited to the third dose of vaccine for which the attributable risk (all ages) was 1 in 12 500 doses. Completion of vaccination by 4 months instead of 10 months after the change in the UK to an accelerated immunisation schedule may have resulted in a 4-fold decrease in febrile convulsions attributable to DTP vaccine. 67% of admissions for a convulsion 6-11 days after MMR vaccination were attributable to the measles component of the vaccine (risk 1 in 3000 doses). An excess of admissions for a convulsion 15-35 days after MMR vaccination was found only for vaccines containing the Urabe mumps strain (1 in 2600 Urabe doses). There was a causal association between MMR vaccination and ITP resulting in admission 15-35 days subsequently; there was no evidence of a mumps strain-specific effect. The estimated absolute risk of 1 in 24 000 doses was 5 times that calculated from cases passively reported by clinicians. This finding emphasises the need for active surveillance of adverse events. The record linkage method that we used is an effective way to identify vaccine-attributable adverse events.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,STAT UNIT,LONDON NW9 5EQ,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,PUBL HLTH LAB,NOTTINGHAM NG7 2UH,ENGLAND; LEICESTER ROYAL INFIRM,PUBL HLTH LAB,LEICESTER,LEICS,ENGLAND; WILLIAM HARVEY HOSP,PUBL HLTH LAB,ASHFORD,KENT,ENGLAND; ROYAL PRESTON HOSP,PUBL HLTH LAB,PRESTON,LANCS,ENGLAND	Public Health England; Public Health England; University of Nottingham; University of Leicester; Royal Preston Hospital				Farrington, Conor Patrick/0000-0002-7148-2612				BEGG NT, 1989, PUBLIC HEALTH, V103, P81, DOI 10.1016/S0033-3506(89)80021-6; FARRINGTON CP, IN PRESS BIOMETRICS; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GRIFFIN MR, 1990, JAMA-J AM MED ASSOC, V263, P1641, DOI 10.1001/jama.263.12.1641; GRIFFIN MR, 1991, PEDIATRICS, V88, P881; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; MILLER E, 1993, LANCET, V341, P979, DOI 10.1016/0140-6736(93)91069-X; NEIMINEN U, 1993, ACTA PAEDIATR, V82, P267; POLLOCK TM, 1983, LANCET, V1, P753; SCHMITT HJ, 1993, EUR J PEDIATR, V152, P387, DOI 10.1007/BF01955892; WEIRSBITZKY S, 1993, LANCET, V341, P379	11	240	243	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					567	569		10.1016/S0140-6736(95)90471-9	http://dx.doi.org/10.1016/S0140-6736(95)90471-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7619183	Bronze			2022-12-28	WOS:A1995QK44400016
J	KONSTANTINIDES, S				KONSTANTINIDES, S			A COMPARISON OF SURGICAL AND MEDICAL THERAPY FOR ATRIAL SEPTAL-DEFECT IN ADULTS	HERZ KREISLAUF			German	Article														Konstantinides, Stavros/0000-0001-6359-7279					0	6	10	0	1	RICHARD PFLAUM VERLAG  GMBH & CO KG	MUNICH	PO BOX BOX 19 07 37, 80607 MUNICH, GERMANY	0046-7324			HERZ KREISLAUF	Herz Kreislauf	NOV	1995	27	11					354	354						1	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	TG645	7623878				2022-12-28	WOS:A1995TG64500001
J	GIOVANNUCCI, E; EGAN, KM; HUNTER, DJ; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; SPEIZER, FE				GIOVANNUCCI, E; EGAN, KM; HUNTER, DJ; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; SPEIZER, FE			ASPIRIN AND THE RISK OF COLORECTAL-CANCER IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; LARGE-BOWEL; INDOMETHACIN TREATMENT; COLON CARCINOGENESIS; INTESTINAL TUMORS; REDUCED RISK; ADENOMAS; POLYPS; RATS	Background. Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists. The effects of the dose and the duration of aspirin consumption on the risk of colorectal cancer are not well understood. Methods. We determined rates of colorectal cancer according to the number of consecutive years of regular aspirin use (defined as two or more tablets per week) among women in the Nurses' Health Study who reported regular aspirin use on three consecutive questionnaires (1980, 1982, and 1984) and compared the rates in this group with the rates among women who said they did not use aspirin. Cases of cancer occurring from 1984 through 1992 (the eight years after the 1984 questionnaire) were included. Results. From 1984 through 1992, we documented 331 new cases of colorectal cancer during 551,651 person-years of follow-up. Women who consistently took two or more aspirin tablets per week had no appreciable reduction in the risk of colorectal cancer as compared with nonusers after four years (relative risk, 1.06; 95 percent confidence interval, 0.78 to 1.45) or after five to nine years (relative risk, 0.84; 95 percent confidence interval, 0.55 to 1.28). There was a slight reduction in risk among women who took aspirin for 10 to 19 years, but it was not statistically significant (relative risk, 0.70; 95 percent confidence interval, 0.41 to 1.20). However, there was a statistically significant reduction after 20 years of consistent use of aspirin (relative risk, 0.56; 95 percent confidence interval, 0.36 to 0.90; P for trend=0.008). The maximal reduction in risk was observed among women who took four to six tablets per week; higher doses had a similar apparent benefit. Controlling for risk factors for colorectal cancer, including diet, did not change the results, and the earlier diagnosis and removal of colorectal adenomas among aspirin users did not account for the results. Conclusions. Regular aspirin use, at doses similar to those recommended for the prevention of cardiovascular disease, substantially reduces the risk of colorectal cancer. However, this benefit may not be evident until after at least a decade of regular aspirin consumption.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	GIOVANNUCCI, E (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075, R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOMALASKI JS, 1986, BIOCHEM BIOPH RES CO, V139, P115, DOI 10.1016/S0006-291X(86)80087-0; CRAVEN PA, 1992, CARCINOGENESIS, V13, P541, DOI 10.1093/carcin/13.4.541; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HEATH CW, 1994, CANCER-AM CANCER SOC, V74, P2885, DOI 10.1002/1097-0142(19941115)74:10<2885::AID-CNCR2820741023>3.0.CO;2-P; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LAAKSO M, 1986, J RHEUMATOL, V13, P522; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MARNETT LJ, 1992, CANCER RES, V52, P5575; MERETO E, 1994, CANCER LETT, V76, P5, DOI 10.1016/0304-3835(94)90127-9; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NARISAWA T, 1981, CANCER RES, V41, P1954; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; PINCZOWSKI D, 1994, GASTROENTEROLOGY, V107, P117, DOI 10.1016/0016-5085(94)90068-X; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; POWIS G, 1994, EUR J CANCER, V30A, P1138, DOI 10.1016/0959-8049(94)90473-1; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; REDDY BS, 1987, CANCER RES, V47, P5340; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Ruffin M. T., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P600; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; TRUJILLO MA, 1994, DIGEST DIS SCI, V39, P2260; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105	42	879	914	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					609	614		10.1056/NEJM199509073331001	http://dx.doi.org/10.1056/NEJM199509073331001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637720	Bronze			2022-12-28	WOS:A1995RR84000001
J	DALESSANDRO, U; LEACH, A; DRAKELEY, CJ; BENNETT, S; OLALEYE, BO; FEGAN, GW; JAWARA, M; LANGEROCK, P; GEORGE, MO; TARGETT, GAT; GREENWOOD, BM				DALESSANDRO, U; LEACH, A; DRAKELEY, CJ; BENNETT, S; OLALEYE, BO; FEGAN, GW; JAWARA, M; LANGEROCK, P; GEORGE, MO; TARGETT, GAT; GREENWOOD, BM			EFFICACY TRIAL OF MALARIA VACCINE SPF66 IN GAMBIAN INFANTS	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; SYNTHETIC VACCINE; IMMUNE-RESPONSE; WEST-AFRICA; RURAL AREA; IMMUNOGENICITY; CHILDREN; SAFETY; MOSQUITOS; CULICIDAE	SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-erythrocytic and asexual brood-stage proteins of Plasmodium falciparum, SPf66 was found to have a 31% protective efficacy in an area of intensive malaria transmission in Tanzanian chiIdren, 1-5 years old. We report a randomised, double-blind, placebo-controlled trial of SPf66 against clinical P falciparum malaria in Gambian infants. 630 children, aged 6-11 months at time of the first dose, received three doses of SPf66 or injected polio Vaccine (IPV). Morbidity was monitored during the following rainy season by means of active and passive case detection. Cross-sectional surveys were carried out at the beginning and at the end of the rainy season. An episode of clinical malaria was defined as fever (greater than or equal to 37.5 degrees C) and a parasite density of 6000/mu L or more. Analysis of efficacy was done on 547 children (316 SPf66/231 IPV). No differences in mortality or in health centre admissions were found between the two groups of children. 347 clinical episodes of malaria were detected during the three acid a half months of surveillance. SPf66 vaccine was associated with a protective efficacy against the first or only clinical episode of 8% (95% CI -18 to 29, p=0.50) and against the overall incidence of clinical episodes of malaria of 3% (95% CI -24 to 24, p=0.81). No significant differences in parasite rates or in any other index of malaria were found between the two groups of children. The findings of this study differ from previous reports on SPf66 efficacy from South America and from Tanzania. In The Gambia, protection against clinical attacks of malaria during the rainy season after immunisation in children 6-11 months old at time of the first dose was not achieved.	MRC LABS,BANJUL,GAMBIA; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; MINIST HLTH & SOCIAL WELF,BANJUL,GAMBIA	MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine	DALESSANDRO, U (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Fegan, Greg W/O-8079-2018; Leach, Amanda/AAS-1120-2020; D'Alessandro, Umberto/D-3457-2015	Fegan, Greg W/0000-0002-2663-2765; Leach, Amanda/0000-0002-7114-9967; D'Alessandro, Umberto/0000-0001-6341-5009				ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; AMADOR R, 1992, VACCINE, V10, P179, DOI 10.1016/0264-410X(92)90009-9; AMADOR R, 1992, J INFECT DIS, V166, P139, DOI 10.1093/infdis/166.1.139; ARMSTRONGSCHELL.JR, 1994, PARASITOL TODAY, V10, P439; BURKOT TR, 1981, AM J TROP MED HYG, V30, P1336, DOI 10.4269/ajtmh.1981.30.1336; COOPER JA, 1993, PARASITOL TODAY, V9, P50, DOI 10.1016/0169-4758(93)90031-A; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q; GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P595, DOI 10.1016/0035-9203(89)90364-7; LEACH A, 1995, PARASITE IMMUNOL, V17, P441, DOI 10.1111/j.1365-3024.1995.tb00912.x; LOPEZ MC, 1994, VACCINE, V12, P585, DOI 10.1016/0264-410X(94)90261-5; MURILLO LA, 1992, PARASITE IMMUNOL, V14, P87, DOI 10.1111/j.1365-3024.1992.tb00008.x; NOYA O, 1994, J INFECT DIS, V170, P396, DOI 10.1093/infdis/170.2.396; PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8; PATARROYO ME, 1991, PARASITE IMMUNOL, V13, P509, DOI 10.1111/j.1365-3024.1991.tb00547.x; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; PORT GR, 1980, B ENTOMOL RES, V70, P133, DOI 10.1017/S0007485300009834; RILEY EM, 1991, PARASITOL TODAY, V7, P5, DOI 10.1016/0169-4758(91)90076-Z; SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; WIRTZ RA, 1987, J MED ENTOMOL, V24, P433, DOI 10.1093/jmedent/24.4.433	26	151	152	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					462	467		10.1016/S0140-6736(95)91321-1	http://dx.doi.org/10.1016/S0140-6736(95)91321-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637479				2022-12-28	WOS:A1995RP85700009
J	GRAY, DWR				GRAY, DWR			MYCOPHENOLATE MOFETIL FOR TRANSPLANTATION - NEW DRUG, OLD PROBLEMS	LANCET			English	Editorial Material											GRAY, DWR (corresponding author), OXFORD RADCLIFFE HOSP,OXFORD TRANSPLANT CTR,NUFFIELD DEPT SURG,OXFORD,ENGLAND.							AZUMA H, 1995, TRANSPLANTATION, V59, P460; 1995, LANCET, V345, P1321	2	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					390	390		10.1016/S0140-6736(95)92775-1	http://dx.doi.org/10.1016/S0140-6736(95)92775-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623565				2022-12-28	WOS:A1995RN65600004
J	SUNG, P; ROBBERSON, DL				SUNG, P; ROBBERSON, DL			DNA STRAND EXCHANGE MEDIATED BY A RAD51-SSDNA NUCLEOPROTEIN FILAMENT WITH POLARITY OPPOSITE TO THAT OF RECA	CELL			English	Article							ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; RAD51; RECOMBINATION; PROTEIN; GENE; SEQUENCE; HOMOLOG; REPAIR	Yeast RAD51 gene functions in genetic recombination and DNA double-strand break repair. In vitro, in the presence of ATP and replication protein A, RAD51 protein pairs single-stranded DNA (ssDNA) with homologous double-stranded DNA (dsDNA) and catalyzes strand exchange between the synapsed DNA partners. Electron microscopic analyses show that RAD51 forms helical filaments on both ssDNA and dsDNA, in which the DNA is highly extended. However, results presented here indicate that only the RAD51-ssDNA nucleoprotein filament is functionally relevant. Strand exchange is arrested when heterology is encountered in the duplex partner, and analysis of the configuration of the terminal joint thus formed reveals that pairing and strand exchange initiate at the 5' end of the complementary strand in the linear duplex, a reaction polarity opposite to that of the bacterial prototype RecA.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	SUNG, P (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ESO7061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; KMIEC EB, 1983, CELL, V33, P857, DOI 10.1016/0092-8674(83)90028-4; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LOVETT ST, 1987, GENETICS, V116, P547; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	26	420	434	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					453	461		10.1016/0092-8674(95)90434-4	http://dx.doi.org/10.1016/0092-8674(95)90434-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634335	Bronze			2022-12-28	WOS:A1995RP24200015
J	LABARCA, C; NOWAK, MW; ZHANG, HY; TANG, LX; DESHPANDE, P; LESTER, HA				LABARCA, C; NOWAK, MW; ZHANG, HY; TANG, LX; DESHPANDE, P; LESTER, HA			CHANNEL GATING GOVERNED SYMMETRICALLY BY CONSERVED LEUCINE RESIDUES IN THE M2 DOMAIN OF NICOTINIC RECEPTORS	NATURE			English	Article							DESENSITIZATION	IN nicotinic acetylcholine receptors (nAChR), as well as glycine, GABA(A) (gamma-aminobutyric acid), serotonin (5-HT3), and GluCl glutamate receptors, a leucine residue at the approximate midpoint of the M2 transmembrane domain (the 9' position(1)) is conserved across most known subunits(2). Structural data for the nAChR suggest that the Leu 9' residues occupy a 'kink' in each of the five M2 helices and point into the closed channel; in the opening step, the M2 helices rotate so that Leu 9' side chains no longer occlude the conduction pathway(3), Mutation of Leu 9' to one of several other residues slows desensitization and increases sensitivity to agonist(4-6). We have exploited the alpha(2) beta gamma delta stoichiometry of muscle nAChR to express receptors with m(s)* = 0 to 5 Leu 9'Scr mutated subunits. Strikingly, each Leu 9'Ser mutation shifts the dose-response relation for ACh to the left by similar to 10-fold; a nAChR with m(s)* = 4 is 10(4)-fold more sensitive than the wild type, The results suggest that each of the five Leu 9' residues participates independently and symmetrically in a key step in the structural transition between the closed and open states.			LABARCA, C (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.			Nowak, Mark/0000-0001-5097-2682				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; CHARNET P, 1990, NEURON, V2, P87; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; JACKSON MB, 1984, P NATL ACAD SCI-BIOL, V81, P3901, DOI 10.1073/pnas.81.12.3901; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SIGURDSON W, 1994, BIOPHYS J, V66, pA212; SIGWORTH FJ, 1987, BIOPHYS J, V52, P147; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WATHEY JC, 1979, BIOPHYS J, V27, P145, DOI 10.1016/S0006-3495(79)85208-X; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030	15	266	269	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					514	516		10.1038/376514a0	http://dx.doi.org/10.1038/376514a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637783				2022-12-28	WOS:A1995RN62200044
J	NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK				NEWMAN, M; STRZELECKA, T; DORNER, LF; SCHILDKRAUT, I; AGGARWAL, AK			STRUCTURE OF BAM-HI ENDONUCLEASE BOUND TO DNA - PARTIAL FOLDING AND UNFOLDING ON DNA-BINDING	SCIENCE			English	Article							REPRESSOR OPERATOR COMPLEX; CRYSTAL-STRUCTURE; RESTRICTION ENDONUCLEASE; WEISSENBERG CAMERA; DIFFRACTION DATA; RESOLUTION; CRYSTALLOGRAPHY; RECOGNITION; REFINEMENT; ECORI	The crystal structure of restriction endonuclease Bam HI complexed to DNA has been determined at 2.2 angstrom resolution. The DNA binds in the cleft and retains a B-DNA type of conformation. The enzyme, however, undergoes a series of conformational changes, including rotation of subunits and folding of disordered regions. The most striking conformational change is the unraveling of carboxyl-terminal alpha helices to form partially disordered ''arms.'' The arm from one subunit fits into the minor groove while the arm from the symmetry related subunit follows the DNA sugar-phosphate backbone. Recognition of DNA base pairs occurs primarily in the major groove, with a few interactions occurring in the minor groove. Tightly bound water molecules play an equally important role as side chain and main chain atoms in the recognition of base pairs. The complex also provides new insights into the mechanism by which the enzyme catalyzes the hydrolysis of DNA phosphodiester groups.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915	Columbia University					NIGMS NIH HHS [GM-44006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRUNGER AT, 1992, XPLOR V3 0 MANUAL; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; Creighton T. E., 1993, PROTEINS STRUCTURES; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; FITAGERALD PMD, 1988, J APPL CRYSTALLOGR, V20, P383; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GRASBY JA, 1992, BIOCHEMISTRY-US, V31, P7855, DOI 10.1021/bi00149a016; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P993; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JELTSCH A, 1993, P NATL ACAD SCI USA, V90, P8499, DOI 10.1073/pnas.90.18.8499; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Roberts R, 1993, NUCLEASES, P35; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEITZ T, NIH GM44006 GRAN; STRZELECKA T, 1994, J MOL BIOL, V239, P430, DOI 10.1006/jmbi.1994.1383; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; XUONG NH, 1978, ACTA CRYSTALLOGR A, V34, P289, DOI 10.1107/S0567739478000546	38	295	297	1	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					656	663		10.1126/science.7624794	http://dx.doi.org/10.1126/science.7624794			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624794				2022-12-28	WOS:A1995RM70200023
J	SIMMONDS, AJ; BROOK, WJ; COHEN, SM; BELLE, JB				SIMMONDS, AJ; BROOK, WJ; COHEN, SM; BELLE, JB			DISTINGUISHABLE FUNCTIONS FOR ENGRAILED AND INVECTED IN ANTERIOR-POSTERIOR PATTERNING IN THE DROSOPHILA WING	NATURE			English	Article							GENE; EXPRESSION; DISK; MELANOGASTER; DIRECTS; LOCUS	SUBDIVISION Of the limb primordia into compartments initiates pattern formation in the developing limbs(1,2). Interaction between distinctly specific cells in adjacent compartments leads to localized expression of the secreted signalling molecules Wingless (Wg) or Decapentaplegic (Dpp) which in turn organize pattern and control growth of the limbs The homeobox gene engrailed has been implicated in specification of posterior cell fate(9-12), whereas the LIM/homeobox gene, apterous, specifies dorsal fate(3). Removing apterous activity causes a complete transformation from dorsal to ventral fate and leads to the formation of an ectopic dorsal-ventral boundary organizer(3,13). By contrast, removing engrailed activity causes incomplete morphological transformation from posterior to anterior fate in the wing(10,14,15), and fails to produce an ectopic anterior-posterior organizer (reviewed in ref, 2). Complete transformation can only be effected by simultaneously eliminating activity of engrailed and its homologue invected(16-18). Here we show that invected functions principally to specify posterior cell fate. Thus establishment of the anterior-posterior organizer and control of compartment identity are genetically distinguishable, and invected may perform a discrete subset of functions previously ascribed to engrailed.	UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2E9,CANADA; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	University of Alberta; European Molecular Biology Laboratory (EMBL)			Simmonds, Andrew J/D-3675-2009; Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163; Simmonds, Andrew/0000-0001-7165-9302				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Eker R, 1929, HEREDITAS, V12, P217; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GUBB D, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P236, DOI 10.1007/BF00848252; HIDALGO A, 1994, CURR BIOL, V4, P1087, DOI 10.1016/S0960-9822(00)00247-5; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LAWRENCE PA, 1982, EMBO J, V7, P827; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; SANICOLA M, 1995, GENETICS, V139, P745; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; SERRANO N, 1995, DEVELOPMENT, V121, P1691; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, IN PRESS DEVELOPMENT; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1990, GENETICS, V125, P833; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WURST W, 1994, DEVELOPMENT, V120, P2065	31	103	106	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					424	427		10.1038/376424a0	http://dx.doi.org/10.1038/376424a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630417				2022-12-28	WOS:A1995RM63900051
J	HALAAS, JL; GAJIWALA, KS; MAFFEI, M; COHEN, SL; CHAIT, BT; RABINOWITZ, D; LALLONE, RL; BURLEY, SK; FRIEDMAN, JM				HALAAS, JL; GAJIWALA, KS; MAFFEI, M; COHEN, SL; CHAIT, BT; RABINOWITZ, D; LALLONE, RL; BURLEY, SK; FRIEDMAN, JM			WEIGHT-REDUCING EFFECTS OF THE PLASMA-PROTEIN ENCODED BY THE OBESE GENE	SCIENCE			English	Article							RATS	The gene product of the ob locus is important in the regulation of body weight. The ob product was shown to be present as a 16-kilodalton protein in mouse and human plasma but was undetectable in plasma from C57BL/6J ob/ob mice. Plasma levels of this protein were increased in diabetic (db) mice, a mutant thought to be resistant to the effects of ab. Daily intraperitoneal injections of either mouse or human recombinant OB protein reduced the body weight of ob/ob mice by 30 percent after 2 weeks of treatment with no apparent toxicity but had no effect on db/db mice. The protein reduced food intake and increased energy expenditure in ob/ob mice. Injections of wild-type mice twice daily with the mouse protein resulted in a sustained 12 percent weight loss, decreased food intake, and a reduction of body fat from 12.2 to 0.7 percent. These data suggest that the OB protein serves an endocrine function to regulate body fat stores.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,GENET MOLEC LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOPHYS LABS,NEW YORK,NY 10021; ROCKEFELLER UNIV,MASS SPECTROMETRY LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT STAT,NEW YORK,NY 10027; BROOKWOOD BIOMED CTR,BIRMINGHAM,AL 35209	Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Columbia University				Burley, Stephen K./0000-0002-2487-9713	NCRR NIH HHS [RR00862] Funding Source: Medline; NIDDK NIH HHS [DK41096] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTTIST; HALAAS JL, UNPUB; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS RBS, 1987, INT J OBESITY, V11, P275; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; HERVEY GR, 1976, P PHYSL SOC, V266, pP65; KEESEY RC, 1984, ASS RES NERVOUS MENT, V62, P87; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEIBELT RA, 1965, ANN NY ACAD SCI, V131, P559; PARAMESWARAN SV, 1977, AM J PHYSIOL, V232, pR150, DOI 10.1152/ajpregu.1977.232.5.R150; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	3946	4170	7	239	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					543	546		10.1126/science.7624777	http://dx.doi.org/10.1126/science.7624777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624777				2022-12-28	WOS:A1995RL49500029
J	GROVE, A; LIPWORTH, BJ				GROVE, A; LIPWORTH, BJ			BRONCHODILATOR SUBSENSITIVITY TO SALBUTAMOL AFTER TWICE-DAILY SALMETEROL IN ASTHMATIC-PATIENTS	LANCET			English	Article							BETA-ADRENOCEPTOR RESPONSIVENESS; CONGESTIVE-HEART-FAILURE; INHALED SALBUTAMOL; TERBUTALINE; RESPONSES; DESENSITIZATION; TACHYPHYLAXIS; METHACHOLINE; RECEPTORS; EXERCISE	In view of current concerns about use of regular beta-2 agonists, and the place of the newer long-acting drugs, we decided to evaluate whether continuous exposure to twice daily salmeterol results in a blunting of the acute bronchodilator response to repeated doses of salbutamol, as might be administered in the management of an acute asthma attach. After a 2 week run-in without beta-2 agonists, 17 asthmatic patients (mean [SE] age 34 [3] years, mean forced expiratory volume in 1 s [FEV(1)] 64 [2.7]% of predicted) were randomised to receive salmeterol 50 mu g twice daily or placebo for 4 weeks in a double-blind crossover fashion. A histamine challenge test was done 12 b after the last dose of each treatment period, and dose-response curves to inhaled salbutamol (200-3200 mu g) were constructed 36 h after the last dose. Patients treated with salmeterol had reduced bronchodilator responses to salbutamol in terms of FEV(1) and peak expiratory flow rate (PEEP) than those treated with placebo. The reduction in response equated with a 2.5-fold and a fourfold greater dose of salbutamol being required to produce a given FEV(1) and PEFR, respectively. There was a significant reduction in lymphocyte beta-2 adrenoceptor density after salmeterol compared with placebo and run-in. Salmeterol remained effective in terms of disease control, with a significant improvement in morning PEFR compared with placebo that was maintained over the 4 week treatment period. Continuous exposure to salmeterol 50 mu g twice daily results in subsensitivity to the acute bronchodilator response to repeated doses of inhaled salbutamol. Thus patients receiving regular treatment with salmeterol might require higher doses of salbutamol when used for relief of acute bronchoconstriction.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CLIN PHARMACOL, DUNDEE DD1 9SY, SCOTLAND	University of Dundee								[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BOOTH H, 1993, THORAX, V48, P1121, DOI 10.1136/thx.48.11.1121; BRODDE OE, 1985, J CLIN INVEST, V76, P1096, DOI 10.1172/JCI112063; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; HUI KKP, 1982, CLIN PHARMACOL THER, V32, P566, DOI 10.1038/clpt.1982.204; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; LIPWORTH BJ, 1989, EUR J CLIN PHARMACOL, V36, P239, DOI 10.1007/BF00558154; LIPWORTH BJ, 1990, AM REV RESPIR DIS, V142, P338, DOI 10.1164/ajrccm/142.2.338; LIPWORTH BJ, 1994, LANCET, V344, P760; MAISEL AS, 1990, J CLIN INVEST, V85, P462, DOI 10.1172/JCI114460; MAISEL AS, 1990, CIRCULATION, V82, P2003, DOI 10.1161/01.CIR.82.6.2003; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; NEWNHAM DM, 1993, EUR J CLIN PHARMACOL, V45, P535, DOI 10.1007/BF00315310; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; QING F, 1994, THORAX, V49, pP1046; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; TATTERSFIELD AE, 1993, LIFE SCI, V52, P2161, DOI 10.1016/0024-3205(93)90730-Q; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; VANTITS LJH, 1990, AM J PHYSIOL, V258, pE191, DOI 10.1152/ajpendo.1990.258.1.E191; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1993, BRIT MED J, V306, P776	25	165	170	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	1995	346	8969					201	206		10.1016/S0140-6736(95)91265-7	http://dx.doi.org/10.1016/S0140-6736(95)91265-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616798				2022-12-28	WOS:A1995RK41900007
J	TOWERS, CV				TOWERS, CV			GROUP-B STREPTOCOCCUS - THE US CONTROVERSY	LANCET			English	Editorial Material							SELECTIVE INTRAPARTUM CHEMOPROPHYLAXIS; EARLY-ONSET DISEASE; PREGNANCY; CARRIAGE				TOWERS, CV (corresponding author), LONG BEACH MEM WOMENS HOSP,CTR PERINATAL,LONG BEACH,CA, USA.							BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; BOYER KM, 1983, J INFECT DIS, V148, P802, DOI 10.1093/infdis/148.5.802; BOYER KM, 1983, J INFECT DIS, V148, P795, DOI 10.1093/infdis/148.5.795; DILLON HC, 1982, J INFECT DIS, V145, P794, DOI 10.1093/infdis/145.6.794; LEWIN EB, 1981, AM J OBSTET GYNECOL, V139, P512, DOI 10.1016/0002-9378(81)90509-3; ROUSE DJ, 1994, OBSTET GYNECOL, V83, P483, DOI 10.1097/00006250-199404000-00001; TOWERS CV, 1990, AM J OBSTET GYNECOL, V163, P965, DOI 10.1016/0002-9378(90)91105-L; YANCEY MK, 1992, OBSTET GYNECOL, V80, P1038; 1992, ACOG TECH B, V170, P1; 1993, ACOG NEWSL, V37, P2; 1992, PEDIATRICS, V90, P775	11	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					197	199		10.1016/S0140-6736(95)91262-2	http://dx.doi.org/10.1016/S0140-6736(95)91262-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616795				2022-12-28	WOS:A1995RK41900004
J	YOUNG, NS				YOUNG, NS			APLASTIC-ANEMIA	LANCET			English	Review							BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; VERSUS-HOST DISEASE; SAA WORKING PARTY; ANTILYMPHOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; RANDOMIZED TRIAL; ANEMIA; GRAFT; METHYLPREDNISOLONE				YOUNG, NS (corresponding author), NHLBI,HEMATOL BRANCH,BLDG 10,ROOM 7C103,BETHESDA,MD 20892, USA.							AITCHISON RGM, 1989, BRIT J HAEMATOL, V73, P541, DOI 10.1111/j.1365-2141.1989.tb00294.x; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; BACIGALUPO A, 1993, BRIT J HAEMATOL, V83, P145, DOI 10.1111/j.1365-2141.1993.tb04645.x; BACIGALUPO A, 1980, BLUT, V41, P168; BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; BACIGALUPO A, 1988, BRIT J HAEMATOL, V70, P177, DOI 10.1111/j.1365-2141.1988.tb02460.x; BACIGALUPO A, 1994, WORKING PARTIES REPO, P49; CAMITTA B, 1993, BLOOD, V82, pA344; CAMITTA BM, 1976, BLOOD, V48, P63; CHAMPLIN RE, 1985, BLOOD, V66, P184, DOI 10.1182/blood.V66.1.184.184; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHAMPLIN RE, 1989, BLOOD, V73, P694; CRUMP M, 1992, AM J MED, V92, P596, DOI 10.1016/0002-9343(92)90776-8; Ehrlich P., 1888, CHARITE ANN, V13, P301; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; GLUCKMAN E, 1992, BLOOD, V79, P269; HAMAJIMA N, 1988, BLOOD, V72, P995; HIBBS JR, 1992, JAMA-J AM MED ASSOC, V267, P2051; HOFFMAN R, 1982, MEDICINE, V61, P373, DOI 10.1097/00005792-198211000-00003; HOWS JM, 1994, BONE MARROW TRANSP S, P143; ISSARAGRISIL S, 1991, BLOOD, V77, P2166; KAGAN WA, 1976, P NATL ACAD SCI USA, V73, P2890, DOI 10.1073/pnas.73.8.2890; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; KOJIMA S, 1991, BLOOD, V77, P937; LEONARD EM, 1989, BRIT J HAEMATOL, V72, P278, DOI 10.1111/j.1365-2141.1989.tb07695.x; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MACIEJEWSKI JP, 1994, EXP HEMATOL, V22, P1102; MARSH JCW, 1993, BRIT J HAEMATOL, V84, P731, DOI 10.1111/j.1365-2141.1993.tb03153.x; MARSH JCW, 1994, LANCET, V344, P172, DOI 10.1016/S0140-6736(94)92763-4; MARSH JCW, 1991, BRIT J HAEMATOL, V78, P258, DOI 10.1111/j.1365-2141.1991.tb04426.x; MATHE G, 1970, BMJ-BRIT MED J, V2, P131, DOI 10.1136/bmj.2.5702.131; MAY WS, 1993, BONE MARROW TRANSPL, V11, P459; NIMER SD, 1994, BLOOD, V84, P923; NIMER SD, 1991, BLOOD, V78, P163; NISTICO A, 1994, ANN INTERN MED, V120, P463, DOI 10.7326/0003-4819-120-6-199403150-00003; PAQUETTE RL, 1995, BLOOD, V85, P283, DOI 10.1182/blood.V85.1.283.bloodjournal851283; RAEFSKY EL, 1986, BLOOD, V68, P712; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; SCHREZENMEIER H, 1995, EXP HEMATOL, V23, P81; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; Vaquez MH, 1904, B MEM SOC MED HOP P, V21, P288; WILLIAMS DM, 1978, CLIN HAEMATOL, V7, P467; YOUNG N, 1984, APLASTIC ANEMIA STEM, P221; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385	47	61	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					228	232		10.1016/S0140-6736(95)91273-8	http://dx.doi.org/10.1016/S0140-6736(95)91273-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616805				2022-12-28	WOS:A1995RK41900015
J	CHAPMAN, S				CHAPMAN, S			PECKED TO DEATH BY (FLYING) DUCKS - COURT DECISION MAY EXTINGUISH SMOKING ON AIRCRAFT	BRITISH MEDICAL JOURNAL			English	Article								A case this month in the Australian court may force Australia's national airline, Qantas, to make all its flights non-smoking now rather than next year and in the meantime offers hope of compensation to Australian passengers who are refused non-smoking seats. Mrs Leone Cameron brought a case against Qantas for seating her in the smoking section of a Sydney to Bangkok flight after she had booked a non-smoking seat. She subsequently suffered minor illnesses. She and nine other similarly affected passengers claimed that Qantas had misled them. The judged ruled that Qantas had misled passengers in five of the cases though he refused to rule that Qantas had misled those placed in non-smoking seats next to the smoking area. He also refused to order Qantas to make all its flights non-smoking. The ruling is important for enabling other passengers to seek compensation through consumer claims tribunals when refused a requested non-smoking seat. It also brings closer the day when smoking will be forbidden on all flights.			CHAPMAN, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT PUBL HLTH & COMMUNITY MED,WESTMEAD,NSW 2145,AUSTRALIA.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					38	40		10.1136/bmj.311.6996.38	http://dx.doi.org/10.1136/bmj.311.6996.38			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613326	Green Published			2022-12-28	WOS:A1995RG97500027
J	CLARKE, A				CLARKE, A			POPULATION SCREENING FOR GENETIC SUSCEPTIBILITY TO DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHOLESTEROL CONCENTRATION; HEALTH; HYPERCHOLESTEROLEMIA; PREVENTION	Genetic screening for susceptibility to common diseases, such as the common cancers, cardiovascular disease, and diabetes, may soon be technically feasible. Commercial interests should not be allowed to introduce such screening before proper evaluation or without adequate counselling and support. The evaluation of such testing should include psychosocial and medical outcomes and outcomes for those given low risks as well as high risks. These tests may distract attention away from environmental factors contributing to disease, for which social and political measures may be more appropriate than individualised susceptibility screening and lifestyle modification.			CLARKE, A (corresponding author), UNIV WALES COLL CARDIFF, COLL MED, DEPT MED GENET, CARDIFF CF4 4XW, S GLAM, WALES.							BACHMAN RP, 1993, AM J DIS CHILD, V147, P382, DOI 10.1001/archpedi.1993.02160280032013; BAIRD PA, 1990, PERSPECT BIOL MED, V33, P203; BERGMAN AB, 1967, NEW ENGL J MED, V276, P1008, DOI 10.1056/NEJM196705042761804; BRETT AS, 1991, AM J MED, V91, P642, DOI 10.1016/0002-9343(91)90218-M; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLARKE A, 1994, J MED GENET, V31, P785, DOI 10.1136/jmg.31.10.785; COULTER A, 1994, BRIT MED J, V308, P308; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DAVISON C, 1989, Health Education Research, V4, P329, DOI 10.1093/her/4.3.329; DAVISON C, 1992, SOC SCI MED, V34, P675, DOI 10.1016/0277-9536(92)90195-V; GREEN J, 1993, J MED GENET, V30, P575, DOI 10.1136/jmg.30.7.575; GUSTAVSON KH, 1989, CLIN GENET, V36, P327; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HOLTZMAN NA, 1992, FASEB J, V6, P2806, DOI 10.1096/fasebj.6.10.1634043; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; LIFSHITZ F, 1989, AM J DIS CHILD, V143, P537, DOI 10.1001/archpedi.1989.02150170035015; LIPMANN A, 1993, MISCONCEPTIONS, V1, P39; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MCCORMICK J, 1994, LANCET, V344, P390; MULLERHILL B, 1993, NATURE, V362, P491, DOI 10.1038/362491a0; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PLOMIN R, 1994, BEHAV GENET, V24, P107, DOI 10.1007/BF01067815; RAMSEY M, 1994, GENETIC COUNSELLING, P241; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; TOWNSEND P, 1990, INT J HEALTH SERV, V20, P373, DOI 10.2190/9Q6H-2KE7-X6FN-3DK8; Townsend P., 1988, INEQUALITIES HLTH BL; VANDERSTEENSTRATEN IM, 1994, AM J HUM GENET, V55, P618; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WEBER JL, 1994, NAT GENET, V7, P343, DOI 10.1038/ng0794-343; WILLIAMS RR, 1988, NEW ENGL J MED, V318, P769, DOI 10.1056/NEJM198803243181208; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313; 1990, REPRODUCTION GENETIC, V3, P287	38	33	33	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					35	38		10.1136/bmj.311.6996.35	http://dx.doi.org/10.1136/bmj.311.6996.35			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG975	7613325	Green Published			2022-12-28	WOS:A1995RG97500026
J	LOKKEN, P; STRAUMSHEIM, PA; TVEITEN, D; SKJELBRED, P; BORCHGREVINK, CF				LOKKEN, P; STRAUMSHEIM, PA; TVEITEN, D; SKJELBRED, P; BORCHGREVINK, CF			EFFECT OF HOMEOPATHY ON PAIN AND OTHER EVENTS AFTER ACUTE TRAUMA - PLACEBO-CONTROLLED TRIAL WITH BILATERAL ORAL-SURGERY	BRITISH MEDICAL JOURNAL			English	Article							ACETYLSALICYLIC-ACID; POSTOPERATIVE COURSE; SURGICAL REMOVAL; CLINICAL-TRIALS; DRUG EVALUATION; MOLAR TEETH; MODEL	Objective-To examine whether homoeopathy has any effect on pain and other inflammatory events after surgery. Design-Randomised double blind, placebo controlled crossover trial with ''identical'' oral surgical procedures performed on two separate occasions in 24 patients. Interventions-Treatment started 3 hours after surgery with either homoeopathy or placebo. Main outcome measures-Postoperative pain and preference for postoperative course assessed by patients on visual analogue scales. Measurements of postoperative swelling and reduction in ability to open mouth. Assessment of bleeding after surgery. Results-Pain after surgery was essentially the same whether treated with homoeopathy or placebo. Postoperative swelling was not significantly affected by homoeopathy, but treatment tended to give less reduction in ability to open mouth. No noticeable difference was seen in postoperative bleeding, side effects, or complaints. Thirteen of the 24 patients preferred the postoperative course with placebo. Conclusions-No positive evidence was found for efficacy of homoeopathic treatment on pain and other inflammatory events after an acute soft tissue and bone injury inflicted by a surgical intervention. Differences in the order of 30% to 40% would have been needed to show significant effects.	UNIV OSLO,DENT PHARMACOL & PHARMACOTHERAPEUT SECT,N-0316 OSLO,NORWAY; ST HANSHAUGEN MED CTR,N-0168 OSLO,NORWAY; NORWEGIAN INST NAT MED,N-1340 BEKKESTUA,NORWAY; OSLO CITY HOSP,MAXILLOFACIAL SURG SECT,N-0407 OSLO,NORWAY; UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO,NORWAY	University of Oslo; University of Oslo								Albertini H, 1985, J AM I HOMEOPATH, V3, P126; ALBUM B, 1977, INT J ORAL MAXILLOF, V6, P177, DOI 10.1016/S0300-9785(77)80051-3; BUCKMAN R, 1994, BRIT MED J, V309, P103, DOI 10.1136/bmj.309.6947.103; Campbell A., 1976, BR HOMOEOPATH J, V65, P154; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; GIBSON DM, 1972, BRIT HOMOEOPATHY J, V61, P167; IVES G, 1984, COMMUNICATIONS MIDLA, V11, P71; Jones B., 2015, DESIGN ANAL CROSS OV, V3rd; KAZIRO GSN, 1984, BRIT J ORAL MAX SURG, V22, P42, DOI 10.1016/0266-4356(84)90007-X; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LESSELL CB, 1983, DENTAL PRESCRIBER; LOKKEN P, 1975, EUR J CLIN PHARMACOL, V8, P209, DOI 10.1007/BF00567117; LOKKEN P, 1980, BR J CLIN PHARM, V10, P27; MCIVOR EG, 1973, J AM I HOMOEOPATHY, V66, P81; MEURIS J, 1981, HEMEOPATHIE ODONTOST; PINSENT RJ, 1986, COMMUN BR HOMOEOPATH, V15, P3; Righetti M, 1988, FORSCHUNG HOMOOPATHI; SKJELBRED P, 1982, EUR J CLIN PHARMACOL, V21, P391, DOI 10.1007/BF00542325; SKJELBRED P, 1983, BRIT J CLIN PHARMACO, V15, P221, DOI 10.1111/j.1365-2125.1983.tb01489.x; SKJELBRED P, 1984, BRIT J CLIN PHARMACO, V17, P379, DOI 10.1111/j.1365-2125.1984.tb02361.x; SKJELBRED P, 1977, EUR J CLIN PHARMACOL, V12, P257, DOI 10.1007/BF00607424; SKJELBRED P, 1980, EUR J CLIN PHARMACOL, V18, P327, DOI 10.1007/BF00561390; 1991, HOMOOPATHISCHES ARZE	23	41	44	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1439	1442		10.1136/bmj.310.6992.1439	http://dx.doi.org/10.1136/bmj.310.6992.1439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613277	Green Published			2022-12-28	WOS:A1995RC10500018
J	BRADLEY, C; MARSHALL, M; GATH, D				BRADLEY, C; MARSHALL, M; GATH, D			WHY DO SO FEW PATIENTS APPEAL AGAINST DETENTION UNDER SECTION-2 OF THE MENTAL-HEALTH ACT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine why most patients do not exercise their right of appeal against detention under section 2 of the Mental Health Act 1983. Design-Part one-retrospective analysis of the clinical notes of patients detained under section 2 of the Mental Health Act. Part two-interviews with patients on the penultimate day before the deadline for lodging an appeal. Setting-In part one, five districts in the Oxfordshire Regional Health Authority. In part two, six hospitals from three districts in the region. Subjects-In part one all patients detained under section 2 in the five districts in 1993 (n = 418). In part two interviews with 40 patients detained under section 2 in the six hospitals. Results-Patients were more likely to appeal if they were educated to A level standard (odds = 2.26; P = 0.0014) or had had a previous admission (2.19, P = 0.0029). Patients with a diagnosis of depression (0.31; P = 0.015) or dementia (0.0003, P = 0.0001) were less likely to appeal. Compared with those who appealed (n = 12) those who did not (n = 28) showed less understanding of their rights (P = 0.034) and poorer comprehension of sentences from the booklet describing patients' rights (P = 0.057). The main reasons given for not appealing were not being aware of the appeals process and being deterred by having to appeal in writing. After they received a full explanation of their rights 12 of those who did not appeal said that they wished to appeal and four did so within the time remaining before the deadline. Of 40 patients, 39 said there should be an automatic right of appeal. Conclusions-The appeals procedure against detention under section 2 of the Mental Health Act is not a satisfactory way of protecting the civil liberties of patients. If patients were fully informed of their rights they would probably be much more likely to appeal.	UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND	University of Oxford								ALTMAN DG, 1994, PRACTICAL STATISTICS; CUNNINGHAM SJ, 1991, PSYCHIATRIC B, V15, P643; EASTMAN N, 1994, BRIT MED J, V308, P43, DOI 10.1136/bmj.308.6920.43; HAUCK WW, 1977, J AM STAT ASSOC, V72, P851, DOI 10.2307/2286473; MALCOLM NT, 1994, PSYCHIATRIC B, V18, P577; NEVILL P, 1991, PSYCHIATRIC B, V15, P642; NORUSIS MJ, 1992, SPSS WINDOWS ADV STA; PEAY, 1989, TRIBUNALS TRIAL; Saad K. F. G., 1992, PSYCHIAT B, V16, P470; WEBSTER L, 1989, PSYCHIATRIC B, V13, P473; Wilkinson P., 1993, PSYCHIATRIC B, V17, P337; WOOD J, 1993, BRIT J PSYCHIAT, V162, P14, DOI 10.1192/bjp.162.1.14; 1993, MENTAL HLTH REV TRIB; 1990, PSYCHIATRIC B, V14, P48	14	24	24	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					364	367		10.1136/bmj.310.6976.364	http://dx.doi.org/10.1136/bmj.310.6976.364			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG721	7632216	Green Published			2022-12-28	WOS:A1995QG72100018
J	MANSON, JE; WILLETT, WC; STAMPFER, MJ; COLDITZ, GA; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; SPEIZER, FE				MANSON, JE; WILLETT, WC; STAMPFER, MJ; COLDITZ, GA; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; SPEIZER, FE			BODY-WEIGHT AND MORTALITY AMONG WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELATIVE WEIGHT; CIGARETTE-SMOKING; UNITED-STATES; MASS INDEX; FOLLOW-UP; OBESITY; HEALTH; DEATH; RISK; MEN	Background. The relation between body weight and overall mortality remains controversial despite considerable investigation. Methods. We examined the association between body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and both overall mortality and mortality from specific causes in a cohort of 115,195 U.S. women enrolled in the prospective Nurses' Health Study. These women were 30 to 55 years of age and free of known cardiovascular disease and cancer in 1976. During 16 years of follow-up, we documented 4726 deaths, of which 881 were from cardiovascular disease, 2586 from cancer, and 1259 from other causes. Results. In analyses adjusted only for age, we observed a J-shaped relation between body-mass index and overall mortality. When women who had never smoked were examined separately, no increase in risk was observed among the leaner women, and a more direct relation between weight and mortality emerged (P for trend <0.001). In multivariate analyses of women who had never smoked and had recently had stable weight, in which the first four years of follow-up were excluded, the relative risks of death from all causes for increasing categories of body-mass index were as follows: body-mass index <19.0 (the reference category), relative risk = 1.0, 19.0 to 21.9, relative risk = 1.2; 22.0 to 24.9, relative risk = 1.2; 25.0 to 26.9, relative risk = 1.3; 27.0 to 28.9, relative risk = 1.6; 29.0 to 31.9, relative risk = 2.1; and greater than or equal to 32.0, relative risk = 2.2 (P for trend <0.001). Among women with body-mass indexes of 32.0 or higher who had never smoked, the relative risk of death from cardiovascular disease was 4.1 (95 percent confidence interval, 2.1 to 7.7), and that of death from cancer was 2.1 (95 percent confidence interval, 1.4 to 3.2), as compared with the risk among women with body-mass indexes below 19.0. A weight gain of 10 kg (22 lb) or more since the age of 18 was associated with increased mortality in middle adulthood. Conclusions. Body weight and mortality from all causes were directly related among these middle-aged women. Lean women did not have excess mortality. The lowest mortality rate was observed among women who weighed at least 15 percent less than the U.S. average for women of similar age and among those whose weight had been stable since early adulthood.	HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COMSTOCK GW, 1966, AM J EPIDEMIOL, V83, P548, DOI 10.1093/oxfordjournals.aje.a120606; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GARRISON RJ, 1993, INT J OBESITY, V17, P417; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; HARLAN WR, 1988, AM J EPIDEMIOL, V128, P1065; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HENNEKENS CH, 1979, LANCET, V1, P1390; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; MANN GV, 1974, NEW ENGL J MED, V291, P178, DOI 10.1056/NEJM197407252910405; MANN GV, 1974, NEW ENGL J MED, V291, P226, DOI 10.1056/NEJM197408012910504; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROMIEU I, 1988, AM J CLIN NUTR, V47, P406, DOI 10.1093/ajcn/47.3.406; SCHROLL M, 1981, DAN MED BULL, V28, P106; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; TROY LM, IN PRESS INT J OBES; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; VANDENBROUCKE JP, 1984, JAMA-J AM MED ASSOC, V252, P2859, DOI 10.1001/jama.252.20.2859; VANITALLIE TB, 1979, AM J CLIN NUTR, V32, P2723, DOI 10.1093/ajcn/32.12.2723; WAALER HT, 1984, ACTA MED SCAND, P1; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; [No title captured]; 1990, NUTRITION YOUR HLTH; 1959, STAT B METROP INSUR, V40, P1; [No title captured]; 1987, VITAL HLTH STATIS 11, V238; 1980, BUILD STUDY 1979	41	1450	1495	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					677	685		10.1056/NEJM199509143331101	http://dx.doi.org/10.1056/NEJM199509143331101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637744				2022-12-28	WOS:A1995RV22700001
J	THIBAULT, GE				THIBAULT, GE			STUDYING THE CLASSICS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							VALVOTOMY; DISEASE	A 25-year-old Hispanic woman in the 27th week of pregnancy came to the emergency room complaining of cough and shortness of breath. She reported that she had been well until two days earlier. In the past day she had also been nauseated, and she had vomited once. In the emergency room she was found to have a temperature of 38 degrees C (100.5 degrees F) and was thought to be dehydrated. Intravenous fluids, ampicillin, and gentamicin were administered. She was given a prescription for erythromycin and sent home. She returned the next day because she was more dyspneic and explained that she had coughed up a half-cup blood. She also reported that she had been treated with antibiotics one month earlier for a presumed upper respiratory infection. Since then she had been tired and short of breath. Four previous pregnancies and deliveries had been unremarkable. Four years earlier she had been treated for tuberculosis. On examination her temperature was 38.6 degrees C (101.4 degrees F), her pulse was 120 to 130 beats per minute, her blood pressure was 94/50 mm Hg, and the respiratory rate was 30 per minute. The cardiac examination was considered to be unremarkable, but the chest examination revealed bibasilar rhonchi and wheezes. Her arterial oxygen saturation was 94 percent while she was breathing oxygen at a rate of 2 liters per minute.			THIBAULT, GE (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABASCAL VM, 1990, CIRCULATION, V82, P448, DOI 10.1161/01.CIR.82.2.448; BLAND EF, 1951, CIRCULATION, V4, P836, DOI 10.1161/01.CIR.4.6.836; BRAUNWAL.E, 1965, NEW ENGL J MED, V273, P509, DOI 10.1056/NEJM196509022731001; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1007; CARABELLO BA, 1994, NEW ENGL J MED, V331, P1014, DOI 10.1056/NEJM199410133311509; EBRINGER R, 1970, BRIT HEART J, V32, P350; ELKAYAM U, 1990, CARDIAC PROBLEMS PRE, P5; ELLIS LB, 1957, CIRCULATION, V15, P924, DOI 10.1161/01.CIR.15.6.924; GORLIN R, 1951, AM HEART J, V41, P1, DOI 10.1016/0002-8703(51)90002-6; HARVEY WP, 1973, VALVULAR HEART DISEA, V5, P77; HENRY WL, 1975, CIRCULATION, V51, P827, DOI 10.1161/01.CIR.51.5.827; HUGENHOLTZ PG, 1962, AM J CARDIOL, V10, P773, DOI 10.1016/0002-9149(62)90171-6; JOSWIG BC, 1982, AM HEART J, V104, P1400, DOI 10.1016/0002-8703(82)90185-5; OLESEN KH, 1962, BRIT HEART J, V24, P349; PALACIOS I, 1987, CIRCULATION, V75, P778, DOI 10.1161/01.CIR.75.4.778; PALACIOS IF, 1988, CATHETER CARDIO DIAG, V15, P109, DOI 10.1002/ccd.1810150210; REYES VP, 1994, NEW ENGL J MED, V331, P961, DOI 10.1056/NEJM199410133311501; ROWE JC, 1960, ANN INTERN MED, V52, P741, DOI 10.7326/0003-4819-52-4-741; SZEKELY P, 1973, BRIT HEART J, V35, P1293; Walsh BJ, 1940, ARCH INTERN MED, V65, P321, DOI 10.1001/archinte.1940.00190080103006; WILSON JK, 1954, CAN MED ASSOC J, V71, P323; WOOD P, 1954, Br Med J, V1, P1051; ZAKY A, 1968, CIRCULATION, V37, P789, DOI 10.1161/01.CIR.37.5.789	23	9	9	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					648	652		10.1056/NEJM199509073331009	http://dx.doi.org/10.1056/NEJM199509073331009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637728				2022-12-28	WOS:A1995RR84000009
J	ZIMMER, T; STOLZEL, U; BADER, M; FETT, U; FOSS, HD; RIECKEN, EO; REHFELD, JF; WIEDENMANN, B				ZIMMER, T; STOLZEL, U; BADER, M; FETT, U; FOSS, HD; RIECKEN, EO; REHFELD, JF; WIEDENMANN, B			BRIEF REPORT - A DUODENAL GASTRINOMA IN A PATIENT WITH DIARRHEA AND NORMAL SERUM GASTRIN-CONCENTRATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ZOLLINGER-ELLISON SYNDROME; ENDOCRINE TUMORS; SECRETIN; LOCALIZATION; PROGASTRIN; DIAGNOSIS; CALCIUM	THE Zollinger-Ellison syndrome manifests itself in 90 to 95 percent of cases as severe peptic ulcer disease.(1) About half the time, the ulcer disease is associated with diarrhea, and in approximately 10 percent of patients, diarrhea is the only clinical manifestation.(2,3) Basal serum gastrin concentrations are usually elevated in patients with this syndrome.(4) Normal basal serum gastrin values with abnormal results of secretin tests have been reported, however, in a few patients.(5-7) We describe a patient with a duodenal gastrinoma, a two-year history of diarrhea, and no peptic ulcer disease. The patient had persistently normal serum gastrin concentrations, but abnormal results of a secretin test and increased serum concentrations of the total progastrin product.	FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,GASTROENTEROL ABT,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT NUCL MED,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT PATHOL,D-12200 BERLIN,GERMANY; UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN BIOCHEM,DK-2100 COPENHAGEN,DENMARK	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Rigshospitalet; University of Copenhagen				Wiedenmann, Bertram/0000-0002-7890-2552				BARDRAM L, 1990, GASTROENTEROLOGY, V98, P1420, DOI 10.1016/0016-5085(90)91071-D; BARDRAM L, 1988, ANAL BIOCHEM, V175, P537, DOI 10.1016/0003-2697(88)90580-5; BONFILS S, 1981, ANN SURG, V194, P692, DOI 10.1097/00000658-198112000-00005; DEVENEY CW, 1977, ANN INTERN MED, V87, P680, DOI 10.7326/0003-4819-87-6-680; ELLISON EH, 1964, ANN SURG, V160, P512, DOI 10.1097/00000658-196409000-00013; FELDMAN M, 1987, GASTROENTEROLOGY, V93, P59, DOI 10.1016/0016-5085(87)90314-3; FRUCHT H, 1989, ANN INTERN MED, V111, P713, DOI 10.7326/0003-4819-111-9-713; Jensen Robert T., 1993, P931; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; MCGUIGAN JE, 1968, NEW ENGL J MED, V278, P1308, DOI 10.1056/NEJM196806132782402; MCGUIGAN JE, 1980, GASTROENTEROLOGY, V79, P1324; MEE AS, 1983, Q J MED, V52, P256; ROSCH T, 1992, NEW ENGL J MED, V326, P1721, DOI 10.1056/NEJM199206253262601; SHIMODA SS, 1968, GASTROENTEROLOGY, V55, P705; SLOAS DD, 1990, J CLIN GASTROENTEROL, V12, P573, DOI 10.1097/00004836-199010000-00017; WOLFE MM, 1985, ANN INTERN MED, V103, P215, DOI 10.7326/0003-4819-103-2-215; ZIMMER T, 1995, DEUT MED WOCHENSCHR, V120, P87, DOI 10.1055/s-2008-1047641; ZIMMER T, 1994, GUT, V35, P471, DOI 10.1136/gut.35.4.471; ZIMMER T, 1994, ANN NY ACAD SCI, V733, P425, DOI 10.1111/j.1749-6632.1994.tb17292.x	19	31	31	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					634	636		10.1056/NEJM199509073331005	http://dx.doi.org/10.1056/NEJM199509073331005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637724				2022-12-28	WOS:A1995RR84000005
J	BROWN, SD; GUTIERREZ, G				BROWN, SD; GUTIERREZ, G			IN SUPPORT OF EXPERIENCE AND JUDGMENT	LANCET			English	Editorial Material							CRITICALLY ILL PATIENTS; OXYGENATION; MORTALITY; INDEX; PH				BROWN, SD (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,HOUSTON,TX 77225, USA.		Gutierrez, Guillermo/ABC-1894-2020	Gutierrez, Guillermo/0000-0001-7754-5816				DOGLIO GR, 1991, CRIT CARE MED, V19, P1037, DOI 10.1097/00003246-199108000-00011; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLLEF MH, 1994, CRIT CARE CLIN, V10, P1; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; MAYNARD N, 1993, JAMA-J AM MED ASSOC, V270, P1203, DOI 10.1001/jama.270.10.1203; WAGNER DP, 1994, CRIT CARE MED, V22, P1359, DOI 10.1097/00003246-199409000-00004; ZIMMERMAN JE, 1994, CRIT CARE MED, V22, P1373, DOI 10.1097/00003246-199409000-00005	9	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					456	457		10.1016/S0140-6736(95)91317-3	http://dx.doi.org/10.1016/S0140-6736(95)91317-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637476				2022-12-28	WOS:A1995RP85700005
J	BURGERING, BMT; COFFER, PJ				BURGERING, BMT; COFFER, PJ			PROTEIN-KINASE-B (C-AKT) IN PHOSPHATIDYLINOSITOL-3-OH INASE SIGNAL-TRANSDUCTION	NATURE			English	Article							REGULATED KINASE-2; MOLECULAR-CLONING; PATHWAYS	A serine/threonine kinase, named protein kinase B (PKB)(1) for its sequence homology to both protein kinase A and C, has previously been isolated. PKB, which is identical to the kinase Rad, was later found to be the cellular homologue of the transforming v-Akt(3). Here we show that PKB is activated by stimuli such as insulin, platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). Activation of PKB was inhibited by the phosphatidylinositol-3-OH kinase (PI(3)K) inhibitor wortmannin and by coexpression of a dominant-negative mutant of PI(3)K. PDGF receptor mutants that lack detectable associated PI(3)K activity also fail to induce PKB activation. PKB kinase activity is correlated with phosphorylation of PKB on serine. Finally, we show that a constructed Gag-PKB fusion protein, homologous to the v-akt oncogene, displays significantly increased ligand-independent kinase activity. Furthermore, this activity is sufficient to activate the p70 S6-kinase (p70(S6k)). These results suggest a role for PKB in PI(3)K-mediated signal transduction.	NETHERLANDS INST DEV BIOL, HUBRECHT LAB, 3584 CT UTRECHT, NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	BURGERING, BMT (corresponding author), UNIV UTRECHT, PHYSIOL CHEM LAB, UNIV WEG 100, 3584 CG UTRECHT, NETHERLANDS.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Burgering, Boudewijn/0000-0002-4044-9596				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; WENNSTROM S, 1994, ONCOGENE, V9, P651	19	1796	1848	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 17	1995	376	6541					599	602		10.1038/376599a0	http://dx.doi.org/10.1038/376599a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637810				2022-12-28	WOS:A1995RP75600053
J	GOSHIMA, Y; NAKAMURA, F; STRITTMATTER, P; STRITTMATTER, SM				GOSHIMA, Y; NAKAMURA, F; STRITTMATTER, P; STRITTMATTER, SM			COLLAPSIN-INDUCED GROWTH CONE COLLAPSE MEDIATED BY AN INTRACELLULAR PROTEIN RELATED TO UNC-33	NATURE			English	Article							AXONAL GUIDANCE; ELEGANS; GAP-43; OUTGROWTH; NEURONS; BRAIN	COLLAPSIN(1), a member of the newly recognized semaphorin family(2-4), contributes to axonal pathfinding during neural development by inhibiting growth cone extension(1-5). The mechanism of collapsin action is poorly understood, Here we use a Xenopus laevis oocyte expression system to identify molecules involved in collapsin signalling, because several experiments have raised the possibility that heterotrimeric GTP-binding proteins might participate in these events(6-9). A collapsin response mediator protein of relative molecular mass (M(r)) 62K (CRMP-62) required for collapsin-induced inward currents in X. laevis oocytes is isolated. CRMP-62 shares homology with UNC-33, a nematode neuronal protein required for appropriately directed axonal extension(10-12), CRMP-62 is localized exclusively in the developing chick nervous system. Introduction of anti-CRMP-62 antibodies into dorsal root ganglion neurons blocks collapsin-induced growth cone collapse. CRMP-62 appears to be an intracellular component of a signalling cascade initiated by an unidentified transmembrane collapsin-binding protein.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT NEUROBIOL,NEW HAVEN,CT 06520	Yale University; Yale University			Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BORASIO GD, 1989, NEURON, V2, P1087; DURIEUX ME, 1992, AM J PHYSIOL, V363, pC896; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LAPOINTE G, 1994, APPL ENVIRON MICROB, V60, P888, DOI 10.1128/AEM.60.3.888-895.1994; LI W, 1992, GENETICS, V132, P675; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MORIARTY TM, 1990, G PROTEINS, P479; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; RAPER JA, 1990, NEURON, V2, P21; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TYGYL G, 1992, J BIOL CHEM, V267, P21360; YANG YS, 1993, J BIOL CHEM, V268, P10870	22	612	626	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					509	514		10.1038/376509a0	http://dx.doi.org/10.1038/376509a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637782				2022-12-28	WOS:A1995RN62200043
J	MCADAMS, HH; SHAPIRO, L				MCADAMS, HH; SHAPIRO, L			CIRCUIT SIMULATION OF GENETIC NETWORKS	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; BACTERIOPHAGE-LAMBDA; PHAGE-LAMBDA; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; LOGICAL ANALYSIS; RIGHT OPERATOR; ANTISENSE RNA; REPRESSOR; INFECTION	Genetic networks with tens to hundreds of genes are difficult to analyze with currently available techniques. Because of the many parallels in the function of these biochemically based genetic circuits and electrical circuits, a hybrid modeling approach is proposed that integrates conventional biochemical kinetic modeling within the framework of a circuit simulation. The circuit diagram of the bacteriophage lambda lysis-lysogeny decision circuit represents connectivity in signal paths of the biochemical components. A key feature of the lambda genetic circuit is that operons function as active integrated logic components and introduce signal time delays essential for the in vivo behavior of phage lambda.			MCADAMS, HH (corresponding author), STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.							ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; CAMPBELL A, 1983, LAMBDA, V2, P365; Casjens S, 1992, SEMINARS VIROLOGY, V3, P383; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; ECHOLS H, 1983, LAMBDA, V2, P75; Friedman DI, 1992, CURR OPIN GENET DEV, V2, P727, DOI 10.1016/S0959-437X(05)80133-9; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GOTTA SL, 1991, J BACTERIOL, V173, P6647, DOI 10.1128/jb.173.20.6647-6649.1991; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HARTWELL LH, 1991, GENETICS, V129, P975; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; Hendrix R. W, 1983, LAMBDA, VII; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HO YS, 1985, J BIOL CHEM, V260, P1838; HOOPES BC, 1985, P NATL ACAD SCI USA, V82, P3134, DOI 10.1073/pnas.82.10.3134; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HOYT MA, 1982, CELL, V31, P565, DOI 10.1016/0092-8674(82)90312-9; KAUFMAN M, 1985, J THEOR BIOL, V114, P527, DOI 10.1016/S0022-5193(85)80042-4; KIM SK, 1992, ANNU REV MICROBIOL, V46, P117, DOI 10.1146/annurev.mi.46.100192.001001; KORNBERG A, 1992, DNA REPLICATION, P246; KOURILSKY P, 1973, MOL GEN GENET, V122, P183, DOI 10.1007/BF00435190; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KRINKE L, 1990, GENE DEV, V4, P2223, DOI 10.1101/gad.4.12a.2223; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEONG JM, 1986, J MOL BIOL, V189, P603, DOI 10.1016/0022-2836(86)90491-2; LEVINE A, 1979, J MOL BIOL, V131, P655, DOI 10.1016/0022-2836(79)90014-7; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; LUK KC, 1983, J GEN VIROL, V64, P183, DOI 10.1099/0022-1317-64-1-183; MASON SW, 1992, J BIOL CHEM, V267, P19418; MCFALLNGAI MJ, 1991, SCIENCE, V254, P1491, DOI 10.1126/science.1962208; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; MONOD J, 1961, COLD SPRING HARB SYM, V26, P389, DOI 10.1101/SQB.1961.026.01.048; NOBLE JA, 1993, P NATL ACAD SCI USA, V90, P10866, DOI 10.1073/pnas.90.22.10866; PTASHNE M, 1992, GENETIC SWITCH GENE; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROBERTS JW, 1983, LAMBDA, V2, P123; SCHMEISSNER U, 1980, P NATL ACAD SCI-BIOL, V77, P3191, DOI 10.1073/pnas.77.6.3191; SHEA MA, 1985, J MOL BIOL, V181, P211, DOI 10.1016/0022-2836(85)90086-5; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; THOMAS R, 1991, J THEOR BIOL, V153, P1, DOI 10.1016/S0022-5193(05)80350-9; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; Wulff DL, 1983, LAMBDA, VII, P53; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; ZAMBETTI GP, 1984, MOL GEN GENET, V193, P322, DOI 10.1007/BF00330688	51	366	389	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	1995	269	5224					650	656		10.1126/science.7624793	http://dx.doi.org/10.1126/science.7624793			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624793				2022-12-28	WOS:A1995RM70200022
J	TANAKA, T; AMES, JB; HARVEY, TS; STRYER, L; IKURA, M				TANAKA, T; AMES, JB; HARVEY, TS; STRYER, L; IKURA, M			SEQUESTRATION OF THE MEMBRANE-TARGETING MYRISTOYL GROUP OF RECOVERIN IN THE CALCIUM-FREE STATE	NATURE			English	Article							BINDING PROTEIN; NERVOUS-SYSTEM; TRANSLOCATION; HIPPOCALCIN; TERMINUS; CLONING; FAMILY; RODS	RECOVERIN, a retinal calcium-binding protein of relative molecular mass (M(r)) 23K, participates In the recovery phase of visual excitation and in adaptation to background light(1-3) The Ca2+-bound form of recoverin prolongs the photoresponse(4), probably by blocking phosphorylation of photoexcited rhodopsin. Retinal recoverin contains a covalently attached myristoyl group or related acyl group at its amino terminus(6) and two Ca2+-binding sites(7). Ca2+ binding to myristoylated, but not unmyristoylated, recoverin induces its translocation to bilayer membranes, indicating that the myristoyl group is essential to the read-out of calcium signals (calcium-myristoyl switch)(8,9). Here we present the solution structure of Ca2+-free, myristoylated recombinant recoverin obtained by heteronuclear multidimensional NMR spectroscopy. The myristoyl group is sequestered in a deep hydrophobic pocket formed by many aromatic and other hydrophobic residues from five flanking helices.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	TANAKA, T (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.		Harvey, Timothy S/F-9863-2013	Harvey, Timothy S/0000-0001-6270-1943; Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BABU YS, 1988, J MOL BIOL, V24, P191; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KIM JY, 1994, J BIOL CHEM, V269, P28214; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Koch K W, 1994, Rev Physiol Biochem Pharmacol, V125, P149, DOI 10.1007/BFb0030910; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LADANT D, 1995, J BIOL CHEM, V270, P3179; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; STRYER L, 1991, J BIOL CHEM, V266, P10711; WALKER F, 1993, J BIOL CHEM, V268, P19552; YAMAGATA K, 1990, NEURON, V2, P469; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	32	278	282	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 3	1995	376	6539					444	447		10.1038/376444a0	http://dx.doi.org/10.1038/376444a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM639	7630423				2022-12-28	WOS:A1995RM63900058
J	BLAMEY, A; MUTRIE, N; AITCHISON, T				BLAMEY, A; MUTRIE, N; AITCHISON, T			HEALTH PROMOTION BY ENCOURAGED USE OF STAIRS	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,INST BIOMED & LIFE SCI,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow	BLAMEY, A (corresponding author), GREATER GLASGOW HLTH BOARD,GLASGOW G2 4JT,LANARK,SCOTLAND.							BROWNELL KD, 1980, AM J PSYCHIAT, V137, P1540; CAMPBELL MJ, 1993, MED STAT COMMONSENSE, P126; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; 1992, ALLIED DUNBAR NATION	4	114	116	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					289	290		10.1136/bmj.311.7000.289	http://dx.doi.org/10.1136/bmj.311.7000.289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633234	Green Published			2022-12-28	WOS:A1995RM71900021
J	BRADSHAW, A				BRADSHAW, A			HAS NURSING LOST ITS WAY - NURSING AND MEDICINE - COOPERATION OR CONFLICT	BRITISH MEDICAL JOURNAL			English	Article											BRADSHAW, A (corresponding author), RADCLIFFE INFIRM,NATL INST NURSING,OXFORD OX2 6HE,ENGLAND.							CALMAN K, 1993, HLTH TRENDS, V25, P1; COCHRANE A, 1989, BRIT MED J, P82; du Boulay S, 1984, C SAUNDERS; Hay R, 1994, Nurs Stand, V8, P42; MacIntyre A., 1985, AFTER VIRTUE, V2nd; PEARCE E, 1969, NURSE PATIENT; PEARSON A, 1986, NURSING MODELS PRACT; Salvage J., 1985, POLITICS NURSING; WALTON DETCHANT, 1990, METHOD MED; WEBB C, 1986, WOMENS HLTH; WEBBJOHNSON, 1969, NURSE PATIENT	11	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					304	305		10.1136/bmj.311.7000.304	http://dx.doi.org/10.1136/bmj.311.7000.304			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633243	Green Published			2022-12-28	WOS:A1995RM71900031
J	PELES, E; NATIV, M; CAMPBELL, PL; SAKURAI, T; MARTINEZ, R; LEV, S; CLARY, DO; SCHILLING, J; BARNEA, G; PLOWMAN, GD; GRUMET, M; SCHLESSINGER, J				PELES, E; NATIV, M; CAMPBELL, PL; SAKURAI, T; MARTINEZ, R; LEV, S; CLARY, DO; SCHILLING, J; BARNEA, G; PLOWMAN, GD; GRUMET, M; SCHLESSINGER, J			THE CARBONIC-ANHYDRASE DOMAIN OF RECEPTOR TYROSINE PHOSPHATASE-BETA IS A FUNCTIONAL LIGAND FOR THE AXONAL CELL RECOGNITION MOLECULE CONTACTIN	CELL			English	Article							ADHESION MOLECULE; NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; MULTIFUNCTIONAL PROTEIN; NEUROTROPHIN RECEPTORS; GLYCOPROTEIN; EXPRESSION; IMMUNOGLOBULIN; BINDING; GROWTH	Receptor-type protein tyrosine phosphatase beta (RPTP beta) is expressed in the developing nervous system and contains a carbonic anhydrase (CAH) domain as well as a fibronectin type III repeat in its extracellular domain. Fusion proteins containing these domains were used to search for ligands of RPTP beta. The CAH domain bound specifically to a 140 kDa protein expressed on the surface of neuronal cells. Expression cloning in COS7 cells revealed that this protein is contactin, a GPI membrane-anchored neuronal cell recognition molecule. The CAH domain of RPTP beta induced cell adhesion and neurite growth of primary tectal neurons, and differentiation of neuroblastoma cells. These responses were blocked by antibodies against contactin, demonstrating that contactin is a neuronal receptor for RPTP beta. These experiments show that an individual domain of RPTP beta acts as a functional ligand for the neuronal receptor contactin. The Interaction between contactin and RPTP beta may generate unidirectional or bidirectional signals during neural development.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	PELES, E (corresponding author), SUGEN INC,515 GALVESTON DR,REDWOOD CITY,CA 94063, USA.		Lev, Sima/AAP-7880-2020; grumet, martin/ABC-6462-2020	Lev, Sima/0000-0002-2108-3330; Peles, Elior/0000-0002-3325-0597	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021629] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21629] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNEA G, 1994, J BIOL CHEM, V269, P14349; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BARNEA G, 1994, CELL, V76, P205, DOI 10.1016/0092-8674(94)90328-X; BERGLUND EO, 1994, GENOMICS, V21, P571, DOI 10.1006/geno.1994.1316; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BRUMMENDORF T, 1993, NEURON, V10, P711; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DURBEC P, 1992, J CELL BIOL, V117, P877, DOI 10.1083/jcb.117.4.877; FAIVRESARRAILH C, 1992, J NEUROSCI, V12, P257; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GENNARINI G, 1989, J CELL BIOL, V109, P755; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HAWROT E, 1979, METHOD ENZYMOL, V58, P547; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAMMERS R, 1993, J BIOL CHEM, V168, P24456; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LUDECKE G, 1990, CANCER, V65, P2270, DOI 10.1002/1097-0142(19900515)65:10<2270::AID-CNCR2820651019>3.0.CO;2-4; MAA JS, 1990, J BIOL CHEM, V265, P1569; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MORALES G, 1993, NEURON, V11, P1113, DOI 10.1016/0896-6273(93)90224-F; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; REID RA, 1994, MOL BRAIN RES, V21, P1, DOI 10.1016/0169-328X(94)90372-7; ROUGON G, 1994, J MED BIOL RES, V2, P409; SAHIN M, 1995, J COMP NEUROL, V351, P617, DOI 10.1002/cne.903510410; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; SHITARA K, 1994, J BIOL CHEM, V269, P20189; SHOCK LP, 1995, MOL BRAIN RES, V28, P110, DOI 10.1016/0169-328X(94)00190-P; THEVENIAU M, 1992, J CELL BIOCHEM, V48, P61, DOI 10.1002/jcb.240480110; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WALSH FS, 1991, CELL BIOL INT REP, V15, P1151, DOI 10.1016/0309-1651(91)90061-M; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	56	353	363	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					251	260		10.1016/0092-8674(95)90312-7	http://dx.doi.org/10.1016/0092-8674(95)90312-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628014	Bronze			2022-12-28	WOS:A1995RL76000012
J	HANSEN, JG; SCHMIDT, H; ROSBORG, J; LUND, E				HANSEN, JG; SCHMIDT, H; ROSBORG, J; LUND, E			PREDICTING ACUTE MAXILLARY SINUSITIS IN A GENERAL-PRACTICE POPULATION	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-EXAMINATION; DIAGNOSIS; HISTORY; ULTRASONOGRAPHY; SYMPTOMS; SIGNS; NASAL	Objective-To evaluate the diagnostic value of symptoms, signs, erythrocyte sedimentation rate, and C reactive protein for acute maxillary sinusitis. Design-Prospective cohort study. Setting-Danish general practice in cooperation with the otorhinolaryngology and neuroradiology department at Aalborg County Hospital. Subjects-174 patients aged 18-65 years who were suspected by the general practitioner of having acute maxillary sinusitis. Main outcome measure-The independent association of symptoms, signs, erythrocyte sedimentation rate, and concentration of C reactive protein in patients with acute maxillary sinusitis defined as purulent or mucopurulent antral aspirate. Results-Only raised erythrocyte sedimentation rate (P=0.01) and raised C reactive protein (P=0.007) were found to be independently associated with a diagnosis of acute maxillary sinusitis. The combination of the two variables had a sensitivity of 0.82 and a specificity of 0.57. Conclusion-Erythrocyte sedimentation rate and C reactive protein are useful diagnostic criteria for acute maxillary sinusitis.	AALBORG CTY HOSP,DEPT OTORHINOLARYNGOL,AALBORG,DENMARK; AALBORG CTY HOSP,DEPT NEURORADIOL,AALBORG,DENMARK	Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital								Antila J., 1993, Rhinology (Utrecht), V31, P145; AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BERG O, 1985, LARYNGOSCOPE, V95, P851; BERG O, 1981, ANN OTO RHINOL LARYN, V90, P272, DOI 10.1177/000348948109000316; Bro F, 1986, Ugeskr Laeger, V148, P2540; DRUCE HM, 1992, J ALLERGY CLIN IMMUN, V90, P436, DOI 10.1016/0091-6749(92)90165-X; FLINN J, 1994, CLIN OTOLARYNGOL, V19, P287, DOI 10.1111/j.1365-2273.1994.tb01232.x; Hansen J G, 1994, Ugeskr Laeger, V156, P1934; HJORTDAHL P, 1991, Scandinavian Journal of Primary Health Care, V9, P3, DOI 10.3109/02813439109026574; Hovelius B, 1986, INFEKTIONER PRIMARVA, P75; JANNERT M, 1982, ACTA OTOLARYNGOL S, V389, P29; KATHOLM M, 1984, ACTA OTOLARYNGOL S S, V412, P88; KAY NJ, 1984, ANN OTO RHINOL LARYN, V93, P37, DOI 10.1177/000348948409300109; Lindbaek Morten, 1993, Tidsskrift for den Norske Laegeforening, V113, P700; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; UNGER JM, 1984, LARYNGOSCOPE, V94, P1319; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705	20	132	138	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					233	236		10.1136/bmj.311.6999.233	http://dx.doi.org/10.1136/bmj.311.6999.233			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL441	7627042	Green Published			2022-12-28	WOS:A1995RL44100025
J	ANDERSON, NE; BROAD, JB; BONITA, R				ANDERSON, NE; BROAD, JB; BONITA, R			DELAYS IN-HOSPITAL ADMISSION AND INVESTIGATION IN ACUTE STROKE	BRITISH MEDICAL JOURNAL			English	Article							TIME		AUCKLAND HOSP,AUCKLAND,NEW ZEALAND; SCH MED AUCKLAND,GERIATR MED SECT,AUCKLAND,NEW ZEALAND	Auckland City Hospital; University of Auckland			Broad, Joanna B/D-1194-2010	Broad, Joanna B/0000-0003-0157-7031				ALBERTS MJ, 1990, JAMA-J AM MED ASSOC, V263, P65, DOI 10.1001/jama.263.1.65; BARSAN WG, 1993, ARCH INTERN MED, V153, P2558, DOI 10.1001/archinte.153.22.2558; BONITA R, 1995, INT J EPIDEMIOL, V24, P535, DOI 10.1093/ije/24.3.535; BONITA R, 1993, LANCET, V342, P470; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835	5	51	53	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					162	162		10.1136/bmj.311.6998.162	http://dx.doi.org/10.1136/bmj.311.6998.162			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613428	Green Published			2022-12-28	WOS:A1995RK15900022
J	RAMSAY, R; FAHY, T				RAMSAY, R; FAHY, T			RECENT ADVANCES - PSYCHIATRY	BRITISH MEDICAL JOURNAL			English	Article							OBSESSIVE-COMPULSIVE DISORDER; BEHAVIOR-THERAPY; SEXUAL ABUSE; CLOZAPINE; DRUG; MANAGEMENT; DEPRESSION				RAMSAY, R (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,BETHLEM ROYAL & MAUDSLEY NHS TRUST,LONDON SE5 8AZ,ENGLAND.							AKISKAL HS, 1994, J CLIN PSYCHIAT, V55, P46; ALEXANDER PC, 1992, J CONSULT CLIN PSYCH, V60, P185, DOI 10.1037/0022-006X.60.2.185; ANDERSON J, 1993, J AM ACAD CHILD PSY, V32, P911, DOI 10.1097/00004583-199309000-00004; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BEBBINGTON P, 1994, PSYCHOL MED, V24, P707, DOI 10.1017/S0033291700027860; Caldicott F, 1994, PSYCHIAT B, V18, P385; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; COX BJ, 1993, J BEHAV THER EXP PSY, V24, P149, DOI 10.1016/0005-7916(93)90043-V; ESMAN AH, 1994, AM J PSYCHIAT, V151, P1101; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; FISHMAN RHB, 1994, LANCET, V344, P1291, DOI 10.1016/S0140-6736(94)90773-0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOODWIN GM, 1994, BRIT J PSYCHIAT, V164, P149, DOI 10.1192/bjp.164.2.149; GREENFIELD SF, 1994, BRIT J PSYCHIAT, V164, P831, DOI 10.1192/bjp.164.6.831; HARRIS B, 1994, BRIT MED J, V308, P949, DOI 10.1136/bmj.308.6934.949; HOLLANDER D, 1994, PSYCHIAT B, V18, P532; HOLLOWAY F, 1994, PSYCHIATRIC B, V18, P593; INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739; KATONA CLE, 1995, BRIT J PSYCHIAT, V166, P80, DOI 10.1192/bjp.166.1.80; KERWIN RW, 1994, BRIT J PSYCHIAT, V164, P141, DOI 10.1192/bjp.164.2.141; KINGDON D, 1994, BRIT J PSYCHIAT, V164, P581, DOI 10.1192/bjp.164.5.581; KUPFER DJ, 1993, J CLIN PSYCHIAT, V54, P29; LUCEY JV, 1994, J PSYCHOPHARMACOL, V8, P250, DOI 10.1177/026988119400800408; MARKS IM, 1994, BRIT J PSYCHIAT, V165, P179, DOI 10.1192/bjp.165.2.179; MCGUIRE PK, 1994, BRIT J PSYCHIAT, V164, P159; MULLEN PE, 1994, BRIT J PSYCHIAT, V165, P35, DOI 10.1192/bjp.165.1.35; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; PILOWSKY LS, 1992, LANCET, V340, P199, DOI 10.1016/0140-6736(92)90467-H; PRUDIC JM, 1994, PSYCHIAT ANN, V24, P228, DOI 10.3928/0048-5713-19940501-08; RAPOPORT JL, 1992, ARCH GEN PSYCHIAT, V49, P517; RAUNCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Ritchie J., 1994, REPORT INQUIRY CARE; RORTY M, 1994, AM J PSYCHIAT, V151, P1122; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; RUBIN RT, 1922, ARCH GEN PSYCHIAT, V49, P695; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SHAIKH S, 1993, LANCET, V341, P116, DOI 10.1016/0140-6736(93)92594-J; STCLAIR D, 1994, BRIT J PSYCHIAT, V164, P153, DOI 10.1192/bjp.164.2.153; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; TARRIER N, 1993, BRIT J PSYCHIAT, V162, P524, DOI 10.1192/bjp.162.4.524; TSAI MS, 1994, AM J HUM GENET, V54, P643; WATSON JP, 1994, PSYCHIAT B, V18, P531; 1994, AM J PSYCHIATRY S, V151, P1; 1993, BRIT J PSYCHIAT, V163, P150; 1993, AM J PSYCHIATRY S, V150, P1; 1994, NHSME HSG9427 MAN EX	48	2	2	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					167	170		10.1136/bmj.311.6998.167	http://dx.doi.org/10.1136/bmj.311.6998.167			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RK159	7613431	Green Published			2022-12-28	WOS:A1995RK15900025
J	POPE, C; MAYS, N				POPE, C; MAYS, N			REACHING THE PARTS OTHER METHODS CANNOT REACH - AN INTRODUCTION TO QUALITATIVE METHODS IN HEALTH AND HEALTH-SERVICES RESEARCH	BRITISH MEDICAL JOURNAL			English	Article								Qualitative research methods have a long history in the social sciences and deserve to be an essential component in health and health services research. Qualitative and quantitative approaches to research tend to be portrayed as antithetical; the aim of this series of papers is to show the value of a range of qualitative techniques and how they can complement quantitative research.	KINGS FUND INST,LONDON W2 4HT,ENGLAND		POPE, C (corresponding author), UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,22-28 PRINCESS RD W,LEICESTER LE1 6TP,LEICS,ENGLAND.							Abell Peter, 1990, WHAT HAS SOCIOLOGY A, P94; AMOS A, 1991, HLTH ED RES, V6, P443; BLOOR MJ, 1976, J LARYNGOL OTOL, V92, P883; BLOOR MJ, 1976, J LARYNGOL OTOL, V92, P791; Brannen, 2017, MIXING METHODS QUALI, P3; Bryman A, 1993, ANAL QUALITATIVE DAT; Cornwell Jocelyn, 1984, HARD EARNED LIVES AC; Denzin N.K., 1970, RES ACT; GRAHAM H, 1993, WHEN LIFES DRAG WOME; Hammersley M, 1992, MIXING METHODS QUALI, P39; MICHIE S, IN PRESS PSYCHOL HLT; MORGAN M, 1988, SOCIOL HEALTH ILL, V10, P561, DOI 10.1111/1467-9566.ep10837256; POLLITT C, 1990, J SOC POLICY, V19, P169, DOI 10.1017/S0047279400001987; POPE C, 1993, BRIT MED J, V306, P315, DOI 10.1136/bmj.306.6873.315; Silverman D., 1987, COMMUNICATION MED PR; STRONG PM, 1979, CEREMONIAL ORDER CLI; WELLING SK, 1994, SEXUAL BEHAVIOUR BRI; 1993, NEW ENGL J MED, V329, P977	18	1443	1469	2	128	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					42	45		10.1136/bmj.311.6996.42	http://dx.doi.org/10.1136/bmj.311.6996.42			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG975	7613329	Green Published			2022-12-28	WOS:A1995RG97500029
J	REES, J; PRICE, J				REES, J; PRICE, J			ABC OF ASTHMA - TREATMENT OF CHRONIC ASTHMA	BRITISH MEDICAL JOURNAL			English	Article																			0	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1459	1463		10.1136/bmj.310.6992.1459	http://dx.doi.org/10.1136/bmj.310.6992.1459			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613284	Green Published			2022-12-28	WOS:A1995RC10500033
J	BOGUSKI, MS				BOGUSKI, MS			HUNTING FOR GENES IN COMPUTER-DATA BASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											BOGUSKI, MS (corresponding author), NIH,NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,8600 ROCKVILLE PIKE,BETHESDA,MD 20894, USA.							BOGUSKI MS, 1994, CURRENT PROTOCOLS HU; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509	4	11	11	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	1995	333	10					645	647		10.1056/NEJM199509073331008	http://dx.doi.org/10.1056/NEJM199509073331008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR840	7637727				2022-12-28	WOS:A1995RR84000008
J	PSATY, BM; HECKBERT, SR; KOEPSELL, TD; SISCOVICK, DS; RAGHUNATHAN, TE; WEISS, NS; ROSENDAAL, FR; LEMAITRE, RN; SMITH, NL; WAHL, PW; WAGNER, EH; FURBERG, CD				PSATY, BM; HECKBERT, SR; KOEPSELL, TD; SISCOVICK, DS; RAGHUNATHAN, TE; WEISS, NS; ROSENDAAL, FR; LEMAITRE, RN; SMITH, NL; WAHL, PW; WAGNER, EH; FURBERG, CD			THE RISK OF MYOCARDIAL-INFARCTION ASSOCIATED WITH ANTIHYPERTENSIVE DRUG THERAPIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD-PRESSURE; NIFEDIPINE; DISEASE; ANGINA; TRIAL; PREVENTION; BLOCKERS	Objective.-To assess the association between first myocardial infarction and the use of antihypertensive agents. Design and Setting.-We conducted a population-based case-control study among enrollees of the Group Health Cooperative of Puget Sound (GHC). Patients and Methods.-Cases were hypertensive patients who sustained a first fatal or nonfatal myocardial infarction from 1986 through 1993 among women and from 1989 through 1993 among men. Controls were a stratified random sample of hypertensive GHC enrollees, frequency matched to the cases on age, sex, and calendar year, All 623 cases and 2032 controls had pharmacologically treated hypertension. Data collection included a review of the ambulatory medical record and a brief telephone interview of consenting survivors. Antihypertensive therapy was assessed using the GHC's computerized pharmacy database. Results.-The first analysis included only the 335 cases and 1395 controls initially free of cardiovascular disease. Compared with users of diuretics alone, the adjusted risk ratio of myocardial infarction was increased by about 60% among users of calcium channel blockers with or without diuretics (risk ratio=1.62; 95% confidence interval [CI], 1.11 to 2.34; P=.01). The second analysis was restricted to 384 cases and 1108 controls who were taking either a calcium channel blocker or a beta-blocker. Among these subjects, the use of calcium channel blockers compared with beta-blockers was associated with about a 60% increase in the adjusted risk of myocardial infarction (risk ratio=1.57; 95% CI, 1.21 to 2.04; P<.001). While high doses of beta-blockers were associated with a decreased risk of myocardial infarction (trend P=.04), high doses of calcium channel blockers were associated with an increased risk (trend P<.01). Conclusions.-In this study of hypertensive patients, the use of short-acting calcium channel blockers, especially in high doses, was associated with an increased risk of myocardial infarction. Ongoing targe-scale clinical trials will assess the effect of various antihypertensive therapies, including calcium channel blockers, on several important cardiovascular end points. Until these results are available, the findings of this study support the current guidelines from the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure that recommend diuretics and beta-blockers as first-line agents unless contraindicated, unacceptable; or not tolerated.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98101 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98101 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98101 USA; UNIV MICHIGAN, SURVEY RES CTR, INST SOCIAL RES, ANN ARBOR, MI USA; LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, LEIDEN, NETHERLANDS; CTR HLTH STUDIES, GRP HLTH COOPERAT PUGET SOUND, SEATTLE, WA USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; Leiden University; Leiden University Medical Center (LUMC); Group Health Cooperative; Wake Forest University; Wake Forest Baptist Medical Center	PSATY, BM (corresponding author), UNIV WASHINGTON, DEPT MED, CARDIOVASC HLTH RES UNIT, SEATTLE, WA 98101 USA.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040628, R01HL040628, R01HL043201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43201, HL40628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amery A, 1991, Aging (Milano), V3, P287; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BETO JA, 1992, AM J HYPERTENS, V5, P125, DOI 10.1093/ajh/5.3.125; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAVIS BR, IN PRESS AM J HYPERT; EGSTRUP K, 1993, AM J CARDIOL, V71, P177, DOI 10.1016/0002-9149(93)90735-U; FERGUSON JJ, 1994, CIRCULATION, V90, P2194; FURBERG CD, 1989, AM J MED, V86, P37, DOI 10.1016/0002-9343(89)90188-5; FURBERG CD, IN PRESS CIRCULATION; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HILLEGASS WB, 1994, AM J CARDIOL, V73, P835, DOI 10.1016/0002-9149(94)90805-2; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MCCLELLAN K, 1994, INPHARMA, V932, P4; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PSATY BM, 1987, J GEN INTERN MED, V2, P381, DOI 10.1007/BF02596362; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; PSATY BM, 1991, STAT MED, V10, P653, DOI 10.1002/sim.4780100416; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; PSATY BM, 1993, HYPERTENSION PRIMER, P197; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; RUZICKA M, 1992, HYPERTENSION PATHOPH, P2815; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEWESTER CS, 1994, DRUG FACTS COMP; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1993, BLOOD PRESS, V2, P314	38	877	887	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	1995	274	8					620	625		10.1001/jama.274.8.620	http://dx.doi.org/10.1001/jama.274.8.620			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP702	7637142				2022-12-28	WOS:A1995RP70200029
J	WU, HM; WANG, H; CHEUNG, AY				WU, HM; WANG, H; CHEUNG, AY			A POLLEN-TUBE GROWTH-STIMULATORY GLYCOPROTEIN IS DEGLYCOSYLATED BY POLLEN TUBES AND DISPLAYS A GLYCOSYLATION GRADIENT IN THE FLOWER	CELL			English	Article							SELF-INCOMPATIBILITY; CELL-WALL; NICOTIANA-ALATA; AXONS; PROTEINS; MOVEMENT; INVITRO; CHEMOTROPISM; POLLINATION; CHEMOTAXIS	In plant sexual reproduction, pollen tubes elongate from the stigma, through the stylar transmitting tissue, to the ovary of the pistil to deliver the male gametes for fertilization. TTS protein is a tobacco transmitting tissue glycoprotein shown to attract pollen tubes and promote their growth. Here, we show TTS proteins adhere to the pollen tube surface and tips, suggesting that they may serve as adhesive substrates for pollen tube growth. TTS proteins are also incorporated into pollen tube walls and are deglycosylated by pollen tubes, suggesting that they may provide nutrients to this process, Within the transmitting tissue, TTS proteins display a gradient of increasing glycosylation from the stigmatic end to the ovarian end of the style, coincident with the direction of pollen tube growth. These results together suggest that the TTS protein-bound sugar gradient may contribute to guiding pollen tubes from the stigma to the ovary.			WU, HM (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.			Wang, Hong/0000-0003-4130-8741				CHEUNG AY, 1995, P NATL ACAD SCI USA, V92, P3077, DOI 10.1073/pnas.92.8.3077; CHEUNG AY, 1995, CELL, V82, P383, DOI 10.1016/0092-8674(95)90427-1; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DU H, 1994, PLANT CELL, V6, P1643, DOI 10.1105/tpc.6.11.1643; FOOTE HCC, 1994, P NATL ACAD SCI USA, V91, P2265, DOI 10.1073/pnas.91.6.2265; GRAY JE, 1991, PLANT CELL, V3, P271, DOI 10.1105/tpc.3.3.271; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEATH IB, 1990, TIP GROWTH PLANT FUN; HERRERO M, 1980, PLANTA, V148, P217, DOI 10.1007/BF00380030; Heslop-Harrison Y., 1988, Sexual Plant Reproduction, V1, P182, DOI 10.1007/BF00193749; HESLOPHARRISON J, 1987, INT REV CYTOL, V107, P1, DOI 10.1016/S0074-7696(08)61072-4; HESLOPHARRISON Y, 1985, ACTA BOT NEERL, V34, P193, DOI 10.1111/j.1438-8677.1985.tb01879.x; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JAUH GY, 1995, SEX PLANT REPROD, V8, P168, DOI 10.1007/BF00242262; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KANDASARNY MK, 1994, DEVELOPMENT, V20, P3405; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Knox R. B., 1984, Cellular interactions, P508; LI XM, 1994, PLANT CELL, V6, P1923, DOI 10.1105/tpc.6.12.1923; LI YQ, 1992, PLANTA, V188, P532, DOI 10.1007/BF00197045; LI YQ, 1994, SEX PLANT REPROD, V7, P145; LIND JL, 1994, PLANT J, V6, P491, DOI 10.1046/j.1365-313X.1994.6040491.x; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MASCARENHAS JP, 1975, BOT REV, V41, P259, DOI 10.1007/BF02860839; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MASCARENHAS JP, 1962, AM J BOT, V49, P482, DOI 10.2307/2439418; MASCARENHAS JP, 1962, NATURE, V196, P292, DOI 10.1038/196292a0; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NEWBIGIN E, 1993, PLANT CELL, V5, P1315, DOI 10.1105/tpc.5.10.1315; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PLACZEK M, 1990, DEVELOPMENT, V110, P19; REGER BJ, 1992, SEX PLANT REPROD, V5, P201, DOI 10.1007/BF00189812; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROSEN WG, 1961, AM J BOT, V48, P889, DOI 10.2307/2439530; SANDERS LC, 1989, SCIENCE, V243, P1606, DOI 10.1126/science.243.4898.1606; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SOMMERVILLE J, 1987, ELECTRON MICROSCOPY; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TRINKAUS JP, 1985, J NEUROSCI RES, V13, P1, DOI 10.1002/jnr.490130102; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; WANG C, 1989, DEV BIOL, V136, P405, DOI 10.1016/0012-1606(89)90266-2; WANG H, 1993, PLANT CELL, V5, P1639, DOI 10.1105/tpc.5.11.1639; YARIV J, 1967, BIOCHEM J, V105, P10; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	51	217	233	2	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					395	403		10.1016/0092-8674(95)90428-X	http://dx.doi.org/10.1016/0092-8674(95)90428-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634329	hybrid			2022-12-28	WOS:A1995RP24200009
J	SAFRAN, C; RIND, DM; DAVIS, RB; IVES, D; SANDS, DZ; CURRIER, J; SLACK, WV; MAKADON, HJ; COTTON, DJ				SAFRAN, C; RIND, DM; DAVIS, RB; IVES, D; SANDS, DZ; CURRIER, J; SLACK, WV; MAKADON, HJ; COTTON, DJ			GUIDELINES FOR MANAGEMENT OF HIV-INFECTION WITH COMPUTER-BASED PATIENTS RECORD	LANCET			English	Article							MEDICAL RECORD; 2 HOSPITALS; REMINDERS; CARE; PHYSICIANS; SYSTEM; AIDS	Computers are steadily being incorporated in clinical practice. We conducted a nonrandomised, controlled, prospective trial of electronic messages designed to enhance adherence to clinical practice guidelines. We studied 126 physicians and nurse practitioners who used electronic medical records when caring for 349 patients with HIV infection in a primary care practice. We analysed the response times of clinicians to the situations that triggered alerts and reminders, the number of ambulatory visits, and hospitalisation. The median response times to 303 alerts in the intervention group and 388 alerts in the control group were 11 and 52 days (p<0.0001), respectively. The median response time to 432 reminders in the intervention group was 114 days and that for 360 reminders in the control group was over 500 days (p<0.0001). There was no effect on visits to the primary care practice. There was, however, a significant increase in the rate of visits outside the primary care practice (p=0.02), which is explained by the increased frequency of visits to ophthalmologists. There were no differences in admission rates (p=0.47), in admissions for pneumocystosis (p=0.09), in visits to the emergency ward (p=0.24), or in survival (p=0.19). We conclude that the electronic medical record was effective in helping clinicians adhere to practice guidelines.	THORNDIKE LAB,BOSTON,MA		SAFRAN, C (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,CTR CLIN COMP,BOSTON,MA 02215, USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006288] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS 06288] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BARNETT GO, 1993, ANN INTERN MED, V119, P1046, DOI 10.7326/0003-4819-119-10-199311150-00014; BARNETT GO, 1976, DHEW HRA763145 PUBL; BLEICH HL, 1989, M D COMPUT, V6, P149; BLEICH HL, 1985, NEW ENGL J MED, V312, P756, DOI 10.1056/NEJM198503213121205; DEGOULET P, 1990, AM J HYPERTENS, V3, P156, DOI 10.1093/ajh/3.2.156; DEGOULET P, 1980, AM J MED, V68, P560; FORDHAM D, 1990, M D COMPUT, V7, P289; FRAME P S, 1990, Journal of General Internal Medicine, V5, pS112, DOI 10.1007/BF02600855; HARRIS RP, 1990, AM J PREV MED, V6, P145, DOI 10.1016/S0749-3797(18)31019-5; KAPLAN EI, J AM STAT ASSOC, V53, P457; MAKADON HJ, 1990, J ACQ IMMUN DEF SYND, V3, P123; MAKADON HJ, 1990, J GEN INTERN MED, V5, P446, DOI 10.1007/BF02599436; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RIND DM, 1995, M D COMPUT, V12, P122; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; SAFRAN C, 1995, M D COMPUT, V12, P187; Safran C., 1992, MEDINFO 92. Proceedings of the Seventh World Congress on Medical Informatics, P495; SAFRAN C, 1989, M D COMPUT, V6, P141; SAFRAN C, 1991, M D COMPUT, V8, P291; Safran C, 1993, Proc Annu Symp Comput Appl Med Care, P224; SAFRAN E, 1993, M D COMPUT, V10, P292; SCHERRER JR, 1990, M D COMPUT, V7, P81; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; VANDERLEI J, 1991, LANCET, V338, P1504, DOI 10.1016/0140-6736(91)92311-O; WARNER HR, 1972, COMPUT BIOMED RES, V5, P65, DOI 10.1016/0010-4809(72)90007-9; WYATT J, 1993, LANCET, V344, P11682; WYATT J, 1993, LANCET, V344, P1543; WYATT J, 1993, LANCET, V344, P1609; 1994, 940572 US DEP HLTH H; 1994, LANCET, V343, P871; 1994, ANN INTERN MED, V120, P310	36	107	107	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					341	346		10.1016/S0140-6736(95)92226-1	http://dx.doi.org/10.1016/S0140-6736(95)92226-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623532				2022-12-28	WOS:A1995RM71300009
J	CLOUD, DT				CLOUD, DT			DR TAKEMI AND THE ATOMIC-BOMB - A FOOTNOTE TO HISTORY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		CHURCHILL WS, 1953, TRIUMPH TRAGEDY, P642; COSTELLO J, 1981, PACIFIC WAR; Grew Joseph C., 1944, 10 YEARS JAPAN; LUNDBERG GD, 1983, JAMA-J AM MED ASSOC, V249, P949; MORISON SE, 1963, HIST US NAVAL OPERAT, V3, P79; Republic Arizona, 1995, ARIZONA REPUBLI 0414; Rhodes Richard, 1988, MAKING ATOMIC BOMB; Spector Ronald H., 1985, EAGLE SUN AM WAR JAP; STRICKER RB, 1983, JAMA-J AM MED ASSOC, V250, P640, DOI 10.1001/jama.250.5.640; TAKEMI T, 1983, JAMA-J AM MED ASSOC, V250, P618, DOI 10.1001/jama.250.5.618; TAKEMI T, 1982, SOCIALIZED MED JAPAN; TRUMAN M, 1989, BUCK STOPS PERSONAL, P206; 1983, MED EFFECTS NUCLEAR, P4	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					413	415						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616638				2022-12-28	WOS:A1995RL41600028
J	DORSI, CJ; KARELLAS, A				DORSI, CJ; KARELLAS, A			ON LINE FOR DIGITAL MAMMOGRAPHY	LANCET			English	Editorial Material							CLUSTERED MICROCALCIFICATIONS; DIAGNOSIS				DORSI, CJ (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT RADIOL,WORCESTER,MA 01655, USA.							CHAN HP, 1990, INVEST RADIOL, V25, P1102, DOI 10.1097/00004424-199010000-00006; DERSHAW DD, 1993, AM J ROENTGENOL, V161, P554; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; DORSI CJ, 1992, RADIOLOGY, V184, P619, DOI 10.1148/radiology.184.3.1509042; GISVOLD JJ, 1994, AM J ROENTGENOL, V162, P815, DOI 10.2214/ajr.162.4.8140997; KARELLAS A, 1992, MED PHYS, V19, P1015, DOI 10.1118/1.596819; KARSSEMEIJER N, 1993, INVEST RADIOL, V28, P413, DOI 10.1097/00004424-199305000-00005; MAIDMENT ADA, 1993, MED PHYS, V20, P1621, DOI 10.1118/1.596949; NISHIKAWA RM, 1993, MED PHYS, V20, P1661, DOI 10.1118/1.596952; WINFIELD D, 1994, INVEST RADIOL, V29, P507, DOI 10.1097/00004424-199404000-00021; WONG AWK, 1994, RADIOGRAPHICS, V14, P1119, DOI 10.1148/radiographics.14.5.7991818	11	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 29	1995	346	8970					263	264		10.1016/S0140-6736(95)92161-3	http://dx.doi.org/10.1016/S0140-6736(95)92161-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL757	7630243				2022-12-28	WOS:A1995RL75700006
J	RODRIGUES, JJ; MEHENDALE, SM; SHEPHERD, ME; DIVEKAR, AD; GANGAKHEDKAR, RR; QUINN, TC; PARANJAPE, RS; RISBUD, AR; BROOKMEYER, RS; GADKARI, DA; GOKHALE, MR; ROMPALO, AM; DESHPANDE, SG; KHALANDKAR, MM; MAWAR, N; BOLLINGER, RC				RODRIGUES, JJ; MEHENDALE, SM; SHEPHERD, ME; DIVEKAR, AD; GANGAKHEDKAR, RR; QUINN, TC; PARANJAPE, RS; RISBUD, AR; BROOKMEYER, RS; GADKARI, DA; GOKHALE, MR; ROMPALO, AM; DESHPANDE, SG; KHALANDKAR, MM; MAWAR, N; BOLLINGER, RC			RISK-FACTORS FOR HIV-INFECTION IN PEOPLE ATTENDING CLINICS FOR SEXUALLY-TRANSMITTED DISEASES IN INDIA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the risk factors for HIV infection in patients attending clinics for sexually transmitted diseases in India. Design-Descriptive study of HN serology, risk behaviour, and findings on physical examination. Subjects-2800 patients presenting to outpatient clinics between 13 May 1993 and 15 July 1994. Setting-Two clinics and the National AIDS Research Institute, in Pune, Maharashtra State, India. Main outcome measure-HIV status, presence of sexually transmitted diseases, and sexual behaviour. Results-The overall proportion of patients infected with HIV was 23.4% (655/2800); 34% (184) of the women and 21% (459) of the men were positive for HN infection. Of the 560 women screened, 338 (60%) had a reported history of sex working, of whom 153 (45%) were infected with HIV-1. The prevalence of HIV-1 infection in the 222 women who were not sex workers was 14%. The significant independent characteristics associated with HIV infection based on a logistic regression analysis included being a female sex worker, sexual contact with a sex worker, lack of formal education, receptive anal sex in the previous three months, lack of condom use in the previous three months, current or previous genital ulcer or genital discharge, and a positive result of a Venereal Disease Research Laboratory test. Conclusions-In India the prevalence of HIV infection is alarmingly high among female sex workers and men attending clinics for sexually transmitted diseases, particularly in those who had recently had contact with sex workers. A high prevalence of HIV infection was also found in monogamous, married women presenting to the clinics who denied any history of sex working. The HIV epidemic in India is primarily due to heterosexual transmission of HIV-1 and, as in other countries, HIV infection is associated with ulcerative and non-ulcerative sexually transmitted diseases.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; NATL AIDS RES INST,POONA,MAHARASHTRA,INDIA; NIAID,BETHESDA,MD 20892; BJ MED COLL,POONA,MAHARASHTRA,INDIA; SASSOON GEN HOSP,POONA,MAHARASHTRA,INDIA; PUNE MUNICIPAL CORP,DR KOTNIS HLTH CTR,POONA,MAHARASHTRA,INDIA	Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); B.J. Govt. Medical College & Sassoon General Hospitals, Pune				Bollinger, Robert/0000-0002-6798-6834; Paranjape, Ramesh/0000-0003-2948-9148	FIC NIH HHS [D43 TW0000] Funding Source: Medline; NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NIAID NIH HHS [AI 33879-02] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [N01TW000000] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAVE GG, 1992, 8TH INT C AIDS AMST; BHAVE GG, 1990, 6TH INT C AIDS SAN F; BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; HASMUKH S, 1992, 8TH INT C AIDS AMST; JACOB M, 1992, 8 INT C AIDS AMST; JAIN MK, 1994, J ACQ IMMUN DEF SYND, V7, P1185; JOSHI SH, 1992, 8 INT C AIDS AMST; KULKARNI S, 1992, INDIAN J MED RES-A, V95, P213; Kumar B, 1990, Int J STD AIDS, V1, P438; MANIAR JK, 1992, 8 INT C AIDS AMST; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; SIMOES EAF, 1987, INDIAN J MED RES, V85, P335; THAKUR T S, 1991, Indian Journal of Medical Sciences, V45, P332; THAKUR T S, 1991, Journal of Communicable Diseases, V23, P38; TRIPATHY S, 1993, 9TH INT C AIDS BERL; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1993, OVERVIEW HIV TRENDS	17	98	101	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					283	286		10.1136/bmj.311.7000.283	http://dx.doi.org/10.1136/bmj.311.7000.283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633230	Green Published			2022-12-28	WOS:A1995RM71900017
J	MAYS, N; POPE, C				MAYS, N; POPE, C			QUALITATIVE RESEARCH .3. OBSERVATIONAL METHODS IN HEALTH-CARE SETTINGS	BRITISH MEDICAL JOURNAL			English	Article								Clinicians used to observing individual patients, and epidemiologists trained to observe the course of disease, may be forgiven for misunderstanding the term observational method as used in qualitative research. In contrast to the clinician or epidemiologist, the qualitative researcher systematically watches people and events to find out about behaviours and interactions in natural settings. Observation, in this sense, epitomises the idea of the researcher as the research instrument. It involves ''going into the field''-describing and analysing what has been seen. In health care settings this method has been insightful and illuminating, but it is not without pitfalls for the unprepared researcher.	UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 6TP,LEICS,ENGLAND	University of Leicester	MAYS, N (corresponding author), KINGS FUND INST,LONDON W2 4HT,ENGLAND.			Pope, Catherine/0000-0002-8935-6702				BLOOR M, 1976, SOCIOLOGY, V10, P43, DOI 10.1177/003803857601000103; BLOOR M, 1978, SOCIOLOGY, V12, P545, DOI 10.1177/003803857801200307; Bryman A, 1993, ANAL QUALITATIVE DAT; FIELDING N, 1981, NATIONAL FRONT; Goffman E, 1961, ENCOUNTERS 2 STUDIES; GOLD RL, 1958, SOC FORCES, V36, P217, DOI 10.2307/2573808; HUGHES D, 1990, SOCIOLOGY HLTH ILLNE, V11, P382; HUGHES JA, 1976, SOCIOLOGICAL ANAL ME; Humphreys Laud, 1970, TEAROOM TRADE IMPERS; Jeffery R, 1979, Sociol Health Illn, V1, P90, DOI 10.1111/1467-9566.ep11006793; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Pearson Geoffrey, 1983, HOOLIGAN HIST RESPEC; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; Roethlisberger F. J., 1939, MANAGEMENT WORKER; Roth JA., 1963, TIMETABLES STRUCTURI; Whyte William Foote, 1955, STREET CORNER SOC	16	271	278	2	37	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					182	184		10.1136/bmj.311.6998.182	http://dx.doi.org/10.1136/bmj.311.6998.182			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RK159	7613435	Green Published			2022-12-28	WOS:A1995RK15900029
J	POZNANSKY, MC; COKER, R; SKINNER, C; HILL, A; BAILEY, S; WHITAKER, L; RENTON, A; WEBER, J				POZNANSKY, MC; COKER, R; SKINNER, C; HILL, A; BAILEY, S; WHITAKER, L; RENTON, A; WEBER, J			HIV-POSITIVE PATIENTS FIRST PRESENTING WITH AN AIDS-DEFINING ILLNESS - CHARACTERISTICS AND SURVIVAL	BRITISH MEDICAL JOURNAL			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; INFECTION; ZIDOVUDINE; DIAGNOSIS	Objectives-To study the presentation and survival of patients who present with their first diagnosis of being HIV positive at the same time as their AIDS defining illness. Design-Retrospective study of patients presenting with AIDS between 1991 and 1993. Setting-Department of genitourinary medicine, St Mary's Hospital, London. Main outcome measures-AIDS defining illness at presentation and survival after diagnosis of AIDS. Results-Between January 1991 and December 1993, 97 out of 436 patients (22%) presented with their first AIDS defining illness coincident with their first positive result of an HIV test (group B). The remaining 339 patients (78%) had tested positive for, HIV-1 infection within the previous eight years and had consequently been followed up in clinics before developing their first AIDS defining illness (group A). The two groups of patients did not differ in age and sex distribution, risk factors for HIV-1 infection, nationality, country of origin, or haematological variables determined at the time of the AIDS defining illness. However, the defining illnesses differed between the two groups. Illnesses associated with severe immunodeficiency (the wasting syndrome, cryptosporidiosis, and cytomegalovirus infection) were seen almost exclusively in group A whereas extrapulmonary tuberculosis and Pneumocystis carinii pneumonia were more common in group B. The survival of patients in group B after the onset of AIDS was significantly longer than that of patients in group A as determined by Kaplan-Meier log rank analysis (P = 0.0026). Conclusions-Subjects who are HIV positive and present late are a challenge to the control of the spread of HIV infection because they progress from asymptomatic HIV infection to AIDS without receiving health care. The finding that presentation with an AIDS defining illness coincident with a positive result in an HIV test did not have a detrimental effect on survival gives insights into the effects of medical intervention on disease progression after a diagnosis of AIDS.	ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1NY,ENGLAND	Imperial College London	POZNANSKY, MC (corresponding author), ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED & COMMUNICABLE DIS,LONDON W2 1NN,ENGLAND.		Poznansky, Mark C/M-4996-2015	Poznansky, Mark C/0000-0003-1344-7103				BACHETTI P, 1988, J INFECT DIS, V157, P1044; COKER RJ, 1992, LANCET, V340, P1099, DOI 10.1016/0140-6736(92)93120-C; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HANSON DL, 1993, J ACQ IMMUN DEF SYND, P624; ODDONE EZ, 1993, BRIT MED J, V307, P1322, DOI 10.1136/bmj.307.6915.1322; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; PORTER K, 1993, BRIT MED J, V307, P20, DOI 10.1136/bmj.307.6895.20; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; 1993, LANCET, V343, P871; 1987, MMWR S3, V36, pS15	13	57	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					156	158		10.1136/bmj.311.6998.156	http://dx.doi.org/10.1136/bmj.311.6998.156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613426	Green Published			2022-12-28	WOS:A1995RK15900020
J	HAMPTON, HL				HAMPTON, HL			CURRENT CONCEPTS - CARE OF THE WOMAN WHO HAS BEEN RAPED	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEXUAL ASSAULT; VICTIMS; WOMEN				HAMPTON, HL (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT OBSTET & GYNECOL,2500 N STATE ST,JACKSON,MS 39216, USA.							Burgess AW, 1974, RAPE VICTIMS CRISIS, P37; CHAKRABORTY R, 1991, SCIENCE, V254, P1735, DOI 10.1126/science.1763323; DAVIS TC, 1993, J ADOLESCENT HEALTH, V14, P220, DOI 10.1016/1054-139X(93)90009-E; DEMING JE, 1983, J FORENSIC SCI, V28, P572; Geist R F, 1988, Emerg Med Clin North Am, V6, P439; GRAVES HCB, 1985, NEW ENGL J MED, V312, P338, DOI 10.1056/NEJM198502073120603; JENNY C, 1990, NEW ENGL J MED, V322, P713, DOI 10.1056/NEJM199003153221101; MARCHBANKS PA, 1990, AM J EPIDEMIOL, V132, P540, DOI 10.1093/oxfordjournals.aje.a115690; MCCAULEY J, 1986, PEDIATRICS, V78, P1039; MIRABILE PJ, 1980, TULANE LAW REV, V54, P456; RAMBOW B, 1992, ANN EMERG MED, V21, P727, DOI 10.1016/S0196-0644(05)82788-X; RAMIN SM, 1992, OBSTET GYNECOL, V80, P860; SCHWARCZ SK, 1990, REV INFECT DIS, V12, pS682; SCHWARTZ IL, 1991, AM J PREV MED, V7, P363, DOI 10.1016/S0749-3797(18)30873-0; SLAUGHTER L, 1992, AM J OBSTET GYNECOL, V166, P83, DOI 10.1016/0002-9378(92)91834-W; WARNER CG, 1980, RAPE SEXUAL ASSAULT, P47; YOUNG WW, 1992, OBSTET GYNECOL, V80, P878; YUZPE AA, 1982, FERTIL STERIL, V37, P508; 1993, MMWR-MORBID MORTAL W, V42, P8; 1988, UNIFORM CRIME REPORT, P46; 1993, MMWR-MORBID MORTAL W, V42, P1	21	45	46	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					234	237		10.1056/NEJM199501263320407	http://dx.doi.org/10.1056/NEJM199501263320407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7619112				2022-12-28	WOS:A1995QC27000007
J	LECKBAND, D				LECKBAND, D			THE SURFACE FORCE APPARATUS - A TOOL FOR PROBING MOLECULAR PROTEIN INTERACTIONS	NATURE			English	Article							ADHESION; LIQUIDS	Force measurements can probe directly the molecular impact of proteins' electrostatic surface properties, specific bond strengths, membrane composition, and membrane fluidity on biological recognition events.			LECKBAND, D (corresponding author), UNIV ILLINOIS,DEPT CHEM ENGN,URBANA,IL 61801, USA.		Ueno, Hiroshi/C-3301-2009					BALGI G, 1995, BIOPHYS J, V68, P2251, DOI 10.1016/S0006-3495(95)80407-8; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HUNTER RJ, 1989, F COLLOID SCI, V1; ISRAELAC.JN, 1973, J COLLOID INTERF SCI, V44, P259, DOI 10.1016/0021-9797(73)90218-X; ISRAELACHVILI J, 1987, P NATL ACAD SCI USA, V84, P4722, DOI 10.1073/pnas.84.14.4722; ISRAELACHVILI JN, 1978, J CHEM SOC FARAD T 1, V74, P975, DOI 10.1039/f19787400975; ISRAELACHVILI JN, 1992, SURF SCI REP, V14, P109, DOI 10.1016/0167-5729(92)90015-4; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; LECKBAND D, 1993, ENZYME MICROB TECH, V15, P450, DOI 10.1016/0141-0229(93)90077-F; LECKBAND D, IN PRESS BIOCHEMISTR; LECKBAND D, IN PRESS BIOPHYS J; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE CS, 1989, P NATL ACAD SCI USA, V86, P8392, DOI 10.1073/pnas.86.21.8392; MARRA J, 1986, BIOPHYS J, V49, P815; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; OKUSA H, 1994, LANGMUIR, V10, P3577, DOI 10.1021/la00022a034; PATEL SS, 1989, ANNU REV PHYS CHEM, V40, P597; TABOR D, 1969, PROC R SOC LON SER-A, V312, P435, DOI 10.1098/rspa.1969.0169; TIMBS MM, 1991, BIOCHIM BIOPHYS ACTA, V1064, P219, DOI 10.1016/0005-2736(91)90305-R	23	52	54	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					617	618		10.1038/376617a0	http://dx.doi.org/10.1038/376617a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7637815				2022-12-28	WOS:A1995RP75600059
J	NELSON, R; NORTON, N; CAUTLEY, E; FURNER, S				NELSON, R; NORTON, N; CAUTLEY, E; FURNER, S			COMMUNITY-BASED PREVALENCE OF ANAL INCONTINENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FECAL INCONTINENCE	Objective.-To determine the prevalence of and Characteristics associated with anal incontinence in the general community. Setting.-Community survey. Participants.-The population of the state of Wisconsin sampled in the Wisconsin Family Health Survey. Subjects were identified by random digit dialing with telephone interview. The individual within each household identified as most knowledgeable about the health status of all other members of the household was asked about the health status of each member of the household. Approximately 200 households were surveyed each month. Main Outcome Measures.-The presence of anal incontinence to solid or liquid feces or gas, who suffered from it, the frequency of anal incontinence, and how the incontinent person coped with it. Results.-A total of 2570 households comprising 6959 individuals were surveyed, and 153 individuals were reported to have anal incontinence, representing 2.2% of the population (95% confidence interval [Cl], +/-0.3%). Thirty percent of the incontinent subjects were older than 65 years, and 63% were women. Of those with anal incontinence, 36% were incontinent to solid feces, 54% to liquid feces, and 60% to gas, In a multivariate analysis, independent associations of the following risk factors with anal incontinence were found: female sex (odds ratio [OR], 1.5, Cl, 1.1 to 2.1), age (continuously adjusted) (OR, 1.01; Cl, 1.01 to 1.02), physical limitations (OR, 1.8; Cl, 1.2 to 2.7), and poor general health (OR, 1.6, Cl, 1.4 to 1.9). Conclusions.-Anal incontinence was reported in 2.2% of the general population. Independent risk factors for incontinence include female sex, advancing age, poor general health, and physical limitations.	UNIV ILLINOIS,COLL MED,DEPT SURG,COLON & RECTAL SURG SECT,CHICAGO,IL; UNIV ILLINOIS,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,CHICAGO,IL; INT FDN BOWEL DYSFUNCT,MILWAUKEE,WI; STATE WISCONSIN DEPT HLTH & SOCIAL SERV,MADISON,WI	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								CAMPBELL AJ, 1985, AGE AGEING, V14, P65, DOI 10.1093/ageing/14.2.65; DEAN AG, 1991, EPI INFO MANUAL VERS; DENIS P, 1992, GASTROEN CLIN BIOL, V16, P344; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; DROSSMAN DA, 1989, AM J GASTROENTEROL, V84, P355; KOK ALM, 1992, AGE AGEING, V21, P211, DOI 10.1093/ageing/21.3.211; LEIGH RJ, 1982, LANCET, V1, P1349; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MADOFF RD, 1992, NEW ENGL J MED, V326, P1002; SCHILLER LR, 1982, NEW ENGL J MED, V307, P1666, DOI 10.1056/NEJM198212303072702; SMALL KA, 1990, AUST NZ J OBSTET GYN, V90, P41; Thomas T M, 1984, Community Med, V6, P216; 1994, 1993 WISCONSIN FAMIL; 1989, VITAL HLTH STAT 14, V33; 1994, PROFILE WISCONSIN NU	15	482	499	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	1995	274	7					559	561		10.1001/jama.274.7.559	http://dx.doi.org/10.1001/jama.274.7.559			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN466	7629985				2022-12-28	WOS:A1995RN46600027
J	ELLIS, J; MULLIGAN, I; ROWE, J; SACKETT, DL				ELLIS, J; MULLIGAN, I; ROWE, J; SACKETT, DL			INPATIENT GENERAL MEDICINE IS EVIDENCE BASED	LANCET			English	Article							THERAPY; METAANALYSIS; MULTICENTER; DISEASE; ANGINA; TRIAL	For many years clinicians have had to cope with the accusation that only 10-20% of the treatments they provide have any scientific foundation. Their interventions, in other words, are seldom ''evidence based''. Is the profession guilty as charged? In April, 1995, a general medical team at a university-affiliated district hospital in Oxford, UK, studied the treatments given to all 109 patients managed during that month on whom a diagnosis had been reached. Medical sources (including databases) were then searched for randomised controlled trial (RCT) evidence that the treatments were effective. The 109 primary treatments were then classified: 82% were evidence based (ie, there was RCT support [53%] or unanimity on the team about the existence of convincing non-experimental evidence [29%]). This study, which needs to be repeated in other clinical settings and for other disciplines, suggests that earlier pessimism over the extent to which evidence-based medicine is already practised is misplaced.	OXFORD RADCLIFFE NHS TRUST, NUFFIELD DEPT CLIN MED, CTR EVIDENCE BASED MED, OXFORD OX3 9DU, ENGLAND; JOHN RADCLIFFE HOSP, GEN MED SERV, OXFORD, ENGLAND	University of Oxford; University of Oxford			Tick, Beata/ABA-1728-2020; rowe, james B/C-3661-2013	rowe, james B/0000-0001-7216-8679				ABE O, 1992, LANCET, V339, P71; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1978, ASSESSING EFFICACY S; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARRITT DW, 1960, LANCET, V1, P1309; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CHAPMAN KR, 1991, NEW ENGL J MED, V325, P585; COCHRANE AD, 1994, EUR J CARDIO-THORAC, V8, P194, DOI 10.1016/1010-7940(94)90114-7; DEVITA C, 1994, LANCET, V343, P1115; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Dubinsky M, 1990, Int J Technol Assess Health Care, V6, P480; HARGREAVES MR, 1995, LANCET, V345, P13, DOI 10.1016/S0140-6736(95)91151-0; HOHNLOSER SH, 1992, AM J CARDIOL, V70, pA3, DOI 10.1016/0002-9149(92)91071-B; HOLMES OW, 1968, FAMILIAR QUOTATIONS, P124; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Le Chevalier T, 1991, Cancer Treat Res, V58, P139; LEE HN, 1993, CLIN RES, V41, pA543; LEVINE MN, 1986, ARCH INTERN MED, V146, P353, DOI 10.1001/archinte.146.2.353; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MCLENACHAN JM, 1988, BRIT HEART J, V59, P685; RAPHAEL JC, 1989, LANCET, V2, P414; SMITH R, 1992, J MED ETHICS, V18, P117, DOI 10.1136/jme.18.3.117; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; SONTAG SJ, 1992, GASTROENTEROLOGY, V102, P109, DOI 10.1016/0016-5085(92)91790-B; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; The SOLVD Investigators, 1991, NEW ENGL J MED, V325, P294; VALE JA, 1993, BRIT MED J, V306, P78, DOI 10.1136/bmj.306.6870.78; WALLENTIN L, 1990, LANCET, V336, P827; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303; WILLIAMSON JW, 1979, MED PRACTICE INFORMA; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1995, STROKE MODULE COCHRA; 1983, IMPACT RANDOMISED CL	37	324	331	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 12	1995	346	8972					407	410		10.1016/S0140-6736(95)92781-6	http://dx.doi.org/10.1016/S0140-6736(95)92781-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623571	Bronze			2022-12-28	WOS:A1995RN65600010
J	MORRONE, MC; BURR, DC; VAINA, LM				MORRONE, MC; BURR, DC; VAINA, LM			2 STAGES OF VISUAL PROCESSING FOR RADIAL AND CIRCULAR MOTION	NATURE			English	Article							OPTICAL-FLOW; STIMULI; FIELD; SUMMATION; MONKEY; SIZE	As we move through our environment, the flow of the deforming images on our retinae provides rich information about ego motion and about the three-dimensional structure of the external world, Flow-fields comprise five independent compenents, including radial and circular motion(1-3). Here we provide psychophysical evidence for the existence of neural mechanisms in human vision that integrate motion signals along these complex trajectories, Signal-to-noise sensitivity for discriminating the direction of radial, circular and translational motion increased predictably with the number of exposed sectors, implying the existence of specialized detectors that integrate motion signals of different directions from different locations, However, contrast sensitivity for complex motion did not increase greatly with sector number, implying that the specialized detectors are preceded by a first stage of local-motion mechanisms that impose a contrast threshold. These findings fit well with recent electrophysiological evidence in monkey(4-7) showing that whereas motion-sensitive neurons in primary visual cortex respond best to local translation, many neurons in the medial superior temporal cortex have large receptive fields tuned to radial, circular or spiral motion.	CNR,IST NEUROFISIOL,I-56127 PISA,ITALY; SCUOLA NORMALE SUPER PISA,PISA,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,I-00185 ROME,ITALY; BOSTON UNIV,COLL ENGN,DEPT BIOMED ENGN,BOSTON,MA 02215	Consiglio Nazionale delle Ricerche (CNR); Scuola Normale Superiore di Pisa; Sapienza University Rome; Boston University			Morrone, Maria Concetta/C-6756-2014	Morrone, Maria Concetta/0000-0002-1025-0316; Burr, David/0000-0003-1541-8832	NEI NIH HHS [R01 EY007861] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007861] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON SJ, 1991, J OPT SOC AM A, V8, P1330, DOI 10.1364/JOSAA.8.001330; ANDERSON SJ, 1987, VISION RES, V27, P621, DOI 10.1016/0042-6989(87)90047-2; BARLOW HB, 1978, VISION RES, V18, P637, DOI 10.1016/0042-6989(78)90143-8; BEVERLEY KI, 1979, VISION RES, V19, P1093, DOI 10.1016/0042-6989(79)90004-X; BRADDICK O, 1974, VISION RES, V14, P519, DOI 10.1016/0042-6989(74)90041-8; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; FREDERICKSEN RE, 1994, VISION RES, V34, P3171, DOI 10.1016/0042-6989(94)90082-5; GRAHAM N, 1977, VISION RES, V17, P637, DOI 10.1016/0042-6989(77)90140-7; GRAZIANO MSA, 1994, J NEUROSCI, V14, P54; GREEN DM, 1966, SIGNAL DETECTION THE; HANNON WH, 1988, NATURE, V336, P162; HELMHOLTZ H, 1858, CRELLES J, V55, P25, DOI DOI 10.1515/CRLL.1858.55.25; KOENDERINK JJ, 1986, VISION RES, V26, P161, DOI 10.1016/0042-6989(86)90078-7; MORGAN MJ, 1992, NATURE, V355, P344, DOI 10.1038/355344a0; NELDER JA, 1964, COMPUT J, V7, P308; ORBAN GA, 1992, P NATL ACAD SCI USA, V89, P2595, DOI 10.1073/pnas.89.7.2595; PELLI DG, 1985, J OPT SOC AM A, V2, P1508, DOI 10.1364/JOSAA.2.001508; PETERSIK JT, 1981, VISION RES, V21, P829, DOI 10.1016/0042-6989(81)90182-6; REGAN D, 1978, VISION RES, V18, P415, DOI 10.1016/0042-6989(78)90051-2; Saito H. A., 1986, J NEUROSCI, V7, P177; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; VERRI A, 1990, J OPT SOC AM A, V7, P912, DOI 10.1364/JOSAA.7.000912; WARREN WH, 1990, J OPT SOC AM A, V7, P160, DOI 10.1364/JOSAA.7.000160; WATAMANIUK SNJ, 1992, VISION RES, V32, P2341, DOI 10.1016/0042-6989(92)90097-3; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; YANG YD, 1994, NATURE, V371, P793, DOI 10.1038/371793a0	26	215	216	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					507	509		10.1038/376507a0	http://dx.doi.org/10.1038/376507a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637781				2022-12-28	WOS:A1995RN62200042
J	TOMLINSON, P; SUGARMAN, ID				TOMLINSON, P; SUGARMAN, ID			COMPLICATIONS WITH SHUNTS IN ADULTS WITH SPINA-BIFIDA	BRITISH MEDICAL JOURNAL			English	Article							INTRACRANIAL-PRESSURE; CHILDREN	Objective-To assess the incidence of malfunction of shunts in adults with spina bifida who have shunts to control hydrocephalus. Design-A retrospective review of the medical notes and contact by questionnaire of adults with spina bifida to assess symptoms, function of shunts, frequency of operative procedures, and follow up. Subjects-110 patients with shunts who attended Lord Mayor Treloar College for the physically disabled between 1978 and 1993. Results-The average (range) number of revisions of shunts per person was 3.6 (0-28). Although 37 patients underwent an emergency operation for revision in their first year of life, there was a continuing low incidence, increasing in the early teenage years, which persisted into the third decade. Intervals between emergency revisions varied:. 202/ 320 occurred within one year of the last shunt operation, 56 occurred after five years, 24 after 10 years, and 15 after 15 or more years. Fifteen patients had chronic intermittent headaches, of whom four died and three suffered severe morbidity. Thirteen died; three had raised intracranial pressure, and four died suddenly; these deaths were presumed to be related to their shunts. Up to the age of 16 there was 100% hospital follow up, but after that only 40% of young adults underwent review, including review of their shunt function. Conclusion-Shunts to control hydrocephalus may fail after many years without symptoms, This is difficult to diagnose and if missed may lead to chronic morbidity and death. As hospital follow up of this group is falling, both general practitioners and hospital doctors must be aware that a shunt may malfunction after prolonged quiescent periods.	LORD MAYOR TRELOAR COLL,ALTON,HANTS,ENGLAND; UNIV SOUTHAMPTON,DEPT CHILD HLTH,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton								BRYDON HL, 1994, EUR J PEDIATR SURG, V4, P37; DOYLE J, 1992, J CLIN MONITOR, V8, P81, DOI 10.1007/BF01618093; DRAKE JM, 1991, J NEUROSURG, V75, P535, DOI 10.3171/jns.1991.75.4.0535; EPSTEIN F, 1982, MONOGR NEURAL SCI, V8, P105; HEMMER R, 1976, DEV MED CHILD NEUROL, V18, P69; HEMMER R, 1982, MONOGR NEURAL SCI, V8, P227; LORBER J, 1982, MONOGR NEUROL SCI, V8, P134; MOSS SM, 1991, EUR J PEDIATR SURG, V1, P25, DOI 10.1055/s-2008-1042533; PIATT JH, 1993, PEDIATR NEUROSURG, V19, P233, DOI 10.1159/000120738; POPLE IK, 1992, CHILD NERV SYST, V8, P124, DOI 10.1007/BF00298265; RICHMOND TS, 1993, CLIN ISSUES CRITICAL, V4, P148; UVEBRANT P, 1992, CHILD NERV SYST, V8, P76, DOI 10.1007/BF00298444	12	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					286	287		10.1136/bmj.311.7000.286	http://dx.doi.org/10.1136/bmj.311.7000.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633231	Green Published			2022-12-28	WOS:A1995RM71900018
J	SIEGEL, V				SIEGEL, V			A 2ND SIGNAL RECOGNITION EVENT REQUIRED FOR TRANSLOCATION INTO THE ENDOPLASMIC-RETICULUM	CELL			English	Review							SEQUENCE; PROTEIN; EXPORT; SEC61P						Siegel, Vivian/E-9604-2010; Siegel, Vivian/N-3672-2014	Siegel, Vivian/0000-0001-9537-9989				CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LAURING B, 1995, IN PRESS P NATL ACAD; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	17	17	17	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					167	170		10.1016/0092-8674(95)90301-1	http://dx.doi.org/10.1016/0092-8674(95)90301-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628005	Bronze			2022-12-28	WOS:A1995RL76000001
J	MIETTINEN, PJ; BERGER, JE; MENESES, J; PHUNG, Y; PEDERSEN, RA; WERB, Z; DERYNCK, R				MIETTINEN, PJ; BERGER, JE; MENESES, J; PHUNG, Y; PEDERSEN, RA; WERB, Z; DERYNCK, R			EPITHELIAL IMMATURITY AND MULTIORGAN FAILURE IN MICE LACKING EPIDERMAL GROWTH-FACTOR RECEPTOR	NATURE			English	Article							FACTOR EXPRESSION; LUNG MATURATION; MOUSE; GENE; ALPHA; MILK; EGF	SINCE the discovery that epidermal growth factor (EGF) can accelerate opening of the eyelids(1), the EGF receptor (EGF-R) has been extensively studied and is now considered to be a prototype tyrosine kinase receptor(2). Binding of EGF or of transforming growth factor-alpha (TGF-alpha) or other related factors activates the receptor and induces cell proliferation and differentiation. Although it is not found on haematopoietic cells, the EGF-R is widely expressed in mammals and has been implicated in various stages of embryonic development(3). Here we investigate the developmental and physiological roles of this receptor and its ligands by inactivating the gene encoding EGF-R. We find that EGF-R(-/-) mice survive for up to 8 days after birth and suffer from impaired epithelial development in several organs, including skin, lung and gastrointestinal tract.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEV BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	MIETTINEN, PJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143, USA.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BEARDMORE JM, 1983, PEDIATR RES, V17, P825, DOI 10.1203/00006450-198310000-00012; CATTERTON WZ, 1979, PEDIATR RES, V13, P104, DOI 10.1203/00006450-197902000-00004; COHEN S, 1962, J BIOL CHEM, V237, P1555; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; FONDACCI C, 1994, J CLIN INVEST, V93, P1149, DOI 10.1172/JCI117067; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FUJITA Y, 1991, J CLIN ENDOCR METAB, V72, P1340, DOI 10.1210/jcem-72-6-1340; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GOETZMAN BW, 1993, PEDIATR RES, V35, P30; Hogan B, 1994, MANIPULATING MOUSE E; JOBE AH, 1991, ANN MED, V23, P687, DOI 10.3109/07853899109148104; Joyner AL, 1993, GENE TARGETING PRACT; LUETTEKE NC, 1994, GENE DEV, V6, P399; LUETTEKE NC, 1993, CELL, V73, P249; MALO C, 1982, GASTROENTEROLOGY, V83, P28; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MENARD D, 1988, GASTROENTEROLOGY, V94, P656, DOI 10.1016/0016-5085(88)90236-3; MIETTINEN PJ, 1993, PEDIATR RES, V33, P481, DOI 10.1203/00006450-199305000-00012; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; OKADA M, 1991, LIFE SCI, V48, P1151, DOI 10.1016/0024-3205(91)90452-H; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P55, DOI 10.1073/pnas.90.1.55; PLOPPER CG, 1992, AM J PHYSIOL, V262, pL313, DOI 10.1152/ajplung.1992.262.3.L313; RAABERG L, 1995, PEDIATR RES, V37, P175, DOI 10.1203/00006450-199502000-00009; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIBILLIA M, IN PRESS SCIENCE; SUNDELL HW, 1980, AM J PATHOL, V100, P707; THREADGILL DW, IN PRESS SCIENCE; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; YASUI S, 1993, PEDIATR PULM, V15, P251, DOI 10.1002/ppul.1950150412	32	820	843	1	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					337	341		10.1038/376337a0	http://dx.doi.org/10.1038/376337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630400				2022-12-28	WOS:A1995RL44300046
J	BRITTEN, N				BRITTEN, N			QUALITATIVE RESEARCH .4. QUALITATIVE INTERVIEWS IN MEDICAL-RESEARCH	BRITISH MEDICAL JOURNAL			English	Article							VIEWS	Much qualitative research is interview based, and this paper provides an outline of qualitative interview techniques and their application in medical settings. It explains the rationale for these techniques and shows how they can be used to research kinds of questions that are different from those dealt with by quantitative methods. Different types of qualitative interviews are described, and the way in which they differ from clinical consultations is emphasised. Practical guidance for conducting such interviews is given.			BRITTEN, N (corresponding author), UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND.		Jolugbo, Olajide/D-3216-2017	Jolugbo, Olajide/0000-0001-6512-4117				BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRITTEN N, 1991, SOCIOL HEALTH ILL, V13, P83, DOI 10.1111/1467-9566.ep11340325; CANNON S, 1989, SOCIOL HEALTH ILL, V11, P62, DOI 10.1111/1467-9566.ep10844052; FIELD PA, 1989, NURSING RES APPLICAT; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; GREEN JM, 1993, BRIT MED J, V307, P607, DOI 10.1136/bmj.307.6904.607; HOLLAND J, 1990, SOCIOL HEALTH ILL, V12, P336, DOI 10.1111/1467-9566.ep11347264; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Oakley A., 1981, DOING FEMINIST RES, P30; PATTON MQ, 1987, HOW USE QUALITATIVE, P108; WHYTE WF, 1982, FIELD RES SOURCEBOOK, P111	11	857	890	2	113	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	1995	311	6999					251	253		10.1136/bmj.311.6999.251	http://dx.doi.org/10.1136/bmj.311.6999.251			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RL441	7627048	Green Published			2022-12-28	WOS:A1995RL44100032
J	VLADECK, BC; KING, KM				VLADECK, BC; KING, KM			MEDICARE AT 30 - PREPARING FOR THE FUTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HLTH CARE FINANCING ADM,ADM OFF,WASHINGTON,DC									Gornick M, 1985, Health Care Financ Rev, VSuppl, P13; GORNICK M, 1976, SOC SECUR B     0703, P3; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; MOON M, 1993, MEDICARE NOW FUTURE; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V273, P1483, DOI 10.1001/jama.273.19.1483; VLAECK BC, 1994, JAMA-J AM MED ASSOC, V271, P1896; Waldo D R, 1989, Health Care Financ Rev, V10, P111; 1994, ANN REPORT C MONITOR	8	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	1995	274	3					259	262		10.1001/jama.274.3.259	http://dx.doi.org/10.1001/jama.274.3.259			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH937	7609237				2022-12-28	WOS:A1995RH93700034
J	HANIF, M; MOBARAK, MR; RONAN, A; RAHMAN, D; DONOVAN, JJ; BENNISH, ML				HANIF, M; MOBARAK, MR; RONAN, A; RAHMAN, D; DONOVAN, JJ; BENNISH, ML			FATAL RENAL-FAILURE CAUSED BY DIETHYLENE GLYCOL IN PARACETAMOL ELIXIR - THE BANGLADESH EPIDEMIC	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN	Objective-To determine the cause of a large increase in the number of children with unexplained renal failure. Design-Case-control study. Setting-Children's hospital in Dhaka, Bangladesh. Subjects-Cases were all 339 children with initially unexplained renal failure; controls were 90 children with cause of renal failure identified; all were admitted to hospital during 35 months after January 1990. Main outcome measures-Differences between the case and control patients in clinical and histological features and outcome; toxicological examination of 69 bottles of paracetamol from patients and pharmacies. Results-Compared with children with an identified cause for their renal failure, children with initially unexplained renal failure were significantly (P < 0 . 05) more likely to have hepatomegaly (58% v 33%), oedema (37% v 20%), and hypertension (58% v 23%); to have a higher serum creatinine concentration (mean 519 mu mol/l v 347 mu mol/l) and lower serum bicarbonate concentration (10 . 1 mmol/l v 12 . 4 mmol/l); to have been given a drug for fever (91% v 31%); to have ingested a brand of paracetamol shown to contain diethylene glycol (20% v 0%); and to have died in hospital (70% v 33%). Diethylene glycol was identified in 19 bottles of paracetamol, from 7 of 28 brands tested. In the 12 months after a government ban on the sale of paracetamol elixir, new cases of renal failure decreased by 54%, and cases of unexplained renal failure decreased by 84%. Conclusion-Paracetamol elixirs with diethylene glycol as a diluent were responsible for a large outbreak of fatal renal failure in Bangladesh.	TUFTS UNIV NEW ENGLAND MED CTR,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111; DHAKA SHISHU HOSP,DEPT NEPHROL,DHAKA,BANGLADESH; INT CTR DIARRHOEAL DIS RES,DHAKA,BANGLADESH; MASSACHUSETTS DEPT PUBL HLTH,STATE LAB INST,BOSTON,MA 02116	Tufts Medical Center; International Centre for Diarrhoeal Disease Research (ICDDR); Massachusetts Department of Public Health								ANDREWS LS, 1991, CASARETT DOULLS TOXI, P704; BOWIE MD, 1972, S AFR MED J, V46, P931; CANTARELL MC, 1987, ANN INTERN MED, V106, P478, DOI 10.7326/0003-4819-106-3-478_2; Castelo A, 1991, J Clin Epidemiol, V44 Suppl 2, p21S; CHETLEY A, 1992, POLICY PRACTICE FUTU, P53; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; GRANT JP, 1994, STATE WORLDS CHILDRE, P64; MASLAND T, 1990, NEWSWEEK        1105, P22; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; REICH MR, 1994, HEALTH POLICY PLANN, V9, P130, DOI 10.1093/heapol/9.2.130; ROY SK, 1993, WHO SEA98 DRUGS DRUG; SILVERMAN M, 1992, BAD MED PRESCRIPTION, P209; TIRANTI DJ, 1986, ESSENTIAL DRUGS BANG, P11; van Leusen R, 1987, Ned Tijdschr Geneeskd, V131, P768; VANDERLINDENCRE.PM, 1985, NED TIJDSCHR GENEESK, V129, P1890; WINDHOLZ M, 1983, MERCK INDEX, P453; 1977, PEDIATR S, V59, P803; 1985, LANCET, V2, P254; 1992, WHO TECHNICAL REPORT, V825, P22; 1981, TREATMENT MANAGEMENT	21	103	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					88	91		10.1136/bmj.311.6997.88	http://dx.doi.org/10.1136/bmj.311.6997.88			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613408	Green Published			2022-12-28	WOS:A1995RJ03000020
J	MEYER, HE; TVERDAL, A; FALCH, JA				MEYER, HE; TVERDAL, A; FALCH, JA			CHANGES IN BODY-WEIGHT AND INCIDENCE OF HIP FRACTURE AMONG MIDDLE-AGED NORWEGIANS	BRITISH MEDICAL JOURNAL			English	Article									AKER HOSP,DEPT INTERNAL MED,N-0514 OSLO,NORWAY	University of Oslo	MEYER, HE (corresponding author), NATL HLTH SCREENING SERV,POB 8155,N-0033 OSLO,NORWAY.		Meyer, Haakon E./AAH-9333-2019	Tverdal, Aage/0000-0002-2909-5678				CUMMING RG, 1994, AM J EPIDEMIOL, V139, P493, DOI 10.1093/oxfordjournals.aje.a117032; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622; REID IR, 1994, J CLIN ENDOCR METAB, V79, P950, DOI 10.1210/jc.79.4.950; 1988, CARDIOVASCULAR DISEA	5	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	1995	311	6997					91	92		10.1136/bmj.311.6997.91	http://dx.doi.org/10.1136/bmj.311.6997.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ030	7613409	Green Published			2022-12-28	WOS:A1995RJ03000021
J	RASKIN, JB; WHITE, RH; JACKSON, JE; WEAVER, AL; TINDALL, EA; LIES, RB; STANTON, DS				RASKIN, JB; WHITE, RH; JACKSON, JE; WEAVER, AL; TINDALL, EA; LIES, RB; STANTON, DS			MISOPROSTOL DOSAGE IN THE PREVENTION OF NONSTEROIDAL ANTIINFLAMMATORY DRUG-INDUCED GASTRIC AND DUODENAL-ULCERS - A COMPARISON OF 3 REGIMENS	ANNALS OF INTERNAL MEDICINE			English	Article						MISOPROSTOL; ANTIINFLAMMATORY AGENTS, NONSTEROIDAL; DUODENAL ULCER; PEPTIC ULCER; DOSE-RESPONSE RELATIONSHIP, DRUG	CONTROLLED TRIAL; ANTIINFLAMMATORY DRUGS; BLOOD-LOSS; RANITIDINE; ARTHRITIS; THERAPY; MUCOSA; INJURY; AGENTS	Objective: To compare the effectiveness and tolerability of three misoprostol dosing regimens for the prevention of gastric and duodenal ulcers associated with long-term nonsteroidal anti-inflammatory drug (NSAID) therapy. Design: A multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel, four-limb study. Patients: Eligibility criteria included upper gastrointestinal symptoms during NSAID therapy and no endoscopic evidence of gastric or duodenal ulcers. A total of 1623 patients was enrolled; 1197 of these met major accession and regimen-compliance criteria and completed the trial. These 1197 patients composed the evaluable group. Interventions: Patients were randomly assigned to one of four regimens: placebo four times daily; 200 mu g of misoprostol twice daily and placebo twice daily; 200 mu g of misoprostol three times daily and placebo once daily; and 200 mu g of misoprostol four times daily. Measurements: Upper gastrointestinal endoscopic examinations for ulcers were done after 4, 8, and 12 weeks of therapy. Tolerability and safety of the regimens were assessed by adverse-event monitoring. Results: In the placebo group, the incidence of gastric ulcers was 15.7% and the incidence of duodenal ulcers was 7.5%. The incidence of gastric ulcers was significantly lower in the groups receiving misoprostol twice daily (8.1%; difference, 7.6% [95% CI, 2.7% to 12.5%]; P = 0.002), three times daily (3.9%; difference, 11.8% [CI, 7.4% to 16.3%]; P < 0.001), and four times daily (4%; difference, 11.7% [CI, 6.7% to 16.8%]; P < 0.001) compared with placebo. The gastric ulcer rate was significantly higher in patients receiving misoprostol twice daily compared with those receiving misoprostol three times daily (difference, 4.2% [95% CI, 0.7% to 7.7%]; P = 0.02). A significant (P = 0.02) misoprostol dose-response effect was noted in the prevention of gastric ulcers. The incidence of duodenal ulcers was significantly lower in the groups receiving misoprostol twice daily (2.6%; difference, 4.9% [CI, 1.5% to 8.2%]; P = 0.004), three times daily (3.3%; difference, 4.2% [CI, 0.6% to 7.7%]; P = 0.019), and four times daily (1.4%; difference, 6.1% [CI, 2.6% to 9.6%]; P = 0.007) compared with placebo. No significant difference was detected between patients receiving misoprostol twice daily and those receiving misoprostol three times daily, and no dose-response effect was noted with duodenal ulcers. The incidence of withdrawals for adverse events was significantly lower in the groups receiving misoprostol twice daily (12%) and three times daily (12%) than in the group receiving it four times daily (20%). The incidence of gastrointestinal adverse events was significantly higher in the group receiving misoprostol four times daily (74%) than in the placebo group (62%). Conclusion: Misoprostol, 200 mu g twice or three times daily, offers substantial protection against gastric and duodenal ulcers in patients receiving long-term NSAID therapy. These dosages were better tolerated than the currently approved regimen of 200 mu g four times daily.	VET AFFAIRS MED CTR, MIAMI, FL USA; UNIV MIAMI, SCH MED, MIAMI, FL USA; UNIV CALIF DAVIS, MED CTR, SACRAMENTO, CA 95817 USA; WALKER CLIN EVALUAT INC, INDIANAPOLIS, IN USA; ARTHRIT CTR NEBRASKA, LINCOLN, NE USA; PORTLAND ADVENTIST MED CTR, PORTLAND, OR USA; WICHITA CLIN, WICHITA, KS USA; WESTERN MED CTR, SANTA ANA, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of California System; University of California Davis								Agrawal N. M., 1993, European Journal of Rheumatology and Inflammation, V13, P17; AGRAWAL NM, 1991, ANN INTERN MED, V115, P195, DOI 10.7326/0003-4819-115-3-195; [Anonymous], 1990, DRUG THER B, V28, P25; CARUSO I, 1980, BRIT MED J, V280, P75, DOI 10.1136/bmj.280.6207.75; COHEN MM, 1985, DIGEST DIS SCI, V30, P605, DOI 10.1007/BF01308407; DAJANI EZ, 1985, DIGEST DIS SCI, V30, pS194, DOI 10.1007/BF01309408; DELMAS P D, 1990, Arthritis and Rheumatism, V33, pS152; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; FRIES JF, 1991, AM J MED, V91, P213, DOI 10.1016/0002-9343(91)90118-H; FRIES JF, 1992, SCAND J RHEUMATOL, P21; GEIS GS, 1991, J RHEUMATOL, V18, P11; GILBERT DA, 1984, GASTROENTEROLOGY, V86, P339; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1993, ANN INTERN MED, V119, P257, DOI 10.7326/0003-4819-119-4-199308150-00001; HOLLANDER D, 1994, AM J MED, V96, P274, DOI 10.1016/0002-9343(94)90153-8; LANZA F L, 1990, Gastroenterology, V98, pA76; LANZA FL, 1981, AM J GASTROENTEROL, V75, P17; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; LEONARDS JR, 1973, NEW ENGL J MED, V289, P1020, DOI 10.1056/NEJM197311082891908; LICHTENSTEIN DR, 1995, ARTHRITIS RHEUM, V38, P5, DOI 10.1002/art.1780380103; LOEB DS, 1992, MAYO CLIN PROC, V67, P354, DOI 10.1016/S0025-6196(12)61552-3; MAGNUSSON B, 1977, SCAND J RHEUMATOL, V6, P62; MILLER RR, 1977, AM J MED SCI, V274, P271, DOI 10.1097/00000441-197711000-00005; MITCHELL DM, 1986, ARTHRITIS RHEUM-US, V29, P706, DOI 10.1002/art.1780290602; REDFERN JS, 1989, GASTROENTEROLOGY, V96, P596, DOI 10.1016/S0016-5085(89)80055-1; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; ROTH SH, 1987, ARCH INTERN MED, V147, P1798, DOI 10.1001/archinte.147.10.1798; SCHEIMAN JM, 1992, SEMIN ARTHRITIS RHEU, V21, P201, DOI 10.1016/0049-0172(92)90050-N; SILVERSTEIN FE, 1994, GASTROENTEROLOGY, V106, pA180	29	134	144	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					344	350		10.7326/0003-4819-123-5-199509010-00004	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625622				2022-12-28	WOS:A1995RQ98800004
J	STANDAERT, SM; DAWSON, JE; SCHAFFNER, W; CHILDS, JE; BIGGIE, KL; SINGLETON, BS; GERHARDT, RR; KNIGHT, ML; HUTCHESON, RH				STANDAERT, SM; DAWSON, JE; SCHAFFNER, W; CHILDS, JE; BIGGIE, KL; SINGLETON, BS; GERHARDT, RR; KNIGHT, ML; HUTCHESON, RH			EHRLICHIOSIS IN A GOLF-ORIENTED RETIREMENT COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN INFECTION; TICKS; CANIS	Background. Ehrlichiosis due to Ehrlichia chaffeensis usually occurs sporadically or in small clusters, with an annual incidence estimated at 3 to 5 cases per 100,000 population in areas of endemic disease. The putative principal vector is the Lone Star tick (Amblyomma americanum). We investigated an outbreak of ehrlichiosis that occurred in June 1993 among members of a golf-oriented retirement community (community A) in Tenessee. The community is densely wooded and borders a wildlife-management area where deer are numerous. Methods. We conducted a case-control study, using medical-history reviews, serologic testing, and testing with the polymerase chain reaction for E. chaffeensis infection. We also surveyed a sample of 10 percent of the households in community A and in another golf-oriented community (community B) more than 20 miles (32 km) from the wildlife-management area. Survey participants completed a questionnaire and provided specimens for serologic testing. In both communities, searches for ticks were undertaken. Results. Eleven cases of symptomatic ehrlichiosis were identified in the case-control study, 10 of which were in community A (attack rate, 330 per 100,000). Of 311 surveyed residents of community-A, 12.5 percent had serologic evidence of past E. chaffeensis infection, as compared with 3.3 percent of 92 in community B (relative risk in community A as compared with community B, 3.9; 95 percent confidence interval, 1.2 to 12.2). The risk of infection was associated with tick bites, exposure to wildlife, golfing, and among golfers, retrieving lost golf balls from the rough. Persons who never used insect repellent were more likely to have had infection than persons who did. In community A, thousands of Lone Star ticks were found; in community B, only three ticks were found. Conclusions. The high rate of E. chaffeensis infection in community A resulted from its proximity to a wildlife reserve. When outdoor recreational activities are common and concentrations of ticks are high, outbreaks of arthropod-borne zoonoses can be anticipated.	VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37232; NATL CTR INFECT DIS,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA; TENNESSEE DEPT HLTH,NASHVILLE,TN; UNIV TENNESSEE,DEPT ENTOMOL & PLANT PATHOL,KNOXVILLE,TN; TENNESSEE VALLEY AUTHOR,GOLDEN POND,KY	Vanderbilt University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Tennessee Department Health; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Tennessee Valley Authority			Childs, James E/B-4002-2012					ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1993, AM J TROP MED HYG, V49, P239, DOI 10.4269/ajtmh.1993.49.239; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DAWSON JE, 1994, J CLIN MICROBIOL, V32, P2725, DOI 10.1128/JCM.32.11.2725-2728.1994; Dean A. G., 1990, EPI INFO VERSION 5 W; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; FISHBEIN DB, 1987, JAMA-J AM MED ASSOC, V257, P3100, DOI 10.1001/jama.257.22.3100; Hair J.A., 1986, P406; Harkess J R, 1991, Infect Dis Clin North Am, V5, P37; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; KARDATZKE JT, 1992, J MED ENTOMOL, V29, P669, DOI 10.1093/jmedent/29.4.669; LEDERBERG J, 1992, EMERGING INFECTIONS, P206; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; ROHRBACH BW, 1990, AM J PUBLIC HEALTH, V80, P442, DOI 10.2105/AJPH.80.4.442; SCHWARTZ BS, 1990, AM J EPIDEMIOL, V131, P877, DOI 10.1093/oxfordjournals.aje.a115578; TAYLOR JP, 1988, J INFECT DIS, V158, P217, DOI 10.1093/infdis/158.1.217; Telford S R 3rd, 1991, Infect Dis Clin North Am, V5, P7; TOPPING NH, 1947, NEW YORK STATE J MED, V47, P1585; WALKER DH, 1994, NEW ENGL J MED, V331, P1651, DOI 10.1056/NEJM199412153312410; YEVICH SJ, 1995, J INFECT DIS, V171, P1266, DOI 10.1093/infdis/171.5.1266; 1988, MMWR-MORBID MORTAL W, V37, P270; 1988, MMWR-MORBID MORTAL W, V37, P275	27	94	99	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 17	1995	333	7					420	425		10.1056/NEJM199508173330704	http://dx.doi.org/10.1056/NEJM199508173330704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP243	7616991				2022-12-28	WOS:A1995RP24300004
J	MURPHY, JA; ROSS, LM; GIBSON, BES				MURPHY, JA; ROSS, LM; GIBSON, BES			VINCRISTINE TOXICITY IN 5 CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Letter							PHARMACOKINETICS				MURPHY, JA (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT HAEMATOL,GLASGOW G3 8SJ,LANARK,SCOTLAND.							CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407; FEDELI L, 1989, CANCER, V64, P1805, DOI 10.1002/1097-0142(19891101)64:9<1805::AID-CNCR2820640908>3.0.CO;2-D; TSURUO T, 1982, CANCER RES, V42, P4730; VANDENBERG HW, 1982, CANCER CHEMOTH PHARM, V8, P215, DOI 10.1007/BF00255487	5	31	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					443	443		10.1016/S0140-6736(95)92816-2	http://dx.doi.org/10.1016/S0140-6736(95)92816-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623589				2022-12-28	WOS:A1995RN65600046
J	CLEMENT, K; VAISSE, C; MANNING, BS; BASDEVANT, A; GUYGRAND, B; RUIZ, J; SILVER, KD; SHULDINER, AR; FROGUEL, P; STROSBERG, AD				CLEMENT, K; VAISSE, C; MANNING, BS; BASDEVANT, A; GUYGRAND, B; RUIZ, J; SILVER, KD; SHULDINER, AR; FROGUEL, P; STROSBERG, AD			GENETIC-VARIATION IN THE BETA(3)-ADRENERGIC RECEPTOR AND AN INCREASED CAPACITY TO GAIN WEIGHT IN PATIENTS WITH MORBID-OBESITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-3-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION	Background. The beta(3)-adrenergic receptor, located mainly in adipose tissue, is involved in the regulation of lipolysis and thermogenesis, The potential relevance of this receptor to obesity in humans led us to screen obese French patients for a recently identified mutation in the gene for the receptor. Methods. We used the polymerase chain reaction to amplify a region of the gene for the beta(3)-adrenergic receptor encoding amino acid residues 27 to 110 in genomic DNA extracted from leukocytes from 185 patients with morbid obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], >40) and 94 normal subjects. A mutation resulting in the replacement of tryptophan by arginine at position 64 (Trp64Arg) was detected by an analysis of restriction-fragment-length polymorphisms with the use of the endonuclease BstNI, which discriminates between the normal and mutant sequences. Results. The frequency of the Trp64Arg allele was similar in the morbidly obese patients and the normal subjects (0.08 and 0.10, respectively), However, the patients with morbid obesity who were heterozygous for the Trp64Arg mutation had an increased capacity to gain weight; the mean weight in the 14 heterozygous patients was 140 kg, as compared with 126 kg in the 171 patients without the mutation (P=0.03), There were no homozygotes in this sample, The cumulative 25-year change in weight (from the age of 20 years) was 67 kg in the Trp64Arg heterozygotes, as compared with 51 kg in those without the mutation. The maximal weight differential (the maximal lifetime weight minus the weight at 20 years of age) in the Trp64Arg heterozygotes was 74 kg, as compared with 59 kg in the patients without the mutation (P=0.02), Conclusions. People with the Trp64Arg mutation of the gene for the beta(3)-adrenergic receptor may have an increased capacity to gain weight.	INST PASTEUR,CNRS,UNITE EP10,F-59019 LILLE,FRANCE; UNIV HOSP LILLE,LILLE,FRANCE; HOP HOTEL DIEU,DEPT NUTR,F-75181 PARIS,FRANCE; INST COCHIN GENET MOLEC,IMMUNOPHARMACOL MOLEC LAB,CNRS,UNITE UPR 0415,F-75014 PARIS,FRANCE; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Johns Hopkins University			Clément, karine/R-1120-2017; FROGUEL, Philippe/O-6799-2017; Vaisse, Christian/F-1067-2011	FROGUEL, Philippe/0000-0003-2972-0784; Shuldiner, Alan/0000-0001-9921-4305				Adams T D, 1993, Obes Res, V1, P261; Arbeeny C. M., 1994, International Journal of Obesity, V18, P4; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BOUCHARD C, 1988, ANNU REV NUTR, V8, P259, DOI 10.1146/annurev.nu.08.070188.001355; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; PRICE RA, 1990, HUM BIOL, V62, P747; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; Sambrook J, 1989, MOL CLONING LABORATO; Susulic V. S., 1994, International Journal of Obesity, V18, P5; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603	15	581	600	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					352	354		10.1056/NEJM199508103330605	http://dx.doi.org/10.1056/NEJM199508103330605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN082	7609752				2022-12-28	WOS:A1995RN08200005
J	BELL, TW; HOU, Z; LUO, Y; DREW, MGB; CHAPOTEAU, E; CZECH, BP; KUMAR, A				BELL, TW; HOU, Z; LUO, Y; DREW, MGB; CHAPOTEAU, E; CZECH, BP; KUMAR, A			DETECTION OF CREATININE BY A DESIGNED RECEPTOR	SCIENCE			English	Article							TORANDS; ASSAY	An artificial receptor has been designed to bind creatinine with a color change (chromogenic response) caused by proton transfer from one end of the receptor to the other. The receptor was synthesized and found to extract creatinine from water into chlorocarbon solvents. The color change in the organic layer is specific for creatinine relative to other organic solutes, and it is selective far creatinine relative to sodium, potassium, and ammonium ions. The chromogenic mechanism is revealed by x-ray crystal structures of creatinine, the free receptor, and the complex, showing ''induced fit'' binding resulting from electronic complementarity between host and guest.	SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794; UNIV READING,DEPT CHEM,READING RG6 2AD,BERKS,ENGLAND; BAYER CORP,DIV DIAGNOST,TARRYTOWN,NY 10591	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Reading; Bayer AG								BALL P, 1994, NATURE, V371, P202, DOI 10.1038/371202a0; BECKLES DL, 1995, TETRAHEDRON, V51, P363, DOI 10.1016/0040-4020(94)00902-7; BELL TW, 1993, PURE APPL CHEM, V65, P361, DOI 10.1351/pac199365030361; BELL TW, 1994, NATURE, V367, P441, DOI 10.1038/367441a0; BELL TW, 1986, J AM CHEM SOC, V108, P8109, DOI 10.1021/ja00285a049; BELL TW, 1993, FLUORESCENT CHEMOSEN, P85; BELL TW, 1993, ORG SYNTH, V8, P87; BUHLMANN P, 1993, TETRAHEDRON, V49, P7627, DOI 10.1016/S0040-4020(01)87238-0; BUTLER AR, 1985, J CHEM SOC PERK T 2, P1465, DOI 10.1039/p29850001465; CALABRESE GS, 1988, TOP CURR CHEM, V143, P49; CRAM DJ, 1986, ANGEW CHEM INT EDIT, V25, P1039, DOI 10.1002/anie.198610393; DUPRE S, 1955, ACTA CRYSTALLOGR, V8, P311, DOI 10.1107/S0365110X55000972; FOSSATI P, 1983, CLIN CHEM, V29, P1494; FREE HM, 1991, MODERN URINE CHEM; HIRSHFELD FL, 1980, ACTA CRYSTALLOGR B, V36, P406, DOI 10.1107/S0567740880003366; JAYNES PK, 1982, CLIN CHEM, V28, P114; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; Johnson D., 1989, CLIN CHEM, P55; KENYON GL, 1971, J AM CHEM SOC, V93, P5552, DOI 10.1021/ja00750a039; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LEHN JM, 1993, SCIENCE, V260, P1762, DOI 10.1126/science.8511582; MAJEWICZ TG, 1974, J ORG CHEM, V39, P720, DOI 10.1021/jo00919a033; NARAYANAN S, 1980, CLIN CHEM, V26, P1119; SHELDRICK GM, 1993, SHELXI PROGRAM CRYST; Stewart J. J. P., 1993, MOPAC93; VANLENTE F, 1990, CLIN CHEM NEWS   OCT, P8	26	101	106	1	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					671	674		10.1126/science.7624796	http://dx.doi.org/10.1126/science.7624796			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7624796				2022-12-28	WOS:A1995RM70200027
J	LEE, SL; WESSELSCHMIDT, RL; LINETTE, GP; KANAGAWA, O; RUSSELL, JH; MILBRANDT, J				LEE, SL; WESSELSCHMIDT, RL; LINETTE, GP; KANAGAWA, O; RUSSELL, JH; MILBRANDT, J			UNIMPAIRED THYMIC AND PERIPHERAL T-CELL DEATH IN MICE LACKING THE NUCLEAR RECEPTOR NGFI-B (NUR77)	SCIENCE			English	Article							CLONAL DELETION; THYMOCYTES; APOPTOSIS; ANTIBODIES; HYBRIDOMAS; INVIVO; GENE	T cell hybridomas require the immediate-early gene NGFI-B (nur77) for T cell receptor (TCR)-mediated apoptosis, a model for negative selection of self-reactive T cells. TCR-mediated death was examined in mice bearing an NGFI-B loss-of-function mutation, either by administration of antibodies to CD3 (anti-CD3) or in two well-characterized transgenic models expressing self-reactive TCRs. Both the extent and the rate of thymocyte death were unimpaired. Anti-CD3-induced death was normal in CD4+ peripheral T cells, in which death is mediated predominantly by the Fas signaling pathway. Thus, no unique requirement for NGFI-B is observed for thymic or peripheral T cell death.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Russell, John/0000-0002-3680-9587; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KISLELOW P, 1988, NATURE, V333, P742; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Lee S. A., UNPUB; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WATSON MA, UNPUB; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0	28	222	225	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					532	535		10.1126/science.7624775	http://dx.doi.org/10.1126/science.7624775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7624775				2022-12-28	WOS:A1995RL49500025
J	WEEKS, KM; CECH, TR				WEEKS, KM; CECH, TR			PROTEIN FACILITATION OF GROUP-I INTRON SPLICING BY ASSEMBLY OF THE CATALYTIC CORE AND THE 5'-SPLICE-SITE DOMAIN	CELL			English	Article							BASE-PAIRING INTERACTION; GUANOSINE-BINDING-SITE; TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; RIBONUCLEASE-P; RIBOSOMAL-RNA; SECONDARY STRUCTURE; GUIDE SEQUENCE; MESSENGER-RNA; CBP2 PROTEIN	The yeast mitochondrial group 1 intron b15 undergoes self-splicing at high Mg2+ concentrations, but requires the splicing factor CBP2 for reaction under physiological conditions. Chemical accessibility and UV crosslinking experiments now reveal that self-processing is slow because functional elements are not properly positioned in an active tertiary structure. Folding anergy provided by CBP2 drives assembly of two RNA domains that comprise the catalytic core and meditates association of an similar to 100 nt 5' domain that contains the 5' splice site. Thus, the protein assembles RNA secondary structure elements into a specific three-dimensional array while the RNA provides the catalytic center. The division of labor between RNA and protein illustrated by this simple system reveals principles applicable to complex ribonucleoprotein assemblies such as the spliceosome and ribosome.			WEEKS, KM (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P102; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; GUO QB, 1991, J BIOL CHEM, V266, P1809; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER TS, 1988, P NATL ACAD SCI USA, V88, P11105; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JANDROSITZ A, 1995, EMBO J, V14, P820, DOI 10.1002/j.1460-2075.1995.tb07060.x; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MOHR G, 1991, NATURE, V347, P578; MURPHY FL, 1994, SCIENCE, V265, P1709, DOI 10.1126/science.8085157; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024; PARTONO S, 1990, P NATL ACAD SCI USA, V87, P8192, DOI 10.1073/pnas.87.21.8192; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RITCHINGS BW, 1992, NUCLEIC ACIDS RES, V20, P2349, DOI 10.1093/nar/20.9.2349; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WOLLENZIEN PL, 1983, CELL, V32, P397, DOI 10.1016/0092-8674(83)90459-2; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	49	103	106	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					221	230		10.1016/0092-8674(95)90309-7	http://dx.doi.org/10.1016/0092-8674(95)90309-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7628013	Bronze			2022-12-28	WOS:A1995RL76000009
J	BIRKHEAD, GS; LEBARON, CW; PARSONS, P; GRABAU, JC; BARRGALE, L; FUHRMAN, J; BROOKS, S; ROSENTHAL, J; HADLER, SC; MORSE, DL				BIRKHEAD, GS; LEBARON, CW; PARSONS, P; GRABAU, JC; BARRGALE, L; FUHRMAN, J; BROOKS, S; ROSENTHAL, J; HADLER, SC; MORSE, DL			THE IMMUNIZATION OF CHILDREN ENROLLED IN THE SPECIAL SUPPLEMENTAL FOOD PROGRAM FOR WOMEN, INFANTS, AND CHILDREN (WIC) - THE IMPACT OF DIFFERENT STRATEGIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEASLES	Objective.-To assess the impact of different interventions to increase measles vaccination coverage among preschool children enrolled in the Special Supplemental Food Program for Women, Infants, and Children (WIC). Design.-Public health intervention trial. Setting.-Six volunteer WIC sites in New York City. Study Participants.-Children aged 12 to 59 months presenting for WIC certification between April 1 and September 30, 1991, who were eligible for measles vaccination. Interventions.-Two WIC sites were assigned at random to one of three immunization strategies: (1) escort: child was escorted to a nearby pediatric clinic for immunization; (2) voucher incentive: the family returned monthly, rather than every 2 months, to pick up WIC food vouchers until the child was immunized; or (3) referral: the family was passively referred for immunization. Main Outcome Measure.-Proportion of eligible children receiving measles vaccination. Results.-Of children eligible for measles immunization, 74% (618/836) were immunized. Children at escort sites were 5.5 times (relative risk [RR]=5.5; 95% confidence interval [CI], 3.7 to 8.1) and those at voucher incentive sites were 2.9 times (RR=2.9; 95% CI, 1,9 to 4.5) more likely to be immunized than children at referral sites. Children were immunized more rapidly at escort sites (median, 14 days) and voucher incentive sites (median, 26 days) than at referral sites (median, 45 days; P<.001). Conclusions.-Both escort and voucher incentive models resulted in more children being immunized more rapidly than passive referral. Because of ease of administration, voucher incentives may be a more suitable immunization intervention for use at WIC sites, with addition of escort where feasible.	NEW YORK STATE DEPT HLTH,DIV NUTR,ALBANY,NY 12237; SUNY ALBANY,SCH PUBL HLTH,DEPT EPIDEMIOL,ALBANY,NY 12222; CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30341	State University of New York (SUNY) System; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Centers for Disease Control & Prevention - USA	BIRKHEAD, GS (corresponding author), NEW YORK STATE DEPT HLTH,BUR COMMUNICABLE DIS CONTROL,ROOM 651,CORNING TOWER,ESP,ALBANY,NY 12237, USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560	PHS HHS [H23/CCH204473-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atkinson William L., 1992, Morbidity and Mortality Weekly Report, V41, P1; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BIRKHEAD GS, 1992, NY STATE J MED, V10, P415; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; HUTCHINS SS, 1993, AM J PUBLIC HEALTH, V83, P862, DOI 10.2105/AJPH.83.6.862; MASON JO, 1992, PUBLIC HEALTH REP, V107, P241; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; SHALALA DE, 1993, JAMA-J AM MED ASSOC, V269, P1844, DOI 10.1001/jama.269.14.1844; 1989, MMWR-MORBID MORTAL W, V38, P219; 1990, MMWR-MORBID MORTAL W, V39, P353; 1989, MMWR-MORBID MORTAL W, V38, P205; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1993, 1992 P NAT WIC IMM C; 1988, SAS STAT USERS GUIDE; 1991, MMWER MORB MORTAL WK, V40, P369; 1993, JAMA-J AM MED ASSOC, V269, P1817	16	50	50	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					312	316		10.1001/jama.274.4.312	http://dx.doi.org/10.1001/jama.274.4.312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609260				2022-12-28	WOS:A1995RJ89800033
J	GREENBERGER, P				GREENBERGER, P			ALLERGIC RHINITIS IN AN ALLERGY CLINIC NURSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GREENBERGER, P (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					358	358						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7609269				2022-12-28	WOS:A1995RJ89800042
J	SHEN, ZX; LI, JM; WANG, ZY; HAN, ZC; CAEN, JP; BELLUCCI, SA				SHEN, ZX; LI, JM; WANG, ZY; HAN, ZC; CAEN, JP; BELLUCCI, SA			THROMBOCYTOPOIETIC EFFECT OF HEPARIN GIVEN IN CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA	LANCET			English	Note								Our previous in-vitro and in-vivo studies showed that heparin enhanced murine and human megakaryocytopoiesis. 20 patients with chronic immune thrombocytopenic purpura were randomly divided into two groups and given 10 mg per day of prednisone for 30 days, for haemostatic purposes. One group received in addition heparin (1250 IU twice a day subcutaneously for 30 days). From day 10, a significant increase in platelet count was observed in eight of the ten patients treated with heparin (p<0.05), with return to the initial value after heparin cessation in six of the responders. These data demonstrate the effectiveness of heparin and suggest its use or that of other related compounds for therapy of chronic immune thrombocytopenic purpura.	SHANGHAI INST HAEMATOL,SHANGHAI,PEOPLES R CHINA; HOP LARIBOISIERE,INST VAISSEAUX & SANG,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite			Han, Zhong Chao/D-7157-2016	Han, Zhong Chao/0000-0002-2687-7682				BELLEM PJ, 1987, J CLIN INVEST, V80, P33; BELLUCCI S, 1991, EUR J HAEMATOL, V47, P86; BELLUCCI S, 1989, CLIN HAEMATOL BAILLI, V2, P695; BERCHTOLD P, 1989, BLOOD, V74, P2309; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; HAN ZC, 1989, EXP HEMATOL, V17, P46; HAN ZC, 1992, J LAB CLIN MED, V120, P645; HAN ZC, 1993, EXP HEMATOL, V21, P1016; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; SHEN ZX, 1994, BRIT J HAEMATOL, V88, P608, DOI 10.1111/j.1365-2141.1994.tb05080.x	10	17	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					220	221		10.1016/S0140-6736(95)91269-X	http://dx.doi.org/10.1016/S0140-6736(95)91269-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7616802				2022-12-28	WOS:A1995RK41900011
J	GRADY, CL; MCINTOSH, AR; HORWITZ, B; MAISOG, JM; UNGERLEIDER, LG; MENTIS, MJ; PIETRINI, P; SCHAPIRO, MB; HAXBY, JV				GRADY, CL; MCINTOSH, AR; HORWITZ, B; MAISOG, JM; UNGERLEIDER, LG; MENTIS, MJ; PIETRINI, P; SCHAPIRO, MB; HAXBY, JV			AGE-RELATED REDUCTIONS IN HUMAN RECOGNITION MEMORY DUE TO IMPAIRED ENCODING	SCIENCE			English	Article							HUMAN FRONTAL-CORTEX; WORKING MEMORY; PREFRONTAL CORTEX; DENDRITIC GROWTH; DENTATE GYRUS; HUMAN AMNESIA; HUMAN-BRAIN; HIPPOCAMPUS; MONKEYS; ACTIVATION	The participation of the medial temporal cortex and other cerebral structures in the memory impairment that accompanies aging was examined by means of positron emission tomography. Cerebral blood flow (rCBF) was measured during encoding and recognition of faces. Young people showed increased rCBF in the right hippocampus and the left prefrontal and temporal cortices during encoding and in the right prefrontal and parietal cortex during recognition. Old people showed no significant activation in areas activated during encoding in young people but did show right prefrontal activation during recognition. Age-related impairments of memory may be due to a failure to encode the stimuli adequately, which is reflected in the lack of cortical and hippocampal activation during encoding.	NIMH, PSYCHOL & PSYCHOPATHOL LAB, FUNCT BRAIN IMAGING SECT, BETHESDA, MD 20892 USA; NIMH, NEUROPSYCHOL LAB, NEUROCIRCUITRY SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	GRADY, CL (corresponding author), NIA, NEUROSCI LAB,BRAIN AGING & DEMENTIA SECT,BLDG 10, ROOM 6C414, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Pietrini, Pietro/Z-4202-2019; McIntosh, Anthony R/G-4955-2011	McIntosh, Anthony/0000-0002-1784-5662; Pietrini, Pietro/0000-0002-6768-5556				AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2; BALL MJ, 1977, ACTA NEUROPATHOL, V37, P111, DOI 10.1007/BF00692056; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; BUELL SJ, 1981, BRAIN RES, V214, P23, DOI 10.1016/0006-8993(81)90436-4; CREASEY H, 1985, ANN NEUROL, V17, P2, DOI 10.1002/ana.410170103; DOYERE V, 1993, NEUROPSYCHOLOGIA, V31, P1031, DOI 10.1016/0028-3932(93)90031-T; EACOTT MJ, 1992, EUR J NEUROSCI, V4, P1320, DOI 10.1111/j.1460-9568.1992.tb00157.x; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; FLOOD DG, 1985, BRAIN RES, V345, P366, DOI 10.1016/0006-8993(85)91018-2; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; GALLAGHER M, 1993, BEHAV BRAIN RES, V57, P155, DOI 10.1016/0166-4328(93)90131-9; GEINISMAN Y, 1992, HIPPOCAMPUS, V2, P437, DOI 10.1002/hipo.450020411; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994; GREENLEE MW, 1993, J NEUROSCI, V13, P2565, DOI 10.1523/JNEUROSCI.13-06-02565.1993; HAXBY JV, 1994, INVEST OPHTH VIS SCI, V35, P1813; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HORWITZ B, 1995, BEHAV BRAIN RES, V66, P187, DOI 10.1016/0166-4328(94)00139-7; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; JACOBS B, 1993, J COMP NEUROL, V327, P83, DOI 10.1002/cne.903270107; LANDFIELD PW, 1993, NEUROSCI RES COMMUN, V13, pS19; LIGHT LL, 1986, J CLIN EXP NEUROPSYC, V8, P62, DOI 10.1080/01688638608401297; LIPPA CF, 1992, NEUROBIOL AGING, V13, P405, DOI 10.1016/0197-4580(92)90115-E; MASLIAH E, 1993, NEUROLOGY, V43, P192, DOI 10.1212/WNL.43.1_Part_1.192; MCDOWD JM, 1991, J GERONTOL, V46, pP340, DOI 10.1093/geronj/46.6.P340; MEUNIER M, 1993, J NEUROSCI, V13, P5418, DOI 10.1523/JNEUROSCI.13-12-05418.1993; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; NAKAMURA S, 1985, ACTA NEUROPATHOL, V65, P281, DOI 10.1007/BF00687009; Nebes R D, 1986, Psychol Aging, V1, P261, DOI 10.1037/0882-7974.1.3.261; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; SALTHOUSE TA, 1990, DEV REV, V10, P101, DOI 10.1016/0273-2297(90)90006-P; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SEKULER R, 1986, J OPT SOC AM A, V3, P864, DOI 10.1364/JOSAA.3.000864; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Talairach J, 1988, CO PLANAR STEREOTAXI; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; VENERO JL, 1993, BRAIN RES, V631, P89, DOI 10.1016/0006-8993(93)91191-T; ZOLAMORGAN S, 1985, BEHAV NEUROSCI, V99, P22, DOI 10.1037/0735-7044.99.1.22; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	47	524	556	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 14	1995	269	5221					218	221		10.1126/science.7618082	http://dx.doi.org/10.1126/science.7618082			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RJ029	7618082				2022-12-28	WOS:A1995RJ02900038
J	LICINIO, J; GOLD, PW; WONG, ML				LICINIO, J; GOLD, PW; WONG, ML			A MOLECULAR MECHANISM FOR STRESS-INDUCED ALTERATIONS IN SUSCEPTIBILITY TO DISEASE	LANCET			English	Note							CORTICOTROPIN-RELEASING-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD IMMUNOCYTES; INTERLEUKIN-1; REPLICATION; EXPRESSION; SEQUENCE; HORMONE; CLONING; GENE	Corticotropin-releasing hormone (CRH) is a 41-aminoacid peptide which mediates behavioural and physiological responses to stress. A major target of CRH is the proopiomelanocortin (POMC) gene. Three transcription factors have been identified that affect transcription of the POMC gene by binding to two different sites within the CRH-responsive element of that promoter. We searched Genbank and found that nucleotide sequences in the POMC promoter which bind POMC-transcription factors are also contained in the genome of HIV-1 and cytomegalovirus, in c-fes and human MAT-1 breast cancer oncogenes, and in proinflammatory molecules, such as the interleukin-1 beta converting enzyme. We hypothesise a mechanism of hormone action by which a peptide hormone, such as CRH, might affect disease susceptibility by eliciting the production of transcription factors which may bind to unexpected intracellular targets, such as viruses, oncogenes, or the genes encoding for inflammatory mediators, infection, inflammation, and neoplastic transformation would thus be facilitated. This hypothesis can be tested, if confirmed. CRH antagonists may prove useful in the treatment of disorders whose pathophysiology involves molecules that respond to CRH-regulated POMC transcription factors.			LICINIO, J (corresponding author), NIMH, CLIN NEUROENDOCRINOL BRANCH, BETHESDA, MD 20892 USA.		Licinio, Julio/L-4244-2013; Wong, Ma-Li/D-7903-2011; Wong, Ma-Li/ABD-5525-2020	Licinio, Julio/0000-0001-6905-5884; Wong, Ma-Li/0000-0003-1512-3073; 				ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; ALCALAY M, 1990, ONCOGENE, V5, P267; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DEBELLIS MD, 1993, AM J PSYCHIAT, V150, P656; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; GAGNER JP, 1985, MOL CELL ENDOCRINOL, V40, P25, DOI 10.1016/0303-7207(85)90154-6; GOLD PW, 1986, NEW ENGL J MED, V314, P1335, DOI 10.1056/NEJM198605223142102; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; JIN WD, 1994, MOL ENDOCRINOL, V8, P1377, DOI 10.1210/me.8.10.1377; JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7; JUCKER M, 1992, ONCOGENE, V7, P943; KARALIS K, 1991, SCIENCE, V254, P421, DOI 10.1126/science.1925600; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; LU Y, 1993, BIOCHEM BIOPH RES CO, V193, P779, DOI 10.1006/bbrc.1993.1693; POTTER E, 1994, P NATL ACAD SCI USA, V91, P8777, DOI 10.1073/pnas.91.19.8777; RIEGEL AT, 1990, NUCLEIC ACIDS RES, V18, P4513, DOI 10.1093/nar/18.15.4513; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; SINGH VK, 1993, IMMUNOL LETT, V35, P239, DOI 10.1016/0165-2478(93)90189-9; SPIEGEL D, 1989, LANCET, V2, P888; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; STRAYER DS, 1991, VIROLOGY, V185, P585, DOI 10.1016/0042-6822(91)90529-K; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WONG ML, 1994, ENDOCRINOLOGY, V135, P2275, DOI 10.1210/en.135.5.2275	30	27	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 8	1995	346	8967					104	106		10.1016/S0140-6736(95)92119-2	http://dx.doi.org/10.1016/S0140-6736(95)92119-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7626147				2022-12-28	WOS:A1995RH22000017
J	EVANS, JMM; MCMAHON, AD; MCGILCHRIST, MM; WHITE, G; MURRAY, FE; MCDEVITT, DG; MACDONALD, TM				EVANS, JMM; MCMAHON, AD; MCGILCHRIST, MM; WHITE, G; MURRAY, FE; MCDEVITT, DG; MACDONALD, TM			TOPICAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND ADMISSION TO HOSPITAL FOR UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION - A RECORD LINKAGE CASE-CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the relation between topically applied non-steroidal anti-inflammatory drugs and upper gastrointestinal bleeding and perforation. Design-A case-control study with 1103 patients admitted to hospital for upper gastrointestinal bleeding or perforation between January 1990 and December 1992 (cases). Two different control groups were used, with six community controls and with two hospital controls for each case. Previous exposure to topical and oral non-steroidal antiinflammatory drugs and ulcer healing drugs was assessed. Study population-The population of 319465 people who were resident in Tayside and were registered with a Tayside general practitioner between January 1989 and October 1994. A record linkage database containing all data on hospital events and dispensed drugs between 1989 and 1992 was used for this population. Main outcome measures-Unadjusted and adjusted odds ratios of exposure in those admitted to hospital compared with controls. Results-Significant unadjusted associations were detected between all three classes of drug and upper gastrointestinal complications. The significant association detected for topical non-steroidal anti-inflammatory drugs was no longer evident in analyses which adjusted for the confounding effect of concomitant exposure to oral anti-inflammatories and ulcer healing drugs (odds ratio=1.45; 95% confidence interval 0.84 to 2.50 with community controls; 1.06; 0.60 to 1.88 with hospital controls). Conclusion-In this study topical non-steroidal anti-inflammatory drugs were not significantly associated with upper gastrointestinal bleeding and perforation after adjustment for the confounding effects of concomitant use of oral anti-inflammatories and ulcer healing drugs.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CLIN PHARMACOL, MED MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Dundee			McMahon, Alex D/C-4304-2008	MacDonald, Thomas/0000-0001-5189-6669				BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; DEAN AD, 1990, EPI INFO DATA PROCES; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; KOHLI H S, 1992, Health Bulletin (Edinburgh), V50, P14; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P223; NEWBERY R, 1992, EUR J CLIN RES, V3, P139; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; Wood S. M., 1993, Pharmaceutical Medicine (London), V7, P203; 1991, SAS P217 TECHN REP	13	125	128	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					22	26		10.1136/bmj.311.6996.22	http://dx.doi.org/10.1136/bmj.311.6996.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613317	Green Accepted, Green Published			2022-12-28	WOS:A1995RG97500020
J	THIBAULT, GE				THIBAULT, GE			DIAGNOSTIC STRATEGY - THE SHOTGUN VERSUS THE ARROW	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CHRONIC PULMONARY THROMBOEMBOLISM; EMBOLISM; HYPERTENSION				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKY,BOSTON,MA 02132, USA.							CHITWOOD WR, 1985, ANN SURG, V201, P11; DALEN JE, 1969, NEW ENGL J MED, V280, P1194, DOI 10.1056/NEJM196905292802202; MILLS SR, 1980, RADIOLOGY, V136, P301, DOI 10.1148/radiology.136.2.7403501; MONREAL M, 1989, CHEST, V95, P976, DOI 10.1378/chest.95.5.976; MOSER KM, 1990, CIRCULATION, V81, P1735, DOI 10.1161/01.CIR.81.6.1735; RICH S, 1988, ANN INTERN MED, V108, P425, DOI 10.7326/0003-4819-108-3-425; SUTTON GC, 1977, BRIT HEART J, V39, P1135; SYMBAS PN, 1971, AM J CARDIOL, V28, P342, DOI 10.1016/0002-9149(71)90125-1; 1990, JAMA-J AM MED ASSOC, V263, P2753	9	9	9	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					321	325		10.1056/NEJM199502023320509	http://dx.doi.org/10.1056/NEJM199502023320509			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7619113				2022-12-28	WOS:A1995QD39600008
J	GIUGLIANO, D; MARFELLA, R; VERRAZZO, G; ACAMPORA, R; DONZELLA, C; QUATRARO, A; COPPOLA, L; DONOFRIO, F				GIUGLIANO, D; MARFELLA, R; VERRAZZO, G; ACAMPORA, R; DONZELLA, C; QUATRARO, A; COPPOLA, L; DONOFRIO, F			ABNORMAL RHEOLOGIC EFFECTS OF GLYCERYL TRINITRATE IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND REVERSAL BY ANTIOXIDANTS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; ANTIOXIDANTS; NITRATES; RHEOLOGY; HEMODYNAMICS	GLYCEMIC CONTROL; NITRIC-OXIDE; RISK-FACTORS; VISCOSITY; NITRATES; DISEASE	Objective: io evaluate 1) the hemorrheologic and hemodynamic effects of glyceryl trinitrate in patients with non-insulin-dependent diabetes mellitus and 2) the influence of antioxidants on these effects. Design: Case-control study. Setting: University hospital clinic. Patients: 40 patients with diabetes and no evidence of cardiovascular complications and 40 controls matched for demographic variables and body habitus. Interventions: Sublingual glyceryl trinitrate (0.3 mg) and transdermal glyceryl trinitrate patches (10 mg/d). Vitamin E, 300 mg/d orally for 7 days, and glutathione, 600 mg intravenously or intramuscularly, were given to test the effects of antioxidant supplementation. Measurements: Systolic, diastolic, and mean arterial pressure and heart rate; left ventricular ejection fraction; platelet aggregation, blood viscosity, and blood filterability in vitro and ex vivo. Results: Compared with controls, patients with diabetes had increased platelet aggregation to adenosine diphosphate (P < 0.005), increased blood viscosity (P < 0.001), and decreased blood filterability (P = 0.041) at baseline; blood pressure, heart rate, and ejection fraction were similar in the two groups. In controls, both sublingual glyceryl trinitrate and transdermal glyceryl trinitrate patches significantly reduced platelet aggregation (-38%; 95% CI, -49% to -27%) and blood viscosity (-8%; CI, -11% to -5%) and increased blood filterability (10%; CI, 7.0% to 13.1%). Slight but significant decreases in blood pressure and ejection fraction and an increase in heart rate were also seen in controls after administration of glyceryl trinitrate (both preparations). In patients with diabetes, glyceryl trinitrate paradoxically increased platelet aggregation (24%; CI, 15% to 33%) and blood viscosity (6%; CI, 2.9% to 8.8%) and decreased blood filterability (-7%; CI, -9.5% to -4.4%); hemodynamic values did not change significantly. In both groups, theologic responses to glyceryl trinitrate (end concentration, 100 and 200 ng/mL) in vitro were similar to those seen in ex vivo studies. Vitamin E and glutathione normalized theologic responses to glyceryl trinitrate in patients with diabetes. Conclusions: Organic nitrates have beneficial effects on blood theology in controls but not in patients with diabetes, in whom a paradoxical deterioration is seen. Antioxidant supplementation can normalize primary tolerance to the theologic effects of nitrates in diabetes.	UNIV NAPLES 2, NAPLES, ITALY; DIABET CLIN LEPANTO, NAPLES, ITALY; DIABET CLIN SANTA RITA, TARANTO, ITALY	Universita della Campania Vanvitelli			Marfella, Raffaele/C-6899-2012	Marfella, Raffaele/0000-0003-3960-9270; Giugliano, Dario/0000-0002-9377-873X				ABRAIRA C, 1992, DIABETES CARE, V15, P1560, DOI 10.2337/diacare.15.11.1560; BEKS PJ, 1995, DIABETOLOGIA, V38, P86, DOI 10.1007/s001250050257; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CERIELLO A, 1993, DIABETOLOGIA, V36, P265, DOI 10.1007/BF00399961; COLLIER A, 1989, DIABETES METAB, V15, P420; COLWELL JA, 1993, DIABETES, V42, P8, DOI 10.2337/diab.42.1.8; COOKE JP, 1993, CIRCULATION, V88, P2451, DOI 10.1161/01.CIR.88.5.2451; DENT M T, 1991, Diabetologia, V34, pA74; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; FITZGERALD DJ, 1984, CIRCULATION, V70, P297, DOI 10.1161/01.CIR.70.2.297; FUNG HL, 1992, AM J CARDIOL, V70, pB4, DOI 10.1016/0002-9149(92)90588-P; GIUGLIANO D, 1995, METABOLISM, V44, P363, DOI 10.1016/0026-0495(95)90167-1; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAMPTON J. R., 1967, CARDIOVASC RES, V1, P101, DOI 10.1093/cvr/1.2.101; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; KOENIG W, 1994, LANCET, V344, P711, DOI 10.1016/S0140-6736(94)92207-1; KUNISAKI M, 1993, DIABETES, V42, P1138, DOI 10.2337/diabetes.42.8.1138; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MALMBERG K, 1988, EUR HEART J, V9, P259, DOI 10.1093/oxfordjournals.eurheartj.a062494; MALMBERG KA, 1994, DIABETES CARE, V17, P1007, DOI 10.2337/diacare.17.9.1007; MARFELLA R, 1994, DIABETES, V43, P607, DOI 10.2337/diabetes.43.4.607; MCMILLAN DE, 1988, MAYO CLIN PROC, V63, P517, DOI 10.1016/S0025-6196(12)65652-3; MCVEIGH G, 1994, DIABETOLOGIA, V37, P115, DOI 10.1007/BF00428787; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; REID HL, 1976, J CLIN PATHOL, V29, P855, DOI 10.1136/jcp.29.9.855; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TESFAMARIAM B, 1994, FREE RADICAL BIO MED, V16, P383, DOI 10.1016/0891-5849(94)90040-X; UZEL N, 1987, HORM METAB RES, V19, P89, DOI 10.1055/s-2007-1011748; WILBRANDT W, 1956, EXP CELL RES, V11, P59, DOI 10.1016/0014-4827(56)90190-2; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; YUSUF S, 1988, LANCET, V1, P1088	34	34	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					338	343		10.7326/0003-4819-123-5-199509010-00003	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7625621				2022-12-28	WOS:A1995RQ98800003
J	DENNING, DW				DENNING, DW			CAN WE PREVENT AZOLE RESISTANCE IN FUNGI	LANCET			English	Editorial Material									N MANCHESTER GRP HOSP,DEPT INFECT DIS & TROP MED,MONSALL UNIT,MANCHESTER,LANCS,ENGLAND		DENNING, DW (corresponding author), UNIV MANCHESTER,MANCHESTER,LANCS,ENGLAND.		Denning, David/AAC-6931-2019	Denning, David/0000-0001-5626-2251				[Anonymous], INT C AIDS; Bossche Hugo Vanden, 1994, Trends in Microbiology, V2, P393; GOFF DA, 1995, CLIN INFECT DIS, V20, P77, DOI 10.1093/clinids/20.1.77; JOHNSON EM, 1995, J ANTIMICROB CHEMOTH, V35, P103, DOI 10.1093/jac/35.1.103; KELLY SL, IN PRESS BIOCH BIOPH; KELLY SL, 1993, NATO ASI SCI H, V69, P200; LAW D, 1994, J ANTIMICROB CHEMOTH, V34, P659, DOI 10.1093/jac/34.5.659; ODDS FC, 1993, J ANTIMICROB CHEMOTH, V31, P463, DOI 10.1093/jac/31.4.463; SANGEORZAN JA, 1994, AM J MED, V97, P339, DOI 10.1016/0002-9343(94)90300-X; VAILY GG, 1994, AIDS, V8, P787; VUFFRAY A, 1994, AIDS, V8, P708, DOI 10.1097/00002030-199405000-00023; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803	12	46	46	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 19	1995	346	8973					454	455		10.1016/S0140-6736(95)91314-9	http://dx.doi.org/10.1016/S0140-6736(95)91314-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP857	7637473	Bronze			2022-12-28	WOS:A1995RP85700002
J	TELFORD, SR; LEPORE, TJ; SNOW, P; WARNER, CK; DAWSON, JE				TELFORD, SR; LEPORE, TJ; SNOW, P; WARNER, CK; DAWSON, JE			HUMAN GRANULOCYTIC EHRLICHIOSIS IN MASSACHUSETTS	ANNALS OF INTERNAL MEDICINE			English	Note									NANTUCKET COTTAGE HOSP, NANTUCKET, MA 02554 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	TELFORD, SR (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT TROP PUBL HLTH, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI19693] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019693, R01AI019693] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BROUQUI P, 1994, NEW ENGL J MED, V330, P1760; BRUNET LR, 1995, IN PRESS INFECT IMMU; CHEN SM, 1994, CLIN MICROBIOL, V32, P598; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DAWSON JE, 1994, J CLIN MICROBIOL, V32, P2725, DOI 10.1128/JCM.32.11.2725-2728.1994; DONATIEN A., 1935, Bulletin de la Societe de Pathologie Exotique, V28, P418; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; LILLE RD, 1948, HISTOPATHOLOGIC TECH, P300; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MISAO T., 1955, Kyushu Journal of Medical Science, V6, P145; PANCHOLI P, IN PRESS J INFECT DI; RICH SM, 1995, IN PRESS P NATL ACAD; RYNKIEWICZ DL, 1994, NEW ENGL J MED, V330, P292, DOI 10.1056/NEJM199401273300418; TELFORD SR, 1992, AM J TROP MED HYG, V47, P55, DOI 10.4269/ajtmh.1992.47.55	18	68	68	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1995	123	4					277	279		10.7326/0003-4819-123-4-199508150-00006	http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN665	7611594				2022-12-28	WOS:A1995RN66500006
J	BOSE, R; VERHEIJ, M; HAIMOVITZFRIEDMAN, A; SCOTTO, K; FUKS, Z; KOLESNICK, R				BOSE, R; VERHEIJ, M; HAIMOVITZFRIEDMAN, A; SCOTTO, K; FUKS, Z; KOLESNICK, R			CERAMIDE SYNTHASE MEDIATES DAUNORUBICIN-INDUCED APOPTOSIS - AN ALTERNATIVE MECHANISM FOR GENERATING DEATH SIGNALS	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SPHINGANINE N-ACYLTRANSFERASE; NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; HL-60 CELLS; ANTICANCER DRUGS; SPHINGOLIPID BIOSYNTHESIS; CHEMOTHERAPEUTIC AGENTS; FUSARIUM-MONILIFORME; SPHINGOMYELIN	The sphingomyelin pathway, which is initiated by sphingomyelin hydrolysis to generate the second messenger ceramide, signals apoptosis for tu mor necrosis factor alpha, Fas, and ionizing radiation. In the present studies, the anticancer drug daunorubicin also stimulated ceramide elevation and apoptosis in P388 and U937 cells, Cell-permeable analogs of ceramide, but not other lipid second messengers, mimicked daunorubicin in inducing apoptosis. Daunorubicin-stimulated ceramide elevation, however, did not result from sphingomyelin hydrolysis, but rather from de novo synthesis via activation of the enzyme ceramide synthase. An obligatory role for ceramide synthase was defined, since its natural specific inhibitor, fumonisin B1, blocked daunorubicin-induced ceramide elevation and apoptosis. These studies demonstrate that ceramide synthase activity can be regulated in eukaryotes and constitute definitive evidence for a requirement for ceramide elevation in the induction of apoptosis.	MEM SLOAN KETTERING CANC CTR,EUKARYOT TRANSCRIPT LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DIV RADIAT ONCOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	BOSE, R (corresponding author), MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R01CA057400] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462, CA57400, CA42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS DS, 1971, CLIN PHARMACOL THER, V12, P96; ANILKUMAR TV, 1992, BRIT J CANCER, V65, P552, DOI 10.1038/bjc.1992.113; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRESI P, 1990, PHARMACOL BASIS THER, P1202; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CIFONE MG, 1994, J EXP MED, V177, P1547; DIVE C, 1993, FRONTIERS PHARM CANC, P21; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUVALL E, 1985, IMMUNOLOGY, V56, P351; DYSON JED, 1986, CELL TISSUE KINET, V19, P311, DOI 10.1111/j.1365-2184.1986.tb00683.x; EPSTEIN RJ, 1990, J CLIN ONCOL, V8, P2062, DOI 10.1200/JCO.1990.8.12.2062; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDM.A, 1994, J EXP MED, V180, P525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAREL R, 1993, J BIOL CHEM, V268, P14476; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LING YH, 1993, CANCER RES, V53, P1845; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SMITH PJ, 1994, ANN HEMATOL, V69, pS7, DOI 10.1007/BF01757348; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPETH PAJ, 1989, SEMIN ONCOL, V16, P2; STRUM JC, 1994, J BIOL CHEM, V269, P15493; THAKKAR NS, 1992, BIOCHEM PHARMACOL, V43, P1683, DOI 10.1016/0006-2952(92)90697-H; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZWELLING LA, 1993, BIOCHEM PHARMACOL, V45, P516, DOI 10.1016/0006-2952(93)90091-A	57	764	798	1	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					405	414		10.1016/0092-8674(95)90429-8	http://dx.doi.org/10.1016/0092-8674(95)90429-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634330	Bronze			2022-12-28	WOS:A1995RP24200010
J	GERACE, L				GERACE, L			NUCLEAR EXPORT SIGNALS AND THE FAST-TRACK TO THE CYTOPLASM	CELL			English	Review							PROTEINS; ENVELOPE; COMPLEX; RNA		SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute	GERACE, L (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ADAM SA, 1995, TRENDS CELL BIOL, V5, P189, DOI 10.1016/S0962-8924(00)88991-6; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1995, IN PRESS NATURE; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; STUTZ F, 1994, EMBO J, V13, P4097; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	29	215	219	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					341	344		10.1016/0092-8674(95)90420-4	http://dx.doi.org/10.1016/0092-8674(95)90420-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7634321	Bronze			2022-12-28	WOS:A1995RP24200001
J	PELLEGRINI, L; SONG, T; RICHMOND, TJ				PELLEGRINI, L; SONG, T; RICHMOND, TJ			STRUCTURE OF SERUM RESPONSE FACTOR CORE BOUND TO DNA	NATURE			English	Article							TERNARY COMPLEX-FORMATION; C-FOS; SACCHAROMYCES-CEREVISIAE; BINDING SPECIFICITIES; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; PROTEIN; MCM1; ELEMENT; SRF	The human serum response factor is a transcription factor belonging to the MADS domain protein family with members characterized from the plant and animal kingdoms. The X-ray crystal structure of the serum response factor core in a specific-recognition DNA complex shows that the functions of DNA binding, dimerization and accessory-factor Interaction are compactly Integrated into a novel protein unit. The intrinsic and induced conformation of the serum response element DNA is the principal DNA feature recognized in the specific complex.	ETH ZURICH,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Pellegrini, Luca/AAE-2312-2022	Pellegrini, Luca/0000-0002-9300-497X				AFFOLTER M, 1994, DEVELOPMENT, V120, P743; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUHN L, 1992, MOL CELL BIOL, V12, P3563, DOI 10.1128/MCB.12.8.3563; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAGEN DC, 1993, MOL CELL BIOL, V13, P6866, DOI 10.1128/MCB.13.11.6866; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LLANG H, 1994, STRUCT BIOL, V1, P871; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKANO Y, 1991, GENE, V99, P285; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NURRISH SJ, IN PRESS MOL CELL BI; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Sprague G F Jr, 1990, Adv Genet, V27, P33; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRELSMAN R, 1994, CURR OPIN GENE DEV, V4, P96; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	51	291	296	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					490	498		10.1038/376490a0	http://dx.doi.org/10.1038/376490a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7637780				2022-12-28	WOS:A1995RN62200038
J	BROMBERG, JEC; RINKEL, GJE; ALGRA, A; GREEBE, P; VANDUYN, CM; HASAN, D; LIMBURG, M; TERBERG, HWM; WIJDICKS, EFM; VANGIJN, J				BROMBERG, JEC; RINKEL, GJE; ALGRA, A; GREEBE, P; VANDUYN, CM; HASAN, D; LIMBURG, M; TERBERG, HWM; WIJDICKS, EFM; VANGIJN, J			SUBARACHNOID HEMORRHAGE IN FIRST-DEGREE AND 2ND-DEGREE RELATIVES OF PATIENTS WITH SUBARACHNOID HEMORRHAGE	BRITISH MEDICAL JOURNAL			English	Article							INTRACRANIAL ANEURYSMS; HEMORRHAGE		UNIV ROTTERDAM,DEPT NEUROL,ROTTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,1105 AZ AMSTERDAM,NETHERLANDS; SITTARD HOSP,DEPT NEUROL,SITTARD,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam	BROMBERG, JEC (corresponding author), UNIV UTRECHT,DEPT NEUROL,POB 85500,3508 GA UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008	Hasan, Djo/0000-0003-4610-5433				BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; RONKAINEN A, 1993, NEUROSURGERY, V33, P787; TERBERG HWM, 1992, STROKE, V23, P1024, DOI 10.1161/01.STR.23.7.1024; WANG PS, 1995, ARCH NEUROL-CHICAGO, V52, P202, DOI 10.1001/archneur.1995.00540260108026	5	134	136	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	1995	311	7000					288	289		10.1136/bmj.311.7000.288	http://dx.doi.org/10.1136/bmj.311.7000.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM719	7633233	Green Published			2022-12-28	WOS:A1995RM71900020
J	BRAY, D				BRAY, D			PROTEIN MOLECULES AS COMPUTATIONAL ELEMENTS IN LIVING CELLS	NATURE			English	Review							INTERCONVERTIBLE ENZYME CASCADES; BACTERIAL CHEMOTAXIS; METABOLIC-REGULATION; SYSTEMS; PHOSPHORYLATION; SUPERIORITY; RECEPTOR; KINASE	Many proteins in living cells appear to have as their primary function the transfer and processing of information, rather than the chemical transformation of metabolic intermediates or the building of cellular structures. Such proteins are functionally linked through allosteric or other mechanisms into biochemical 'circuits' that perform a variety of simple computational tasks including amplification, integration and information storage.			BRAY, D (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							ANHOLT RRH, 1994, TRENDS NEUROSCI, V17, P37, DOI 10.1016/0166-2236(94)90033-7; ANWYL R, 1994, CURR BIOL, V4, P854, DOI 10.1016/S0960-9822(00)00192-5; ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAY D, 1990, J THEOR BIOL, V143, P215, DOI 10.1016/S0022-5193(05)80268-1; BRAY D, 1994, BIOPHYS J, V66, P972, DOI 10.1016/S0006-3495(94)80878-1; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; Bray D., 1992, CELL MOVEMENTS; CHOCK PB, 1977, P NATL ACAD SCI USA, V74, P2766, DOI 10.1073/pnas.74.7.2766; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hille B., 1992, IONIC CHANNELS EXCIT; HJELMFELT A, 1993, SCIENCE, V260, P335, DOI 10.1126/science.260.5106.335; JOHNSON LN, 1994, REV BIOPHYS STRUCT B, V22, P199; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P710; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02478259; Minsky M., 1969, PERCEPTRONS; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MURRAY A, 1993, CELL CYCLE; OKAMOTO M, 1988, BIOL CYBERN, V58, P295, DOI 10.1007/BF00363938; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; Rumelhart D., 1986, PARALLEL DISTRIBUTED; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SHACTER E, 1984, J BIOL CHEM, V259, P2252; STADTMAN ER, 1977, P NATL ACAD SCI USA, V74, P2761, DOI 10.1073/pnas.74.7.2761; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; ZIMMERMAN SB, 1994, ANNU REV BIOPH BIOM, V22, P27	40	508	515	1	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					307	312		10.1038/376307a0	http://dx.doi.org/10.1038/376307a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7630396				2022-12-28	WOS:A1995RL44300039
J	BOCZKO, EM; BROOKS, CL				BOCZKO, EM; BROOKS, CL			FIRST-PRINCIPLES CALCULATION OF THE FOLDING FREE-ENERGY OF A 3-HELIX BUNDLE PROTEIN	SCIENCE			English	Article							MOLTEN GLOBULE STATE; THERMODYNAMIC ANALYSIS; STAPHYLOCOCCUS-AUREUS; MOLECULAR-DYNAMICS; SIMULATIONS; DENATURATION; SEQUENCE; PEPTIDE	The folding and unfolding of a three-helix bundle protein were explored with molecular-dynamics simulations, cluster analysis, and weighted-histogram techniques. The folding-unfolding process occurs by means of a ''folding funnel,'' in which a uniform and broad distribution of conformational states is accessible outside of the native manifold. This distribution narrows near a transition region and becomes compact within the native manifold. Key thermodynamic steps in folding include initial interactions around the amino-terminal helix-turn-helix motif, interactions between helices I and II, and, finally, the docking of helix III onto the helix I-II subdomain. A metastable minimum in the calculated free-energy surface is observed at approximately 1.5 times the native volume. Folding-unfolding thermodynamics are dominated by the opposing influences of protein-solvent energy, which favors unfolding, and the overall entropy, which favors folding by means of the hydrophobic effect.			BOCZKO, EM (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM48807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048807] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Allen M. P., 1989, COMPUTER SIMULATION, DOI DOI 10.1093/OSO/9780198803195.001.0001; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BOCZKO EM, 1993, J PHYS CHEM-US, V97, P4509, DOI 10.1021/j100119a043; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1993, CURR OPIN STRUC BIOL, V3, P92, DOI 10.1016/0959-440X(93)90207-2; BROOKS CL, 1985, J CHEM PHYS, V83, P5897, DOI 10.1063/1.449621; BROOKS CL, 1993, CHEM REV, V93, P2487, DOI 10.1021/cr00023a008; BROOKS CL, 1992, J MOL BIOL, V227, P375, DOI 10.1016/0022-2836(92)90893-O; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; DAGGETT V, 1994, CURR OPIN STRUC BIOL, V4, P291, DOI 10.1016/S0959-440X(94)90322-0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1995, PROTEIN SCI, V4, P561; GILL SJ, 1988, ADV PROTEIN CHEM, V39, P191; GORDON AD, 1987, J ROY STAT SOC A STA, V150, P119, DOI 10.2307/2981629; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; HONIG B, 1994, OCT COLD SPRING HARB; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KOLINSKI A, 1994, PROTEINS, V18, P353, DOI 10.1002/prot.340180406; KUMAR S, 1992, J COMPUT CHEM, V13, P169; KURITA T, 1991, PATTERN RECOGN, V24, P205, DOI 10.1016/0031-3203(91)90062-A; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAZARIDIS T, 1992, J PHYS CHEM-US, V96, P3847, DOI 10.1021/j100188a051; LEOPOLD PE, 1992, P NATL ACAD SCI USA, V89, P8721, DOI 10.1073/pnas.89.18.8721; LIEBERMAN M, 1994, J AM CHEM SOC, V116, P5035, DOI 10.1021/ja00091a002; LUTHEYSCHULTEN Z, 1995, J PHYS CHEM-US, V99, P2177, DOI 10.1021/j100007a057; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; SKOLNICK J, 1991, J MOL BIOL, V221, P499, DOI 10.1016/0022-2836(91)80070-B; SKOLNICK J, 1993, CURR BIOL, V3, P414, DOI 10.1016/0960-9822(93)90348-R; TADDEI N, 1994, EUR J BIOCHEM, V225, P811, DOI 10.1111/j.1432-1033.1994.0811b.x; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, FEBS LETT, V321, P15; VALLEAU JP, 1977, GUIDE MONTE CARLO ST, V2, P169; VEITH M, 1994, J MOL BIOL, V237, P361; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; XU S, 1993, PATTERN RECOGN LETT, V14, P7, DOI 10.1016/0167-8655(93)90127-Y; YU HA, 1988, J CHEM PHYS, V89, P2366, DOI 10.1063/1.455080	45	358	361	1	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					393	396		10.1126/science.7618103	http://dx.doi.org/10.1126/science.7618103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618103				2022-12-28	WOS:A1995RK42700046
J	COHEN, JE				COHEN, JE			POPULATION GROWTH AND EARTH'S HUMAN CARRYING CAPACITY	SCIENCE			English	Review							WORLD-POPULATION; BIOLOGICAL POPULATIONS; STABLE POINTS; SCIENCE; PEOPLE; CYCLES	Earth's capacity to support people is determined both by natural constraints and by human choices concerning economics, environment, culture (including values and politics), and demography. Human carrying capacity is therefore dynamic and uncertain. Human choice is not captured by ecological notions of carrying capacity that are appropriate for nonhuman populations. Simple mathematical models of the relation between human population growth and human carrying capacity can account for faster-than-exponential population growth followed by a slowing population growth rate, as observed in recent human history.			COHEN, JE (corresponding author), ROCKEFELLER UNIV, POPULAT LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ANDERSON R M, 1991; [Anonymous], 1939, THEORIE ANAL ASS BIO; [Anonymous], 1954, CHALLENGE MANS FUTUR; [Anonymous], 1992, CONCISE HIST WORLD P; AUSTIN AL, 1971, TECHNOL FORECAST SOC, V3, P23, DOI 10.1016/S0040-1625(71)80002-1; AUSUBEL JH, 1993, SCIENCES, V33, P14, DOI 10.1002/j.2326-1951.1993.tb03132.x; AUSUBEL JH, 1994, 121 COUNC AGR SCI TE; Berlinski D., 1976, SYSTEMS ANAL; BIRABEN JN, 1979, POPULATION, V34, P13, DOI 10.2307/1531855; BLAXTER K, 1986, PEOPLE FOOD RESOURCE; BONGAARTS J, 1994, SCIENCE, V263, P771, DOI 10.1126/science.8303293; BROWN H, 1957, NEXT 100 YEARS MANS; Brown L. R., 1994, FULL HOUSE REASSESSI; Buringh P., 1975, COMPUTATION ABSOLUTE; Cepede M., 1964, POPULATION FOOD; CHEN R, 1990, HUNGER REPORT 1990; CIPOLLA CM, 1994, IND REVOLUTION EUROP, P137; CIPOLLA CM, 1974, EC HIST WORLD POPULA, P56; CLARK C, 1958, NATURE, V181, P1235, DOI 10.1038/1811235a0; COALE AJ, 1931, SCIENCE, V133, P936; COHEN JE, 1992, LIMITS GLOBAL COLLAP, P108; COHEN JE, IN PRESS MANY PEOPLE; COLE HSD, 1973, MODEL DOOM CRITIQUE; DASGUPTA P, 1987, POPULATION GROWTH EC, P631; DEANGELIS DL, 1992, DYNAMICS NUTRIENT CY, P38; DEEVEY ES, 1960, SCI AM, V203, P195; DEMENY P, 1994, POPULATION DEV; DEMENY P, 1989, POPULATION RESOURCES, P232; Demeny P., 1991, RESOURCES ENV POPULA, P408; DORN HF, 1962, SCIENCE, V135, P283, DOI 10.1126/science.135.3500.283; Duchin F., 1995, FUTURE ENV ECOLOGICA; DURAND JD, 1977, POPUL DEV REV, V3, P253, DOI 10.2307/1971891; EHRLICH PR, 1977, ECOSCIENCE POPULATIO, P730; EYRE SR, 1978, REAL WEALTH NATIONS; Fearnside P., 1986, HUMAN CARRYING CAPAC; FOERSTER HV, 1960, SCIENCE, V132, P1291; FORESTER HV, 1962, SCIENCE, V136, P173, DOI 10.1126/science.136.3511.173-a; Forrester J. W., 1971, WORLD DYNAMICS; FREMLIN JH, 1964, NEW SCI, V24, P285; GERTLER PJ, 1994, DEMOGRAPHY, V31, P33, DOI 10.2307/2061907; GEVER J, 1986, OIL THREAT FOOD FUEL; GILBERT AJ, 1991, MODELLING POPULATION; HARDESTY DL, 1977, ECOLOGICAL ANTHR, P209; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HASTINGS A, 1993, ANNU REV ECOL SYST, V24, P1, DOI 10.1146/annurev.es.24.110193.000245; HIGGINS GM, POTENTIAL POPULATION; HORIUCHI S, 1992, SCIENCE, V257, P761, DOI 10.1126/science.1496396; HOUSE PW, 1975, CARRYING CAPACITY NA; KAYSEN C, 1972, FOREIGN AFF, V50, P660, DOI 10.2307/20037939; KEYFITZ N, 1982, POPULATION CHANGE SO, pCH13; KNIBBS GH, 1917, MATH THEORY POPULATI, V1, P455; Kremer M, 1993, Q J ECON, V108, P681, DOI 10.2307/2118405; LEDERBERG J, 1988, JAMA-J AM MED ASSOC, V260, P684, DOI 10.1001/jama.260.5.684; LEE R, 1993, EXPLOR ECON HIST, V30, P1, DOI 10.1006/exeh.1993.1001; Lee R., 1986, STATE POPULATION THE, P96; Lee R D, 1988, Math Popul Stud, V1, P265; LEE RD, 1992, POPULATION, V47, P1533, DOI 10.2307/1534086; LEE RD, 1991, RESOURCES ENV POPULA, P315; Liebig J.F. von, 1855, PRINCIPLES AGR CHEM; LIETH H, 1973, HUM ECOL, V1, P303, DOI 10.1007/BF01536729; Lutz W., 1994, POPULATION DEV ENV U, DOI 10.1007/978-3-662-03061-5; Malthus T. R., 1798, ESSAY PRINCIPLE POPU; MAY RM, 1986, ECOLOGY, V67, P1115, DOI 10.2307/1938668; MAY RM, 1975, J THEOR BIOL, V51, P511, DOI 10.1016/0022-5193(75)90078-8; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, AM NAT, V110, P573, DOI 10.1086/283092; MAYER J, 1964, DAEDALUS, V93, P830; McEvedy C., 1978, ATLAS WORLD POPULATI; Meadows D.H., 1992, LIMITS GLOBAL COLLAP; Meadows D.H., 1974, LIMITS GROWTH; Mesarovic M. D., 1974, MANKIND TURNING POIN; Mill J.S., 2018, EC POPULATION, P97; MILLMAN SR, 1991, HUNGER REPORT UPDATE; Morse Stephen S., 1993, EMERGING VIRUSES; Myers N., 1994, SCARCITY ABUNDANCE D; Myrberg P., 1962, J MATH PURES APPL, V9, P339; NORDHAUS WD, 1973, ECON J, V83, P1156, DOI 10.2307/2230846; PEARL R, 1936, HUM BIOL, V8, P399; PEARL R, 1924, STUDIES HUMAN BIOL, P632; PENCK A, 1925, Z GEOPOLITIK, V2, P330; PIMENTEL D, 1994, POPUL ENVIRON, V15, P347, DOI 10.1007/BF02208317; PRYOR FL, 1982, J DEV ECON, V10, P325, DOI 10.1016/0304-3878(82)90034-7; PULLIAM HR, 1994, B ECOL SOC AM, V75, P141; Repetto R., 1985, GLOBAL POSSIBLE RESO; ROBERTSON J, 1961, SCIENCE, V133, P936, DOI 10.1126/science.133.3456.936; ROGERS PP, 1985, GLOBAL POSSIBLE RESO, P294; SCHMITT WR, 1965, ANN NY ACAD SCI, V118, P647, DOI 10.1111/j.1749-6632.1965.tb40736.x; SMIL V, 1991, POPUL DEV REV, V17, P569, DOI 10.2307/1973598; SMIL V, 1994, POPUL DEV REV, V20, P255, DOI 10.2307/2137520; SORENSON PE, 1971, POPULATION ENV PEOPL, P13; STOTO MA, 1983, J AM STAT ASSOC, V78, P13, DOI 10.2307/2287094; VANDEWALLE E, 1975, SCIENCE, V189, P1077; VANLEEUWENHOEK A, 1948, COLLECTED LETT; WAGGONER PE, 1994, 11 COUNC AGR SCI TEC; Warford J.J., 1993, WORLD END EC ENV SUS; WESTING AH, 1981, ENVIRON CONSERV, V8, P177, DOI 10.1017/S0376892900027533; Wilkinson R. G., 1973, POVERTY PROGR ECOLOG; ZABA B, 1994, ENV POPULATION CHANG, P197; [No title captured]; 1994, WORLD POPULATION 199; 1992, 1992 UN DEV PROGR HU, P36; 1994, WORLD RESOURCES 1994; 1993, STESASERA136 UN WORL, P74; 1992, STESASERA125 UN PUBL; 1994, DUURZAME RISICOS BLI, P9; 1992, MATLAB REFERENCE GUI, P208; 1924, SITZUNGSBERICHTE PRE, V22, P242; 1994, WORLD POPULATION DAT; 1992, FOCUS CARRYING CAPAC, V1, P57	109	284	319	25	372	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 21	1995	269	5222					341	346		10.1126/science.7618100	http://dx.doi.org/10.1126/science.7618100			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RK427	7618100				2022-12-28	WOS:A1995RK42700031
J	MARTIN, PT; ETTINGER, AJ; SANES, JR				MARTIN, PT; ETTINGER, AJ; SANES, JR			A SYNAPTIC LOCALIZATION DOMAIN IN THE SYNAPTIC CLEFT PROTEIN LAMININ BETA-2 (S-LAMININ)	SCIENCE			English	Article							BASAL LAMINA; NEUROMUSCULAR-JUNCTION; ACETYLCHOLINE-RECEPTORS; MOUSE MUSCLE; ADHESION; CELLS; DIFFERENTIATION; EXPRESSION; VARIANTS; SEQUENCE	The basal lamina that ensheaths skeletal muscle fibers traverses the synaptic cleft at the neuromuscular junction. Synaptic and extrasynaptic portions of the basal lamina contain different laminin beta chains: beta 2 (or s) at synapses and beta 1 (or beta 1) extrasynaptically. Laminin beta 2 is also confined to synapselike parches on myotube surfaces in vitro, whereas beta 1 is present throughout the extracellular matrix. This differential localization of laminin beta chains was analyzed by expression of chimeric beta 1-beta 2 molecules in cultured mouse myotubes. A 16-amino acid carboxyl-terminal sequence in beta 2 was necessary for synaptic localization, and an amino-terminal domain in beta 1 promoted association with extracellular fibrils. The synaptic targeting sequence of beta 2 contains a site previously shown to be adhesive for motor neurons.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Martin, Paul/0000-0002-0674-6191				ABRAHAMSON DR, 1989, J CELL BIOL, V109, P3477, DOI 10.1083/jcb.109.6.3477; Apel Elizabeth D., 1995, Current Opinion in Neurobiology, V5, P62, DOI 10.1016/0959-4388(95)80088-3; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHIU AY, 1984, DEV BIOL, V103, P4556; COHEN MW, 1980, J EXP BIOL, V89, P43; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FAMBROUGH DM, 1979, PHYSIOL REV, V59, P165, DOI 10.1152/physrev.1979.59.1.165; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1991, J NEUROSCI, V11, P3960; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; REING J, 1992, J BIOL CHEM, V267, P23143; SANES JR, 1983, DEV BIOL, V97, P123, DOI 10.1016/0012-1606(83)90070-2; SANES JR, 1984, J NEUROSCI, V4, P464; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCHITTNY JC, 1993, EUR J BIOCHEM, V216, P437, DOI 10.1111/j.1432-1033.1993.tb18161.x; SILBERSTEIN L, 1982, NATURE, V295, P143, DOI 10.1038/295143a0; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; UTANI A, 1994, J BIOL CHEM, V269, P19167; WEWER UM, 1994, LAB INVEST, V71, P719; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0	38	84	84	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 21	1995	269	5222					413	416		10.1126/science.7618109	http://dx.doi.org/10.1126/science.7618109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK427	7618109				2022-12-28	WOS:A1995RK42700052
J	JULIUSSON, G; VITOLS, S; LILIEMARK, J				JULIUSSON, G; VITOLS, S; LILIEMARK, J			MECHANISMS BEHIND HYPOCHOLESTEROLEMIA IN HAIRY-CELL LEUKEMIA	BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUKEMIA		HUDDINGE HOSP,DEPT MED,DIV CLIN HAEMATOL & ONCOL,HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT CLIN PHARMACOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT ONCOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital								HAKIMIAN D, 1991, BLOOD S1, V78, pA454; JULIUSSON G, 1992, BLOOD, V79, P888; JULIUSSON G, IN PRESS CANCER; VITOLS S, 1985, LANCET, V2, P1150; VITOLS S, 1991, CANCER CELL-MON REV, V3, P488	5	5	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	1995	311	6996					27	27		10.1136/bmj.311.6996.27	http://dx.doi.org/10.1136/bmj.311.6996.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613319	Green Published			2022-12-28	WOS:A1995RG97500022
J	SANDERSON, PJ				SANDERSON, PJ			PREVENTING HOSPITAL-ACQUIRED URINARY AND RESPIRATORY-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							CATHETER-ASSOCIATED BACTERIURIA; NOSOCOMIAL INFECTION; MEATAL COLONIZATION				SANDERSON, PJ (corresponding author), EDGWARE GEN HOSP,EDGWARE HA8 0AD,MIDDX,ENGLAND.							AYLIFFE GAJ, 1986, INFECT CONT HOSP EP, V7, P92, DOI 10.1017/S0195941700065541; BULTITUDE M I, 1973, British Journal of Urology, V45, P678, DOI 10.1111/j.1464-410X.1973.tb12239.x; Craven D E, 1990, Semin Respir Infect, V5, P157; GARIBALDI RA, 1980, NEW ENGL J MED, V303, P316, DOI 10.1056/NEJM198008073030605; GUZE LB, 1956, NEW ENGL J MED, V255, P474, DOI 10.1056/NEJM195609062551006; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HALEY RW, 1981, AM J MED, V70, P947, DOI 10.1016/0002-9343(81)90561-1; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; HELMHOLZ HF, 1950, J UROLOGY, V64, P158, DOI 10.1016/S0022-5347(17)68615-4; HUTH TS, 1992, J INFECT DIS, V165, P14, DOI 10.1093/infdis/165.1.14; KUNIN CM, 1971, J UROLOGY, V106, P928, DOI 10.1016/S0022-5347(17)61439-3; KUNIN CM, 1966, NEW ENGL J MED, V274, P1155, DOI 10.1056/NEJM196605262742101; MCLAWS ML, 1988, MED J AUSTRALIA, V149, P582, DOI 10.5694/j.1326-5377.1988.tb120795.x; Meers PD, 1981, J HOSPITAL INFECTI S, V2, P1, DOI DOI 10.1016/S0195-6701(81)80003-5; ONEIL AGB, 1981, BRIT J UROL, V53, P368, DOI 10.1111/j.1464-410X.1981.tb03199.x; SCHAEFFER AJ, 1983, J UROLOGY, V130, P1096, DOI 10.1016/S0022-5347(17)51701-2; WARREN JW, 1982, J INFECT DIS, V146, P719, DOI 10.1093/infdis/146.6.719	17	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1452	1453		10.1136/bmj.310.6992.1452	http://dx.doi.org/10.1136/bmj.310.6992.1452			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613281	Green Published			2022-12-28	WOS:A1995RC10500027
